PN 79001
RN 00981 
AN 79120857
AU Jensen-O.
TI 'Rusters'.  The corrosive action of palmar sweat: I. Sodium chloride
   in sweat.
SO Acta-Derm-Venereol (Stockh). 1979. 59(2). P 135-8.
MJ CORROSION.  HYPERHIDROSIS.  METALLURGY.  OCCUPATIONAL-MEDICINE.
   SODIUM-CHLORIDE.  SWEAT: an.
MN ADMINISTRATION-TOPICAL.  ADOLESCENCE.  ADULT.  ALUMINUM: tu.
   CHLORIDES: tu.  CYSTIC-FIBROSIS: co.  DERMATOLOGIC-AGENTS: tu.
   FEMALE.  HAND.  HUMAN.  HYPERHIDROSIS: dt.  IONTOPHORESIS.  MALE.
   MIDDLE-AGE.  PILOCARPINE.  SODIUM-CHLORIDE: an.
AB Sweat from 8 'rusters' and 8 control persons was examined for its
   sodium concentration. Sweating was induced by iontophoresis of
   pilocarpine on the distal forearm. In no case did the concentrations
   exceed the normal upper limit for this procedure, and no difference
   was found between the two groups. In this way the study failed to
   confirm earlier reports of elevated sodium chloride concentrations in
   sweat from 'rusters'. Proposals of a relationship between 'rusters'
   and patients with pancreatic cystic fibrosis were not substantiated.
   Hyperhidrosis of the palms and volar surfaces of the fingers was
   present in all 'rusters'. This seemed to be the main cause of the
   corrosive tendency, and patients referred for palmar hyperhidrosis
   were found to produce corrosion similar to the 'rusters'. Topical
   application of aluminium chloride hexahydrate in a 25% solution in
   absolute ethyl alcohol proved effective against both hyperhidrosis
   and the corrosive tendency.
RF 001   ALLEN JA              BR J DERMATOL                   90   277 974
   002   BANG PEDERSEN N       BR J DERMATOL                   96   332 977
   003   BUCKLEY WR            J OCCUP MED                      2    23 960
   004   BURTON JL             BR J DERMATOL                   95   417 976
   005   DARLING RC            ARCH PHYS MED                   29   150 948
   006   EISLER SJ             CORROSION                       10   237 954
   007   EVANS UR              INTRODUCTION TO METAL CORR            28 963
   008   FISHER AA             CONTACT DERMATITIS                    94 973
   009   FLENSBORG EW          IONTROPHORESIS APPARATUS                 971
   010   GIBSON LE             PEDIATRICS                      23   545 959
   011   HUFF WJ               CHEM MET ENG                    25   865 921
   012   JOHNSON BB            J INVEST DERMATOL               53   116 969
   013   LOBITZ WC             ARCH DERMATOL SYPHIL            56   462 947
   014   ROBINSON S            PHYSIOL REV                     34   202 954
   015   SATO K                J INVEST DERMATOL               55   433 970
   016   SHELLY WB             ACTA DERM VENEREOL (STOCKH)     55   241 975
CT   1   JENSEN O              ACTA DERM VENEREOL (STOCKH)     59   139 979
     2   TAYLOR JS             J AM ACAD DERMATOL              11  1007 984

PN 79002
RN 00982 
AN 79205962
AU Bak-Pedersen-K.  Larsen-P-K.
TI Inflammatory middle ear diseases in patients with cystic fibrosis.
SO Acta-Otolaryngol [Suppl] (Stockh). 1979. (360). P 138-40.
MJ CYSTIC-FIBROSIS: co.  OTITIS-MEDIA: et.
MN ACOUSTIC-IMPEDANCE-TESTS.  ADOLESCENCE.  ADULT.  AUDIOMETRY.  CHILD.
   CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: pp.  FEMALE.
   HEARING-LOSS-PARTIAL: et.  HUMAN.  INFANT.  MALE.  NASAL-POLYPS: et.
   OTITIS-MEDIA: co, pp.  PROSPECTIVE-STUDIES.
AB 111 patients with cystic fibrosis (CF), aged 7 months to 29 years,
   were examined to detect inflammatory middle ear diseases. 35% had a
   history of one or more attacks of acute otitis media, an incidence at
   the same level as in non-CF patients. None had chronic suppurative
   otitis. Only 4 out of the 88 patients able to cooperate in audiometry
   had a hearing impairment. In 2, the hearing loss was perceptive, in 3
   very mild, and in the fourth case, moderately severe. The middle ear
   pressure was measured in 108 patients, in 86 of whom it proved
   normal. In 15 patients the middle ear pressure was lower than--100
   mmH2O, indicating tubal occlusion, and in 7 patients the impedance
   minimum was lacking, indicating an accumulation of mucus. These 7
   patients (6%) had secretory otitis media. Nasal polyps were or had
   been present in 32%. There was no correlation between nasal polyps
   and tubal occlusion or secretory otitis. The incidence of
   inflammatory middle ear diseases in CF patients was in the same range
   as in non-CF patients, a finding at variance with some previous
   investigations showing middle ear pathology in 25--48%.
RF 001   BAK-PEDERSEN K        THESIS                                   977
   002   FORCUCCI RA           ARCH OTOLARYNGOL                96   361 972
   003   FRITZE W              Z KINDERHEILK                  114   111 973
   004   JERGER J              ARCH OTOLARYNGOL                93   111 971
   005   JOHANSEN PG           LANCET                           1   455 968
   006   KULCZYCKI LL          CLIN PEDIATR                     9   390 970
   007   NEELY JG              TRANS AM ACAD OPHTHALMOL OTOL   76   313 972
   008   PENNINGTON CL         ARCH OTOLARYNGOL                63   576 956
   009   SIEGEL J              ARCH OTOLARYNGOL                92   523 970
   010   TAYLOR BW             ARCH DIS CHILD                  49   133 974
   011   TYGSTRUP I            UGESKR LAEG TRANS DAN MED        1     6 972
CT   1   PEDERSEN M            CLIN OTOLARYNGOL                 7   373 982
     2   VANCAUWENBERGE PB     ACTA OTOLARYNGOL STOCKH SUPPL  414   147 984
     3   DAVID TJ              J ROY SOC MED                   79    23 986

PN 79003
RN 00983 
AN 79228230
AU Hoiby-N.  Hertz-J-B.
TI Precipitating antibodies against Escherichia coli, Bacteroides
   fragilis ss.  thetaiotaomicron and Pseudomonas aeruginosa in serum
   from normal persons and cystic fibrosis patients, determined by
   means of crossed immunoelectrophoresis.
SO Acta-Paediatr-Scand. 1979 Jul. 68(4). P 495-500.
MJ ANTIBODIES-BACTERIAL.  BACTEROIDES-FRAGILIS: im.  CYSTIC-FIBROSIS: im.
   ESCHERICHIA-COLI: im.  PSEUDOMONAS-AERUGINOSA: im.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: mi.
   FEMALE.  HUMAN.  IMMUNOELECTROPHORESIS-TWO-DIMENSIONAL.  INFANT.
   MALE.
AB Serum from normal persons and from 133 cystic fibrosis patients was
   examined for precipitins against faecal bacteria (E. coli and B.
   fragilis) and against P. aeruginosa by means of crossed
   immunoelectrophoresis.  27% of the normal sera contained 1-2
   precipitins against E. coli, 16% contained one precipitin against B.
   fragilis and 6% contained one precipitin against P. aeruginosa.  In
   sera from cystic fibrosis patients, there was a significantly
   increased prevalence of precipitins against E. coli (76%), B.
   fragilis (38%) and P. aeruginosa (63%), and the mean number of
   precipitins against each of these bacteria was 3 (range: 1-12), 1.4
   (range: 1-4), and 16 (range: 1-60), respectively.  Increased numbers
   of precipitins against P. aeruginosa were correlated with chronic
   lung infection caused by this species and with poor prognosis,
   whereas such associations were not revealed as regards precipitins
   against the two other bacterial species.  Increased numbers of
   precipitins against E. coli and B. fragilis were significantly
   associated with increased numbers of precipitins against P.
   aeruginosa.  It is suggested that this association is due to immune
   reactions in the intestinal mucosa, resulting in increased
   absorption of antigens from the gut.
RF 001   BJORNEBOE M           LANCET                           1    58 972
   002   DIEM K                DOCUMENTA GEIGY SCIENTIFIC TA            962
   003   FINEGOLD SM           ANAEROBIC BACTERIA HUMAN DIS             977
   004   GIBBONS A             BR MED J                         1   120 976
   005   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   006   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   007   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   008   HOIBY N               SCAND J RESPIR DIS              56    38 975
   009   HOIBY N               SCAND J IMMUNOL SUPPL 2          4   187 975
   010   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   85   142 977
   011   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     1 977
   012   MCFARLANE H           BR MED J                         1   423 975
   013   SASAKI M              JAPAN J EXP MED                 45   335 975
   014   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   86    37 978
   015   SCHWAB JH             BACT REV                        39   121 975
   016   SKIDMORE BJ           J IMMUNOL                      114   770 975
   017   THERKELSEN AJ         MEDICINSK STATISTIK AKADEMISK            968
   018   TOLO K                IMMUNOLOGY                      33   733 977
   019   WALLWORK JC           CLIN EXP IMMUNOL                18   303 974
   020   WALLWORK JC           CLIN ALLERGY                     6   349 976
   021   WEEKE B               SCAND J IMMUNOL SUPPL 1          2    15 973
   022   WEEKE B               SCAND J IMMUNOL SUPPL 1          2    47 973
CT   1   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
     2   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   89   185 981
     3   KOCH C                ALLERGY                         37   191 982
     4   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
     5   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
     6   BERG RD               EOS RIV IMMUNOL IMMUNOFARMACO    5   161 985
     7   GOTZ M                MONATSSCHR KINDERHEILKD        133   718 985

PN 79004
RN 00984 
AN 79121155
AU Berg-N-O.  Dahlqvist-A.  Lindberg-T.
TI Exocrine pancreatic insufficiency, small intestinal dysfunction and
   protein intolerance.  A chance occurrence or a connection?.
SO Acta-Paediatr-Scand. 1979 Mar. 68(2). P 275-6.
MJ CELIAC-DISEASE: co.  CYSTIC-FIBROSIS: co.
MN CASE-REPORT.  CHILD.  DIPEPTIDASES: me.  DISACCHARIDASES: me.
   FEMALE.  GLUTEN: du.  HUMAN.  INTESTINAL-MUCOSA: en, pa.
   INTESTINE-SMALL: en, pa.  MALE.
AB The coexistence of cystic fibrosis (CF) and coeliac disease (CD) is
   reported in eight children, the odds against this occurring in the
   same child being 1:2 million to 1:5.9 million.  In Sweden, it would
   be around 1:3 million (incidence of CF 1:3000 and of CD 1:1000).
   The coexistence of these two diseases is thought to be chance,
   although CF might predispose to the development of CD.  In a 10-year
   period (with 33405 live births), we observed three children with
   exocrine pancreatic insufficiency and small intestine dysfunction.
RF 001   ANTONOWICZ I          PEDIATRICS                      42   492 968
   003   DAHLQVIST A           ACTA PAEDIATR SCAND             59   621 970
   004   GOODCHILD MC          ARCH DIS CHILD                  48   684 973
   005   KATZ AJ               PEDIATRICS                      57   715 976
   006   KOLLBERG H            ACTA UNIV UPSALIENSIS          192       974
   007   LEBENTHAL E           GASTROENTEROLOGY                70   508 976
   008   MORIN CL              J PEDIATR                       88   213 976
   009   SHMERLING DH          HELV PAEDIATR ACTA              24   547 969
   010   SHWACHMAN H           J PEDIATR                       65   645 964
CT   1   SJOSTROM H            J BIOL CHEM                    255  1332 980

PN 79005
RN 00985 
AN 79228250
AU Taussig-L-M.
TI Increased intracranial pressure in infants with cystic fibrosis
   [letter].
SO Acta-Paediatr-Scand. 1979 Jul. 68(4). P 615-6.
MJ CYSTIC-FIBROSIS: pp.  INTRACRANIAL-PRESSURE.
MN HUMAN.  INFANT.
EX Although the mechanism proposed by Dr Katznelson for the increased
   intracranial pressure observed in three infants with cystic fibrosis
   cannot be discounted, another explanation is possible.  It has been
   reported previously that a deficiency of vitamin A may predispose to
   development of increased intracranial pressure and bulging
   fontanelles in cystic fibrosis.  Finally, it is somewhat difficult to
   understand how such marked airway obstruction which produced
   increased intracranial pressure could occur with preservation of
   arterial blood gases. - Vitamin A and carotene blood levels were not
   determined in our cases and therefore obviously this possibility
   cannot be excluded, at least in two of the cases.  Dr Taussig's
   suggestion that the improvement in the intracranial pressure in our
   cases was really the result of the "unknowing" associated
   administration of vitamin A and not to the improvements in the
   pulmonary status, as I proposed, fails to note the clinical
   observation that there had been a "rise and fall" in the bulge of the
   fontanel concomitantly with the increase and decrease of respiratory
   obstruction signs.  As to the question of the severity of airway
   obstruction, the clinical reversible picture of severe tachypnea with
   poor air entry, clear lung fields on X-ray with overdistended lungs
   and small heart appear most suggestive of airway obstruction in C.F.
RF 001   KATZNELSON D          ACTA PAEDIATR SCAND             67   607 978
   002   KEATING JP            PEDIATRICS                      46    41 970

PN 79006
RN 00986 
AN 80150170
AU Schiotz-P-O.  Hoiby-N.
TI Precipitating antibodies against Haemophilus influenzae and
   Staphylococcus aureus in sputum and serum from patients with cystic
   fibrosis.
SO Acta-Pathol-Microbiol-Scand [B]. 1979 Dec. 87(6). P 345-51.
MJ ANTIBODIES-BACTERIAL: an.  CYSTIC-FIBROSIS: mi.
   HAEMOPHILUS-INFLUENZAE: im.  PRECIPITINS: an.  SPUTUM: mi.
   STAPHYLOCOCCUS-AUREUS: im.
MN ADOLESCENCE.  ADULT.  CHILD.  CROSS-REACTIONS.  CYSTIC-FIBROSIS: im.
   FEMALE.  HUMAN.  IMMUNOELECTROPHORESIS-TWO-DIMENSIONAL.  MALE.
AB Serum and sputum sol phase from 23 patients with cystic fibrosis (CF)
   were examined for occurrence and titres of precipitins against
   Haemophilus influenzae and Staphylococcus aureus by means of crossed
   immunoelectrophoresis with intermediate gel. The patients had from
   four to nine H. influenzae precipitins in serum and in most cases
   fewer precipitins in sputum, but, on an average, there was no
   difference between the titres of the antibodies in serum and sputum.
   Most of the antibodies were cross-reactive with other species,
   notably those of the Haemophilus genus. S. aureus precipitins were
   generally found in higher numbers in serum than in sputum, but, on an
   average, the titre of the precipitins in sputum was higher than in
   serum. Three of the precipitins were detectable only in sputum and
   not in serum, and one of these is a S. aureus-specific precipitin.
   Most of the antibodies were cross-reactive with other species, and
   these antibodies were often present in sputum in much higher titres
   than in the corresponding sera. Antibodies against teichoic acid of
   the S. aureus cell wall could not be demonstrated in sputum, while
   they were present in 22 sera. The possible role of the local
   pulmonary humoral immune response in protective immunity and in the
   pathology of the lung disease in CF is discussed.
RF 001   BROGAN TD             THORAX                          30    72 975
   002   DIEM K                DOCUMENTA GEIGY SCIENTIFIC TA            962
   003   GIBSON LE             PEDIATRICS                      23   545 959
   004   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   005   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   006   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   007   HOIBY N               SCAND J RESPIR DIS              56    38 975
   008   MAY JR                ARCH DIS CHILD                  47   908 972
   009   MEARNS MB             ARCH DIS CHILD                  47   902 972
   010   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   83   469 975
   011   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   86    37 978
   012   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (B)   87   337 979
   013   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (B)   87   329 979
CT   1   ESPERSEN F            ACTA PATH MICROBIOL SCAND (B)   88   237 980
     2   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   88   275 980
     3   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
     4   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
     5   PRESSLER T            ACTA PAEDIATR SCAND             73   541 984

PN 79007
RN 00987 
AN 80016770
AU Schiotz-P-O.  Hoiby-N.  Permin-H.  Wiik-A.
TI IgA and IgG antibodies against surface antigens of Pseudomonas
   aeruginosa in sputum and serum from patients with cystic fibrosis.
SO Acta-Pathol-Microbiol-Scand [C]. 1979 Jun. 87C(3). P 229-33.
MJ CYSTIC-FIBROSIS: im.  IGA.  IGG.  PSEUDOMONAS-AERUGINOSA: im.
   SPUTUM: im.
MN ADOLESCENCE.  ADULT.  ANTIBODIES-BACTERIAL.  ANTIGENS-BACTERIAL.
   ANTIGENS-SURFACE.  CHILD.  CHRONIC-DISEASE.  FEMALE.
   FLUORESCENT-ANTIBODY-TECHNIC.  HUMAN.
   IMMUNOELECTROPHORESIS-TWO-DIMENSIONAL.  MALE.
AB Eleven cystic fibrosis (CF) patients chronically infected in the
   lungs with mucoid Pseudomonas aeruginosa and presenting multiple
   precipitins in serum against this bacterium (CF + P) and 10 CF
   patients without P. aeruginosa infection (CF-P) had their serum and
   sputum sol phase specimens examined for antibodies of the IgA and IgG
   classes against surface antigens of P. aeruginosa by means of an
   indirect immunofluorescence technique. Both the IgA and IgG antibody
   titres demonstrated in serum and sputum of the CF + P patients were
   significantly higher than in those of the CF-P patients (p less than
   0.01). The titre of IgA antibodies in the sputum was higher than in
   serum in 3 cases indicating local pulmonary production of specific
   IgA antibodies. The role of the demonstrated antibodies in the local
   pulmonary immune defense mechanisms and the possible patogenesis of
   the pulmonary tissue damage in CF patients is discussed.
RF 001   BERGAN T              ACTA PATH MICROBIOL SCAND (B)   83   553 975
   002   BIGGAR WD             PROC NAT ACAD SCI USA           68  1716 971
   003   BJORNSON AB           J INFECT DIS SUPPL             130   119 974
   004   BJORNSON AB           J INFECT DIS SUPPL             130   127 974
   005   BOXERBAUM B           AM REV RESPIR DIS              108   777 973
   006   BROGAN TD             THORAX                          30    72 975
   007   DIEM K                DOCUMENTA GEIGY SCIENTIFIC TA            962
   008   DOGGETT RG            IN: LAWSON D PROC 5TH INT CF         175 969
   009   GIBSON LE             PEDIATRICS                      23   545 959
   010   GOVAN JRW             J MED MICROBIOL                  8   513 975
   011   HANN S                INFECT IMMUN                    14   114 976
   012   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   013   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   014   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   015   HOIBY N               SCAND J IMMUNOL SUPPL 2          4   187 975
   016   HOIBY N               SCAND J RESPIR DIS              58    65 977
   017   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   85   107 977
   018   KOCH C                ACTA PATH MICROBIOL SCAND (C)   83   144 975
   019   MCFARLANE H           BR MED J                         1   423 975
   020   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   83   469 975
   021   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   85    57 977
   022   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   86    37 978
   023   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   87     1 979
   024   WIIK A                IMMUNOLOGY                      23    53 972
   025   YOUNG LS              J INFECT DIS SUPPL             130   111 974
CT   1   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   88   275 980
     2   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   89   185 981
     3   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
     4   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    63 982
     5   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
     6   SCHILLER NL           PEDIATR RES                     17   747 983
     7   DORING G              J INFECT DIS                   147   744 983
     8   KOHLER B              Z KLIN MED                      40  1773 985
     9   BALTIMORE RS          PEDIATR RES                     20  1085 986

PN 79008
RN 00988 
AN 79162009
AU Schiotz-P-O.  Sorensen-H.  Hoiby-M.
TI Activated complement in the sputum from patients with cystic
   fibrosis.
SO Acta-Pathol-Microbiol-Scand [C]. 1979 Feb. 87C(1). P 1-5.
MJ COMPLEMENT-ACTIVATION.  COMPLEMENT.  CYSTIC-FIBROSIS: im.  SPUTUM: im.
MN ADOLESCENCE.  ADULT.  ALBUMINS: an.  CHILD.  CHRONIC-DISEASE.
   COMPLEMENT-3: an.  COMPLEMENT-4: an.  COMPLEMENT-5: an.
   COMPLEMENT: an.  CYSTIC-FIBROSIS: co.  FEMALE.  HUMAN.
   IMMUNOELECTROPHORESIS-TWO-DIMENSIONAL.  MALE.  PNEUMONIA: et, im.
   PSEUDOMONAS-INFECTIONS: et, im.  SERUM-ALBUMIN: an.
AB 14 cystic fibrosis (CF) patients chronically infected with mucoid P.
   aeruginosa and presenting multiple precipitins in serum against this
   bacterium (CF + P) and 13 CF patients without P. aeruginosa infection
   (CF-P) had their plasma and sputum sol phase examined for albumin,
   Clq. C3/C3c, C4 and C5 by means of electroimmunoassays. Their sputum
   sol phase was examined also for factor B by
   rocketimmunoelectrophoresis. C3c was demonstrated in the sputum sol
   phase but significantly more frequent (p less than 0.01) among the CF
   + P patients than among the CF-P patients. Factor B was also
   demonstrated in the sputum sol phase, but no significant difference
   in frequency could be demonstrated between the CF + P and the CF-P
   patients. None of the results indicated that a local pulmonary
   production of complement factors took place. Complement activation
   was significantly (p less than 0.01) associated with inflammation
   expressed as increased (formula: see text). The results show the
   importance of complement mediated inflammation in the pathogenesis of
   pulmonary tissue damage in patients with CF and support the concept
   of chronic P. aeruginosa lung infection as an immune complex disease
   in CF patients.
RF 001   BROGAN TD             THORAX                          30    72 975
   002   DIEM K                DOCUMENTA GEIGY SCIENTIFIC TA            962
   003   GEWURTZ H             J EXP MED                      128  1049 968
   004   GIBSON LE             PEDIATRICS                      23   545 959
   005   GREENBLATT J          INFECT IMMUN                    19   296 978
   006   HOFF GE               ACTA PATH MICROBIOL SCAND (B)   83   219 975
   007   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   008   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   009   HOIBY N               SCAND J RESPIR DIS              58    65 977
   010   LAURELL CB            SCAND J CLIN LAB INVEST SUPPL  124    21 972
   011   NELSON RA JR          IN: ZWEIFACH BW                  3    37 974
   012   REYNOLDS HY           J LAB CLIN MED                  84   559 974
   013   ROBERTSON J           J IMMUNOL                      117   900 976
   014   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   83   469 975
   015   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   85    57 977
   016   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   86    37 978
   017   STALENHEIM G          IMMUNOCHEMISTRY                 10   501 973
   018   TEISBERG P            CLIN CHIM ACTA                  62    35 975
   019   THUESEN-PEDERSEN J    DAN MED BULL                    21    12 974
CT   1   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   87   229 979
     2   ETIEVANT M            ANN IMMUNOL (PARIS)           D131    13 980
     3   SKOV PS               ALLERGY                         35    23 980
     4   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   88   275 980
     5   SMITH TF              INFECT IMMUN                    33    43 981
     6   MOSS RB               CLIN EXP IMMUNOL                47   301 982
     7   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
     8   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    63 982
     9   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
    10   SCHIOTZ PO            ACTA PAEDIATR SCAND             72   283 983
    11   PIER GB               J INFECT DIS                   150   223 984
    12   SORDELLI DO           EUR J RESPIR DIS                67   118 985
    13   GOTZ M                MONATSSCHR KINDERHEILKD        133   718 985
    14   KHARAZMI A            EUR J CLIN INVEST               16   143 986
    15   HOIBY N               ANNU REV MICROBIOL              40    29 986
    16   EDWARDS KM            ARCH VIROL                      88    49 986
    17   MOSS RB               AM REV RESPIR DIS              133   648 986

PN 79009
RN 00989 
AN 80084554
AU Schiotz-P-O.  Egeskjold-E-M.  Hoiby-N.  Permin-H.
TI Autoantibodies in serum and sputum from patients with cystic
   fibrosis.
SO Acta-Pathol-Microbiol-Scand [C]. 1979 Oct. 87(5). P 319-24.
MJ AUTOANTIBODIES: an.  CYSTIC-FIBROSIS: im.  SPUTUM: im.
MN ADOLESCENCE.  ADULT.  ANTINUCLEAR-FACTORS: an.  CHILD.
   CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: co.  DNA: im.  FEMALE.
   FLUORESCENT-ANTIBODY-TECHNIC.  HUMAN.  IGA: an.  IGG: an.  IGM: an.
   IMMUNOELECTROPHORESIS-TWO-DIMENSIONAL.  LATEX-FIXATION-TESTS.  MALE.
   PSEUDOMONAS-AERUGINOSA.  PSEUDOMONAS-INFECTIONS: co, im.
   RHEUMATOID-FACTOR: an.
AB Sera from 89 patients with cystic fibrosis (CF) and 88 control
   persons were examined for the occurrence of rheumatoid factors (RF)
   of the IgG, IgA and IgM classes by an indirect immunofluorescence
   method and by the latex fixation slide test. The prevalence of RF-IgG
   was significantly higher (88%) (p less than 0.0005) among the CF
   patients than among the control persons (7%), while no difference was
   found between the two groups with regard to RF of the IgA or IgM
   classes. Fifty-five of the CF patients had chronic Pseudomonas
   aeruginosa infection in their lungs and two or more precipitins
   against these bacteria in their sera determined by crossed
   immunoelectrophoresis. These CF patients did not differ from the 34
   CF patients without chronic P. aeruginosa infection, neither with
   regard to prevalence nor titer of RFs, but there was a positive
   correlation between the number of P. aeruginosa precipitins in the 55
   chronically infected CF patients and their titers of IgG-RF. Nineteen
   CF patients were examined also for RFs, antinuclear antibodies (ANA)
   and anti-DNA antibodies in their sputum sol phase and corresponding
   sera. RFs were demonstrated in the sputum sol phase from 6 of the
   patients by the latex fixation test, whereas their sera were negative
   in this test, possibly indicating a local production of RF. Positive
   reactions for ANA and anti-DNA antibodies were found in 7 and 10 of
   the sputa respectively, and in higher titers than in the
   corresponding sera, also suggesting a local production. Titers of
   autoantibodies in sputum were low and no difference was found between
   patients with chronic P. aeruginosa infection and patients without P.
   aeruginosa infection. The possible role of autoantibodies in the
   patogenesis of pulmonary tissue damage in CF patients is discussed.
RF 001   BARTFELD H            ANN NY ACAD SCI                168    30 969
   002   BONOMO L              AM J CLIN PATHOL                45   313 966
   003   BROGAN TD             THORAX                          30    72 975
   004   CARSON DA             CLIN EXP IMMUNOL                31   100 978
   005   DEHORATIUS RJ         ARCH INTERN MED                129   441 972
   006   DEHORATIUS RJ         ARTHRITIS RHEUM                 15   293 972
   007   DIEM K                DOCUMENTA GEIGY SCIENTIFIC TA            962
   008   ESTES D               ARTHRITIS RHEUM                 16    59 973
   009   GIBSON LE             PEDIATRICS                      23   545 959
   010   HODSON ME             BR J DIS CHEST                  70    83 976
   011   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   012   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   013   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   014   HOIBY N               SCAND J RESPIR DIS              56    38 975
   015   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   85   107 977
   016   HOIBY N               SCAND J RESPIR DIS              58    65 977
   017   KALLERUP HE           SCAND J RHEUMATOL                8     1 979
   018   KOFFLER D             J EXP MED                      126   607 967
   019   KOFFLER D             J EXP MED                      134   169 971
   020   LIEBERMAN J           LAB INVEST                      14   249 965
   021   LIND I                SCAND J IMMUNOL                  3   689 974
   022   MCCORMICK JN          IN: DUMONDE D                         68 976
   023   MCFARLANE H           BR MED J                         1   423 975
   024   MUNTHE E              CLIN EXP IMMUNOL                 8   249 971
   025   PERMIN H              ACTA MED SCAND                 203    61 978
   026   RHEINS MS             J LAB CLIN MED                  50   113 957
   027   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   83   469 975
   028   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   85    57 977
   029   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   86    37 978
   030   TAN EM                J CLIN INVEST                   45  1732 966
   032   THUESEN-PEDERSEN J    DAN MED BULL                    21    12 974
   033   TURNER-WARWICK M      BR MED J                         3   492 970
   034   WALLER M              J INFECT DIS                   125    45 972
   035   WIIK A                IMMUNOLOGY                      23    53 972
   036   WIIK A                ANN RHEUM DIS                   33   515 974
   037   WINCHESTER RJ         CLIN EXP IMMUNOL                 6   689 970
CT   1   EGESKJOLD EM          ALLERGY                         36   573 981
     2   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   89   185 981
     3   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
     4   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    63 982
     5   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
     6   EGESKJOLD EM          SCAND J RHEUMATOL               14    51 985
     7   DISIS ML              PEDIATR RES                     20   385 986
     8   LIMSCHOU EME          DAN MED BULL                    33   249 986
     9   HOIBY N               ANNU REV MICROBIOL              40    29 986

PN 79010
RN 00990 
AN 80172132
AU Taussig-L-M.  Lemen-R-J.
TI Chronic obstructive lung disease.
SO Adv-Pediatr. 1979. 26. P 343-416. (REVIEW).
MJ LUNG-DISEASES-OBSTRUCTIVE.
MN AIRWAY-OBSTRUCTION: di.  ASTHMA: di.  ATELECTASIS: di.
   BRONCHIAL-DISEASES: di.  CYSTIC-FIBROSIS: di.  HUMAN.
   HYPOVENTILATION: et.  IMMUNOLOGIC-DEFICIENCY-SYNDROMES: di.
   LUNG-DISEASES-OBSTRUCTIVE: di, et, th.  MEDICAL-HISTORY-TAKING.
   PHYSICAL-EXAMINATION.  PNEUMONIA-ASPIRATION: di.  REVIEW.
   TRACHEAL-DISEASES: di.
EX This chapter deals with the problems of chronic obstructive lung
   disease in children by first considering an approach to the
   evaluation, diagnosis and management of various forms of chronic
   obstructive lung disease with emphasis on history, physical and
   laboratory data.  A brief overview of therapeutic principles that can
   be applied to most forms of chronic obstructive lung disease are
   included.  The second part of this chapter consists of reviews of
   some of the more common diseases producing chronic airway obstruction
   in infancy and childhood.  Patient evaluation topics discussed
   include history and physical examination and laboratory studies.
   Therapeutic principles in the management of chronic obstructive lung
   disease, pediatric precursors of chronic obstructive lung disease,
   and chronic obstructive lung disorders (asthma, cystic fibrosis,
   bronchopulmonary dysplasia, aspiration pneumonitis, atelectasis,
   bronchomalacia and tracheomalacia, immunodeficiency, bronchiectasis,
   chronic bronchitis, and chronic upper airway obstruction with
   hypoventilation) are examined.
RF 001   TAUSSIG LM            ARIZ MED                        33   205 976
   002   HOLSCLAW DS           PEDIATR ANN                      6   438 977
   003   ANON                  US NATL HEALTH SURVEY                    975
   004   WARING WW             RESPIR CARE                     20  1138 975
   005   HOGG JC               IN: KENDIG EL JR                         977
   006   DUNNILL MS            THORAX                          17   329 962
   007   WILLIAMS HE           RESPIRATORY ILLNESS IN CHILDR            975
   008   TAUSSIG LM            AM REV RESPIR DIS              116   233 977
   009   WARING WW             IN: KENDIG EL JR                     105 977
   010   SMITH CB              RADIOL CLIN NORTH AM            11   261 973
   011   FLETCHER BD           IN: KENDIG EL JR                         977
   012   LEMEN RG              IN: KENDIG EL JR                     166 977
   013   POLGAR G              PULMONARY FUNCTION TESTING IN            971
   014   ANON                  GAP CONF REP PROB SWEAT TESTI            975
   015   ANON                  J PEDIATR                       88   711 976
   016   GODFREY S             EXERCISE TESTING IN CHILDREN             974
   017   WARING WW             DIAGNOSTIC PROCEDURES PRACTIC            975
   018   EULER AR              PEDIATRICS                      60    65 977
   019   CHRISTIE DL           J PEDIATR                       93    23 978
   020   JONES FL JR           IN: JOHNSTON RF                          973
   021   RICKARD K             PEDIATR CLIN NORTH AM           24   157 977
   022   SUSKIND RM            MALNUTRITION AND THE IMMUNE R    7       977
   023   HAMBRAEUS L           PEDIATR CLIN NORTH AM           24    17 977
   024   FELDMAN J             AM REV RESPIR DIS              119   239 979
   025   HARTSELL M            AM REV RESPIR DIS              117   204 978
   026   WARING WW             IN: KENDIG EL JR                      77 977
   027   TAUSSIG LM            J PEDIATR                       84   619 974
   028   KEENS TG              AM REV RESPIR DIS              116   853 977
   029   MACKOWIAK PA          N ENGL J MED                   298    21 978
   030   AMMANN AJ             N ENGL J MED                   297   897 977
   031   AUSTRIAN R            N ENGL J MED                   297   938 977
   032   MONSET-COUCHARD M     CURR PROB PEDIATR NO 4           5       975
   033   LUCAS RV              MINN MED                        52  1537 969
   034   HEINEMANN H           AM J MED                        64   367 978
   035   BERGLUND E            AM J CARDIOL                    11   477 963
   036   BLAND R               J CLIN INVEST                   62   601 978
   037   TAUSSIG LM            PEDIATR RES                     11   216 977
   038   KERREBIJN KF          ACTA PAEDIATR SCAND SUPPL      261     3 977
   039   LANG WR               BR MED J                         1    73 969
   040   GOLD R                J CAN ASSOC RADIOL              20   218 969
   041   BECROFT DMO           J CLIN PATHOL                   24    72 971
   042   COLLEY JRT            BR MED J                         2   213 970
   043   COLLEY JRT            BR MED BULL                     27     9 971
   044   HOLLAND WW            BR MED J                         2   205 969
   045   DOUGLAS JWB           BR J PREV SOC MED               20     1 966
   046   ZAPLETAL A            AM REV RESPIR DIS              107   400 973
   047   HARLAP S              LANCET                           1   529 974
   048   COLLEY JRT            LANCET                           2  1031 974
   049   COLLEY JRT            BR MED J                         2   201 974
   050   BLAND M               ARCH DIS CHILD                  53   100 978
   051   LEBOWITZ MD           CHEST                           69    48 976
   052   SCHILLING RSF         AM J EPIDEMIOL                 106   274 977
   053   SEELY JE              SCIENCE                        172   741 971
   054   HAYNES WF JR          AM REV RESPIR DIS SUPPL         93   730 966
   055   COLLEY JRT            BR MED J                         3   195 973
   056   KIERNAN KE            RESPIRATION                     33   236 976
   057   BURROWS B             AM REV RESPIR DIS              115   751 977
   058   LOUGHLIN GM           J PEDIATR                       94   365 979
   059   BECKERMAN RC          PEDIATR RES                     12   559 978
   060   KATTAN M              PEDIATRICS                      59   683 977
   061   SIMS DG               BR MED J                         1    11 978
   062   KONIG P               ARCH DIS CHILD                  47   578 972
   063   ROONEY JC             J PEDIATR                       79   744 971
   064   ZWEIMAN B             J ALLERGY                       37    48 966
   065   HILL DJ               AM REV RESPIR DIS              106   873 972
   066   MCFADDEN ER JR        J ALLERGY CLIN IMMUNOL          56    18 975
   067   PALMER KNV            BR MED J                         1   485 975
   068   BLAIR H               ARCH DIS CHILD                  52   613 977
   069   BURANAKUL B           AM J DIS CHILD                 128   343 974
   070   DEES SC               ADV ASTHMA ALLERGY               1    12 974
   071   LEVISON H             PEDIATR CLIN NORTH AM           21   951 974
   072   GOLD WM               J APPL PHYSIOL                  33   496 972
   073   OLIVE JT              AM REV RESPIR DIS              106   366 972
   074   TSUCHIYA Y            J ALLERGY                       36   514 965
   075   TURIAF J              REV TUBERC                      26   238 962
   076   INNES IR              IN: GOODMAN LS                       447 975
   077   SCHAER H              PFLUEGERS ARCH                 347   297 974
   078   STALCUP SA            N ENGL J MED                   297   592 977
   079   GALANT SP             PEDIATRICS                      61    46 978
   080   MCFADDEN ER JR        N ENGL J MED                   288   221 973
   081   EGGLESTON PA          PEDIATRICS                      54   442 974
   082   WEISS EB              CIBA FOUND SYMP                 27    71 975
   083   WEINBERGER M          POSTGRAD MED J                  61    85 977
   084   CHAI H                ADV ASTHMA ALLERGY               2     1 975
   085   BIERMAN CW            PEDIATRICS                      54   245 974
   086   WALSON PD             J PEDIATR                       91   321 977
   087   KOCH-WEBER J          N ENGL J MED                   297   476 977
   088   INGRAM RH JR          AM REV RESPIR DIS              101   364 970
   089   WOOD DW               ANN ALLERGY                     31   607 973
   090   PIERSON WE            PEDIATRICS                      54   282 974
   091   BERMAN SZ             J ALLERGY CLIN IMMUNOL          56   206 975
   092   MCINTOSH K            J PEDIATR                       82   578 973
   093   SHAPIRO GG            PEDIATRICS                      53   867 974
   094   MINOR TE              JAMA                           227   292 974
   095   TAUSSIG LM            IN: KELLEY VC                    4     1 976
   096   NADLER HL             IN: STANBURY JB                     1683 978
   097   WOOD RE               AM REV RESPIR DIS              113   833 976
   098   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   099   ZUELZER WW            PEDIATRICS                       4    53 949
   100   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   101   BEDROSSIAN CWM        HUM PATHOL                       7   195 976
   102   LAMARRE A             PEDIATRICS                      50   291 972
   103   LANDAU LI             AM REV RESPIR DIS              108   593 973
   104   ZAPLETAL A            PEDIATRICS                      48    64 971
   105   FOX WW                PEDIATRICS                      54   293 974
   106   LANDAU LI             AM REV RESPIR DIS              111   725 975
   107   TAUSSIG LM            J PEDIATR                       84   724 974
   108   LLOYD-STILL JD        PEDIATRICS                      53   678 974
   109   FELLOWS KE            RADIOLOGY                      114   551 975
   110   HOLSCLAW DS           J PEDIATR                       76   829 970
   111   STRUNK RC             ARCH DIS CHILD                  52   687 977
   112   MCFARLANE H           BR MED J                         1   423 975
   113   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   85    57 977
   114   SCHWARTZ RH           AM J DIS CHILD                 120   432 970
   115   WARREN CPW            CLIN ALLERGY                     5     1 975
   116   BARDANA EJ JR         AM J DIS CHILD                 129  1164 975
   117   GALANT SP             AM REV RESPIR DIS              114   325 976
   118   LANDAU LI             J PEDIATR                       82   863 973
   119   SHAPIRO GG            PEDIATRICS                      58   740 976
   120   WARNER JO             ARCH DIS CHILD                  51   507 976
   121   TALAMO RC             IN: MANGOS JA                        195 976
   122   SCHWARTZ RH           AM J DIS CHILD                 111   408 966
   123   MARTINEZ-TELLO FJ     J IMMUNOL                      101   989 968
   124   PENNINGTON JE         AM J MED                        58   629 975
   125   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   559 974
   126   BIGGAR WD             PROC NAT ACAD SCI USA           68  1716 971
   127   BOXERBAUM B           AM REV RESPIR DIS              108   777 973
   128   STEIN AA              J PEDIATR                       65   495 964
   129   HOIBY N               SCAND J RESPIR DIS              56    38 975
   130   HODSON ME             BR J DIS CHEST                  70    83 976
   131   ORENSTEIN DM          AM J DIS CHILD                 131   973 977
   132   WARWICK WJ            J CHRON DIS                     28   609 975
   133   WARING WW             ADV PEDIATR                     23   401 976
   134   THOMPSON T            J PERINATAL MED                  5   149 977
   135   NORTHWAY WH JR        N ENGL J MED                   276   357 967
   136   BENOIST MR            BULL EUR PHYSIOPATH RESP        12   703 976
   137   JOHNSON JD            J PEDIATR                       84   272 974
   138   RHODES PG             PEDIATRICS                      55   788 975
   139   HARROD JR             J PEDIATR                       84   277 974
   140   SPOELSTRA AJG         BIOL NEONATE                    17   321 971
   141   SHEPARD FM            N ENGL J MED                   279  1063 968
   142   BOSS JA               PEDIATRICS                      29   890 962
   143   TAGHIZADEH A          AM J PATHOL                     82   241 976
   144   ANDERSON WR           ARCH PATHOL                     91   506 971
   145   LALANDE J             ANN RADIOL (PARIS)              15   R74 973
   146   STAHLMAN M            PEDIATR CLIN NORTH AM           20   433 973
   147   BRYAN MH              PEDIATRICS                      52   169 973
   148   OUTERBRIDGE EW        AM J DIS CHILD                 123    99 972
   149   LAMARRE A             AM REV RESPIR DIS              108    56 973
   150   WESTGATE HD           DIS CHEST                       55   465 969
   151   WATTS JL              PEDIATRICS                      60   273 977
   152   STOCKS J              PEDIATRICS                      57   352 976
   153   BARNES ND             LANCET                           2  1096 969
   154   COATES AL             J PEDIATR                       90   611 977
   155   EDWARDS DK            PEDIATRICS                      59   839 977
   156   DELEMOS R             ANESTHESIOLOGY                  30   609 969
   157   LEE CJ                J THORAC CARDIOVASC SURG        53   759 967
   158$  NASH G                ARCH PATHOL                     21   234 971
   159   BERG TJ               PEDIATRICS                      55    51 975
   160   FLETCHER BD           ANN RADIOL (PARIS)              16   R78 973
   161   PHILIP AGS            PEDIATRICS                      55    44 975
   162   REYNOLDS EOR          ARCH DIS CHILD                  49    50 974
   163   LILAND AE             J SURG RES                      20    85 976
   164   RASCHE RFH            PEDIATRICS                      50   632 972
   165   SAHEBJAMI H           AM REV RESPIR DIS              110   566 974
   166   BADEN M               PEDIATRICS                      50   526 972
   167   PINNEY MA             PEDIATRICS                      58   856 976
   168   MCNAMARA JJ           PEDIATRICS                      43   527 969
   169   DAVIS MV              ANN THORAC SURG                  3    99 967
   170   HERBST JJ             J PEDIATR                       92    73 978
   171   LEAPE LL              PEDIATRICS                      60   924 977
   172   WILLIAMS HE           RESPIRATORY ILLNESS IN CHILDR            975
   173   JOHNSON DG            PEDIATRICS                      59    62 977
   174   JAMES V               Q J MED                         25   121 956
   175   WARING WW             PEDIATRICS                      39   166 967
   176   NEMIR RL              IN: KENDIG EL JR                     553 977
   177   STANGER P             PEDIATRICS                      43   760 969
   178   WILLIAMS H            ARCH DIS CHILD                  35   182 960
   179   WILLIAMS HE           ARCH DIS CHILD                  47   423 972
   180   GUPTA TCM             AM J DIS CHILD                 115    88 968
   182   AGOSTI E              ACTA PAEDIATR SCAND             63   616 974
   183   WAYNE KS              AM REV RESPIR DIS              114    15 976
   184   LANDING BH            PERSPECT PEDIATR PATHOL          1       973
   185   EIGEN H               AM REV RESPIR DIS              113   823 976
   186   JONES JF              ARIZ MED                        33   359 976
   187   POLMAR SH             IN: KIRKPATRICK CH                   191 976
   188   STIEHM ER             IMMUNOL DISORD INFANT CHILD          145 973
   189   AMMANN AJ             CURR PROB PEDIATR                5       975
   190   BACHMANN R            SCAND J CLIN LAB INVEST         17   316 965
   191   HUGHES WT             N ENGL J MED                   297  1381 977
   192   FIELD CE              ARCH DIS CHILD                  44   551 969
   193   WIGLESWORTH FW        MCGILL MED J                    24   189 955
   194   ELIASSON R            N ENGL J MED                   297     1 977
   195   GLAUSER EM            ACTA PAEDIATR SCAND SUPPL      165       966
   196   LANDAU LI             THORAX                          29   304 974
   197   MOORE JR              SURG GYNECOL OBSTET             89   146 949
   198   STRANG LB             ARCH DIS CHILD                  35   224 960
   199   AVERY ME              BULL JOHNS HOPKINS HOSP        109    20 961
   200   CHERNIACK RM          RESPIRATION IN HEALTH AND DIS        331 972
   201   MCNAMARA MJ           AM REV RESPIR DIS              100    19 969
   202   GUMP DW               AM REV RESPIR DIS              113   465 976
   203   MCFADDEN ER JR        N ENGL J MED                   292   555 975
   204   HIRSCH SR             CHEST                           63     9 973
   205   BURROWS B             ANN INTERN MED                  77   993 972
   206   NOONAN JA             CIRCULATION SUPPL 2             32   164 965
   207   MENASHE VD            J PEDIATR                       67   198 965
   208   LUKE MJ               PEDIATRICS                      37   762 966
   209   AINGER LE             BR HEART J                      30   356 968
   210   DJALILIAN M           MAYO CLIN PROC                  50    11 975
   211   GUILLEMINAULT C       PEDIATRICS                      58    23 976
   212   PERLMAN M             ARCH DIS CHILD                  50   727 975
   213   COGSWELL JJ           ARCH DIS CHILD                  49   520 974
CT   1   POLGAR G              WIEN KLIN WOCHENSCHR            95    14 983
     2   COLOMBO JL            PEDIATR PULMONOL                 3    86 987

PN 79011
RN 00991 
AN 80172130
AU Antonowicz-I.  Shwachman-H.
TI Meconium in health and in disease.
SO Adv-Pediatr. 1979. 26. P 275-310. (REVIEW).
MJ INFANT-NEWBORN-DISEASES: pa.  INTESTINAL-OBSTRUCTION: pa.
   MECONIUM: an.
MN CYSTIC-FIBROSIS: di, en, pa.  HUMAN.  INFANT-NEWBORN.
   INFANT-NEWBORN-DISEASES: di.  INTESTINAL-OBSTRUCTION: di.
   MASS-SCREENING.  MECONIUM: en.  REVIEW.
EX Meconium is the first gastrointestinal excretion normally expelled by
   the neonate.  This review discusses the composition of meconium:
   proteins, lipids, steroid and sterols, bile pigments and bile acids,
   glycoproteins, mineral composition, and enzymes.  The major
   complications relating to meconium are serious: they include
   aspiration pneumonia, which may prove fatal and is not related to
   cystic fibrosis, the "meconium plug syndrome" and meconium ileus.
   Screening for cystic fibrosis is also examined.
RF 001   EMERY JL              ARCH DIS CHILD                  32    17 957
   002   WINDLE WF             PHYSIOLOGY OF THE FETUS                  940
   003   POLLIFRONI GC         LATTANTE                        23   331 952
   004   JIRASEK JE            ACTA HISTOCHEM                  22    33 965
   005   SCHAFFER AJ           DISEASES OF THE NEWBORN              267 971
   006   SHERRY SN             J PEDIATR                       46   158 955
   007   ZACHARY RB            PROG PEDIATR SURG                2    57 971
   008   GRULEE CG             NEWBORN PHYSIOLOGY AND CA                926
   009   DAVY J                MEDICO CHIRURGICAL TRANS        27   189 844
   010   RAPOPORT S            SCIENCE                        112   150 950
   011$  FELDMAN WM            PRINCIPLES OF ANE NATAL              191 920
   013   YOSIDA KI             Z GESAMTE EXP MED               63   331 928
   014$  OKAJIMA S             JAPAN J MED SCI VII SOC MED H    3    54 940
   015   BUCHANAN DJ           PROC SOC EXP BIOL MED           77   114 951
   016   BUCHANAN DJ           J BIOL CHEM                    192   251 951
   017   PUTKONEN T            ACTA MED FENN DUODENUM (A)               930
   018   ODIN L                ACTA CHEM SCAND                  9   862 955
   019   SCHACHTER H           CAN J BIOCHEM                   43   381 965
   020   KIMURA A              SEIKAGAKU                       36   454 964
   021   CURTAIN CC            AUST J EXP BIOL MED SCI         31   349 953
   022   BUCHANAN DJ           PEDIATRICS                       9   304 952
   023   GREEN MN              PEDIATRICS                      21   635 958
   024   SCHUTT WH             ARCH DIS CHILD                  43   178 968
   025   KNAUFF RE             PROC SOC EXP BIOL MED          127   801 968
   026   BERNHARD K            HELV CHIM ACTA                  39  1443 956
   027   KINSELLA RA JR        J CLIN ENDOCRINOL METAB         32   801 971
   028$  ENEROTH P             FEBS                           3-4   129 969
   029   GUSTAFSSON JA         PROC R SOC LOND BIOL           180   179 972
   030   BACK P                HOPPE SEYLERS Z PHYSIOL CHEM   354    83 973
   031   LAVY U                J LIPID RES                     18   232 977
   032   BROWN AK              IN: SMITH CA                         323 976
   033$  WATKINS JB            IN: PAUMGARTNER G                   3582 976
   034   DELEZE G              EXP J CLIN INVEST                8    41 978
   035   SHARP HL              PEDIATR RES                      5   274 971
   036   FRASER D              CLIN CHIM ACTA                  59   301 975
   037   SCHRAGER J            ARCH ORAL BIOL                  16   287 971
   038   BOUCHIER IAD          CLIN CHIM ACTA                  35   219 971
   039   BROGAN TD             BIOCHEM J                       71   125 959
   040   BROGAN TD             BR J EXP PATHOL                 41   288 960
   041   OATES MDG             BIOCHEM J                       97   697 965
   042   HOUGH L               CARBOHYD RES                    23     1 972
   043   DISCHE Z              ARCH BIOCHEM BIOPHYS           135     1 969
   044   LIEBERMAN J           GASTROENTEROLOGY                50   183 966
   046   EMERY JL              ARCH DIS CHILD                  27   257 952
   047   SHIVELY JA            AM J CLIN PATHOL                22  1220 952
   048   DE FILIPPI F          PEDIATRICS                      15   114 954
   049   MACCHIA A             RIV PEDIAT SICILIANA            12   285 967
   050   EGGERMONT E           BIOL NEONATE                    10   266 966
   051   ANTONOWICZ I          GASTROENTEROLOGY                72  1299 977
   052   EGGERMONT E           ACTA GASTROENTEROL BELG         34   655 971
   053   FOMINA LS             VOPR MED KHIM                    2       956
   054   ZWEIFEL               ARCH J GYNAEK                    7   474 875
   055   MULLER F              Z BIOL                          20   327 884
   056   WIDDOWSON EM          LANCET                           2   373 962
   057   KOPITO L              J PEDIATR                       68   313 966
   058   DESROCHES A           J GYN OBSTET BIOL REPR           3   321 974
   059   SCHWARZ E             ANN PAEDIATR                   181   306 953
   060   LINDBERG T            CLIN SCI                        30   505 966
   061   GRUNDIG CA            ACTA BIOL MED GER               19   193 967
   062   POTTEVIN MH           C R SOC BIOL (PARIS)            11   589 900
   063   GALERNE D             J GYN OBSTET BIOL REPR           2   969 973
   064   GEYER VH              Z KLIN CHEM KLIN BIOCHEM         8   145 970
   065   DAHLQVIST A           CLIN SCI                        30   517 966
   066   ANTONOWICZ I          PEDIATRICS                      56   782 975
   067   AURICCHIO S           PEDIATRICS                      35   944 965
   068   SHEEHY TW             AM J DIS CHILD                 121   464 971
   069   ANTONOWICZ I          GASTROENTEROLOGY                67    51 974
   070   ANTONOWICZ I          BIOL NEONATE                    32   280 977
   071   ANDERSEN H            ACTA PATH MICROBIOL SCAND       61   377 964
   072   WATZKA M              VERH ANAT GES                   66       971
   073   BIERRING F            ACTA PATH MICROBIOL SCAND       61   365 964
   074   LEV R                 HISTOCHEMIE                     29   103 972
   076   TAKIMOTO M            BIOL NEONATE                    18    66 971
   077   ELIAKIS E             MED LEG DOMM CORP                4   163 971
   078   ASENSIO C             MEDICAMENTA MARK                15    51 956
   079   HERNANDEZ-JODRA M     ENZYME                          12   682 971
   081   CLATWORTHY HW         SURGERY                         39   131 956
   082   ROSENSTEIN BJ         AM J DIS CHILD                 132   167 978
   083   EMERY JL              ARCH DIS CHILD                  29    34 954
   084   GRIFFITHS AD          BIORHEOLOGY                     13   225 976
   085   YOUNG DM              PROC SOC EXP BIOL MED           99   673 958
   086   FARBER S              J PEDIATR                       24   387 944
   087   NOBLETT HR            J PEDIATR SURG                   4   190 969
   088   GLANZMANN E           ANN PAEDIATR                   175    33 950
   089   LANDSTEINER K         ZENTRALBL ALLG PATHOL           16   903 905
   090   NEUHAUSER EBD         RADIOLOGY                       46   319 946
   091   DONNISON AB           PEDIATRICS                      37   833 966
   092   HOLSCLAW DS           AM J DIS CHILD                 109   101 965
   093   ANON                  CF FND 1976 REP SURVI STUD PA          3 973
   094   BERNSTEIN JG          AM J DIS CHILD                  99   804 960
   095   GROSS RE              SURGERY OF INFANCY AND CHILDH            953
   096   SANTULLI TV           IN: BENSON CD                            953
   097   BISHOP HC             ANN SURG                       145   410 957
   098   SHWACHMAN H           IN: KENDIG EL JR                 1   524 972
   099   ELIAN E               N ENGL J MED                   264    13 961
   100   GREEN MN              PEDIATRICS                      21   635 958
   101   WISER WC              PEDIATRICS                      33   115 964
   102   CHODOS DD             PROC SOC EXP BIOL MED           99   775 958
   103   RULE AH               PEDIATRICS                      45   847 970
   104   RULE AH               PEDIATRICS                      48   601 971
   105   RYLEY HC              ARCH DIS CHILD                  49   901 974
   106   PECAU Y               BIOL GASTROENTEROL               8   193 975
   107   ZUELZER WW            PEDIATRICS                       4    53 949
   108   OPPENHEIMER EH        ARCH PATHOL                     96   149 973
   109   THOMAIDIS TS          J PEDIATR                       63   444 963
   110   HINDEN E              ARCH DIS CHILD                  25    99 950
   111   STEPHAN U             IN: MANGOS JA                        281 973
   112   GOTTSCHALK B          DTSCH GESUNDHEITSW              32  2439 977
   113   HOLSCLAW DS           PEDIATR ANN                      7    29 968
   114   STEPHAN U             PEDIATRICS                      55    35 975
   116   ALPERS DH             BIOCHIM BIOPHYS ACTA           401    28 975
   117   SEETHARAM B           LIFE SCI                        18    89 976
   118   ANTONOWICZ I          LANCET                           1   746 976
   119   SHWACHMAN H           AM J DIS CHILD                 132   112 978
   120   SHWACHMAN H           IN: MANGOS JA                        277 973
CT   1   PARK RW               GASTROENTEROLOGY                81  1143 981
     2   KNIGHT PJ             SURGERY                         89   332 981
     3   SHWACHMAN H           J PEDIATR SURG                  18   570 983
     4   KOPELMAN H            N ENGL J MED                   312   329 985
     5   EGGERMONT E           ACTA PAEDIATR SCAND SUPPL 317 1985    16 985
     6   DEHNER LP             HUM PATHOL                      17   807 986
     7   KING A                PEDIATR RES                     20   536 986
     8   HUNSINGER RN          CLIN CHIM ACTA                 156   165 986

PN 79012
RN 00992 
AN 79184947
AU Palin-D.  Underwood-B-A.  Denning-C-R.
TI The effect of oral zinc supplementation on plasma levels of vitamin
   A and retinol-binding protein in cystic fibrosis.
SO Am-J-Clin-Nutr. 1979 Jun. 32(6). P 1253-9.
MJ CYSTIC-FIBROSIS: me.  RETINOL-BINDING-PROTEINS: me.  VITAMIN-A: bl.
   ZINC: pd.
MN ADOLESCENCE.  ADULT.  CHILD.  CYSTIC-FIBROSIS: dt.  DIET.
   GROWTH: de.  HAIR: me.  HUMAN.  PLACEBOS.  TASTE: de.  TIME-FACTORS.
   ZINC: bl, tu.
AB Oral zinc supplementation with 100 mg zinc sulfate over an 8-week
   period in 36 patients with cystic fibrosis and 17 siblings did not
   affect the vitamin A transport system, as evidenced by an absence of
   consistent and significant quantitative changes in plasma levels of
   vitamin A, retinol-binding protein, and zinc, nor did the exogenous
   zinc appear to stimulate growth or exert any clinical benefit to the
   cystic fibrosis patients. The lack of response to zinc
   supplementation might be explained by the fact that the group of
   cystic fibrosis subjects studied was fairly healthy in regard to
   clinical status and certain blood parameters, including zinc.
RF 001   MAY CD                J CLIN INVEST                   27   226 948
   002   BENNETT MJ            AM J CLIN NUTR                  20   415 967
   003   UNDERWOOD BA          BULL NY ACAD MED                47    34 971
   004   ANDERSEN DH           J PEDIATR                       15   763 939
   005   SMITH FR              J LAB CLIN MED                  80   423 972
   006   NAVAB M               J BIOL CHEM                    252  5107 977
   007   STEVENSON J           J ANIMAL SCI                    15  1036 956
   008   SMITH JC JR           SCIENCE                        181   954 973
   009   SMITH JC JR           J NUTR                         106   569 976
   010   CARNEY SM             J NUTR                         106  1773 976
   011   HALSTED JA            LANCET                           1   322 970
   012   DISCHE Z              PEDIATRICS                      24    74 959
   013   CAGGIANO V            AM J MED SCI                   257   305 969
   014   UNDERWOOD BA          PEDIATR RES                      6    26 972
   015   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            971
   016   ANON                  NUTRITIVE VALUE OF FOODS HOME            971
   017   PRASAD AS             ZINC METABOLISM                          966
   018   LARKIN D              FOOD RES                        19   211 954
   019   SCHROEDER HA          J CHRON DIS                     20   179 967
   020   GORMICAN A            J AM DIET ASSOC                 56   397 970
   021   MURPHY EW             J AM DIET ASSOC                 66   345 975
   022   HENKIN RI             J CLIN INVEST                   42   727 963
   023   NEELD JB              J NUTR                          79   454 963
   024   MANCINI G             IMMUNOCHEMISTRY                  2   235 965
   025   HACKLEY B             CLIN CHEM                       14     1 968
   026   ANON                  MANUAL FOR NUTRITION SURVEYS         133 963
   027   HENRY R               AM J CLIN PATHOL                34   381 960
   028   KALOW W               CAN J BIOCHEM PHYSIOL           33   568 955
   029   RICHTERICH R          CLINICAL CHEMISTRY THEORY AND            969
   030   DIXON R               J CLIN PATHOL                   27   341 974
   031   KLEVAY LM             AM J CLIN NUTR                  23   284 970
   032   STEEL RGD             PRIN PROC OF STATISTICS                  960
   033   NIE NH                STAT PACKAGE FOR THE SOCIAL S            975
   034   BAKER H               AM J CLIN NUTR                  20   850 967
   035   SMITH FR              J CLIN INVEST                   50  2426 971
   036   HARPER HA             REVIEW PHYSIOLOGICAL CHEMI           201 969
   037   ANON                  RECOMMENDED DIETARY ALLOWANCE            974
   038   JACOB RA              AM J CLIN NUTR                  31   638 978
   039   PETERSEN RA           AM J DIS CHILD                 116   662 968
   040   BLACKFAN KD           J PEDIATR                       13   627 938
   041   UNDERWOOD BA          WORLD REV NUTR DIET             19   123 974
   042   KOPITO L              NATURE                         202   501 964
   043   KOPITO L              AM J CLIN NUTR                  21   533 968
   044   LOBECK CC             IN: STANBURY JB                     1605 972
   045   MCCOLLUM AT           J PEDIATR                       77   571 970
CT   1   NAVARRO J             AM J CLIN NUTR                  34  1439 981
     2   SOLOMONS NW           AM J CLIN NUTR                  34   462 981
     3   GORDON EF             J PEDIATR                       99   341 981
     4   JOHNSON MA            AM J CLIN NUTR                  35  1332 982
     5   SOLOMONS NW           NUTR REV                        41    33 983
     6   RUSSELL RM            ANN INTERN MED                  99   227 983
     7   GAETANI S             NUTR REP INT                    30   111 984
     8   BALY DL               AM J CLIN NUTR                  40   199 984
     9   HUBBARD VS            SEM RESPIR MED                   6   308 985
    10   BAER MT               AM J CLIN NUTR                  41  1220 985
    11   DUHAMEL JF            ARCH FR PEDIATR                 43   229 986

PN 79013
RN 00993 
AN 80062331
AU Roy-C-C.  Delage-G.  Fontaine-A.  Robitaille-L.  Chartrand-L.
   Weber-A.  Morin-C-L.
TI The fecal microflora and bile acids in children with cystic fibrosis.
SO Am-J-Clin-Nutr. 1979 Dec. 32(12). P 2404-9.
MJ ANTIBIOTICS: tu.  BILE-ACIDS-AND-SALTS: me.  CYSTIC-FIBROSIS: me, mi.
   FECES: an, mi.
MN CARBENICILLIN: tu.  CHILD.  CHILD-PRESCHOOL.  CLOXACILLIN: tu.
   CYSTIC-FIBROSIS: dt.  DRUG-THERAPY-COMBINATION.  GENTAMICINS: tu.
   GRAM-NEGATIVE-AEROBIC-BACTERIA.  HUMAN.  INFANT.
AB Fecal fat, bile acids, and the rectal microflora were studied in
   seven control children and in three groups of patients with cystic
   fibrosis (CF).  Seven were off antibiotics, ten on oral cloxacillin,
   and six on i.v. triple therapy (cloxacillin, gentamycin, and
   carbenicillin) for at least 2 weeks.  Controls had lower
   concentrations (milligrams per gram dry stool) of both fat (P <
   0.005) and vile acids (P < 0.025) than CF children off antibiotics.
   Antibiotics had little or no effect on fat but led to a striking
   decrease (P < 0.01) of bile acids in the triple therapy group.
   Concomitantly, there was reduced deconjugation of bile acids (P <
   0.01) and formation of secondary bile acids (P < 0.005).  This was
   associated with a 5-fold increase in the percentage of bile acids
   found in the aqueous phase of stools and with a marked reduction (P
   < 0.001) of the anaerobic flora (log counts per gram wet stool) in
   children on triple therapy (4.3 plus or minus 1.9) when compared to
   controls (9.8 plus or minus 0.1), CF off antibiotics (9.1 plus or
   minus 0.1) and CF on cloxacillin (9.6 plus or minus 0.2).  The close
   relationship between the anaerobic flora, the extent of bile acid
   microbial transformation, and fecal bile acid concentrations suggest
   that reduction of the anaerobic flora decreases adsorption of bile
   acids to dietary residues and microbes, favors bile acid absorption,
   and leads to a decreased fecal loss of bile acids in CF.
RF 001   ROY CC                CLIN GASTROENTEROL               6   377 977
   002   ROY CC                N ENGL J MED                   297  1301 977
   003   WEBER AM              GUT                             17   295 976
   004   WEBER AM              N ENGL J MED                   289  1001 973
   005   LEFEBVRE D            EXPERIENTIA                     33   616 977
   006   HOLDEMAN LV           ANAEROBE LABORATORY MANUAL               975
   007   BEST WR               AM J CLIN NUTR                  23  1609 970
   008   JEEJEEBHOY KN         CLIN BIOCHEM                     3   157 970
   009   LEVIN SJ              ANAL CHEM                       33  1407 961
   010   WEBER AM              CLIN CHIM ACTA                  39   524 972
   011   BANCROFT TA           TOPICS IN INTERMED STAT METH     1   100 968
   012   HOLDEMAN LV           APPL ENVIRON MICROBIOL          31   539 976
   013   MOORE WEC             APPL MICROBIOL                  27   961 974
   014   ATTEBERY HR           AM J CLIN NUTR                  25  1931 972
   015   MATA LJ               AM J CLIN NUTR                  25  1380 972
   016   FLOCH MH              AM J CLIN NUTR                  25  1418 972
   017   SUTTER VL             J INFECT DIS                   131   417 975
   018   SUTTER VL             ANTIMICROB AGENTS CHEMOTHER     10   736 976
   019   MIDTVEDT T            AM J CLIN NUTR                  27  1341 974
   020   GARBUTT JT            GASTROENTEROLOGY                56   711 969
   021   KRAG E                J CLIN INVEST                   53  1686 974
   022   GUSTAFSSON BE         ACTA PATH MICROBIOL SCAND       72   433 968
   023   EASTWOOD MA           BIOCHIM BIOPHYS ACTA           152   165 968
   024   GUSTAFSSON BE         SCAND J GASTROENTEROL            3   125 968
   025   SCHIFF ER             J CLIN INVEST                   51  1351 972
   026   EASTWOOD M            AM J CLIN NUTR                  29  1461 976
CT   1   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
     2   BALISTRERI WF         J PEDIATR GASTROENTEROL NUTR     2   105 983
     3   ISENBERG JN           J PEDIATR GASTROENTEROL NUTR     2   447 983
     4   WESLEY A              PEDIATR RES                     17    65 983
     5   COLOMBO C             J PEDIATR GASTROENTEROL NUTR     3   556 984
     6   TAZAWA Y              J PEDIATR GASTROENTEROL NUTR     3   378 984
     7   GRYBOSKI JD           AM J GASTROENTEROL              80   871 985
     8   WEBER AM              ACTA PAEDIATR SCAND SUPPL 317 1985     9 985
     9   LEROY C               DIG DIS SCI                     31   911 986
    10   LONNQVIST B           J INFECT DIS                   153   175 986

PN 79014
RN 00994 
AN 79184974
AU Lloyd-Still-J-D.  Demers-L-M.
TI Serum glycine-conjugated bile acids in pediatric hepatobiliary
   disorders.
SO Am-J-Clin-Pathol. 1979 Apr. 71(4). P 444-51.
MJ BILE-ACIDS-AND-SALTS: bl.  CYSTIC-FIBROSIS: bl.
   INFANT-NEWBORN-DISEASES: bl.  INTESTINAL-DISEASES: bl.
   LIVER-DISEASES: bl.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  CHOLESTASIS: bl.
   DIARRHEA-INFANTILE: bl.  GLYCOCHENODEOXYCHOLIC-ACID: bl.
   GLYCOCHOLIC-ACID: bl.  GLYCODEOXYCHOLIC-ACID: bl.  HEPATITIS: bl.
   HUMAN.  INFANT.  INFANT-NEWBORN.  REYES-SYNDROME: bl.
AB Measurements of serum bile acids (glycine conjugates of cholic,
   chenodeoxycholic, deoxycholic, and lithocholic acids) by
   radioimmunoassay in a variety of pediatric hepatobiliary disorders
   showed elevations in neonatal hepatitis syndromes, cholestasis, and
   hepatitis of extrahepatic or intrahepatic origin. Measurements of
   individual serum bile acids failed to differentiate between the
   various neonatal hepatitis syndromes. In one patient with
   cholestasis, the increased levels of bile acids observed returned to
   normal following therapy with cholestyramine and phenobarbital. In
   chronic active hepatitis the serum bile acid values correlated well
   with the bilirubin and SGOT in response to therapy with
   corticosteroids. These data confirm suggestions that serum
   cholylglycine and chenodeoxycholylglycine levels are a sensitive
   indicator of disturbed hepatic function and can be used in monitoring
   the course, activity, and therapeutic response in various hepatitis
   syndromes. In Reye's syndrome and protracted diarrhea of infancy,
   elevations in serum bile acids were detected without associated
   hyperbilirubinemia and provided additional evidence of disturbed
   hepatic function.
RF 001   BALISTRERI WF         IN: POLLACK JD                       269 975
   002   BALISTRERI WF         PEDIATR RES                      8   378 974
   003   BOVE KE               GASTROENTEROLOGY                69   685 975
   004   BURKE V               AUST PAEDIATR J                  2   219 966
   005   DASHER CA             CLIN RES                        24   11A 976
   006   DEMERS LM             CLIN CHEM                       22   602 976
   007   DI SANTAGNESE PA      GASTROENTEROLOGY                40    64 961
   008   GOODCHILD MC          ARCH DIS CHILD                  50   769 975
   009   GRACEY M              GUT                             12   683 971
   010   JAVITT NB             POSTGRAD MED J                  50   354 974
   011   JAVITT NB             GASTROENTEROLOGY                70  1172 976
   012   JAVITT NB             J CLIN INVEST                   47  1002 968
   013   JAVITT NB             J PEDIATR                       90   786 977
   014   KAPLOWITZ N           JAMA                           225   292 973
   015   KORMAN MG             N ENGL J MED                   290  1399 974
   016   LANDING BH            PROG PEDIATR SURG                6   113 974
   017   LLOYD-STILL JD        PEDIATRICS                      59   626 977
   018   LLOYD-STILL JD        AM J DIS CHILD                 125   358 973
   019   MURPHY GM             GUT                             15   151 974
   020   NORMAN A              ACTA PAEDIATR SCAND             62   253 973
   021   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   022   POLEY JR              J LAB CLIN MED                  63   838 964
   023   SANDBERG DH           PEDIATR RES                      4   262 970
   024   SCHEUER P             LIVER BIOPSY INTERPRETATION           22 973
   025   TOULOUKIAN RJ         ARCH SURG                      106    58 973
   026   UTILI R               GASTROENTEROLOGY                70   248 976
   027   WATKINS JB            PEDIATR CLIN NORTH AM           21   501 974
   028   WATKINS JB            PEDIATR RES                      7   341 973
   029   WATKINS JB            GASTROENTEROLOGY                67   835 974
   030   WEBER AM              GUT                             17   295 976
   031   WEBER AM              N ENGL J MED                   289  1001 973
CT   1   FINNI K               ANN CLIN RES                    12   168 980
     2   MATSUI A              J CLIN PATHOL                   35  1011 982
     3   FINNI K               EUR J PEDIATR                  138    53 982
     4   STREET JM             J LIPID RES                     24   491 983
     5   STRANDVIK B           SCAND J GASTROENTEROL           20   381 985

PN 79015
RN 00995 
AN 79252922
AU Warwick-W-J.  Hansen-L.  Viela-I.  Matheson-J.
TI Comparison of the chloride electrode and gravimetric chloride
   titration sweat tests.
SO Am-J-Clin-Pathol. 1979 Aug. 72(2). P 142-5.
MJ CHLORIDES.  CYSTIC-FIBROSIS: di.  SWEATING.
MN COMPARATIVE-STUDY.  COMPUTERS.  ELECTRODES.  HUMAN.
   MODELS-BIOLOGICAL.  PROBABILITY.
AB The chloride electrode sweat test and gravimetric chloride titration
   technic are compared. The two technics gave comparable mean values,
   ogives, equivalent points, and overlap for patients with cystic
   fibrosis and healthy subjects. As a single test with either technic
   has an unacceptable risk for false-positive or false-negative
   results, tests should always be done in pairs. A statistical
   interpretation technic based on prevalence and technical variability
   of the two tests will decrease the number of undiagnosed subjects and
   will define probability of cystic fibrosis in the undiagnosed group.
RF 001   GIBSON LE             CLIN PEDIATR                    12   450 973
   002   GIBSON LE             PEDIATRICS                      23   545 959
   003   HANSEN L              MINN MED                        50  1191 967
   004   HANSEN L              AM J CLIN PATHOL                49   834 968
   005   KOPITO L              PEDIATRICS                      43   794 969
   006   ANON                  J PEDIATR                       88   711 976
   007   WARWICK WJ            CF CLUB ABST                           5 975
   008   WARWICK WJ            PEDIATRICS                      36   261 965
   009   WARWICK WJ            CLIN CHEM                       24   381 978
CT   1   WEBSTER HL            CRC CRIT REV CLIN LAB SCI       18   313 983

PN 79016
RN 00996 
AN 79252934
AU Warwick-W-J.  Viela-I.  Hansen-L-G.
TI Comparison of the errors due to the use of gauze and the use of
   filter paper in the gravimetric chloride titration sweat test.
SO Am-J-Clin-Pathol. 1979 Aug. 72(2). P 211-5.
MJ CHLORIDES.  CYSTIC-FIBROSIS: di.  SWEATING.
MN COMPARATIVE-STUDY.  HUMAN.  MATHEMATICS.
AB Potential sources of error in the Gibson and Cooke method of sweat
   testing using gauze and filter paper as collection media as
   described. The absolute chloride content of gauze was higher than
   that of filter paper; however, the variability of chloride contents
   between the two was insignificant. Complete chloride elution from
   filter paper requires more time than elution from gauze. A method of
   determining probability of a clinically acceptable measurement based
   on sweat sample size, chloride determination, and variability of
   chloride in collection media is also described.
RF 001   GIBSON LE             PEDIATRICS                      23   545 959
   002   HANSEN L              MINN MED                        50  1191 967
   003   SCHALES O             J BIOL CHEM                    140   879 941
   004   SHWACHMAN H           MOD PROBL PEDIATR               10   158 967
CT   1   SCHWACHMAN H          J PEDIATR                       98   576 981

PN 79017
RN 00997 
AN 79253016
AU Nussbaum-E.  Boat-T-F.  Wood-R-E.  Doershuk-C-F.
TI Cystic fibrosis with acute hypoelectrolytemia and metabolic
   alkalosis in infancy.
SO Am-J-Dis-Child. 1979 Sep. 133(9). P 965-6.
MJ ALKALOSIS: et.  WATER-ELECTROLYTE-IMBALANCE: et.
MN ALKALOSIS: th.  CASE-REPORT.  COLD.  CYSTIC-FIBROSIS: co.  FEMALE.
   FLUID-THERAPY.  HUMAN.  INFANT.  MALE.  SEASONS.  SWEATING.
   SUPPORT-U-S-GOVT-P-H-S.  WATER-ELECTROLYTE-IMBALANCE: th.
EX We describe two infants with previously undiagnosed cystic fibrosis
   who had electrolyte depletion, metabolic alkalosis, and dehydration
   in the winter and three infants known to have CF in whom similar
   manifestations developed.  We confirm previous reports that salt
   depletion and metabolic alkalosis do occur throughout the year in the
   northern United States and England.  When metabolic alkalosis and
   hypoelectrolytemia in infancy are not explained on the basis of other
   clinical conditions, CF should be suspected.  Pediatricians should
   measure serum electrolyte values promptly and consider early
   parenteral fluid and electrolyte therapy as a preventive measure for
   infants with CF with persistent vomiting and/or diarrhea.
RF 001   KESSLER WR            PEDIATRICS                       8   648 951
   002   GIBSON LE             PEDIATRICS                      23   545 959
   003   RENDLE-SHORT J        ARCH DIS CHILD                  31    28 956
   004   DI SANTAGNESE PA      JAMA                           172  2014 960
   005   GOTTLIEB RP           J PEDIATR                       79   930 971
   006   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   007   STOLL E               HELV PAEDIATR ACTA              25   234 970
   008   BECKERMAN RC          PEDIATRICS                      63   580 979
   009   NOUSIA-ARVANITAKIS S  J PEDIATR                       82   535 973
   010   HOCHMAN HI            ARCH DIS CHILD                  51   390 976
CT   1   LAUGHLIN JJ           PEDIATRICS                      68   203 981
     2   RAPAPORT R            J PEDIATR                       98   768 981
     3   SORSCHER EJ           LANCET                           1   368 982
     4   ZAMMARCHI E           RIV ITAL PEDIATR                 9   505 983
     5   ORENSTEIN DM          PEDIATR RES                     17   267 983
     6   ORENSTEIN DM          J APPL PHYSIOL                  57   408 984

PN 79018
RN 00998 
AN 79185026
AU Mischler-E-H.  Chesney-P-J.  Chesney-R-W.  Mazess-R-B.
TI Demineralization in cystic fibrosis detected by direct photon
   absorptiometry.
SO Am-J-Dis-Child. 1979 Jun. 133(6). P 632-5.
MJ BONE-AND-BONES: me.  BONE-DISEASES: et.  CYSTIC-FIBROSIS: co.
   GROWTH-DISORDERS: et.  MINERALS: me.
MN ADOLESCENCE.  ADULT.  ALKALINE-PHOSPHATASE: bl.  BONE-DEVELOPMENT.
   BONE-DISEASES: di, me.  CALCIUM: bl, me.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: me.  DENSITOMETRY.  FEMALE.  GROWTH-DISORDERS: me.
   HUMAN.  MALE.  METHODS.  PHOSPHORUS: bl.
AB Bone mineral content, bone width, and their ratio were measured in
   patients with cystic fibrosis (CF) using monoenergetic photon
   absorptiometry. Serial measurements of the radius and ulna were made
   in 27 patients with CF and were compared with 968 age-matched
   controls. Demineralization was found in 37% of the boys and 63% of
   the girls. Patients under age 10 years had normal bone mineral
   content and nine of 15 patients aged 13 or older were demineralized
   (P less than .01). Demineralization correlated with the extent of
   weight reduction in patients (P less than .001). Patients most likely
   to be demineralized were adolescent girls. To our knowledge, this is
   the first report of bone mineral status of children with CF, and the
   results indicate that a sizable proportion of these patients may be
   demineralized without overt rickets.
RF 001   NADLER HL             IN: STANBURY JB                     1683 978
   002   SCOTT J               AM J MED                        63   488 977
   003   AVIOLI LV             METABOLISM                      22   507 973
   004   CHESNEY RW            PEDIATRICS                      60   864 977
   005   CHESNEY RW            AM J DIS CHILD                 132   768 978
   006   LEVIN ME              N ENGL J MED                   294   241 976
   007   CHRISTIANSEN C        AM J ROENTGENOL                126  1302 976
   008   CAMERON JR            INVEST RADIOL                    3   141 968
   009   MAZESS RB             INVEST RADIOL                    6    52 971
   010   CHRISTIANSEN C        SCAND J CLIN LAB INVEST         35   425 975
   011   MAZESS RB             GROWTH                          36    77 972
   012   MAZESS RB             AM J ANTHROPOL                  35   399 971
   013   MAZESS RB             IN: MAZESS RB                        228 974
   014   TAUSSIG LM            J PEDIATR                       82   380 973
   015   SPROUL A              J PEDIATR                       65   664 964
   016   ANON                  MONTHLY VITAL STAT REPORT USD   25    76 976
   017   LACHMAN E             AM J ROENTG RAD THER NUCL MED   74   712 955
   018   SIWE SA               DTSCH ARCH KLIN MED            173   339 932
   019   OPPENHEIMER EH        BULL JOHNS HOPKINS HOSP         98   353 956
   020   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   021   PARK EA               ARCH DIS CHILD                  29   269 954
   022   BYERS PD              IN: AVIOLI LV                        184 977
   023   COOKE RE              J PEDIATR                       57   326 960
   024   SIMOPOULOS AP         PEDIATR RES                      6    95 972
   025   WEBER AM              GUT                             17   295 976
   026   FARRELL PM            PEDIATR RES                     11   113 977
   027   GALLAGHER JC          N ENGL J MED                   298   193 978
CT   1   PITT MJ               RADIOL CLIN NORTH AM            19   581 981
     2   SOLOMONS NW           AM J CLIN NUTR                  34   462 981
     3   CHESNEY RW            AM J DIS CHILD                 136   578 982
     4   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
     5   FARRELL PM            J DENT CHILD                    50   385 983
     6   LANDIN LA             ACTA ORTHOP SCAND               54     1 983
     7   HUBBARD VS            SEM RESPIR MED                   6   308 985
     8   HELIN I               ACTA PAEDIATR SCAND             74   264 985
     9   REITER EO             J PEDIATR                      106    21 985
    10   STEAD RJ              CLIN ENDOCRINOL                 26   187 987

PN 79019
RN 00999 
AN 79142382
AU Strauss-G-D.  Pedersen-S.  Dudovitz-D.
TI Psychosocial support for adults with cystic fibrosis: a group
   approach.
SO Am-J-Dis-Child. 1979 Mar. 133(3). P 301-5.
MJ CYSTIC-FIBROSIS: px.  SELF-HELP-GROUPS.
MN ADAPTATION-PSYCHOLOGICAL.  ADULT.  ATTITUDE-TO-HEALTH.  FEMALE.
   HUMAN.  MALE.  NURSING-STAFF-HOSPITAL.  PSYCHIATRY.  ROLE.
   SOCIAL-WORK.
AB This article describes the first time-limited psychosocial support
   group for adults with cystic fibrosis (CF).The chronology of the
   group is traced, focusing on issues of importance for health
   professionals who work with patients with CF. Some of the issues
   raised by patient members include doubts about the competence of
   nonpediatricians to adequately treat CF; resentment towards "normals"
   (those without CF), including health professionals; and the desire to
   control as many areas of their lives as possible. Covert (ie,
   unrecognized) issues, the role of staff, risks, and outcome are
   detailed as a guide for others who may wish to conduct such groups.
   The literature on groups for medical patients and a rationale for the
   beneficial effects on the group are given.
RF 001   BOWMAN BH             N ENGL J MED                   294   937 976
   002   WARWICK WJ            JAMA                           238  2159 977
   003   ROSENLUND ML          ANN INTERN MED                  78   959 973
   004   PATTERSON PR          PSYCHOSOCIAL ASPECTS OF CF               973
   005   BOYLE IR              J PEDIATR                       88   318 976
   006   DENNING CR            IN: MANGOS JA                        127 976
   007   PRATT JH              JAMA                            49   755 907
   008   CUNNINGHAM J          COMPR PSYCHIATRY                19   135 978
   009   REID J                GERIATRICS                      17   823 962
   010   DUDLEY DL             AM REV RESPIR DIS              100   575 969
   011   FORTIN JN             INT J GROUP PSYCHOTHER           6   838 956
   012   GUY W                 ARCH DERMATOL SYPHIL            70   767 954
   013   ADSETT CA             CAN MED ASSOC J                 99   577 968
   014   LONG RT               J NERV MENT DIS                119   366 954
   015   TEITELBAUM SH         GROUP PSYCHOTHER                17    49 964
   016   PARSELL S             AM J NURS                       74   650 974
   017   SCHOENBERG B          J CHRON DIS                     19   649 966
   018   COOKE M               CF SOCIALWORK HIGHLIGHTS         1     5 977
CT   1   STRAUSS GD            J CHRON DIS                     34   141 981

PN 79020
RN 01000 
AN 79121969
AU di-Santagnese-P-A.  Davis-P-B.
TI Cystic fibrosis in adults.  75 cases and a review of 232 cases in
   the literature.
SO Am-J-Med. 1979 Jan. 66(1). P 121-32.
MJ CYSTIC-FIBROSIS: co.  INTESTINAL-OBSTRUCTION: et.
   LUNG-DISEASES-OBSTRUCTIVE: et.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: mi, ra.  FEMALE.  HUMAN.
   LUNG-DISEASES-OBSTRUCTIVE: di.  LUNG: ra.
   MALE.  RESPIRATORY-FUNCTION-TESTS.  SPUTUM: mi.
AB Cystic fibrosis is now the most common cause of chronic obstructive
   pulmonary disease (COPD) and of pancreatic insufficiency in the
   first three decades of life in the United States.  In this report we
   describe 75 patients with cystic fibrosis aged 18 to 47 years and
   review another 232 cases reported in the literature.  All of these
   307 patients had elevated sweat chloride and sodium levels, which
   proved excellent discriminants for cystic fibrosis even in patients
   in the older age group.  COPD, present in 97 per cent, was the major
   cause of morbidity and mortality, and differed from COPD of other
   etiologies.  The progressive downhill course in these patients was
   punctuated by recurrent symptomatic exacerbations of chronic
   bacterial bronchitis caused by Pseudomonas aeruginosa and
   Staphyloccocus aureus, and terminated in pulmonary insufficiency,
   cor pulmonale and death.  COPD was complicated by minor hemoptysis
   in 60 per cent, massive hemoptysis in 7 per cent and pneumothorax in
   16 per cent, problems rare in children.  Sinusitis was present in
   all those examined roentgenographically, and 48 per cent had nasal
   polyposis.  Pancreatic insufficiency was present in 95 per cent of
   the patients, but in contrast to younger patients it was seldom
   symptomatic although steatorrhea and azotorrhea were still massive.
   Intussusception and meconium ileus equivalent (fecal accumulation)
   are frequent in adults (21 per cent) but rare in children, and they
   require immediate diagnostic and therapeutic intervention with
   enemas of diatrizoate sodium.  Glycosuria, biliary cirrhosis,
   cholelithiasis and aspermia were among other complications.  Height
   and weight were usually within the lower limits of normal, but 17
   per cent of the men were above 180 cm in height and 7 per cent were
   overweight.  Therefore, a high index of suspicion is needed to make
   the diagnosis, because older patients with cystic fibrosis may look
   quite well.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   002   MANGOS JA             TEX REP BIOL MED                31   651 973
   003   KAISER D              PEDIATR RES                      5   167 971
   004   SCHULZ IJ             J CLIN INVEST                   48  1470 969
   005   ANON                  CF FND 1974 REP SURVI STUD PA            976
   006   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
   007   MITCHELL-HEGGS PF     Q J MED                         45   479 976
   008   GRACEY M              AUSTRALAS ANN MED               18    91 969
   009   STERN RC              ANN INTERN MED                  87   188 977
   010   SCHWARTZ EE           AM J ROENTG RAD THER NUCL MED  122   708 974
   011   HODSON ME             BR MED J                         2   790 976
   012   FRIEDMAN PJ           AM REV RESPIR DIS              113   159 976
   013   GIBSON LE             PEDIATRICS                      23   545 959
   014   SCHWERT GW            BIOCHIM BIOPHYS ACTA            16   570 955
   015   ANDERSEN DH           AM J DIS CHILD                  63   643 942
   016   FOLK JE               J BIOL CHEM                    235  2272 960
   017   VAN LOON EJ           AM J CLIN PATHOL                22  1134 952
   018   SUN DCH               GASTROENTEROLOGY                44   602 963
   019   TAUSSIG LM            PEDIATRICS                      54   229 974
   020   VAN DE KAMER JH       J BIOL CHEM                    177   347 949
   021   WOLLAEGER EE          GASTROENTEROLOGY                 9   272 947
   022   TANNER JM             ARCH DIS CHILD                  41   454 966
   023   NICKLAUS TM           AM REV RESPIR DIS               93   889 966
   024   TAUSSIG LM            J PEDIATR                       82   380 973
   025   JENSEN KG             ACTA PAEDIATR SCAND             51   344 962
   026   DI SANTAGNESE PA      IN: DOWNEY JA                         25 974
   027   WARWICK WJ            J CHRON DIS                     28   609 975
   028   STERN RC              J PEDIATR                       89   406 976
   029   KRAEMER R             ACTA PAEDIATR SCAND             67    33 978
   030   ORENSTEIN DM          AM J DIS CHILD                 131   973 977
   031   WOOD RE               AM REV RESPIR DIS              113   833 976
   032   ANON                  J PEDIATR                       88   711 976
   033   DI SANTAGNESE PA      PEDIATRICS                      12   178 953
   034   ELIASSON R            N ENGL J MED                   297     1 977
   035   COREY M               AM REV RESPIR DIS              114  1085 976
   036   LANDAU LI             AM REV RESPIR DIS              108   593 973
   037   ZAPLETAL A            PEDIATRICS                      48    64 971
   038   FOX WW                PEDIATRICS                      54   293 974
   039   COOPER DM             AM REV RESPIR DIS              109   519 974
   040   REYNOLDS HY           JAMA                           236  2190 976
   041   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   042   BEDROSSIAN CWM        HUM PATHOL                       7   195 976
   043   MILLIS RM             CHEST                           71   508 977
   044   DAVIS PB              JAMA                           239  1851 978
   045   BOAT TF               AM REV RESPIR DIS              116     1 977
   046   TAGER I               N ENGL J MED                   292   563 975
   047   ROSENTHAL A           PEDIATRICS                      59   588 977
   048   SIASSI B              J PEDIATR                       78   794 971
   049   ROSENTHAL A           PEDIATRICS                      59   588 977
   050   RYSSING E             ACTA PAEDIATR SCAND             66   753 977
   051   LEVITSKY S            JAMA                           213   125 970
   052   FELLOWS KE            RADIOLOGY                      114   551 975
   053   SCHUSTER SR           J PEDIATR SURG                  12   889 977
   054   LUCK SR               J THORAC CARDIOVASC SURG        74   834 977
   055   KATTWINKEL J          JAMA                           226   557 973
   056   TAUSSIG LM            J PEDIATR                       90   574 977
   057   COHEN LF              J PEDIATR                       90   574 977
   058   SHWACHMAN H           PEDIATRICS                      30   389 962
   059   CAPLIN I              ANN ALLERGY                     29   631 971
   060   KULCZYCKI LL          JAMA                           175   358 961
   061   RACHELEFSKY GS        AM J DIS CHILD                 128   355 974
   062   WARNER JO             ARCH DIS CHILD                  51   507 976
   063   KOPITO LE             PEDIATR RES                     10   742 976
   064   DI SANTAGNESE PA      IN: YOUNG DS                             976
   065   SHWACHMAN H           PEDIATRICS                      55    86 975
   066   LAPEY A               J PEDIATR                       84   328 974
   067   ROY CC                N ENGL J MED                   297  1301 977
   068   NOUSIA-ARVANITAKIS S  J PEDIATR                       90   302 977
   069   UNDERWOOD BA          PEDIATR RES                      6    26 972
   070   SCOTT J               AM J MED                        63   488 977
   071   HUBBARD VS            LANCET                           2  1302 977
   072   MULLINS F             JAMA                           192   741 965
   073   MATSESHE JW           GASTROENTEROLOGY                72   732 977
   074   MCPARTLIN JF          BR J SURG                       60   707 973
   075   KATTWINKEL J          J PEDIATR                       82   234 973
   076   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   077   CRAIG JM              AM J DIS CHILD                  93   357 957
   078   STERN RC              GASTROENTEROLOGY                70   645 976
   079   HUBBARD VS            PEDIATR RES                     12   437 978
   080   ISENBERG JN           AM J GASTROENTEROL              65   134 976
   081   WEBER AM              N ENGL J MED                   289  1001 973
   082   HANDWERGER S          N ENGL J MED                   281   451 969
   083   LIPPE BM              J PEDIATR                       90   751 977
   084   STAHL M               J PEDIATR                       84   821 974
   085   MULLER WA             AM J MED                        54    52 973
   086   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   087   TAUSSIG LM            N ENGL J MED                   287   586 972
   088   HOLSCLAW DS           J UROL                         106   568 971
   089   KAPLAN E              N ENGL J MED                   279    65 968
   090   OPPENHEIMER EH        J PEDIATR                       75   806 969
   091   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   092   HERROD HG             J PEDIATR                       91   276 977
   093   DI SANTAGNESE PA      IN: VAUGHAN VC III                   903 975
   094   KOPITO LE             FERTIL STERIL                   24   512 973
   095   OPPENHEIMER EH        J PEDIATR                       77   991 970
CT   1   ANON                  BR MED J                         2   626 979
     2   GURWITZ D             PEDIATR CLIN NORTH AM           26   603 979
     3   HOLSCLAW DS           CLIN CHEST MED                   1   407 980
     4   COHEN LF              LANCET                           2   842 980
     5   LELANNOU D            ANN UROLOGIE                    14    94 980
     6   HODSON ME             THORAX                          35   801 980
     7   MATTHAY RA            BR HEART J                      43   474 980
     8   DAVIS PB              AM J MED                        69   643 980
     9   FAIRFAX AJ            BR J DIS CHEST                  74   345 980
    10   SANDERS JS            CHEST                           77   226 980
    11   HUBBARD VS            AM J DIS CHILD                 134   317 980
    12   WILLI UV              AM J ROENTGENOL                134  1005 980
    13   HODSON ME             PRACTITIONER                   224   301 980
    14   PASSERO MA            CLIN PEDIATR                    20   264 981
    15   BLACKWOOD LL          INFECT IMMUN                    32   443 981
    16   EVANS RT              J CLIN PATHOL                   34   911 981
    17   RUTLAND J             THORAX                          36   654 981
    18   LELANNOU D            SEM HOP PARIS                   57   608 981
    19   MATTHAY RA            MED CLIN NORTH AM               65   489 981
    20   WELCH MJ              PEDIATRICS                      67   664 981
    21   PENNINGTON JE         J CLIN INVEST                   68  1140 981
    22   JACOBS WH             AM J GASTROENTEROL              76   342 981
    23   LAMBERT JR            GASTROENTEROLOGY                80   169 981
    24   FRIEDMAN PJ           AM J ROENTGENOL                136  1131 981
    25   HODSON ME             EUR J PEDIATR                  137   117 981
    26   CORKEY CWB            AM J OBSTET GYNECOL            140   737 981
    27   OBOYLE CP             IR J MED SCI                   150   286 981
    28   OGRADY JG             IR J MED SCI                   150   220 981
    29   TABACHNIK NF          SURG GYNECOL OBSTET            152   837 981
    30   MACONE AB             N ENGL J MED                   304  1445 981
    31   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
    32   HOOGENRAAD TU         NEUROOPHTHALMOL                  2   267 982
    33   JAGGER KS             J CLIN MICROBIOL                15  1054 982
    34   MCKIERNAN J           PEDIATR RES                     16    60 982
    35   PUGASHETTI BK         J CLIN MICROBIOL                16   686 982
    36   HARVEY J              BR J HOSP MED                   27   278 982
    37   KISTLER I             HELV PAEDIATR ACTA              36   495 982
    38   OHMAN DE              INFECT IMMUN                    37   662 982
    39   PENKETH ARL           THORAX                          37   850 982
    40   HUBBARD VS            J AM DIET ASSOC                 80   127 982
    41   NOLAN G               J PEDIATR                      101   626 982
    42   RIVERA M              AM REV RESPIR DIS              126   833 982
    43   STERN RC              AM J DIS CHILD                 136  1067 982
    44   TSCHOLAKOFF D         FORTSCHR GEB RONTG NUKL        137    18 982
    45   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
    46   GUIDOTTI TL           AM J MED SCI                   283   157 982
    47   BONFORTE RJ           LANCET                           1    71 983
    48   SHAWKER TH            J ULTRASOUND MED                 2   439 983
    49   WAGENER JS            AM J PEDIATR HEMATOL ONCOL       5   153 983
    50   WEBSTER HL            CRC CRIT REV CLIN LAB SCI       18   313 983
    51   BRECHER DB            AM FAM PHYSICIAN                28   187 983
    52   KRAMER NR             J CAN ASSOC RADIOL              34   271 983
    53   DAVIS PB              J CHRON DIS                     36   269 983
    54   JEFFREY I             J CLIN PATHOL                   36  1292 983
    55   DORING G              INFECT IMMUN                    42   197 983
    56   GUIDOTTI TL           RESPIRATION                     44   351 983
    57   JACOBS RL             ANN ALLERGY                     51   500 983
    58   GEMBITSKAYA TE        KLIN MED                        61     9 983
    59   JOHNSON SR            OBSTET GYNECOL                  61  S  2 983
    60   DOHERTY DE            SOUTH MED J                     76  1580 983
    61   ALLEN JM              GASTROENTEROLOGY                85  1379 983
    62   PORTER DK             J THORAC CARDIOVASC SURG        86   409 983
    63   ANON                  ANN INTERN MED                  98  1033 983
    64   DAVIS PB              AM REV RESPIR DIS              128    34 983
    65   PORTER DK             ARCH INTERN MED                143   287 983
    66   BOUCHER RC            LUNG                           161     1 983
    67   ROSENBERG E           KLIN PAEDIATR                  195   323 983
    68   HANLY JG              BR MED J                       286  1411 983
    69   HODSON ME             BR MED J                       286  1381 983
    70   ZENTLERMUNRO PL       GUT                             25   500 984
    71   MCCLURE HM            ADV VET SCI COMP MED            28   267 984
    72   MATTHEWS LW           PEDIATR CLIN NORTH AM           31   133 984
    73   PENKETH A             THORAX                          39   299 984
    74   COWEN L               PSYCHOSOM MED                   46   363 984
    75   WILSONSHARP RC        ARCH DIS CHILD                  59   923 984
    76   LEWIS MI              S AFR MED J                     65   641 984
    77   ABRAMS CK             J CLIN INVEST                   73   374 984
    78   SLAVIN RG             J ALLERGY CLIN IMMUNOL          73   712 984
    79   JACOBS RL             J ALLERGY CLIN IMMUNOL          74    61 984
    80   HODGES P              J AM DIET ASSOC                 84   664 984
    81   DAVIS PB              CHEST                           85   802 984
    82   MCCARTHY VP           GASTROENTEROLOGY                86   564 984
    83   SPINO M               J PEDIATR                      105   829 984
    84   GUGGER M              SCHWEIZ MED WOCHENSCHR         114   620 984
    85   SIGG C                SCHWEIZ MED WOCHENSCHR         114  1942 984
    86   GEFFNER ME            AM J DIS CHILD                 138   677 984
    87   HANDELSMAN DJ         N ENGL J MED                   310  1670 984
    88   SPRINCE  NL           N ENGL J MED                   310   375 984
    89   PINKERTON P           LANCET                           2   761 985
    90   CRAWFORD AM           RHEUMATOL INT                    5   283 985
    91   DAVIS PB              SEM RESPIR MED                   6   261 985
    92   DAVIS PB              SEM RESPIR MED                   6   314 985
    93   DAVIS PB              SEM RESPIR MED                   6   319 985
    94   HUBBARD VS            SEM RESPIR MED                   6   299 985
    95   LESTER LA             SEM RESPIR MED                   6   285 985
    96   SHAW LMA              J OBSTET GYNAECOL BR COMMONW     6     1 985
    97   SWOBODNIK W           J CLIN ULTRASOUND               13   469 985
    98   REINIG JW             PEDIATR RADIOL                  15   222 985
    99   SEAMAN WB             HOSP PRACT                      20   123 985
   100   KAHAN A               PHARMACOL THER                  28   163 985
   101   GRAHAM N              CLIN RADIOL                     36   199 985
   102   TRENTO A              ANN THORAC SURG                 39   254 985
   103   DAVIS PB              THORAX                          40   376 985
   104   HUNT B                THORAX                          40    23 985
   105   AMES P                INFECT IMMUN                    49   281 985
   106   HANLY JG              Q J MED                         56   377 985
   107   MEARNS MB             ARCH DIS CHILD                  60   272 985
   108   BERKIN KE             EUR J RESPIR DIS                67   103 985
   109   ROTH RM               SOUTH MED J                     78   573 985
   110   ISPIZUA AU            MED CLIN                        85   628 985
   111   REITER EO             J PEDIATR                      106    21 985
   112   MELLIS CM             MED J AUST                     143   227 985
   113   OCONNOR KW            ARCH INTERN MED                145   153 985
   114   OHMAN DE              J BACTERIOL                    162  1068 985
   115   ISPIZUA AU            REV CLIN ESP                   176   417 985
   116   KNOPFLE G             KLIN PAEDIATR                  197   481 985
   117   HUGHES RL             ACTA PAEDIATR SCAND SUPPL 317 1985    42 985
   118   OHMAN DE              EUR J CLIN MICROBIOL             5     6 986
   119   PENNINGTON JE         REV INFECT DIS                   8  S426 986
   120   RUSH PJ               SEM ARTHRITIS RHEUM             15   213 986
   121   KRIEG DP              J CLIN MICROBIOL                24   986 986
   122   PIER GB               J CLIN MICROBIOL                24   189 986
   123   OJEDA VJ              DIS COLON RECTUM                29   567 986
   124   ROBERTS JA            SCOTT MED J                     31   109 986
   125   RODMAN HM             MEDICINE                        65   389 986
   126   PIER GB               J CLIN INVEST                   77   491 986
   127   DINWIDDIE R           J ROY SOC MED                   79     6 986
   128   ROSENSTEIN BJ         SOUTH MED J                     79   319 986
   129   WELLER PH             J ROY SOC MED                   79    36 986
   130   TRAVIS WD             AM J CLIN PATHOL                85   419 986
   131   ABDULKARIM FW         ARCH PATHOL LAB MED            110   602 986
   132   MCGLENNEN RC          ARCH PATHOL LAB MED            110   879 986
   133   COHEN AM              AM J DIS CHILD                 140    74 986
   134   ROSENSTEIN BJ         AM J DIS CHILD                 140   966 986
   135   KRUHLAK RT            WEST J MED                     145   196 986
   136   STEINKAMP G           EUR J PEDIATR                  145   526 986
   137   KUMARISUBAIYA S       J PEDIATR GASTROENTEROL NUTR     6    71 987
   138   STEAD RJ              CLIN ENDOCRINOL                 26   187 987
   139   STEAD RJ              THORAX                          42    59 987
   140   MCHUGO JM             BR J RADIOL                     60   137 987
   141   DAVIS PB              J DENT RES                      66   667 987
   142   BAILEY DJ             PEDIATRICS                      79   281 987

PN 79021
RN 01001 
AN 80062584
AU Fisher-N-L.
TI Genetic counseling and prenatal diagnosis of cystic fibrosis
   [letter].
SO Am-J-Obstet-Gynecol. 1979 Nov 1. 135(5). P 699.
MJ CYSTIC-FIBROSIS: fg.  GENETIC-COUNSELING.  PRENATAL-DIAGNOSIS.
MN CYSTIC-FIBROSIS: di.  FEMALE.  HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.
   PREGNANCY.
EX Turner and associates cited cystic fibrosis as an example of the
   application of the judicious use of genetic counseling and prenatal
   diagnosis.  The reader who is unfamiliar with genetic disorders,
   prenatal diagnosis, and genetic counseling may have taken the "cystic
   fibrosis example" as fact rather than a model, as intended.  Cystic
   fibrosis is a recessive disorder for which prenatal diagnosis and
   heterozygote detection are not yet possible.  Currently, because of
   the present inability to detect the heterozygous state, genetic
   counseling of individuals with a family history of cystic fibrosis
   frequently means a statistical prediction is given, rather than a
   precise recurrence risk.
RF 000   TURNER JH             AM J OBSTET GYNECOL            134    83 979

PN 79022
RN 01002 
AN 79206917
AU Imrie-J-R.  Fagan-D-G.  Sturgess-J-M.
TI Quantitative evaluation of the development of the exocrine pancreas
   in cystic fibrosis and control infants.
SO Am-J-Pathol. 1979 Jun. 95(3). P 697-707.
MJ CYSTIC-FIBROSIS: pa.  PANCREAS: pa.
MN COMPARATIVE-STUDY.  CONNECTIVE-TISSUE: pa.  FEMALE.  GESTATIONAL-AGE.
   HUMAN.  INFANT-NEWBORN.  MALE.  MECONIUM.  PREGNANCY.
AB The development of the exocrine pancreas has been determined
   quantitatively in 31 infants with cystic fibrosis (CF) both  with and
   without meconium ileus and in 29 control infants. In the normal
   pancreas, the ratio of acinar to connective tissue volume is 0.5 at
   32 weeks postconceptional age (PCA) and increases linearly to 2.0 at
   52 weeks PGA. In cystic fibrosis infants, with or without meconium
   ileus, the ration is 0.5 at 35 weeks PCA  anddecreases linearly to
   0.3 at 52 weeks PCA. The volume of acinar and duct lumens is greater
   in CF than control infants but is independent of age or acinar
   volume. The development of the exocrine pancreas in infants with CF
   with and without meconium ileus diverges from the normal pattern:
   There is consistent lack of exocrine tissue before or a full-term
   birth, which persists throghout the age range of this study. CF
   infants above 42 weeks PCA can be discriminated from controls on the
   basis of the quantitative assessment of acinar volume.
RF 001   FARBER S              J PEDIATR                       24   387 944
   002   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   003   KORNBLITH BA          AM J PATHOL                      5   249 929
   004   HURWITT ES            AM J DIS CHILD                  64   443 942
   005   GLANZMANN E           ANN PAEDIATR                   166   289 946
   006   THOMAIDIS TS          J PEDIATR                       63   444 963
   007   WEIBEL ER             MORPHOMETRY OF THE HUMAN LUNG            963
   008   OPPENHEIMER EH        ARCH PATHOL                     96   149 973
   009   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   010   DONNISON AB           PEDIATRICS                      37   833 966
   011   KOPITO LE             PEDIATR RES                     10   742 976
   012   RICKHAM PP            PROG PEDIATR SURG                2    73 971
CT   1   GILLARD BK            PEDIATR RES                     14  1168 980
     2   CARREL O              HELV PAEDIATR ACTA              36   405 981
     3   PARK RW               GASTROENTEROLOGY                81  1143 981
     4   STURGESS J            AM J PATHOL                    106   303 982
     5   REID L                INT REV EXP PATHOL              24   335 983
     6   MASOERO G             AM J DIS CHILD                 137   167 983
     7   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983
     8   GOTZ M                ATEMWEGS LUNGENKRANKH           10   594 984
     9   LANGLEY FA            CLIN OBSTET GYNAECOL            11    79 984
    10   MULLER F              PRENAT DIAGN                     5   109 985
    11   HUBBARD VS            SEM RESPIR MED                   6   299 985
    12   GOTZ M                MED KLIN                        80   657 985
    13   FRIEND PA             J INFECT                        13    55 986
    14   DODGE JA              J ROY SOC MED                   79    27 986
    15   HUNSINGER RN          CLIN CHIM ACTA                 156   165 986

PN 79023
RN 01003 
AN 79185761
AU Larsen-G-L.  Barron-R-J.  Cotton-E-K.  Brooks-J-G.
TI A comparative study of inhaled atropine sulfate and isoproterenol
   hydrochloride in cystic fibrosis.
SO Am-Rev-Respir-Dis. 1979 Mar. 119(3). P 399-407.
MJ ATROPINE: du.  CYSTIC-FIBROSIS: pp.  ISOPROTERENOL: du.
   RESPIRATION: de.
MN ADOLESCENCE.  AEROSOLS.  AIRWAY-RESISTANCE: de.  ATROPINE: ad, pd.
   CHILD.  COMPARATIVE-STUDY.  DOSE-RESPONSE-RELATIONSHIP-DRUG.  FEMALE.
   HUMAN.  ISOPROTERENOL: ad, pd.  MALE.  MAXIMAL-EXPIRATORY-FLOW-RATE.
   MAXIMAL-EXPIRATORY-FLOW-VOLUME-CURVES.  RESIDUAL-VOLUME.
   TOTAL-LUNG-CAPACITY.  VITAL-CAPACITY.
AB To investigate the contribution of vagal tone to the obstructive
   airway disease in cystic fibrosis, we evaluated the pulmonary
   function response to administration of 0.1 mg of atropine sulfate
   per kg of body weight, 0.05 mg of isoproterenol hydrochloride per kg
   of body weight, or isotonic saline (control solution) administered
   by nebulization on 3 different days to each of 10 patients with
   cystic fibrosis in a single blind study.  The doses of atropine
   sulfate and isoproterenol hydrochloride were based on published
   dose-response characteristics of the drugs.  Each day, thoracic gas
   volume and airway resistance were measured in a volume displacement
   body plethysmograph, and maximal expiratory flow-volume curves were
   performed before and at 15, 30, and 60 min after the inhalation.
   After inhalation of saline, group mean values for all pulmonary
   functions indicated greater airway obstruction at 15, 30, and 60 min
   when compared to pretreatment values.  After inhalation of
   isoproterenol and atropine, significant improvement (P < 0.05) was
   noted in maximal expiratory flows at 60 per cent of total lung
   capacity, specific airway conductance, thoracic gas volume, and
   residual volume.  Inhalation of atropine also significantly improved
   maximal expiratory flow at 25 per cent of vital capacity.
   Isoproterenol increased the mean flows by 8 to 46 per cent above
   baseline, and decreased thoracic gas volume and residual volume by
   11 to 16 per cent with the maximal response at 15 or 30 min.
   Atropine increased mean flows by 15 to 77 per cent and decreased
   thoracic gas volume and residual volume by 16 to 25 per cent with
   the maximal effect at 30 to 60 min.  The mean response to atropine,
   expressed as a percentage of baseline, was always greater than or
   equal to that for isoproterenol.  We conclude that vagal tone, which
   may reflect increased irritant receptor activity, contributes to the
   obstructive pulmonary function in cystic fibrosis.  Inhalation of
   atropine sulfate will decrease the pulmonary function abnormality,
   but side effects prohibit its clinical usefulness.
RF 001   WEST JR               PEDIATRICS                      13   155 954
   002   COOK CD               PEDIATRICS                      24   181 959
   003   BEIER FR              AM REV RESPIR DIS               94   430 966
   004   GANDEVIA B            ARCH DIS CHILD                  34   511 959
   005   POLGAR G              AM J DIS CHILD                 100   733 960
   006   MELLINS RB            PEDIATRICS                      41   560 968
   007   MEARNS MB             ARCH DIS CHILD                  43   528 968
   008   LIFSCHITZ MI          AM REV RESPIR DIS               99   399 969
   009   PHELAN PD             ARCH DIS CHILD                  44   393 969
   010   FEATHERBY EA          CAN MED ASSOC J                102   835 970
   011   ZAPLETAL A            PEDIATRICS                      48    64 971
   012   CHANG N               AM REV RESPIR DIS              106   867 972
   013   LANDAU LI             J PEDIATR                       82   863 973
   014   SHAPIRO GG            PEDIATRICS                      58   740 976
   015   DAY G                 ARCH DIS CHILD                  48   355 973
   016   SKORECKI K            ACTA PAEDIATR SCAND             65    39 976
   017   EMPEY DW              AM REV RESPIR DIS              113   131 976
   018   KLOCK LE              AM REV RESPIR DIS              112   371 975
   019   CROPP GJA             AM REV RESPIR DIS              112   599 975
   020   TAUSSIG LM            J PEDIATR                       82   380 973
   021   BARRON R              AM REV RESPIR DIS SUPPL        115   275 977
   022   CAVANAUGH MJ          AM REV RESPIR DIS              114   517 976
   023   TINKELMAN D           ANN ALLERGY                     38   298 977
   024   MERCER TT             ANN ALLERGY                     23   314 965
   025   MEAD J                J APPL PHYSIOL                  15   736 960
   026   DUBOIS AB             J CLIN INVEST                   35   322 956
   027   DUBOIS AB             J CLIN INVEST                   35   322 956
   028   POLGAR G              PULMONARY FUNCTION TESTING IN            971
   029   WENG TR               AM REV RESPIR DIS               99   879 969
   030   DEMUTH GR             PEDIATRICS                      35   200 965
   031   MATTHYS H             RESPIRATION                     27   447 970
   032   ZAPLETAL A            J APPL PHYSIOL                  26   308 969
   033   STEEL RGD             PRIN PROC OF STATISTICS                  960
   034   HAHN GJ               BIOMETRIKA                      58   323 971
   035   LANDAU LI             AM REV RESPIR DIS              108   593 973
   036   MANSELL A             AM REV RESPIR DIS              109   190 974
   037   COOPER DM             AM REV RESPIR DIS              109   519 974
   038   INGRAM RH             J CLIN INVEST                   59   696 977
   039   ALLAN JD              CLIN ALLERGY                     5   255 975
   040   WARNER JO             ARCH DIS CHILD                  51   507 976
   041   MELLIS CM             PEDIATRICS                      61   446 978
   042   WANNER A              AM REV RESPIR DIS              116    73 977
CT   1   BOHADANA AB           CLIN RESP PHYSIOL               16   769 980
     2   KATTAN M              THORAX                          35   531 980
     3   BERGMAN KR            CHEST                           78   891 980
     4   BOUSHEY HA            AM REV RESPIR DIS              121   389 980
     5   LARSEN GL             AM J DIS CHILD                 134  1143 980
     6   KRAEMER R             PEDIATR RES                     15  1433 981
     7   KRADJAN WA            AM REV RESPIR DIS              123   471 981
     8   VANASPEREN P          AM J DIS CHILD                 135   815 981
     9   GRIFFIN MP            J APPL PHYSIOL                  53  1576 982
    10   PAK CCF               AM REV RESPIR DIS              125   331 982
    11   DAVIS PB              J CHRON DIS                     36   269 983
    12   FRANCIS PB            MED CLIN NORTH AM               67   657 983
    13   DAVIS PB              CHEST                           85   802 984
    14   HEIDEPRIEM CC         DRUG INTEL CLIN PHARM           19   732 985
    15   SCHONI MH             PEDIATR RES                     19    47 985
    16   KONIG P               ANN ALLERGY                     55    95 985
    17   HORDVIK NL            AM REV RESPIR DIS              131   889 985
    18   DARGA LL              PEDIATR PULMONOL                 2    82 986
    19   KNOWLES MR            CLIN CHEST MED                   7   285 986
    20   BROWN SE              CHEST                           89     7 986
    21   BOUCHER RC            TOXICOL APPL PHARMACOL          87   264 987

PN 79024
RN 01004 
AN 79185775
AU Reid-L-M.
TI The pulmonary circulation: remodeling in growth and disease.  The
   1978 J. Burns Amberson lecture.
SO Am-Rev-Respir-Dis. 1979 Apr. 119(4). P 531-46.
MJ PULMONARY-ARTERY: pa.
MN ADULT.  ANIMAL.  ANOXIA: pa.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: pa.  HEART-DEFECTS-CONGENITAL: pa.
   HEART-SEPTAL-DEFECTS-VENTRICULAR: pa.  HEART-VENTRICLE: pa.  HUMAN.
   HYPERTENSION-PULMONARY: et, pa.  INFANT.  INFANT-NEWBORN.
   LUNG: bs, em, gd.  PULMONARY-ARTERY: ah, gd.
   PULMONARY-HEART-DISEASE: pa.  RATS.  SWINE.
EX This account draws on studies of young and mature lung, on normal and
   morbid anatomic features, on normal adaptations as in growth, and
   remodeling by disease.  Qualitative analysis of the vascular bed,
   development of the pulmonary circulation, right ventricular
   hypertrophy or cor pulmonale, remodeling in disease, and experimental
   studies are discussed.  Pulmonary hypertension offers us a complex
   pattern of structural and functional interaction; we are just
   beginning to realize how complex it is.  Information on normal
   structure, its modification and remodeling by growth and disease, and
   appropriate techniques are available that will enable us to formulate
   our questions with due regard for anatomic precision and functional
   implication.  And so research will lead to understanding and, it can
   be expected, to control of the undesirable aspects of pulmonary
   hypertension.
RF 001   ELLIOTT FM            THESIS                                   964
   002   ONEAL RM              ARCH PATHOL                     60   267 955
   003   WEIBEL ER             J APPL PHYSIOL                  17   343 962
   004   DUNNILL MS            THORAX                          17   329 962
   005   HAYWARD J             THORAX                           7    89 952
   006   BUCHER U              THORAX                          16   207 961
   007   BRIGHT R              GUYS HOSP REP                    1   338 836
   008   SHORT DS              J FACULTY RADIOL                 8   118 956
   009   HISLOP A              THORAX                          25   682 970
   010   ELLIOTT FJ            CLIN RADIOL                     16   193 965
   011$  REID L                IN: SCIENTIFIC BASIS OF M            289 968
   012   HISLOP A              J ANAT                         113    35 972
   013   HISLOP A              THORAX                          28   313 973
   014   HISLOP A              THORAX                          28   129 973
   015   HISLOP A              IN: DAVIS JA                         214 974
   016   REID L                AM J ROENTGENOL                129   777 977
   017   HISLOP A              IN: HODSON WA                    6    37 977
   018   BOYDEN EA             AM J ANAT                      121   749 967
   019   DAVIES G              THORAX                          25   669 970
   020   ANON                  WHO TECH REP SER NO 213                  961
   021   FULTON RM             BR HEART J                      14   413 952
   022   HISLOP A              J CLIN PATHOL                   25   534 972
   023   WEEKS JR              PROC SOC EXP BIOL MED          104   646 960
   024   HERGET J              ARCH INT PHARMACODYN THER      198   107 972
   025   RABINOVITCH M         CIRCULATION SUPPL 2             56   275 977
   026   RENDAS A              J APPL PHYSIOL                  45   806 978
   027   DAVIES GM             IN: LAWSON D PROC 5TH INT CF         350 969
   028   RYLAND D              THORAX                          30   285 975
   029   ANDERSON EG           J PATHOL                       110   273 973
   030   MEYRICK B             BR J DIS CHEST                  68    11 974
   031   HISLOP A              BR HEART J                      35  1178 973
   032   HISLOP A              BR HEART J                      37  1014 975
   033   HAWORTH SG            AM J CARDIOL                    40   781 977
   034   HAWORTH SG            THORAX                          32   129 977
   035   HAWORTH SG            THORAX                          32   121 977
   036   HAWORTH SG            BR HEART J                      39    80 977
   037   GROVER RF             AM HEART J                      66     1 963
   038   ANDERSON G            CLIN RADIOL                     24   113 973
   039   HAWORTH SG            BR HEART J                      40   826 978
   040   RABINOVITCH M         CIRCULATION SUPPL 2             56   193 977
   041   RABINOVITCH M         CIRCULATION                     58  1107 978
   042   HEATH D               CIRCULATION                     18   533 958
   043   MEYRICK B             COLLOQ INSERM ECHANG GAZ PUL    51   145 975
   044   HISLOP A              BR J EXP PATHOL                 57   542 976
   045   MEYRICK B             ANAT REC                       193    71 979
   046   MEYRICK B             J ANAT                         125   209 978
   047   MEYRICK B             LAB INVEST                      38   188 978
   048   HISLOP A              BR J EXP PATHOL                 58   653 977
   050   HISLOP A              BR J EXP PATHOL                 55   153 974
   051   MEYRICK B             AM J PATHOL                     94    37 979
   052   RENDAS A              J THORAC CARDIOVASC SURG        77   109 979
   053   CHEUNG DLC            THESIS                                   977
   054   UNGER M               J APPL PHYSIOL                  43   662 977
CT   1   REID L                J PEDIATR                       95   836 979
     2   RENDAS A              AM REV RESPIR DIS              121   873 980
     3   SCHNEEBERGER EE       CIRC RES                        49  1102 981
     4   JANNEY CG             AM J CLIN PATHOL                76   722 981
     5   INSELMAN LS           J PEDIATR                       98     1 981
     6   GEWITZ MH             PEDIATR PHARMACOL                2    57 982
     7   DAVIES P              HUM PATHOL                      13   911 982
     8   BERGOFSKY EH          BULL EUR PHYSIOPATH RESP        18    63 982
     9   DAVIES P              J APPL PHYSIOL                  53   859 982
    10   VANDEVENNE A          SEM HOP PARIS                   58   397 982
    11   REID L                ANN NY ACAD SCI                384     3 982
    12   MEYRICK B             CLIN CHEST MED                   4   199 983
    13   SOIFER SJ             J DEV PHYSIOL                    5   237 983
    14   GAULIN P              CAN J SURG                      26   250 983
    15   ZHU YJ                J APPL PHYSIOL                  54   680 983
    16   PITT BR               J APPL PHYSIOL                  55   383 983
    17   SOBIN SS              J APPL PHYSIOL                  55  1445 983
    18   WILCKEN B             J PEDIATR                      102   383 983
    19   GAULTIER C            AM REV RESPIR DIS              127   527 983
    20   HALES CA              AM REV RESPIR DIS              128   747 983
    21   KAY JM                AM REV RESPIR DIS              128  S 53 983
    22   LISTER G              PEDIATR PHARMACOL                4    85 984
    23   SCHALL SA             INT J CARDIOL                    5   103 984
    24   HEYMANN MA            J DEV PHYSIOL                    6   281 984
    25   LUCAS CL              CRC CRIT REV BIOMED ENG         10   317 984
    26   LYRENE RK             CLIN PERINATOL                  11   551 984
    27   SOIFER SJ             CLIN PERINATOL                  11   745 984
    28   BRIGHAM KL            CIRC RES                        54   623 984
    29   PITT BR               J APPL PHYSIOL                  57  1158 984
    30   CASSIO A              ACTA PAEDIATR SCAND             73   554 984
    31   REID LM               BR J DIS CHEST                  78   113 984
    32   PERKIN RM             J PEDIATR                      105   511 984
    33   HALES CA              SEM RESPIR MED                   7   136 985
    34   KINSELLA JP           PEDIATR RADIOL                  15   340 985
    35   GAULTIER C            BULL EUR PHYSIOPATH RESP        21    55 985
    36   BURROWS FA            CAN ANAESTH SOC J               32   364 985
    37   MEYRICK B             J APPL PHYSIOL                  59   443 985
    38   ABMAN SH              PEDIATRICS                      75    80 985
    39   COTTON DJ             CHEST                           87   217 985
    40   MICHAEL JR            LUNG                           163    65 985
    41   HUREWITZ AN           HEART LUNG                      15   327 986
    42   THOMPSON BT           HEART LUNG                      15   457 986
    43   BENITZ WE             PEDIATR RES                     20   966 986
    44   HEYMANN MA            DRUGS                           32   164 986
    45   CUSTER JR             J APPL PHYSIOL                  60    32 986
    46   OU LC                 RESPIR PHYSIOL                  64    81 986
    47   REID LM               CHEST                           89   279 986

PN 79025
RN 01005 
AN 80063276
AU Nelson-L-A.  Callerame-M-L.  Schwartz-R-H.
TI Aspergillosis and atopy in cystic fibrosis.
SO Am-Rev-Respir-Dis. 1979 Oct. 120(4). P 863-73.
MJ ASPERGILLOSIS-ALLERGIC-BRONCHOPULMONARY: et.  CYSTIC-FIBROSIS: co.
MN ADOLESCENCE.  ADULT.  ASPERGILLOSIS-ALLERGIC-BRONCHOPULMONARY: di, im.
   ASPERGILLUS: ip.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: im, mi.
   EOSINOPHILS.  FOLLOW-UP-STUDIES.  HUMAN.  IGE: an.
   PRECIPITINS: an.  SKIN-TESTS.  SPUTUM: cy, mi.  SUPPORT-U-S-GOVT-P-H-S.
AB Forty-six patients with cystic fibrosis (CF) were studied for
   colonization and sensitization by Aspergillus organisms. The fungus
   was cultured from 21 of 37 (57%) patients who produced sputum. The
   non-CF sputum isolation rate was 6.5%. Sputum hyphae were seen in 95%
   of patients with positive cultures. Sputum eosinophilia accompanied
   colonization by Aspergillus. Aspergillus precipitins were found in
   37% of CF patients; positive immediate skin tests were found in 39%.
   "Atopy" defined by skin test criteria was found in 46%. All of these
   findings were more common in patients with more severe disease (p
   less than 0.05). CF patients had predominant mold sensitivity in
   contrast to predominant pollen sensitivity in a control group of
   asthmatic subjects. Serum IgE concentrations were increased in 22% of
   CF patients. CF patients who had increased serum concentrations of
   IgE were more likely to have a family history of atopy. Wheezing was
   more common in those who were atopic, especially the group with
   predominant mold sensitivity who had more severe disease. Four
   patients fulfilled the diagnostic criteria for allergic
   bronchopulmonary aspergillosis (ABPA) during the time of study and
   follow-up. A fifth patient had ABPA diagnosed before the study. The
   incidence of ABPA during a 2-yr period in our CF population was 11%.
RF 001   MEARNS MB             LANCET                           1   538 967
   002   SCHWARTZ RH           AM J DIS CHILD                 120   432 970
   003   WARREN CPW            CLIN ALLERGY                     5     1 975
   004   BARDANA EJ JR         AM J DIS CHILD                 129  1164 975
   005   GALANT SP             AM REV RESPIR DIS              114   325 976
   006   WELLS ID              J ALLERGY CLIN IMMUNOL          57   234 976
   007   YOUNG RC              MEDICINE (BALTIMORE)            49   147 970
   008   MEARNS MB             THORAX                          20   385 965
   009   BATTEN JC             MOD PROBL PEDIATR               10   227 967
   010   ORES CN               CF CLUB ABST                    16    48 975
   011   TAUSSIG LM            J PEDIATR                       82   380 973
   012   SLAVIN RG             J ALLERGY                       46   150 970
   013   SAFIRSTEIN BH         AM REV RESPIR DIS              108   450 973
   014   ROSENBERG M           ANN INTERN MED                  86   405 977
   015   SLAVIN RG             IN: MIDDLETON E                      843 978
   016   ESTERLY JR            JOHNS HOPKINS MED J            122    94 968
   017   NEMIR RL              IN: KENDIG EL JR                     446 977
   018   FRASER RG             DIAGNOSIS OF DISEASES OF CHES            970
   019   COMSTOCK GW           MYCOPATHOL MYCOL APPL           54    55 974
   020   AUSTWICK PKC          IN: LENNETTE EH                          974
   021   SCHNEIERSON SS        ATLAS OF DIAGNOSTIC MICROBIOL            974
   022   KJELLMAN NIM          THESIS                                   976
   023   BLYTH W               SABOURAUDIA                      9   273 971
   024   BLYTH W               SABOURAUDIA                      9   283 971
   025   SLAVIN RG             J ALLERGY CLIN IMMUNOL          62     7 978
   026   HENDERSON AH          THORAX                          23   501 968
   027   IRANI FA              AM REV RESPIR DIS              103   552 971
   028   ROSENBERG M           J PEDIATR                       91   194 977
   029   RACHELEFSKY GS        AM J DIS CHILD                 128   355 974
   030   ALLAN JD              CLIN ALLERGY                     5   255 975
   031   BARRON R              CF CLUB ABST                          23 977
   032   BUCKLEY RH            N ENGL J MED                   281   465 969
   033   TOWNSEND RW           IN: FEINGOLD BF                          973
   034   MORROW MB             ANN ALLERGY                     22   575 964
   035   CAMPBELL MJ           AM REV RESPIR DIS               89   186 964
   036   SCHWARTZ HJ           J ALLERGY CLIN IMMUNOL          62     9 978
   037   PEPYS J               CLIN ALLERGY SUPPL               3   491 973
   038   NOVEY HS              WEST J MED                     180     1 979
   039   MELLIS CM             PEDIATRICS                      61   446 978
   040   SMITH JM              IN: MIDDLETON E                      633 978
   041   PATTERSON R           INT ARCH ALLERGY                46   150 974
   042   MARX JJ               J ALLERGY CLIN IMMUNOL          57   328 976
   043   GEHA RS               J ALLERGY CLIN IMMUNOL          60   357 977
   044   WARNER JO             ARCH DIS CHILD                  51   507 976
   045   LEWISTON NJ           CF CLUB ABST                          47 973
   046   IMBEAU SA             J ALLERGY CLIN IMMUNOL          52    91 978
   047   SHADOMY S             IN: LENNETTE EH                      569 974
CT   1   SLY PD                AUST PAEDIATR J                 16   205 980
     2   HODSON ME             THORAX                          35   801 980
     3   LARSEN GL             AM J DIS CHILD                 134  1143 980
     4   SCHWARTZ RH           J ALLERGY CLIN IMMUNOL          68   290 981
     5   CLARKE CW             BR J DIS CHEST                  75    15 981
     6   GLIMP RA              CHEST                           80    85 981
     7   LEWISTON NJ           CHEST                           80   389 981
     8   MOSS RB               J PEDIATR                       99   215 981
     9   HENRY RL              AUST PAEDIATR J                 18   110 982
    10   PITCHERWILMOTT RW     ARCH DIS CHILD                  57   582 982
    11   VOSS MJ               J ALLERGY CLIN IMMUNOL          69   536 982
    12   MANTHEI U             AM REV RESPIR DIS              126   253 982
    13   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
    14   KATZ SM               JAMA                           248  2284 982
    15   GUIDOTTI TL           AM J MED SCI                   283   157 982
    16   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    17   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
    18   SCHOLER HJ            MYKOSEN                         26   173 983
    19   LAUFER P              CUTIS                           31   665 983
    20   BACULARD A            ARCH FR PEDIATR                 40   109 983
    21   EFTHIMIOU J           THORAX                          39   150 984
    22   SMITH MJ              THORAX                          39   369 984
    23   BIRX DL               ANN ALLERGY                     53   124 984
    24   LAUFER P              J ALLERGY CLIN IMMUNOL          73    44 984
    25   ROHATGI PK            SOUTH MED J                     77  1291 984
    26   SLAVIN RG             CLIN REV ALLERGY                 3   167 985
    27   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
    28   LESTER LA             SEM RESPIR MED                   6   285 985
    29   LAUFER P              J ASTHMA                        22   253 985
    30   LAUFER P              CUTIS                           35   557 985
    31   LAUFER P              CUTIS                           36   245 985
    32   DUPONT B              ARCH FR PEDIATR                 42   943 985
    33   BERKIN KE             EUR J RESPIR DIS                67   103 985
    34   ISPIZUA AU            MED CLIN                        85   628 985
    35   FINK JN               CHEST                           87  S 81 985
    36   SCHONHEYDER H         ACTA PATH MICROB IMMU SCA (B)   93   105 985
    37   WILMOTT RW            AM J DIS CHILD                 139   669 985
    38   GORDON IJ             J ROY COLL PHYSICIANS LOND      20   206 986
    39   PATY E                ARCH FR PEDIATR                 43   243 986
    40   SLAVIN RG             ARCH INTERN MED                146  1799 986

PN 79026
RN 01006 
AN 79163856
AU Feldman-J.  Traver-G-A.  Taussig-L-M.
TI Maximal expiratory flows after postural drainage.
SO Am-Rev-Respir-Dis. 1979 Feb. 119(2). P 239-45.
MJ BRONCHITIS: th.  CYSTIC-FIBROSIS: th.  RESPIRATION.
MN ADOLESCENCE.  ADULT.  AGED.  BRONCHITIS: pp.  CHILD.
   CYSTIC-FIBROSIS: pp.  FEMALE.  FORCED-EXPIRATORY-VOLUME.  HUMAN.
   MALE.  MAXIMAL-EXPIRATORY-FLOW-VOLUME-CURVES.  MIDDLE-AGE.
   PEAK-EXPIRATORY-FLOW-RATE.  PHYSICAL-THERAPY.  POSTURE.
   TOTAL-LUNG-CAPACITY.  SUPPORT-U-S-GOVT-P-H-S.  VITAL-CAPACITY.
AB Flows measured from maximal expiratory flow-volume (MEFV) curves were
   used to evaluate the efficacy of postural drainage in improving
   ventilatory function acutely. Maximal expiratory flow-volume curves
   were obtained for 9 cystic fibrosis subjects and 10 subjects with
   chronic bronchitis before and 5, 15, and 45 min after a 30-min
   session of postural drainage with percussion, vibration, and
   coughing. Forced vital capacity (FVC) was significantly increased 45
   min after drainage for the combining group. Flows at high lung
   volumes were different for the 2 subgroups. Subjects with cystic
   fibrosis demonstrated a significant increase in peak expiratory flow
   rates 45 min after drainage and an increase in forced expiratory
   volume in one sec at all time intervals. The subjects with chronic
   bronchitis had a decreased peak expiratory flow rate 5 min after
   drainage, but by 45 min, it had returned to baseline. There was no
   significant change in one-sec forced expiratory volume at any time
   interval for the chronic bronchitis subgroup. Changes in flows at low
   lung volumes were similar for the 2 subgroups. Forty-five min after
   drainage there was an increase in flow rates near 50 per cent of FVC.
   Flows near 25 per cent of FVC were increased 15 and 45 min after
   drainage. This study demonstrated that postural drainage with
   coughing resulted in significant improvement in flows at low lung
   volumes. Changes in flows at high lung volumes were less consistent.
RF 001   THACKER EW            POSTURAL DRAINAGE AND RESPIRA            971
   002   PETTY TL              INTENSIVE AND REHABILITATIVE             974
   003   GASKELL DV            BROMPTON HOSP GUIDE TO CHEST             973
   004   JONES NL              AM REV RESPIR DIS              110   132 974
   005   HUBER AL              J ALLERGY CLIN IMMUNOL          53   109 974
   006   KANG B                J ALLERGY CLIN IMMUNOL          53   109 974
   007   MARCH H               ARCH PHYS MED REHABIL           52   528 971
   008   PETERSEN SE           ACTA MED SCAND                 182   293 967
   009   TECKLIN JS            PHYS THER                       55  1081 975
   010   MOTOYAMA EK           IN: MANGOS JA                        335 973
   011   HYATT RE              AM REV RESPIR DIS              107   191 973
   012   LANDAU LI             AM REV RESPIR DIS              108   593 973
   013   GELB AF               N ENGL J MED                   288   395 973
   014   TAUSSIG LM            J PEDIATR                       82   380 973
   015   WALKER HM             STATISTICAL INFERENCE                    953
   016   DUNN OJ               APPLIED STATISTICS ANALYSIS O            974
   017   POLGAR G              PULMONARY FUNCTION TESTING IN            971
   018   BATES DV              RESPIRATORY FUNCTION IN DISEA            971
   019   ANTHONISEN P          ACTA MED SCAND                 175   715 964
   020   MEAD J                J APPL PHYSIOL                  22    95 967
   021   MEAD J                J APPL PHYSIOL                  44   156 978
CT   1   NEWTH CJL             PEDIATR CLIN NORTH AM           26   617 979
     2   CONNORS AF            CHEST                           78   559 980
     3   DARROW G              AM REV RESPIR DIS              122   155 980
     4   ROCHESTER DF          AM REV RESPIR DIS              122   133 980
     5   PASSERO MA            CLIN PEDIATR                    20   264 981
     6   HUDSON LD             MED CLIN NORTH AM               65   629 981
     7   PETTY TL              SEM RESPIR MED                   3   263 982
     8   KERREBIJN KF          EUR J RESPIR DIS                63    35 982
     9   MALONEY FP            ARCH PHYS MED REHABIL           63   423 982
    10   SUTTON PP             EUR J RESPIR DIS                63   188 982
    11   REDDING GJ            AM REV RESPIR DIS              126    31 982
    12   SUTTON PP             EUR J RESPIR DIS                64    62 983
    13   ZAPLETAL A            EUR J RESPIR DIS                64   426 983
    14   DESMOND KJ            J PEDIATR                      103   538 983
    15   DEBOECK C             AM REV RESPIR DIS              129   182 984
    16   WOLLMER P             EUR J RESPIR DIS                66   233 985
    17   KIRILOFF LH           CHEST                           88   436 985
    18   FALING LJ             CLIN CHEST MED                   7   599 986
    19   VANDERSCHANS CP       THORAX                          41   448 986
    20   VERBOON JML           EUR J RESPIR DIS                69   169 986
    21   WEBBER BA             BR J DIS CHEST                  80   353 986

PN 79027
RN 01007 
AN 79207490
AU Zambie-M-F.  Gupta-S.  Lemen-R-J.  Hilman-B.  Waring-W-W.  Sly-R-M.
TI Relationship between response to exercise and allergy in patients
   with cystic fibrosis.
SO Ann-Allergy. 1979 May. 42(5). P 290-4.
MJ CYSTIC-FIBROSIS: co.  EXERTION.  HYPERSENSITIVITY: co.
MN ADOLESCENCE.  ADULT.  BODY-HEIGHT.  CHILD.  FEMALE.
   FORCED-EXPIRATORY-VOLUME.  HUMAN.  MALE.  PEAK-EXPIRATORY-FLOW-RATE.
   VITAL-CAPACITY.
AB Responses to treadmill exercise of 36 patients with cystic fibrosis
   were studied to evaluate their usefulness in identifying those with
   atopy. Ten of 36 patients with cystic fibrosis (28%) had an abnormal
   response to exercise but had no more frequent atopic characteristics
   than those who had normal exercise responses. Response to treadmill
   exercise alone cannot identify patients with atopic disease among
   those with cystic fibrosis.
RF 001   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   002   VAN METRE TE JR       J ALLERGY CLIN IMMUNOL          31   141 960
   003   KULCZYCKI LL          JAMA                           175   358 961
   004   RACHELEFSKY GS        AM J DIS CHILD                 128   355 974
   005   WARNER JO             ARCH DIS CHILD                  51   507 976
   006   WARNER JO             LANCET                           1   990 976
   007   FEATHERBY EA          CAN MED ASSOC J                102   835 970
   008   WARREN CPW            CLIN ALLERGY                     5     1 975
   009   MCFARLANE H           CLIN ALLERGY                     7   279 977
   010   SPITZ E               J ALLERGY CLIN IMMUNOL          49   337 972
   011   GODFREY S             EXERCISE TESTING IN CHILDREN             974
   012   CROPP GJA             PEDIATR CLIN NORTH AM           22    63 975
   013   SLY RM                IN: WEISS EB                             976
   014   BIERMAN CW            PEDIATRICS                      56   847 975
   015   HANSEL FK             CLIN ALLERGY                             953
   016   KJELLMAN NIM          CLIN ALLERGY                     6    51 976
   017   DERBES VJ             J ALLERGY                       28   287 957
   018   MELLIS CM             PEDIATRICS                      61   446 978
   019   ROTHSTEIN RJ          J ALLERGY CLIN IMMUNOL          53   100 974
   020   HEIMLICH EM           J ALLERGY CLIN IMMUNOL          37   103 966
   021   DAY G                 ARCH DIS CHILD                  48   355 973
   022   SKORECKI K            ACTA PAEDIATR SCAND             65    39 976
   023   GIMENO F              THORAX                          29    16 974
   024   BARBEE RA             ANN INTERN MED                  84   129 976
   025   SLY RM                ANN ALLERGY                     28     1 970
   026   CROPP GJA             PEDIATRICS SUPPL                56   868 975
   027   KATTAN M              J PEDIATR                       92   718 978
CT   1   SLY PD                AUST PAEDIATR J                 16   205 980

PN 79028
RN 01008 
AN 80086311
AU Stagg-B-H.  Wood-T-P.
TI Radioimmunoassay of trypsin.  A new aid in the assessment of
   pancreatic function.
SO Ann-Clin-Biochem. 1979 May. 16(3). P 147-51.
MJ PANCREAS: en.  PANCREATIC-DISEASES: di.  TRYPSIN: an.
MN CYSTIC-FIBROSIS: di.  DIABETES-MELLITUS-INSULIN-DEPENDENT: di.
   HUMAN.  PANCREATIC-DISEASES: en.  PANCREATIC-NEOPLASMS: di.
   PANCREATITIS: di.  RADIOIMMUNOASSAY: mt.
AB This review describes the development and application of a novel test
   to determine levels of human immunoreactive trypsin, an enzyme
   produced solely by the pancreas, in biological fluids. Being organ-
   specific, the assay of immunoreactive trypsin should be an ideal
   marker of pancreatic function, and this is supported by the results
   of a number of clinical and research investigations. Use of this
   assay in studies of chronic pancreatitis, juvenile-onset diabetes,
   and cystic fibrosis has yielded much valuable data, and it is
   expected that further research will lead to an improved understanding
   of these and other conditions associated with the pancreas in health
   and disease.
RF 001   ADRIAN TE             GUT                             19  A960 978
   002   ADRIAN TE             CLIN SCI MOL MED                54   13P 978
   004   BAMBULE-DICK J        IR J MED SCI SUPPL 1           146     3 978
   005   BRAY PT               CLIN CHIM ACTA                  80   333 977
   006   CROSSLEY JR           LANCET                           2  1093 977
   007   CROSSLEY JR           LANCET                           1   472 979
   008   DANDONA P             BR MED J                         2  1125 978
   009   DOMSCHKE S            AM J DIG DIS                    20   309 975
   010   ELIAS E               LANCET                           2    66 977
   011   FEDAIL SS             GUT                             19  A445 978
   012   FRIER BM              GUT                             17   685 976
   013   GOWENLOCK AH          ANN CLIN BIOCHEM                14    61 977
   014   GREENE LJ             IN: FRITZ H                          188 974
   016   KOOP H                PROC EUROP PANCREAS 11TH SYM             978
   017   LAKE-BAKAAR G         GUT                             19  A446 978
   018   LAKE-BAKAAR G         GUT "CLEARANCE OF"              19  A960 978
   019   LAKE-BAKAAR G         GUT                             19  A445 978
   020   LAKE-BAKAAR G         GUT "URINE TRYPSIN"             19  A960 978
   021   LIEBOW C              SCIENCE                        189   472 975
   023   PROSSER R             ARCH DIS CHILD                  49   597 974
   024   SMALLEY CA            LANCET                           2   415 978
   025   TEMLER RS             BIOCHIM BIOPHYS ACTA           236    72 971
   026   TEMLER RS             BIOCHIM BIOPHYS ACTA           445   720 976
   027   TEMLER RS             ENZYME                          22   249 977
   028   WOOD TP               LANCET                           1   781 979
CT   1   BURLINA A             SCAND J GASTROENTEROL           15    35 980
     2   FAHRENKRUG J          CLIN CHEM                       26  1573 980
     3   ODONNELL MD           CLIN CHIM ACTA                 104   265 980
     4   BUTTERWORTH J         ANAL BIOCHEM                   106   156 980
     5   FIEDLER F             HOPPE SEYLERS Z PHYSIOL CHEM   361  1661 980
     6   FAHRENKRUG J          CLIN CHEM                       27  1655 981
     7   KOEHN HD              CLIN CHEM                       27   502 981
     8   OCONNOR CM            CLIN CHIM ACTA                 114    29 981
     9   LAWRENCE CH           BIOCHIM BIOPHYS ACTA           657    13 981
    10   BECKER H              LANGENBECKS ARCH CHIR            S    47 983
    11   HAFKENSCHEID JCM      J CLIN CHEM CLIN BIOCHEM        21   167 983
    12   BOHNER J              J CLIN CHEM CLIN BIOCHEM        22   943 984
    13   LEUNG FY              CLIN CHEM                       30  1361 984
    14   ASH KO                J MED TECHNOL                    2   427 985
    15   LESI C                CLIN BIOCHEM                    18   317 985
    16   LESI C                DIG DIS SCI                     30   552 985

PN 79029
RN 01009 
AN 79208273
AU Swersky-R-B.  Chang-J-B.  Wisoff-B-G.  Gorvoy-J.
TI Endobronchial balloon tamponade of hemoptysis in patients with
   cystic fibrosis.
SO Ann-Thorac-Surg. 1979 Mar. 27(3). P 262-4.
MJ CATHETERIZATION: mt.  CYSTIC-FIBROSIS: co.  HEMOPTYSIS: th.
   HEMOSTATIC-TECHNICS.  TAMPONS.
MN ADOLESCENCE.  ADULT.  BRONCHOSCOPY: is.  CATHETERIZATION: is.
   CYSTIC-FIBROSIS: ra.  FEMALE.  FIBER-OPTICS.  HEMOPTYSIS: et, ra.
   HEMOSTATIC-TECHNICS: is.  HUMAN.  MALE.  METHODS.  RECURRENCE.
AB The flexible bronchoscope with Fogarty balloon and irrigating
   catheters is used effectively to manage and treat hemoptysis in a
   series of patients with cystic fibrosis.  This procedure is well
   suited to such patients, who are prone to recurrent hemoptysis, and
   may also be indicated in any inoperable patient with poor
   cardiopulmonary reserve.
RF 001   CROCCO JA             ARCH INTERN MED                121   495 968
   002   FELLOWS KE            RADIOLOGY                      114   551 975
   003   FOGARTY T             SURG GYNECOL OBSTET            116   241 963
   004   GOTTLIEB LS           CHEST                           67   482 975
   005   GOURIN A              CHEST                           68   120 975
   006   HIEBERT CA            CHEST                           66   397 974
   007   HOLSCLAW DS           J PEDIATR                       76   829 970
   008   MEARNS MB             ARCH DIS CHILD                  47   499 972
   009   ORES CN               AM REV RESPIR DIS               99   790 969
   010   REMY J                RADIOLOGY                      122    33 977
   011   SAW EC                CHEST                           70   589 976
   012   SCHUSTER SR           J THORAC CARDIOVASC SURG        48   750 964
   013   SMIDDY JF             CHEST                           64   158 973
   014   WHOLEY MH             JAMA                           236  2501 976
CT   1   DAROSA JFT            ANN THORAC SURG                 30   409 980
     2   FERMON C              NY STATE J MED                  81  1223 981
     3   TABACHNIK NF          SURG GYNECOL OBSTET            152   837 981
     4   MARMON L              J PEDIATR SURG                  18   811 983
     5   PORTER DK             ARCH INTERN MED                143   287 983
     6   HOWARD WJ             POSTGRAD MED                    77    53 985

PN 79030
RN 01010 
AN 79230232
AU Maybury-B-A.  Blessing-Moore-J.  deWit-S-A.  Lewiston-N-J.
   Yeager-A-S.
TI Antimicrobial susceptibilities of rough, smooth, and mucoid colony
   types of Pseudomonas isolated from cystic fibrosis patients.
SO Antimicrob-Agents-Chemother. 1979 Mar. 15(3). P 494-6.
MJ ANTIBIOTICS: pd.  CYSTIC-FIBROSIS: mi.  PSEUDOMONAS: de.
MN HUMAN.  PSEUDOMONAS: cy.  SPUTUM: mi.
AB Minimal inhibitory concentrations of carbenicillin, chloramphenicol,
   tetracycline, gentamicin, tobramycin, and trimethoprim-
   sulfamethoxazole were determined for rough, smooth, and mucoid
   Pseudomonas sp. isolates from sputa collected from 40 cystic
   fibrosis patients.  Ninety-four percent of the minimal inhibitory
   concentrations obtained by using mixed inocula of colonies of
   different morphological types fell within one serial dilution of the
   most resistant minimal inhibitory concentration obtained when each
   colony type was tested separately.
RF 001   BARRY AL              ANTIMICROBIC SUSCEPTIBILI                976
   002   BARRY AL              ANTIMICROB AGENTS CHEMOTHER     13    61 978
   003   BERGAN T              ACTA PATH MICROBIOL SCAND (B)   83   553 975
   004   DOGGETT RG            INFECT IMMUN                     6   628 972
   005   GAVAN TL              IN: BALOWS A                          88 974
   006   GAVAN TL              AM J CLIN PATHOL                53   880 970
   007   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   008   HOIBY N               SCAND J RESPIR DIS              58    65 977
   009   WASHINGTON JA II      IN: LENNETTE EH                      410 974
   010   ZIERDT CH             J BACTERIOL                     87  1003 964
CT   1   KELLY HW              DRUG INTEL CLIN PHARM           18   772 984

PN 79031
RN 01011 
AN 80264180
AU Greven-Brauns-G.  Mulkens-E.
TI Results of 10 years of screening of newborn infants for inherited
   metabolic diseases in the province of Limburg (Belgium).
SO Arch-Belg-Med-Soc. 1979 Oct. 37(8). P 516-9.
MJ METABOLISM-INBORN-ERRORS: oc.
MN AMINO-ACID-METABOLISM-INBORN-ERRORS: oc.  BELGIUM.
   CYSTIC-FIBROSIS: oc.  GALACTOSEMIA: oc.  HUMAN.  INFANT-NEWBORN.
   PHENYLKETONURIA: oc.
AB In the province of Limburg, all newborn babies are screened for
   metabolic anomalies: for amino acidopathies since 1968, for
   galactosemia since 1974 and for mucoviscidosis since 1978.  On
   127,676 newborns, there were 12 cases of phenylketonuria and 3 other
   inherited anomalies.  A meaningful policy of the government on
   neonatal screening necessarily requires a good organization, to put
   together the screening data, diagnosis, treatment and follow-up.
RF 001   BEUTLER E             J LAB CLIN MED                  68   137 966
   002   CLOW C                AM J DIS CHILD                 117    48 969
   003   EFRON ML              N ENGL J MED                   270  1378 964
   004   GREVEN-BRAUNS G       BELG ARCH SOC GENEESK HYG ARB   28   538 970
   005   GREVEN-BRAUNS G       BELG ARCH SOC GENEESK HYG ARB   33   253 975
   006   GUTHRIE R             PEDIATRICS                      32   338 963
   007   LEVY HL               CLIN BIOCHEM                     1   200 968
   008   SCRIVER CR            LANCET                           2   230 964

PN 79032
RN 01012 
AN 80018835
AU Maxwell-M.  Redmond-A.
TI Comparative trial of manual and mechanical percussion technique with
   gravity-assisted bronchial drainage in patients with cystic fibrosis.
SO Arch-Dis-Child. 1979 Jul. 54(7). P 542-4.
MJ CYSTIC-FIBROSIS: th.  DRAINAGE.  PHYSICAL-THERAPY: mt.
MN ADOLESCENCE.  ADULT.  CHILD.  COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: pp.
   FORCED-EXPIRATORY-VOLUME.  GRAVITATION.  HUMAN. PHYSICAL-THERAPY: is.
   RANDOM-ALLOCATION.  SPUTUM.  VITAL-CAPACITY.  CLINICAL-TRIALS.
AB Chest physiotherapy still remains one of the most important aspects
   in the treatment of chest complications of cystic fibrosis. A
   mechanical device that allows the patient with cystic fibrosis to do
   his own chest physiotherapy will be of great benefit if it is as
   effective as manual percussion. 14 patients with cystic fibrosis
   using mechanical and manual percussion physiotherapy were studied by
   measuring sputum volumes, and FEV and FVC. Results with mechanical
   percussor were as good as with the manual percussor and, therefore,
   it would be reasonable for the older patient to use the former on his
   own.
RF 001   ANDERSON CM           CF A MANUAL OF DIAGNOSIS AND             976
   002   DENTON R              AM REV RESPIR DIS               86    41 962
   003   KENDIG EL JR          IN: WARING W                         114 977
CT   1   ANON                  LANCET                           2   729 979
     2   DARROW G              AM REV RESPIR DIS              122   155 980
     3   SUTTON PP             EUR J RESPIR DIS                63   188 982
     4   SUTTON PP             SEM RESPIR MED                   5   353 984
     5   WANNER A              AM REV RESPIR DIS              130   701 984
     6   SUTTON PP             EUR J RESPIR DIS                66   147 985

PN 79033
RN 01013 
AN 79164522
TI Paediatric Research Society.  Plymouth, 15 and 16 September 1978:
   Abstracts.
SO Arch-Dis-Child. 1979 Feb. 54(2). P 160-5.
MJ ASTHMA: th.  CYSTIC-FIBROSIS: me.  PEDIATRICS.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CONGRESSES.  FEMALE.
   GREAT-BRITAIN.  HUMAN.  INFANT.  INFANT-NEWBORN.  MIDDLE-AGE.
   RESEARCH.  SOCIETIES-MEDICAL.
EX Abstracts are given for articles on abnormalities of the complement
   system in children with liver disease, hepatic collagen synthesis and
   its modification by colchicine is a rat model of cirrhosis of the
   liver, postprandal total serum bile acid concentrations in cystic
   fibrosis, release of endogenous secretin in children with cystic
   fibrosis, bronchial allergy in children with cystic fibrosis, and
   other topics.
RF 001   MCNEISH AS            LANCET                           2   946 975
   001   POPA VT               J ALLERGY CLIN IMMUNOL          59    54 977
   001   CHARLESWORTH JA       CLIN EXP IMMUNOL                28   496 977
   001   HOLMES H              LANCET                           1   755 977
   001   MASHIGE F             CLIN CHIM ACTA                  70    79 976
   002   OFEK I                NATURE                         265   623 977
   002   SOOTHILL JF           CLIN EXP IMMUNOL                27    30 977
   003   WURTMAN RJ            N ENGL J MED                   296  1383 977
CT   1   MCKIERNAN J           IR MED J                        74    89 981
     2   MCKIERNAN J           IR J MED SCI                   150    66 981

PN 79034
RN 01014 
AN 79164528
AU Ryley-H-C.  Neale-L-M.  Brogan-T-D.  Bray-P-T.
TI Screening for cystic fibrosis in the newborn by meconium analysis.
SO Arch-Dis-Child. 1979 Feb. 54(2). P 92-7.
MJ CYSTIC-FIBROSIS: pc.  MASS-SCREENING: mt.  MECONIUM: an.
MN ALBUMINS: an.  ALPHA-1-ANTITRYPSIN: an.  COMPARATIVE-STUDY.
   CYSTIC-FIBROSIS: di.  FALSE-NEGATIVE-REACTIONS.  FECES: an.  HUMAN.
   INFANT.  INFANT-NEWBORN.  PROTEASE-INHIBITORS: an.  TIME-FACTORS.
AB During a 4-year routine screening programme for cystic fibrosis (CF)
   15 464 specimens were examined for raised meconium albumin levels by
   a test strip method and by electroimmunoassay. The incidence of false-
   positive results was about 5 per 1000 specimens in either test. This
   could be reduced by 90% by determining the ratio of albumin : alpha-1-
   trypsin inhibitor (a ratio below 2.0 being considered as a negative
   result), and it could be reduced to zero by determining the ratio in
   subsequent faecal specimens. Three of 12 meconium specimens from
   infants with proved CF gave false-negative results in all 3 tests.
   The other 9 specimens had greater than 100 mg albumin/g dry weight
   and albumin: alpha-1-trypsin inhibitor ratios of greater than 3.0; in
   subsequent faecal specimens the ratios were over 4.0. 176 meconium
   specimens from elsewhere in the UK were examined and these included
   23 from infants who were subsequently proved to have CF. Six of these
   23 CF specimens gave false-negative results, the other 17 being
   strongly positive. The origins of meconium serum protein suggest that
   infants with CF in whom meconium gives false-negative results have
   normal pancreatic functions at birth. The specificity of current
   meconium tests therefore cannot be improved as they depend on
   pancreatic dysfunction.
RF 001   ANON                  J PEDIATR                       88   711 976
   002   GITLIN D              AM J OBSTET GYNECOL            113   632 972
   003   GRIFFITHS AD          ARCH DIS CHILD                  51   321 976
   004   HUANG NN              AM J DIS CHILD                 120   289 970
   005   KOLLBERG H            ACTA PAEDIATR SCAND             64   477 975
   006   MAKAREM A             IN: HENRY RJ                        1123 974
   007   ORENSTEIN DM          AM J DIS CHILD                 131   973 977
   008   PROSSER R             ARCH DIS CHILD                  49   597 974
   009   RULE AH               PEDIATRICS                      45   847 970
   010   RYLEY HC              CLIN CHIM ACTA                  64   117 975
   011   RYLEY HC              ARCH DIS CHILD                  51   641 976
   012   SCHUTT WH             ARCH DIS CHILD                  43   178 968
   013   SCHUTTRINGER G        CLIN CHIM ACTA                  83   109 978
   014   SHWACHMAN H           PEDIATRICS                      46   335 970
   015   STEPHAN U             PEDIATRICS                      55    35 975
   016   STERN RC              J PEDIATR                       89   406 976
   017   WARWICK WJ            MINN MED                        52  1567 969
   018   WISER WC              PEDIATRICS                      33   115 964
CT   1   TARNOKY AL            J ROY SOC MED                   73    73 980
     2   LITTLEWOOD JM         PRACTITIONER                   224   305 980
     3   MASTELLA G            RIV ITAL PEDIATR                 7   581 981
     4   LAMBOTTE C            J GENET HUM                     29    85 981
     5   EVANS RT              J CLIN PATHOL                   34   911 981
     6   RYLEY HC              J CLIN PATHOL                   34   906 981
     7   RYLEY HC              J CLIN PATHOL                   34   179 981
     8   PEDERZINI F           RIV ITAL PEDIATR                 9   445 983
     9   HEELEY AF             CLIN CHEM                       29  2011 983
    10   CASSIO A              ACTA PAEDIATR SCAND             73   554 984
    11   ORENSTEIN DM          SEM RESPIR MED                   6   252 985

PN 79035
RN 01015 
AN 80018840
AU Jenner-B-M.  Landau-L-I.  Phelan-P-D.
TI Pulmonary candidiasis in cystic fibrosis.
SO Arch-Dis-Child. 1979 Jul. 54(7). P 555-6.
MJ CYSTIC-FIBROSIS: co.  LUNG-DISEASES-FUNGAL: et.  CANDIDIASIS: et.
MN ASTHMA: co.  CASE-REPORT.  CHILD.  FEMALE.  HUMAN.
AB A child with cystic fibrosis and asthma developed pulmonary
   candidiasis. Predisposing factors in this patient were prolonged
   antibiotic therapy, high-dose corticosteroids, and intravenous
   catherisation. A diagnosis was made by lung puncture and confirmed by
   rapid response to 5-fluorocytosine.
RF 001   BANDT PD              JAMA                           220  1578 972
   002   GOLDSTEIN E           J INFECT DIS                   125   190 972
   003   HURLEY DL             J INFECT DIS                   132   393 975
   004   KLEIN JO              PEDIATRICS                      44   486 969
   005   KOHLSCHUTTER A        ARCH DIS CHILD                  49   154 974
   006   MIRSKY HS             CANCER                          30   348 972
   007   MONTGOMERIE JZ        J INFECT DIS                   132    82 975
   008   WINNER HI             PROC SYMP ON CANDIDA INFECTIO         87 966
CT   1   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
     2   LESTER LA             SEM RESPIR MED                   6   285 985
     3   MALFROOT A            PEDIATR INFECT DIS               5   376 986
     4   RUBIO TT              AM J MED                        81    73 986

PN 79036
RN 01016 
AN 79122941
AU Harries-J-T.  Muller-D-P.  McCollum-J-P.  Lipson-A.  Roma-E.
   Norman-A-P.
TI Intestinal bile salts in cystic fibrosis: studies in the patient and
   experimental animal.
SO Arch-Dis-Child. 1979 Jan. 54(1). P 19-24.
MJ BILE-ACIDS-AND-SALTS: me.  CYSTIC-FIBROSIS: me.  DUODENUM: me.
   INTESTINAL-SECRETIONS: me.
MN ADOLESCENCE.  ANIMAL.  CHILD.  CHILD-PRESCHOOL.
   ENTEROHEPATIC-CIRCULATION.  FEMALE.  HUMAN.  ILEUM: me.  INFANT.
   INTESTINAL-ABSORPTION: de.  MALE.  RATS.  RICINOLEIC-ACIDS: pd.
   SERUM-ALBUMIN-BOVINE: pd.  TAUROCHOLIC-ACID: me.  TRIOLEIN: pd.
AB The quantitative and qualitative distribution of bile salts in the
   duodenal juice of 13 patients with cystic fibrosis (CF) was studied
   after a test meal. The effects of triolein (TO), bovine serum albumin
   (BSA), and ricinoleic acid (RA) on the absorption of taurocholate
   (TCA) in the distal ileum of the rat in vivo was also studied. The
   mean (and ranges) of total bile salt concentrations, glycine: taurine
   conjugate ratios, and percentage of dihydroxy bile salts in the
   patients with CF and pancreatic insufficiency were 3.5 (1.3--6.6)
   mmol/l, 8.6 (greater than 10-3.1), and 37 (10--60) compared with
   control values of 7.4 (3.0--16.0) mmol/l, 3.0 (1.3--4.5), and 61 (52--
   70) respectively. The differences between the control and CF values
   were statistically significant (P less than 0.01--P less than 0.001).
   Three of the 13 CF patients had total bile salt concentrations less
   than 2 mmol/l, 8 had much higher glycine: taurine ratios, and 8 had a
   reduced percentage of dihydroxy bile salts. In 2 patients with normal
   pancreatic enzyme activities, duodenal bile salts were both
   quantitatively and qualitatively normal. TO (10 and 30 mmol/l), BSA
   (3%), and RA (5 mmol/l) had no inhibitory effect on the ileal
   absorption of TCA. These results show pronounced abnormalities of
   duodenal juice bile salts in CF with pancreatic insufficiency
   consistent with a broken enterohepatic circulation (EHC); such
   abnormalities may contribute to defective lipid absorption in CF. The
   data in the experimental animal do not support the suggestion that
   unhydrolysed dietary substrates play a role in the pathophysiology of
   the broken EHC.
RF 001   ANTONOWICZ I          PEDIATRICS                      42   492 968
   002   DAWSON AM             PROC SOC EXP BIOL MED          142   906 973
   003   DEREN JJ              N ENGL J MED                   288   949 973
   004   DOWLING RH            GASTROENTEROLOGY                62   122 972
   005   FREYE HB              J PEDIATR                       64   575 964
   006   GIBBONS ISE           IN: LAWSON D PROC 5TH INT CF         279 969
   007   GOODCHILD MC          ARCH DIS CHILD                  50   769 975
   008   HARRIES JT            GUT                             13   596 972
   009   HEATON KW             BILE SALTS IN HEALTH AND DISE            972
   010   HOFMANN AF            IN: JAMES AT                         362 964
   011   IWATA T               J BIOCHEM (TOKYO)               56   424 964
   012   MCCOLLUM JPK          ARCH DIS CHILD                  52   887 977
   013   MAKINO I              ANAL LETT                        5   341 972
   014   MATTHEWS DM           GUT                              6   411 965
   015   MORIN CL              J PEDIATR                       88   213 976
   016   POLEY JR              J LAB CLIN MED                  63   838 964
   017   ROLLER RJ             GASTROENTEROLOGY                72   661 977
   018   ROY CC                N ENGL J MED                   297  1301 977
   019   SLADEN GE             BIOCHIM BIOPHYS ACTA           288   443 972
   020   THOMAIDIS TS          J PEDIATR                       63   444 963
   021   TOSKES PP             J CLIN INVEST                   52  1660 973
   022   WATKINS JB            GASTROENTEROLOGY                67   835 974
   023   WATKINS JB            GASTROENTEROLOGY                73  1023 977
   024   WEBER AM              N ENGL J MED                   289  1001 973
   025   WEBER AM              GUT                             17   295 976
CT   1   FREDRIKZON B          PEDIATR RES                     14  1387 980
     2   GORIUP U              HELV PAEDIATR ACTA              35   177 980
     3   BALISTRERI WF         J PEDIATR                       96   582 980
     4   ELIAS E               LANCET                           2  1319 981
     5   FONDACARO JD          PROC SOC EXP BIOL MED          168   276 981
     6   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
     7   MULLER DPR            CLIN GASTROENTEROL              11   119 982
     8   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
     9   HEUBI JE              GASTROENTEROLOGY                83   804 982
    10   FREDRIKZON B          ACTA PAEDIATR SCAND SUPPL 296 1982    75 982
    11   BALISTRERI WF         J PEDIATR GASTROENTEROL NUTR     2   105 983
    12   ISENBERG JN           J PEDIATR GASTROENTEROL NUTR     2   447 983
    13   ROY CC                J PEDIATR GASTROENTEROL NUTR     2   152 983
    14   FONDACARO JD          PROC SOC EXP BIOL MED          173   118 983
    15   COLOMBO C             J PEDIATR GASTROENTEROL NUTR     3   556 984
    16   TAZAWA Y              J PEDIATR GASTROENTEROL NUTR     3   378 984
    17   ZENTLERMUNRO PL       GUT                             25   500 984
    18   ABRAMS CK             J CLIN INVEST                   73   374 984
    19   MCKENNA MC            J PEDIATR GASTROENTEROL NUTR     4    45 985
    20   DARLING PB            PEDIATR RES                     19   578 985
    21   ROBB TA               GUT                             26  1246 985
    22   SETCHELL KDR          CLIN CHIM ACTA                 151   101 985
    23   WEBER AM              ACTA PAEDIATR SCAND SUPPL 317 1985     9 985
    24   WEIZMAN Z             GUT                             27  1043 986
    25   LEROY C               DIG DIS SCI                     31   911 986
    26   DUTTA SK              GASTROENTEROLOGY                91  1243 986

PN 79037
RN 01017 
AN 79254866
AU Hubbard-V-S.  Davis-P-B.  di-SantAgnese-P-A.
TI Possible hazard of timed-release aspirin in a patient with
   pancreatic insufficiency.
SO Arch-Intern-Med. 1979 Sep. 139(9). P 1054-5.
MJ ASPIRIN: ae.  CYSTIC-FIBROSIS: co.  HEMORRHAGE-GASTROINTESTINAL: ci.
MN ADULT.  ASPIRIN: ad.  CASE-REPORT.  DELAYED-ACTION-PREPARATIONS.
   HUMAN.  INTESTINE-SMALL: de.  MALE.
   OSTEOARTHROPATHY-SECONDARY-HYPERTROPHIC: dt, et.
AB An episode of severe small intestinal hemorrhage occurred in a cystic
   fibrosis patient having pancreatic insufficiency and receiving timed-
   release aspirin therapy for disabling hypertrophic pulmonary
   osteoarthropathy. The increased acidity of small intestinal contents
   due to decreased bicarbonate secretion observed in patients with
   pancreatic insufficiency may alter the luminal environment and result
   in mucosal erosions and/or ulcerations in association with the
   presence of aspirin. Thus, physicians should be aware of the
   possibility that timed-release aspirin causes small intestinal
   hemorrhage in such patients.
RF 001   LANGMAN MJS           GUT                             11   627 970
   002   LOEBL DH              JAMA                           237   976 977
   003   GARTNER AH            JADA                            93   111 976
   004   TREADWELL BLJ         NZ MED J                        78   435 973
   005   ROSSOUW JE            RHEUMATOL REHAB                 15    31 976
   006   HOON JR               JAMA                           229   841 974
   007   TAUSSIG LM            RADIOLOGY                      106   369 973
   008   HADORN B              J PEDIATR                       73    39 968
   009   THJODLEIFSSON B       SCAND J GASTROENTEROL           11   273 976
   010   THJODLEIFSSON B       SCAND J GASTROENTEROL           11   505 976
   011   IVEY KJ               GASTROENTEROLOGY                76    50 979
CT   1   PARIENTE EA           GASTROENTEROL CLIN BIOL          6    16 982
     2   HUBBARD VS            SEM RESPIR MED                   6   299 985
     3   PHILLIPS BM           J ROY SOC MED                   79    44 986

PN 79038
RN 01018 
AN 79123379
AU Duffner-P-K.  Cohen-M-E.
TI Cystic fibrosis with brain abscess.
SO Arch-Neurol. 1979 Jan. 36(1). P 27-8.
MJ BRAIN-ABSCESS: co.  CYSTIC-FIBROSIS: co.
   STREPTOCOCCAL-INFECTIONS: co.
MN ADULT.  BRAIN-ABSCESS: ra.  BRAIN: ra.  CASE-REPORT.  HUMAN.  MALE.
   STREPTOCOCCAL-INFECTIONS: ra.  TOMOGRAPHY-X-RAY-COMPUTED.
AB A 21-year-old patient with cystic fibrosis developed bilateral brain
   abscesses due to anaerobic Streptococcus. This rare association
   presents an interesting etiologic study.
RF 001   GATES EM              MEDICINE                        29    71 950
   002   BREWER NS             ANN INTERN MED                  82   571 975
   003   MARTINEZ-TELLO FJ     J IMMUNOL                      101   989 968
   004   SCHWARTZ RH           AM J DIS CHILD                 111   408 966
   005   NETER E               J INFECT DIS SUPPL             130   132 974
   006   DIAZ F                J INFECT DIS                   121   269 970
   007   HALBERT SP            PEDIATRICS                      26   792 960
CT   1   FISCHER EG            J PEDIATR                       95   385 979
     2   MCCARTHY MM           CLIN PEDIATR                    19   746 980
     3   AYRES J               BR J DIS CHEST                  76    99 982
     4   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
     5   RABKIN CS             ANN NEUROL                      15   608 984
     6   KLINE MW              PEDIATR INFECT DIS               4    72 985
     7   CANNY GJ              THORAX                          41   221 986
     8   KURLAND G             PEDIATRICS                      78  1097 986

PN 79039
RN 01019 
AN 79208794
AU Forman-Franco-B.  Abramson-A-L.  Gorvoy-J-D.  Stein-T.
TI Cystic fibrosis and hearing loss.
SO Arch-Otolaryngol. 1979 Jun. 105(6). P 338-42.
MJ CYSTIC-FIBROSIS: co.  HEARING-LOSS-CONDUCTIVE: et.
   HEARING-LOSS-PARTIAL: et.  HEARING-LOSS-SENSORINEURAL: et.
MN ACOUSTIC-IMPEDANCE-TESTS.  ADOLESCENCE.  ADULT.  AUDIOMETRY.
   AUDITORY-THRESHOLD.  CHILD.  EAR-OSSICLES: pp.  EAR-MIDDLE: pp.
   FEMALE.  GENTAMICINS: ae.  HUMAN.  MALE.  PRESSURE.  STAPES: pp.
   TOBRAMYCIN: ae.  TYMPANIC-MEMBRANE: pp.
AB The mucosal epithelium of the middle ear and Eustachian tube is in
   direct continuity with the upper respiratory tract. Since the
   otolaryngological aspects of cystic fibrosis (CF) are dominated by
   involvement of the paranasal sinuses, it might be assumed that
   children with CF would be expected to have a higher than usual
   incidence of middle ear disease. Eighty patients who were afflicted
   with CF had audiological evaluations, which consisted of hearing
   threshold levels (250 to 8,000 Hz) and speech and impedance
   audiometry. We found no greater incidence of a conductive or
   sensorineural hearing loss in patients with CF when compared with a
   normal age-adjusted population.
RF 001   KULCZYCKI LL          CLIN PEDIATR                     9   390 970
   002   ANON                  TRANS AM ACAD OPHTHALMOL OTOL   63   236 959
   003   JERGER J              ARCH OTOLARYNGOL                93   111 971
   004   TAYLOR BW             ARCH DIS CHILD                  49   133 974
   005   GOODMAN A             ASHA                             7   262 965
   006   RULON JT              ARCH OTOLARYNGOL                78   192 963
   007   CRIFO S               PRACT OTORHINOLARYNGOL          33   394 971
   008   KULCZYCKI LL          ARCH OTOLARYNGOL                92    54 970
   009   ROBINSON CG           CAN MED ASSOC J                 97  1199 967
   010   EAGLES E              LARYNGOSCOPE                    73    12 963
   011   SIEGEL J              ARCH OTOLARYNGOL                92   523 970
   012   FORCUCCI RA           ARCH OTOLARYNGOL                96   361 972
   013   FRITZE W              Z KINDERHEILK                  114   111 973
   014   WATSON TJ             PROC R SOC MED                  62   455 969
   015   BROOKS DN             INT AUDIOL                       8   563 969
   016   NEELY JG              TRANS AM ACAD OPHTHALMOL OTOL   76   313 972
CT   1   CRIFO S               INT J PEDIATR OTORHINOLARYNGO    2   251 980
     2   FRASER GL             DRUG INTEL CLIN PHARM           19   757 985
     3   DAVID TJ              J ROY SOC MED                   79    23 986

PN 79040
RN 01020 
AN 79230729
AU Goldberg-R-T.  Isralsky-M.  Shwachman-H.
TI Vocational development and adjustment of adolescents with cystic
   fibrosis.
SO Arch-Phys-Med-Rehabil. 1979 Aug. 60(8). P 369-74.
MJ ATTITUDE.  CAREER-CHOICE.  CYSTIC-FIBROSIS: rh.  DECISION-MAKING.
   GOALS.
MN ADOLESCENCE.  CHILD-DEVELOPMENT.  COMPARATIVE-STUDY.
   CYSTIC-FIBROSIS: px.  EDUCATION.  HUMAN.  SOCIAL-VALUES.
   VOCATIONAL-GUIDANCE.
AB Adolescents with cystic fibrosis were compared with normal
   adolescents of the same age and educational grade on several measures
   of vocational development and adjustment. The cystic fibrosis group
   in ages 12--16 and in grades 7, 8, and 9 scored lower than their
   normal counterparts in measures of vocational and educational plans,
   and were less realistic than normals in considering their limitations
   and financial constraints. In contrast, the cystic fibrosis group at
   nearly all age and grade levels scored significantly higher on
   strength of commitment to vocational choice, work values, and
   awareness of occupational information. Compared to 4 additional
   handicapped groups already studied, adolescents with cystic fibrosis
   scored favorably. They not only plan to work but also hold strong
   work values compared to normals. Rehabilitation programs should
   emphasize preparation for a career and the development of educational
   and vocational plans while the adolescent is still in high school.
RF 001   BOYLE IR              J PEDIATR                       88   318 976
   002   TROPAUER A            AM J DIS CHILD                 119   424 970
   003   CYTRYN L              IN: ANTHONY EJ                        37 973
   004   GAYTON WF             AM J DIS CHILD                 126   856 973
   005   ROSENLUND ML          ANN INTERN MED                  78   959 973
   006   SHWACHMAN H           PEDIATRICS                      46   335 970
   007   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
   008   SHWACHMAN H           N ENGL J MED                   296  1519 977
   009   TURK J                PEDIATRICS                      34    67 964
   010   MCCOLLUM AT           J PEDIATR                       77   571 970
   011   MCCRAE WM             PHYSIOTHERAPY                   61   252 975
   012   MATTHEWS LW           VOCATIONAL AND LIFE ADJUSTMEN            969
   013   GOLDBERG RT           SCAND J REHAB MED                9    85 977
   014   GOLDBERG RT           J COUNSELING PSYCH              21   428 974
   015   GOLDBERG RT           REHAB COUNS BULL                19   140 975
   016   GOLDBERG RT           SCAND J REHAB MED               10   215 978
   017   GOLDBERG RT           VOCATIONAL AND SOCIAL REHABIL            972
   018   KULCZYCKI LL          IN: PATTERSON PR                     117 973
CT   1   PINKERTON P           LANCET                           2   761 985
     2   SIMMONS RJ            PSYCHOSOM MED                   47   111 985
     3   GOLDBERG RT           ARCH PHYS MED REHABIL           66   492 985

PN 79041
RN 01021 
AN 80175020
AU Bergan-T.  Michalsen-H.
TI Pharmacokinetics of azlocillin in children with cystic fibrosis.
SO Arzneimittelforschung. 1979. 29(12a). P 1955-7.
MJ CYSTIC-FIBROSIS: me.  PENICILLINS: me.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.
   DOSE-RESPONSE-RELATIONSHIP-DRUG.  FEMALE.  HALF-LIFE.  HUMAN.
   KINETICS.  MALE.  PENICILLINS: bl, ur.  TIME-FACTORS.
AB 6-E1(R)-2-(oxo-imidazolidine-1-carboxamido)-2-phenyl-acetamido]-
   penicillanic acid sodium salt (azlocillin, Securopen) was given in
   doses of 100 and 200 mg/kg body weight to children with cystic
   fibrosis. After intravenous bolus infections, the serum half-life was
   0.82 +/- 0.12 h after the lower dose and 0.98 +/- 0.18 h after the
   higher dose. This was consequent to a dose limited elimination
   kinetics due to limitation in both renal and non-renal processes of
   elimination. Upon doubling of the dose from 100 to 200 mg/kg, the
   total body clearance dropped from 13.93 to 5.10 1/h. Evaluation of
   data presented in other publications indicate that a dose limited
   elimination kinetics is the normal situation for azlocillin. Besides,
   the serum concentrations of patients with cystic fibrosis were
   considerably lower than seen in the healthy state. The reason is
   faster elimination by the renal route in cystic fibrosis.
RF 001   BERGAN T              ANTIMICROB AGENTS CHEMOTHER     13   801 978
   002   BERGAN T              ACTA PATH MICROBIOL SCAND (B)   80   101 972
   003   EVANS MAL             J ANTIMICROB CHEMOTHER           4   255 978
   004   GIAMARELLOU H         INT SYMPOS ACYLUREIDOPENICILL         68 978
   005   JUSKO WJ              PEDIATRICS                      56  1038 975
   006   KONIG HB              INFECTION                        5   170 977
   007   KRASEMANN C           INT SYMPOS ACYLUREIDOPENICILL         84 978
   008   LODE H                INFECTION                        5   163 977
   009   REEVES DS             INT SYMPOS ACYLUREIDOPENICILL         18 978
   010   WAGNER JG             FUND CLIN PHARMACOKINETICS               975
   011   WIRTH K               INFECTION                        4    25 976
   012   YAFFE SJ              J INFECT DIS                   135   828 977
CT   1   MICHALSEN H           ANTIMICROB AGENTS CHEMOTHER     19  1029 981
     2   BERGAN T              SCAND J INFECT DIS            1981    33 981
     3   MALMBORG AS           SCAND J INFECT DIS            1981    64 981
     4   MICHALSEN H           SCAND J INFECT DIS            1981    92 981
     5   LEVY J                J ANTIMICROB CHEMOTHER          10   235 982
     6   ELIOPOULOS GM         ANN INTERN MED                  97   755 982
     7   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
     8   MICHALSEN H           ACTA PAEDIATR SCAND SUPPL 301 1982   101 982
     9   AGOSTINI M            DRUGS UNDER EXP CLIN RES         9   671 983
    10   BERGAN T              J ANTIMICROB CHEMOTHER          11   101 983
    11   MASTELLA G            J ANTIMICROB CHEMOTHER          12   297 983
    12   ISLES A               AM REV RESPIR DIS              127   417 983
    13   MARTINI N             J CLIN HOSP PHARM                9   303 984
    14   SINGLAS E             PRESSE MED                      13   788 984
    15   LEEDER JS             CLIN PHARMACOL THER             36   355 984
    16   PENKETH A             THORAX                          39   299 984
    17   MICHALSEN H           PATHOL RES PRACT               178   261 984
    18   ANON                  LANCET                           1  1020 985
    19   WOOLF RA              CLIN PHARMACY                    4   664 985
    20   PRANDOTA J            DEVELOP PHARM THER               8   311 985
    21   HORREVORTS AM         CHEST                           88   260 985
    22   JACOBS RF             J PEDIATR                      106  1001 985
    23   WILSON CB             J PEDIATR                      106  1049 985
    24   SORGEL F              EUR J PEDIATR                  143   249 985
    25   MICHALSEN H           METH FIND EXP CLIN PHARMACOL     8   727 986
    26   BENDER SW             INFECTION                       14    17 986
    27   SCHAAD UB             ACTA PAEDIATR SCAND             75   128 986

PN 79042
RN 01022 
AN 80129795
AU Chapman-J-A.  Goodall-J.
TI Dying children need help too.
SO Aust-Fam-Physician. 1979 Dec. 8(12). P 1236-7.
MJ CHILD-HOSPITALIZED.  CYSTIC-FIBROSIS: th.  TERMINAL-CARE.
MN ATTITUDE-TO-DEATH.  CASE-REPORT.  FAMILY.  FEMALE.  GRIEF.  HUMAN.
   INFANT.  PAIN.
EX The control of symptoms in dying children is often sadly neglected.
   This neglect is reflected in a review of the case notes of two
   children who died of cystic fibrosis within three years of each
   other.  The girls were under the care of the same consultant, who in
   the interval between the two cases was introduced to the concern of
   proper terminal care for children.
RF 001   BRETT EM              DEVELOP MED CHILD NEUROL        12   655 970
   002   SHAFFER D             IN: RUTTER M                             977
   003   TWYCROSS RG           IN: SAUNDERS CM                          978

PN 79043
RN 01023 
AN 80129794
AU Phelan-P-D.
TI Cystic fibrosis: is it relevant to family practitioners?.
SO Aust-Fam-Physician. 1979 Dec. 8(12). P 1232-4.
MJ CYSTIC-FIBROSIS: di.  FAMILY-PRACTICE.
MN ADOLESCENCE.  ADULT.  AUSTRALIA.  CHILD.  CYSTIC-FIBROSIS: oc, th.
   HUMAN.  PATIENT-CARE-TEAM.
AB There has been a major change in the outlook for children with cystic
   fibrosis during the last 20 years. Provided the diagnosis is made
   before serious irreversible lung disease has occurred, most patients
   can expect to reach adult life without very serious disability.

PN 79044
RN 01024 
AN 80019967
AU Carey-W-F.  Hosli-P.
TI Inhibition of Tamm-Horsfall glycoprotein induction of alkaline
   phosphatase in cystic fibrosis fibroblasts by medium conditioned by
   normal cells.
SO Aust-J-Exp-Biol-Med-Sci. 1979 Apr. 57(2). P 225-30.
MJ ALKALINE-PHOSPHATASE: me.  CELLS-CULTURED: me.  CYSTIC-FIBROSIS: me.
   FIBROBLASTS: me.  GLYCOPROTEINS: pd.
MN COMPARATIVE-STUDY.  CULTURE-MEDIA.  CYSTIC-FIBROSIS: en.  HUMAN.
   TIME-FACTORS.
AB It is confirmed that the level of alkaline phosphatase in fibroblasts
   derived from cystic fibrosis patients can be induced many-fold by
   growing the cells in the presence of Tamm-Horsfall glycoprotein. It
   is further shown that normal fibroblasts produce a "CF corrective
   factor" which markedly inhibits this phenomenon. These observations
   support a previous hypothesis on the nature of the metabolic defect
   in cystic fibrosis.
RF 001   BACH G                PROC NAT ACAD SCI USA           69  2048 972
   002   FRATANTONI JC         PROC NAT ACAD SCI USA           64   360 969
   003   HOSLI P               ADV EXP MED BIOL                68     1 976
   004   HOSLI P               CLIN CHEM                       23  1476 977
   005   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      79   741 977
   006   HOSLI P               HUM GENET                       41   169 978
   007   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      73   209 976
   008   HOSLI P               PROC INT CF CONG 7TH                 278 976
   009   HOSLI P               ACTA PAEDIATR SCAND             67   617 978
CT   1   CAREY WF              MED J AUST                       2   604 979
     2   LYNN KL               BIOCHEM J                      194   561 981
     3   CEDER O               ULTRASTRUCTURAL PATHOL           4   305 983
     4   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
     5   BUYS CHCM             CLIN CHIM ACTA                 136   229 984

PN 79045
RN 01025 
AN 80087357
AU Feery-B-J.  Phelan-P-D.  Gallichio-H-A.  Hampson-A-W.
TI Antibody responses to influenza virus vaccine in patients with
   cystic fibrosis.
SO Aust-Paediatr-J. 1979 Sep. 15(3). P 181-2.
MJ ANTIBODIES-VIRAL: im.  CYSTIC-FIBROSIS: im.  INFLUENZA-VACCINE: im.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.
   HEMAGGLUTINATION-INHIBITION-TESTS.  HUMAN.  INFLUENZA-VACCINE: ad.
   ORTHOMYXOVIRUSES-TYPE-A: im.
AB Patients with cystic fibrosis were immunized with subunit influenza
   vaccine and their haemagglutination-inhibiting (HI) antibody
   responses were compared with responses in young healthy adults.
   There was no significant difference in the antibody levels reached
   after immunization and no evidence of any impairment of responses in
   the patient group.
RF 001   DAVENPORT FM          J EXP MED                       98   641 953
   002   ANON                  MED J AUST                       1  1310 970
   003   PALMER DF             ADVANCED LABORATORY TECHNIQUE            975

PN 79046
RN 01026 
AN 79255569
AU Bogart-B-I.  Conod-E-J.  Gaerlan-P-F.  Denning-C-R.  Conover-J.
TI Biological activities of cystic fibrosis serum.  III.  CF serum
   induced uptake of 45Ca++ by rabbit tracheal explants.
SO Biochem-Biophys-Res-Commun. 1979 Jun 27. 88(4). P 1398-404.
MJ CALCIUM: me.  CYSTIC-FIBROSIS: bl.
MN ANIMAL.  CELL-MEMBRANE-PERMEABILITY: de.  CILIA: pp.
   CYSTIC-FIBROSIS: me, pp.  GALLOPAMIL: pd.  HETEROZYGOTE.  HUMAN.
   IGG: ph.  RABBITS.  TRACHEA: me.
AB Cystic Fibrosis (CF) serum and its isolated component IgG fraction
   produce an increased uptake of 45Ca++ in rabbit tracheal explants
   when compared to control serum and its isolated IgG fraction.
   Heterozygote serum also produced an increased uptake of 45Ca++ but
   not to the same extent as CF serum.  The calcium channel blocker
   D600 inhibited the CF serum induced uptake of 45Ca++ indicating that
   CF serum may be acting on the plasma membrane to produce changes in
   calcium permeability in rabbit tracheal explants.
RF 001   SPOCK A               PEDIATR RES                      1   173 967
   002   CONOVER JH            PEDIATR RES                      7   220 973
   003   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   004   BOWMAN BH             SCIENCE                        164   325 969
   005   BOGART BI             PEDIATR RES                     11   131 977
   006   BOGART BI             PEDIATR RES                     12    15 978
   007   PUTNEY JW             J PHARMACOL EXP THER           199   526 976
   008   CONOD EJ              PEDIATR RES                     11    45 977
   009   BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      64  1310 975
   010   CONOVER JH            BIOCHEM BIOPHYS RES COMMUN      83  1595 978
   011   FLECKENSTEIN A        IN: CARAFOLI E                       555 975
   012   BANSCHBACH MW         BIOCHEM BIOPHYS RES COMMUN      84   922 978
CT   1   BOWMAN BH             FED PROC                        39  3195 980
     2   SCHONI M              SCHWEIZ MED WOCHENSCHR         111   658 981
     3   WILSON GB             MED HYPOTHESES                   8   527 982
     4   BOGART BI             PEDIATR RES                     16   223 982
     5   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
     6   KATZ S                CELL CALC                        5   421 984

PN 79047
RN 01027 
AN 79144816
AU Alhadeff-J-A.  Watkins-P.
TI Differential concanavalin A binding of cystic fibrosis and normal
   liver alpha-L-fucosidase.
SO Biochem-Biophys-Res-Commun. 1979 Feb 14. 86(3). P 787-92.
MJ CONCANAVALIN-A: me.  CYSTIC-FIBROSIS: en.  FUCOSIDASE: me.  LIVER: en.
MN COMPARATIVE-STUDY.  HUMAN.  KINETICS.  PROTEIN-BINDING.
   SUPPORT-U-S-GOVT-P-H-S.
AB A novel technique has been employed to demonstrate that alpha-L-
   fucosidase purified from cystic fibrosis and control livers exhibits
   differential binding to the lectin Concanavalin A.  The
   concentration of alpha-CH3-mannoside necessary to prevent 50%
   binding of alpha-L-fucosidase to Concanavalin A is considerably
   lower for the cystic fibrosis enzyme (13.5 vs. 33.3 mM).  Comparable
   results were found when binding studies were done on crude
   supernatant alpha-L-fucosidase from 8 cystic fibrosis and 8 control
   livers (5.6 plus or minus 0.4 mM and 13.2 plus or minus 3.4
   respectively), without any overlap of values between the cystic
   fibrosis and control livers.  These results suggest that comparative
   lectin binding studies on cystic fibrosis and normal glycoproteins
   from readily available tissues might result in an assay for
   detecting the cystic fibrosis genotype.
RF 001   MCCOMBS ML            TEX REP BIOL MED                31   615 973
   002   NADLER HL             IN: STANBURY JB                     1683 978
   003   WRIGHT SW             AM J HUM GENET                  20   157 968
   005   ALHADEFF JA           CLIN GENET                      13   417 978
   006   ALHADEFF JA           J BIOL CHEM                    250  7106 975
   007   ALHADEFF JA           MOL CELL BIOCHEM                18    33 977
   008   ALHADEFF JA           CLIN GENET                      10    63 976
   009   ALHADEFF JA           IN: GLEW RH                          247 977
   010   BISHAYEE S            BIOCHIM BIOPHYS ACTA           334   378 974
   011   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      79   741 977
   012   SCANLIN TF JR         BIOCHEM BIOPHYS RES COMMUN      79   869 977
   013   SCANLIN TF JR         PEDIATR RES ABST 549            11   463 977
   014   LIS H                 IN: SELA M                       4   429 977
CT   1   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      93    50 980
     2   ALHADEFF JA           CLIN CHIM ACTA                 105   131 980
     3   HALLINAN F            MED HYPOTHESES                   7   793 981
     4   ALHADEFF JA           CLIN CHIM ACTA                 117   227 981
     5   MALER T               J BIOL CHEM                    256  1420 981
     6   SCANLIN TF            BIOCHEMISTRY                    21   491 982
     7   BOURASSA C            CLIN CHIM ACTA                 129   263 983
     8   HERMELIN B            CELL MOL BIOL                   33    83 987

PN 79048
RN 01028 
AN 80069763
AU Adams-T-H.  Ramsay-G-M.  Wisdom-G-B.
TI Enzyme immunoassay of albumin as an aid to the diagnosis of cystic
   fibrosis in the newborn human [proceedings].
SO Biochem-Soc-Trans. 1979 Oct. 7(5). P 1018-9.
MJ CYSTIC-FIBROSIS: di.  SERUM-ALBUMIN: an.
MN CYSTIC-FIBROSIS: bl.  HUMAN.  IMMUNOENZYME-TECHNICS.  INFANT-NEWBORN.
   MECONIUM: an.
EX One of the symptoms of cystic fibrosis (mucoviscidosis) is pancreatic
   insufficiency.  The reduced proteolytic activity in the gut of
   children with the disease results in an elevated concentration of
   protein, especially serum albumin, in the meconium.  This feature is
   used in the diagnosis of the disease in the newborn, and we decided
   to examine the utility of enzyme immunoassay for the measurement of
   albumin in meconium samples from normal and cystic fibrosis infants.
   Normal samples were found to have apparent albumin concentrations in
   the range 0.05-0.26 mg/g dry wt., whereas cystic fibrosis samples had
   concentrations in the range 60-230 mg/g dry wt.  The assay provides a
   cheap and relatively rapid method of differentiating cystic fibrosis
   positive and negative meconium samples.
RF 001   HELLSING K            SCAND J CLIN LAB INVEST         33   333 974
   002   MAIOLINI R            J IMMUNOL METH                   8   223 975
   003   NAKANE PK             J HISTOCHEM CYTOCHEM            22  1084 974
   004   RYLEY HC              CLIN CHIM ACTA                  64   117 975
CT   1   NAYLOR EW             SEM PERINATOL                    9   232 985

PN 79049
RN 01029 
AN 80021202
AU Wijcik-L.  Buchwald-M.  Riordan-J-R.
TI Induction of alkaline phosphatase in cultured human fibroblasts.
   Comparison of normal cells and those from patients with cystic
   fibrosis.
SO Biochim-Biophys-Acta. 1979 Jul 4. 585(3). P 374-82.
MJ ALKALINE-PHOSPHATASE: bi.  CYSTIC-FIBROSIS: en.  FIBROBLASTS: en.
MN CELL-DIVISION.  CELLS-CULTURED.  COMPARATIVE-STUDY.  DNA: bi.
   ENZYME-INDUCTION: de.  HUMAN.  TIME-FACTORS.
AB The membrane glycoprotein enzyme, alkaline phosphatase was induced in
   cultured human fibroblasts by dibutyryl cyclic AMP, sodium butyrate,
   the serum glycoprotein fetuin, the Tamm-Horsfall urinary
   glycoprotein, and by a number of inhibitors of DNA synthesis. The
   uninduced basal enzyme activity increased at later stages of growth
   when the cells became confluent. Induction by dibutyryl cyclic AMP or
   fetuin was most effective when the agents were added after the cells
   had reached stationary phase and was maximal after at least two days
   of exposure. The levels of induction resulting from the addition of
   pairs of the agents, dibutyryl cyclic AMP, n-butyrate and fetuin were
   additive indicating that these have different modes of action. The
   inhibitors of DNA synthesis, cytosine arabinoside, hydroxyurea, and
   methothrexate were less effective inducers. Bromodeoxyuridine which
   also has non-DNA mediated effects induced to the same extent as
   dibutyryl cyclic AMP. Similar experiments with sex- and age-matched
   cell strains derived from patients with cystic fibrosis failed to
   detect differences in the levels of induction from those observed in
   normal cells. In addition, the combined inductive effects of Tamm-
   Horsfall glycoprotein, isoproterenol and theophylline, were similar
   with normal and cystic fibrosis cells.
RF 001   STEPAN J              EXPERIENTIA                     29   948 973
   002   FISHMAN WH            AM J MED                        56   617 974
   003   LIN CW                J HISTOCHEM CYTOCHEM            24   659 976
   004   RIORDAN JR            IN: JULIONO RL                   2   146 978
   005   KOYAMA H              BIOCHEM BIOPHYS RES COMMUN      46   305 972
   006   MAZIERE JC            BIOCHIMIE                       59   221 977
   007   NOSE K                JAPAN J EXP MED                 46   347 976
   008   COX RJ                BIOCHEM J                      105   155 967
   009   COX RP                J MOL BIOL                      58   197 971
   010   GRIFFIN MJ            ARCH BIOCHEM BIOPHYS           164   619 974
   011   MIEDEMA E             EXP CELL RES                    53   488 968
   012   VANNEUVILLE FJ        BIOCHEM SOC TRANS                5  1117 977
   013   LUNDGREN E            EXP CELL RES                   110    25 977
   014   HOSLI P               ADV EXP MED BIOL                68     1 974
   015   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      73   209 976
   016   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      79   741 977
   017   RIORDAN JR            J SUPRAMOL STRUCT SUPPL          2   126 978
   018   TAMM I                J EXP MED                       95    71 952
   019   BUCHWALD M            MOD PROBL PEDIATR               19   165 977
   020   STANNERS CP           NATURE NEW BIOL                230    52 971
   021   BOHLEN P              ARCH BIOCHEM BIOPHYS           155   213 973
   022   DEUTSCH SI            BIOCHIM BIOPHYS ACTA           499   382 977
   023   GHOSH NK              NATURE                         267   435 977
   024   HENNEBERRY RC         NATURE                         268   252 977
   025   TALLMAN JF            PROC NAT ACAD SCI USA           74   873 977
   026   MERIMEE TJ            J CLIN ENDOCRINOL METAB         43  1190 976
   027   FISHMAN PH            BIOCHEM BIOPHYS RES COMMUN      59   292 974
   028   GHOSH NK              NATURE                         267   435 977
   029   WRIGHT JA             EXP CELL RES                    78   456 973
   030   GINSBURG E            PROC NAT ACAD SCI USA           70  2457 973
   031   HENNEBERRY RC         CELL                             5     1 975
   032   VIDALI G              PROC NAT ACAD SCI USA           75  2239 978
   033   HORVAT A              J CELL PHYSIOL                  83    59 974
   034   MAZIERE C             BIOCHIMIE                       59   225 977
CT   1   CAREY WF              MED J AUST                       2   604 979
     2   BUCHWALD M            ADV CYCLIC NUCLEO RES           12   243 980
     3   MALER T               BIOCHIM BIOPHYS ACTA           598     1 980
     4   CROFTON PM            CRC CRIT REV CLIN LAB SCI       16   161 982
     5   BUCHWALD M            CLIN BIOCHEM                    17   143 984
     6   ZGURSKII AA           BIOCHEMISTRY USSR               49  1380 984
     7   ZGURSKY AA            TSITOLOGIYA                     27   775 985
     8   YANG AH               IN VITRO CELL DEVEL BIOL        23    34 987
     9   WHYTE MP              CALC TISS INT                   40   244 987

PN 79050
RN 01030 
AN 80000602
AU Riordan-J-R.  Alon-N.  Buchwald-M.
TI Plasma membrane lipids of human diploid fibroblasts from normal
   individuals and patients with cystic fibrosis.
SO Biochim-Biophys-Acta. 1979 Jul 27. 574(1). P 39-47.
MJ CYSTIC-FIBROSIS: me.  MEMBRANE-LIPIDS: an.
MN CELLS-CULTURED.  CHOLESTEROL: an.  FATTY-ACIDS: an.  FIBROBLASTS.
   HUMAN.  MEMBRANE-FLUIDITY.  PHOSPHOLIPIDS: an.  SKIN: an.
AB The lipid composition of isolated plasma membranes of human skin
   fibroblasts is described for the first time. Plasma membranes from a
   number of strains of fibroblasts from patients with cystic fibrosis
   and matched normals were isolated by a recently described procedure
   and analysed for major phospholipid classes, cholesterol and fatty
   acids. No differences in the quantities of these compounds were
   detected between cells of the two different origins. The fetal calf
   serum used to supplement the growth medium contained relatively more
   palmitoleate and oleate but less stearate than the membranes. There
   were also no consistent differences between cystic fibrosis and
   normal membranes in terms of the fatty acid compositions of their
   individual phospholipid classes. Consistent with this lack of
   chemical change in the lipids of membranes of cystic fibrosis cells,
   the degree of fluorescence polarization of diphenylhexatriene, an
   index of fluidity, was also unchanged.
RF 001   KARTNER N             J MEMBR BIOL                    36   191 977
   002   KUO PT                J PEDIATR                       60   394 962
   003   CAREN R               J CLIN ENDOCRINOL METAB         26   470 966
   004   SANJURJO P            LANCET                           1   752 977
   005   ROSENLUND ML          PEDIATRICS                      59   428 977
   006   RIVERS JPW            LANCET                           2   642 975
   007   ELLIOTT RB            PEDIATRICS                      57   474 976
   008   DI SANTAGNESE PA      N ENGL J MED                   295   534 976
   009   FARIAS RN             BIOCHIM BIOPHYS ACTA           415   231 975
   010   LUCY JA               FEBS LETTERS SUPP 1             40  5105 974
   011   CHRISTIAN ST          BIOCHEM BIOPHYS RES COMMUN      79   966 977
   012   LOWRY OH              J BIOL CHEM                    193   265 951
   013   FOLCH J               J BIOL CHEM                    226   497 957
   014   BARTLETT GR           J BIOL CHEM                    234   466 959
   015   ROUSER G              IN: MARINETTI GV                 1    99 967
   016   VAN HOEVEN RP         J MEMBR BIOL                     9   105 972
   017   SHINITZKY M           BIOCHIM BIOPHYS ACTA           433   133 976
   018   MALKIEWICZ-WASOWICZ B BIOCHIM BIOPHYS ACTA           482   358 977
   019   BENEDETTI EL          IN: DALTON AJ                         33 968
   020   PATTON S              J THEOR BIOL                    29   489 970
   021   PFLEGER RC            BIOCHEMISTRY                     7  2826 968
   022   WOOD RE               ARCH BIOCHEM BIOPHYS           141   174 970
   023   HENNING R             HOPPE SEYLERS Z PHYSIOL CHEM   351  1191 970
   024   HOROWITZ AF           PROC NAT ACAD SCI USA           71  3115 974
   025   CAMPBELL IM           PEDIATRICS                      57   480 976
   026   CHANGUS JE            ARCH PATHOL LAB MED            100     7 976
   027   SCHROEDER F           J BIOL CHEM                    251  5015 976
   028   SAHU S                AM REV RESPIR DIS              115   233 977
   029   MCEVOY FA             LANCET                           2   236 975
   030   DALE RE               J BIOL CHEM                    252  7500 977
CT   1   KEELEY FW             CAN J BIOCHEM                   57  1273 979
     2   PHILLIPS MC           ATHEROSCLEROSIS                 36   409 980
     3   RIORDAN JR            CAN J BIOCHEM                   58   928 980
     4   MALER T               BIOCHIM BIOPHYS ACTA           598     1 980
     5   KOIZUMI K             BIOCHIM BIOPHYS ACTA           619   344 980
     6   ROGIERS V             PEDIATR RES                     16   761 982
     7   FIELDING CJ           J BIOL CHEM                    257   955 982
     8   ROTHBLAT GH           J BIOL CHEM                    257  4775 982
     9   HARRIS A              CLIN CHIM ACTA                 128    41 983
    10   HUBBARD VS            EUR J PEDIATR                  141    68 983
    11   SLOTTE JP             BIOCHEM J                      220   605 984
    12   SLOTTE JP             BIOCHIM BIOPHYS ACTA           793   423 984
    13   RIORDAN JR            PHARMACOL THER                  28    51 985
    14   LUNDBERG B            ATHEROSCLEROSIS                 56   345 985
    15   BRAUNAGEL SC          BIOCHIM BIOPHYS ACTA           813   183 985
    16   GOLDBERG DM           CLIN PHYSIOL BIOCHEM             4   305 986
    17   LUNDBERG B            ACTA CHEM SCAND (A)             40   315 986

PN 79051
RN 01031 
AN 79232883
AU Lappe-M.
TI 2. Theories of genetic causation in human disease.
SO Birth-Defects. 1979. 15(2). P 33-45.
MJ GENETICS-MEDICAL.  HEREDITARY-DISEASES.
MN ALCOHOLISM: fg.  CYSTIC-FIBROSIS: fg.  GENETICS-BEHAVIORAL.
   GENOTYPE.  HUMAN.  LESCH-NYHAN-SYNDROME: fg.  PHENOTYPE.
   PHENYLKETONURIA: fg.  VARIATION-GENETICS.  XYY-KARYOTYPE.
EX The central problem of the mid-20th century genetic counselor has
   been to determine the place of the genes in the origin of complex
   human characteristics - such as neural tube defects, cleft palate,
   diabetes, and congenital heart disease - in short, the major
   malformation and polygenic syndromes which make up the bulk of what
   we call birth defects.  Of comparable importance in terms of genetic
   counseling is understanding the origin and incidence of the newly
   recognized genetic heterogeneity lying behind what had previously
   been regarded as simple, single-gene determined diseases.  Topics
   include dealing with genetic heterogeneity, phenotypes and genotypes,
   where genetic causation defies simple analysis, and sources of
   variation.  Behavior disorders with presumptive single-gene causation
   (Lesch-Nyhan disease), presumptive sex-linked causation
   (aggressivity), and presumptive polygenic causation (alcoholism) are
   also discussed.
RF 000   JOHANSSEN W           IN: PETERS JA                            959
   001   KAUFMAN S             N ENGL J MED                   293   785 975
   002   BLANCK RR             JAMA                           235  1364 976
   003   DARLINGTON CD         GENETICS AND MAN                     102 969
   004   NEWMAN HH             EVOLUTION GENETICS AND EUGENI        485 969
   005   WRIGHT S              GENETICS                        19   537 934
   006   BECK F                IN: ROBSON JM                          1 965
   007   FRASER FC             PROC INT CONF CONGENITA 1ST          179 961
   008   KALTER H              TERATOLOGY                      13     1 976
   009   BARLOW SM             TERATOLOGY                      12    97 975
   010   ERWAY L               SCIENCE                        152  1766 966
   011   ANON                  COLUMBIA JOURNALISM REVIEW MA            975
   012   LENZ W                J MED GENET                     10    34 973
   013   DEGENHARDT KH         IN: RASPE G                      6       971
   014   ROSENTHAL MR          LANCET                           2   250 976
   015   VAN DE PUTTE I        LANCET                           2   251 976
   016   CAVALLI-SFORZA LL     AM J HUM GENET                  25   618 973
   017   ANDERSON LT           PSYCHOLOGICAL SPECTATOR         10     4 975
   018   SELMANOFF MK          NATURE                         253   529 975
   019   SELMANOFF MK          BEHAV GENET                      6    53 976
   020   LAGERSPETZ KMJ        IN: VAN ABEELEN                      321 974
   021   RANDT CT              DEVELOP PSYCHOBIOL               8   275 975
   023   OMENN GS              ANN NY ACAD SCI                197    16 972
   024   FULLER JL             COMPARATIVE PHYSIOL PSYCHOL     57    85 965
   025   RANDALL CL            SCIENCE                        189   149 975
   026   HIRSCH J              IN: HIRSCH J                         416 967

PN 79052
RN 01032 
AN 79233368
AU MacErlean-D-P.  Gray-B-J.  FitzGerald-M-X.
TI Bronchial artery embolization in the control of massive haemoptysis.
SO Br-J-Radiol. 1979 Jul. 52(619). P 558-61.
MJ BRONCHIAL-ARTERIES.  EMBOLIZATION-THERAPEUTIC.  HEMOPTYSIS: th.
MN ADOLESCENCE.  ADULT.  ASPERGILLOSIS: co.  BRONCHIAL-ARTERIES: ra.
   CASE-REPORT.  CYSTIC-FIBROSIS: co.  FEMALE.  HEMOPTYSIS: et.  HUMAN.
   LUNG-DISEASES-FUNGAL: co.  MALE.
AB Bronchial artery embolization is a useful palliative treatment for
   life-threatening haemoptyses where surgery is contra-indicated.
   Patients presenting with haemoptyses complicating cystic fibrosis and
   aspergilloma have been embolized. Control of haemoptysis was achieved
   in the former, but late recurrence of haemoptysis in the latter led
   to asphyxiation.
RF 001   BOOKSTEIN JJ          CHEST                           72   658 977
   002   BREDIN CP             CHEST                           72   258 977
   003   KARDJIEV V            RADIOLOGY                      112    81 974
   004   MACERLEAN DP          BR J RADIOL                     51   414 978
   005   REMY J                RADIOLOGY                      122    33 977
   006   SCHUSTER SR           J PEDIATR SURG                  12   889 977
   007   STONE RM              SURG FORUM                      17   109 966
   008   WHOLEY MH             JAMA                           236  2501 976
CT   1   COLLINS JV            BR J HOSP MED                   23   179 980
     2   FAIRFAX AJ            BR J DIS CHEST                  74   345 980
     3   MAGILLIGAN DJ         ANN THORAC SURG                 32   392 981
     4   FERRIS EJ             CHEST                           80   710 981
     5   KUCERA V              THORAC CARDIOVASC SURG          30   152 982
     6   GRENIER P             AM J ROENTGENOL                140   467 983
     7   NAAR CA               AM J ROENTGENOL                140   271 983
     8   PORTER DK             ARCH INTERN MED                143   287 983
     9   UFLACKER R            RADIOLOGY                      146   627 983
    10   TAFRESHI M            NY STATE J MED                  85    38 985
    11   KLAMUT M              FORTSCHR GEB RONTG NUKL        143   645 985
    12   NOLAN MT              IR J MED SCI                   154   336 985

PN 79053
RN 01033 
AN 80044035
TI Cystic fibrosis in adults [editorial].
SO Br-Med-J. 1979 Sep 15. 2(6191). P 626.
MJ CYSTIC-FIBROSIS: co.
MN ADOLESCENCE.  ADULT.  BRONCHIAL-DISEASES: et.  CYSTIC-FIBROSIS: oc.
   FEMALE.  HUMAN.  LUNG-DISEASES: et.  MALE.  PANCREATIC-DISEASES: et.
EX Cystic fibrosis is the commonest semilethal genetic disorder in
   Caucasians.  The biochemical sequence that leads to widespread
   dysfunction of exocrine glands has yet to be determined.  Cystic
   fibrosis in adults has been the subject of extensive review.  We
   still do not know the cause of the changes in the lungs.  Pancreatic
   insufficiency was recorded in 95% of the patients, but the older ones
   needed little dietary restriction and some seemed to thrive without
   pancreatic replacement.  Ninety-five per cent of males have aspermia
   due to failure of development of the vas deferens, epididymis, and
   seminal vesicles.  Despite the obvious handicap and emotional and
   social strains in all four series, adolescent and adult patients with
   cystic fibrosis not only did well at school and at work but managed
   to fit in well in their social framework.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   002   DI SANTAGNESE PA      AM J MED                        66   121 979
   003   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
   004   MITCHELL-HEGGS PF     Q J MED                         45   479 976
   005   GRACEY M              AUSTRALAS ANN MED               18    91 969

PN 79054
RN 01034 
AN 80044037
AU Flower-K-A.  Eden-R-I.  Lomax-L.  Mann-N-M.  Burgess-J.
TI New mechanical aid to physiotherapy in cystic fibrosis.
SO Br-Med-J. 1979 Sep 15. 2(6191). P 630-1.
MJ CYSTIC-FIBROSIS: th.  PERCUSSION: is.  PHYSICAL-THERAPY: is.
MN ADOLESCENCE.  ADULT.  AGED.  HUMAN.  MIDDLE-AGE.  PRESSURE.
AB The force of impact and frequency of percussion by physiotherapists
   and parents of children with cystic fibrosis were analysed on a
   special test rig and incorporated in a prototype percussor. In adult
   volunteers and cadavers a maximum intrathoracic pressure could be
   achieved by a critical frequency of mechanical percussion which was
   higher than that reached by physiotherapists and parents.
   Consequently the percussor was redesigned to operate at this optimum
   frequency. It was then discovered that if the percussor was pressed
   firmly enough against the chest, this maximum intrathoracic pressure
   could be indicated by quivering of the voice. In a continuing study
   of intrathoracic pressures obtained mechanically and manually the
   Salford percussor's produced higher pressures than the
   physiotherapists' and maintained them constantly, while the
   physiotherapists' efforts and results varied from one to another.
   Hospital and domiciliary use of the percussor have shown it to help
   in the first stage of the physiotherapy routine for patients with
   cystic fibrosis. The percussor should enable adolescents and adults
   to treat themselves and encourage twice-daily and more effective
   chest treatments. It is easy to apply and its speed and efficiency
   should enable parents to improve the quality of their chest therapy
   for younger children at home. Its long-term benefits are difficult to
   assess because of the nature of the disease.
RF 001   SHWACHMAN H           CF CLUB ABST                    13       974
   002   ROBINSON MJ           ARCH DIS CHILD                  50   962 975
   003   CROZIER DN            PEDIATR CLIN NORTH AM           21   935 974
   004   HODSON ME             BR MED J                         1   971 978
   005   LOUGH MD              PEDIATRIC RESPIRATORY THERAPY            974
CT   1   ANON                  LANCET                           2   729 979
     2   FREEDMAN BJ           EUR J RESPIR DIS                61   254 980
     3   HOLODY B              AM REV RESPIR DIS              124   372 981
     4   KERREBIJN KF          EUR J RESPIR DIS                63    35 982
     5   BATTISTINI A          RIV ITAL PEDIATR                10   220 984

PN 79055
RN 01035 
AN 80021861
AU Pryor-J-A.  Webber-B-A.  Hodson-M-E.  Batten-J-C.
TI Evaluation of the forced expiration technique as an adjunct to
   postural drainage in treatment of cystic fibrosis.
SO Br-Med-J. 1979 Aug 18. 2(6187). P 417-8.
MJ BREATHING-EXERCISES.  CYSTIC-FIBROSIS: th.
MN ADOLESCENCE.  ADULT.  COMPARATIVE-STUDY.  FEMALE.  HUMAN.  MALE.
   PHYSICAL-THERAPY: mt.  POSTURE.  SPUTUM.
AB Sixteen patients with cystic fibrosis were treated with conventional
   physiotherapy aided by an assistant. The results were compared with
   those produced by physiotherapy using the forced expiration technique
   cleared more sputum in less time than conventional physiotherapy. A
   sputum in less time than conventional physiotherapy. A second study
   showed that an assistant did not further improve the results obtained
   by the patient performing the forced expiration technique himself.
   These findings mean that patients with cystic fibrosis who have had
   to rely on the help of others for their home treatment may now
   perform more effective treatment without help. The forced expiration
   technique might also be helpful for patients with chronic bronchitis,
   asthma, or bronchiectasis.
RF 001   COCHRANE GM           BR MED J                         2  1181 977
   002   GASKELL DV            BROMPTON HOSP GUIDE TO CHEST             977
   003   THOMPSON BJ           NZ J PHYSIOTHERAPY               4     4 973
   004   MEAD J                J APPL PHYSIOL                  22    95 967
   005   DAWSON SV             J APPL PHYSIOL                  43   498 977
   006   DE KOCK MA            DYNAMIC BRONCHOSCOPY                     977
CT   1   NICKERSON BG          AM REV RESPIR DIS              122   859 980
     2   HODSON ME             PRACTITIONER                   224   301 980
     3   SUTTON PP             EUR J RESPIR DIS                63   188 982
     4   HARRISON AC           NZ MED J                        95   270 982
     5   ROSSMAN CM            AM REV RESPIR DIS              126   131 982
     6   SUTTON PP             EUR J RESPIR DIS                64    62 983
     7   HODSON ME             PRACTITIONER                   227  1723 983
     8   SUTTON PP             SEM RESPIR MED                   5   353 984
     9   HODSON ME             POSTGRAD MED J                  60   225 984
    10   FALK M                EUR J RESPIR DIS                65   423 984
    11   DEBOECK C             AM REV RESPIR DIS              129   182 984
    12   MACKENZIE CF          CRIT CARE MED                   13   483 985
    13   MEARNS MB             ARCH DIS CHILD                  60   272 985
    14   SUTTON PP             EUR J RESPIR DIS                66   147 985
    15   KIRILOFF LH           CHEST                           88   436 985
    16   MAZZOCCO MC           CHEST                           88   360 985
    17   COCHRANE GM           BR MED J                       290  1026 985
    18   OBERWALDNER B         PEDIATR PULMONOL                 2   358 986
    19   FALING LJ             CLIN CHEST MED                   7   599 986
    20   HOFMEYR JL            THORAX                          41   951 986
    21   KIM CS                J APPL PHYSIOL                  60   908 986
    22   BLOMQUIST M           ARCH DIS CHILD                  61   362 986
    23   TYRRELL JC            ARCH DIS CHILD                  61   598 986
    24   DINWIDDIE R           J ROY SOC MED                   79     6 986
    25   CURRIE DC             BR J DIS CHEST                  80   249 986
    26   WEBBER BA             BR J DIS CHEST                  80   353 986
    27   SUTTON PP             THORAX                          42   159 987
    28   KIM CS                J APPL PHYSIOL                  62   959 987
    29   ANDREASSON B          ACTA PAEDIATR SCAND             76    70 987

PN 79056
RN 01036 
AN 79146187
AU Chapman-J-A.  Goodall-J.
TI Dying children need help too.
SO Br-Med-J. 1979 Mar 3. 1(6163). P 593-4.
MJ CHILD-CARE.  TERMINAL-CARE.
MN CASE-REPORT.  CHILD-CARE: mt, st.  CHILD.  COMPARATIVE-STUDY.
   CYSTIC-FIBROSIS: th.  FEMALE.  HUMAN.  TERMINAL-CARE: mt, st.
EX The control of symptoms in dying children is often sadly neglected.
   This neglect is reflected in a review of the case notes of two
   children who died of cystic fibrosis within three years of each
   other.  The girls were under the care of the same consultant, who in
   the interval between the two cases was introduced to the concept of
   proper terminal care for children.  These two cases show that illness
   can cause physical, emotional, and spiritual pain to family and
   staff.  In retrospect these areas of distress were not clearly
   defined in either case and opportunities to alleviate suffering were
   missed.  The principles of controlling symptoms need to be remembered
   as much during distressing treatment as during the distress of dying.
RF 001   BRETT EM              DEVELOP MED CHILD NEUROL        12   655 970
   002   SHAFFER D             IN: RUTTER M                             977
   003   TWYCROSS RG           IN: SAUNDERS CM                          978

PN 79057
RN 01037 
AN 79125271
AU Bradley-J-A.  Axon-A-T.  Hill-G-L.
TI Nocturnal elemental diet for retarded growth in a patient with
   cystic fibrosis.
SO Br-Med-J. 1979 Jan 20. 1(6157). P 167.
MJ CYSTIC-FIBROSIS: co.  FOOD-FORMULATED.  NUTRITION-DISORDERS: dh.
MN ADOLESCENCE.  BODY-WEIGHT.  CASE-REPORT.  FEMALE.  HUMAN.
   INTUBATION-GASTROINTESTINAL.  NUTRITION-DISORDERS: et.  POTASSIUM: me.
EX The combination of chronic pulmonary sepsis and pancreatic
   insufficiency in children with cystic fibrosis may lead to
   malnutrition.  We describe our experience of the long-term use of
   continuous nocturnal infusion of elemental diet in a patient with
   cystic fibrosis.  Our patient tolerated the long-term nocturnal
   elemental diet well, and it enabled her to continue normal
   everyday activity and eat normal meals.  The periods of nutritional
   support coincided with periods of increased body weight and total
   body potassium, indicating that the lean body mass was increased.
   We think that these results show a need for further studies of home
   treatment in children with cystic fibrosis.
RF 001   WEIHOFEN DM           J AM DIET ASSOC                 54   206 969
   002   SHWACHMAN H           PEDIATR CLIN NORTH AM           22   787 975
   003   COUCH R               FED PROC                        19    13 960
   004   ANDRASSY RJ           SURGERY                         82   205 977
   005   BERRY HK              AM J DIS CHILD                 129   165 975
CT   1   POULIN E              CAN J SURG                      25   584 982
     2   WORTHEN DB            DRUG INTEL CLIN PHARM           18   794 984
     3   BERTRAND JM           J PEDIATR                      104    41 984
     4   SOUTTER VL            CLIN GASTROENTEROL              15   137 986
     5   MOORE MC              AM J CLIN NUTR                  44    33 986

PN 79058
RN 01038 
AN 80043560
AU Zapletal-A.  Houstek-J.  Samanek-M.  Vavrova-V.  Srajer-J.
TI Lung function abnormalities in cystic fibrosis and changes during
   growth.
SO Bull-Eur-Physiopathol-Respir. 1979 Jul-Aug. 15(4). P 575-92.
MJ CYSTIC-FIBROSIS: pp.  LUNG: pp.
MN ADOLESCENCE.  ADULT.  AIRWAY-RESISTANCE.  CHILD.  CHILD-PRESCHOOL.
   COMPARATIVE-STUDY.  FEMALE.  FOLLOW-UP-STUDIES.  HUMAN.
   LUNG-COMPLIANCE.  LUNG-VOLUME-MEASUREMENTS.  LUNG: gd.  MALE.
AB Static lung volumes (VC, TLC, FRC, RV), elastic recoil pressure of
   the lungs (Pst(1) at 100, 90, and 60% of TLC), static lung compliance
   [Cst(1)], specific airway conductance at FRC level (Gaw/TGVex),
   forced expiratory volume in the first second (FEV1), maximal
   expiratory flows (Vmax.) at 25 and 50% of VC and at 60% of TLC, and
   "upstream" airway conductance (Gus) at 60% of TLC were studied in 28
   patients with cystic fibrosis, 5 to 25 years old, over a period of 1
   to 5 years. The data were compared individually with normal values,
   related to body height in the form of regression equations and
   expressed in percentage of predicted values. From the indices
   assessing airway function, Vmax. at low lung volumes, Gus at 60% TLC,
   RV and RV/TLC were the functional parameters most consistently
   abnormal. Among the indices characterizing lung elasticity, Pst(1) at
   60% TLC was the most abnormal. Generally, the values of the majority
   of lung function indices [VC, TLC, FRC, Pst(1)] declined during
   growth. Vmax. at all lung volumes and Gus at 60% TLC did not
   deteriorate with growth probably due to the great abnormality of
   these parameters already in young patients. It was also observed that
   lung function did not change significantly over a period of 1 to 5
   years corresponding to a 10 cm increase in body height. However, over
   that period, lung function improved in some of the subjects, did not
   change in over 50% of the cases and deteriorated in the others.
RF 001   BEIER FR              AM REV RESPIR DIS               94   430 966
   002   COOK CD               PEDIATRICS                      24   181 959
   003   COREY M               AM REV RESPIR DIS              114  1085 976
   004   DEMUTH GR             AM J DIS CHILD                 103   129 962
   005   FEATHERBY EA          AM REV RESPIR DIS              102   737 970
   006   GOLDRING RM           J PEDIATR                       65   501 964
   007   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            963
   008   HOUSTEK J             PRAKT LEKAR                     49   216 969
   009   HOUSTEK J             VNITR LEK                       16   449 970
   010   LOUGH MD              PEDIATRIC RESPIRATORY THERAPY            974
   011   MANSELL A             AM REV RESPIR DIS              109   190 974
   012   MEAD J                J APPL PHYSIOL                  22    95 967
   013   MELLINS RB            PEDIATRICS                      41   560 968
   014   NEUBURGER N           AM REV RESPIR DIS              114   753 976
   015   SAMANEK M             ACTA PAEDIATR SCAND             60   149 971
   016   STERN RC              J PEDIATR                       89   406 976
   017   VAVROVA V             CESK PEDIATR                    28   528 973
   018   WILLIAMS HE           RESPIRATORY ILLNESS IN CHILDR            975
   019   ZAPLETAL A            PEDIATRICS                      48    64 971
   020   ZAPLETAL A            CESK PEDIATR                    31   532 976
   021   ZAPLETAL A            J APPL PHYSIOL                  40   953 976
   022   ZAPLETAL A            Z ERKR ATMUNGSORGANE           149   343 977
   023   ZAPLETAL A            CAS LEK CES                    113  1225 974
   024   ZAPLETAL A            CESK PEDIATR                    32   513 977
CT   1   GOTZ M                EUR J RESPIR DIS                61   122 980
     2   SOLYMAR L             EUR J RESPIR DIS                61   275 980
     3   DESWINIARSKI R        BULL EUR PHYSIOPATH RESP        18    39 982
     4   ZAPLETAL A            EUR J RESPIR DIS                64   426 983
     5   LEUPOLD W             Z KLIN MED                      40   661 985
     6   ZACH MS               AM REV RESPIR DIS              131   537 985
     7   WIESEMANN HG          MONATSSCHR KINDERHEILKD        133   726 985
     8   OBERWALDNER B         PEDIATR PULMONOL                 2   358 986
     9   ANDREASSON B          ACTA PAEDIATR SCAND             76    70 987

PN 79059
RN 01039 
AN 80021639
AU Coates-A-L.  Boyce-P.  Muller-D.  Mearns-M.  Godfrey-S.
TI The role of nutritional status, airway obstruction, hypoxia and
   abnormalities in serum lipid composition in limiting exercise
   tolerance in children with cystic fibrosis.
SO Bull-Eur-Physiopathol-Respir. 1979 Mar-Apr. 15(2). P 341-2.
MJ AIRWAY-OBSTRUCTION: bl.  ANOXIA: bl.  CYSTIC-FIBROSIS: bl.  EXERTION.
   LIPIDS: bl.  NUTRITION-DISORDERS: bl.
MN CARBON-DIOXIDE: bl.  CHILD.  HEART-RATE.  HUMAN.
   LUNG-VOLUME-MEASUREMENTS.  OXYGEN: bl.
EX This study investigated the roles of hypoxia, pulmonary mechanics,
   nutritional status and serum fatty acid composition in limiting
   exercise tolerance in cystic fibrosis.  Twenty children with CF of
   carrying severity performed two progressive exercise tests on a cycle
   ergometer, once while breathing air, once while breathing O2. The
   children with the lower maximal mid-expiratory flow rates tended to
   have very little respiratory reserve at the final work load.  We
   conclude that nutritional status and airway obstruction are closely
   correlated with exercise tolerance in CF and that, unlike the adult
   with chronic obstructive pulmonary disease, exercise limiting
   dyspnoea occurs in the presence of normal end-tidal CO2.
CT   1   LEUPOLD W             Z KLIN MED                      40   661 985

PN 79060
RN 01040 
AN 79234522
AU Sams-C-A.
TI One breath at a time: a family teaching program for children with
   cystic fibrosis.
SO Can-Nurse. 1979 Sep. 75(8). P 20-3.
MJ CYSTIC-FIBROSIS: rh.  PARENTS: ed.  PATIENTS: ed.
   PATIENT-EDUCATION.
MN ADOLESCENCE.  ADULT.  BREATHING-EXERCISES.  CASE-REPORT.  CHILD.
   CHILD-PRESCHOOL.  FAMILY.  FEMALE.  HUMAN.  MALE.
   RESPIRATORY-THERAPY.
EX We have found patients who have cystic fibrosis to be very special
   people; they have to overcome apparently insurmountable odds.  Our
   teaching program comes from a basic belief that with support,
   encouragement and affection, information and a focus on the positive
   aspects of life, a person with CF can live well, even if only one
   breath at a time.
RF 001   ANDERSON CM           CF A MANUAL OF DIAGNOSIS AND             976
   001   LEFEBVRE A            DISSERTATION                             974
   002   BURNETTE BA           AM J NURS                       75  1986 975
   002   STEINHAUER PD         PEDIATR CLIN NORTH AM           21   825 974
   003   MCCOLLUM AT           COPING WITH PROLONG HLTH IMP             975
   004   FAKKEM L              AM J NURS                       59  1269 959
   005   LEONARD CO            N ENGL J MED                   287   433 972

PN 79061
RN 01041 
AN 80022554
AU Berger-H-J.  Zaret-B-L.
TI Noninvasive radionuclide assessment of right ventricular performance
   in man.
SO Cardiovasc-Clin. 1979. 10(2). P 91-104.
MJ HEART-VENTRICLE: ri.  RADIONUCLIDE-IMAGING: mt.
MN ADULT.  CYSTIC-FIBROSIS: pp, ri.  DIAGNOSIS-DIFFERENTIAL.
   HEART-VENTRICLE: pp.  HUMAN.  LUNG-DISEASES-OBSTRUCTIVE: pp, ri.
   MYOCARDIAL-INFARCTION: pp, ri.  RESPIRATION.  STROKE-VOLUME.
   SUPPORT-U-S-GOVT-P-H-S.
EX This chapter focuses on the application of radionuclide
   angiocardiography to assessment of right ventricular ejection
   fraction and the relationship between right and left heart
   performance demonstrated by this technique.  Prior to discussion of
   the clinical applications, the functional geometry of the two
   ventricles will be reviewed.  In addition, the first-pass radiotracer
   techniques will be compared to other radionuclide imaging approaches
   of the right heart.  First-pass radionuclide angiocardiographic
   techniques are now suitable for clinical application.  They have been
   validated and standardized and can be relied upon for accurate,
   reproducible noninvasive assessment of right and left ventricular
   performance.  They already have been applied to the study of patients
   with cardiopulmonary disease; future directions will include earlier
   evaluation of myocardial infarction, application to children and
   adults with a variety of congenital cardiac abnormalities (primarily
   those affecting the right heart), and assessment of the effects of
   physiologic stress upon right ventricular function.  With this
   background valuable clinical and investigative insights should become
   available during the coming years.
RF 001   STARR I               AM HEART J                      26   291 943
   002   BURROWS B             N ENGL J MED                   286   912 972
   003   PONTOPPIDAN H         N ENGL J MED                   287   690 972
   004   COHN J                AM J CARDIOL                    33   209 974
   005   BERGER HJ             AM J CARDIOL                    41   897 978
   006   ELLIS J               CHEST SUPPL                     71   281 977
   007   FISHER EA             AM J CARDIOL                    36    67 975
   008   ARCILLA R             CHEST                           60   446 971
   009   GRAHAM TP JR          CIRCULATION                     47   144 973
   010   GRAHAM TP JR          CIRCULATION                     51   881 975
   011   GENTZLER R            CIRCULATION                     50   324 974
   012   MARSHALL RC           CIRCULATION                     56   820 977
   013   RUSHMER RF            CARDIOVASCULAR DYNAMICS               89 976
   014   FERLINZ J             CIRCULATION                     52   608 975
   015   JAFFE C               CURR PROB RADIOL                 4     1 974
   016   BLUMGART HL           J CLIN INVEST                    4   399 927
   017   PRINZMETAL M          SCIENCE                        108   340 948
   018   VAN DYKE D            J NUCL MED                      13   585 972
   019   WEBER P               J NUCL MED                      13   815 972
   020   SHELBERT H            CIRCULATION                     51   902 975
   021   STEELE P              AM J CARDIOL                    34   179 974
   022   STEELE P              AM J CARDIOL                    37   388 976
   023   ELLIS J               CHEST                           69   575 976
   024   STEELE P              CHEST                           70    51 976
   025   TOBINICK E            CIRCULATION SUPPL               56   140 977
   026   MARSHALL RC           AM J CARDIOL                    41   531 978
   027   BERGER HJ             CLIN RES                        25  209A 977
   028   BORKOWSKI H           CIRCULATION SUPPL               56   198 977
   029   STEELE P              AM J MED                        59    21 975
   030   KLINE L               CHEST                           72     5 977
   031   MATTHAY R             AM HEART J                      92   730 976
   032   MATTHAY R             CHEST                           72   407 977
   033   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
   034   YATER WM              AM HEART J                      36   683 948
   035   ERHARDT L             ACTA MED SCAND SUPPL           560     1 974
   036   SHARPE N              CIRCULATION SUPPL 2             54    76 976
   037   BUSEMAN SOKOLE E      CIRCULATION SUPPL 3             56    62 977
   038   REDUTO L              ANN INTERN MED                  89   441 978
   039   RIGO P                CIRCULATION                     52   268 975
CT   1   ARVAN S               VASC SURG                       18    72 984
     2   DETRANO R             J AM COLL CARDIOL                5  1377 985
     3   DEC GW                N ENGL J MED                   312   885 985

PN 79062
RN 01042 
AN 79126800
AU Hoogkamp-Korstanje-J-A.  Westerdaal-N-A.
TI In vitro susceptibility of pseudomonas to four
   beta-lactamantibiotics (ampicillin, cephalothin, carbenicillin,
   piperacillin), to four aminoglycosides (kanamycin, amikacin,
   gentamicin, tobramycin) and to colimycin.
SO Chemotherapy. 1979. 25(1). P 48-53.
MJ AMINOGLYCOSIDES: pd.  CEPHALOTHIN: pd.  COLISTIN: pd.
   PENICILLINS: pd.  PSEUDOMONAS: de.
MN AMIKACIN: pd.  AMPICILLIN: pd.  CARBENICILLIN: pd.  CHILD.
   COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: mi.  DRUG-RESISTANCE-MICROBIAL.
   GENTAMICINS: pd.  HUMAN.  KANAMYCIN: pd.
   MICROBIAL-SENSITIVITY-TESTS.  SPUTUM: mi.  TOBRAMYCIN: pd.
AB Of 97 well-defined strains of Pseudomonas, isolated from sputum of
   patients with cystic fibrosis (CF), the minimum inhibitory
   concentration (MIC) of several antibiotics was determined with a
   broth dilution method. The majority of the strains were resistant to
   ampicillin and cephalothin, moderately susceptible to carbenicillin
   (70% to 100 microgram/ml) and highly susceptible to piperacillin
   (100% to 25 microgram/ml, 88% to 6.25 microgram and 60% to 3.12
   microgram/ml). If the pharmacological properties of piperacillin are
   comparable with those of carbenicillin, it can be expected that the
   sputum level of this drug will be adequate to treat Pseudomonas
   pulmonary infections. At the lowest concentration tested (0.78
   microgram/ml) 3% of the strains were susceptible to kanamycin, 85,5%
   to amikacin, 95% to gentamicin, 98% of tobramycin, and 80% to
   colimycin. With regard to clinically attainable concentrations, 98.9%
   of the strains were susceptible to gentamicin and tobramycin 97.9% to
   amikacin, 96.9% to colimycin, 88.6%  to piperacillin, 38% to
   carbenicillin, 25.7% to kanamycin, 12.3% to ampicillin, and 1% to
   cephalothin.
RF 001   BLAIR JE              MANUAL OF CLINICAL MICROBIOLO            970
   002   BOXERBAUM B           J INFECT DIS SUPPL             122    59 970
   003   BOXERBAUM B           J INFECT DIS SUPPL             124   293 971
   004   COWAN ST              MANUAL FOR THE IDENTIFICATION            973
   005   ERICSSON HM           ACTA PATH MICROBIOL SCAND     S217       971
   006   MARKS MI              J PEDIATR                       79   822 971
   007   MONROE PW             APPL MICROBIOL                  18   214 969
   008   PENNINGTON JE         ANTIMICROB AGENTS CHEMOTHER      4   299 973
   009   PHAIR JP              AM J DIS CHILD                 120    22 970
   010   REYNOLDS AV           BR MED J                         3   778 974
   011   SAGGERS BA            ARCH DIS CHILD                  43   404 968
   012   WOOD RE               PSEUDOMONAS INFECTION IN CF P            975
   013   ZIERDT CH             J CLIN MICROBIOL                 1   521 975
CT   1   HOOGKAMPKORSTANJE JAA J ANTIMICROB CHEMOTHER           8   101 981
     2   HOOGKAMPKORSTANJE JAA INFECTION                       10  S257 982
     3   HOOGKAMPKORSTANJE JAA J ANTIMICROB CHEMOTHER          12   175 983
     4   SEGNI G               CURR THER RES CLIN EXP          33   265 983

PN 79063
RN 01043 
AN 79190706
AU Allen-H-D.  Taussig-L-M.  Gaines-J-A.  Sahn-D-J.  Goldberg-S-J.
TI Echocardiographic profiles of the long-term cardiac changes in
   cystic fibrosis.
SO Chest. 1979 Apr. 75(4). P 428-33.
MJ CYSTIC-FIBROSIS: co.  ECHOCARDIOGRAPHY.  HEART-DISEASES: di.
MN ADOLESCENCE.  ADULT.  AORTIC-DISEASES: di, et.  CHILD.
   CHILD-PRESCHOOL.  FEMALE.  HEART-DISEASES: et.  HUMAN.  INFANT.
   MALE.  PROGNOSIS.  SUPPORT-U-S-GOVT-P-H-S.
AB In this echocardiographic study, assessment of the heart in children
   with cystic fibrosis has shown that changes occur in not only the
   right ventricle but also in the left ventricle and aorta, as compared
   with normal. Echocardiograms could be successfully performed in 34 of
   37 patients. The thickness of the right ventricular anterior wall and
   the dimension of the right ventricular cavity  were abnormal, even in
   patients with mild disease (National Institutes of Health [NIH] score
   for severity of disease of 85 or greater). Larger, older children
   with lower NIH score had disproportionately larger right ventricular
   anterior walls and cavities. The thickness of the septal wall, the
   thickness of the left ventricular posterior wall, and the aortic
   dimensions were increased in those with severe disease. The
   dimensions of the left ventricular cavity for the population were
   slightly but significantly smaller than normal in systole and in
   diastole throughout the course of the disease. This study
   demonstrates that echocardiography is an effective noninvasive means
   of assessing the long-term changes in children with cystic fibrosis.
   These changes occur in both sides of the heart and appear to worsen
   as the disease progresses.
RF 001   ANON                  CIRCULATION                     27   594 963
   002   LIEBMAN J             CHEST                           63   218 973
   003   RYLAND D              THORAX                          30   285 975
   004   SIASSI B              J PEDIATR                       78   794 971
   005   MOSS AJ               J PEDIATR                       67   797 965
   006   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   007   WARSHAWSKY JK         IN: KULCZYCKI LL                      16 974
   008   GEWITZ M              AM J DIS CHILD                 131   275 977
   009   ROSENTHAL A           PEDIATR CLIN NORTH AM           23   327 976
   010   TAUSSIG LM            J PEDIATR                       82   380 973
   011   GOLDBERG SJ           PEDIATRIC AND ADOLESCENT ECHO            975
   012   ALLEN HD              WORKBOOK IN PEDIATRIC ECHOCAR            978
   013   EPSTEIN ML            CIRCULATION                     51  1124 975
   014   GRIFFITH JM           IEEE TRANS BIOMED ENG           22   337 975
   015   ROYCE SW              PEDIATRICS                       8   255 951
   016   LARTER WE             CIRCULATION                     53    19 976
   017   WEYMAN AE             CIRCULATION                     54   179 976
   018   STEELE P              AM J MED                        59    21 975
   019   MITCHELL RS           AM REV RESPIR DIS              114   147 976
   020   WILLIAMS JF JR        J CLIN INVEST                   47  1143 968
   021   KOUNTZ WB             AM HEART J                      11   163 936
   022   SCOTT RW              AM HEART J                      22    56 941
   023   MICHELSON N           DIS CHEST                       38   435 960
   024   FLUCK DC              BR HEART J                      28    92 966
   025   RAO BS                AM J MED                        45   229 968
   026   BAUM GL               N ENGL J MED                   285   361 971
   027   FULTON RM             BR HEART J                      14   413 952
CT   1   LESTER LA             J PEDIATR                       97   742 980
     2   FRANCIS PWJ           AM J DIS CHILD                 134   734 980
     3   JACOBSTEIN MD         CHEST                           80   399 981
     4   MOSS AJ               PEDIATRICS                      70   728 982
     5   TEPPER RS             CHEST                           84   388 983
     6   CHERON G              ACTA PAEDIATR SCAND             73   697 984
     7   MICHAEL JR            AM REV RESPIR DIS              130   516 984
     8   LESTER LA             SEM RESPIR MED                   6   285 985

PN 79064
RN 01044 
AN 79168494
AU Lieberman-J.  Kaneshiro-W.
TI Lymphocytic acid-hydrolases and response to mitogens in cystic
   fibrosis.
SO Chest. 1979 Feb. 75(2 Suppl). P 220-3.
MJ ACID-PHOSPHATASE: bl.  CYSTIC-FIBROSIS: en.  GLYCOSIDE-HYDROLASES: bl.
   LYMPHOCYTES: en.  MITOGENS: pd.
MN ACETYLGLUCOSAMINIDASE: bl.  AMYLASES: bl.  BETA-GALACTOSIDASES: bl.
   BLOOD-PROTEINS: an.  CELLS-CULTURED.  COMPARATIVE-STUDY.
   CULTURE-MEDIA.  CYSTIC-FIBROSIS: fg.  FUCOSIDASE: bl.
   GLUCOSIDASES: bl.  GLUCURONIDASE: bl.  HETEROZYGOTE.  HOMOZYGOTE.
   HUMAN.  MANNOSIDASES: bl.  STIMULATION-CHEMICAL.
   SUPPORT-U-S-GOVT-NON-P-H-S.  SUPPORT-U-S-GOVT-P-H-S.  XYLOSIDASES: bl.
EX In the present study, we compared the levels of a series of cultured
   lymphocytic acid-hydrolase enzymes in cystic fibrosis homozygotes,
   heterozygotes and controls; compared the effects of three different
   mitogens on these levels; and studied the effect of CF vs control
   serum in the culture medium.  Our observations provide an entirely
   new interpretation for the apparent changes occurring in lymphocytic
   enzymes during culture of lymphocytes with mitogens, and suggest that
   a serum factor is present in cystic fibrosis serum that mimics
   mitogens in this regard.  Lymphocytic acid-hydrolases and total
   protein are present in higher concentrations in lymphocytes cultured
   for 48 hours without mitogen when CF homozygous or heterozygous serum
   is present in the culture media.  This appears to result from a CF
   serum factor that has mitogen-like activity and prevents loss of cell
   protein during culture.  Responsiveness of the cellular proteins to
   mitogens is blunted when CF serum is present in the culture media,
   either because the cell proteins are already maximally stimulated by
   the CF serum factor, or the factor blocks or modifies the action of
   mitogens on lymphocyte protein content.  This phenomenon is useful
   for detection of CF heterozygosity, and appears to reflect the
   genetic abnormality causing cystic fibrosis.
RF 001   MARCHI AG             HELV PAEDIATR ACTA              28   427 973
   002   LIEBERMAN J           AM REV RESPIR DIS              116  1047 977
   003   ANTONOWICZ I          PEDIATR RES                      6   803 972
CT   1   SEALE TW              ANN CLIN LAB SCI                12   415 982

PN 79065
RN 01045 
AN 79190766
AU Weng-T-R.  Spence-J-A.  Polgar-G.  Nyboer-J.
TI Measurement of regional lung function by tetrapolar electrical
   impedance plethysmography.
SO Chest. 1979 Jul. 76(1). P 64-9.
MJ PLETHYSMOGRAPHY-IMPEDANCE: mt.  PULMONARY-CIRCULATION.
   RESPIRATORY-FUNCTION-TESTS: mt.
MN ADOLESCENCE.  CASE-REPORT.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: pp.  ELECTRODES.  FEMALE.
   HEART-DEFECTS-CONGENITAL: pp.  HUMAN.  MALE.
   PLETHYSMOGRAPHY-IMPEDANCE: is.  PULMONARY-VEINS: ab.
   RESPIRATORY-FUNCTION-TESTS: is.  RESPIRATORY-INSUFFICIENCY: pp.
   VENTILATION-PERFUSION-RATIO.
AB This study demonstrates the clinical feasibility of atraumatically
   measuring dynamic regional lung function with tetrapolar electrical
   impedance plethysmography (EIP) in the pediatric age group. A
   tetrapolar electrode system was used because of its ability to detect
   local baseline and pulsatile impedance changes, minimal electrode-
   tissue impedance interference, and uniform current distribution.
   Studies performed on 4 children 4 to 15 years old with various
   pulmonary diseases are presented. The information obtained on their
   regional ventilation and pulsatile perfusion by EIP was found to
   agree closely with pulmonary ventilation and perfusion scans. In one
   case, EIP detected pulsatile perfusion abnormalities which were not
   apparent in the non-pulsatile perfusion scan but were demonstrated by
   cineangiography. It is concluded that tetrapolar EIP can provide
   safe, reliable regional information about ventilation and perfusion
   in diseased lungs, and because of its atraumatic approach, is
   technically most suitable for use in children.
RF 001   OLSSON T              ACTA PAEDIATR SCAND SUPPL 20         390 970
   002   VAN DE WATER JM       CHEST                           64   598 973
   003   POMERANTZ M           ANN SURG                       171   686 970
   004   LABABIDI Z            PEDIATRICS                      47   870 971
   005   HOON RS               BR HEART J                      39    61 977
   006   DENNISTON JC          J APPL PHYSIOL                  19   166 964
   007   ALLISON RD            J APPL PHYSIOL                  19   166 964
   008   NYBOER J              PROC INT CONG OF BIOL 2ND            216 976
   009   SPENCE JA             PEDIATR RES ABST                11   579 977
   010   POLGAR G              CF CLUB ABST                           4 978
   011   NYBOER J              PROC INT CONG OF BIOL 2ND              5 976
   012   NYBOER J              ELECTRICAL IMPEDANCE PLETHYSM        390 970
   013   NYBOER J              PROC J SOC CLIN INVEST          19   963 940
   014   NYBOER J              ANN NY ACAD SCI                170   421 970
   015   KAUFMAN SS            NAT RES COUNC COMM AVIAT               1 944
   016   GOLDENSOHN ES         J APPL PHYSIOL                  14   463 959
   017   GEDDES LA             PRINCIPLES OF APPL BIOMEDICAL        616 975
   018   KUBICEK WG            AEROSP MED                      37  1208 966
   019   NYBOER J              HARPER HOSP BULL                22   232 964
   020   NYBOER J              AM J ROENTG RAD THER NUCL MED   98   497 966
   021   KIRA S                JAPAN HEART J                   11   149 970
   022   KAWAKAMI K            MED BIOL ENG                    11   460 973
   023   KAWAKAMI K            J RADIOL ELECTROL MED NUCL      54   135 973
   024   WELTMAN G             ANN BIOMED ENG                   1    69 972
   025   SCHRAIBMAN IG         BR J SURG                       63   413 976
CT   1   PENNEY BC             CRC CRIT REV BIOMED ENG         13   227 986
     2   WENG TR               AVIAT SPACE ENVIRON MED         57   449 986

PN 79066
RN 01046 
AN 79190761
AU Keens-T-G.  Mansell-A.  Krastins-I-R.  Levison-H.  Bryan-A-C.
   Hyland-R-H.  Zamel-N.
TI Evaluation of the single-breath diffusing capacity in asthma and
   cystic fibrosis.
SO Chest. 1979 Jul. 76(1). P 41-4.
MJ ASTHMA: di.  CARBON-MONOXIDE: du.  CYSTIC-FIBROSIS: di.
   PULMONARY-DIFFUSING-CAPACITY.
MN ADOLESCENCE.  ADULT.  AIRWAY-OBSTRUCTION: pp.  ASTHMA: pp.
   BRONCHODILATOR-AGENTS: du.  CHILD.  CYSTIC-FIBROSIS: pp.  HUMAN.
   MICROCIRCULATION.  PULMONARY-CIRCULATION.
AB To explain why the single-breath carbon monoxide diffusing capacity
   (Dsb) was, on the average, elevated in 163 asthmatic subjects and 175
   patients with cystic fibrosis, we simulated this elevation in ten
   normal subjects by having them perform the test for Dsb through an
   inspiratory obstruction. This resulted in an 18 percent increase in
   Dsb corrected for pulmonary volume. Inhalation of a bronchodilator
   drug was associated with relief of obstruction and a fall in the
   corrected Dsb in 31 asthmatic subjects but did not change either the
   obstruction or the corrected Dsb in 17 patients with cystic fibrosis.
   We suggest that elevated Dsb in asthma and cystic fibrosis is partly
   due to maximal inspiration against obstructed airways. This requires
   abnormally negative intrathoracic pressures, increasing the pulmonary
   capillary blood volume, and, thereby, increasing the Dsb.
RF 001   WENG TR               AM REV RESPIR DIS               99   719 969
   002   OGILVIE CM            BR MED J                         1   768 968
   003   EVANS CC              LANCET                           1   891 968
   004   COTES JE              J APPL PHYSIOL                  15   372 960
   005   STEINER SH            J CLIN INVEST                   44  1623 965
   006   SMITH TC              J APPL PHYSIOL                  27   826 969
   007   OGILVIE CM            J CLIN INVEST                   36     1 957
   008   ROUGHTON FJM          J APPL PHYSIOL                  11   290 957
   009   CAREL RS              ISR J MED SCI                    9  1535 973
   010   PECORA LJ             J ALLERGY                       37   204 966
   011   WAGNER PD             J APPL PHYSIOL                  31   847 971
   012   HYATT RE              J APPL PHYSIOL                  21   477 966
CT   1   WEINBERGER SE         CHEST                           78   483 980
     2   DAVIES NJH            BR J DIS CHEST                  76   105 982
     3   RUSSELL NJ            BR J DIS CHEST                  76    35 982
     4   OBRODOVICH HM         AM REV RESPIR DIS              125   670 982
     5   OGILVIE C             THORAX                          38     5 983
     6   COTTON DJ             RESPIR PHYSIOL                  54    19 983
     7   GRAHAM BL             AM REV RESPIR DIS              129   403 984
     8   COTTON DJ             CHEST                           87   217 985
     9   PAOLETTI P            AM REV RESPIR DIS              132   806 985
    10   LEBECQUE P            CHEST                           91   693 987

PN 79067
RN 01047 
AN 79126767
AU Hirschfeld-S-S.  Fleming-D-G.  Doershuk-C.  Liebman-J.
TI Echocardiographic abnormalities in patients with cystic fibrosis.
SO Chest. 1979 Mar. 75(3). P 351-5.
MJ CYSTIC-FIBROSIS: pp.  ECHOCARDIOGRAPHY.  HEART: pp.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: co.
   FEMALE.  HEART-FAILURE-CONGESTIVE: di, et, pp.  HEART-VENTRICLE: pp.
   HUMAN.  INFANT.  MALE.  MYOCARDIAL-CONTRACTION.  RESIDUAL-VOLUME.
   SYSTOLE.  VITAL-CAPACITY.
AB An echographic study was undertaken to evaluate left (LV) and right
   ventricular (RV) function in 30 patients with cystic fibrosis.
   Echographic recording of the pulmonary and aortic valve echogram
   permitted measurement of the phases of right and left ventricular
   systole. The ratio of the LV preejection period/LV ejection time
   (LPEP/LVET) and shortening of the LV internal dimension %SID was
   employed to reflect LV function, while RV preejection period/RV
   ejection time (RPEP/RVET) has excellent correlation with pulmonary
   artery diastolic pressure. RPEP/RVET and two other echographic
   measurements, right ventricular wall (RVW) and internal dimension
   (RVD) were compared with pulmonary function tests and clinical
   scores. RPEP/RVET correlated well with percent vital capacity(%VC), r
   = -0.73, percent residual volume (%RVol) r = +0.72, and clinical
   score, r = -0.77. Multilinear regression of RPEP/RVET, RVD, and RVW
   improved correlation for %VC (r = -0.80), %RVol, r = +0.82, and
   clinical score, r = -0.84. Patients in overt right heart failure
   exhibited elevated RPEP/RVET (mean = 0.48) when compared to patients
   not in right heart failure (mean = .33). Marked diminution of LV
   function was present in two patients. A variety of cardiovascular
   abnormalities were demonstrated echographically and were valuable in
   assessing the degree of cardiac involvement in patients with cystic
   fibrosis.
RF 001   LIEBMAN J             IN: MANGOS JA                         41 976
   002   WOOD RE               AM REV RESPIR DIS              113   833 976
   003   SIASSI B              J PEDIATR                       78   794 971
   004   GOLDRING RM           J PEDIATR                       65   501 964
   005   THOMAS AJ             BR HEART J                      34   653 972
   006   LIEBMAN J             CIRCULATION                     35   552 967
   007   ROSENTHAL A           PEDIATR CLIN NORTH AM           23   327 976
   008   RYSSING E             ACTA PAEDIATR SCAND             66   753 977
   009   GEWITZ M              AM J DIS CHILD                 131   275 977
   010   HIRSCHFELD S          CIRCULATION                     51   304 975
   011   HIRSCHFELD S          CIRCULATION                     52   641 975
   012   RIGGS T               CIRCULATION                     57   939 978
   013   WEISSLER AM           IN: YU PN                        1   155 972
   014   FORTUIN NJ            CIRCULATION                     46    26 972
   015   HELLIESEN PJ          PEDIATRICS                      22    80 958
   016   DUBOIS AB             J CLIN INVEST                   35   322 956
   017   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   018   GALANT SP             PEDIATRICS                      61    46 978
   019   MEYER RA              ECHOCARDIOGRAPHY                     257 977
   020   GUTGESELL HP          CIRCULATION                     56   457 977
CT   1   MATTHAY RA            BR HEART J                      43   474 980
     2   LESTER LA             J PEDIATR                       97   742 980
     3   FRANCIS PWJ           AM J DIS CHILD                 134   734 980
     4   BERGER HJ             AM J CARDIOL                    47   950 981
     5   JACOBSTEIN MD         CHEST                           80   399 981
     6   NEWTH CJL             AM REV RESPIR DIS              124   463 981
     7   MOSS AJ               PEDIATRICS                      70   728 982
     8   HIRSCHFELD SS         CHEST                           82   524 982
     9   MATTHAY RA            CLIN CHEST MED                   4   269 983
    10   MATTHAY RA            CRIT CARE MED                   11   329 983
    11   MACDONALD NE          J PEDIATR                      103   985 983
    12   KELLY HW              DRUG INTEL CLIN PHARM           18   772 984
    13   BENSON LN             AM REV RESPIR DIS              130   987 984
    14   MOSKOWITZ WB          PEDIATR PHARMACOL                5   139 985
    15   LESTER LA             SEM RESPIR MED                   6   285 985
    16   PANIDIS IP            J AM COLL CARDIOL                6   701 985
    17   PIEPSZ A              PEDIATR PULMONOL                 3    24 987

PN 79068
RN 01048 
AN 80090384
AU Price-J-F.  Weller-P-H.  Harper-S-A.  Matthew-D-J.
TI Response to bronchial provocation and exercise in children with
   cystic fibrosis.
SO Clin-Allergy. 1979 Nov. 9(6). P 563-70.
MJ ASTHMA: et.  BRONCHIAL-PROVOCATION-TESTS.  CYSTIC-FIBROSIS: co.
MN ADOLESCENCE.  ASPERGILLUS-FUMIGATUS: im.  ASTHMA: di.  CHILD.
   EXERTION.  FEMALE.  HUMAN.  MALE.  SKIN-TESTS.
AB Ten of fifteen cystic fibrosis children with positive skin prick
   tests to common antigens gave an immediate bronchial reaction to the
   antigen inhaled, five of them also gave a late reaction; however only
   one gave a history of asthma. The antigen most commonly eliciting a
   positive skin reaction in cystic fibrosis patients is Aspergillus
   fumigatus. In six children tested to this antigen the bronchial
   response varied, two were negative, one gave an immediate reaction
   and three gave a dual (immediate and late) reaction. None of the
   children showed the characteristic pattern of response to exercise
   seen in asthmatic patients, an initial rise in Peak Expiratory Flow
   Rate followed by a fall of greater than 14% below the resting level.
   Two patients showed an abnormal rise in Peak Expiratory Flow Rate
   during exercise, a pattern described previously in cystic fibrosis.
   The results suggest that bronchial allergy, immediate or late does
   completely explain susceptibility to asthma, and that other factors
   including perhaps the type of bronchial reactivity shown by
   bronchoconstriction after exercise may be required. However the
   majority of the children tested had bronchial allergy and anti-
   allergy therapy such as inhaled sodium cromoglycate may have a place
   in the management of selected patients with cystic fibrosis.
RF 001   ALLAN JD              CLIN ALLERGY                     5   255 975
   002   ANDERSON SD           THESIS                                   972
   003   CHRISPIN AR           PEDIATR RADIOL                   2   101 974
   004   COGSWELL JJ           BR J DIS CHEST                  69   177 975
   005   COGSWELL JJ           BR J DIS CHEST                  69   177 975
   006   DAY G                 ARCH DIS CHILD                  48   355 973
   007   GODFREY RC            CLIN ALLERGY                     6    79 976
   008   GODFREY S             EXERCISE TESTING IN CHILDREN             974
   009   KONIG P               ARCH DIS CHILD                  48   513 973
   010   LANDAU LI             J PEDIATR                       82   863 973
   011   MCCARTHY DS           IN: LAWSON D PROC 5TH INT CF         194 969
   012   MEARNS MB             LANCET                           1   538 967
   013   MEARNS MB             THORAX                          20   385 965
   014   ORES CN               CF CLUB ABST                    16    48 975
   015   PRICE JF              PROC INT CF CONG 7TH                 253 976
   016   RACHELEFSKY GS        AM J DIS CHILD                 128   355 974
   017   SILVERMAN M           ARCH DIS CHILD                  53   873 978
   018   SKORECKI K            ACTA PAEDIATR SCAND             65    39 976
   019   WARNER JO             ARCH DIS CHILD                  51   507 976
   020   WARNER JO             ARCH DIS CHILD                  51   507 976
   021   WARNER JO             LANCET                           1   990 976
   022   WARREN CPW            CLIN ALLERGY                     5     1 975
CT   1   WONNE R               CLIN ALLERGY                    15   455 985

PN 79069
RN 01049 
AN 79190129
AU Ganier-M.  Lieberman-P.
TI IgE mediated hypersensitivity to pancreatic extract (PE) in parents
   of cystic fibrosis (CF) children.
SO Clin-Allergy. 1979 Mar. 9(2). P 125-32.
MJ CYSTIC-FIBROSIS: co.  DRUG-HYPERSENSITIVITY: im.
   HYPERSENSITIVITY-IMMEDIATE: ci.  PANCREATIC-EXTRACTS: ae.  PARENTS.
MN ADULT.  ANTIGENIC-DETERMINANTS.  CASE-REPORT.  CHILD.
   CHILD-PRESCHOOL.  DRUG-HYPERSENSITIVITY: co.  FEMALE.
   HISTAMINE-LIBERATION.  HUMAN.  HYPERSENSITIVITY-IMMEDIATE: co.
   MIDDLE-AGE.  IMMUNIZATION-PASSIVE.  RADIOALLERGOSORBENT-TEST.
   SKIN-TESTS.
AB On exposure to pancreatic extract (PE), four parents of cystic
   fibrosis (CF) children developed immediate hypersensitivity-like
   symptoms: i.e. rhinoconjunctivitis, asthma, and/or anaphylaxis. IgE
   to PE was demonstrated in the subjects by skin testing, leucocyte
   histamine release and radioallergosorbent test (RAST). No serum
   precipitating antibodies were found. Bronchial challenge caused an
   immediate asthmatic response. No delayed asthmatic response or
   hypersensitivity pneumonitis-like reaction occurred. The responsible
   antigen for PE induced asthma is unknown; trypsin failed to inhibit
   PE-RAST and is therefore not responsible in these subjects. Caution
   should be exercised in using PE for skin testing and bronchial
   challenge in subjects with suspected hypersensitivity to PE. Certain
   measures were found useful in preventing the occurrence of symptoms
   in the four subjects.
RF 001   ABERNATHY RS          PEDIATRICS                      56   141 975
   002   ALLAN JD              CLIN ALLERGY                     5   255 975
   003   BATES DV              J CANADA                        18   211 962
   004   BERGNER A             PEDIATRICS                      55   814 975
   005   BERNSTEIN IL          J ALLERGY CLIN IMMUNOL          57   141 976
   006   BOOTH BH III          IN: PATTERSON R                       74 972
   007   COLTEN HR             N ENGL J MED                   292  1050 975
   008   DOLAN TF JR           AM REV RESPIR DIS              110   812 974
   009   HILL D                MED J AUST                       2   553 975
   010   KOPEL FB              GASTROENTEROLOGY                62   483 972
   011   KULCZYCKI LL          JAMA                           175   358 961
   012   MURPHY RLH JR         IN: WEISS EB                         517 976
   013   NAKAMURA S            J ASTHMA RES                    10    37 972
   014   OUCHTERLONY O         HANDBOOK OF IMMUNODIFFUSION A            968
   015   PEPYS J               CLIN ALLERGY                     2   225 972
   016   PRAUSNITZ C           ZENTRALBL BAKTERIOL             86   160 921
   017   PRUZANSKY JJ          J ALLERGY                       38   315 966
   018   RACHELEFSKY GS        AM J DIS CHILD                 128   355 974
   019   ROBERTSON DG          J ALLERGY CLIN IMMUNOL          54   244 974
   020   SAKALA A              LANCET                           1   193 977
   021   SCHLEUTER D           IN: STOLLERMAN G                     153 972
   022   SHORE PA              J PHARMACOL EXP THER           127   182 959
   023   TWAROG FJ             J ALLERGY CLIN IMMUNOL          59    35 977
   024   WIDE L                LANCET                           2  1105 967
   025   WOOD RE               AM REV RESPIR DIS              113   833 976
CT   1   MATHEWS KP            AFR J CLIN EXP IMMUNOL           3    69 982
     2   BAUR X                DTSCH MED WSCHR                109   257 984
     3   WIESSMANN KJ          EUR J RESPIR DIS                66    13 985
     4   WARREN CPW            AM J MED                        81   939 986
     5   DAVIS PB              THORAX                          42   120 987

PN 79070
RN 01050 
AN 79211680
AU Kutty-K-M.  Guha-A-K.  Chandra-R-K.  Vaze-D.
TI A study of erythrocyte fatty acids, adenosinetriphosphatase and
   acetylcholinesterase in cystic fibrosis.
SO Clin-Biochem. 1979 Jun. 12(3). P 98-9.
MJ ACETYLCHOLINESTERASE: bl.  ADENOSINE-TRIPHOSPHATASE: bl.
   CYSTIC-FIBROSIS: bl.  ERYTHROCYTES: me.  FATTY-ACIDS-UNSATURATED: bl.
MN ARACHIDONIC-ACIDS: bl.  HUMAN.  LINOLEIC-ACIDS: bl.
AB 1. The proportions of both saturated and polyunsaturated fatty acids
   were measured in the erythrocytes in Cystic Fibrosis (CF) patients
   along with two membrane bound enzymes ATPase and
   acetylcholinesterase. Linoleic acid was found to be significantly
   decreased and arachidonic acid increased in CF patients. The
   proportion of saturated fatty acids were not significantly different
   from the controls. Only adenosinetriphosphatase activity was found to
   be reduced and not acetylcholinesterase in CF patients.
RF 001   LEHINGER AL           MOLECULAR BASIS OF CELL              660 975
   002   ROTHFIELD LI          STRUCTURE AND FUNCTION OF BIO        196 971
   003   LEE JB                PERSPECTIVES ON THE PROSTAGLA          8 973
   004   BONELLI EJ            LIPID ANALYSIS BY GAS CHROMAT            968
   005   DUNHAM ET             J PHYSIOL (LOND)               156   274 961
   007   MCEVOY FA             LANCET                           2   236 975
   008   BALFE JW              SCIENCE                        162   689 968
CT   1   HUBBARD VS            CLIN CHIM ACTA                 102   115 980
     2   WARWICK WJ            AM J MED TECHNOLOGY             48   539 982

PN 79071
RN 01051 
AN 80002169
AU Chalmers-R-A.  Valman-H-B.  Liberman-M-M.
TI Measurement of 4-hydroxyphenylacetic aciduria as a screening test
   for small-bowel disease.
SO Clin-Chem. 1979 Oct. 25(10). P 1791-4.
MJ INTESTINAL-DISEASES: di.  MANDELIC-ACIDS: ur.
MN ADOLESCENCE.  AGE-FACTORS.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: ur.  HUMAN.  INFANT.  INFANT-NEWBORN.
   INTESTINAL-DISEASES: ur.  MASS-SCREENING.  REFERENCE-VALUES.
AB We evaluted measurement of urinary 4-hydroxyphenyl acetic acid as a
   potential screening method for small-bowel disease and bacterial
   overgrowth syndromes in 360 unselected acutely ill infants and
   children. Control data were obtained on 120 healthy children, ages
   1.5 to 15 years, from a general medical practice, 48 healthy infants,
   ages one to five years, from local day nurseries, and 150 healthy
   babies, ages less than one to eight days. Comparative data were from
   300 acutely ill hospitalized babies and children, ranging in age from
   less than one day to 15 years and without clinical evidence for small-
   bowel disease and bacterial overgrowth syndrome. No false-negative
   results and only 2% false-positive results were observed. Among the
   10 patients whose urinary excretion of the analyte was considered to
   be abnormal were patients with Giardia lamblia infestation, ileal
   resection with blind loop, and other diseases of the small intestine
   associated with bacterial overgrowth. We conclude that measurement of
   4-hydroxyphenylacetic acid excretion is useful in screening for such
   diseases.
RF 001   GARRETTSON LK         AM J CLIN PATHOL                55   318 971
   002   GIBBONS ISE           LANCET                           1   877 967
   003   GJESSING LR           LANCET                           2    47 967
   004   VAN DER HEIDEN C      CLIN CHIM ACTA                  31   133 971
   005   VAN DER HEIDEN C      CLIN CHIM ACTA                  34   289 971
   006   CHALMERS RA           ANN CLIN BIOCHEM                14   149 977
   007   CHALMERS RA           CLIN CHEM                       22  1292 976
   008   CHALMERS RA           ANALYST                         97   958 972
   009   HEALY MJR             J CHROMATOGR                    87   365 973
   010   LAWSON AM             CLIN CHEM                       22  1283 976
   011   FELLMAN JH            CLIN BIOCHEM                    10   171 977
   012   BORUD O               ACTA PHARMACOL TOXICOL          30   185 971
   013   AMENT ME              PEDIATR CLIN NORTH AM           22   807 975
   014   BURKE JA              AM J DIS CHILD                 129  1304 975
   015   CHALLACOMBE DN        AM J DIS CHILD                 128   719 974
   016   GORBACH S             IN: DIETSCHY JM                      137 976
   017   AARBAKKE J            SCAND J GASTROENTEROL           11   409 976
CT   1   WATTS RWE             J MENT DEFIC RES                24   257 980
     2   WILLIAMS DA           J SMALL ANIMAL PRACT            22   263 981
     3   GRACEY M              J PEDIATR GASTROENTEROL NUTR     1    13 982
     4   BURROWS CF            J AM VET MED ASSOC             183   318 983
     5   GRACEY M              NAHRUNG                         28   659 984
     6   BYRD DJ               KLIN PAEDIATR                  196   298 984
     7   HAAN E                EUR J PEDIATR                  144    63 985

PN 79072
RN 01052 
AN 79105836
AU Shwachman-H.  Mohmoodian-A.
TI Quality of sweat test performance in the diagnosis of cystic
   fibrosis.
SO Clin-Chem. 1979 Jan. 25(1). P 158-61.
MJ CYSTIC-FIBROSIS: di.  SWEATING.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: pp.
   HUMAN.  INFANT.  PILOCARPINE: du.  SWEAT: ph.
AB The sweat test, correctly performed, appears to be reliable, but
   results were found to be unreliable about half the time in 84 small
   community hospitals assessed. The reasons are inexperienced and
   untrained technicians, the infrequency of test performance, the use
   of unstandardized equipment, and the lack of appropriate standards.
   It behooves all clinical laboratory directors to re-examine and
   standardize their procedures and use the recommendations of the
   Cystic Fibrosis Foundation. Physicians should be made aware of the
   current situation and send their patients only to laboratories that
   perform the test reliably.
RF 001   GIBSON LE             PEDIATRICS                      23   545 959
   002   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            963
   003   SCHALES O             J BIOL CHEM                    140   879 941
   004   SHWACHMAN H           N ENGL J MED                   255   999 956
   005   SHWACHMAN H           PEDIATRICS                      30   167 962
   006   KOPITO L              N ENGL J MED                   272   504 965
   007   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
   008   WEBSTER L             MED J AUST                       1   923 977
CT   1   SHWACHMAN H           CLIN CHEM                       25  1008 979
     2   SHWACHMAN H           J PEDIATR                       95   661 979
     3   SEALE TW              PEDIATR RES                     14  1398 980
     4   DENNING CR            PEDIATRICS                      66   752 980
     5   WONG LTK              GUT                             23   744 982
     6   BOWLING SA            AM J MED TECHNOLOGY             48    25 982
     7   RANDOLPH VS           AM J MED TECHNOLOGY             48    15 982
     8   KIRK JM               ANN CLIN BIOCHEM                20   369 983
     9   HEELEY AF             CLIN CHEM                       29  2011 983
    10   GREEN A               ANN CLIN BIOCHEM                22   171 985
    11   ITANO M               RESPIRATION                     47   220 985
    12   WARWICK WJ            CLIN CHEM                       32   850 986
    13   ROSENSTEIN BJ         CLIN PEDIATR                    26    78 987

PN 79073
RN 01053 
AN 79105888
AU Willcox-P.
TI Secretion of beta-N-acetylglucosaminidase isoenzymes by cultured
   cystic fibrosis fibroblasts.
SO Clin-Chim-Acta. 1979 Jan 1. 91(1). P 81-9.
MJ ACETYLGLUCOSAMINIDASE: se.  CYSTIC-FIBROSIS: en.  GLUCOSAMINIDASE: se.
   ISOENZYMES: se.
MN CELLS-CULTURED.  FIBROBLASTS: en.  HUMAN.
AB Secretion of the lysosomal enzyme beta-N-acetylglucosaminidase (EC
   3.2.1.30) by normal and cystic fibrosis fibroblasts has been
   compared. In contrast to an earlier report, no differences were found
   in either the rate of secretion, or in the molecular forms of the
   enzyme secreted by normal fibroblast cultures and cultures initiated
   from patients with cystic fibrosis. The B isoenzyme of beta-N-
   acetylglucosaminidase from cystic fibrosis fibroblasts was converted
   to a more negatively charged form during preincubation for 3 h at pH
   5.0 and 37 degrees C. The enzyme from normal fibroblasts was
   unaffected by this treatment.
RF 001   LOBECK CC             IN: STANBURY JB                     1605 972
   002   WILLCOX P             EUR J BIOCHEM                   73   579 977
   003   WILLCOX P             BIOCHEM J                      173   433 978
   004   WARREN L              J BIOL CHEM                    234  1971 959
   005   LOWRY OH              J BIOL CHEM                    193   265 951
   006   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      79   741 977
   007   SCANLIN TF JR         BIOCHEM BIOPHYS RES COMMUN      79   869 977
   008   DI SANTAGNESE PA      N ENGL J MED                   295   534 976
   009   ALHADEFF JA           CLIN GENET                      10    63 976
CT   1   WILLCOX P             BIOCHIM BIOPHYS ACTA           586   442 979
     2   BUTTERWORTH J         CLIN CHIM ACTA                 110   319 981
     3   FIGARELLA C           EUR J CLIN INVEST               12   145 982

PN 79074
RN 01054 
AN 79211819
AU Casola-L.  Di-Matteo-G.  Romano-M.  Rutigliano-B.  Mastella-G.
TI Glycosidases in serum of cystic fibrosis patients.
SO Clin-Chim-Acta. 1979 May 16. 94(1). P 83-8.
MJ CYSTIC-FIBROSIS: en.  GLYCOSIDE-HYDROLASES: bl.
MN ACETYLGLUCOSAMINIDASE: bl.  ADULT.  ARYLSULFATASES: bl.
   BETA-GALACTOSIDASES: bl.  CHILD.  COMPARATIVE-STUDY.
   CYSTIC-FIBROSIS: fg.  FUCOSIDASE: bl.  GLUCURONIDASE: bl.  HUMAN.
   MANNOSIDASES: bl.  REFERENCE-VALUES.
AB In a study of eight glycosidases in serum samples from 72 cystic
   fibrosis patients, 85 cystic fibrosis parents and 34 healthy and
   diseased controls, significant elevations of mean alpha-glucosidase
   levels were found in cystic fibrosis patients. All other glycosidases
   did not show any significant change. Mean alpha-glucosidase levels in
   obligate heterozygotes were the same as in control individuals.
   Moreover, alpha-glucosidase levels in cystic fibrosis patients
   correlated with the degree of clinical impairment as measured by the
   Schwachman score.
RF 001   BARTMAN J             J PEDIATR                       76   430 970
   002   DANES BS              LANCET                           1  1061 968
   003   DANES BS              J EXP MED                      129   775 969
   004   MATALON R             BIOCHEM BIOPHYS RES COMMUN      33   954 968
   005   DANES BS              BIOCHEM BIOPHYS RES COMMUN      36   919 969
   006   KRAUS I               PEDIATRICS                      47  1010 971
   007   ANTONOWICZ I          PEDIATR RES                      6   803 972
   008   BUTTERWORTH J         CLIN CHIM ACTA                  41   367 972
   009   BUTTERWORTH J         CLIN CHIM ACTA                  40   139 972
   010   WILSON RG             CLIN CHIM ACTA                  36   189 972
   011   MARCHI AG             HELV PAEDIATR ACTA              28   427 973
   012   GIBBS GE              SCIENCE                        167   993 970
   013   GRIFFIN GD            PROC SOC EXP BIOL MED          137   438 971
   014   GIBBS GE              J INVEST DERMATOL               51   200 968
   015   EVANS BW              AM J DIS CHILD                 127   660 974
   016   BENKE PJ              N ENGL J MED                   284   731 971
   017   FILLIAT M             PATHOL BIOL (PARIS)             21    13 973
   018   RUSSELL SB            J MED GENET                      8   441 971
   019   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      73   209 976
   020   ALHADEFF JA           CLIN GENET                      10    63 976
   021   STAHL P               ARCH BIOCHEM BIOPHYS           170    53 975
   022   MORELL AG             J BIOL CHEM                    246  1461 971
   023   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   024   DAHLQVIST A           ANAL BIOCHEM                     7    18 964
   025   SMITH BW              J BIOL CHEM                    227   357 957
   026   ANNUNZIATA P          CLIN CHIM ACTA                  90   101 978
   027   JEFFREY PL            BIOCHEMISTRY                     9  1416 970
   028   NIKOLAJEK WP          EUR J PEDIATR                  122   289 976
   029   TOWNES PL             AM J HUM GENET                  28   378 976
   030   STANBURY JB           METABOLIC BASIS OF INHERITED             972
   031   KAWASAKI T            J BIOL CHEM                    251  1296 976
CT   1   ALHADEFF JA           CLIN CHIM ACTA                 105   131 980
     2   MALER T               FEBS LETTERS                   121   153 980
     3   BARLOW JJ             J NATL CANCER INST              67  1005 981
     4   ALHADEFF JA           CLIN CHIM ACTA                 117   227 981
     5   CALVO P               CLIN CHIM ACTA                 119    15 982
     6   CABRINI G             RIV ITAL PEDIATR                10   405 984
     7   ALHADEFF JA           PEDIATR RES                     19   171 985
     8   PORTER WH             CLIN CHEM                       32   652 986

PN 79075
RN 01055 
AN 80045420
AU Butterworth-J.  Duncan-J-J.
TI Carboxypeptidase B activity of cultured skin fibroblasts and
   relationship to cystic fibrosis.
SO Clin-Chim-Acta. 1979 Sep 15. 97(1). P 39-43.
MJ CARBOXYPEPTIDASES: me.  CYSTIC-FIBROSIS: en.
MN ARGININE: aa, me.  CELLS-CULTURED.  DITHIOTHREITOL: pd.
   FIBROBLASTS: en.  HIPPURATES: me.  HUMAN.  HYDROGEN-ION-CONCENTRATION.
   SUBCELLULAR-FRACTIONS: en.
AB Enzyme activity against hippuryl-L-arginine was studied in cultured
   skin fibroblasts from controls and cystic fibrosis patients. The
   enzyme had a lysosomal distribution and an acid optimum of pH 4.5
   with little or no activity present above pH 7.0. Dithiothreitol was
   required for full activity and the kinetics of thiol activation were
   different for the control and cystic fibrosis enzyme. The properties
   and lysosomal distribution of the enzyme indicated that it was a
   carboxypeptidase B. Substrate affinity, thermolability, pH stability,
   the fall and rise in activity with subculture, the cyclical pattern
   of activity through serial passage and the level of activity were
   similar for the control and cystic fibrosis enzyme.
RF 001   CONOVER JH            LIFE SCI                        14   253 974
   002   BUTTERWORTH J         CLIN CHIM ACTA                  44   295 973
   003   GUY GJ                CLIN CHIM ACTA                  87    63 978
   004   BUTTERWORTH J         CLIN CHIM ACTA                  40   139 972
   005   LOWRY OH              J BIOL CHEM                    193   265 951
   006   DAWSON RMC            DATA FOR BIOCHEMICAL RESEARCH            972
   007$  MARINKOVIC DV         BIOCHEM J                      163   265 951
   008   ERDOS EG              BIOCHEM PHARMACOL               11   585 962
   009   OSHIMA G              BIOCHIM BIOPHYS ACTA           365   344 974
   010   PLUMMER TH            J BIOL CHEM                    253  3907 978
   011   LIEBERMAN J           AM REV RESPIR DIS              111   100 975
   012   KOHEIL A              BIOCHIM BIOPHYS ACTA           524   156 978
   013   GREENBAUM LM          J BIOL CHEM                    237  1082 962
   014   OTTO K                BIOCHIM BIOPHYS ACTA           379   462 975
   015   NINJOOR V             BIOCHIM BIOPHYS ACTA           370   308 974
   016   TAYLOR SL             BIOCHIM BIOPHYS ACTA           341    99 974
   017   MCDONALD JK           IN: BARRETT AJ                       311 977
   018   SHAPIRO BL            PROC SOC EXP BIOL MED          144   181 973
CT   1   BUTTERWORTH J         ANAL BIOCHEM                   106   156 980
     2   BUTTERWORTH J         CLIN CHIM ACTA                 108   143 980
     3   BUTTERWORTH J         CLIN CHIM ACTA                 108   347 980
     4   BUTTERWORTH J         CLIN CHIM ACTA                 122    51 982
     5   BUYS CHCM             CLIN CHIM ACTA                 136   229 984

PN 79076
RN 01056 
AN 80045463
AU Ben-Yoseph-Y.  Defranco-C-L.  Nadler-H-L.
TI Decreased sialic acid and altered binding to lectins of purified
   alpha 2-macroglobulin from patients with cystic fibrosis.
SO Clin-Chim-Acta. 1979 Nov 15. 99(1). P 31-5.
MJ ALPHA-MACROGLOBULINS.  CYSTIC-FIBROSIS: bl.  LECTINS.
   SIALIC-ACIDS: an.
MN ALPHA-MACROGLOBULINS: ip.  CONCANAVALIN-A.  CYSTIC-FIBROSIS: fg.
   HETEROZYGOTE-DETECTION.  HEXOSES: an.  HUMAN.
   SUPPORT-U-S-GOVT-P-H-S.
AB Purified preparations of plasma alpha 2-macroglobulin from patients
   with cystic fibrosis are shown to have normal amounts of total hexose
   but as much as 40% decrease in their sialic acid content. The binding
   of these preparations to concanavalin A and wheat-germ agglutinin was
   markedly reduced as compared to normal values in controls.
   Intermediate values were found in obligate heterozygotes. These
   results suggest a possible alteration in the carbohydrate moiety of
   alpha 2-macroglobulin in cystic fibrosis, presumably due to a
   defective posttranslational process.
RF 001   ALHADEFF JA           CLIN GENET                      14   189 978
   002   NADLER HL             IN: STANBURY JB                     1683 978
   003   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      79   741 977
   004   HICKMAN S             BIOCHEM BIOPHYS RES COMMUN      57    55 974
   005   ALHADEFF JA           CLIN GENET                      13   417 978
   006   SCHULTZE HE           MOLECULAR BIOL OF HUMAN PROTE    1       966
   007   DUNN JT               J BIOL CHEM                    242  5549 967
   008   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      71   864 976
   009   SHAPIRA E             CLIN CHIM ACTA                  78   359 977
   010   SHAPIRA E             J BIOL CHEM                    252  7923 977
   011   PORATH J              NATURE                         215  1401 967
   012   WEBER K               J BIOL CHEM                    244  4406 969
   013   SPIRO RG              IN: NEUFELD EF                   8     3 966
   014   WARREN L              J BIOL CHEM                    234  1971 959
   015   GOLDSTEIN IJ          ADV CARBOHYDR CHEM BIOCHEM      35   127 978
   016   GREENAWAY PJ          NATURE NEW BIOL                241   191 973
   017   ROUSSON R             BIOCHEM J                      180   501 979
CT   1   COMINGS DE            AM J HUM GENET                  32   273 980
     2   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      93    50 980
     3   BENYOSEPH Y           BIOCHEM J                      189     9 980
     4   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
     5   HALLINAN F            MED HYPOTHESES                   7   793 981
     6   BENYOSEPH Y           PEDIATR RES                     15   839 981
     7   MALER T               J BIOL CHEM                    256  1420 981
     8   OWENSWILLIAMS L       J PEDIATR GASTROENTEROL NUTR     1   567 982
     9   BURY AF               IRCS MED SCI BIOCHEM            10   255 982
    10   BLITZER MG            PEDIATR RES                     16   203 982
    11   ROBERTS RC            PEDIATR RES                     16   416 982
    12   BRIDGES MA            CLIN CHIM ACTA                 118    33 982
    13   BURY AF               CLIN CHIM ACTA                 118    45 982
    14   TUMMLER B             CLIN CHIM ACTA                 125   219 982
    15   MARGOLIES R           PEDIATR RES                     17   931 983
    16   BACK SA               BIOCHEM MED                     30    34 983
    17   SLOMIANY A            J BIOL CHEM                    258  8535 983
    18   BRIDGES MA            ANN NY ACAD SCI                421   360 983
    19   SHAPIRA E             ANN NY ACAD SCI                421   352 983
    20   ANDERSON CM           J PEDIATR GASTROENTEROL NUTR     3    15 984
    21   EAGER KB              PEDIATR RES                     18   999 984
    22   KARLSSON S            J MED GENET                     21   441 984
    23   GUEANT JL             CLIN CHIM ACTA                 143   217 984
    24   PARK CM               PEDIATR RES                     19   344 985

PN 79077
RN 01057 
AN 79084606
AU Scanlin-T-F.  Matacic-S-S.  Glick-M-C.
TI Abnormal distribution of alpha-L-fucosidase in cystic fibrosis:
   decreased activity in serum.
SO Clin-Chim-Acta. 1979 Jan 15. 91(2). P 197-202.
MJ CYSTIC-FIBROSIS: bl.  FUCOSIDASE: bl.
MN ACETYLGLUCOSAMINIDASE: bl.  ACID-PHOSPHATASE: bl.  ADULT.  CHILD.
   COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: en.  FIBROBLASTS: en.
   FUCOSIDASE: an.  HUMAN.  INFANT-NEWBORN.  SKIN: en.
   SUPPORT-U-S-GOVT-P-H-S.
AB The activity of alpha-L-fucosidase is decreased in the serum of
   cystic fibrosis patients when compared to age-matched controls. This
   result, combined with the elevated activity in skin fibroblasts,
   supports the concept of an abnormal intracellular and extracellular
   distribution of alpha-L-fucosidase in cystic fibrosis.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   002   WOOD RE               AM REV RESPIR DIS              113   833 976
   003   SCANLIN TF JR         BIOCHEM BIOPHYS RES COMMUN      79   869 977
   004   ZIELKE K              J LAB CLIN MED                  79   164 972
   005   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   006   SCANLIN TF JR         PROC INT CF CONG 7TH                  44 976
   007   SCANLIN TF JR         PEDIATR RES ABST 549            11   463 977
   008   NG WG                 AM J HUM GENET                  28    42 976
   009   RAMAGE P              BIOCHIM BIOPHYS ACTA           403   473 975
   010   TURNER BM             AM J HUM GENET                  27   651 975
   011   DI MATTEO G           BIOCHIM BIOPHYS ACTA           429   538 976
   012   CHESTER MA            BIOCHIM BIOPHYS ACTA           485   147 977
   013   ALHADEFF JA           CLIN GENET                      10    63 976
   014   SCANLIN TF JR         PEDIATR RES                     12   457 978
   015   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      79   741 977
   016   NEUFELD EF            ANNU REV BIOCHEM                44   357 975
   017   KAPLAN A              PROC NAT ACAD SCI USA           74  2026 977
   018   HIEBER V              BIOCHEM BIOPHYS RES COMMUN      73   710 976
CT   1   SCANLIN TF            CLIN CHEST MED                   1   424 980
     2   TARNOKY AL            J ROY SOC MED                   73    73 980
     3   ALHADEFF JA           CLIN CHIM ACTA                 105   131 980
     4   BARLOW JJ             J NATL CANCER INST              67  1005 981
     5   JAKEL HP              BIOL ZENTRALBL                 100   273 981
     6   BUTTERWORTH J         CLIN CHIM ACTA                 110   319 981
     7   SCANLIN TF            CLIN CHIM ACTA                 114   269 981
     8   ALHADEFF JA           CLIN CHIM ACTA                 117   227 981
     9   MALER T               J BIOL CHEM                    256  1420 981
    10   SCANLIN TF            BIOCHEMISTRY                    21   491 982
    11   SHEPHERD VL           J RETICULOENDOTHEL SOC          32   423 982
    12   BOURASSA C            CLIN CHIM ACTA                 129   263 983
    13   SCANLIN TF            PEDIATR RES                     19   368 985

PN 79078
RN 01058 
AN 80023017
AU Lake-C-R.  Davis-P-B.  Ziegler-M.  Kopin-I-J.
TI Electrolytes and norepinephrine levels in blood of patients with
   cystic fibrosis.
SO Clin-Chim-Acta. 1979 Mar 1. 92(2). P 141-6.
MJ CYSTIC-FIBROSIS: bl.  ELECTROLYTES: bl.  NOREPINEPHRINE: bl.
MN ADOLESCENCE.  ADULT.  HUMAN.  BLOOD-PRESSURE.
   DOPAMINE-BETA-HYDROXYLASE: bl.  EXERTION.  FEMALE.  MALE.  POSTURE.
   SEASONS.
AB Young adults with cystic fibrosis in good to excellent condition have
   reduced plasma sodium and chloride and elevated plasma potassium
   compared to a group of healthy young adult control subjects. Blood
   pressure was also lower in the patients with cystic fibrosis.
   However, plasma norepinephrine and dopamine-beta-hydroxylase and
   their response to standing and isometric hand grip were normal in the
   cystic fibrosis patients.
RF 001   DAVIS PB              PEDIATR RES                     12   703 978
   002   BARBERO GJ            CF CLUB ABST                           4 967
   003   BONGIOVANNI AM        LAB INVEST                      10   956 961
   004   HENRY DP              LIFE SCI                        16   375 975
   005   LAKE CR               LIFE SCI                        18  1315 976
   006   WEINSHILBOUM RM       SCIENCE                        174  1349 971
   007   TAUSSIG LM            J PEDIATR                       82   380 973
   008   WEINSHILBOUM RM       CIRC RES                        28   307 971
   009   BOLANDE RP            ARCH PATHOL                     95   172 973
   010   LAKE CR               CIRCULATION                     57   774 978
   011   LAKE CR               AM SOC NEPHROL ABST                  50A 979
   012   OGIHARA T             J LAB CLIN MED                  85   566 975
   013   LIEBERMAN J           ANN INTERN MED                  82   806 975
   014   DI SANTAGNESE PA      ANN NY ACAD SCI                 93   555 962
   015   QUINTERO-ATENCIO J    N ENGL J MED                   274  1224 966
   016   LEVI J                ISR J MED SCI                    6   665 970
   017   MCCANE RA             LANCET                           1   823 936
   018   MCCANE RA             PROC R SOC LOND BIOL           119   245 936
   019   SIMOPOULOS AP         PEDIATR RES                      5   626 971
   020   ROBSON AM             J PEDIATR                       79    42 971
   021   GRAND RJ              J PEDIATR                       70   357 967
   022   MONTALVO JM           J CLIN ENDOCRINOL METAB         28   582 968
   023   ROSENTHAL A           PEDIATRICS                      59   588 977
   024   STROBER W             PEDIATRICS                      43   416 969
CT   1   DAVIS PB              IRCS MED SCI BIOCHEM             8   413 980
     2   LEMANSKE RF           AM REV RESPIR DIS              123   622 981
     3   SEALE TW              ANN CLIN LAB SCI                12   415 982
     4   ZAMMARCHI E           RIV ITAL PEDIATR                 9   505 983
     5   DAVIS PB              J CHRON DIS                     36   269 983
     6   DAVIS PB              J CLIN INVEST                   71  1787 983
     7   DAVIS PB              SEM RESPIR MED                   6   319 985
     8   SCHONI MH             PEDIATR RES                     19    47 985
     9   MITCHELL EA           AUST PAEDIATR J                 21   127 985
    10   DAVIS PB              HORM METAB RES                  18   217 986
    11   SCHONI MH             EUR J PEDIATR                  145    80 986

PN 79079
RN 01059 
AN 80023013
AU Butterworth-J.  Guy-G-J.
TI Primary amniotic fluid cell, skin fibroblast and liver
   alpha-L-fucosidase and its relation to cystic fibrosis.
SO Clin-Chim-Acta. 1979 Mar 1. 92(2). P 109-16.
MJ CYSTIC-FIBROSIS: en.  FUCOSIDASE: me.
MN AMNIOTIC-FLUID: en.  CELLS-CULTURED.  CHROMATOGRAPHY-DEAE-CELLULOSE.
   CHROMATOGRAPHY-GEL.  FUCOSIDASE: an.  HUMAN.
   HYDROGEN-ION-CONCENTRATION.  ISOELECTRIC-FOCUSING.  LIVER: en.
   SKIN: en.
AB Cultured skin fibroblast and primary amniotic fluid cell alpha-L-
   fucosidase had a double optimum of pH 5.0 and 6.0. Alpha-L-fucosidase
   was largely bound as a single peak to DEAE-cellulose at pH 6.6.
   Sucrose density isoelectric focusing revealed up to seven components
   with pI values of 4.9, 5.2, 5.4, 5.8, 6.1, 6.5 and 7.1 with their
   apparent KM values (77--500 mumol/l) being higher than that (57
   mumol/l) of the unfocused enzyme. Liver, skin fibroblast and amniotic
   fluid cell alpha-L-fucosidase was separated into two peaks by gel
   filtration. Peak one was more active and stable at low pH and more
   thermostable at 50 degrees C than peak two, while both peaks had an
   apparent KM of 52 mumol/l. Apart from the different proportions of
   the peaks separated by gel filtration, the results for the three
   tissues were similar. The properties of alpha-L-fucosidase studied
   were similar for control and cystic fibrosis liver or skin
   fibroblasts.
RF 001   VAN HOOF F            LANCET                           1  1198 968
   002   ZIELKE K              J EXP MED                      136   197 972
   003   POENARU L             CLIN GENET                      10   260 976
   004   BUTTERWORTH J         CLIN CHIM ACTA                  40   139 972
   005   SCANLIN TF JR         BIOCHEM BIOPHYS RES COMMUN      79   869 977
   006   ALHADEFF JA           CLIN GENET                      10    63 976
   007   BUTTERWORTH J         CLIN CHIM ACTA                  78   335 977
   008   DAWSON RMC            DATA FOR BIOCHEMICAL RESEARCH            972
   009   BUTTERWORTH J         CLIN GENET                      12   297 977
   010   BUTTERWORTH J         CLIN GENET                       9   505 976
   011   LOWRY OH              J BIOL CHEM                    193   265 951
   012   GODSON NG             ANAL BIOCHEM                    35    66 970
   013   BERATIS NG            PEDIATR RES                     11   862 977
   014   ROBINSON D            CLIN CHIM ACTA                  55    65 974
   015   BERATIS NG            J PEDIATR                       87  1193 975
   016   ELLIS RB              CLIN SCI MOL MED                49   543 973
   017   WILLCOX P             EUR J BIOCHEM                   73   579 977
   018   ROBINSON D            CLIN CHIM ACTA                  47   403 973
   019   ALHADEFF JA           CLIN CHIM ACTA                  57   307 974
   020   THORPE R              FEBS LETTERS                    54    89 975
   021   DI MATTEO G           BIOCHIM BIOPHYS ACTA           429   527 976
   022   TURNER BM             AM J HUM GENET                  27   651 975
   023   WIEDERSCHAIN GY       CLIN CHIM ACTA                  46   305 973
   024   WOOD S                J LAB CLIN MED                  88   469 976
   025   CHESTER MA            BIOCHIM BIOPHYS ACTA           485   147 977
   026   CARLSEN RB            J BIOL CHEM                    247    23 972
   027   ALHADEFF JA           J BIOL CHEM                    250  7106 975
   028   ANDREWS P             BIOCHEM J                       96   595 965
CT   1   ALHADEFF JA           CLIN CHIM ACTA                 105   131 980
     2   BUTTERWORTH J         ANAL BIOCHEM                   106   156 980
     3   BUTTERWORTH J         CLIN CHIM ACTA                 108   347 980
     4   BUTTERWORTH J         CLIN CHIM ACTA                 108   143 980
     5   MALER T               FEBS LETTERS                   121   153 980
     6   JAKEL HP              BIOL ZENTRALBL                 100   273 981
     7   BUTTERWORTH J         CLIN CHIM ACTA                 110   319 981
     8   HARRIS A              CLIN CHIM ACTA                 116   171 981
     9   MALER T               J BIOL CHEM                    256  1420 981
    10   COHENFORD MA          COMP BIOCHEM PHYSIOL (B)        72   695 982
    11   BURY AF               CLIN CHIM ACTA                 118    45 982
    12   BUTTERWORTH J         CLIN CHIM ACTA                 122    51 982
    13   BEYER EM              CLIN CHIM ACTA                 123   251 982
    14   BOURASSA C            CLIN CHIM ACTA                 129   263 983
    15   WAUTERS J             ARCH INT PHYSIOL BIOCHIM        92  B115 984
    16   HERMELIN B            CELL MOL BIOL                   33    83 987

PN 79080
RN 01060 
AN 79147574
AU Carswell-F.  Oliver-J.  Silverman-M.
TI Allergy in cystic fibrosis.
SO Clin-Exp-Immunol. 1979 Jan. 35(1). P 141-6.
MJ CYSTIC-FIBROSIS: im.  HYPERSENSITIVITY-IMMEDIATE: et.
MN ADULT.  ANTIGENS: im.  ASPERGILLUS-FUMIGATUS: im.  CHILD.
   CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: co, fg.  FEMALE.  HETEROZYGOTE.
   HOMOZYGOTE.  HUMAN.  HYPERSENSITIVITY-IMMEDIATE: fg, im.  IGE: an.
   IGG: an.  MALE.  RESPIRATORY-FUNCTION-TESTS.  SKIN-TESTS.
AB Forty-four patients with cystic fibrosis, sixty-seven parents, and
   thirty-nine controls were compared with regard to their immediate
   cutaneous hypersensitivity, total and specific serum IgE and serum
   IgG4 concentrations. The patients had increased prick test reactions
   and specific IgE to Aspergillus fumigatus. The development of
   reactions to A. fumigatus correlated with the severity of the
   disease. There were no other significant differences when serum total
   IgE, specific IgE and IgG4 concentrations or skin test reactivity
   were compared in the patients, parents and controls.
RF 001   ALLAN JD              CLIN ALLERGY                     5   255 975
   002   BATTEN JC             MOD PROBL PEDIATR               10   227 967
   003   BUTLER U              PROC BPA RESPIRATORY GROUP MT            977
   004   COGSWELL JJ           BR J DIS CHEST                  69   177 975
   005   CHRISPIN AR           PEDIATR RADIOL                   2   101 974
   006   DAVIS JB              CLIN ALLERGY                     6   329 976
   007   GODFREY RC            CLIN ALLERGY                     6    79 976
   008   GODFREY S             BR J DIS CHEST                  64    15 970
   009   JOHANSSON SGO         IN: VYAS GN                          225 975
   010   KJELLMAN NIM          ACTA PAEDIATR SCAND             65   465 976
   011   KJELLMAN NIM          CLIN ALLERGY                     6    51 976
   012   MCCARTHY DS           IN: LAWSON D PROC 5TH INT CF         194 969
   013   MCFARLANE H           LANCET                           1  1241 976
   014   MCFARLANE H           CLIN ALLERGY                     7   279 977
   015   MALO JL               THORAX                          32   269 977
   016   SARSFIELD JK          ARCH DIS CHILD                  49   711 974
   017   SHAKIB F              J IMMUNOL METH                   8    17 975
   018   SHAKIB F              CLIN ALLERGY                     6   237 976
   019   STANWORTH DR          CLIN ALLERGY                     3    37 973
   020   VIJAY HM              INT ARCH ALLERGY APPL IMMUNOL   53    78 977
   021   WALLWORK JC           CLIN EXP IMMUNOL                18   303 974
   022   WARNER JO             LANCET                           1   990 976
   023   WARNER JO             ARCH DIS CHILD                  51   507 976
   024   WARNOCK DW            J CLIN PATHOL                   30   388 977
   025   WARREN CPW            CLIN ALLERGY                     5     1 975
CT   1   REEN DJ               CLIN ALLERGY                    11   571 981
     2   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
     3   WONNE R               CLIN ALLERGY                    15   455 985
     4   MOSS RB               MONOGR ALLERGY                  19   202 986
     5   MOSS RB               CHEST                           91   522 987

PN 79081
RN 01061 
AN 80002327
AU Super-M.  van-Schalkwyk-D-J.
TI Heterozygote advantage in cystic fibrosis: mosquito tests.
SO Clin-Genet. 1979 Aug. 16(2). P 65-8.
MJ CYSTIC-FIBROSIS: fg.  INSECT-BITES-AND-STINGS.  MOSQUITOES.
MN HETEROZYGOTE.  HUMAN.  MALARIA: mo, oc.
AB Tests to demonstrate a preference by mosquitoes for stinging controls
   as opposed to obligate heterozygotes for Cystic Fibrosis proved
   negative. If a heterozygote advantage caused a lower malarial
   incidence in carriers in South West Africa, it must have worked
   through the malarial parasite being adversely affected by a serum
   factor. This remains to be tested.
RF 001   ANDERSON CM           MOD PROBL PEDIATR               10   381 967
   003   COHEN FL              J MED GENET                     11   253 974
   004   CONNEALLY PM          TEX REP BIOL MED                31   639 973
   005   CRAWFURD MDA          HEREDITY                        29   126 972
   006   DANKS DM              ANN HUM GENET                   28   323 965
   007   EDWARDS JH            ARCH DIS CHILD                  52   343 977
   009   GAIRDNER D            LANCET                           1   279 975
   010   GIBSON LE             PEDIATRICS                      23   545 959
   012   KNUDSON AG JR         AM J HUM GENET                  19   388 967
   013   MASTERSON J           PROC EWGCF 6TH ANNU MTG                  975
   014   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            971
   015   SPOCK A               PEDIATR RES                      1   173 967
   016   STUART AB             LANCET                           2  1521 974
   017   SUPER M               S AFR MED J                     49   818 975
   018   SUPER M               THESIS                                   978

PN 79082
RN 01062 
AN 80090635
AU Koheil-A.  Corey-M.  Forstner-G.
TI Deficiency of serum carboxypeptidase B-like (anaphylatoxin
   inactivator, carboxypeptidase N) activity in sera from patients with
   cystic fibrosis.
SO Clin-Invest-Med. 1979. 2(2-3). P 99-103.
MJ CARBOXYPEPTIDASES: df.  CYSTIC-FIBROSIS: en.
   ARGININE-CARBOXYPEPTIDASE: df.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: bl.  FEMALE.
   HUMAN.  ARGININE-CARBOXYPEPTIDASE: bl.  MALE.
AB Serum from 95 patients with cystic fibrosis and 47 control subjects
   without cystic fibrosis was analyzed for carboxypeptidase B-like
   activity in the presence of optimal concentrations of Co2+ ion,
   hippuryl-L-lysine and serum.  Fourteen of the cystic fibrosis
   patients had no steatorrhea and therefore minimal pancreatic
   dysfunction.  Patients with cystic fibrosis and controls were of
   comparable age.  Serum carboxypeptidase B-like activity was
   significantly decreased in cystic fibrosis patients including cystic
   fibrosis patients without steatorrhea.  Significantly low values
   were found in both male and female cystic fibrosis patients when
   compared with controls of similar sex.  Although values were
   unaffected by age in the control population, values in older
   patients with cystic fibrosis were significantly lower than values
   in younger patients.  No correlation was obtained between serum
   carboxypeptidase B-like activity and pulmonary or hepatic function.
   Serum carboxypeptidase B-like activity therefore falls with
   progression of the disease and may limit the ability to degrade
   circulating peptides in older patients with cystic fibrosis.
   Deficient serum carboxypeptidase B-like activity is less likely,
   however, to be a factor in the development of the early
   manifestations of the disease.
RF 001   OSHIMA G              BIOCHIM BIOPHYS ACTA           365   344 974
   002   BOKISCH VA            J CLIN INVEST                   49  2427 970
   003   ERDOS EG              BIOCHEM PHARMACOL               13   893 964
   004   ERDOS EG              BIOCHEM PHARMACOL               11   585 962
   005   ERDOS EG              BIOCHEM PHARMACOL                8   112 961
   006   CORBIN NC             ANAL BIOCHEM                    73    41 976
   007   ERDOS EG              BIOCHEM PHARMACOL               16  1287 967
   008   ERDOS EG              CLIN CHIM ACTA                  11    39 965
   009   CONOVER JH            LANCET                           2  1501 973
   010   CONOVER JH            LIFE SCI                        14   253 974
   011   LIEBERMAN J           AM REV RESPIR DIS              111   100 975
   012   CUSHMAN DW            BIOCHEM PHARMACOL               20  1637 971
   013   COREY M               AM REV RESPIR DIS              114  1085 976
   014   NIE NH                STAT PACKAGE FOR THE SOCIAL S            975
   015   KOHEIL A              BIOCHIM BIOPHYS ACTA           524   156 978
CT   1   SCHWEISFURTH H        DTSCH MED WSCHR                109   166 984
     2   SCHWEISFURTH H        DTSCH MED WSCHR                109  1254 984
     3   SCHWEISFURTH H        CLIN BIOCHEM                    18   242 985
     4   SCHWEISFURTH H        CLIN BIOCHEM                    20    43 987

PN 79083
RN 01063 
AN 79235200
AU Crass-J-R.  LHeureux-P.  Loken-M.
TI False-positive 111In-labeled leukocyte scan in cystic fibrosis.
SO Clin-Nucl-Med. 1979 Jul. 4(7). P 291-3.
MJ CYSTIC-FIBROSIS: ri.  INDIUM: du.  RADIOISOTOPES: du.
MN ABDOMEN: ri.  CASE-REPORT.  CHILD.  DIAGNOSIS-DIFFERENTIAL.
   FALSE-POSITIVE-REACTIONS.  FEMALE.  HUMAN.  INFLAMMATION: ri.
   ISOTOPE-LABELING.  LEUKOCYTES.  LUNG-DISEASES: ri.  PELVIS: ri.
AB A false-positive 111In-labeled leukocyte scan was obtained in a girl
   with cystic fibrosis and infection. There was focal accumulation of
   111In activity in the abdomen and marked pulmonary uptake. Surgical
   exploration and postmortem examination revealed no abdominal
   abnormality. The abnormal activity was apparently due to swallowed
   sputum which contained labeled leukocytes. Broader clinical
   implications are discussed.
RF 001   THAKUR ML             J NUCL MED                      18  1014 977
   002   THAKUR ML             J LAB CLIN MED                  89   217 977
CT   1   GOODWIN DA            CLIN NUCL MED                    8    36 983
     2   KIPPER MS             CLIN NUCL MED                    8   449 983
     3   KRIEVES DA            CLIN NUCL MED                    8   243 983
     4   GAINEY MA             CLIN NUCL MED                    9    71 984
     5   LOKEN MK              CLIN NUCL MED                   10   902 985
     6   LOMENA F              MED CLIN                        84    58 985
     7   MCAFEE JG             RADIOLOGY                      155   221 985
     8   FLOYD JL              J NUCL MED                      27   495 986
     9   DATZ FL               RADIOLOGY                      160   635 986
    10   WILLIAMSON SL         CLIN NUCL MED                   12    27 987

PN 79084
RN 01064 
AN 80090738
AU Clamp-J-R.  Gough-M.
TI Study of the oligosaccharide units from mucus glycoproteins of
   meconium from normal infants and from cases of cystic fibrosis with
   meconium ileus.
SO Clin-Sci. 1979 Nov. 57(5). P 445-51.
MJ CYSTIC-FIBROSIS: me.  MECONIUM: an.  MUCOPROTEINS.
   OLIGOSACCHARIDES: an.
MN CARBOHYDRATES: me.  COMPARATIVE-STUDY.  FUCOSE: me.  HUMAN.
   INFANT-NEWBORN.  INFANT-NEWBORN-DISEASES: me.
   INTESTINAL-OBSTRUCTION: me.  MECONIUM: me.  MONOSACCHARIDES: an.
AB 1. The mucus glycoproteins in meconium from normal infants and from
   infants having cystic fibrosis with meconium ileus have been studied.
   2. Whereas normal meconium contained about 50% protein-bound
   carbohydrate, the meconium from cystic fibrosis contained only about
   10%. 3. Glycopolypeptides were prepared from the mucus of
   glycoproteins. The oligosaccharide units from this material were
   released and fractionated. The fractions ranged widely in size and
   composition. 4. The fractions from cystic fibrosis specimens had a
   significantly higher content of fucose than those from normal
   specimens.
RF 001   ALHADEFF JA           BIOCHEM BIOPHYS RES COMMUN      86   787 979
   002   ALLEN A               BR MED BULL                     34    28 978
   003   BOORMAN KE            INTRO BLOOD GROUP SEROL               72 970
   004   BUCHANAN DJ           PROC SOC EXP BIOL MED           77   114 951
   005   CARLSON DM            J BIOL CHEM                    243   616 968
   006   CLAMP JR              BIOCHEM SOC TRANS                5  1693 977
   007   DISCHE Z              ANN NY ACAD SCI                106   259 963
   008   DISCHE Z              PEDIATRICS                      24    74 959
   009   DUBOIS M              ANAL CHEM                       28   350 956
   010   DURAND P              J PEDIATR                       75   665 969
   011   FRASER D              THESIS                               122 974
   012   FRASER D              CLIN CHIM ACTA                  59   301 975
   013   GIBBONS RA            BR MED BULL                     34    34 978
   014   HARRIES JT            BR MED BULL                     34    75 978
   015   LIST SJ               BIOCHEM J                      175   565 978
   016   ROELFS RE             AM J DIS CHILD                 113   419 967
   017   SCANLIN TF JR         BIOCHEM BIOPHYS RES COMMUN      79   869 977
   018   SCANLIN TF JR         CLIN CHIM ACTA                  91   197 979
CT   1   MALER T               J BIOL CHEM                    256  1420 981
     2   SCANLIN TF            BIOCHEMISTRY                    21   491 982
     3   WESLEY AW             ADV EXP MED BIOL               144   145 982
     4   WESLEY A              PEDIATR RES                     17    65 983
     5   JACOBS LR             DIG DIS SCI                     28   422 983
     6   RUDICK VL             J CELL PHYSIOL                 115   143 983
     7   HARRIS A              CLIN CHIM ACTA                 128    41 983
     8   ALHADEFF JA           CLIN CHIM ACTA                 134     1 983
     9   RYLEY HC              CLIN CHIM ACTA                 135    49 983
    10   SLOMIANY A            BIOCHIM BIOPHYS ACTA           750   253 983
    11   CROWTHER RS           J PHARMACY PHARMACOL            36    21 984
    12   ALBAZZAZ FJ           RESPIRATION                     46    88 984
    13   SCANLIN TF            PEDIATR RES                     19   368 985
    14   EGGERMONT E           ACTA PAEDIATR SCAND SUPPL 317 1985    16 985
    15   SMITH AC              CLIN GASTROENTEROL              15   815 986
    16   SCHACHTER M           J HISTOCHEM CYTOCHEM            34   927 986

PN 79085
RN 01065 
AN 79212183
AU Pennington-J-E.
TI Pseudomonas aeruginosa infection: pathogenesis and therapy.
SO Compr-Ther. 1979 May. 5(5). P 14-22.
MJ PSEUDOMONAS-INFECTIONS: th.
MN BACTERIAL-VACCINES: tu.  BURNS: co.  CARBENICILLIN: tu.
   CROSS-INFECTION: et.  CYSTIC-FIBROSIS: co.  GENTAMICINS: tu.  HUMAN.
   IMMUNOSUPPRESSION: ae.  PSEUDOMONAS-AERUGINOSA: im.
   PSEUDOMONAS-INFECTIONS: di, et.  TICARCILLIN: tu.  TOBRAMYCIN: tu.
   WOUND-INFECTION: et.
EX Infection with the gram-negative bacillus, Pseudomonas aeruginosa, is
   less common than infections with Escherichia coli, Klebsiella
   pneumoniae, and Proteus sp; however, the mortality associated with
   pseudomonas sepsis exceeds that found with the more commonly isolated
   gram-negative bacilli by a considerable margin.  While explanations
   exist for this increased virulence of pseudomonas, including
   secretions of toxic exoproducts and a high degree of antibiotic
   resistance, the precise reasons for such unfavorable clinical
   experience with this organism are uncertain.  The current interest in
   pseudomonas infection is partly due to the ever-increasing numbers of
   immunosuppressed and granulocytopenic patients seen in clinical
   practice.  The organism, pathogenesis, clinical presentations (burn
   patients, nosocomial infections, immunosuppressed patients, cystic
   fibrosis), and therapy are discussed.
RF 001   REYNOLDS HY           ANN INTERN MED                  82   819 975
   002   LIU PV                J INFECT DIS SUPPL             130    94 974
   003   YOUNG LS              J INFECT DIS SUPPL             130   111 974
   004   TAPPER ML             J INFECT DIS SUPPL             130    14 974
   005   STEVENS RM            ARCH INTERN MED                134   106 974
   006   IANNINI PB            JAMA                           230   558 974
   007   PENNINGTON JE         AM J MED                        55   155 973
   008   SCHIMPFF SC           ANN INTERN MED                  77   707 972
   009   PENNINGTON JE         J INFECT DIS                   131   158 975
   010   NOONE P               BR MED J                         1   477 974
   011   ANDRIOLE VT           J INFECT DIS                   129   124 974
   012   PARRY MF              AM J MED                        64   961 978
   013   KLASTERSKY J          CHEST                           61   117 972
   014   FEELEY TW             N ENGL J MED                   293   471 975
   015   PENNINGTON JE         J INFECT DIS SUPPL             130   159 974
CT   1   HEIMBACH DM           REV INFECT DIS                   6  S744 984
     2   KNOLLE P              BURNS                           11    54 984
     3   HOLDER IA             CAN J MICROBIOL                 31   393 985
     4   SCHENTAG JJ           AM J MED                        78    34 985

PN 79086
RN 01066 
AN 80112075
AU Rosenlund-M-L.  Walsh-E-P.  Scott-D-A.  Kritchevsky-D.
TI Lipids in cystic fibrosis.
SO Curr-Concepts-Nutr. 1979. 8. P 219-27. (REVIEW).
MJ CYSTIC-FIBROSIS: dh.  DIETARY-FATS.
MN ADOLESCENCE.  CELLS-CULTURED.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: bl, me.  FATTY-ACIDS: bl, me.
   FATTY-ACIDS-ESSENTIAL: df.  FEMALE.  FIBROBLASTS: me.  HUMAN.  MALE.
   OILS.  REVIEW.  SUPPORT-U-S-GOVT-P-H-S.
EX There are certain aspects of the symptomatology of cystic fibrosis
   that bear a resemblance to those of essential fatty acid deficiency.
   We fed a group of patients essential fatty acids orally since
   intravenous administration is not a practical method for long term
   treatment.  Results of the study were varied.  Although some response
   was noted in all patients, there were no consistent clinical changes
   seen in every patient.  The oral EFA therapy effected no change in
   sputum cultures.  After one year of EFA, the sweat sodium
   concentration was lower in all but one patient.  The clinical aspect
   of our study is small, but promising.  The results suggest a role for
   EFAs in the care of CF.  Whether EFA is a factor in the etiology of
   CF or merely a manifestation of malabsorption requires further
   investigation.
RF 001   WARWICK WJ            JAMA                           238  2159 977
   002   BURR GO               J BIOL CHEM                     86   587 930
   003   KRAMAR J              J NUTR                          50   149 953
   004   HANSEN AE             TEX REP BIOL MED                 9   491 951
   005   HANSEN AE             PEDIATRICS                      31   171 963
   006   ELLIOTT RB            PEDIATR RES                      7   427 973
   007   ELLIOTT RB            PEDIATRICS                      57   474 976
   008   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   009   GIBSON LE             PEDIATRICS                      23   545 959
   010   KUO PT                J CLIN INVEST                   44  1924 965
   011   CAREN R               J CLIN ENDOCRINOL METAB         26   470 966
   012   WIESE HF              AM J CLIN NUTR                  18   155 966
   013   UNDERWOOD BA          ANN NY ACAD SCI                203   237 972
   014   BENNETT MJ            AM J CLIN NUTR                  20   415 967
   015   ROSENLUND ML          NATURE                         251   719 974
   016   ROSENLUND ML          PEDIATRICS                      59   428 977
   017   MOHRHAUER H           J LIPID RES                      4   151 963
   018   PELUFFO RO            BIOCHIM BIOPHYS ACTA           441    25 976
   019   SPRECHER H            IN: KUNAU WH                           1 977
   020   HOWARD BV             BIOCHIM BIOPHYS ACTA           187   293 969
CT   1   PARNHAM MJ            AGENTS ACTIONS                  14   223 984

PN 79087
RN 01067 
AN 80112266
AU Houstek-J.  Zapletal-A.  Samanek-M.  Vavrova-V.
TI Obstruction of the respiratory pathways, its evaluation by methods
   of functional examination of the lungs and development in patients
   with cystic fibrosis.
SO Czech-Med. 1979. 2(1-2). P 1-10.
MJ CYSTIC-FIBROSIS: pp.  LUNG: pp.
MN ADOLESCENCE.  ADULT.  AIRWAY-OBSTRUCTION: et.  CHILD.
   CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: co.  FORCED-EXPIRATORY-FLOW-RATES.
   FUNCTIONAL-RESIDUAL-CAPACITY.  HUMAN.  RESIDUAL-VOLUME.
   RESPIRATORY-FUNCTION-TESTS.  TOTAL-LUNG-CAPACITY.  VITAL-CAPACITY.
AB In 28 patients with cystic fibrosis aged 5--24 years the values of
   maximum expiratory flow rates (Vmax) at lower volume levels were
   assessed, as well as the "specific" conductance of the respiratory
   pathways (Gaw/TGV), the vital capacity (VC), total lung capacity
   (TLC), residual volume (RV), functional residual capacity (FRC),
   RV/TLC and FRC/TLC ratios and the one-second forced expiration of the
   vital capacity (FEV1) to evaluate obstruction of the respiratory
   pathways. Most markedly and most frequently abnormal were the values
   of Vmax, RV and of the RV/TLC ratio. These findings revealed that in
   almost all patients with CF there was already during the initial
   examination an obstruction of the peripheral respiratory pathways and
   hyperinflation of the lungs. During repeated measurement of the above
   values of lung function in 15 patients with cystic fibrosis during a
   period of 1--5 years when the patients increased in height by 10 cm
   on average, the above values did not deteriorate on average. There
   was, however, an individual variability of the investigated values
   during this period. The comprehensive treatment provided in our
   country prevented in patients with CF a deterioration of obstruction
   of the respiratory pathways during the period of investigation.
RF 001   COOK CD               PEDIATRICS                      24   181 959
   002   COREY M               AM REV RESPIR DIS              114  1085 976
   003   HOUSTEK J             Z ERKR ATMUNGSORGANE           139     7 974
   004   HOUSTEK J             PRAKT LEKAR                     49   216 969
   005   VAVROVA V             CESK PEDIATR                    28   528 973
   006   ZAPLETAL A            PEDIATRICS                      48    64 971
   007   ZAPLETAL A            CESK PEDIATR                    31   532 976
   008   ZAPLETAL A            CESK PEDIATR                    32   513 977
   009   ZAPLETAL A            Z ERKR ATMUNGSORGANE           149   343 977

PN 79088
RN 01068 
AN 80070028
AU Harris-A.
TI Prenatal diagnosis of cystic fibrosis [letter].
SO Dev-Med-Child-Neurol. 1979 Oct. 21(5). P 675-6.
MJ CYSTIC-FIBROSIS: di.
MN FEMALE.  HUMAN.  PREGNANCY.  PRENATAL-DIAGNOSIS: mt.
EX As far as I know, no test for the prenatal diagnosis of cystic
   fibrosis has yet been shown to be reliable, but several experimental
   studies on prenatal diagnosis of cystic fibrosis are being carried
   out.  Deficient protease activity, assayed by 4-methylumbelliferyl
   guanidinobenzoate, an active site titrant of serine proteases, has
   been reported in plasma and cultivated skin fibroblasts from patients
   with cystic fibrosis.  Another prenatal diagnostic test for cystic
   fibrosis involves the observed resistance of patients' skin
   fibroblasts to dexamethasone (a synthetic glucocorticoid) toxicity,
   in comparison to normal fibroblasts.  Specific induction of alkaline
   phosphatase with Tamm Horsfall glycoprotein, isoproterenol and
   theophylline has been recorded in skin-derived fibroblasts from
   affected patients.
RF 001   WALSH-PLATT M         AM J HUM GENET                  29  111A 977
   002   RAO GJS               ENZYME                          23   314 978
   003   WALSH-PLATT M         PEDIATR RES                     12   874 978
   004   WALSH-PLATT M         LANCET                           1   622 979
   005   EPSTEIN JL            PROC NAT ACAD SCI USA           74  5642 977
   006   BRESLOW JL            CELL                            13   663 978
   007   BRESLOW JL            SCIENCE                        201   180 978
   008   HOSLI P               HUM GENET                       41   169 978

PN 79089
RN 01069 
AN 79192319
AU MacLeod-S-M.
TI Clinical pharmacology in a paediatric hospital.
SO Dimens-Health-Serv. 1979 May. 56(5). P 33-4.
MJ DRUG-THERAPY: st.  HOSPITALS-PEDIATRIC.  HOSPITALS-SPECIAL.
   PEDIATRICS.  PHARMACOLOGY.
MN ADOLESCENCE.  CANADA.  CHILD.  CHILD-PRESCHOOL.
   COMMUNICABLE-DISEASES: dt.  CYSTIC-FIBROSIS: dt.  SUBSTANCE-ABUSE.
   DRUG-EVALUATION.  DRUG-INFORMATION-SERVICES.  HUMAN.  INFANT.
   INFANT-NEWBORN.  NERVOUS-SYSTEM-DISEASES: dt.  PHARMACOLOGY: ed, td.
   PHARMACY-SERVICE-HOSPITAL.  RESEARCH.
EX Despite the critical role played by a clinical pharmacologist, there
   are only three in Canada who specialize in paediatrics.  The role of
   paediatric clinical pharmacologists in the promotion of safer and
   more effective drug use, in research, in teaching, and in service are
   discussed, as well as contributions from clinical pharmacology.

PN 79090
RN 01070 
AN 80024183
AU Walsh-Platt-M.  Rao-G-J.  Nadler-H-L.
TI Protease deficiency in plasma of patients with cystic fibrosis.
   Reduced reaction of 4-methylumbelliferylguanidinobenzoate with
   plasma of patients with cystic fibrosis.
SO Enzyme. 1979. 24(4). P 224-9.
MJ CYSTIC-FIBROSIS: en.  HYMECROMONE: bl.  PEPTIDE-HYDROLASES: df.
   UMBELLIFERONES: bl.
MN BENZAMIDINES: pd.  CHILD.  GUANIDINES: bl, me.  HUMAN.
   HYMECROMONE: aa, me.  PEPTIDE-HYDROLASES: bl.  TRYPSIN-INHIBITORS: me.
   SUPPORT-U-S-GOVT-P-H-S.
AB Protease activity in plasma is assayed using 4-
   methylumbelliferylguanidinobenzoate. The assay is modified by
   carrying out the reaction in the presence and absence of benzamidine,
   a competitive inhibitor of trypsin-like proteases. The parameters of
   the assay are described in detail. Using this assay, our earlier
   demonstration of a deficiency of protease activity in plasma of
   patients with cystic fibrosis is confirmed. The activity, corrected
   for the nonspecific hydrolysis of 4-
   methylumbelliferylguanidinobenzoate by benzamidine, is expressed as
   nanomoles of 4-methylumbelliferone released per milliliter plasma.
   Under standard conditions, the activity in plasma activated with
   chloroform-ellagic acid was 127.2 +/- 23.1 in 7 controls, 70.4 +/-
   11.7 in 11 obligate heterozygotes, and 48.7 +/- 16.6 in 12 patients
   with cystic fibrosis. Identical results were obtained when
   unactivated plasma was used. These data demonstrate that the
   judicious use of specific inhibitors such as benzamidine might be
   useful in assaying low levels of protease activity in crude systems.
RF 001   ARMITAGE P            STATISTICAL METHODS IN MEDICA            971
   002   BENDER ML             J AM CHEM SOC                   88  5890 966
   003   CHASE T JR            BIOCHEMISTRY                     8  2212 969
   004   JAMESON GW            BIOCHEM J                      131   107 973
   005   RAO GJS               J PEDIATR                       80   573 972
   006   RAO GJS               PEDIATR RES                      8   684 974
   007   RAO GJS               PEDIATR RES                      9   739 975
   008   RAO GJS               SCIENCE                        177   610 972
   009   RAO GJS               ENZYME                          23   314 978
   010   WALSH-PLATT M         AM J HUM GENET                  29  111A 977
   011   WALSH-PLATT M         PEDIATR RES                     12   874 978
   012   WALSH-PLATT M         LANCET                           1   622 979
   013   WALSH-PLATT M         PEDIATR RES                     12   874 978
CT   1   NADLER HL             LANCET                           2    96 980
     2   NADLER HL             PEDIATRICS                      66   690 980
     3   WALSH MMJ             AM J OBSTET GYNECOL            137   978 980
     4   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
     5   SCHWARTZ M            LANCET                           2  1226 981
     6   BRANCHINI BR          LANCET                           1   618 982
     7   CAREY WF              MED J AUST                       2   314 982
     8   BURY AF               PEDIATR RES                     16   613 982
     9   SCHWARTZ M            CLIN CHIM ACTA                 124   213 982
    10   TUMMLER B             CLIN CHIM ACTA                 125   219 982
    11   GREEN JR              EUR J PEDIATR                  139    35 982
    12   CAREY WF              MED J AUST                       2   528 983
    13   BROCK DJH             PRENAT DIAGN                     3     1 983
    14   POENARU L             PRENAT DIAGN                     3   169 983
    15   BRANCHINI BR          PEDIATR RES                     17   850 983
    16   HEELEY AF             CLIN CHEM                       29  2011 983
    17   BRIDGES MA            ANN NY ACAD SCI                421   360 983
    18   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
    19   ANON                  LANCET                           2   249 985
    20   QURESHI AR            J PEDIATR                      106   913 985

PN 79091
RN 01071 
AN 79169319
AU Paporisz-U.  Posselt-H-G.  Wonne-R.  Ristow-W.  Roser-D.  Knothe-H.
   Bender-S-W.
TI Evaluation of long term tobramycin therapy in patients with cystic
   fibrosis and advanced pulmonary disease.
SO Eur-J-Pediatr. 1979 Apr 3. 130(4). P 259-69.
MJ ANTIBIOTICS: tu.  CYSTIC-FIBROSIS: dt.  LUNG-DISEASES: dt.
   TOBRAMYCIN: tu.
MN ADOLESCENCE.  ADULT.  CHILD.  CYSTIC-FIBROSIS: ra.  FEMALE.  HUMAN.
   LUNG-DISEASES: ra.  MALE.  PSEUDOMONAS-INFECTIONS: dt.
   RESPIRATORY-FUNCTION-TESTS.  TIME-FACTORS.  TOBRAMYCIN: ad, ae.
AB To nine cystic fibrosis patients with chronic bronchopulmonary
   infection of severely damaged lungs invaded by Pseudomonas
   aeruginosa, eleven courses of prolonged tobramycin treatment (5
   mg/kg/day) for four to 16 weeks were administered. Pulmonary symptoms
   improved and a better quality of life was achieved in all but one
   patient. Objective parameters (chest X-ray, pulmonary function tests)
   changed to a lesser extent. In only one patient was Pseudomonas
   eradicated from the sputum but reappeared after discontinuation of
   therapy. In the rest of the patients Pseudomonas was significantly
   suppressed or replaced by other pathogens. Four patients showed rises
   of antibody titres to Candida and two to Aspergillus fumigatus. No
   nephrotoxic side effects were observed, but vestibular function was
   reversibly impaired in one patient without corresponding clinical
   symptoms. No bacterial resistance to tobramycin was observed during
   therapy.
RF 001   BOXERBAUM B           J INFECT DIS SUPPL             124   293 971
   002   DOGGETT RG            SOUTH MED J                     61  1347 968
   003   DOGGETT RG            J BACTERIOL                     87   427 964
   004   DOGGETT RG            SOUTH MED J                     57  1476 964
   005   DOGGETT RG            SOUTH MED J                     57  1470 964
   006   DOGGETT RG            SOUTH MED J                     61  1346 968
   007   DOGGETT RG            IN: LAWSON D PROC 5TH INT CF         175 969
   008   DOGGETT RG            BACT PROC                       69    87 969
   009   DOGGETT RG            INFECT IMMUN                     6   628 972
   010   HAWLEY HB             CURR THER RES                   16   414 974
   011   HARRISON GM           PAEDIATRICIAN                    1   180 972
   012   HOFF GE               SCAND J INFECT DIS               6   333 974
   013   HOIBY N               SCAND J RESPIR DIS              58    65 977
   014   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   015   HUMPHREY JH           ADV IMMUNOL                     11    75 969
   016   MAY JR                CHEMOTHERAPY OF CHRONIC BRONC            968
   017   MEARNS MB             ARCH DIS CHILD                  47   902 972
   018   WAITZ JA              ANTIMICROB AGENTS CHEMOTHER      2   431 972

PN 79092
RN 01072 
AN 80004150
AU Hosli-P.  Vogt-E.
TI Cystic fibrosis: decreased thermostability of alpha-mannosidase in
   crude extracellular fluids of patients and carriers.
SO FEBS-Lett. 1979 Aug 15. 104(2). P 271-4.
MJ CYSTIC-FIBROSIS: en.  EXTRACELLULAR-SPACE: en.  MANNOSIDASES: me.
   SKIN: en.
MN CELLS-CULTURED.  DRUG-STABILITY.  FIBROBLASTS: en.  HEAT.
   HETEROZYGOTE.  HUMAN.  KINETICS.
EX We wish to demonstrate that an abnormal thermostability has been
   found in crude extracellular fluids for alpha-mannosidase.  More
   extensive studies involving several of the 'leaky' hydrolases are
   under way and they indicate that the observed thermolabilities can
   be exploited to develop the urgently needed simple diagnostic tools
   for cystic fibrosis.
RF 001   WOOD RE               AM REV RESPIR DIS              113   833 976
   002   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   003   GIBSON LE             PEDIATRICS                      23   545 959
   004   SCHWARZ V             ARCH DIS CHILD                  43   695 968
   005   STEPHAN U             PEDIATRICS                      55    35 975
   006   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      73   209 976
   007   PAPP Z                CLIN GENET                      11   431 977
   008   BRESLOW JL            SCIENCE                        201   180 978
   009   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      79   741 977
   010   HOSLI P               PROC INT CF CONG 7TH                 278 976
   011   HOSLI P               MONOGR PAEDIATR                 10    90 979
   012   NEUFELD EF            J SUPRAMOL STRUCT                6    95 977
   013   KAPLAN A              PROC NAT ACAD SCI USA           74  2026 977
CT   1   HIRANI S              LANCET                           2   906 979
     2   HOSLI P               FEBS LETTERS                   106  U421 979
     3   BUTTERWORTH J         CLIN CHIM ACTA                 108   347 980
     4   CAREY WF              MED J AUST                       2   314 982
     5   CRISTOL P             SEM HOP PARIS                   58   449 982
     6   CEDER O               CLIN GENET                      23   298 983
     7   CEDER O               ACTA PAEDIATR SCAND             72   291 983
     8   KOHLSCHUTTER A        FEBS LETTERS                   155   223 983
     9   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
    10   BOZON D               ARCH BIOCHEM BIOPHYS           249   546 986

PN 79093
RN 01073 
AN 80114944
AU Kraemer-R.  Rudeberg-A.  Klay-M.  Rossi-E.
TI Relationship between clinical conditions, radiographic findings and
   pulmonary functions in patients with cystic fibrosis.
SO Helv-Paediatr-Acta. 1979. 34(5). P 417-28.
MJ CYSTIC-FIBROSIS: pp.  LUNG-VOLUME-MEASUREMENTS.
MN ADOLESCENCE.  ADULT.  BLOOD-GAS-ANALYSIS.  CHILD.
   CYSTIC-FIBROSIS: di, ra.  FEMALE.  FORCED-EXPIRATORY-VOLUME.
   FUNCTIONAL-RESIDUAL-CAPACITY.  HUMAN.  MALE.  PARTIAL-PRESSURE.
   TOTAL-LUNG-CAPACITY.
AB Clinical and radiological findings, quantified by special scores, in
   36 patients with cystic fibrosis are compared with lung function
   measurements, including the ratio of RV/TLC and FEV/VC and the
   arterial blood gases at rest and during exercise. Although
   respiratory function tests were found to correlate well with both the
   pulmonary finding score and the chest radiographic score, distinction
   of three severity groups was possible only by a vector calculation of
   the blood gases in PaO2-PaCO2-diagram, at rest and during exercise.
   Thus, measurements of pO2 and pCO2 at rest and on exercise appear to
   be a helpful adjuvant to routine spirometry for the individual
   appraisal of the degree of lung involvement, performance and care
   level.
RF 001   BACHOFEN H            SCHWEIZ MED WOCHENSCHR         102  1061 972
   002   BACHOFEN H            J APPL PHYSIOL                  34   137 973
   003   BACHOFEN H            PNEUMONOLOGY                   153   160 976
   004   BATSCHELET E          STATISTICAL METHODS FOR THE A            965
   005   BEIER FR              AM REV RESPIR DIS               94   430 966
   006   CHRISPIN AR           PEDIATR RADIOL                   2   101 974
   007   COREY M               AM REV RESPIR DIS              114  1085 976
   008   DEMUTH GR             AM J DIS CHILD                 103   129 962
   009   DOERSHUK CF           J PEDIATR                       65   677 964
   010   DOERSHUK CF           PEDIATRICS                      36   675 965
   011   FEATHERBY EA          AM REV RESPIR DIS              102   737 970
   012   GODFREY S             ARCH DIS CHILD                  45   534 970
   013   GODFREY S             ARCH DIS CHILD                  46   144 971
   014   GODFREY S             ARCH DIS CHILD                  53    83 978
   015   GREENWOOD JA          ANN MATH STAT                   26   233 955
   016   JOHNSON RL JR         J APPL PHYSIOL                  25     1 968
   017   KNOKE JD              PEDIATR RES                     12   676 978
   018   KRAEMER R             MONOGR PAEDIATR                 10    61 979
   019   KRAEMER R             PADIAT FORTBILDK PRAXIS         48     7 979
   020   LAMARRE A             PEDIATRICS                      50   291 972
   021   LANDAU LI             AM REV RESPIR DIS              108   593 973
   022   LANDAU LI             AM REV RESPIR DIS              111   725 975
   023   MARDIA KV             STATISTICS OF DIRECTION DATA             972
   024   MATTHEW DJ            PEDIATR RADIOL                   5   198 977
   025   MEARNS MB             ARCH DIS CHILD                  43   528 968
   026   MELLINS RB            PEDIATRICS                      44   315 969
   027   PHELAN PD             ARCH DIS CHILD                  44   393 969
   028   STRUTT JW             NATURE                          72   318 905
   029   SCHERRER M            SCHWEIZ MED WOCHENSCHR         107  1072 977
   030   SPEARMAN C            AM J PSYCHOL                    15    72 904
   031   WATSON GS             BIOMETRIKA                      43   344 956
   032   WEST JB               N ENGL J MED                   284  1232 971
   033   WEST JB               J APPL PHYSIOL                  30   479 971
   034   WHEELER S             BIOMETRIKA                      51   256 964
   035   ZAPLETAL A            PEDIATRICS                      48    64 971
CT   1   KRAEMER R             METH INF MED                    19    50 980
     2   KRAEMER R             EUR J RESPIR DIS                61   118 980
     3   KRAEMER R             EUR J PEDIATR                  138   172 982
     4   HARMS HK              KLIN PAEDIATR                  195    24 983
     5   SUTER S               J INFECT DIS                   149   523 984
     6   SUTER S               PEDIATR RES                     19   346 985
     7   SCHAAD UB             ACTA PAEDIATR SCAND             75   128 986

PN 79094
RN 01074 
AN 80114945
AU Strauss-R-G.
TI Complement in cystic fibrosis.
SO Helv-Paediatr-Acta. 1979. 34(5). P 429-35.
MJ COMPLEMENT-3: an.  CYSTIC-FIBROSIS: im.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.
   COMPLEMENT-PATHWAY-ALTERNATIVE.  COMPLEMENT-PATHWAY-CLASSICAL.
   COMPLEMENT-3B-INACTIVATORS: an.  HUMAN.  INULIN: du.
AB Quantitative and functional assessments were made of both the
   classical and alternative pathways of complement activation in sera
   from 23 patients with cystic fibrosis. The classical pathway
   functioned similarly in patients and controls as measured by CH50
   titre. Alternative pathway function, initiated in patient sera by
   incubation with inulin, was equal to that of controls as determined
   by cleavage of Factor B and C3, and by the consumption of terminal
   components. Factor B, however, was more readily activated in patient
   than in control sera. This rapid alteration of Factor B did not lead
   to accelerated or more extensive activation of the terminal
   complement components via the alternative pathway when assessed by C3
   cleavage and the consumption of terminal components. Thus, a
   complement deficiency was not found. The importance of the easily
   activated Factor B is undefined.
RF 001   BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      64  1310 975
   002   BUESCHER ES           J PEDIATR                       93   530 978
   003   CONOVER JH            LANCET                           2  1501 973
   004   CONOVER JH            TEX REP BIOL MED                34    45 976
   005   FORRISTAL J           CLIN EXP IMMUNOL                23    61 977
   006   GOTZ M                EUR J PEDIATR                  127   133 978
   007   GOTZE O               J EXP MED                      134   90S 971
   008   HOLZHAUER RJ          PEDIATR RES                     10   365 976
   009   HANN S                LANCET                           2   520 974
   010   KABAT EA              EXPERIMENTAL IMMUNOCHEMISTRY             961
   011   LIEBERMAN J           AM REV RESPIR DIS              111   100 975
   012   LYRENE RK             J PEDIATR                       91   681 977
   013   POLLEY MJ             J MED GENET                     11   249 974
   014   SCANLIN TF JR         LANCET                           1  1382 974
   015   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   86    37 978
   016   STRAUSS RG            PEDIATR RES                     11   285 977
   017   STRUNK RC             ARCH DIS CHILD                  52   687 977
   018   WEST CD               J IMMUNOL                       96   650 966
   019   WILSON GB             J LAB CLIN MED                  92   463 978
CT   1   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985

PN 79095
RN 01075 
AN 80005196
AU Cusack-D.  Cannon-D.  Skrabanek-P.  Powell-D.
TI Substance P plasma levels in pregnancy and in various clinical
   disorders.
SO Horm-Metab-Res. 1979 Jul. 11(7). P 448-51.
MJ PREGNANCY.  SUBSTANCE-P: bl.
MN CYSTIC-FIBROSIS: bl.  FEMALE.  HUMAN.  INTESTINAL-DISEASES: bl.
   NEOPLASMS: bl.  RADIOIMMUNOASSAY.  THYROID-DISEASES: bl.
AB Using radioimmunoassay, immunoreactive SP (iSP) has been measured in
   the plasma of 162 hospital patients with various disorders and in the
   plasma of 67 pregnant women. In pregnancy, iSP was undetectable in
   40% women as compared to 12% in other hospital patients. The mean iSP
   plasma level in pregnancy was 37.8 +/- 4.6 (SEM) as compared to 77.1
   +/- 4.9 (SEM) pg/ml in other hospital patients. The results support
   earlier observations based on bioassay, suggesting that the blood of
   pregnant women contains higher concentrations of a SP-inactivating
   factor. Of the hospital patients, elevated levels of iSP were found
   in patients with chronic leukaemia, in one patient with a basaloid
   carcinoma of the anus, and in one patient with toxic liver damage and
   pancreatic insufficiency. No correlation was found between thyroid
   function and iSP plasma levels. ISP plasma levels in various
   gastrointestinal disorders were similar to those found in normal
   subjects.
RF 001   ALUMETS J             HISTOCHEMISTRY                  52   217 977
   002   CANNON D              BIOCHEM SOC TRANS                5  1776 977
   003   EHRENPREIS T          ACTA PHYSIOL SCAND              27   380 953
   004$  HARKINS J             BRAIN RES                      147   405 978
   005   KOCIC-METROVIC D      PROC SCI SOC BOSNIA HERZEGOVI    1   113 961
   006   NAKANO T              JAPAN J PHARMACOL               25   43P 975
   007   OCONNELL R            IR J MED SCI                   145   392 976
   008   PARTINGTON MW         ARCH DIS CHILD                  52   386 977
   009$  PEARSE AGE            HISTOCHEMISTRY                  41   373 975
   010   PERNOW B              PROC SCI SOC BOSNIA HERZEGOVI    1    57 961
   011   POLAK JM              IN: FUJITA T                         103 976
   013   SKRABANEK PD          IR J MED SCI                   145   399 976
   014   SKRABANEK PD          IR J MED SCI                   147    47 978
   015   SKRABANEK PD          SUBSTANCE P                              978
   016   STERN PI              PROC SCI SOC BOSNIA HERZEGOVI    1   139 961
CT   1   SKRABANEK P           EUR J OBSTE GYNECOL REPR BIOL   11   157 980
     2   KAIYA  H              PSYCHIATRY RES                   5    11 981
     3   POLLOCK M             NEUROLOGY                       32  1311 982
     4   VERMA PS              EUR J PHARMACOL                 86   275 982
     5   SKRABANEK P           OBSTET GYNECOL                  61   641 983
     6   SKRABANEK P           IR J MED SCI                   153    47 984
     7   ZHANG CL              ACTA ZOOL SINICA                31   106 985

PN 79096
RN 01076 
AN 80070842
AU Tucker-R-D.  Hudrlik-T-R.  Gibbs-G-E.  Christensen-M-B.
TI The effect of serum from patients with pancreatic disease on the
   short circuit current of rat jejunum.
SO IEEE-Trans-Biomed-Eng. 1979 Nov. 26(11). P 607-13.
MJ BIOLOGICAL-ASSAY: mt.  JEJUNUM: ph.  PANCREATIC-DISEASES: bl.
MN ANIMAL.  BIOLOGICAL-ASSAY: is.  CYSTIC-FIBROSIS: bl.
   DIABETES-MELLITUS: bl.  ELECTRIC-CONDUCTIVITY.  HUMAN.
   MEMBRANE-POTENTIALS.  PANCREATITIS: bl.  RATS.
AB The short circuit current rat jejunum bioassay, first employed in an
   attempt to discern the cystic fibrosis (CF) serum "factor," was
   evaluated using sera from patients with pancreatic disease.  The
   data suggest other pancreatic diseases, specifically genetic
   diabetes and alcoholic pancreatitis, also present with a serum
   "factor" (or "factors") which reduce the short circuit current of
   rat jejunum, an effect very similar to that of the CF serum
   "factor."  A large number of sera from presumed normal subjects also
   exhibited a significant reduction in short circuit current; these
   (false positives) represent a yet to be defined mechanism, however,
   they do decrease the likelihood that the observed effect is merely
   due to pancreatic destruction.  Detailed procedure and equipment
   specifications for the bioassay system are included.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   002   WOOD RE               AM REV RESPIR DIS              113   833 976
   003   KOPEL FB              GASTROENTEROLOGY                62   483 972
   004   CRAIG JM              AM J DIS CHILD                  93   357 957
   005   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   006   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   007   SPOCK A               PEDIATR RES                      1   173 967
   008   BOWMAN BH             SCIENCE                        164   325 969
   009   BESLEY GTN            J MED GENET                      6   278 969
   010   CHERRY JD             J PEDIATR                       79   937 971
   011   POSSELT HG            Z KINDERHEILK                  110    93 971
   012   ARAKI H               PEDIATR RES                      9   932 975
   013   ARAKI H               PROC INT CF CONG 7TH                  28 976
   014   GILMORE JP            PROC SOC EXP BIOL MED          157    70 978
   016   CONOVER JH            LANCET                           1  1194 973
CT   1   TUCKER RD             COMPUT BIOL MED                 11   153 981

PN 79097
RN 01077 
AN 79129529
AU Sorensen-R-U.  Stern-R-C.  Chase-P.  Polmar-S-H.
TI Defective cellular immunity to gram-negative bacteria in cystic
   fibrosis patients.
SO Infect-Immun. 1979 Feb. 23(2). P 398-402.
MJ ANTIGENS-BACTERIAL: im.  CYSTIC-FIBROSIS: im.
   ENTEROBACTERIACEAE: im.  LYMPHOCYTE-TRANSFORMATION.
   PSEUDOMONAS-AERUGINOSA: im.
MN HUMAN.  KLEBSIELLA-PNEUMONIAE: im.  PROTEUS-MIRABILIS: im.
   SERRATIA-MARCESCENS: im.  SUPPORT-U-S-GOVT-P-H-S.
AB In vitro lymphocyte responses to Pseudomonas aeruginosa have been
   found to be impaired in cystic fibrosis patients with advanced
   clinical disease. The responses to Klebsiella pneumoniae, Serratia
   marcescens, and Proteus mirabilis were studied in a similar group of
   cystic fibrosis patients and normal individuals. Cystic fibrosis
   patients found to be unresponsive to pseudomonas were also
   unresponsive to klebsiella, serratia, and proteus. Responsiveness to
   Staphylococcus aureus was not impaired in cystic fibrosis patients.
   We postulate that in vitro lymphocyte responses to several gram-
   negative bacteria require the function of a lymphocyte subpopulation
   which may be impaired in some cystic fibrosis patients.
RF 001   CHANDRA RK            PEDIATRICS                      59   423 977
   002   DOERSHUK CF           J PEDIATR                       65   677 964
   003   FERGUSON AC           J PEDIATR                       85   717 974
   004   GREEN GM              AM REV RESPIR DIS              102   691 970
   005   GREEN GM              J EXP MED                      119   167 964
   006   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   559 974
   007   KALTREIDER HB         AM REV RESPIR DIS              113   347 976
   008   LIEBERMAN J           AM REV RESPIR DIS              116  1047 977
   009   MOORE VL              RES J RETICULOENDOTHEL SOC      21   131 977
   010   NEUMANN CG            AM J CLIN NUTR                  28    89 975
   011   PRESSMAN D            IN: SAUNTER M                         11 971
   012   SELLMEYER E           ARCH DIS CHILD                  47   429 972
   013   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   014   SORENSEN RU           INFECT IMMUN                    18   735 977
   015   SORENSEN RU           J PEDIATR                       93   201 978
   016   THORSBY E             HISTOCOMPATIBILITY TESTING           655 970
   017   WALLWORK JC           CLIN EXP IMMUNOL                18   303 974
   018   WARR GA               AM REV RESPIR DIS              108   371 973
   019   WEIGLE WO             IMMUNOLOGY                       7   239 964
   020   WEIGLE WO             J EXP MED                      121   289 965
   021   WEIGLE WO             J IMMUNOL                       94   117 965
CT   1   RUUSKANEN O           J CLIN LAB IMMUNOL               4   111 980
     2   RUUSKANEN O           J IMMUNOL                      125   411 980
     3   MATTHEWS WJ           N ENGL J MED                   302   245 980
     4   SORENSEN RU           PEDIATR RES                     15    14 981
     5   JOHNSON DL            RES COMMUN CHEM PATH PHARM      32   377 981
     6   RUBIN HR              CELL IMMUNOL                    57   307 981
     7   SORENSEN RU           AM REV RESPIR DIS              123    37 981
     8   VANGEFFEL R           ANN IMMUNOL (PARIS)           D133   293 982
     9   WILSON GB             MED HYPOTHESES                   8   527 982
    10   SEALE TW              ANN CLIN LAB SCI                12   415 982
    11   LILLIE MA             J CLIN MICROBIOL                16   111 982
    12   WOLFE JHN             ARCH SURG                      117  1266 982
    13   MCIRVINE AJ           ANN SURG                       196   297 982
    14   GUIDOTTI TL           AM J MED SCI                   283   157 982
    15   RUBIN HR              INFECT IMMUN                    39   630 983
    16   PORWOLL JM            INFECT IMMUN                    40   670 983
    17   SORENSEN RU           INFECT IMMUN                    41   321 983
    18   MCIRVINE AJ           SURG CLIN NORTH AM              63   245 983
    19   SORENSEN RU           EUR J RESPIR DIS                64   524 983
    20   MILLER KM             CLIN EXP IMMUNOL                56   415 984
    21   AUERBACH HS           LANCET                           2   686 985
    22   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
    23   ZAPATASIRVENT RI      SURGERY                         97   721 985
    24   ZAPATASIRVENT RL      SURGERY                         99    53 986
    25   HANSBROUGH JF         AM J SURG                      151   249 986
    26   KEANE RM              IR J MED SCI                   155   143 986

PN 79098
RN 01078 
AN 81093097
AU Thomsen-J.  Friis-B.
TI High dosage tobramycin treatment of children with cystic fibrosis.
   Bacteriological effect and clinical ototoxicity.
SO Int-J-Pediatr-Otorhinolaryngol. 1979 Jul. 1(1). P 33-40.
MJ ANTIBIOTICS: ad.  CYSTIC-FIBROSIS: co.  PSEUDOMONAS-INFECTIONS: dt.
   RESPIRATORY-TRACT-INFECTIONS: dt.  TOBRAMYCIN: ad.
MN CARBENICILLIN: ad.  CHILD.  DRUG-THERAPY-COMBINATION.  FEMALE.
   HUMAN.  MALE.  PSEUDOMONAS-INFECTIONS: co, mi.
   RESPIRATORY-TRACT-INFECTIONS: co, mi.  TOBRAMYCIN: ae.
AB The bacteriological effect of chemotherapy against mucoid strains of
   Pseudominas aeruginosa in the lower respiratory tract of patients
   with cystic fibrosis is reported. A comparison of the effect of high
   doses of tobramycin (10 mg/kg/24 h) given alone or in combination
   with carbenicillin showed a significant difference in favour of the
   combination therapy. In 74.5% of the initially successful courses the
   patients were recolonized within one month. Fifty-three patients were
   examined by audiometric and vestibular tests. Only in one patient was
   it possible to register a transient, high tone hearing impairment at
   8000 Hz bilaterally, that might be attributed to the tobramycin
   treatment. It is concluded that high dose tobramycin treatment in
   children and adolescents with normal kidney function implies only a
   minimal clinical risk of adverse ototoxic effects, even after
   repeated courses of treatment. No nephrotoxic side-effects were found
   in this material.
RF 001   BRUMMET RE            ARCH OTOLARYNGOL               101   540 975
   002   BRUMMET RE            ARCH OTOLARYNGOL                96   505 972
   004   HOFF GE               SCAND J INFECT DIS               6   333 974
   005   LOGAN TB              ARCH OTOLARYNGOL                99   190 974
   006   MCCRAE WM             SCOTT MED J                     21    68 976
   007   NEU HC                J INFECT DIS SUPPL             134   206 976
   008   STUPP HF              ACTA OTOLARYNGOL STOCKH SUPPL  262     1 970
   009   WILSON P              BR MED J                         1   259 977
CT   1   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
     2   SCHOFIELD DH          DRUG INTEL CLIN PHARM           18   153 984
     3   MILLER JJ             LANCET                           2   272 985
     4   CHRYSTYN H            J CLIN HOSP PHARM               10   219 985
     5   FRASER GL             DRUG INTEL CLIN PHARM           19   757 985

PN 79099
RN 01079 
AN 79215540
AU Afzelius-B-A.
TI The immotile-cilia syndrome and other ciliary diseases.
SO Int-Rev-Exp-Pathol. 1979. 19. P 1-43. (REVIEW).
MJ CILIA: pp.
MN ADULT.  ANIMAL.  BRAIN: pp.  CILIA: ph, ul.  CYSTIC-FIBROSIS: pp.
   DOGS.  DYNEIN: ph.  EAR: pp.  FEMALE.  HUMAN.  KARTAGENER-TRIAD: pp.
   MALE.  MOVEMENT.  RESPIRATORY-TRACT-INFECTIONS: pp.  REVIEW.
   SPERM-MOTILITY.  SYNDROME.  TUBULIN: ph.  UROGENITAL-SYSTEM: pp.
EX It is the purpose of this review to present evidence for a disorder
   which is believed to be caused by defective cilia and to review some
   data on the occurrence of abnormal cilia, evidently formed in
   response to environmental insults.  The cilium, human ciliated
   structures, the immotile-cilia syndrome and other inborn ciliary
   diseases, cystic fibrosis, and acquired disorders of ciliated
   structures are discussed.  Ciliary activity is not vital, but its
   loss will cause a great deal of discomfort.  The greatest problems
   relate to the lower respiratory tract, which is also a site of most
   of the cilia in the body.  It is striking that a certain degree of
   clearance can be maintained in the lungs in the absence of motile
   cilia by coughing, hawking, and other mechanisms.
RF 001   AARONS GH             POSTGRAD MED J                  45   736 959
   002   ADAMS R               J THORAC SURG                    7   206 937
   003   AFZELIUS BA           J BIOPHYS BIOCHEM CYTOL          5   269 959
   004   AFZELIUS BA           IN: BACCETTI B                       565 970
   005   AFZELIUS BA           SCIENCE                        193   317 976
   006   AFZELIUS BA           J CELL BIOL                     66   225 975
   007   AFZELIUS BA           FERTIL STERIL                   29    72 978
   008   AILSBY RL             J PATHOL                       109    75 973
   009   ALLEN RA              J ULTRASTRUCT RES               12   730 965
   010   AMJAD H               JAMA                           227  1420 974
   011   ANDERSEN I            ARCH ENVIRON HEALTH             29   290 974
   012   ANDERSON H            ACTA OTOLARYNGOL STOCKH SUPPL  247     1 969
   013   ARGE E                LANCET                           1   412 960
   014   AUERBACH O            N ENGL J MED                   256    97 957
   015   BACCETTI B            J SUBMICROSC CYTOL               7   349 975
   016   BALDETORP L           CELL TISSUE RES                180   421 977
   017   BARNES BG             J ULTRASTRUCT RES                5   453 961
   018   BERGSTROM WH          PEDIATRICS                       6   573 950
   019   BISSON JP             J GYN OBSTET BIOL REPR SUPP 1    4    37 975
   020   BLAKE J               J BIOMECH                        8   179 975
   021   BLOM E                NATURE                         209   739 966
   022   BOQUIST L             Z ZELLFORSCH MIKROSK ANAT       89   519 968
   023   BORELL U              ACTA OBSTET GYNECOL SCAND       36    22 957
   024   BOWMAN BH             LIFE SCI                        19  1289 976
   025   BREDBERG G            ACTA OTOLARYNGOL STOCKH SUPPL        301 972
   026   BROKAW CJ             IN: INOUE S                          165 975
   027   BRUSIS T              Z LARYNGOL RHINOL OTOL          52   883 973
   028   BRYAN JHD             CELL TISSUE RES                180   187 977
   029   BURIAN K              ACTA OTOLARYNGOL STOCKH         56   376 963
   030   CAMNER P              ENVIRON PHYSIOL                  1   137 971
   031   CAMNER P              AM REV RESPIR DIS              112   807 975
   032   CARRIG GB             J AM VETER MED                 164  1127 974
   033$  CATHCART RC           J NEUROPATH EXP NEUROL          23    60 964
   034   CHANG KH              J THORAC CARDIOVASC SURG        43    27 962
   035   CHATTERJEE K          J INDIAN MED ASSOC              52   389 969
   036   CHERNIAK NS           AM J MED                        41   562 966
   037   CHEVANCE LG           ACTA OTOLARYNGOL STOCKH         72   121 971
   038   CHUNG JW              CELL TISSUE RES                175   421 976
   039   CHURCHILL ED          J THORAC SURG                   18   279 949
   040   CLYMAN MJ             FERTIL STERIL                   17   281 966
   041   COCKAYNE EA           Q J MED                          7   479 938
   042   COHEN S               J MED SOC NJ                    47   557 950
   043   COLE DB               J THORAC SURG                    9   689 940
   044   COLLIER AM            INFECT IMMUN                     3   694 971
   045   CONOVER JH            LANCET                           1  1194 973
   046   COOK CD               AM J HUM GENET                  14   290 962
   047   DAHLGREN SE           VIRCHOWS ARCH CELL PATHOL       11   211 972
   048   DAROCZY J             ZENTRALBL ALLG PATHOL          118   314 974
   049   DAVID G               J GYN OBSTET BIOL REPR SUPP 1    4    17 975
   050   DE DUVE C             SCIENCE                        189   186 975
   051   DELP MH               J KANSAS MED SOC                47    93 946
   052   DEMPSEY LC            J NEUROSURG                     45    53 976
   053   DI MAURO S            J NEUROL SCI                    27   217 976
   054   DOCHEZ C              TIJDSCHR GASTROENTEROL          18   263 975
   055   DOUEK E               PROC R SOC MED                  69   467 975
   056   DOURMASHKIN RR        J GEN VIROL                      9    77 970
   057   ELIASSON R            N ENGL J MED                   297     1 977
   058   ENGSTROM H            ACTA OTOLARYNGOL STOCKH SUPPL  301    75 972
   059   ERNSTSON S            ACTA OTOLARYNGOL STOCKH         67   521 969
   060   EWERT G               ACTA OTOLARYNGOL STOCKH SUPPL  200     1 965
   061   FADEL HE              FERTIL STERIL                   27  1176 976
   062   FAWCETT DW            J MORPHOL                       94   221 954
   063   FINKLER E             SCHWEIZ MED WOCHENSCHR          86   631 956
   064   FLOCK A               J CELL BIOL                     25     1 965
   065   FLOCK A               ACTA OTOLARYNGOL STOCKH         83    85 977
   066   FLOOD PR              CELL TISSUE RES                183   281 977
   067   FONTE VG              J CELL BIOL                     49   226 971
   068   FORNATTO EJ           LARYNGOSCOPE                    66  1202 956
   069   FOX MH                ANAT REC                       124   189 956
   070   FRASCA JM             EXP MOL PATH                     9   380 968
   071   FREDRICSSON B         Z ZELLFORSCH MIKROSK ANAT       58   387 962
   072   FRIEDMANN I           LARYNGOSCOPE                    81  1852 971
   073   GADDUM-ROSSE P        BIOL REPROD                     14   605 976
   074   GADDUM-ROSSE P        AM J ANAT                      138    26 973
   075   GIBBONS IR            NATURE                         190  1128 961
   076   GIBBONS IR            J BIOPHYS BIOCHEM CYTOL         11   179 961
   077   GIBBONS IR            IN: INOUE S                          207 975
   078   GLAUM K               MEITR KLIN TUBERK               91   421 938
   079   GOODENOUGH UW         J CELL BIOL                     66   480 975
   080   GUDE HE               JAMA                           171  1825 959
   081   GUILLON G             COLLOQ NATL SOC FERTIL STERIL        391 972
   082   HALBERT SP            GYNECOL INVEST                   7   306 976
   083   HANCOCK JL            VET REC                         67   825 955
   084   HARADA Y              ACTA OTOLARYNGOL STOCKH         83   284 977
   085   HERS HG               BIOCHEM J                       86    11 963
   086   HERS HG               LYSOSOMES AND STORAGE DISEASE            973
   087   HILDING AC            ANN INTERN MED                   6   227 932
   088   HILDING AC            ANN OTOL RHINOL LARYNGOL        52     5 943
   089   HILDING AC            N ENGL J MED                   256   634 957
   090   HILDING AC            ANN OTOL RHINOL LARYNGOL        80   306 971
   091   HILDING AC            ANN OTOL RHINOL LARYNGOL        75   281 966
   092   HOLMES LB             AM J MED SCI                   255    13 968
   093   HOLSTEIN AF           ZWANGLOSE ABH GEB NORM PATHOL   20     1 969
   094   HOLSTEIN AF           VIRCHOWS ARCH PATHOL ANAT      367    93 975
   095   HOORN B               PROG MED VIROL                  11   408 969
   096   HUBERMAN D            ACTA PHYSIOL SCAND              99    42 977
   097   HUMMEL KP             J HERED                         50     9 959
   098   JAHNKE V              Z LARYNGOL RHINOL OTOL          51    30 972
   099   JAHNKE V              Z LARYNGOL RHINOL OTOL          55   637 976
   100   JEFFERY PK            IN: BRAIN JD                     5   193 977
   101   JEFFERY PK            IN: AHARONSON EF                     253 976
   102   JONES R               BR MED J                         2   142 972
   103   KAPA E                ACTA ANAT (BASEL)               95   444 976
   104   KARANI S              BR MED J                         2    74 952
   105   KARTAGENER M          BEITR KLIN TUBERK               83   489 933
   106   KARTAGENER M          BEITR KLIN TUBERK               87   331 935
   107   KATSUHARA K           CHEST                           61    56 972
   108   KATZ M                N ENGL J MED                   248   730 953
   109   KAWABATA I            ACTA OTOLARYNGOL STOCKH         67   511 969
   110   KENNEDY JR            J CELL BIOL                     70   80A 976
   111   KIEFER BI             IN: RUDDLE FH                         47 973
   112   KILKUCHI K            J FRANC OTORHINOLARYNGOL        23   697 974
   113   KILBURN KH            J ULTRASTRUCT RES               60    34 977
   114   KONRADOVA V           FOLIA MORPHOL (PRAGUE)          16   398 968
   115   KONRADOVA V           FOLIA MORPHOL (PRAGUE)          23   293 975
   116   KUBOTA K              AM J ANAT                      144   119 975
   117   LATTA H               J BIOPHYS BIOCHEM CYTOL         11   248 961
   118   LAYTON WM             J HERED                         67   336 976
   119   LEONARD SL            ANAT REC                       104    89 949
   120   LINDBERG LA           CELL TISSUE RES                179   121 977
   121   LINDGREN E            ACTA RADIOL                     35   277 951
   122   LOFBERG J             ZOON                             2     3 974
   123   LOGAN WD              DIS CHEST                       48   613 965
   124   LUDWIG H              ARCH CYNAEKOL                  212   380 972
   125   LUFT R                J CLIN INVEST                   41  1776 962
   126   MANN T                PROC SOC STUDY FERT              9     3 958
   127   MATULIONIS DH         AM J ANAT                      145    79 976
   128   MCDOWELL EM           ARCH PATHOL LAB MED            100   429 976
   129   MENCO BPM             MEDEDEL LANDBOUWHOGESCH WAGEN    1    77 977
   130   MEYER CH              FRANKF Z PATHOL                 76    21 966
   131   MOHRI H               IN: PERRY SV                         336 976
   132   MORE IAR              J REPROD FERTIL                 47    19 976
   133   MORITA I              ARCH HISTOL JAP                 26   341 966
   134   MOSSBERG B            SCAND J RESPIR DIS              59    55 978
   135   MYGIND N              ACTA ALLERGOL                   28     9 973
   136   MYKLEBUST R           ANAT EMBRYOL                   151   127 977
   137   NAGY L                BEITR KLIN TUBERK               95    26 940
   138   NAKAYAMA Y            J NEUROCYTOL                     3   449 974
   139   NIELSEN SL            LAB INVEST                      30   618 974
   140   NICHAMIN SJ           JAMA                           161   966 956
   141   NILSSON O             UPSALA J MED SCI                77     3 972
   142   NUNN JF               J CELL SCI                      15   537 974
   143   OKUDA M               ACTA OTOLARYNGOL STOCKH         76   283 973
   144   OLSEN AM              AM REV TUBERC                   47   435 943
   145   PAVELKA M             ACTA ANAT (BASEL)               94   262 976
   146   PEDERSEN H            Z ZELLFORSCH MIKROSK ANAT      123   305 972
   147   PEDERSEN H            NATURE                         262   494 976
   148   PEDERSEN H            BIOL REPROD                     12   541 975
   149   PEDERSEN H            FERTIL STERIL                   22   156 971
   150   PFALLER W             CELL TISSUE RES                166    91 976
   151   PROCTOR DF            IN: FENN WO                      1   309 964
   152   PROCTOR DF            AM REV RESPIR DIS              115    97 977
   153   RANDALL JT            J PROTOZOOL SUPPL                6    30 959
   154   RANDALL J             IN: BEATTY RA                         13 972
   155   RASH JE               J ULTRASTRUCT RES               29   470 969
   156   REED SE               INFECT IMMUN                     6    68 972
   157   REESE TS              J CELL BIOL                     25   209 965
   158   RHODIN JAG            AM REV RESPIR DIS SUPPL 3       93     1 966
   159   ROGERS L              LARYNGOSCOPE                    72   456 962
   160   ROMRELL LJ            J ULTRASTRUCT RES               38   578 972
   161   ROSS SM               THESIS                                   971
   162   ROSSMAN CM            J PEDIATR                       90   579 977
   163   RUNGGER-BRANDLE E     EXP CELL RES                   107   313 977
   164   RUSSAKOFF AH          N ENGL J MED                   235   253 946
   165   SADE J                ARCH OTOLARYNGOL                86   128 967
   166   SAFIAN LS             J FL MED ASSOC                  45  1143 959
   167   SANCHIS J             N ENGL J MED                   288   651 973
   168   SANDOZ D              J CELL BIOL                     71   449 976
   169   SANTA CRUZ R          AM REV RESPIR DIS              109   458 974
   170   SATIR P               J CELL BIOL                     26   805 965
   171   SCHERFT JP            J ULTRASTRUCT RES               19   546 967
   172   SCHOEMPERLEN CB       AM REV RESPIR DIS               88   698 968
   173   SEINSCH W             ACTA ANAT (BASEL)               95   537 976
   174   SETHI BR              J LARYNGOL OTOL                 89   183 975
   175   SEVTENKO G            FOLIA MORPHOL (PRAGUE)          21   261 973
   176   SHACK W               BULL MATH BIOPHYS               34   342 972
   177   SHENEFELT RE          TERATOLOGY                       5   103 972
   178   SIELICKA-ZUBER L      PRZEGL DERMATOL                 61   171 974
   179   SPOCK A               PEDIATR RES                      1   173 967
   180   STEPHENS RE           BIOL BULL                      139   438 970
   181   STOWATER JL           J AM VET RADIOL SOC             17   174 976
   182   SUMMERS K             BIOCHIM BIOPHYS ACTA           416   153 975
   183   TAIANA JA             J THORAC SURG                   30    34 955
   184   TAMM SL               PROC R SOC LOND BIOL           175   219 970
   185   TENDLER H             Z ERKR ATMUNGSORGANE           137   161 972
   186   THOMSON ML            N ENGL J MED                   289   749 973
   187   TIHEN JA              J HERED                         39    29 948
   188   TOREMALM NG           RHINOLOGY                       13   113 975
   189   TORGERSEN J           ACTA RADIOL                     28    17 947
   190   TORGERSEN J           SCHWEIZ MED WOCHENSCHR          82   770 952
   191   TORIKATA C            VIRCHOWS ARCH PATHOL NAT HIS   371   121 976
   192   VARANO NR             INT COLL SURG                   33   131 960
   193   VICKERS TH            ARCH ENTWICKLUNGSMECH ORGAN    153   255 961
   194   WALKER TR             SCIENCE                        153  1248 966
   195   WARNER FD             J CELL BIOL                     63    35 974
   196   WENT HA               EXP CELL RES                   108    63 977
   197   WENT HA               J THEOR BIOL                    68    95 977
   198   WHEATLEY DN           J ANAT                         101   223 967
   199   WHEATLEY DN           EXPERIENTIA                     24  1157 968
   200   WILHELM DL            J PATHOL BACTERIOL              67   361 954
   201   WILKINSON RF          J ULTRASTRUCT RES               48   242 974
   202   WILSON GB             NATURE                         266   463 977
   203   WILSON JG             AM J ANAT                       85   113 949
   204   WILSON JG             AM J ANAT                       92   153 953
   205   WITMAN GB             COLD SPRING HARBOR SYMP         41   969 977
   206   WOLINSKY JS           LAB INVEST                      37   229 977
   207   WONG YC               LAB INVEST                      24    55 971
   208   WOOD RE               AM REV RESPIR DIS              111   733 975
   209   WOODRUFF KH           AM J PATHOL                     72    91 973
   210   WORTHINGTON RC        SCIENCE                        139   221 963
   211   YEATES DB             ARCH DIS CHILD                  51    28 976
   212   YONEDA K              AM REV RESPIR DIS              114   837 976
CT   1   AFZELIUS B            BR MED J                         2   674 979
     2   AFZELIUS BA           J ULTRASTRUCT RES               69    43 979
     3   BACCETTI B            ANDROLOGIA                      12   525 980
     4   NORWOOD JT            BIOL REPROD                     23   788 980
     5   AFZELIUS BA           THORAX                          35   401 980
     6   ROSSMAN CM            CHEST                           78   580 980
     7   AFZELIUS BA           ACTA MED SCAND                 208   145 980
     8   DIRKSEN ER            CELL MOTIL                       1   247 981
     9   VANDEDONK HJM         PHARM INT                        2   157 981
    10   FRIDAY GA             PEDIATR CLIN NORTH AM           28   807 981
    11   AFZELIUS BA           AM J HUM GENET                  33   852 981
    12   ANTONELLI M           ACTA PAEDIATR SCAND             70   571 981
    13   TEGNER H              ACTA PAEDIATR SCAND             70   629 981
    14   ROSSMAN CM            CHEST                           80   860 981
    15   KAPELLEROVA A         SB LEK                          83   316 981
    16   PABST HF              J PEDIATR                       98   223 981
    17   AFZELIUS BA           AM REV RESPIR DIS              124   107 981
    18   SVEDBERGH B           ALB V GRAEF ARCH KLIN EX OPHT  215   265 981
    19   DALEN H               CELL TISSUE RES                220   685 981
    20   HAKANSSON CH          SCANN ELECTRON MICROSC        1981    93 981
    21   JOHANNESSEN JV        DIAGN HISTOPATHOL                5   113 982
    22   VANDEDONK HJM         INT J PHARMACEUT                12    57 982
    23   AUGUST JR             J AM ANIM HOSP ASSOC            18   822 982
    24   FINKELSTEIN D         BIRTH DEF ORIG ART SER          18   197 982
    25   KONRADOVA V           EUR J RESPIR DIS                63   516 982
    26   DUDLEY JP             LARYNGOSCOPE                    92   297 982
    27   HYBBINETTE JC         ACTA OTOLARYNGOL STOCKH         93   151 982
    28   HYBBINETTE JC         ACTA OTOLARYNGOL STOCKH         94   121 982
    29   DORUP J               ANAT EMBRYOL                   164    19 982
    30   WILSMAN NJ            AM J ANAT                      164   343 982
    31   WEN GY                ANAT EMBRYOL                   165   315 982
    32   JONSSON MS            N ENGL J MED                   307  1131 982
    33   AFZELIUS BA           J SUBMICROSC CYTOL              15   111 983
    34   HARD R                TISSUE CELL                     15   217 983
    35   HARD R                TISSUE CELL                     15   227 983
    36   MELTZER EO            PEDIATR CLIN NORTH AM           30   847 983
    37   NEVILLE E             THORAX                          38   929 983
    38   AFZELIUS BA           EUR J RESPIR DIS                64   280 983
    39   NIELSEN MH            EUR J RESPIR DIS                64    19 983
    40   PEDERSEN M            EUR J RESPIR DIS                64    78 983
    41   ROOMANS GM            EUR J RESPIR DIS                64   416 983
    42   SLEIGH MA             EUR J RESPIR DIS                64   157 983
    43   MURPHY S              PEDIATRICS                      72     1 983
    44   KENNEDY HG            J ROY SOC MED                   76  1065 983
    45   LEWIS FH              CHEST                           83   487 983
    46   MYGIND N              ACTA OTOLARYNGOL STOCKH         95   688 983
    47   RUNGGERBRANDLE E      AM J PATHOL                    110   361 983
    48   EDWARDS DF            J AM VET MED ASSOC             183   667 983
    49   BRYAN JHD             VIRCHOWS ARCH PATHOL ANAT HIS  399   265 983
    50   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983
    51   NEWHOUSE MT           SEM RESPIR MED                   5   341 984
    52   KATZ SM               ULTRASTRUCTURAL PATHOL           6   285 984
    53   LUNGARELLA G          ULTRASTRUCTURAL PATHOL           6     1 984
    54   CANET E               PRESSE MED                      13  1607 984
    55   HOLLEY MC             TISSUE CELL                     16   287 984
    56   ISAWA T               J NUCL MED                      25   447 984
    57   RANDOLPH JF           J SMALL ANIMAL PRACT            25   679 984
    58   BECKER B              RESPIRATION                     46   180 984
    59   WELCH MJ              ANN ALLERGY                     52    32 984
    60   GREENSTONE M          ARCH DIS CHILD                  59   704 984
    61   GREENSTONE MA         ARCH DIS CHILD                  59   481 984
    62   WASSERMAN SJ          J ALLERGY CLIN IMMUNOL          73    17 984
    63   HANDEL MA             J HERED                         75   498 984
    64   LIDOW MS              J ULTRASTRUCT RES               86    18 984
    65   ELOFSSON R            J ULTRASTRUCT RES               87   212 984
    66   ERNSTSON S            ACTA OTOLARYNGOL STOCKH         97    83 984
    67   FISCHER L             SCHWEIZ MED WOCHENSCHR         114   610 984
    68   ROSSMAN CM            AM REV RESPIR DIS              129   161 984
    69   WELCH MJ              WEST J MED                     141   509 984
    70   CORNILLIE FJ          PATHOL RES PRACT               178   595 984
    71   AFZELIUS BA           J AM VET MED ASSOC             184   560 984
    72   HANDELSMAN DJ         N ENGL J MED                   310     3 984
    73   CHARPIN D             REV MALAD RESPIR                 2   151 985
    74   GONZALEZ S            ULTRASTRUCTURAL PATHOL           8   345 985
    75   AFZELIUS BA           CRC CRIT REV BIOCHEM            19    63 985
    76   SATO T                EXP MOL PATH                    43    13 985
    77   AFZELIUS BA           EUR J RESPIR DIS                66   173 985
    78   LUNGARELLA G          EUR J RESPIR DIS                66   165 985
    79   BABIN RW              SOUTH MED J                     78   737 985
    80   GREENSTONE M          BR J DIS CHEST                  79     9 985
    81   GREENSTONE M          J LARYNGOL OTOL                 99   985 985
    82   WU R                  J CELL PHYSIOL                 125   167 985
    83   ODOR DL               AM J ANAT                      174   437 985
    84   GONZALEZ S            PATHOL RES PRACT               180   511 985
    85   CARSON JL             N ENGL J MED                   312   463 985
    86   WANNER A              CLIN CHEST MED                   7   247 986
    87   HOLLEY MC             TISSUE CELL                     18   521 986
    88   AFZELIUS BA           HOSP PRACT                      21    73 986
    89   TEICHTAHL H           MED BIOL ENG COMPUT             24   193 986
    90   WOODS RP              ARCH NEUROL                     43  1083 986
    91   HO KL                 ACTA NEUROPATH (BERL)           70    30 986
    92   RAMET J               CHEST                           90   138 986
    93   EAVEY RD              ARCH OTOLARYNG HEAD NECK SURG  112   646 986
    94   SOIFER D              ANN NY ACAD SCI                466     1 986
    95   KAISER D              ATEMWEGS LUNGENKRANKH           13   101 987
    96   DELAROCHA SR          PEDIATR RADIOL                  17    97 987

PN 79100
RN 01080 
AN 80007295
AU Barry-M-M.
TI Cystic fibrosis.
SO J-Am-Diet-Assoc. 1979 Oct. 75(4). P 446-9.
MJ CYSTIC-FIBROSIS: th.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: co, dh, di.  FEMALE.  GROWTH-DISORDERS: co.  HUMAN.
   INFANT.  INFANT-NEWBORN.  INTESTINAL-OBSTRUCTION: co.  MALE.
   MECONIUM.  PANCREATIC-DISEASES: co.  RESPIRATORY-TRACT-INFECTIONS: co.
   SWEATING.
EX Cystic fibrosis is an hereditary disorder that affects infants,
   children, adolescents, and young adults.  Its genetic influence,
   signs and symptoms, diagnostic tests, nutritional management and diet
   therapy, respiratory infection, and growth retardation are discussed.
RF 001   ROSENLUND ML          PEDIATRICS                      59   428 977
   002   FRANCIS DEM           DIETS FOR SICK CHILDREN                  974
   003   ANON                  GUIDE TO DIAGNOSIS AND MANAGE            971
   004   SHWACHMAN H           PEDIATR CLIN NORTH AM           22   787 975
   005   GAYTON WF             PEDIATRICS                      59   888 977
   006   MEARNS MB             BR J HOSP MED                   12   497 974
   007   MORRIS W              AMERICAN HERITAGE DICTIONARY             973
   008   HODSON ME             BR MED J                         2   790 976
   009   PIKE R                DIGESTION AND ABSORPTION-                975
   010   ROLLER RJ             GASTROENTEROLOGY                72   661 977
   011   BARBERO GJ            IN: MANGOS JA                         83 976
   012   ANON                  CYSTIC FIBROSIS                          975
   013   ANON                  TEACHERS' GUIDE TO CF                       
   014   BRUNS WT              AM J DIS CHILD                 131    71 977
   015   DESAI N               J PEDIATR                       91   447 977
   016   KASTRUP E             GASTROINTESTINAL DRUGS FACTS        308B 979
   017   MITCHELL H            COOPERS NUTRITION IN HEALTH          380 968
   018   GOODHART RS           MODERN NUTRITION IN HEALTH AN        826 974
   019   BERRY HK              AM J DIS CHILD                 129   165 975
   020   HUANG NN              GUIDE TO DRUG THERAPY IN PATI            979
   021   FOMON SJ              IN: FOMON SJ                         472 974
   022   WEIHOFEN DM           J AM DIET ASSOC                 54   206 969
   023   KEATING JP            PEDIATRICS                      46    41 970
   024   FILER LJ JR           PEDIATRICS                      48   483 971
   025   MATTHEWS LW           J PEDIATR                       65   558 964
   026   WILMSHURST EG         PEDIATRICS                      55    75 975
   027   RUDOLPH AM            IN: RUDOLPH AM                      1563 977
   028   ANON                  GENETICS OF CF                              
   029   LIEBERMAN J           ANN INTERN MED                  82   806 975
   030   NEWBURGER EH          CLIN PEDIATR                    12   456 973
   031   WATKINS JB            GASTROENTEROLOGY                73  1023 977
CT   1   BELL L                J CAN DIET ASSOC                42    62 981
     2   HODGES P              J AM DIET ASSOC                 84   664 984

PN 79101
RN 01081 
AN 80006346
AU Thomsen-J.  Friis-B.  Jensen-K.  Bak-Pedersen-K.  Larsen-P-K.
TI Tobramycin ototoxicity.  Repeated courses of high dosage treatment
   in children with cystic fibrosis.
SO J-Antimicrob-Chemother. 1979 May. 5(3). P 257-60.
MJ ANTIBIOTICS: ae.  CYSTIC-FIBROSIS: co.  EAR-DISEASES: ci.
   PSEUDOMONAS-INFECTIONS: dt.  RESPIRATORY-TRACT-INFECTIONS: dt.
   TOBRAMYCIN: ae.
MN CHILD.  DRUG-ADMINISTRATION-SCHEDULE.  FEMALE.  HEARING-DISORDERS: ci.
   HUMAN.  MALE.  PSEUDOMONAS-INFECTIONS: co.
   RESPIRATORY-TRACT-INFECTIONS: co.  TOBRAMYCIN: ad, tu.
AB Fifty-three patients with cystic fibrosis were treated with large
   doses of tobramycin sulphate, 10 mg/kg/24 h.  Patients received an
   average of 3.2 courses, each lasting 10 to 14 days.  The patients
   were examined with audiometric and vestibular tests, and in one
   patient, a 10-year-old girl, we found a transient high tone loss at
   8000 Hz bilaterally that might be attributed to the tobramycin
   treatment.  All patients had normal kidney function.  High dose
   tobramycin treatment in children with normal kidney function gives
   minimal clinical risks of adverse ototoxic effects, even after
   repeated courses of treatment.
RF 001   BODEY GP              ANTIMICROB AGENTS CHEMOTHER      2   109 972
   002   BREZEZINSKA M         BIOCHEMISTRY NY                  2   671 972
   003   BRUMMET RE            ARCH OTOLARYNGOL                94    59 971
   004   BRUMMET RE            ARCH OTOLARYNGOL                96   505 972
   005   BRUMMET RE            ARCH OTOLARYNGOL               101   540 975
   006   DRASAR FA             BR MED J                         2  1284 976
   007   FEDERSPIL P           PROC TOBRAMYCIN SEL 8TH INT C         38 973
   009   HIGGINS CE            ANTIMICROB AGENTS CHEMOTHER      7   332 967
   010   HOFF GE               SCAND J INFECT DIS               6   333 974
   011   LOGAN TB              ARCH OTOLARYNGOL                99   190 974
   012   MCCRAE WM             SCOTT MED J                     21    68 976
   013   NEU HC                J INFECT DIS SUPPL             134   206 976
   014   PRAZMA J              LARYNGOSCOPE                    86   259 976
   015   STUPP HF              ACTA OTOLARYNGOL STOCKH SUPPL  262     1 970
   016   WILSON P              BR MED J                         1   259 977
CT   1   RIFF L                SEM PERINATOL                    6   155 982
     2   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
     3   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
     4   BEREZHINSKAYA VV      ANTIBIOTIKI                     28   218 983
     5   RYBAK LP              AM J OTOL                        6   482 985
     6   FRASER GL             DRUG INTEL CLIN PHARM           19   757 985
     7   HUY PTB               J CLIN INVEST                   77  1492 986
     8   PEDERSEN SS           ANTIMICROB AGENTS CHEMOTHER     31   594 987

PN 79102
RN 01082 
AN 80137261
AU Hughes-D-T.  Pines-A.  Percival-A.  Stille-W.
TI Round table discussion--treatment of lower respiratory tract
   infections with co-trimoxazole.
SO J-Antimicrob-Chemother. 1979 Nov. 5(B). P 207-19.
MJ RESPIRATORY-TRACT-INFECTIONS: dt.  SULFAMETHOXAZOLE: tu.
   TRIMETHOPRIM: tu.
MN BRONCHIECTASIS: dt.  BRONCHITIS: co, pc.  CHRONIC-DISEASE.
   CYSTIC-FIBROSIS: dt.  DRUG-COMBINATIONS.  HUMAN.  LUNG-ABSCESS: dt.
   PNEUMONIA: co.  RESPIRATORY-TRACT-INFECTIONS: co.
AB Over one thousand patients with acute and chronic chest infections
   have been treated with a combination of trimethoprim and
   sulphamethoxazole.  The patients may be divided into four groups and
   the results are summarised in this presentation.  Much of the work
   is published elsewhere.
RF 001   HUGHES DTD            BR MED J                         4   470 969
   002   HUGHES DTD            ADV IN ANTIMICROBIAL ANTINEO     1  1105 972
   003   HUGHES DTD            J ANTIMICROB CHEMOTHER           2   320 976
   004   HUGHES DTD            J ANTIMICROB CHEMOTHER           1    55 975
   005   PERCIVAL A            IN: BAKER FJ                         154 972
   006   BUSHBY SRM            BR MED J                         3    50 973
   007   HOWARD AJ             BR MED J                         1  1657 978
   008   LAMBERT HP            SCAND J INFECT DIS SUPPL        14   262 978
   009   MAY JR                BR MED J                         3   376 972
   010   PERCIVAL A            IN: BAKER FJ                         154 972
   011   WONG GA               AM J MED                        59   219 975
   012   BAGG R                J ANTIMICROB CHEMOTHER           4   297 978
   013   PHILLIPS I            IN: PHILLIPS I                        37 974
   014   THORNSBERRY C         CURRENT MICROBIOL                1    51 978

PN 79103
RN 01083 
AN 79151301
AU Frydman-M-I.
TI Epidemiology of cystic fibrosis: a review.
SO J-Chronic-Dis. 1979. 32(3). P 211-9. (REVIEW).
MJ CYSTIC-FIBROSIS: oc.
MN ADULT.  AUSTRALIA.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: fg, pp.
   EUROPE.  FEMALE.  FERTILITY.  HUMAN.  MALE.  REVIEW.  UNITED-STATES.
AB Three main reasons have been advanced for the degree of ignorance
   and confusion surrounding epidemiologic measures of the incidence
   and prevalence of Cystic Fibrosis. (CF)  Relatively recent
   recognition of CF as a specific disease entity.  Wide range of
   clinical manifestations, presentation as a multisystem disease, and
   great natural variation in the severity of involvement of various
   organs.  Past difficulty in establishing a diagnosis based on sound
   laboratory evidence, this being largely due to the lack of a
   screening test that had gained wide acceptance among diagnosticians,
   and inaccuracies in the performance and interpretation of the sweat
   test.  In addition to these factors, there are a number of
   methodological deficiencies and questionable assumptions in several
   of the papers that have here been reviewed.  It may be noteworthy
   that the two sets of authors whose research design most closely
   matched being aimed at providing multiple ascertainment of cases and
   cross-checks of validity, have arrived at nearly the same estimated
   incidence of this particular disorder (1/3700 and 1/3800
   respectively).  The issue of selection and diagnostic criteria is
   one that has important implications for epidemiologic studies of
   cystic fibrosis.  Particularly in a disease like CF, where the
   spectrum of clinical manifestations and severity of involvement is
   so broad, estimates of incidence will vary according to the criteria
   by which cases are ascertained and included.  A greater degree of
   uniformity in standards than has been employed in previous studies
   is necessary before comparisons can meaningfully be made.  There are
   good grounds for regarding most estimates of CF incidence to be
   minimum confirmed figures, and this is particularly so where the
   research design ensures that multiple ascertainments of the same
   case will be identifiable.  Higher estimates are made where several
   sources of error (respondent bias, generalization of hospital data
   to the wider population, multiple ascertainments of the same
   patient) are not recognised.
RF 001   ANON                  CF GUIDELINES FOR HEALTH PERS            976
   002   DI SANTAGNESE PA      IN: DOWNEY JA                         25 974
   003   FANCONI G             WIEN MED WOCHENSCHR             86   753 936
   004   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   005   BLACKFAN KD           J PEDIATR                       13   627 938
   006   ANDERSEN DH           CHILDREN                         7    11 960
   007   WARWICK WJ            MINN MED                        52  1567 969
   008   SHWACHMAN H           PEDIATRICS                      36   689 965
   009   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   010   LIFSCHITZ M           ARCH FOUND THANATOLOGY           1    23 969
   011   POGUE RE              MINN MED                        52  1551 969
   012   BURTON L              HEALTH VISITOR                 456   186 973
   013   LAWLER RH             CAN MED ASSOC J                 94  1043 966
   014   SHWACHMAN H           IN: GELLIS SS                        237 970
   015   SHWACHMAN H           AM J DIS CHILD                  92   347 956
   016   LAPEY A               IN: GELLIS SS                        221 976
   017   MAY CD                J PEDIATR                       34   663 949
   018   MATTHEWS LW           MINN MED                        52  1506 969
   019   CHILDRESS J           IN: PATTERSON PR                         973
   020   ANON                  GAP CONF REP CHRON BRONC CF            1 977
   021   TAUSSIG LM            J PEDIATR                       82   380 973
   022   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   023   ANDERSEN DH           J CHRON DIS                      7    58 958
   024   DI SANTAGNESE PA      JAMA                           172  2065 960
   025   MCPARTLIN JF          ARCH DIS CHILD                  47   207 972
   026   HIATT RB              SURG GYNECOL OBSTET             87   317 948
   027   KULCZYCKI LL          N ENGL J MED                   257   203 957
   028   DI SANTAGNESE PA      AM J MED                        21   406 956
   029   DI SANTAGNESE PA      PEDIATRICS                      24   313 959
   030   ROSENLUND ML          ANN INTERN MED                  78   959 973
   031   LANDAU LI             AM REV RESPIR DIS              108   593 973
   032   STERN RC              J PEDIATR                       89   406 976
   033   TECKLIN JS            PHYS THER                       55  1081 975
   034   HOLSCLAW DS           GAP CONF REP CHRON BRONC CF           13 977
   035   DENNING CR            PEDIATRICS                      41     7 968
   036   KAPLAN E              N ENGL J MED                   279    65 968
   037   HOLSCLAW DS           J UROL                         106   568 971
   038   ANON                  GAP CONF REP PROB REPRO PHYSI          9 975
   039   DI SANTAGNESE PA      N ENGL J MED                   279   103 968
   040   KOCH E                INTERNIST (BERL)                 1    35 960
   041   FEIGELSON J           ARCH FR PEDIATR                 26   937 969
   042   TAUSSIG LM            N ENGL J MED                   287   586 972
   043   MEYEROWITZ JH         IN: PATTERSON PR                      40 973
   044   HOLSCLAW DS           GAP CONF REP PROB REPRO PHYSI          1 975
   045   DENNING CR            GAP CONF REP PROB REPRO PHYSI          2 975
   046   GRAND RJ              JAMA                           195   993 966
   047   NOVY MJ               OBSTET GYNECOL                  30   530 967
   048   SIEGEL B              OBSTET GYNECOL                  16   438 960
   049   POLGAR G              AM REV RESPIR DIS               85   319 962
   050   BALL RE               N ENGL J MED                   265    31 961
   051   ROSENOW EC 3RD        JAMA                           203   227 968
   052   SALHANICK H           GAP CONF REP PROB REPRO PHYSI          4 975
   053   VANDE WIELE R         GAP CONF REP PROB REPRO PHYSI          5 975
   054   LOWE CU               AM J DIS CHILD                  78   349 949
   055   DANKS DM              ANN HUM GENET                   28   323 965
   056   GOODMAN HO            AM J HUM GENET                   4    59 952
   057   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   058   STEINBERG AG          AM J HUM GENET                  12   416 960
   059   SELANDER P            ACTA PAEDIATR SCAND             51    65 962
   060   BAUMANN T             HELV PAEDIATR ACTA SUPPL 8      13     1 958
   061   ROBERTS GBS           ANN HUM GENET                   24   127 960
   062   FANCONI G             SCHWEIZ MED WOCHENSCHR          74    85 944
   063   BRODY H               NY STATE J MED                  41  1256 941
   065   KULCZYCKI LL          CLIN PEDIATR                     3   692 964
   066   KULCZYCKI LL          IN: PATTERSON PR                     117 973
   067   WANG CI               N ENGL J MED                   279  1216 968
   068   HARRIS RL             PEDIATRICS                      41   733 968
   069   HAMAMOTO E            NIPON SHONIKAGAKKAI ZASSHI      65   502 961
   070   YAMAMOTO T            SHONIKA RINSHO                  10  1003 957
   071   LEVIN S               IN: GOLDSCHMIDT E                    294 963
   072   KANDAR HR             ANTISEPTIC                      58   863 961
   073   SALAM M               LEB MED J                       15    61 962
   074   WRIGHT SW             AM J HUM GENET                  20   157 968
   075   MACMAHON B            EPIDEMIOLOGY PRINCIPLES AND M            970
   076   ANDERSEN DH           AM J DIS CHILD                  72    62 946
   077   HARPER MH             MED J AUST                       1   137 949
   078   SUDNOW D              PASSING ON THE SOCIAL ORGANIS         76 967
   079   EVANS AE              N ENGL J MED                   278   138 968
   080   MERRITT AD            J LAB CLIN MED                  60   998 962
   081   KRAMM ER              AM J PUBLIC HEALTH              52  2041 962
   082   KRAMM ER              PEDIATRICS                      28   128 961
   083   GREGG RH              PEDIATRICS                      36   700 965
   084   GIBSON LE             CLIN PEDIATR                    12   450 973
CT   1   SING CF               AM J MED GENET                  13   179 982
     2   LONGNECKER DS         AM J PATHOL                    107   103 982
     3   KUMMER F              ATEMWEGS LUNGENKRANKH           10   567 984
     4   GORTMAKER SL          PEDIATR CLIN NORTH AM           31     3 984

PN 79104
RN 01084 
AN 79151302
AU Kerner-J.  Harvey-B.  Lewiston-N.
TI The impact of grief: a retrospective study of family function
   following loss of a child with cystic fibrosis.
SO J-Chronic-Dis. 1979. 32(3). P 221-5.
MJ CYSTIC-FIBROSIS: px.  DEATH.  FAMILY.  GRIEF.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  FEMALE.
   GENETIC-COUNSELING.  HUMAN.  INFANT.  LIFE-CHANGE-EVENTS.  MALE.
   PARENTS.  RELIGION.  RETROSPECTIVE-STUDIES.
AB The impact of the death of a cystic fibrosis child on subsequent
   family function was evaluated in a retrospective study of 16
   families.  In findings similar to that reported for another model of
   fatal childhood illness, leukemia, there was a high incidence of
   emotional and medical problems in the parents.  There was an
   unexpectedly high incidence (7/16) of incomplete mourning, i.e.,
   maintenance of the child's room as a shrine or weekly grave visit
   for more than six months.  Siblings had less difficulty in adjusting
   to the loss than that reported for the siblings of leukemic
   children.  It is suggested that the prolonged course of a disease
   with a hopeless prognosis prepares the family for the child's death
   but also retards the mourning process.  The family may need
   counseling to ensure that mourning is completed.
RF 001   GOLDBERG IK           IN: PATTERSON PR                     168 973
   002   TURK J                PEDIATRICS                      34    67 964
   003   LAWLER RH             CAN MED ASSOC J                 94  1043 966
   004   MCCOLLUM AT           J PEDIATR                       77   571 970
   005   TROPAUER A            AM J DIS CHILD                 119   424 970
   006   GAYTON WF             AM J DIS CHILD                 126   856 973
   007   FARKAS A              IN: PATTERSON PR                     202 973
   008   BINGER CM             N ENGL J MED                   280   414 969
   009   MEYEROWITZ JH         SOC SCI MED                      1   249 967
   010   HILGARD JR            INTERN PSYCHIATRY CLIN           6   197 969
   011   KOLB LC               MODERN CLINICAL PSYCHIATRY            56 973
   012   FISCHHOFF J           J PEDIATR                       88   140 976
   013   MCCRAE WM             LANCET                           2   141 973
CT   1   SPINETTA JJ           CANCER                          53  2330 984
     2   DEWET B               S AFR MED J                     65   526 984
     3   LEWISTON NJ           SEM RESPIR MED                   6   321 985
     4   MILES MS              NURS RES                        34    76 985
     5   WILSON AL             AM J DIS CHILD                 139  1235 985

PN 79105
RN 01085 
AN 79194554
AU Spicer-K-M.  Allen-R-C.  Hallett-D.  Buse-M-G.
TI Synthesis of hemoglobin Aic and related minor hemoglobin by
   erythrocytes.  In vitro study of regulation.
SO J-Clin-Invest. 1979 Jul. 64(1). P 40-8.
MJ ERYTHROCYTES: me.  HEMOGLOBIN-A: bi.  HEMOGLOBINS: me.
MN ADULT.  CHILD.  CYSTIC-FIBROSIS: bl.  DIABETES-MELLITUS: bl.
   FETAL-HEMOGLOBIN: me.  GLUCOSE: pd.  HEMODIALYSIS.  HEMOGLOBIN-C: me.
   HEMOGLOBIN-SICKLE: me.  HEXOSES: bl.  HUMAN.
   HYDROGEN-ION-CONCENTRATION.  IN-VITRO.  INSULIN: pd.  MALE.
   PHOSPHORYLATION.  TEMPERATURE.  TIME-FACTORS.
   SUPPORT-U-S-GOVT-P-H-S.
AB Factors that influence hemoglobin (Hb)Aic synthesis by intact
   erythrocytes were studied in vitro.  After incubation cells were
   lysed, and hemoglobins were separated by isoelectric focusing on
   polyacrylamide slab gels and quantitated by microdensitometry.
   HbAic increased with time, glucose concentrations (5-500 mM) and
   incubation temperature (4 degrees-37 degrees C).  Low temperatures
   allowed prolonged incubations with minimal hemolysis.  At 4 degrees
   C HbAic increased linearly with time for 6 wk; after incubation at
   the highest glucose concentration, HbAic comprised 50% of total
   hemoglobin.  Insulin (1 and 0.1 mU/ml) did not affect HbAic
   synthesis in vitro.  In addition to glucose, galactose and mannose,
   but not fructose, served as precursors to HbAic.  A good substrate
   for hexokinase (2-deoxy-glucose) and a poor hexokinase substrate
   (3-O-methyl-glucose), were better precursors for HbAic synthesis
   than glucose, suggesting that enzymatic phosphorylation of glucose
   is not required for HbAic synthesis.  Autoradiography after
   erythrocyte incubation with 32P-phosphate showed incorporation of
   radioactivity into HbAia1 and HbAia2, but not HbAib, Aic, or A.
   Acetylated HbA, generated during incubation with acetylsalicylate,
   migrated anodal to HbAic and clearly separated from it.
   Erythrocytes from patients with insulinopenic diabetes mellitus
   synthesized HbAic at the same rate as controls when incubated with
   identical glucose concentrations.  Likewise, the rate of HbAic
   synthesis by erythrocytes from patients with cystic fibrosis and
   congenital spherocytosis paralleled controls.  When erythrocytes
   from cord blood and from HbC and sickle cell anemia patients were
   incubated with elevated concentrations of glucose, fetal Hb, HbC,
   and sickle Hb decreased whereas hemoglobins focusing at isoelectric
   points near those expected for the corresponding glycosylated
   derivatives appeared in proportionately increased amounts.
RF 001   BUNN HF               J CLIN INVEST                   57  1652 976
   002   KOENIG RJ             DIABETES                        25   230 976
   003   KOENIG RJ             N ENGL J MED                   295   417 976
   004   GABBAY KH             J CLIN ENDOCRINOL METAB         44   859 977
   005   GONEN BA              LANCET                           1   734 977
   006   STEVENS VJ            J BIOL CHEM                    252  2998 977
   007   HANEY DN              PROC NAT ACAD SCI USA           73  3534 976
   008   BUNN HF               SCIENCE                        200    21 978
   009   DIXON HBF             BIOCHEM J                      129   203 972
   010   BUNN HF               BIOCHEM BIOPHYS RES COMMUN      67   103 975
   011   KOENIG RJ             J BIOL CHEM                    252  2992 977
   012   SPICER KM             DIABETES                        27   384 978
   013   BEUTLER E             IN: GREENWALT TJ                     189 974
   014   BEUTLER E             J LAB CLIN MED                  80   723 972
   015   BRIDGES KR            J CLIN INVEST                   56   201 975
   016   TRIVELLI LA           N ENGL J MED                   284   353 971
   017   SCHNEK AG             J AM CHEM SOC                   83  1472 961
   018   DRABKIN DL            J BIOL CHEM                    164   703 946
   019   STEVENS VJ            PROC NAT ACAD SCI USA           75  2918 978
   020   PAULSEN EP            DIABETES                        25   890 976
   021   MORGAN HE             CURR TOP MEMBRANES TRANSP        4   255 973
   022   MCDONALD MJ           J BIOL CHEM                    253  2327 978
   023   BUNN HF               HUMAN HEMOGLOBIN                       8 977
   024   BASSETT PY            BLOOD                           51   971 978
   025   ROSE IA               J BIOL CHEM                    239    12 964
   026   BEUTLER E             RED CELL METABOLISM                  123 975
   027   KRISHNAMOORTHY R      FEBS LETTERS                    77    99 977
   028   DOLHOFER R            FEBS LETTERS                    85    86 978
   029   LEFEVRE PG            PHARMACOL REV                   13    39 961
   030   CANTOR SM             J AM CHEM SOC                   62  2113 940
   031   LOS JM                J AM CHEM SOC                   78  1564 956
   032   FLUCKIGER R           FEBS LETTERS                    71   356 976
   033   ZIPPER H              BIOCHIM BIOPHYS ACTA           282   311 972
   034   GAMBHIR KK            DIABETES                        27   701 978
   035   GRAF R                DIABETES SUPPL                  26   368 977
   036   ABDELLA PM            BIOCHIM BIOPHYS ACTA           490   462 977
   037   BUNN HF               J CLIN INVEST                   49  1088 970
CT   1   FITZGERALD MD         AM J HEMATOL                     9   311 980
     2   SVENDSEN PA           DIABETOLOGIA                    19   130 980
     3   BERNSTEIN RE          CLIN CHEM                       26   174 980
     4   MENARD L              CLIN CHEM                       26  1598 980
     5   ROMEN W               KLIN WSCHR                      58  1013 980
     6   BERGER W              SCHWEIZ MED WOCHENSCHR         110   485 980
     7   BARTOSZ G             MECH AGEING DEV                 17   237 981
     8   MONNIER LH            DIABETOLOGIA                    20    12 981
     9   BOUCHER BJ            DIABETOLOGIA                    21    34 981
    10   DEAN PDG              DIABETOLOGIA                    21   579 981
    11   MORTENSEN HB          SCAND J CLIN LAB INVEST         41   451 981
    12   FADEL HE              AM J OBSTET GYNECOL            139   397 981
    13   FADEL HE              AM J OBSTET GYNECOL            141   704 981
    14   GOEBEL FD             RES EXP MED                    179   133 981
    15   PEREJDA AJ            COLLAGEN RELAT RES               2    83 982
    16   ESCHWEGE E            DIABETE METAB                    8   137 982
    17   LEUTENEGGER M         DIABETE METAB                    8   249 982
    18   UITTO J               CONNECT TISS RES                10   287 982
    19   POWELL HC             CLIN BIOCHEM                    15   133 982
    20   PEER G                ISR J MED SCI                   18   960 982
    21   BARTOSZ G             MECH AGEING DEV                 20   223 982
    22   VIALETTES B           DIABETOLOGIA                    22   264 982
    23   HOWARD CF             DIABETES                        31  1105 982
    24   ARNQVIST H            SCAND J CLIN LAB INVEST         42   265 982
    25   PANZER S              BLOOD                           59  1348 982
    26   BACHEM MG             KLIN WSCHR                      60   497 982
    27   SMITH RJ              J CLIN INVEST                   69  1164 982
    28   BASSET P              J CHROMATOGR                   227   267 982
    29   MORTENSEN HB          BIOCHIM BIOPHYS ACTA           707   154 982
    30   MEHL TD               DIABETES CARE                    6    34 983
    31   ZELLER WP             PEDIATR RES                     17   200 983
    32   COHEN MP              EXP GERONTOL                    18   461 983
    33   WETTRE S              DIABETOLOGIA                    24   148 983
    34   CZECH A               J CHRON DIS                     36   803 983
    35   SANDHU RS             CLIN BIOCHEM CONTEM THEO TECH    3   215 984
    36   MIEDEMA K             ANN CLIN BIOCHEM                21     2 984
    37   OLESEN HA             SCAND J CLIN LAB INVEST         44   329 984
    38   DAVIDOFF P            REV MED CHIL                   112     3 984
    39   COSSU G               J CHROMATOGR                   307   103 984
    40   KUMAR A               BIOCHEM MED                     34   112 985
    41   ABRAHAM EC            HEMOGLOBIN                      10   173 986

PN 79106
RN 01086 
AN 79151454
AU Seale-T-W.  Thirkill-H.  Tarpay-M.  Flux-M.  Rennert-O-M.
TI Serotypes and antibiotic susceptibilities of Pseudomonas aeruginosa
   isolates from single sputa of cystic fibrosis patients.
SO J-Clin-Microbiol. 1979 Jan. 9(1). P 72-8.
MJ CYSTIC-FIBROSIS: mi.  PSEUDOMONAS-AERUGINOSA: cl.  SPUTUM: mi.
MN ADOLESCENCE.  ADULT.  ANTIBIOTICS: pd.  CHILD.  CHILD-PRESCHOOL.
   DRUG-RESISTANCE-MICROBIAL.  HAEMOPHILUS-INFLUENZAE: ip.  HUMAN.
   PSEUDOMONAS-AERUGINOSA: de.  SEROTYPING.  STAPHYLOCOCCUS-AUREUS: ip.
   SUPPORT-U-S-GOVT-P-H-S.
AB A phenotypic characterization of Pseudomonas aeruginosa from single
   sputum samples of 21 typical cystic fibrosis patients indicated a
   high frequency of heterogeneity among isolates on the basis of
   differences in antibiotic resistance, colony morphology,
   pigmentation, and serotype.  Two or more isolates with different but
   stable susceptibilities to carnecillin, gentamycin, streptomycin,
   tetracycline, chloramphenicol, and sulfamethoxazole plus
   trimethoprim were detected in 38% of the sputa.  Differences
   generally were independent of the mucoid state of the strain.  O-
   antigen group determination with the Difco typing set showed that
   two or more serologically distinct strains were present in 10/21
   sputum specimens.  Nonmucoid derivatives of mucoid isolates almost
   always retained both the antibiotic susceptibilities and serotype of
   their parent strain.  These data suggest that cystic fibrosis
   patients may be cocolonized/coinfected by difference strains of P.
   aeruginosa more frequently than generally believed.  Alternatively,
   phenotypically distinct strains from a single patient might arise as
   phenotypic dissociants from a single infecting strain.  Because of
   the frequency and multiplicity of phenotypically distinct P.
   aeruginosa isolates which we obtained from our cystic fibrosis
   patients, it is important to select multiple isolates from sputum
   cultures for antimicrobial susceptibility testing so as to assess
   adequately the susceptibility of this organism to antibiotic therapy
   in cystic fibrosis.  We recommend that several colonies of each
   distinguishable colony type of P. aeruginosa be pooled for the
   antibiogram.
RF 001   BAUER AW              AM J CLIN PATHOL                45   493 966
   002   BERGAN T              ACTA PATH MICROBIOL SCAND (B)   83   553 975
   003   BOWMAN BH             IN: MANGOS JA                        277 976
   004   BOXERBAUM B           AM REV RESPIR DIS              108   777 973
   005   DIAZ F                J INFECT DIS                   121   269 970
   006   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   007   DOGGETT RG            J PEDIATR                       68   215 966
   008   GRIEBLE HG            N ENGL J MED                   282   531 970
   009   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     1 977
   010   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   011   LEVISON H             IN: MANGOS JA                          3 976
   012   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
   013   SCHWARZMANN S         INFECT IMMUN                     3   762 971
   014   TALAMO RC             IN: MANGOS JA                        195 976
   015   WILLIAMS RJ           J MED MICROBIOL                  6   409 973
   016   ZIERDT CH             J BACTERIOL                     87  1003 964
   017   ZIERDT CH             J CLIN MICROBIOL                 1   521 975
CT   1   DEMKO CA              CURRENT MICROBIOL                4    69 980
     2   MARKOWITZ SM          J ANTIMICROB CHEMOTHER           6   251 980
     3   GODFREY AJ            ANTIMICROB AGENTS CHEMOTHER     19   705 981
     4   IRVIN RT              ANTIMICROB AGENTS CHEMOTHER     19  1056 981
     5   WILSON LA             AM J OPHTHALMOL                 92   546 981
     6   MARKS MI              J PEDIATR                       98   173 981
     7   SEALE TW              ANN CLIN LAB SCI                12   415 982
     8   JANDA JM              J CLIN MICROBIOL                15   178 982
     9   SHEEHAN DJ            J CLIN MICROBIOL                15   926 982
    10   PUGASHETTI BK         J CLIN MICROBIOL                16   686 982
    11   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    12   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
    13   ANON                  LANCET                           2   257 983
    14   GOVAN JRW             REV INFECT DIS                   5  S874 983
    15   JAGGER KN             J CLIN MICROBIOL                17    55 983
    16   FLOURNOY DJ           METH FIND EXP CLIN PHARMACOL     6   487 984
    17   CHAN R                J CLIN MICROBIOL                19     8 984
    18   MCNEILL WF            AM J CLIN PATHOL                81   742 984
    19   GOLD R                PEDIATR INFECT DIS               4   172 985
    20   LUZAR MA              INFECT IMMUN                    50   577 985
    21   KOMIYAMA K            ORAL SURG                       59   590 985
    22   BERKIN KE             EUR J RESPIR DIS                67   103 985
    23   PIER GB               J INFECT DIS                   151   575 985
    24   PACIFICO L            J INFECT DIS                   152   852 985
    25   MAYO MS               J CLIN MICROBIOL                24   372 986
    26   PIER GB               J CLIN MICROBIOL                24   189 986
    27   KOMIYAMA K            CAN J MICROBIOL                 33   221 987
    28   OGLE JW               J INFECT DIS                   155   119 987

PN 79107
RN 01087 
AN 79174043
AU Lloyd-J-K.
TI Dietary problems associated with the care of chronically sick
   children.
SO J-Hum-Nutr. 1979 Apr. 33(2). P 135-9.
MJ CHRONIC-DISEASE: dh.  DIET.
MN CELIAC-DISEASE: dh.  CHILD.  CYSTIC-FIBROSIS: dh.
   DIABETES-MELLITUS-INSULIN-DEPENDENT: dh.  DIABETIC-DIET.
   HEART-DEFECTS-CONGENITAL: dh.  HUMAN.  KIDNEY-FAILURE-CHRONIC: dh.
   MENINGOMYELOCELE: dh.  MENTAL-RETARDATION: dh.  PHENYLKETONURIA: dh.
AB The dietary problems associated with the care of chronically sick
   children can be considered under two broad headings.  First, there
   are the problems in those children for whom diet is an essential
   part of the treatment of their chronic disorder; and second there
   are nutritional complications which may occur in children with
   chronic diseases in which diet does not have a specific role in
   treatment, and is thus often neglected or considered only at a later
   stage of management.  Many of the problems are of course common to
   both situations.  This paper will review briefly some of the
   difficulties, illustrating these with specific examples; no attempt
   will be made to describe or discuss the treatment of any particular
   disorder.
RF 001   ALLAN JD              AM J DIS CHILD                 126    22 973
   002   BIRBECK JA            ARCH DIS CHILD                  51   467 976
   003   COURT JM              J HUM NUTR                      32   285 978
   004   HAYES-ALLEN MC        BR J PREV SOC MED               27   192 973
   005   LINDE LM              J PEDIATR                       70   413 967
   006   PACKER SM             ARCH DIS CHILD                  53   449 978
   007   RICKARD K             PEDIATR CLIN NORTH AM           24   157 977
   008   ROBINSON MJ           ARCH DIS CHILD                  50   962 975
   009   SMITH I               IN: MCLAREN DS                       263 976
   010   SMITH I               BR MED J                         2   723 978
CT   1   FISCHER M             J MENT DEFIC RES                29   373 985

PN 79108
RN 01088 
AN 79174045
AU Francis-D-E.
TI Inborn errors of metabolism: the need for sugar.
SO J-Hum-Nutr. 1979 Apr. 33(2). P 146-54.
MJ DIETARY-CARBOHYDRATES.  METABOLISM-INBORN-ERRORS: dh.
MN ADOLESCENCE.  AMINO-ACID-METABOLISM-INBORN-ERRORS: dh.
   CARBOHYDRATE-METABOLISM-INBORN-ERRORS: dh.  CHILD.
   CYSTIC-FIBROSIS: dh.  DENTAL-CARIES: et.  DIETARY-FATS.  HUMAN.
   LIPID-METABOLISM-INBORN-ERRORS: dh.  MAPLE-SYRUP-URINE-DISEASE: dh.
   METABOLISM-INBORN-ERRORS: co.  PHENYLKETONURIA: dh.
EX Inborn errors of metabolism are conditions in which the body fails to
   metabolise certain chemicals due to an inherited enzyme deficiency.
   The inborn errors of metabolism considered in this paper are those
   which affect the metabolism of dietary nutrients and which require
   manipulation of the carbohydrate intake.  In these cases the need for
   sugar - either as a source of energy when other energy-supplying
   nutrients have to be suppressed, or for the control of hypoglycaemia
   - is vitally important.  Inborn errors of protein metabolism include
   phenylketonuria, maple-syrup urine disease, organic acidaemias, and
   hyperammonaemia.  Inborn errors of fat metabolism  include
   abetalipoprotinaemia, type I lipoprotein-lipase deficiency, and
   lymphangiectasia.  Inborn errors of carbohydrate metabolism include
   diabetes, galactosaemia, fructosaemia, and glucose-6-phosphate
   deficiency (type I glycogen storage disease).  Inborn errors of
   multiple nutrients include cystic fibrosis.  Dietary carbohydrate,
   psychological considerations, and dental caries are examined.
RF 001   ANDERSON CM           CF A MANUAL OF DIAGNOSIS AND             976
   002   CLAYTON BE            IN: DICKERSON JWT                     29 978
   003   COURT JM              YOUR CHILD HAS DIABETES                  972
   004   CORNBLATH M           DISORDERS CARBOHYD METAB INFA        115 966
   005   CRAIG O               CHILDHOOD DIABETES AND ITS MA            977
   006   CRIGLER JF            CIBA FOUND SYMP 55                   331 978
   007   FRANCIS DEM           DIETS FOR SICK CHILDREN                  974
   008   GREENE HL             N ENGL J MED                   294  1125 976
   009   HENNON DK             JADA                            95   965 977
   010   LEVINE RS             BR DENT J                      137   429 974
   011   LLOYD JK              IN: MCLAREN DS                       254 976
   012   LLOYD JK              IN: PEETERS H                        331 972
   013   PARTIN JC             PEDIATR RES                      8   384 974
   014   SMALLEY CA            ARCH DIS CHILD                  53   477 978
   015   SMITH I               BR MED J                         2   723 978
   016   SMITH I               IN: MCLAREN DS                       263 976
   017   STEPHEN KW            BR DENT J                      144   202 978
   018   WINTER GB             CARIES RES                       8   256 974
   019   YASSA JG              ARCH DIS CHILD                  53   777 978

PN 79109
RN 01089 
AN 80095419
AU Vymola-F.  Trojanova-M.  Pillich-J.  Lochmann-O.
TI Therapeutic possibilities in Pseudomonas infections.
SO J-Hyg-Epidemiol-Microbiol-Immunol (Praha). 1979. 23(1). P 114-7.
MJ PSEUDOMONAS-INFECTIONS: th.
MN ACUTE-DISEASE.  ANTIBIOTICS: tu.  BACTERIOPHAGES.
   CYSTIC-FIBROSIS: th.  GAMMA-GLOBULINS: ad, tu.  HUMAN.
   IMMUNIZATION-PASSIVE.  PSEUDOMONAS-INFECTIONS: dt.  TOXOIDS: ad, tu.
   IMMUNOTHERAPY.
AB Acute pseudomonas infections require treatment with antibiotics
   producing a bactericidal effect. The most useful are gentamicin,
   tobramycin, sisomicin and polymyxin B. In resistant strains, amikacin
   is indicated in addition. Carbenicillin, ticarcillin, carfenicillin
   or azocillin should never be given alone but in combination with some
   of the above preparations. Other drugs, such as chloramphenicol,
   tetracycline or streptomycin, though effective in vitro, should be
   avoided. Chemotherapy may be complemented by passive immunization
   either with hyperimmune specific gama globulin or hyperimmune plasma.
   A programmatic item of combined treatment is active immunization,
   especially with toxoid vaccine. Chronic processes are not, perhaps
   with the exception of urinary infections, suitable for antibiotic
   therapy. For this reason effective polyvalent vaccines should be
   developed from appropriate strains. It is now certain that in
   infections caused by mucous strains (most frequently encountered in
   cystic fibrosis) the vaccine should be prepared from these strains,
   since they have distinct functional and antigenic characteristics.

PN 79110
RN 01090 
AN 80161290
AU Thomassen-M-J.  Demko-C-A.  Boxerbaum-B.  Stern-R-C.  Kuchenbrod-P-J.
TI Multiple of isolates of Pseudomonas aeruginosa with differing
   antimicrobial susceptibility patterns from patients with cystic
   fibrosis.
SO J-Infect-Dis. 1979 Dec. 140(6). P 873-80.
MJ CYSTIC-FIBROSIS: dt.  PSEUDOMONAS-AERUGINOSA: ip.
MN ADOLESCENCE.  ADULT.  CARBENICILLIN: tu.  CHILD.  CHILD-PRESCHOOL.
   GENTAMICINS: tu.  HUMAN.  INFANT.  KANAMYCIN: tu.
   MICROBIAL-SENSITIVITY-TESTS.  TETRACYCLINE: tu.  TICARCILLIN: tu.
   TIME-FACTORS.  TOBRAMYCIN: tu.  SUPPORT-U-S-GOVT-P-H-S.
AB Clinical isolates of Pseudomonas aeruginosa from patients with cystic
   fibrosis were studied in an effort to determine the unique
   characteristics of the infecting strains and to elucidate the pattern
   of colonization. Of 413 patients studied, 81% were chronically
   infected with P. aeruginosa. Patients from whom P. aeruginosa was
   never or only occasionally isolated were in better clinical condition
   than the chronically infected patients. Isolates were classified into
   six morphologic varieties: classic, rough, mucoid, gelatinous, dwarf,
   and enterobacter. Most patients had two or more of these varieties.
   Such multiple varieties from the same individual were of the same
   serotype but often differed in antibiotic susceptibility as
   determined by both the disk and the minimal inhibitory concentration
   methods. These differences were apparent when mucoid strains were
   compared with nonmucoid strains and when nonmucoid strains were
   compared with one another. Studies of antibiotic susceptibility
   should be performed on each morphologically different type of P.
   aeruginosa obtained from patients with cystic fibrosis.
RF 001   DOERSHUK CF           IN: GREEN M                          707 968
   002   DOGGETT RG            APPL MICROBIOL                  18   936 969
   003   MARTIN DR             J MED MICROBIOL                  6   111 973
   004   ZIERDT CH             J BACTERIOL                     87  1003 964
   005   GOVAN JRW             J MED MICROBIOL                  8   513 975
   006   DIAZ F                J INFECT DIS                   121   269 970
   007   WILLIAMS RJ           J MED MICROBIOL                  6   409 973
   008   BERGAN T              ACTA PATH MICROBIOL SCAND (B)   83   553 975
   009   DOERSHUK CF           PEDIATRICS                      36   675 965
   010   SHWACHMAN H           PEDIATRICS                      36   689 965
   011   WAHBA AH              J GEN MICROBIOL                 38   329 965
   012   BAUER AW              AM J CLIN PATHOL                45   493 966
   013   BAILEY WR             DIAGNOSTIC MICROBIOLOGY              313 974
   014   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     1 977
   015   REYNOLDS HY           ANN INTERN MED                  82   819 975
   016   GOVAN JRW             J ANTIMICROB CHEMOTHER           4   233 978
   017   ZIERDT CH             J CLIN MICROBIOL                 1   521 975
CT   1   DEMKO CA              CURRENT MICROBIOL                4    69 980
     2   JANDA JM              J CLIN MICROBIOL                12   626 980
     3   IRVIN RT              ANTIMICROB AGENTS CHEMOTHER     19  1056 981
     4   BLACKWOOD LL          INFECT IMMUN                    32   443 981
     5   THOMASSEN MJ          INFECT IMMUN                    33   512 981
     6   PENNINGTON JE         J CLIN INVEST                   68  1140 981
     7   MARKS MI              J PEDIATR                       98   173 981
     8   MACONE AB             N ENGL J MED                   304  1445 981
     9   JANDA JM              J CLIN MICROBIOL                15   178 982
    10   SHEEHAN DJ            J CLIN MICROBIOL                15   926 982
    11   PUGASHETTI BK         J CLIN MICROBIOL                16   686 982
    12   OHMAN DE              INFECT IMMUN                    37   662 982
    13   THOMASSEN MJ          INFECT IMMUN                    38   802 982
    14   WINNIE GB             INFECT IMMUN                    38  1088 982
    15   SPEERT DP             J PEDIATR                      101   227 982
    16   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    17   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
    18   COSTERTON JW          REV INFECT DIS                   5  S867 983
    19   GOVAN JRW             REV INFECT DIS                   5  S874 983
    20   BOROWSKI RS           CURRENT MICROBIOL                9    25 983
    21   NINANE G              INFECTION                       11  S 16 983
    22   JAGGER KN             J CLIN MICROBIOL                17    55 983
    23   BASSETTI  D           CURR THER RES CLIN EXP          33   874 983
    24   JOHNSON SR            OBSTET GYNECOL                  61  S  2 983
    25   FLOURNOY DJ           METH FIND EXP CLIN PHARMACOL     6   487 984
    26   CHAN R                J CLIN MICROBIOL                19     8 984
    27   MCNEILL WF            AM J CLIN PATHOL                81   742 984
    28   THOMASSEN MJ          J PEDIATR                      104   352 984
    29   GOLD R                PEDIATR INFECT DIS               4   172 985
    30   KOMIYAMA K            ORAL SURG                       59   590 985
    31   THOMASSEN MJ          AM REV RESPIR DIS              131   791 985
    32   PACIFICO L            J INFECT DIS                   152   852 985
    33   MCCARTHY VP           PEDIATR INFECT DIS               5   256 986
    34   GILLJAM H             THORAX                          41   641 986
    35   PITT TL               J ROY SOC MED                   79    13 986
    36   LEVY J                J PEDIATR                      108   841 986
    37   REED MD               PEDIATR PULMONOL                 3   101 987
    38   DUNNE WM              DIAGN MICROBIOL INFECT DIS       6   165 987
    39   SPEERT DP             J HOSP INFECT                    9    11 987
    40   KOMIYAMA K            CAN J MICROBIOL                 33   221 987
    41   OGLE JW               J INFECT DIS                   155   119 987

PN 79111
RN 01091 
AN 80007721
AU Pennington-J-E.  Wolff-S-M.  Puziss-M.
TI Summary of a workshop on infections in patients with cystic fibrosis.
SO J-Infect-Dis. 1979 Aug. 140(2). P 252-6.
MJ BACTERIAL-INFECTIONS: co.  CYSTIC-FIBROSIS: et.
MN ANTIBODIES-BACTERIAL: an.  CONGRESSES.  HUMAN.
   PSEUDOMONAS-AERUGINOSA: im, ip.  SPUTUM: mi.
   NATIONAL-INSTITUTES-OF-HEALTH-U-S.
EX Cystic fibrosis is currently the most common fatal hereditary disease
   of the Caucasian race.  The lack of effective oral antibiotics
   against Pseudomonas aeruginosa precludes either systemic treatment or
   suppression, in an outpatient setting, of the chronic pseudomonas
   bronchitis typically seen in CF patients.  Because of the central
   role of infection, and particularly pseudomonas infection, in the
   sequence of events that leads to respiratory failure and death in CF,
   currently available information regarding the pathogenesis of
   infections caused by P. aeruginosa was emphasized and discussed at a
   workshop on infections in patients with CF, sponsored by the National
   Institute of Allergy and Infectious Diseases in Bethesda, Md., on
   January 9 and 10, 1979.
CT   1   CASSINO RJJ           PEDIATR RES                     14  1212 980
     2   FICK RB               J IMMUNOL METH                  38   103 980
     3   BANNATYNE RM          ANTIMICROB AGENTS CHEMOTHER     20   493 981
     4   MARKS MI              J PEDIATR                       98   173 981
     5   OBOYLE CP             IR J MED SCI                   150   286 981
     6   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
     7   SCHOFIELD DH          DRUG INTEL CLIN PHARM           18   153 984
     8   SUTER S               J INFECT DIS                   149   523 984
     9   JEWETT CV             J PEDIATR                      106   669 985
    10   SUTER S               J INFECT DIS                   153   902 986

PN 79112
RN 01092 
AN 79152690
AU Dreisin-R-B.  Mostow-S-R.
TI Sulfhydryl-mediated depression of ciliary activity: an adverse
   effect of acetylcysteine.
SO J-Lab-Clin-Med. 1979 Apr. 93(4). P 674-8.
MJ ACETYLCYSTEINE: ae.  CILIA: de.  SULFHYDRYL-COMPOUNDS: pd.
MN CYSTIC-FIBROSIS: th.  DEPRESSION-CHEMICAL.
   SUPPORT-U-S-GOVT-P-H-S.
AB Although N-acetyl-L-cysteine (Mucomyst) is an effective mycolytic,
   numerous investigations have failed to demonstrate a consistent
   improvement in pulmonary mechanics following its use. In order to
   determine whether its beneficial mucolytic activity might be
   counterbalanced by a deleterious direct effect on cilia, we studied
   its effect on the activity of ciliated epithelium in the ferret
   tracheal organ culture system. N-acetyl-L-cysteine consistently
   caused progressive time-dependent ciliostasis at concentrations
   clinically employed, with complete ciliary paralysis within 8 hr. The
   effect was only partially reversed by the removal of the drug.
   Control preparations retained full ciliary activity for 3 to 12
   weeks. In order to determine the active site on the N-acetyl-L-
   cysteine molecule, we investigated the ciliostatic effects of five of
   its chemical analogs. Isomolar N-acetyl-L-alanine was not
   ciliostatic, indicating the necessity of a sulfhydryl group for
   activity. Ciliostasis was independent of isomeric structure,
   acetylation, and chain length, as evidenced by the similar
   ciliostatic effects of L-cysteine, D-cysteine, 2-mercaptoethylamine,
   and N-acetyl-L-homocysteine. We conclude that N-acetyl-L-cysteine
   induces partially reversible ciliostasis of tracheal epithelium via
   its sulfhydryl group; prolonged use of this drug may impair
   mucociliary clearance.
RF 001   HURST GA              AM REV RESPIR DIS               96   962 967
   002   HIRSCH SR             J LAB CLIN MED                  74   346 969
   003   SHEFFNER AL           TUBERCULOLOGY                   23    31 966
   004   CARSON S              AM REV RESPIR DIS SUPPL         93    86 966
   005   STAMM SJ              DIS CHEST                       47   414 965
   006   MOSER KM              DIS CHEST                       49   370 966
   007   PULLE DF              CURR THER RES                   12   485 970
   008   HIRSCH SJ             J ALLERGY                       39   265 967
   009   WALTEMATH CL          AM REV RESPIR DIS              108   520 973
   010   TECKLIN JS            PHYS THER                       56   999 976
   011   SILVERS GW            AM REV RESPIR DIS              110   170 974
   012   MOSTOW SR             ARCH GESAMTE VIRUSFORSCH        43   385 973
   013   WILCOXON F            SOME RAPID APPROXIMATE STATIS            964
   014   WANNER A              AM REV RESPIR DIS              116    73 977
   015   SHEFFNER AL           ANN NY ACAD SCI                106   298 963
CT   1   YANAURA S             JAP J PHARMACOL                 31   957 981
     2   ROOMANS GM            EUR J RESPIR DIS                64   416 983
     3   NIEDERMAN MS          AM REV RESPIR DIS              127    85 983
     4   VENTURELLI J          CRIT CARE MED                   12   926 984
     5   FREDERICK KA          LAB ANIM SCI                    35   298 985
     6   LOW PMP               ANN ALLERGY                     54   273 985
     7   STAFANGER G           EUR J RESPIR DIS                70   157 987

PN 79113
RN 01093 
AN 80050997
AU Bria-W-F.  Kenny-W-R.
TI Adult cystic fibrosis: a new therapeutic challenge for the primary
   care physician.
SO J-Med-Assoc-Ga. 1979 Oct. 68(10). P 912-4.
MJ CYSTIC-FIBROSIS: th.
MN ANTIBIOTICS.  CYSTIC-FIBROSIS: fg, pp.  DIET-THERAPY.  HUMAN.
   LUNG: pp.  POSTURE.
EX In this article, we will examine the reasons for the prolonged
   survival of individuals with cystic fibrosis as well as discuss the
   pathogenesis, diagnosis and treatment of this multisystemic disease.
   The reasons for the improved prognosis in CF are multiple: improved
   antibiotic therapy, early diagnosis, specialized care centers, and
   aggressive treatment regimens.  This presents the primary care
   physician with a new and challenging patient population, requiring
   the coordinated effort of the health care team, including
   specialists, nurses, therapists, etc., to achieve effective therapy
   for this truly multisystemic disease.
RF 001   ROSENLUND ML          ANN INTERN MED                  78   959 973
   002   CROZIER DN            PEDIATR CLIN NORTH AM           21   935 974
   003   STERN RC              ANN INTERN MED                  87   188 977
   004   DI SANTAGNESE PA      AM FAM PHYSICIAN                 7   102 973
   005   STERN RC              J PEDIATR                       89   406 976
   006   DOERSHUK CF           J PEDIATR                       65   677 964
   007   HANDWERGER S          N ENGL J MED                   281   451 969
   008   STERN RC              GASTROENTEROLOGY                70   645 976
   009   LOBER CW              CHEST                           66   332 974
   010   KULCZYCKI LL          JAMA                           240    30 978
   011   EWING C               CHEST                           73   750 978
   012   HODSON ME             BR MED J                         2   790 976

PN 79114
RN 01094 
AN 79218787
AU Nevin-G-B.  Nevin-N-C.  Redmond-A-O.
TI Cystic fibrosis in Northern Ireland.
SO J-Med-Genet. 1979 Apr. 16(2). P 122-4.
MJ CYSTIC-FIBROSIS: oc.
MN HUMAN.  INFANT-NEWBORN.  NORTHERN-IRELAND.  RETROSPECTIVE-STUDIES.
AB In a retrospective study of cystic fibrosis in Northern Ireland for
   1961 to 1971, the incidence was 1 in 1857 livebirths, which is
   comparable to figures from Great Britain and the Republic of Ireland.
RF 001   CARTER CO             J MED GENET                     14   316 977
   002   DANKS DM              ANN HUM GENET                   28   323 965
   003   GOODMAN HO            AM J HUM GENET                   4    59 952
   004   HALL BD               J MED GENET                      5   262 968
   005   HONEYMAN MS           AM J HUM GENET                  17   461 965
   006   KRAMM ER              AM J PUBLIC HEALTH              52  2041 962
   007   NEVIN NC              INT J EPIDEMIOL                  7   319 978
   008   OREILLY D             INT J EPIDEMIOL                  3   247 974
   009   PUGH RJ               ARCH DIS CHILD                  42   544 967
   010   SELANDER P            ACTA PAEDIATR SCAND             51    65 962
   011   STEVENSON AC          RADIAT RES SUPPL                 1   306 959
   012   TEN KATE LP           INT J EPIDEMIOL                  6    23 977
CT   1   NEVIN GB              HUM GENET                       56   387 981
     2   GRATAROLI R           PEDIATR RES                     18   130 984
     3   STURGESS JM           AM J MED GENET                  22   383 985
     4   JAMIESON A            HUM GENET                       70   168 985

PN 79115
RN 01095 
AN 79196306
AU Soter-N-A.  Mihm-M-C-Jr.  Colten-H-R.
TI Cutaneous necrotizing venulitis in patients with cystic fibrosis.
SO J-Pediatr. 1979 Aug. 95(2). P 197-201.
MJ CYSTIC-FIBROSIS: co.  PHLEBITIS: pa.  PURPURA: pa.  SKIN: bs.
MN ADOLESCENCE.  ADULT.  BIOPSY.  CASE-REPORT.  HUMAN.  MALE.
   PHLEBITIS: et.  PURPURA: et.  SUPPORT-U-S-GOVT-P-H-S.  VENULES: pa.
AB Palpable purpura was noted to occur late in the course of some
   patients with cystic fibrosis. Skin biopsy specimens showed
   necrotizing venulitis characterized by a perivenular infiltrate
   composed of neutrophilic leukocytes, fibrin, hypogranulated mast
   cells, and endothelial cell necrosis. Circulating immune complexes
   were detected. Recurrent pulmonary infections and the chronic
   administration of therapeutic agents provide sources of potential
   antigens.
RF 001   SOTER NA              IN: SAMTER M                         993 978
   002   PARISH WE             IN: BEUTNER EH                       153 974
   003   MOSCHELLA SL          ARCH DERMATOL                   95   565 967
   004   QUISMORIO FP JR       CLIN IMMUNOL IMMUNOPATHOL        9   184 978
   005   LEVO Y                TRANS ASSOC AM PHYSICIANS       90   167 977
   006   DIENSTAG JL           ANN INTERN MED                  89    34 978
   007   SOTER NA              J INVEST DERMATOL               63   219 974
   008   SAMS WM JR            BR J DERMATOL                   80   555 968
   009   THEOFILOPOULOS AN     J CLIN INVEST                   57   169 976
   010   KAMMER GM             CLIN RES                        25  361A 977
   011   REYNOLDS HY           ANN INTERN MED                  82   819 975
   012   WOOD RE               AM REV RESPIR DIS              113   833 976
   013   DVORAK HF             J EXP MED                      135   235 972
   014   MIHM MC JR            J INVEST DERMATOL               67   305 976
   015   NYDEGGER UE           J CLIN INVEST                   54   297 974
   016   SOTER NA              J ALLERGY CLIN IMMUNOL          59   294 977
   017   BEAVEN MA             CLIN CHIM ACTA                  37    91 972
   018   NIELSEN HE            ACTA PAEDIATR SCAND             67   443 978
   019   SCHROETER AL          ARCH DERMATOL                  104   254 971
   020   BRAVERMAN IM          J INVEST DERMATOL               64   105 975
   021   FEIG PU               JAMA                           236  2065 976
   022   KAMMER GM             CLIN IMMUNOL IMMUNOPATHOL       10   202 978
   023   MARTINEZ-TELLO FJ     J IMMUNOL                      101   989 968
   024   MCFARLANE H           BR MED J                         1   423 975
CT   1   JOHN EG               J PEDIATR                       97   505 980
     2   MATTHEWS WJ           N ENGL J MED                   302   245 980
     3   SORENSEN RU           PEDIATR RES                     15    14 981
     4   MOSS RB               J PEDIATR                       99   215 981
     5   SAVEL P               ANN DERMATOL VENEREOL          109   503 982
     6   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    63 982
     7   GIGLI I               J AM ACAD DERMATOL              11   948 984
     8   SCHIDLOW DV           ARCH DIS CHILD                  59   377 984
     9   AUERBACH HS           LANCET                           2   686 985
    10   RESNICK AH            INT J DERMATOL                  24   139 985
    11   SANCHEZ NP            ARCH DERMATOL                  121   220 985
    12   WISNIESKI JJ          AM REV RESPIR DIS              132   770 985
    13   RUSH PJ               SEM ARTHRITIS RHEUM             15   213 986
    14   SUMMERS GD            BR J RHEUMATOL                  25   393 986
    15   HOIBY N               ANNU REV MICROBIOL              40    29 986
    16   PHILLIPS BM           J ROY SOC MED                   79    44 986
    17   MOSS RB               AM REV RESPIR DIS              133   648 986

PN 79116
RN 01096 
AN 79153525
AU Herrod-H-G.  Amos-D-B.  Spock-A.
TI HLA determinants in families with more than one member with cystic
   fibrosis [letter].
SO J-Pediatr. 1979 Apr. 94(4). P 676.
MJ ANTIGENIC-DETERMINANTS.  CYSTIC-FIBROSIS: fg.  HLA-ANTIGENS.
MN CYSTIC-FIBROSIS: im.  HUMAN.
EX Attempts to identify the carrier state for cystic fibrosis (CF) or to
   make a prenatal diagnosis of CF have been unsuccessful.  One approach
   to this problem is to look for associations between known genetic
   markers and the locus for CF.  In general these studies have looked
   at the frequency of HLA types in patients with CF and have failed to
   demonstrate a strong association.  We attempted to look for linkage
   between HLA haplotypes and CF in families with more than one affected
   member.  The segregation of HLA in these affected sibpairs vary
   little from the expected.  Although the sample size is small, it is
   unlikely that a close linkage exists between the HLA loci and the CF
   locus.
RF 001   LAMM LU               ANN HUM GENET                   38   383 975
   002   GOODCHILD MC          J MED GENET                     13   417 976
   003   AMOS DB               IN: ROSE NR                          797 976
   004   HERROD HG             J PEDIATR                       91   276 977
CT   1   ANON                  LANCET                           2   249 985
     2   MOSS RB               MONOGR ALLERGY                  19   202 986

PN 79117
RN 01097 
AN 79153494
AU Newman-A-J.  Ansell-B-M.
TI Episodic arthritis in children with cystic fibrosis.
SO J-Pediatr. 1979 Apr. 94(4). P 594-6.
MJ ARTHRITIS: co.  CYSTIC-FIBROSIS: co.
MN CHILD.  CHILD-PRESCHOOL.  FEMALE.  HUMAN.  MALE.
EX Five children 2 to 10 years of age with cystic fibrosis developed
   transient episodic arthritis.  Although polyarticular in
   distribution, only one joint might be involved during each attack.
   No laboratory or radiologic evidence of juvenile chronic arthritis
   was present and no permanent joint limitation was noted.
RF 001   LINDSLEY CB           J PEDIATR                       84    16 974
   002   PETTY RE              ARTHRITIS RHEUM                 19   902 976
   003   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
   004   GIBSON TJ             J RHEUMATOL                      2     7 975
   005   MULLIN GT             ANN INTERN MED                  68    75 968
   006   LUCAS PF              GUT                              3   146 962
   007   TANNENBAUM H          J RHEUMATOL                      2    14 975
   008   SMITH BS              BR MED J                         1  1403 966
   009   HASLOCK I             RHEUMATOL REHAB                 13    51 974
   010   STAPLETON FB          N ENGL J MED                   295   246 976
CT   1   VAZE D                J PEDIATR                       96   346 980
     2   SAGRANSKY DM          AM J DIS CHILD                 134   319 980
     3   BYWATERS EGL          N ENGL J MED                   302  1467 980
     4   MOSS RB               J PEDIATR                       99   215 981
     5   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    63 982
     6   DELUMLEY L            ARCH FR PEDIATR                 40   723 983
     7   SCHIDLOW DV           ARCH DIS CHILD                  59   377 984
     8   BRAUDE S              BR MED J                       288   822 984
     9   CRAWFORD AM           RHEUMATOL INT                    5   283 985
    10   LESTER LA             SEM RESPIR MED                   6   285 985
    11   RUSH PJ               SEM ARTHRITIS RHEUM             15   213 986
    12   SUMMERS GD            BR J RHEUMATOL                  25   393 986
    13   CASSIDY JT            PEDIATR CLIN NORTH AM           33  1033 986
    14   HOIBY N               ANNU REV MICROBIOL              40    29 986
    15   PHILLIPS BM           J ROY SOC MED                   79    44 986
    16   COHEN AM              AM J DIS CHILD                 140    74 986

PN 79118
RN 01098 
AN 79196242
AU Worley-L.  Poole-C.  Valdes-Depena-M.
TI Failure to thrive, anemia, and anasarca.
SO J-Pediatr. 1979 Jun. 94(6). P 1005-9.
MJ CYSTIC-FIBROSIS: co.  FOOD-HYPERSENSITIVITY: co.  MILK: ae.
   PROTEIN-LOSING-ENTEROPATHIES: et.
MN ANEMIA: et.  CASE-REPORT.  FEMALE.  HUMAN.  INFANT.
EX A 5-month-old white girl was admitted to an Infant Intensive Care
   Unit of Jackson Memorial Hospital.  According to her mother, the baby
   had been in "her usual state of health" until one week before
   admission, when she began to "spit up" after feedings and her lower
   extremities became puffy.  Vomiting increased in frequency until it
   occurred after every meal; eventually the baby refused all feedings;
   there was no diarrhea.  Ultimately, the family's physician, when
   consulted, recommended that she be admitted to the hospital.  On the
   fourth day she developed renal failure with anuria and rising
   creatinine concentration despite adequate fluid intake; peritoneal
   dialysis was begun.  However, she soon became hypothermic and
   developed pulmonary edema, and she died a few hours later.  A
   discussion of the case is presented.
RF 001   MACLEAN WC JR         J PEDIATR                       83    86 973
   002   LEE PA                JAMA                           228   585 974
   003   COLON AR              SOUTH MED J                     66   641 973
   004   SWISCHUK LE           J PEDIATR                       88   452 976
   005   GRISCOM NT            RADIOLOGY                      117   385 975
   006   MELHEM RE             PEDIATR RADIOL                   4   153 976

PN 79119
RN 01099 
AN 79196248
AU Mihalas-L-S.  Mitchell-I.
TI Bronchial hyperreactivity in cystic fibrosis [letter].
SO J-Pediatr. 1979 Jun. 94(6). P 1013-4.
MJ BRONCHIAL-SPASM: co.  CYSTIC-FIBROSIS: co.
MN HUMAN.
EX Mitchell and co-workers conclude that bronchial hyperreactivity is
   common in cystic fibrosis (CF) but is different from that in asthma.
   Their data were interesting, but I do not agree with their
   conclusion.  One can interpret these data as suggesting a common
   reversible component in both patient groups, and perhaps a common
   denominator in mechanism.  Because of certain problems with baseline
   measurements and withholding of medication, it seems that the
   conclusion of Mitchell et al may not be well supported. - We felt
   justified in studying those patients with a low baseline FEV (forced
   expiratory volume in one second), since a subject's bronchial
   response to methacholine remains stable even if these is moderate
   fluctuation both in initial specific airway conductance and in the
   severity of the disease.  We feel that withholding the drug for a
   longer period would not have affected the comparisons.  Although
   there might be a common underlying mechanism in bronchial
   hyperreactivity in asthma and cystic fibrosis, our data showed a
   number of differences between the two groups of patients.  Although
   these differences would not exclude a common mechanism in bronchial
   hyperreactivity in the two diseases, the existence of the differences
   should lead to caution in concluding that there is a common
   underlying mechanism in the bronchial hyperreactivity in the two
   diseases.
RF 001   MITCHELL I            J PEDIATR                       93   744 978
   002   SPECTOR SL            MED CLIN NORTH AM               58    71 974
   003   CHAI H                J ALLERGY CLIN IMMUNOL          56   323 975
   004   RUBINFELD AR          AM REV RESPIR DIS              115   381 977

PN 79120
RN 01100 
AN 79196281
AU Malis-F.  Fric-P.  Kasafirek-E.  Jodl-J.  Vavrova-V.  Slaby-J.
TI A peroral test of pancreatic insufficiency with
   4-(N-acetyl-L-tyrosyl)aminobenzoic acid in children with cystic
   fibrosis.
SO J-Pediatr. 1979 Jun. 94(6). P 942-4.
MJ P-AMINOBENZOIC-ACID: du.  AMINOBENZOIC-ACIDS: du.
   CYSTIC-FIBROSIS: di.
MN P-AMINOBENZOIC-ACID: aa.  ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: pp.  FEMALE.  HUMAN.  MALE.  PANCREAS: pp.
   TYROSINE: aa, du.
EX We report on the examination of stimulated pancreatic secretion using
   4-(N-acetyl-L-tyrosyl)aminobenzoic acid in children with cystic
   fibrosis.  In controls the urinary excretion of 4-aminobenzoic acid
   amounted to 54.8 +/- 11.7% with 19.6% as the lower limit of normal
   during six hours, and 74.7 +/- 10.8% and 40.5% during eight hours.
   In children with cystic fibrosis the mean values were 5.6% in the
   six-hour test and 13.7% in the eight-hour test.  Both values are
   significantly different in comparison with controls.  It may be
   assumed that both 4-(N-acetyl-L-tyrosyl)aminobenzoic acid and
   4-(N-benzoyl-L-tyrosyl)aminobenzoic acid are suitable for indirect
   determination of exocrine pancreatic secretion in children.
RF 001   IMONDI AR             GUT                             13   726 972
   002   GYR K                 GUT                             17    27 976
   003   ARVANITAKIS C         LANCET                           1   663 976
   004   BORNSCHEIN W          CLIN CHIM ACTA                  67    21 976
   005   NOUSIA-ARVANITAKIS S  J PEDIATR                       92   734 978
   006   MALIS F               J CLIN CHEM CLIN BIOCHEM        14   499 976
   007   MALIS F               ACTA HEPATOGASTROENTEROL        25   233 978
   008   SMITH HW              J CLIN INVEST                   24   388 945
   009   ZASSENHAUS PH         ANAL BIOCHEM                    76   321 976
   010   WOLGEMUTH RL          AM J DIG DIS                    21   821 976
CT   1   FRIC P                HEPATOGASTROENTEROLOGY          27   220 980
     2   NIESSEN KH            MONATSSCHR KINDERHEILKD        128   746 980
     3   SCHONBERGER W         MONATSSCHR KINDERHEILKD        128   195 980
     4   LANKISCH PG           HEPATOGASTROENTEROLOGY          28   333 981
     5   PARK RW               GASTROENTEROLOGY                81  1143 981
     6   NEIS P                MONATSSCHR KINDERHEILKD        129   347 981
     7   LANKISCH PG           GUT                             23   777 982
     8   KOLLBERG H            ACTA PAEDIATR SCAND SUPPL 301 1982    15 982
     9   LANKISCH PG           CLIN GASTROENTEROL              13   717 984
    10   SCOTTA MS             CLIN BIOCHEM                    18   233 985
    11   RIEU D                ANN PEDIATR (PARIS)             32   205 985
    12   CUMMING JGR           ARCH DIS CHILD                  61   573 986

PN 79121
RN 01101 
AN 79131916
AU Cox-K-L.  Isenberg-J-N.  Osher-A-B.  Dooley-R-R.
TI The effect of cimetidine on maldigestion in cystic fibrosis.
SO J-Pediatr. 1979 Mar. 94(3). P 488-92.
MJ CIMETIDINE: tu.  CYSTIC-FIBROSIS: co.  GUANIDINES: tu.
   MALABSORPTION-SYNDROMES: dt.
MN ADOLESCENCE.  ADULT.  CHILD.  CIMETIDINE: bl.  CYSTIC-FIBROSIS: bl.
   DRUG-THERAPY-COMBINATION.  FEMALE.  HUMAN.
   MALABSORPTION-SYNDROMES: bl, et.  MALE.  PANCREATIC-EXTRACTS: tu.
   PANCREATIN: tu.  CELIAC-DISEASE: dt, et.  SUPPORT-U-S-GOVT-P-H-S.
AB Ten patients (6 to 27 years of age) who had severe pancreatic
   exocrine insufficiency due to cystic fibrosis were studied to
   determine whether cimetidine would improve dietary fat and nitrogen
   absorption. When a constant diet was consumed and oral pancreatic
   enzymes were administered, the addition of cimetidine (150 or 200 mg
   taken orally one-half hour before meals) signficantly reduced fecal
   fat excretion from 25.3 +/- 2.9 to 17.3 +/- 2.1 gm/24 hours and fecal
   nitrogen excretion from 4.5 +/- 0.6 to 3.4 +/- 0.5 gm/24 hours (P
   less than 0.05). Lower doses of cimetidine resulted in less
   significant reductions of steatorrhea and azotorrhea. Cimetidine may
   be a useful adjunct to oral pancreatic enzyme therapy in patients
   with cystic fibrosis who continue to have steatorrhea and azotorrhea
   with enzyme therapy alone.
RF 001   HEIZER WD             BULL JOHNS HOPKINS HOSP        116   261 965
   002   GRAHAM DY             N ENGL J MED                   296  1314 977
   003   DIMAGNO EP            N ENGL J MED                   296  1318 977
   004   ROY CC                PEDIATR CLIN GASTROENTEROL               975
   005   HARO EN               CLIN RES                        12   207 964
   006   VEEGER W              N ENGL J MED                   267  1341 962
   007   REGAN PT              N ENGL J MED                   297   854 977
   008   RICHARDSON CT         GASTROENTEROLOGY                74   366 978
   009   SAUNDERS JHB          BR MED J                         1   418 977
   010   WIGGINS HS            GUT                              8   415 967
   011   TIETZ NW              CLIN CHIM ACTA                  13   352 966
   012   WORMSLEY KG           GASTROENTEROLOGY                54   197 968
   013   VAN DE KAMER JH       J BIOL CHEM                    177   347 949
   014   HILLER A              J BIOL CHEM                    177  1401 948
   015   FREYE HB              J PEDIATR                       64   575 964
   016   WALKENSTEIN SS        GASTROENTEROLOGY                74   360 978
   017   POUNDER RE            GUT                             17   161 976
   018   ANTONOWICZ I          J PEDIATR                       92   214 978
   019   MORIN CL              J PEDIATR                       88   213 976
   020   REEMTSMA K            PEDIATRICS                      22   525 958
   021   WATKINS JB            GASTROENTEROLOGY                73  1023 977
   022   ROY CC                N ENGL J MED                   297  1301 977
   023   UFBERG MH             GASTROENTEROLOGY                73   635 977
   024   MCGREGOR CGA          LANCET                           1   122 977
   025   AVELLA J              LANCET                           1   624 978
   026   BRIMBLECOMBE RW       IN: BURLAND WL                           977
CT   1   MARTIN DW             WEST J MED                     131   417 979
     2   GILLARD BK            PEDIATR RES                     14  1168 980
     3   DURIE PR              GUT                             21   778 980
     4   HUBBARD VS            AM J CLIN NUTR                  33  2281 980
     5   LAVARENNE J           THERAPIE                        35    83 980
     6   BOYLE BJ              GASTROENTEROLOGY                78   950 980
     7   BLAKER F              MONATSSCHR KINDERHEILKD        128   626 980
     8   GOW R                 LANCET                           2  1071 981
     9   BRADBEAR RA           BR J CLIN PHARMACOL             12   248 981
    10   MITCHELL EA           AUST PAEDIATR J                 17    89 981
    11   MITCHELL EA           AUST PAEDIATR J                 17   207 981
    12   SCHONI M              HELV PAEDIATR ACTA              36   359 981
    13   DEBIEVILLE F          ACTA PAEDIATR SCAND             70    33 981
    14   PARK RW               GASTROENTEROLOGY                81  1143 981
    15   HALL KW               CAN MED ASSOC J                124  1579 981
    16   STAUB JL              N ENGL J MED                   304  1364 981
    17   CHASE HP              J PEDIATR GASTROENTEROL NUTR     1    49 982
    18   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
    19   SALOM IL              SCAND J GASTROENTEROL           17   129 982
    20   MITCHELL EA           AUST PAEDIATR J                 18   114 982
    21   DIMAGNO EP            DIG DIS SCI                     27   481 982
    22   GRAHAM DY             DIG DIS SCI                     27   485 982
    23   HUBBARD VS            J AM DIET ASSOC                 80   127 982
    24   BRADBEAR RA           J PEDIATR                      100   325 982
    25   ISENBERG JN           J PEDIATR GASTROENTEROL NUTR     2   447 983
    26   SOMOGYI A             CLIN PHARMACOKINET               8   463 983
    27   GRENDELL JH           CLIN GASTROENTEROL              12   551 983
    28   SORKIN EM             DRUG INTEL CLIN PHARM           17   110 983
    29   LANKISCH PG           CLIN GASTROENTEROL              13   985 984
    30   SCHONI M              PEDIATR RES                     18    66 984
    31   ZIEMNIAK JA           EUR J CLIN PHARMACOL            26   183 984
    32   ABRAMS CK             J CLIN INVEST                   73   374 984
    33   HODGES P              J AM DIET ASSOC                 84   664 984
    34   GILLARD BK            AM J DIS CHILD                 138   577 984
    35   HYMAN PE              J PEDIATR GASTROENTEROL NUTR     4   316 985
    36   PERRY RS              CLIN PHARMACY                    4   161 985
    37   ZENTLERMUNRO PL       GUT                             26   892 985
    38   SCHNEIDER MU          HEPATOGASTROENTEROLOGY          32    97 985
    39   CHALMERS DM           ACTA PAEDIATR SCAND             74   114 985
    40   SOMOGYI A             EUR J PEDIATR                  144    72 985
    41   SINAASAPPEL M         ACTA PAEDIATR SCAND SUPPL 317 1985    22 985
    42   RUBINSTEIN S          PEDIATRICS                      78   473 986
    43   LAMERS CBHW           BR MED J                       293   994 986
    44   BRAGGION C            ARCH DIS CHILD                  62   349 987

PN 79122
RN 01102 
AN 79196324
AU Church-J-A.  Keens-T-G.  Wang-C-I.  ONeal-M.  Richards-W.
TI Normal neutrophil and monocyte chemotaxis in patients with cystic
   fibrosis.
SO J-Pediatr. 1979 Aug. 95(2). P 2724.
MJ CHEMOTAXIS-LEUKOCYTE.  CYSTIC-FIBROSIS: bl.
MN ADULT.  HUMAN.  MONOCYTES: im.  NEUTROPHILS: im.
AB The prominent role of infection in the clinical course of cystic
   fibrosis has led to considerable investigation of possible immune
   deficiency in these patients.  Leukotaxis of circulating phagocytic
   cells and the ability to generate chemotactic factors are important
   in host defenses against bacterial invasion.  These properties were
   investigated in patients with clinically stable cystic fibrosis to
   determine if they possess dysfunctional inflammatory responses which
   would predispose them to severe infection.
RF 001   TALAMO RC             IN: MANGOS JA                        195 976
   002   GALLIN JI             IN: BELLANTI JA                      227 975
   003   LETT-BROWN MA         J IMMUNOL                      117   246 976
   004   KLEIN RB              PEDIATRICS                      60   467 977
   005$  ORR W                 J IMMUNOL METH                  20    95 978
   006   SORENSEN RU           J PEDIATR                       93   201 978
   007   CONOVER JH            LANCET                           2  1501 973
   008   HILL HR               J PEDIATR                       84    55 974

PN 79123
RN 01103 
AN 79196343
TI Hyperuricemia in cystic fibrosis [letter].
SO J-Pediatr. 1979 Aug. 95(2). P 330-1.
MJ CYSTIC-FIBROSIS: bl.  URIC-ACID: bl.
MN CYSTIC-FIBROSIS: dt.  HUMAN.  PANCREATIC-EXTRACTS: ae, tu.
EX Davidson et al report hyperuricemia in cystic fibrosis patients
   ingesting large quantities of pancreatic extracts.  This article and
   others emphasize the considerable purine content of these
   preparations as causal to the increased serum and urine uric acid
   levels in patients who consume them.  This may find clinical
   application, since uric acid production from RNA might be decreased
   by an inhibitor of ribonuclease.  While itself a purine chain,
   polyadenylic acid added to pancreatic extracts may prevent the
   hydrolysis of mixed-base ribonucleic acid to uric acid precursors,
   while allowing the beneficial effects of the other pancreatic enzymes
   to prevail. - A number of weaknesses to the proposal bears stressing
   before we begin giving polyadenylic acid to our patients.  No one
   knows whether nucleic acids are malabsorbed in cystic fibrosis.  If
   polyadenylic acid produces only 70% inhibition of pancreatic
   ribonucleases at a one-to-one ratio of substrate and inhibitor, a
   relatively enormous amount of polyadenylic acid would have to be fed
   with the pancreatic extracts.  If there were an intestinal enzyme
   capable of cleaving polyadenylic acid, the treatment would add to,
   not subtract from, the purine load.  Finally, Stapleton et al's
   results suggest that more than 75% of the purine load in the
   pancreatic extracts would probably be absorbed anyway.
RF 001   DAVIDSON GP           J PEDIATR                       93   976 978
   002   STAPLETON FB          N ENGL J MED                   295   246 976
   003   NOUSIA-ARVANITAKIS S  J PEDIATR                       90   302 977
   004   REDDI KK              BIOCHEM BIOPHYS RES COMMUN      67   110 975
   005   SCHMUKLER M           J BIOL CHEM                    250  2206 975
   006   GAHL WA               N ENGL J MED                   297  1349 977
   007   ZIMMERMAN SB          ANAL BIOCHEM                    10   444 965
   008   ZAN-KOWALCZEWSKA M    BIOCHIM BIOPHYS ACTA           341   138 974

PN 79124
RN 01104 
AN 80051503
AU Fellows-K-E.  Khaw-K-T.  Schuster-S.  Shwachman-H.
TI Bronchial artery embolization in cystic fibrosis; technique and
   long-term results.
SO J-Pediatr. 1979 Dec. 95(6). P 959-63.
MJ BRONCHIAL-ARTERIES.  CYSTIC-FIBROSIS: co.  EMBOLIZATION-THERAPEUTIC.
   HEMOPTYSIS: th.
MN ADOLESCENCE.  ADULT.  ANGIOGRAPHY.  BRONCHIAL-DISEASES: ra, th.
   BRONCHOSCOPY.  CHILD.  FEMALE.  FOLLOW-UP-STUDIES.  HEMOPTYSIS: et.
   HUMAN.  MALE.  RECURRENCE.
AB Severe bronchial hemorrhage in 13 patients with cystic fibrosis was
   treated by catheter embolization of bronchial arteries. Indications
   were either excessive bleeding persisting for several days, or
   bleeding serious enough to interfere with pulmonary drainage and
   recurring over weeks or months. In follow-up ranging from one to 30
   months, cessation of major bleeding was achieved in 12 of 13 patients
   (93%), although 5 of 13 patients (40%) did have recurrence of minor
   hemoptysis. No neurologic or other major complications were
   encountered. However, there are potential risks and this approach at
   present should be limited to patients with life-threatening bleeding
   and carried out only by experienced angiographers.
RF 001   HOLSCLAW DS           J PEDIATR                       76   829 970
   002$  STERN RC              AM REV RESPIR DIS              117   825 978
   003   SCHUSTER SR           J PEDIATR SURG                  12   889 977
   004   WHOLEY MH             JAMA                           236  2501 976
   005   HARLEY JD             AM J ROENTGENOL                128   302 977
   006   BOOKSTEIN JJ          CHEST                           72   658 977
   007   REMY J                RADIOLOGY                      122    33 977
   008   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   009   FELLOWS KE            RADIOLOGY                      114   551 975
   010   FEIGELSON HH          RADIOLOGY                       85   663 965
   011   KARDJIEV V            RADIOLOGY                      112    81 974
   012   REUTER S              RADIOLOGY                       84    87 965
   013   DICHIRO G             RADIOLOGY                      112   231 974
   014   DICHIRO G             J NEUROSURG                     39     1 973
   015   TVETEN L              ACTA RADIOL                     17     1 976
   016   TVETEN L              ACTA RADIOL                     17   257 976
   017   BOTENGA ASJ           SELECTIVE BRONCHIAL AND INTER            970
   018   HELENON CH            NOUV PRESSE MED                  6  4209 977
   019   BARTH KH              INVEST RADIOL                   12   273 977
   020   KERBER CW             AM J ROENTGENOL                130  1193 978
CT   1   HOLSCLAW DS           CLIN CHEST MED                   1   407 980
     2   ATHANASOULIS CA       N ENGL J MED                   302  1117 980
     3   FELLOWS KE            RADIOLOGY                      140   249 981
     4   TABACHNIK NF          SURG GYNECOL OBSTET            152   837 981
     5   SILVERMAN NA          CHEST                           82   195 982
     6   HEASTON DK            SEM RESPIR MED                   5    58 983
     7   MARMON L              J PEDIATR SURG                  18   811 983
     8   PORTER DK             J THORAC CARDIOVASC SURG        86   409 983
     9   PORTER DK             ARCH INTERN MED                143   287 983
    10   UFLACKER R            RADIOLOGY                      146   627 983
    11   WHITE RI              ANN RADIOL (PARIS)              27   310 984
    12   BARTH KH              MED CLIN NORTH AM               68  1647 984
    13   DAVIS PB              CHEST                           85   802 984
    14   WHITE RI              AM J ROENTGENOL                142    27 984
    15   LESTER LA             SEM RESPIR MED                   6   285 985
    16   HOFFER FA             PEDIATR CLIN NORTH AM           32  1461 985
    17   TRENTO A              ANN THORAC SURG                 39   254 985
    18   STANKIEWICZ JA        EAR NOSE THROAT J               64   180 985
    19   NOLAN MT              IR J MED SCI                   154   336 985
    20   LOCK JE               J AM COLL CARDIOL                7  1420 986
    21   KAUFMAN SL            AM J CARDIOL                    58  1130 986
    22   MOORE LB              RADIOLOGY                      161   173 986
    23   FERNALD GW            SEM ROENTGENOL                  22    87 987
    24   LOCK JE               CIRCULATION                     75   593 987

PN 79125
RN 01105 
AN 80008528
AU Schwachman-H.
TI Reliability of sweat test in cystic fibrosis [letter].
SO J-Pediatr. 1979 Oct. 95(4). P 661-2.
MJ CYSTIC-FIBROSIS: di.  SWEAT: an.
MN CHLORIDES: an.  FALSE-POSITIVE-REACTIONS.  HUMAN.  SODIUM: an.
EX The report by Huff, Huang, and Arey again calls attention to the
   heterogeneity of cystic fibrosis and to the fact that a properly
   performed sweat test in the normal or borderline range does not rule
   out cystic fibrosis.  This may occur in approximately 1% of patients
   we classify as having cystic fibrosis and confirms our original
   impression that the sweat test has a reliability of between 98% and
   99%.  One must pay close attention to the clinical picture, the
   family history, and especially the pulmonary or gastrointestinal
   findings, and provide rational treatment until more acceptable
   evidence of the disease can be documented.  In the same issue is a
   report on a false positive sweat test in a Canadian patient with the
   Mauriac syndrome.  The authors list a variety of conditions that have
   been reported as yielding elevated sweat electrolytes.  The manner of
   the collections can greatly influence the result. - In patients with
   transient abnormal sweat electrolytes, sodium values were
   consistently higher than chloride values.  Perhaps the finding of
   sodium values in excess of chloride in the abnormal range suggests a
   false positive test.
RF 001   HUFF DS               J PEDIATR                       94   237 979
   002   EPSTEIN JL            PROC NAT ACAD SCI USA           74  5642 977
   003   BRESLOW JL            SCIENCE                        201   180 978
   004   ROSENFELD R           J PEDIATR                       94   240 979
   005   SHWACHMAN H           CLIN CHEM                       25   158 979
CT   1   RUDDY RM              CLIN PEDIATR                    26    83 987

PN 79126
RN 01106 
AN 79069499
AU Hubbard-V-S.  Farrell-P-M.  di-SantAgnese-P-A.
TI 25-Hydroxycholecalciferol levels in patients with cystic fibrosis.
SO J-Pediatr. 1979 Jan. 94(1). P 84-6.
MJ CYSTIC-FIBROSIS: bl.  HYDROXYCHOLECALCIFEROLS: bl.
MN HUMAN.  VITAMIN-D: ad.
EX Assessment of the status of circulating vitamin D in cystic fibrosis
   patients was investigated by determining serum levels of
   25-hydroxycholecalciferol.  The majority of the patients with CF and
   pancreatic insufficiency had levels of 25-OH-D within the normal
   range.  Clinical symptoms or pathologic signs resulting from
   deficiencies of vitamins A and E in patients with CF have been
   repeatedly documented.  In contrast, a paradoxical lack of vitamin D
   deficiency signs has been observed in CF patients.  This is
   especially puzzling since rickets had been commonly associated with
   most other forms of steatorrhea.  We can only speculate why rickets
   was formerly rarely reported in association with CF.  Perhaps because
   of voracious appetites and the selective absorption of vitamin D via
   the lymphatics without requiring esterification, these individuals
   were spared clinical rickets.
RF 001   DI SANTAGNESE PA      AM J MED                        21   406 956
   002   OPPENHEIMER EH        BULL JOHNS HOPKINS HOSP         98   353 956
   003   ANDERSEN DH           J PEDIATR                       15   763 939
   004   PARSONS LG            ARCH DIS CHILD                   2   198 927
   005   WEBER A               PEDIATRICS                      50    73 972
   006   TAUSSIG LM            J PEDIATR                       82   380 973
   007   BELSEY RE             J CLIN ENDOCRINOL METAB         38  1046 974
   008   FARRELL PM            PEDIATR RES                     11   443 977
   009   ARNAUD SB             PEDIATRICS                      57   221 976
   010   HADDAD JG JR          NATURE                         244   515 973
   011   THOMPSON GR           J CLIN INVEST                   45    94 966
   012   BLOMSTRAND R          ACTA CHEM SCAND                 21  1662 967
CT   1   ANON                  NUTR REV                        37   247 979
     2   CHASE HP              J PEDIATR                       95   337 979
     3   WEISMAN Y             J PEDIATR                       95   416 979
     4   MEREDITH SC           CLIN ENDOCRINOL METAB            9   131 980
     5   SOLOMONS NW           AM J CLIN NUTR                  34   462 981
     6   CONGDEN PJ            ARCH DIS CHILD                  56   708 981
     7   COPPENHAVER D         HUM GENET                       57   399 981
     8   PARK RW               GASTROENTEROLOGY                81  1143 981
     9   LOGVINOFF MM          CLIN PEDIATR                    23   389 984
    10   HUBBARD VS            SEM RESPIR MED                   6   308 985
    11   HANLY JG              Q J MED                         56   377 985
    12   REITER EO             J PEDIATR                      106    21 985
    13   DODGE JA              ACTA PAEDIATR SCAND SUPPL 317 1985    31 985
    14   DUHAMEL JF            ARCH FR PEDIATR                 43   229 986

PN 79127
RN 01107 
AN 79069484
AU Hahn-T-J.  Squires-A-E.  Halstead-L-R.  Strominger-D-B.
TI Reduced serum 25-hydroxyvitamin D concentration and disordered
   mineral metabolism in patients with cystic fibrosis.
SO J-Pediatr. 1979 Jan. 94(1). P 38-42.
MJ CALCIUM: bl.  CYSTIC-FIBROSIS: bl.  HYDROXYCHOLECALCIFEROLS: bl.
MN ADOLESCENCE.  ADULT.  BONE-AND-BONES: me.  CALCIUM: ur.  CHILD.
   CYSTIC-FIBROSIS: me.  FEMALE.  HUMAN.  KIDNEY: me.  MALE.
   PARATHYROID-HORMONES: bl.  SUPPORT-U-S-GOVT-P-H-S.
AB Vitamin D and mineral metabolism were studied in 21 adolescents and
   young adults with cystic fibrosis and the results were compared to
   those in 21 matched controls. All CF patients had been maintained on
   standard multivitamin supplements in combination with pancreatic
   enzyme replacement. Despite this supplementation, relative to control
   subjects the CF patients had a 36% reduction in serum 25-
   hydroxyvitamin D concentration, a slight but significant reduction in
   serum calcium concentration, evidence of calcium malabsorption with
   secondary hyperparathyroidism, and a 14% decrease in bone mass
   measured by the photon absorption technique. Currently accepted modes
   of pancreatic enzyme replacement and vitamin D supplementation are
   often inadequate to maintain normal mineral homeostasis in CF
   patients; additional measurements may be required to reduce the risk
   of clinically significant osteopenia concomitant with prolonged
   survival in CF.
RF 001   BENNETT MJ            AM J CLIN NUTR                  20   415 967
   002   TORSTENSON OL         PEDIATRICS                      45   857 970
   003   GUGLER EC             MOD PROBL PEDIATR               10    95 967
   004   DI SANTAGNESE PA      IN: VAUGHAN VC III                   903 975
   005   DI SANTAGNESE PA      N ENGL J MED                   295   597 976
   006   HAHN TJ               N ENGL J MED                   292   550 974
   007   TAUSSIG LM            J PEDIATR                       82   380 973
   008   HAHN TJ               J CLIN ENDOCRINOL METAB         39   274 974
   009   ANON                  MEDICAL LABORATORY TECHNOLOGY        169 969
   010   SLATOPOLSKY E         J CLIN INVEST                   50   492 971
   011   HADDAD JG JR          J LAB CLIN MED                  81    22 973
   012   KERMACK KA            BIOMETRIKA                      37    30 950
   013   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
   014   LAPEY A               J PEDIATR                       84   328 974
   015   PARSONS JA            CLIN ENDOCRINOL METAB            1    33 972
   016   HAHN TJ               DRUGS                           12   201 976
   017   REEMTSMA K            PEDIATRICS                      22   525 958
   018   ARNAUD SB             PROC SOC EXP BIOL MED          149   570 975
   019   THOMPSON GR           J CLIN INVEST                   45    94 966
   020   GERTNER JM            BR MED J                         1  1310 977
   021   DELUCA HF             J LAB CLIN MED                  87     7 976
   022   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   023   TYSON KRT             J PEDIATR SURG                   3   271 968
   024   GARABEDIAN M          PROC NAT ACAD SCI USA           69  1673 972
   025   SCHNEIDER LE          SCIENCE                        196  1452 977
   026   JUBIZ W               J CLIN ENDOCRINOL METAB         44   617 977
   027   LACHMAN E             AM J ROENTG RAD THER NUCL MED   74   712 955
   028   WILSON CR             NORLAND CAMERON BONE MINERAL             972
   029   LEVIN ME              N ENGL J MED                   294   241 976
CT   1   AVIOLI LV             CLIN ENDOCRINOL METAB            8   547 979
     2   ANON                  NUTR REV                        37   247 979
     3   CHASE HP              J PEDIATR                       95   337 979
     4   WEISMAN Y             J PEDIATR                       95   416 979
     5   MEREDITH SC           CLIN ENDOCRINOL METAB            9   131 980
     6   LOVINGER RD           PEDIATRICS                      66   359 980
     7   MITCHELL EA           J PEDIATR                       97   789 980
     8   PITT MJ               RADIOL CLIN NORTH AM            19   581 981
     9   SOLOMONS NW           AM J CLIN NUTR                  34   462 981
    10   CONGDEN PJ            ARCH DIS CHILD                  56   708 981
    11   COPPENHAVER D         HUM GENET                       57   399 981
    12   PARK RW               GASTROENTEROLOGY                81  1143 981
    13   LLOYDSTILL JD         J PEDIATR                       99   580 981
    14   LEVI N                RIV ITAL PEDIATR                 8   695 982
    15   AGUS ZS               KIDNEY INT                      24   113 983
    16   KATZ S                CELL CALC                        5   421 984
    17   GOTZ M                ATEMWEGS LUNGENKRANKH           10   594 984
    18   LOGVINOFF MM          CLIN PEDIATR                    23   389 984
    19   HODGES P              J AM DIET ASSOC                 84   664 984
    20   HUBBARD VS            SEM RESPIR MED                   6   308 985
    21   LO CW                 AM J CLIN NUTR                  42   644 985
    22   HANLY JG              Q J MED                         56   377 985
    23   FRIEDMAN HZ           GASTROENTEROLOGY                88   808 985
    24   REITER EO             J PEDIATR                      106    21 985
    25   DODGE JA              ACTA PAEDIATR SCAND SUPPL 317 1985    31 985
    26   DUHAMEL JF            ARCH FR PEDIATR                 43   229 986

PN 79128
RN 01108 
AN 79241418
AU Weisman-Y.  Reiter-E.  Stern-R-C.  Root-A.
TI Serum concentrations of 25-hydroxyvitamin D and
   24,25-dihydroxyvitamin D in patients with cystic fibrosis.
SO J-Pediatr. 1979 Sep. 95(3). P 416-8.
MJ CYSTIC-FIBROSIS: bl.  DIHYDROXYCHOLECALCIFEROLS: bl.
   HYDROXYCHOLECALCIFEROLS: bl.
MN HUMAN.  SUPPORT-U-S-GOVT-P-H-S.
EX Steatorrhea is a prevalent gastrointestinal manifestation of cystic
   fibrosis.  Although deficiencies of vitamins A, E, and K have been
   described in patients with this disease, vitamin D deficiency and
   rickets have rarely been reported.  The major form of vitamin D,
   cholecalciferol (vitamin D3), is produced by ultraviolet irradiation
   of 7-dehydrocholesterol in the skin.  Ergocalciferol (vitamin D2) is
   a product of plant ergosterol.  We studied the vitamin D status of
   patients with cystic fibrosis by measurement of the serum
   concentrations of the major circulating metabolites of vitamin D:
   25-hydroxyvitamin D and 24,25-dihydroxyvitamin D.  The mean serum
   concentrations of total 25OHD, 25OHD3, and 24,25(OH)2D and
   25OHD3/25OHD ratios in patients with cystic fibrosis were similar to
   values recorded in control subjects.  The present study demonstrates
   that the serum concentrations of the major metabolites of vitamin D
   in patients with cystic fibrosis are similar to those in healthy
   subjects.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   295   597 976
   002   KOPEL FB              GASTROENTEROLOGY                62   483 972
   003   FARRELL PM            J CLIN INVEST                   60   233 977
   004   TORSTENSON OL         PEDIATRICS                      45   857 970
   005   KEATING JP            PEDIATRICS                      46    41 970
   006   WEISMAN Y             J PEDIATR                       91   904 977
   007   STERN RC              J PEDIATR                       89   406 976
   008   PREECE MA             Q J MED                         44   575 975
   009   HADDAD JG JR          NATURE                         244   515 973
   010   HAHN TJ               J PEDIATR                       94    38 979
   011   HUBBARD VS            J PEDIATR                       94    84 979
CT   1   PITT MJ               RADIOL CLIN NORTH AM            19   581 981
     2   PARK RW               GASTROENTEROLOGY                81  1143 981
     3   SHANY S               AM J CLIN NUTR                  40  1290 984
     4   HANLY JG              Q J MED                         56   377 985
     5   REITER EO             J PEDIATR                      106    21 985
     6   DODGE JA              ACTA PAEDIATR SCAND SUPPL 317 1985    31 985
     7   DUHAMEL JF            ARCH FR PEDIATR                 43   229 986

PN 79129
RN 01109 
AN 79111345
AU Huff-D-S.  Huang-N-N.  Arey-J-B.
TI Atypical cystic fibrosis of the pancreas with normal levels of sweat
   chloride and minimal pancreatic lesions.
SO J-Pediatr. 1979 Feb. 94(2). P 237-9.
MJ CHLORIDES: an.  CYSTIC-FIBROSIS: di.  SWEAT: an.
MN CASE-REPORT.  CHILD.  CYSTIC-FIBROSIS: fg, pa.  HUMAN.  INFANT.
   MALE.  PANCREAS: pa.
EX This paper presents additional evidence of the variability and
   independence of the involvement of the sweat glands in cystic
   fibrosis.  A case report of an infant girl, who died at age 9 years
   of progressive pulmonary disease, is presented.  The case indicates
   that fatal cystic fibrosis, or a variant thereof, can exist with
   normal levels of sweat chloride and that the pulmonary disease
   develops independently of the functional abnormality of the sweat
   glands.
RF 001   SHWACHMAN H           BIRTH DEF ORIG ART SER           8   102 972
   002   THOMAIDIS TS          J PEDIATR                       63   444 963
   003   LANDING BH            ANN NY ACAD SCI                 93   518 962
   004   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   005   DI SANTAGNESE PA      JAMA                           172  2065 960
   006   COGSWELL JJ           ARCH DIS CHILD                  49   520 974
   007   SARSFIELD JK          ARCH DIS CHILD                  50   463 975
CT   1   SHWACHMAN H           J PEDIATR                       95   661 979
     2   DAVIS PB              AM J MED                        69   643 980
     3   STERN RC              LANCET                           1  1401 982
     4   WONG LTK              GUT                             23   744 982
     5   BARBERO GJ            J PEDIATR                      100   914 982
     6   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
     7   YEUNG WH              CLIN PEDIATR                    23   603 984
     8   MCCARTHY VP           PEDIATR INFECT DIS               5   256 986
     9   ROSENSTEIN BJ         CLIN PEDIATR                    26    78 987

PN 79130
RN 01110 
AN 79241407
AU Chipps-B-E.  Alderson-P-O.  Roland-J-M.  Yang-S.  van-Aswegen-A.
   Martinez-C-R.  Rosenstein-B-J.
TI Noninvasive evaluation of ventricular function in cystic fibrosis.
SO J-Pediatr. 1979 Sep. 95(3). P 379-84.
MJ CYSTIC-FIBROSIS: pp.  HEART-VENTRICLE: pp.
MN ADOLESCENCE.  ADULT.  ANGIOGRAPHY.  CARBON-DIOXIDE: bl.  CHILD.
   CHILD-PRESCHOOL.  ECHOCARDIOGRAPHY.  ELECTROCARDIOGRAPHY.  FEMALE.
   HEART-VENTRICLE: ra, ri.  HUMAN.  MALE.  OXYGEN: bl.
   RESPIRATORY-FUNCTION-TESTS.  SUPPORT-U-S-GOVT-P-H-S.
AB The cardiac function of 21 patients with cystic fibrosis was studied
   using radionuclides and M-mode echocardiography. The patients (mean
   age 13.2 years, range 4 to 27) had a wide range of clinical and
   pulmonary function abnormalities (mean Shwachman-Kulczycki score
   62.1). Decreased right ventricular ejection fraction was found in 13
   of 18 patients (72%); an additional four patients had abnormal septal
   motion on ECHO. Left ventricular ejection fraction was abnormal at
   rest in four patients (19%); an additional four patients had
   borderline low LVEF. The LV pre-ejection period to ejection time
   ratio increased significantly (i.e., worsening LV performance) with
   deterioration of S-K score, chest radiograph score, and forced
   expiratory volume in 1 second. Three of eight patients with normal
   LVEF at rest had an abnormal response to supine bicycle exercise:
   LVEF fell in two patients and was unchanged in one. Thus evidence of
   LV dysfunction was observed in seven of 21 (33%) of the patients;
   four at rest and in three only during exercise.
RF 001   LIEBMAN J             IN: MANGOS JA                         41 976
   002   SIASSI B              J PEDIATR                       78   794 971
   003   ROSENTHAL A           PEDIATR CLIN NORTH AM           23   327 976
   004   GEWITZ M              AM J DIS CHILD                 131   275 977
   005   FLEMING DG            PEDIATR RES                     12   560 978
   006   MARSHALL RC           CIRCULATION                     56   820 977
   007   KACHEL RG             CHEST                           74   286 978
   008   WILLIAMS JF JR        J CLIN INVEST                   47  1143 968
   009   FRANK MJ              CIRCULATION                     47   798 973
   010   STEELE P              AM J MED                        59    21 975
   011   BAUM GL               N ENGL J MED                   285   361 971
   012   MICHELSON N           DIS CHEST                       38   435 960
   013   BARNES GL             AUST PAEDIATR J                  6    81 970
   014   OPPENHEIMER EH        JOHNS HOPKINS MED J            133   252 973
   015   STRAUSS HW            AM J CARDIOL                    28   575 971
   016   BUROW RD              CIRCULATION                     56  1024 977
   017   QURESHI S             J NUCL MED                      19   135 978
   018   PITT B                N ENGL J MED                   296  1097 977
   019   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   020   BRASFIELD D           PEDIATRICS                      63    24 979
   021   GENTZLER R            CIRCULATION                     50   324 974
   022   DOUGLASS KH           J NUCL MED                      19   670 978
   023   CANTOR A              CIRCULATION                     58  1123 978
   024   POLGAR G              PULMONARY FUNCTION TESTING IN            971
   025   HOOPER RG             CIRCULATION                     50  1205 974
   026   BOWDEN DH             AM J MED                        38   226 965
   027   ZINMAN R              CF CENT DIRECTO 17TH MTG ABST            977
   029   ROBOTHAM JL           J APPL PHYSIOL                  44   703 978
   030   ROBOTHAM JL           J APPL PHYSIOL                  46   411 979
   031   BERGER HJ             AM J CARDIOL                    41   897 978
   032   WEISSLER AM           MOD CONCEPTS CARDIOVASC DIS     40     5 971
   033   BORER JS              N ENGL J MED                   296   839 977
CT   1   LESTER LA             J PEDIATR                       97   742 980
     2   BOVE AA               PROG CARDIOVASC DIS             23   365 981
     3   BERGER HJ             AM J CARDIOL                    47   950 981
     4   MATTHAY RA            MED CLIN NORTH AM               65   489 981
     5   JACOBSTEIN MD         CHEST                           80   399 981
     6   NEWTH CJL             AM REV RESPIR DIS              124   463 981
     7   MOSS AJ               PEDIATRICS                      70   728 982
     8   COATES AL             CHEST                           82   543 982
     9   HIRSCHFELD SS         CHEST                           82   524 982
    10   ROBOTHAM JL           CLIN CHEST MED                   4   161 983
    11   DENNIS JB             SEM NUCL MED                    13   292 983
    12   HESS OM               AM HEART J                     106  1377 983
    13   BADKE FR              AM J CARDIOL                    53  1187 984
    14   CHERON G              ACTA PAEDIATR SCAND             73   697 984
    15   PARRISH M             J PEDIATR                      104   165 984
    16   GOODING CA            J PEDIATR                      105   384 984
    17   BENSON LN             AM REV RESPIR DIS              130   987 984
    18   MICHAEL JR            AM REV RESPIR DIS              130   516 984
    19   MOSKOWITZ WB          PEDIATR PHARMACOL                5   139 985
    20   LESTER LA             SEM RESPIR MED                   6   285 985
    21   PANIDIS IP            J AM COLL CARDIOL                6   701 985
    22   PIEPSZ A              PEDIATR PULMONOL                 3    24 987

PN 79131
RN 01111 
AN 79069472
AU Finkelstein-E.  Hall-K.
TI Aminoglycoside clearance in patients with cystic fibrosis [letter].
SO J-Pediatr. 1979 Jan. 94(1). P 163-4.
MJ AMIKACIN: me.  CYSTIC-FIBROSIS: me.  KANAMYCIN: aa.  KIDNEY: me.
MN CHILD.  HUMAN.
EX We have been utilizing a patient's individual pharmacokinetic profile
   to plan and monitor aminoglycoside therapy, and we have often noted
   what appeared to be an extremely rapid elimination rate of gentamicin
   in our patients with cystic fibrosis.  The patients with cystic
   fibrosis had significantly greater renal and total clearances than
   those without cystic fibrosis.  If this observation could be extended
   to other drugs (such as the aminoglycosides), which are not normally
   subject to renal secretion, it would prove intriguing evidence for a
   possible primary renal defect in these patients.
RF 001   VOGELSTEIN B          J PEDIATR                       91   333 977
   002   CLARKE JT             CLIN PHARMACOL THER             15   610 974
   003   HEWITT WL             AM J MED US AMIKACIN SYMP       62   863 977
   004   JUSKO WJ              PEDIATRICS                      56  1038 975
   005   YAFFE SJ              J INFECT DIS                   135   828 977
CT   1   MICHALSEN H           ANTIMICROB AGENTS CHEMOTHER     19  1029 981
     2   LEVY J                J ANTIMICROB CHEMOTHER          10   227 982
     3   KRAEMER R             EUR J PEDIATR                  138   172 982
     4   THIRUMOORTHI MC       J PEDIATR                      102   941 983
     5   MACDONALD NE          J PEDIATR                      103   985 983
     6   PADOAN R              J PEDIATR                      103   320 983
     7   ISLES A               AM REV RESPIR DIS              127   417 983
     8   NAHATA MC             DEVELOP PHARM THER               7   221 984
     9   MARTINI N             J CLIN HOSP PHARM                9   303 984
    10   KELLY HW              DRUG INTEL CLIN PHARM           18   772 984
    11   SCHOFIELD DH          DRUG INTEL CLIN PHARM           18   153 984
    12   LEEDER JS             CLIN PHARMACOL THER             36   355 984
    13   LEVY J                J PEDIATR                      105   117 984
    14   SPINO M               J PEDIATR                      105   829 984
    15   COURCOL RJ            INT J CLIN PHARMACOL RES         5    87 985
    16   FRASER GL             DRUG INTEL CLIN PHARM           19   757 985
    17   HORREVORTS  AM        CHEST                           88   260 985
    18   SPINO M               J PEDIATR                      107    64 985
    19   GOLDFARB J            J CLIN PHARMACOL                26   222 986
    20   AUTRET E              EUR J CLIN PHARMACOL            31    79 986
    21   RUBIO TT              AM J MED                        81    73 986
    22   KEARNS GL             J PEDIATR                      108   847 986
    23   PEDERSEN SS           ANTIMICROB AGENTS CHEMOTHER     31   594 987

PN 79132
RN 01112 
AN 80008520
AU Loening-Baucke-V-A.  Mischler-E.  Myers-M-G.
TI A placebo-controlled trial of cephalexin therapy in the ambulatory
   management of patients with cystic fibrosis.
SO J-Pediatr. 1979 Oct. 95(4). P 630-7.
MJ AMBULATORY-CARE.  CEPHALEXIN: tu.  CYSTIC-FIBROSIS: co.
MN ADMINISTRATION-ORAL.  ADOLESCENCE.  ADULT.
   BACTERIAL-INFECTIONS: dt, et.  CEPHALEXIN: ad, ae.  CHILD.
   CHILD-PRESCHOOL.  CLINICAL-TRIALS.  CYSTIC-FIBROSIS: pp.  FEMALE.
   HUMAN.  INFANT.  MALE.  PLACEBOS.  RESPIRATORY-TRACT-INFECTIONS: dt.
   SPUTUM: mi.
AB The effects of oral administration of cephalexin were evaluated in a
   double-blind, placebo-controlled, crossover study in 17 patients
   with mild to moderate pulmonary disease due to cystic fibrosis.  For
   two years, four-month periods with cephalexin were alternated with
   four-month placebo periods.  Thus, patients served as their own
   control subjects.  Fungal vulvovaginitis occurred in two patients
   during cephalexin therapy.  During the 2 years of study, the rate of
   colonization with mucoid strains of Pseudomonas aeruginosa increased
   and disease severity deteriorated in patients initially colonized
   with P. aeruginosa.  Short-term courses of sputum culture-specific
   antibiotics improved the course of some patients with mild to
   moderate pulmonary disease due to cystic fibrosis.  Treatment with
   cephalexin decreased the frequency of respiratory illnesses,
   respiratory illnesses requiring antibiotics, and hospitalizations
   for respiratory illnesses in patients initially colonized with
   Staphylococcus aureus and/or Haemophilus influenzae, and also
   reduced colonization with these organisms.  Improved weight gain in
   16 of 17 patients was associated with periods of cephalexin therapy.
   Pulmonary function tests remained stable or improved in 10 or 14
   patients.  Disease severity improved in patients not colonized with
   P. aeruginosa.
RF 001   SHWACHMAN H           N ENGL J MED                   241   185 949
   002   DI SANTAGNESE PA      AM J DIS CHILD                  72    17 946
   003   LAWSON D              IN: LAWSON D PROC 5TH INT CF         225 969
   004   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   005   SHWACHMAN H           PEDIATRICS                      46   335 970
   006   MATTHEWS LW           IN: MANGOS JA                        303 973
   007   GIBSON LE             PEDIATRICS                      23   545 959
   008   MONROE PW             APPL MICROBIOL                  18   214 969
   009   HUANG NN              J PEDIATR                       59   512 961
   010   LENNETTE EH           MANUAL OF CLINICAL MICROBIOLO            974
   011   CATLIN BW             ANTIMICROB AGENTS CHEMOTHER      7   265 975
   012   HUNTBERGER DV         STATISTICAL INFERENCE IN BIOM            970
   013   SNEDECOR GW           STATISTICAL METHODS                      967
   014   LOURIA DB             JAMA                           182  1082 962
   015   LORIAN V              APPL MICROBIOL                  15   564 967
   016   BARTLETT JG           AM REV RESPIR DIS              117  1019 978
   017   STECHENBERG BW        PEDIATRICS                      58   532 976
   018   BURNS MW              LANCET                           1   270 968
   019   MAY JR                LANCET                           2   534 953
   020$  MAY JR                J CLIN MICROBIOL                17   254 964
   021   REYNOLDS HY           ANN INTERN MED                  82   819 975
   022   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   023   DOGGETT RG            J PEDIATR                       68   215 966
   024   DOGGETT RG            INFECT IMMUN                     6   628 972
   025   KULCZYCKI LL          JAMA                           240    30 978
   026   MAY JR                ARCH DIS CHILD                  47   908 972
   027   MEARNS MB             ARCH DIS CHILD                  47   902 972
CT   1   WIENTZEN R            AM J DIS CHILD                 134  1134 980
     2   MARKS MI              J PEDIATR                       98   173 981
     3   NOLAN G               J PEDIATR                      101   626 982
     4   KRAEMER R             EUR J PEDIATR                  138   172 982
     5   DAVIS PB              J PEDIATR                      102   177 983
     6   KELLY HW              DRUG INTEL CLIN PHARM           18   772 984
     7   DAVIS PB              CHEST                           85   802 984
     8   HARRISON CJ           PEDIATR PHARMACOL                5     7 985
     9   DAVIS PB              SEM RESPIR MED                   6   261 985
    10   MISCHLER EH           SEM RESPIR MED                   6   271 985
    11   SMITH SR              J CLIN HOSP PHARM               10   243 985
    12   NELSON JD             J PEDIATR                      106  1030 985
    13   GOTZ M                MONATSSCHR KINDERHEILKD        133   718 985
    14   FRIEND PA             J INFECT                        13    55 986
    15   LITTLEWOOD JM         J ROY SOC MED                   79    55 986
    16   FICK RB               AM REV RESPIR DIS              133   418 986

PN 79133
RN 01113 
AN 79111347
AU Rosenfeld-R.  Spigelblatt-L.  Chicoine-R.
TI False positive sweat test, malnutrition, and the Mauriac syndrome.
SO J-Pediatr. 1979 Feb. 94(2). P 240-2.
MJ CHLORIDES: an.  DWARFISM: co.  HEPATOMEGALY: co.
   NUTRITION-DISORDERS: co.  SWEAT: an.
MN CASE-REPORT.  CHILD.  CYSTIC-FIBROSIS: di.
   DIABETES-MELLITUS-INSULIN-DEPENDENT: co.  FALSE-POSITIVE-REACTIONS.
   FEMALE.  HUMAN.  SYNDROME.
EX Mauriac syndrome is characterised by hepatomegaly, glycogen
   infiltration of the liver, retarded sexual maturation, and short
   stature in diabetic children.  We report the first example of Mauriac
   syndrome, in a patient clinically malnourished and edematous, who had
   a transient false positive sweat test.  Malnourished children who
   have a positive sweat test should have repeated sweat tests once the
   malnourished state has been reversed.  This would eliminate error in
   the diagnosis of cystic fibrosis.
RF 001   CONN JW               ARCH INTERN MED                 83   416 949
   002   HARRIS RC             PEDIATRICS                      31  1044 963
   003   LOBECK CC             J PEDIATR                       62   868 963
   004   ROBINSON GC           PEDIATRICS                      30   797 962
   005   MORSE WI              N ENGL J MED                   264  1021 961
   006   MACE JW               CLIN PEDIATR                    10   285 971
   007   DURAND P              RECENT PROG MED                 44   279 968
   008   DURAND P              J PEDIATR                       75   665 969
   009   MARDOFF L             J PEDIATR                       73   244 968
   010   GIBSON LE             PEDIATRICS                      23   545 959
   011   SCHALES O             J BIOL CHEM                    140   879 941
CT   1   SHWACHMAN H           J PEDIATR                       95   661 979
     2   PARTINGTON MW         AM J MED GENET                  10    65 981
     3   BEER SI               ISR J MED SCI                   17  1181 981
     4   SCHWACHMAN H          J PEDIATR                       98   576 981
     5   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
     6   QUINTON PM            ANNU REV MED                    34   429 983
     7   LUTHI M               HELV PAEDIATR ACTA              38   149 983
     8   DEMAY G               ARCH FR PEDIATR                 41   370 984
     9   MOR A                 MINERAL ELECTROL METAB          11   155 985
    10   CHRISTOFFEL KS        J PEDIATR                      107   231 985
    11   BECK R                ACTA PAEDIATR SCAND             75   639 986
    12   RUDDY RM              CLIN PEDIATR                    26    83 987

PN 79134
RN 01114 
AN 79111346
AU Porter-R-C.  Cloutier-M-M.  Brasfield-D-M.  Mangos-J-A.  Miale-T.
   Tiller-R-E.
TI Cystic fibrosis in two black children with sickle cell anemia.
SO J-Pediatr. 1979 Feb. 94(2). P 239-40.
MJ ANEMIA-SICKLE-CELL: co.  CYSTIC-FIBROSIS: co.
MN CASE-REPORT.  CHILD.  FEMALE.  HUMAN.  INFANT.  MALE.
   SUPPORT-U-S-GOVT-P-H-S.
AB Sickle cell anemia and cystic fibrosis are the most frequent lethal
   inherited diseases in the black and white population, respectively.
   The occurrence of both diseases in the same individual has not been
   reported in the literature.  This report presents two such patients
   and poses questions concerning the possible clinical implications of
   the simultaneous occurrence of both diseases.
RF 001   GIBSON LE             PEDIATRICS                      23   545 959
   002   STEINBERG AG          AM J HUM GENET                  12   416 960
   003   KULCZYCKI LL          CLIN PEDIATR                     3   692 964
   004   KULCZYCKI LL          AM J DIS CHILD                 127    64 974
   005   HEFFER ET             NY STATE J MED                  74  2355 974
   006   SULTZ HA              AM J PUBLIC HEALTH              58   491 968
   007   WINTROBE MM           CLINICAL HEMATOLOGY                  823 974

PN 79135
RN 01115 
AN 79241401
AU Chase-H-P.  Long-M-A.  Lavin-M-H.
TI Cystic fibrosis and malnutrition.
SO J-Pediatr. 1979 Sep. 95(3). P 337-47. (REVIEW).
MJ CYSTIC-FIBROSIS: co.  NUTRITION-DISORDERS: et.
MN CYSTIC-FIBROSIS: me.  DIETARY-PROTEINS: me.  ENERGY-METABOLISM.
   FATTY-ACIDS-ESSENTIAL: df.  HUMAN.  INFANT.  IRON: df.
   LINOLEIC-ACIDS: bl.  REVIEW.  SELENIUM: df.  TRACE-ELEMENTS: df.
   SUPPORT-U-S-GOVT-P-H-S.  VITAMIN-A-DEFICIENCY: et.
   VITAMIN-B-12-DEFICIENCY: et.  VITAMIN-D-DEFICIENCY: et.
   VITAMIN-E-DEFICIENCY: et.  VITAMIN-K-DEFICIENCY: et.  ZINC: df.
AB Cystic fibrosis as a specific disease entity has been known to be
   associated with malnutrition for almost half a century. The
   importance of the malnutrition in the disease process remains
   unknown, as does much information about specific nutritional
   deficiencies in CF. Supplements for children with CF should include
   extra energy as fat or carbohydrate, a form of linoleic acid that can
   be absorbed, hydrolyzed protein, fat-soluble vitamins with vitamins A
   and E in a water emulsion, vitamin B12, probably B vitamins and
   vitamin C, and trace minerals. Routine measurements of nutritional
   status, particularly in children with growth failure, should be made
   at regular intervals and should include a three-day diet record and a
   simultaneous 72-hour stool fat determination. If fat malabsorption is
   not controlled by pancreatic enzymes, the use of antacids or
   cimetidine should be considered. The true role of nutrition in
   patients with CF will not be known until the appropriate studies are
   completed.
RF 001   LOBECK CC             IN: STANBURY JB                     1605 972
   002   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   003   REGAN PT              N ENGL J MED                   297   854 977
   004   KATTWINKEL J          PEDIATRICS                      50   133 972
   005   COX KL                CYSTIC FIBROSIS                 17     7 978
   006   COX KL                CYSTIC FIBROSIS                 17     7 978
   007   DIMAGNO EP            N ENGL J MED                   296  1318 977
   009   KHAW K-T              CF CLUB ABST                          58 978
   010   GRACEY M              ARCH DIS CHILD                  44   401 969
   011   YASSA JG              ARCH DIS CHILD                  53   777 978
   012   CHASE HP              LANCET                           2   236 978
   013   GOODCHILD MC          ARCH DIS CHILD                  50   769 975
   014   HANSEN AE             PEDIATRICS                      31   171 963
   015   DUPONT J              FED PROC                        37   445 978
   016   HOPKINS DT            PROC SOC EXP BIOL MED          114    82 963
   017   FRIEDMAN Z            PEDIATRICS                      58   650 976
   018   ELLIOTT RB            PEDIATRICS                      57   474 976
   019   ROSENLUND ML          PEDIATRICS                      59   428 977
   020   FLEISHER DS           J PEDIATR                       64   341 964
   021   DOLAN TF JR           CLIN PEDIATR                     9   295 970
   022   STROBER W             PEDIATRICS                      43   416 969
   023   WEST CD               AM J DIS CHILD                  72   251 946
   024   ANFANGER H            AM J DIS CHILD                  77   425 949
   025   FRISANCHO AR          AM J CLIN NUTR                  27  1052 974
   026   VAUGHAN WJ            SCIENCE                        199   783 978
   027   BERRY HK              AM J DIS CHILD                 129   165 975
   028   UNDERWOOD BA          PEDIATR RES                      6    26 972
   029   ABERNATHY RS          AM J DIS CHILD                 130  1360 976
   030   SMITH FR              J LAB CLIN MED                  80   423 972
   031   COUSINS RJ            J NUTR                          97   409 969
   032   OWEN GM               J PEDIATR                       78  1042 971
   033   WARWICK WJ            CLIN PEDIATR                    15   807 976
   034   SCOTT J               AM J MED                        63   488 977
   035   HAHN TJ               J PEDIATR                       94    38 979
   036   HUBBARD VS            J PEDIATR                       94    84 979
   037   LUBIN AH              CF CLUB ABST                          71 978
   038   FARRELL PM            J CLIN INVEST                   60   233 977
   039   OSKI FA               J PEDIATR                       70   211 967
   040   DOLAN TF JR           CLIN PEDIATR                    15   597 976
   041   GREEN J               NUTR ABSTR REV                  39   321 969
   042   HOPE WC               PROSTAGLANDINS                  10   557 975
   043   SCOTT ML              IN: DELUCA HF                        357 970
   044   KAPLAN E              N ENGL J MED                   279    65 968
   045   OPPENHEIMER EH        BULL JOHNS HOPKINS HOSP         98   353 956
   046   DARBY CW              ARCH DIS CHILD                  48    72 973
   047   NITOWSKY HM           AM J CLIN NUTR                  10   368 962
   048   TENGERDY RP           INT ARCH ALLERGY                44   221 973
   049   HARRIES JT            ARCH DIS CHILD                  46   341 971
   050   WALTERS TR            AM J DIS CHILD                 124   641 972
   051   KOMP DM               CHEST                           58   501 970
   052   ANSELL JE             JAMA                           238    40 977
   053   FILER LJ JR           PEDIATRICS                      48   483 971
   054   MOSS MH               AM J DIS CHILD                 117   540 969
   055   SUTHERLAND JM         AM J DIS CHILD                 113   524 967
   056   VEEGER W              N ENGL J MED                   267  1341 962
   057   DEREN JJ              N ENGL J MED                   288   949 973
   058   RUCKER RW             N ENGL J MED                   289   329 973
   059   WEBER AM              N ENGL J MED                   289  1001 973
   060   SHWACHMAN H           PEDIATRICS                      25   155 960
   061   DAVIDSON M            IN: RUDOLPH AM                       994 977
   062   HALSTED JA            LANCET                           1   322 970
   063   PALIN HD              PEDIATR RES ABST 343            10   358 976
   064   JACOB RA              AM J CLIN NUTR                  31   638 978
   065   HAMBRIDGE KM          PEDIATR CLIN NORTH AM           24    95 977
   066   SMITH JC JR           SCIENCE                        181   954 973
   067   SMITH JE              J LAB CLIN MED                  84   692 974
   068   PEKAREK RS            PROC SOC EXP BIOL MED          138   728 971
   069   HEINRICH HC           KLIN WOCHENSCHR                 55   587 977
   070   FISCHER WC            J NUTR                         107  1493 977
   071   MISCHLER EH           CF CLUB ABST                          80 978
   072   HELLER RM             J PEDIATR                       92   947 978
   073   CHASE HP              JAMA                           230  1535 974
   074   HANSEN L              AM J CLIN PATHOL                46   133 966
CT   1   CHU JY                NUTR REV                        37   351 979
     2   KARP RJ               CLIN CHEST MED                   1   375 980
     3   LEE JA                ANN CLIN LAB SCI                10   227 980
     4   HUBBARD VS            J PEDIATR                       96   421 980
     5   SHEPHERD R            J PEDIATR                       97   351 980
     6   GOW R                 LANCET                           2  1071 981
     7   HAMILTON RM           LIPIDS                          16   374 981
     8   PASSERO MA            CLIN PEDIATR                    20   264 981
     9   SCHONI M              HELV PAEDIATR ACTA              36   359 981
    10   BELL L                J CAN DIET ASSOC                42    62 981
    11   CONGDEN PJ            ARCH DIS CHILD                  56   708 981
    12   ANON                  J AM DIET ASSOC                 78   443 981
    13   PARK RW               GASTROENTEROLOGY                81  1143 981
    14   CASTILLO R            J PEDIATR                       99   583 981
    15   CORRIGAN JJ           J PEDIATR                       99   254 981
    16   GORDON EF             J PEDIATR                       99   341 981
    17   ROSENFELD RG          J PEDIATR                       99   252 981
    18   REED MD               AM J DIS CHILD                 135   829 981
    19   BRANCHINI BR          LANCET                           1   618 982
    20   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
    21   LEVI N                RIV ITAL PEDIATR                 8   695 982
    22   STAFFORD RJ           CLIN GASTROENTEROL              11   141 982
    23   MILLER M              AM J CLIN NUTR                  36   492 982
    24   HUBBARD VS            J AM DIET ASSOC                 80   127 982
    25   PENCHARZ PB           J PEDIATR GASTROENTEROL NUTR     2   400 983
    26   SHEPHERD RW           J PEDIATR GASTROENTEROL NUTR     2   439 983
    27   MERRITT RJ            ADV NUTR RES                     5    77 983
    28   BRANCHINI BR          PEDIATR RES                     17   850 983
    29   FARRELL PM            J DENT CHILD                    50   385 983
    30   ATER JL               PEDIATRICS                      71   810 983
    31   NEVE J                ACTA PAEDIATR SCAND             72   437 983
    32   SMITH AE              J PEDIATR                      103   820 983
    33   HANSEN RC             ARCH DERMATOL                  119    51 983
    34   HUBBARD VS            EUR J PEDIATR                  141    68 983
    35   HOLT TL               IRCS MED SCI BIOCHEM            12   370 984
    36   SCHONI M              PEDIATR RES                     18    66 984
    37   ZENTLERMUNRO PL       GUT                             25   500 984
    38   ABRAMS CK             J CLIN INVEST                   73   374 984
    39   HODGES P              J AM DIET ASSOC                 84   664 984
    40   PARSONS HG            J PEDIATR                      105   958 984
    41   VICHINSKY EP          J PEDIATR                      105    15 984
    42   KUHN RJ               CLIN PHARMACY                    4   555 985
    43   MCKENNA MC            J PEDIATR GASTROENTEROL NUTR     4    45 985
    44   HUBBARD VS            SEM RESPIR MED                   6   308 985
    45   ZENTLERMUNRO PL       GUT                             26   892 985
    46   MAAK B                Z KLIN MED                      40  1115 985
    47   HOLT TL               AM J CLIN NUTR                  41  1061 985
    48   DODGE JA              ACTA PAEDIATR SCAND SUPPL 317 1985    31 985
    49   FERNANDES J           ACTA PAEDIATR SCAND SUPPL 317 1985     5 985
    50   HUGHES RL             ACTA PAEDIATR SCAND SUPPL 317 1985    42 985
    51   NEIJENS HJ            ACTA PAEDIATR SCAND SUPPL 317 1985    38 985
    52   ANON                  LANCET                           1   249 986
    53   ABMAN SH              J PEDIATR GASTROENTEROL NUTR     5   393 986
    54   GIBSON RA             J PEDIATR GASTROENTEROL NUTR     5   408 986
    55   LESTER LA             J PARENT ENTERAL NUTR           10   289 986
    56   KOHLER JA             J CLIN HOSP PHARM               11    21 986
    57   SOUTTER VL            CLIN GASTROENTEROL              15   137 986
    58   MISCHLER EH           PEDIATR RES                     20    36 986
    59   DUHAMEL JF            ARCH FR PEDIATR                 43   229 986
    60   CRAIGSCHMIDT MC       AM J CLIN NUTR                  44   816 986
    61   MOORE MC              AM J CLIN NUTR                  44    33 986
    62   GOODCHILD MC          J ROY SOC MED                   79    32 986
    63   SHEPHERD RW           J PEDIATR                      109   788 986
    64   DANIELS L             J PEDIATR GASTROENTEROL NUTR     6   381 987
    65   HUBBARD VS            LIPIDS                          22   424 987
    66   ZAKRZEWSKI JT         BR J CLIN PHARMACOL             23    19 987
    67   YOUNGBERG  CA         DIG DIS SCI                     32   472 987

PN 79136
RN 01116 
AN 79069483
AU Moss-T-J.  Austin-G-E.  Moss-A-J.
TI Preatherosclerotic aortic lesions in cystic fibrosis.
SO J-Pediatr. 1979 Jan. 94(1). P 32-7.
MJ AORTA: pa.  ARTERIOSCLEROSIS: pa.  ATHEROSCLEROSIS: pa.
   CYSTIC-FIBROSIS: pa.
MN ADOLESCENCE.  ADULT.  ATHEROSCLEROSIS: co, et.  CHILD.
   CYSTIC-FIBROSIS: co.  ATHEROSCLEROSIS: pa.  FEMALE.  HUMAN.  MALE.
AB Patients with cystic fibrosis have fat malabsorption, providing an
   experimental model for evaluation of the hypothesis that a low-fat
   intake may prevent atherosclerosis. We studied the frequency and
   extent of aortic precursor lesions (fatty streaks, early
   fibromusculoelastic lesions, late fibromusculoelastic lesions) found
   at autopsy in this disease as well as in other patients with
   debilitating disorders but with no apparent impairment of fat
   absorption. Fatty streaks were less common in the cystic fibrosis
   group, as were the late fibromusculoelastic lesions. There was no
   significant difference in the frequency, length, or thickness of the
   early fibromusculoelastic lesions. The findings suggest that fat may
   be responsible for progression but not initiation of the
   fibromusculoelastic precursor lesions, and support the concept that
   early restriction of dietary fat may prevent, delay, or otherwise
   modify atherosclerosis in the adult.
RF 001$  ANON                  ARTERIOSCLEROSIS DHEW PUB NO?    2       971
   002   STRONG JP             J ATHEROSCLER RES                9   251 969
   003   HENNEKENS CH          PEDIATRICS                      58   211 976
   004   GLAGOV S              IN: WISSLER RW                         9 972
   005   MITCHELL S            PEDIATRICS                      49   165 972
   006   SHOHL AT              J PEDIATR                       23   267 943
   007   ANDERSEN DH           AM J DIS CHILD                  69   221 945
   008   ROSS CAC              ARCH DIS CHILD                  30   316 955
   009   BERRY HK              AM J DIS CHILD                 129   165 975
   010   HOLMAN RL             PEDIATRICS                      24    34 959
   011   ROSS R                N ENGL J MED                   295   369 976
   012   WILENS SL             AM J PATHOL                     27   825 951
   013   MCGILL HC JR          LAB INVEST                      18   560 968
   014   SCHWARTZ CJ           ARCH PATHOL                     83   325 967
   015   HARDIN NJ             AM J PATHOL                     73   301 973
   016   GORE I                ARCH PATHOL                     84    49 967
   017   STRONG JP             AM J PATHOL                     34   731 958
   018   FRIEDMAN M            ARCH PATHOL                     79   345 965
CT   1   MOSS TJ               J MENT DEFIC RES                24   137 980
     2   MOSS AJ               PEDIATRICS                      70   728 982

PN 79137
RN 01117 
AN 79069466
AU Sacher-M.  Shmerling-D-H.
TI PABA-test for diagnosis of exocrine pancreatic insufficiency
   [letter].
SO J-Pediatr. 1979 Jan. 94(1). P 159.
MJ P-AMINOBENZOIC-ACID: du.  AMINOBENZOIC-ACIDS: du.
   CYSTIC-FIBROSIS: di.
MN P-AMINOBENZOIC-ACID: ur.  CYSTIC-FIBROSIS: ur.  HUMAN.  INFANT.
   INFANT-NEWBORN.
EX We have also found a significant difference between the 6-hour
   urinary PABA recovery in healthy controls and CF patients, with no
   overlap of the ranges, and a good correlation with fecal chymotrypsin
   activity.  We can stress the usefulness of the test in this age
   group.  In studying a group of healthy newborn infants, however, the
   results were quite different: The PABA recovery was smaller and
   showed greater variations and overlap with results in CF patients
   occurred.  It is clear that the test is not applicable in newborn
   infants when performed in the described manner.  One possible
   explanation is the physiologically limited glomerular filtration rate
   in the newborn infant, which could have delayed the PABA excretion.
RF 001   NOUSIA-ARVANITAKIS S  J PEDIATR                       92   734 978
   002   SACHER M              ARCH DIS CHILD                  53   639 978

PN 79138
RN 01118 
AN 79241408
AU Fischer-E-G.  Shwachman-H.  Wepsic-J-G.
TI Brain abscess and cystic fibrosis.
SO J-Pediatr. 1979 Sep. 95(3). P 385-8.
MJ BRAIN-ABSCESS: et.  CYSTIC-FIBROSIS: co.
MN ADOLESCENCE.  ADULT.  BRAIN-ABSCESS: mi.  CASE-REPORT.  FEMALE.
   HUMAN.  MALE.  PROTEUS-INFECTIONS: et.  PROTEUS-MIRABILIS.
   PSEUDOMONAS-INFECTIONS: et.  STAPHYLOCOCCAL-INFECTIONS: et.
AB Brain abscess has only recently been considered a complication of
   cystic fibrosis. Three patients are reported here and a fourth cited
   from the literature. All of our patients were young adults with
   advanced pulmonary disease. The bacteria involved were mouth
   organisms and were found in the sputum culture in only one of the
   patients. Resistance was present to previously given antibiotics. As
   patients with cystic fibrosis survive into adulthood, the risk of
   developing a brain abscess appears to increase.
RF 001   SHWACHMAN H           CURR PROB PEDIATR NO 10          8       978
   002   DUFFNER PK            ARCH NEUROL                     36    27 979
   003   EVERETT ED            MEDICINE (BALTIMORE)            56    61 977
   004   JAGELS AE             J DENT RES                      55   991 976
   005   MOLINARI GF           NEUROLOGY (MINN)                23  1205 973
   006   PRUITT AA             MEDICINE (BALTIMORE)            57   329 978
   007   MATSON DD             PEDIATRICS                      27   772 961
   008   FISCHBEIN CA          AM J CARDIOL                    34    97 974
   009   NEWHOUSE M            N ENGL J MED                   295  1045 976
   010   WOOD WG JR            J EXP MED                       94   521 951
   011   GELLER A              NEUROLOGY (MINN)                27   185 977
   012   LEROUX BT             BR HEART J                      32   571 970
   013   HARRIS P              HUMAN PULMONARY CIRCULATI                962
   014   WAGENVOORT CA         PATHOLOGY OF PULMONARY HYPERT            977
   015   COMROE JH JR          LUNG CLINICAL PHYSIOLOGY AND             962
   016   ROSENTHAL A           AM J CARDIOL                    27   162 971
   017   ROSENTHAL A           PEDIATRICS                      59   588 977
CT   1   MCCARTHY MM           CLIN PEDIATR                    19   746 980
     2   SHERMAN JM            J PEDIATR                       96   952 980
     3   FISCHER EG            AM J DIS CHILD                 135   746 981
     4   SANGER RG             ORAL SURG                       53   131 982
     5   AYRES J               BR J DIS CHEST                  76    99 982
     6   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
     7   SHWACHMAN H           J PEDIATR SURG                  18   570 983
     8   RABKIN CS             ANN NEUROL                      15   608 984
     9   KLINE MW              PEDIATR INFECT DIS               4    72 985
    10   CANNY GJ              THORAX                          41   221 986
    11   KURLAND G             PEDIATRICS                      78  1097 986

PN 79139
RN 01119 
AN 81009005
AU Venugopal-S.  Shandling-B.
TI Meconium ileus: laparotomy without resection, anastomosis, or
   enterostomy.
SO J-Pediatr-Surg. 1979 Dec. 14(6). P 715-8.
MJ INFANT-NEWBORN-DISEASES: su.  INTESTINAL-OBSTRUCTION: su.
   MECONIUM.
MN CYSTIC-FIBROSIS: co.  FEMALE.  HUMAN.  ILEOSTOMY.  INFANT-NEWBORN.
   INTESTINAL-OBSTRUCTION: co, et.  LAPAROTOMY.  MALE.  METHODS.
AB During the 14 yr from 1965 through 1978, 49 infants presented shortly
   after birth with intestinal obstruction due to impacted meconium.
   Three of these patients did not have fibrocystic disease. Eight
   patients were cured by a Gastrografin enema. There were 18 patients
   who had complications that included associated atresia, volvulus,
   and/or peritonitis. Various operations were done including resection
   with either primary anastomosis or enterostomy or varieties of the
   foregoing. Twenty-three babies had the simple uncomplicated form of
   meconium ileus. Eleven of these underwent resection and six patients
   died. Twelve patients were treated by laparotomy, ileotomy through a
   purse-string suture and prolonged irrigations using acetylcysteine.
   Of this group only one succumbed. This latter course of management is
   recommended for patients with simple uncomplicated meconium ileus as
   it involves no resection, no enterostomy, nor any primary
   anastomosis.
RF 001   DONNISON AB           PEDIATRICS                      37   833 966
   002   KALAYOGLU M           J PEDIATR SURG                   6   290 971
   003   ONEILL JA JR          AM J SURG                      119    99 970
   004   NOBLETT HR            J PEDIATR SURG                   4   190 969
   005   MCPARTLIN JF          ARCH DIS CHILD                  47   207 972
CT   1   GROSS K               J PEDIATR SURG                  20   431 985
     2   GHORY MJ              SURG CLIN NORTH AM              65  1083 985

PN 79140
RN 01120 
AN 80008799
AU Morrissey-S-M.  Tymvios-M-C.
TI The effect of histamine, metiamide and cystic fibrosis factor on the
   electrophysiological properties of the frog's gastric mucosa
   [proceedings].
SO J-Physiol (Lond). 1979 Jun. 291. P 25P-26P.
MJ CYSTIC-FIBROSIS: bl.  GASTRIC-MUCOSA: de.  HISTAMINE: pd.
   METIAMIDE: pd.  THIOUREA: aa.
MN ANIMAL.  BIOLOGICAL-TRANSPORT-ACTIVE: de.  CHLORIDES: me.  ANURA.
   GASTRIC-MUCOSA: ph.  HUMAN.  HYDROGEN-ION-CONCENTRATION.  IN-VITRO.
   MEMBRANE-POTENTIALS: de.
AB The total active transport of Cl ions across the frog's gastric
   mucosa can be considered as: net Cl- flux (serosa to mucosa) = H+ +
   SSC (short-circuit current), all terms expressed as micromole cm-2
   hr-1.  The net chloride flux (Hogben, 1955; Durbin & Heinz, 1958)
   may be divided into two fractions: an acidic one which is equivalent
   to the acid secreted and an electromotive one which accounts for the
   gastric electromotive force.  The changes in SCC can accordingly be
   used as a partial index to the activity of the chloride pump.
   Experiments were designed to investigate the effects of histamine,
   metiamide (H2 receptor antagonist), cystic fibrosis (CF) and non-CF
   plasma on the above parameters using the frog's isolated gastric
   mucosa.  The SCC and the resistance of the mucosal preparation is
   measured by means of an automatic SCC apparatus (de Jesus, 1977).
   The H ion secretion is measured by pH meter.  Results obtained
   (expressed as mean change (delta) plus or minus S.E. of mean) for
   histamine (10-4 M) (n = 10) show an initial increase of the SCC by
   36.94 plus or minus 2.95 microA cm-2 and a parallel small increase
   in H+ output by 0.045 plus or minus 0.003 micromole cm-2 hr-1.  This
   initial increase in SCC is followed by a drop to a steady-state
   level of 23.62 plus or minus 2.23 microA cm-2 and also by a large
   increase in H+ secretion 2.26 plus or minus 0.22 micromole cm-2
   hr-1.  These results support the work of Rehm (1961) in that
   histamine has an effect first on the Cl- pump and then on the H+
   secretion.  Metiamide (10-4 M) (n = 12) caused a drop in the SCC by
   20.16 plus or minus 2.32 microA cm-2 and also reduced the acid
   secretion by 2.21 plus or minus 0.14 micromole cm-2 hr-1, thus
   suggesting an effect on the Cl- pump as well as on the H+ secretion.
   Significant differences are shown (P < 0.001) between CF and non-CF
   plasma results.  The CF plasma (n = 8) increased the SCC by 17.25
   plus or minus 2.94 microA cm-2 and H+ secretion by 2.38 plus or
   minus 0.43 micromole cm-2 hr-1.  Non-CF plasma caused a slight
   increase in SCC by 5.17 plus or minus 1.1 microA cm-2 and had little
   effect on the H+ secretion, 0.34 plus or minus 0.01 micromole cm-2
   hr-1 (n = 8).  The effect of the CF plasma on the Cl- and H+
   mechanism is of interest since in cystic fibrosis there is an
   abnormal increase of Cl- and Na+ in the sweat of patients (di Sant
   Agnese, Darling, Perera & She, 1953).
RF 001   DURBIN RP             J GEN PHYSIOL                   41  1035 958
   002   HOGBEN CAM            AM J PHYSIOL                   180   641 955
   003   DE JESUS HC           J PHYSIOL (LOND)               268   353 977
   004   REHM WS               AM J PHYSIOL                   203    63 961
   005   DI SANTAGNESE PA      AM J DIS CHILD                  86   618 953

PN 79141
RN 01121 
AN 79218491
AU Bond-C-E.  Fraser-P-A.  Smaje-L-H.
TI The chronically ligated submandibular salivary duct of the rabbit as
   a possible model for cystic fibrosis [proceedings].
SO J-Physiol (Lond). 1979 Apr. 289. P 25P.
MJ CYSTIC-FIBROSIS: pp.  SUBMANDIBULAR-GLAND: pp.
MN ANIMAL.  BIOLOGICAL-TRANSPORT.  EPITHELIUM: cy, pp.  LIGATION.
   RABBITS.  SODIUM: ph.
AB Schulz (1969) showed that the raised Na concentration in the sweat
   of children suffering from cystic fibrosis  was due to a defect in
   Na reabsorption in the duct epithelium, but somewhat surprisingly
   the transepithelial potential difference (p.d.) is the same as that
   in normal controls.  Na transport is also reduced in the chronically
   ligated salivary duct of the rabbit submandibular gland (Fraser &
   Smaje, 1978), and because p.d. is unaffected, the ligated gland may
   be a useful model of this aspect of cystic fibrosis.  Here we would
   like to report a further similarity to cystic fibrosis; duct
   ligation leads to goblet cell hyperplasia which also occurs in the
   salivary glands in cystic fibrosis (Lev & Spicer, 1965).  Sections
   of the salivary duct 6 microm thick were taken at 60 microm
   intervals from ducts which had been ligated for between 1 and 5
   weeks and from their contralateral controls following fixation by
   immersion.  Ligation resulted in an increase in luminal diameter by
   distension of the previously convoluted epithelium, but there was no
   significant change in epithelial surface area.  The number of cell
   layers appeared to have increased however and there was a
   proliferation of goblet cells.  The mucus in these cells was stained
   by alcian blue at pH 1 indicating the presence of sulphomucin.  The
   mean goblet cell density rose from 7.62 plus or minus 4.73 mm-2
   (mean plus or minus S.E. of the mean, n = 6) in controls to 114 plus
   or minus 49.6 in ligated ducts.  The transepithelial Na flux in the
   same ducts was reduced from 10.1 plus or minus 0.79 n-mole cm-2
   sec-1 to 1.6 plus or minus 0.84 while p.d. remained at -22 mV,
   similar to those results previously reported.  There was no
   significant correlation between the degree of diminution of Na
   transport and the density of goblet cells but there was a positive
   correlation (r = 0.90) between the number of goblet cells in the
   control and contralateral ligated ducts.
RF 001   FRASER PA             J PHYSIOL (LOND)               285   24P 978
   002   LEV R                 AM J PATHOL                     46    23 965
   003   SCHULZ IJ             J CLIN INVEST                   48  1470 969

PN 79142
RN 01122 
AN 79175557
AU Hicks-J-M.
TI Sweat tests [letter].
SO JAMA. 1979 May 25. 241(21). P 2264-5.
MJ CYSTIC-FIBROSIS: di.  SWEAT: an.
MN HUMAN.
EX I agree that sweat tests are frequently not performed reliably, but I
   wonder why the clinical chemist has been singled out as being
   responsible when most hospital laboratories are still directed by
   pathologists and not by professional clinical chemists.  In addition
   to our laboratory, I know of many other hospital clinical chemistry
   laboratories in which the test is being performed properly.
   Furthermore, the Pediatric Committee of the American Association for
   Clinical Chemistry is working on a review article for the journal,
   Clinical Chemistry, regarding the correct way the sweat test should
   be run.  Clearly, clinical chemists do not "lack interest."
RF 001   SHWACHMAN H           JAMA                           240  2731 978
   002   GIBSON LE             PROC FOR QUANTITATIVE ION                975
CT   1   PRIEST JB             JAMA                           242  1970 979

PN 79143
RN 01123 
AN 80009690
AU Priest-J-B.
TI The sweat test for cystic fibrosis [letter].
SO JAMA. 1979 Nov 2. 242(18). P 1970.
MJ CYSTIC-FIBROSIS: di.  SWEAT: an.
MN HUMAN.
EX The major issue is not the "lack of interest of clinical chemists,"
   but the actual performance of the test.  Neither the pathologist nor
   the clinical chemist, in all likelihood, actually performs the test.
   Rather, it is the medical technologist or technician who carries out
   the actual procedure.  It is a major part of our roles as educators
   and laboratory administrators to ensure that these people are
   adequately trained for the task and that the test meets high enough
   performance standards to provide a clinically relevant answer.
RF 000   HICKS J               JAMA                           241  2264 979
   000   SHWACHMAN H           JAMA                           240  2731 978
   001   ROSENSTEIN BJ         JAMA                           240  1987 978

PN 79144
RN 01124 
AN 80098014
AU Heinrich-H-C.  Gabbe-E-E.  Icagic-F.
TI Immunoreactive serum trypsin in diseases of the pancreas.
SO Klin-Wochenschr. 1979 Nov 15. 57(22). P 1237-8.
MJ PANCREATIC-DISEASES: en.  TRYPSIN: bl.
MN ACUTE-DISEASE.  CHRONIC-DISEASE.  CYSTIC-FIBROSIS: en.  HUMAN.
   PANCREATECTOMY.  PANCREATITIS: en.  RADIOIMMUNOASSAY.
AB Immunoreactive serum trypsin was measured with a double antibody
   radioimmunoassay in normal subjects and patients with various
   diseases of the pancreas. The normal range is 115-350 ng/ml with a
   geometric mean of 212 ng/ml. No trypsin was found in serum after
   total duodenopancreatectomy, in about 75% of patients with cystic
   fibrosis and in a few patients with pancreas carcinoma or chronic
   pancreatitis. Reduced serum trypsin levels between 10 and 100 ng/ml
   were measured in the remaining 25% of cystic fibrosis and in one
   third of the patients with chronic pancreatitis. Serum trypsin was
   increased to 700-17,000 ng/ml in all patients with acute pancreatitis
   or during the acute phase of chronic pancreatitis. Absent or reduced
   serum trypsin is a reliable indicator of total or partial exocrine
   pancreatic insufficiency whereas considerably increased serum trypsin
   concentration do indicate acute pancreatitis.
RF 001   DANDONA P             BR MED J                         2  1125 978
   002   ELIAS E               LANCET                           2    66 977
   003   GEOKAS MC             J LAB CLIN MED                  84   574 974
   004   GOBELET CH            SCHWEIZ MED WOCHENSCHR         108  1902 978
   006   TEMLER RS             BIOCHIM BIOPHYS ACTA           445   720 976
   007   TEMLER RS             ENZYME                          22   249 977
CT   1   HEINRICH HC           KLIN WSCHR                      57  1295 979
     2   FELBER JP             RIC CLIN LAB                    10    55 980
     3   KOEHN HD              CLIN CHEM                       27   502 981
     4   LANKISCH PG           HEPATOGASTROENTEROLOGY          28   333 981
     5   CARREL O              HELV PAEDIATR ACTA              36   405 981
     6   LANKISCH PG           GUT                             23   777 982
     7   AMMANN RW             KLIN WSCHR                      60   243 982
     8   MOLLERPETERSEN J      CLIN CHIM ACTA                 124    31 982
     9   HEER M                SCHWEIZ MED WOCHENSCHR         113  1950 983
    10   KOOP H                CLIN GASTROENTEROL              13   739 984
    11   BORGSTROM A           SCAND J GASTROENTEROL           19   220 984
    12   VEZZADINI P           AM J GASTROENTEROL              79   213 984
    13   VEZZADINI P           SURG GYNECOL OBSTET            158   319 984
    14   DELFAVERO G           RIC CLIN LAB                    15   343 985
    15   GERSMANN A            MED WELT                        36    23 985
    16   DELFAVERO G           KLIN WSCHR                      63   603 985
    17   NIEDERAU C            GASTROENTEROLOGY                88  1973 985
    18   NIEDERAU C            GASTROENTEROLOGY                89  1451 985

PN 79145
RN 01125 
AN 79155182
AU Oppenheimer-E-H.  Rosenstein-B-J.
TI Differential pathology of nasal polyps in cystic fibrosis and atopy.
SO Lab-Invest. 1979 Apr. 40(4). P 445-9.
MJ CYSTIC-FIBROSIS: co.  HYPERSENSITIVITY-IMMEDIATE: co.
   NASAL-POLYPS: pa.
MN ADOLESCENCE.  ADULT.  BASEMENT-MEMBRANE: pa.  CHILD.
   CHILD-PRESCHOOL.  EXOCRINE-GLANDS: pa.  FEMALE.  HUMAN.  MALE.
   METAPLASIA.  MUCOUS-MEMBRANE: pa.  MUCUS.  NASAL-POLYPS: co.
   SUPPORT-U-S-GOVT-P-H-S.
AB Nineteen nasal polyps from 13 patients were examined histologically.
   Nine polyps from seven cystic fibrosis (CF) patients could be
   positively identified by a triad of observations: delicate, barely
   visible basement membrane of surface epithelium without submucosal
   hyalinization, lack of extensive infiltration of eosinophils (Giemsa
   stains), and a preponderance of acid mucin in glands and cysts of the
   polyp and in its surface mucous blanket (Alcian Blue-periodic acid-
   Schiff stains). Two polyps from two patients with CF and atopy showed
   the characteristic findings of CF without modification. Eight polyps
   from four atopic patients without CF were identified by the reverse
   triad of changes: extensive thickening of the epithelial basement
   membrane and its extension into the submucosa as an irregular hyaline
   membrane, high stromal eosinophil count, and mainly neutral mucin in
   mucous glands, cysts, and mucous blanket. Hyperplastic mucous glands,
   mucous cysts of variable sizes, focal metaplasia of surface
   epithelium, and acid mucin in goblet cells were considered
   nonspecific lesions.
RF 001   BLUMSTEIN GI          ARCH OTOLARYNGOL                83   266 966
   003   KULCZYCKI LL          JAMA                           175   358 961
   004   LAMB D                J PATHOL                        98   213 969
   005   LAMB D                BR J DIS CHEST                  66   239 972
   006   NEELY JG              TRANS AM ACAD OPHTHALMOL OTOL   76   313 972
   007   RULON JT              ARCH OTOLARYNGOL                78   192 963
   008   SHWACHMAN H           PEDIATRICS                      30   389 962
   009   TAYLOR BW             ARCH DIS CHILD                  49   133 974
   010   VAN METRE TE JR       J ALLERGY CLIN IMMUNOL          31   141 960
   011   VAN METRE TE JR       J ALLERGY CLIN IMMUNOL          49   131 972
CT   1   BATSAKIS JG           HEAD NECK SURG                   2   410 980
     2   OPPENHEIMER EH        HUM PATHOL                      12    36 981
     3   THAETE LG             AM J ANAT                      162   243 981
     4   COLTEN HR             N ENGL J MED                   304   831 981
     5   MILLS SE              ARCH OTOLARYNGOL               108   530 982
     6   STERN RC              AM J DIS CHILD                 136  1067 982
     7   BUNNAG C              ANN ALLERGY                     50   126 983
     8   KNOWLES MR            SCIENCE                        221  1067 983
     9   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983
    10   STUTTS MJ             PEDIATR RES                     20  1316 986
    11   DAVID TJ              J ROY SOC MED                   79    23 986

PN 79146
RN 01126 
AN 80076794
AU King-D-N.  Heeley-A-F.  Walsh-M-P.  Kuzemko-J-A.
TI Sensitive trypsin assay for dried-blood specimens as a screening
   procedure for early detection of cystic fibrosis.
SO Lancet. 1979 Dec 8. 2(8154). P 1217-9.
MJ CYSTIC-FIBROSIS: di.  TRYPSIN: bl.
MN ADOLESCENCE.  BLOOD-SPECIMEN-COLLECTION.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: bl.  HUMAN.  INFANT.  INFANT-NEWBORN.  PREGNANCY.
   RADIOIMMUNOASSAY: mt.  TRYPSIN: im.  FEMALE.
AB An immunoreactive-trypsin assay uses small dried-blood spots
   (diameter 1.25 mm) and is therefore suitable for incorporation in
   established neonatal screening schemes. Blood specimens from neonates
   with cystic fibrosis had trypsin levels greater than those in control
   subjects, thus confirming earlier findings. Trypsin levels were below
   normal in several older patients with cystic fibrosis.
RF 001   CROSSLEY JR           LANCET                           1   472 979
   002   DANDONA P             LANCET                           1  1032 979
CT   1   DOMINICI R            RIC CLIN LAB                    10   511 980
     2   BONORA G              SCAND J GASTROENTEROL           15    11 980
     3   BURLINA A             SCAND J GASTROENTEROL           15    35 980
     4   TRAVERT G             J GENET HUM                     28   141 980
     5   TRAVERT G             NOUV PRESSE MED                 10  2093 981
     6   DURIE PR              PEDIATR RES                     15  1351 981
     7   KIRBY LT              CLIN CHEM                       27   678 981
     8   EVANS RT              J CLIN PATHOL                   34   911 981
     9   BORGSTROM A           ACTA PAEDIATR SCAND             70   619 981
    10   CROSSLEY JR           CLIN CHIM ACTA                 113   111 981
    11   TOBIN MJ              IR J MED SCI                   150   325 981
    12   COX KL                J PEDIATR GASTROENTEROL NUTR     1   345 982
    13   DURIE PR              J PEDIATR GASTROENTEROL NUTR     1   337 982
    14   BURLINA A             IRCS MED SCI BIOCHEM            10   951 982
    15   WONG LTK              GUT                             23   744 982
    16   ZUCCHELLI GC          J NUCL MED ALLIED SCI           26    35 982
    17   BROWN RC              J CLIN PATHOL                   35   547 982
    18   HEELEY AF             ARCH DIS CHILD                  57    18 982
    19   BORGSTROM A           ACTA PAEDIATR SCAND             71   621 982
    20   BORGSTROM A           ACTA PAEDIATR SCAND             71   849 982
    21   HEELEY AF             CLIN CHEM                       29  2011 983
    22   TRAVERT G             ARCH FR PEDIATR                 40   295 983
    23   ANON                  PEDIATRICS                      72   741 983
    24   WILCKEN B             J PEDIATR                      102   383 983
    25   MASOERO G             AM J DIS CHILD                 137   167 983
    26   HALLINAN FM           IR J MED SCI                   152   409 983
    27   HAMMOND KB            LANCET                           1    42 984
    28   GOLDBERG DM           CLIN PHYSIOL BIOCHEM             2   249 984
    29   KOOP H                CLIN GASTROENTEROL              13   739 984
    30   BLYTHE SA             CLIN BIOCHEM                    17   277 984
    31   HJELM M               CLIN BIOCHEM                    17   284 984
    32   CASSIO A              ACTA PAEDIATR SCAND             73   554 984
    33   REARDON MC            J PEDIATR                      105   271 984
    34   NAYLOR EW             SEM PERINATOL                    9   232 985
    35   PLUMBE RM             ANN CLIN BIOCHEM                22   408 985
    36   DURIE PR              PEDIATR RES                     20   209 986
    37   KUZEMKO JA            J ROY SOC MED                   79     2 986
    38   BOURGUIGNON JP        EUR J PEDIATR                  144   547 986
    39   BOWLING FG            LANCET                           1   826 987

PN 79147
RN 01127 
AN 80076881
AU Harris-A.  Benson-P-F.  Fensom-A-H.
TI Detection of cystic fibrosis with plasma hydrolases [letter].
SO Lancet. 1979 Dec 22-29. 2(8156-8157). P 1371.
MJ ACID-PHOSPHATASE: bl.  CYSTIC-FIBROSIS: di.  MANNOSIDASES: bl.
MN COMPARATIVE-STUDY.  HEAT.  HETEROZYGOTE-DETECTION.  HUMAN.  OILS: du.
   PARAFFIN: du.
EX Dr Hosli and Mrs Hosli reported that differential thermolability of
   plasma alpha-mannosidase and plasma acid phosphatase allowed
   discrimination between normal people, cystic fibrosis carriers, and
   patients.  We have repeated these experiments, paying special
   attention to the technical details given in the Hoslis's paper.  In a
   separate series of experiments we used larger volumes of plasma for
   each assay, which was performed either with or without
   non-fluorescent paraffin oil.  In both cases the blood samples were
   processed exactly as outlined in Hosli and Vogt's paper.  There were
   no significant differences in the heat stability of plasma
   alpha-mannosidase and acid phosphatase between the three groups.
RF 000   PATRICK AD            LANCET                           2  1015 979
   000   HOSLI P               LANCET                           2   543 979
CT   1   SCANLIN TF            CLIN CHEST MED                   1   424 980
     2   BUTTERWORTH J         CLIN CHIM ACTA                 108   347 980
     3   HALLINAN F            MED HYPOTHESES                   7   793 981
     4   KATZNELSON D          ISR J MED SCI                   17   687 981
     5   HULTBERG B            CLIN CHIM ACTA                 112   167 981
     6   SCANLIN TF            CLIN CHIM ACTA                 114   269 981
     7   HEELEY AF             CLIN CHEM                       29  2011 983
     8   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
     9   OGLESBEE LH           CLIN CHIM ACTA                 143   135 984

PN 79148
RN 01128 
AN 80076806
AU Applegarth-D-A.  Davidson-A-G.  Kirby-L-T.  Bridges-M.  Sorensen-P.
   Wong-L-T.  Hardwick-D-F.
TI Dried blood spot screening for cystic fibrosis [letter].
SO Lancet. 1979 Dec 8. 2(8154). P 1236-7.
MJ CYSTIC-FIBROSIS: di.  TRYPSIN: bl.
MN AGE-FACTORS.  BLOOD-SPECIMEN-COLLECTION.  ENZYME-TESTS: mt.  HUMAN.
   INFANT.  INFANT-NEWBORN.
EX We have measured immunoreactive trypsin IRT activity in dried blood
   spot samples and have found abnormally high levels in infants with
   cystic fibrosis (CF).  We agree with Crossley et al. that this test
   deserves further investigation as a screen for CF in the newborn.
   The low value for the 94 week infant is consistent with their finding
   that, in children with low pancreatic enzyme output, the increased
   IRT results are restricted to the first few months of life.  It
   remains to be proved whether older CF patients with residual
   pancreatic enzyme secretion do indeed continue to have increased IRT
   levels.  If they do, the IRT test would also deserve further
   investigation as a tool, to be used in conjunction with stool
   pancreatic enzyme activity, in smaller centres who have had problems
   with inaccurate sweat tests.
RF 001   CROSSLEY JR           LANCET                           1   472 979
   002   STARKEY PM            IN: BARRETT AJ                       663 977
   003   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      71   864 976
CT   1   DOMINICI R            RIC CLIN LAB                    10   511 980
     2   BURLINA A             SCAND J GASTROENTEROL           15    35 980
     3   DURIE PR              PEDIATR RES                     15  1351 981
     4   KIRBY LT              CLIN CHEM                       27   678 981
     5   TOBIN MJ              IR J MED SCI                   150   325 981
     6   WONG LTK              GUT                             23   744 982
     7   ZUCCHELLI GC          J NUCL MED ALLIED SCI           26    35 982
     8   HEELEY AF             ARCH DIS CHILD                  57    18 982
     9   MASOERO G             AM J DIS CHILD                 137   167 983
    10   HALLINAN FM           IR J MED SCI                   152   409 983
    11   NAYLOR EW             SEM PERINATOL                    9   232 985

PN 79149
RN 01129 
AN 79243319
AU Lieberman-J.
TI Age dependence of serum angiotensin-converting enzyme activity
   [letter].
SO Lancet. 1979 Jul 28. 2(8135). P 196.
MJ KININASE-II: bl.
MN ADOLESCENCE.  AGE-FACTORS.  CHILD.  COMPARATIVE-STUDY.
   CYSTIC-FIBROSIS: en.  GRANULOMATOUS-DISEASE-CHRONIC: en.  HUMAN.
EX We examined the age dependence of serum angiotensin-converting enzyme
   (SACE) activity in healthy controls.  While we found no age
   dependence in controls older than 20 years, those under 20 had much
   increased SACE values.  We feel that it is inappropriate to evaluate
   SACE activity in patients under 20 years old with diagnostic criteria
   determined in adults. - Dr Romer and colleagues reported high
   activities of SACE in 3 patients out of 10 with chronic granulomatous
   disease (CGD) and concluded that "CGD is associated with increased
   levels of SACE".  Unfortunately, Romer et al. did not study an
   adequate paedeatric age control group, and their mean values are
   compared primarily with that in 5 children with cystic fibrosis.  Our
   most recent studies confirm our earlier observation that children
   under the age 19 years definitely have higher mean SACE values than
   do adults.  Cystic-fibrosis patients should not be used for
   comparison since they tend to have lower SACE levels than comparable
   aged controls.  In my opinion patients with CGD, according to the
   data published by Romer et al., show no increase in SACE levels for
   their age.
RF 000   ROMER FK              LANCET                           1  1237 979
   001   LIEBERMAN J           AM J MED                        59   365 975
   002   ROHRBACH MS           AM REV RESPIR DIS              119   761 979
   003   LIEBERMAN J           AM J MED                        59   365 975
CT   1   SANTONASTASO CL       ITAL J GASTROENTEROL            16     9 984

PN 79150
RN 01130 
AN 79198307
AU Brock-D-J.  Hayward-C.
TI Methylumbelliferyl-guanidinobenzoate reactive proteases and prenatal
   diagnosis of cystic fibrosis [letter].
SO Lancet. 1979 Jun 9. 1(8128). P 1245-6.
MJ AMNIOTIC-FLUID: en.  CYSTIC-FIBROSIS: di.  PEPTIDE-HYDROLASES: an.
MN CYSTIC-FIBROSIS: en.  FEMALE.  HUMAN.  HYMECROMONE.  PREGNANCY.
EX For several reasons the supernatant fraction of amniotic fluid is not
   often used in the prenatal detection of inborn errors of metabolism.
   In early pregnancy the bulk of the protein in amniotic fluid is
   derived from the maternal circulation, and this can obscure the more
   critical contribution from the fetus needed for prenatal diagnosis.
   10 - 30% of amniotic fluids are significantly contaminated with
   maternal blood, and if the enzyme in question is present in this
   blood (as 4-methylumbelliferyl guanidinobenzoate [MUGB] protease is),
   this can further distort diagnostic conclusions.  For this reason we
   have examined the variation of MUGB protease in a heterogenous
   collection of amniotic fluids.  No significant differences in titre
   between individual weeks in the second trimester were observed.  A
   further 104 second-trimester amniotic fluids from pregnancies with
   abnormal outcome were also investigated.  The means of the four
   groups were not significantly different from that of the normals and
   the ranges were very similar.  We have not yet had the opportunity to
   examine an amniotic fluid from a known case of cystic fibrosis.
   Diagnosis of cystic fibrosis could probably be further refined by
   coupling amniotic-fluid protease titration and isoelectric focusing
   on polyacrylamide gel.
RF 001   WALSH-PLATT M         PEDIATR RES                     12   874 978
   002   RAO GJS               ENZYME                          23   314 978
   003   JAMESON GW            BIOCHEM J                      131   107 973
   004   SUTCLIFFE RG          J OBSTET GYNAECOL BR COMMONW    80   721 973
   005   DANN LG               LANCET                           2   405 978
CT   1   DANN LG               LANCET                           2   907 979
     2   BROCK DJH             LANCET                           1   619 982
     3   CRISTOL P             SEM HOP PARIS                   58   449 982
     4   GREEN JR              EUR J PEDIATR                  139    35 982
     5   BROCK DJH             PRENAT DIAGN                     3     1 983
     6   HODSON ME             POSTGRAD MED J                  60   225 984
     7   SHAW LMA              J OBSTET GYNAECOL BR COMMONW     6     1 985

PN 79151
RN 01131 
AN 79198291
AU Phillips-B.  Davis-J-A.  Goode-M.
TI Screening for cystic fibrosis [letter].
SO Lancet. 1979 Jun 9. 1(8128). P 1238-9.
MJ CYSTIC-FIBROSIS: en.  PEPTIDE-HYDROLASES: bl.
MN CHILD.  HUMAN.  TRYPSIN-INHIBITORS: bl.  TRYPSIN: bl.
EX Our cystic-fibrosis  children usually either have severe lung disease
   with mild steatorrhea or severe maldigestion with lesser pulmonary
   problems.  We therefore measured serum-proteases in cystic-fibrosis
   patients and controls to see if there was any support for the
   following hypothesis: since lack of antitrypsin is associated with
   lung damage, plasma-trypsin in excess of antitrypsin might be
   responsible for the lung damage in cystic fibrosis.  General protease
   and trypsin levels were measured spectrophotometrically using a
   modification of the method of Erlanger, Kojowsky and Cohen.  Our
   result showed no significant difference between protease and trypsin
   levels in cystic-fibrosis patients and controls.  The difference
   between our results and those of Crossley et al. may be explained by
   the differing measuring technique used.  Our trypsin levels were
   measured spectrophotometrically and theirs by radioimmunoassay.
RF 000   CROSSLEY JR           LANCET                           1   472 979

PN 79152
RN 01132 
AN 79198289
AU Romer-F-K.  Faber-V.  Koch-C.  Pedersen-F-K.  Friis-B.  Johansen-K-S.
   Taudorff-E.
TI Serum-angiotensin-converting-enzyme in chronic granulomatous disease
   [letter].
SO Lancet. 1979 Jun 9. 1(8128). P 1237.
MJ GRANULOMATOUS-DISEASE-CHRONIC: en.  KININASE-II: bl.
MN ADOLESCENCE.  ADULT.  AGED.  CHILD.  CHILD-PRESCHOOL.
   COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: en.  FEMALE.
   GRANULOMATOUS-DISEASE-CHRONIC: fg.  HETEROZYGOTE.  HOMOZYGOTE.
   HUMAN.  INFANT.  KININASE-II: ge.  MALE.  MIDDLE-AGE.
EX We have studied serum-angiotensin-converting-enzyme (SACE) in
   sarcoidosis and other granulomatous disorders.  We have measured SACE
   in 10 randomly chosen, consecutive patients with chronic
   granulomatous disease (CGD) and in some of their family members and
   in 5 children with cystic fibrosis and severe chronic pulmonary
   involvement.  SACE levels in the patient with CGD differed
   significantly from those of normal controls and those of family
   members and patients with cystic fibrosis.  Our preliminary studies
   show that CGD is associated with increased levels of SACE.
RF 001   CUSHMAN DW            BIOCHEM PHARMACOL               20  1637 971
   002   LIEBERMAN J           AM J MED                        59   365 975
   004   STUDDY P              LANCET                           2  1331 978
   005   LIEBERMAN J           CLIN RES                        25  145A 977
   006   GEE JBL               LUNG                           155   243 978
   007   SILVERSTEIN E         AM J CLIN PATHOL                69   467 978
   008   PERKS WH              THORAX                          33   101 978
CT   1   ROMER FK              LANCET                           2   860 979
     2   ROMER FK              ACTA MED SCAND                         1 984
     3   FARGE D               AM J NEPHROL                     6    21 986

PN 79153
RN 01133 
AN 79133794
AU Crossley-J-R.  Elliott-R-B.  Smith-P-A.
TI Dried-blood spot screening for cystic fibrosis in the newborn.
SO Lancet. 1979 Mar 3. 1(8114). P 472-4.
MJ BLOOD-STAINS.  CYSTIC-FIBROSIS: di.  TRYPSIN: bl.
MN ANTIGENS.  BLOOD-SPECIMEN-COLLECTION.  CYSTIC-FIBROSIS: en.  HUMAN.
   INFANT.  INFANT-NEWBORN.  RADIOIMMUNOASSAY.  TRYPSIN: im.
AB Serum-immunoreactive-trypsin (I.R.T.) was measured in children with
   cystic fibrosis (C.F.) and a variety of controls. In the first few
   months of life all C.F. children had a raised serum-I.R.T. A dried
   blood-spot assay for I.R.T. was established and has potential as a
   screening test for C.F. in the newborn.
RF 001   CROSSLEY JR           LANCET                           2  1093 977
   002   FRIER BM              GUT                             17   685 976
   003   ELIAS E               LANCET                           2    66 977
   004   DANDONA P             BR MED J                         2  1125 978
CT   1   KING DN               LANCET                           2  1217 979
     2   STAGG BH              ANN CLIN BIOCHEM                16   147 979
     3   BURLINA A             SCAND J GASTROENTEROL           15    35 980
     4   TARNOKY AL            J ROY SOC MED                   73    73 980
     5   ROMEO G               J LAB CLIN MED                  95   116 980
     6   MASTELLA G            RIV ITAL PEDIATR                 7   581 981
     7   BURLINA A             IRCS MED SCI BIOCHEM            10   951 982
     8   MASOERO G             DIG DIS SCI                     27  1089 982
     9   SANDER J              MONATSSCHR KINDERHEILKD        130   843 982
    10   PITT D                MED J AUST                       1   333 983
    11   HEELEY AF             CLIN BIOCHEM                    16   369 983
    12   REY F                 CLIN BIOCHEM                    16    23 983
    13   BUCHANAN KD           SCAND J GASTROENTEROL           18   155 983
    14   HEELEY AF             CLIN CHEM                       29  2011 983
    15   KIRBY LT              CLIN CHEM                       29  1559 983
    16   LUTHI M               HELV PAEDIATR ACTA              38   149 983
    17   TRAVERT G             ARCH FR PEDIATR                 40   295 983
    18   WILCKEN B             ARCH DIS CHILD                  58   863 983
    19   CARRERE J             J IMMUNOL METH                  60   235 983
    20   ANON                  PEDIATRICS                      72   741 983
    21   LYON ICT              NZ MED J                        96   673 983
    22   WILCKEN B             J PEDIATR                      102   383 983
    23   MASOERO G             AM J DIS CHILD                 137   167 983
    24   HALLINAN FM           IR J MED SCI                   152   409 983
    25   JUNGLEE D             BR MED J                       286  1693 983
    26   GOLDBERG DM           CLIN PHYSIOL BIOCHEM             2   249 984
    27   RYLEY HC              PRENAT DIAGN                     4   303 984
    28   ANDRIULLI A           J CLIN GASTROENTEROL             6   239 984
    29   KOOP H                CLIN GASTROENTEROL              13   739 984
    30   FIGARELLA C           RIC CLIN LAB                    14   349 984
    31   BLYTHE SA             CLIN BIOCHEM                    17   277 984
    32   HJELM M               CLIN BIOCHEM                    17   284 984
    33   BORGSTROM A           PEDIATR RES                     18   957 984
    34   PLESS IB              PEDIATR CLIN NORTH AM           31   259 984
    35   HODSON ME             POSTGRAD MED J                  60   225 984
    36   BROCK DJH             BR J OBSTET GYNAECOL            91   449 984
    37   SCHONI MH             J PEDIATR                      104   691 984
    38   REARDON MC            J PEDIATR                      105   271 984
    39   SANDER J              KLIN PAEDIATR                  196   224 984
    40   SHEPS SB              JAMA                           252  2418 984
    41   NAYLOR EW             SEM PERINATOL                    9   232 985
    42   ROSALKI SB            CLIN CHEM                       31   779 985
    43   SZIBOR R              Z KLIN MED                      40   313 985
    44   REDDY S               AUST J EXP BIOL MED SCI         63   667 985
    45   DURIE PR              J PEDIATR                      106   233 985
    46   CLEGHORN G            J PEDIATR                      107   377 985
    47   STOLLINGER O          WIEN MED WOCHENSCHR            135   307 985
    48   MELLIS CM             MED J AUST                     143   227 985
    49   BOLLBACH R            EUR J PEDIATR                  144   167 985
    50   LAROCHE D             J PEDIATR GASTROENTEROL NUTR     5   404 986
    51   MOORE DJ              CLIN BIOCHEM                    19   303 986
    52   DURIE PR              PEDIATR RES                     20   209 986
    53   CARRERE J             BIOL NEONATE                    49   113 986
    54   RAFFLES AKM           ACTA PAEDIATR SCAND             75   502 986
    55   DODGE JA              J ROY SOC MED                   79    27 986
    56   KUZEMKO JA            J ROY SOC MED                   79     2 986
    57   GARCIAPUGES AM        GASTROENTEROLOGY                91    17 986
    58   BOURGUIGNON JP        EUR J PEDIATR                  144   547 986
    59   ROBERTS DD            ARCH BIOCHEM BIOPHYS           245   292 986
    60   CARRERE J             BIOCHIM BIOPHYS ACTA           883    46 986
    61   BLANDIN C             J BIOPHYS BIOMECAN              11     5 987
    62   SARLES J              ARCH FR PEDIATR                 44   311 987

PN 79154
RN 01134 
AN 79155633
TI Allergy and bronchial hyperreactivity in cystic fibrosis [editorial].
SO Lancet. 1979 Mar 31. 1(8118). P 708.
MJ ASTHMA: et.  BRONCHI: im.  CYSTIC-FIBROSIS: im.
MN ALLERGENS: im.  CHILD.  HUMAN.
EX A little-known feature of cystic fibrosis is the frequent occurrence
   of positive skin-prick tests to environmental allergies.  In the
   normal population only about half those with positive prick tests
   actually have clinical allergic disease; so, are the positive
   skin-tests of cystic fibrosis clinically important?  In particular,
   do they mean a high prevalence of asthma, overt or hidden, amongst
   these patients?  A general clinical impression is that asthma is no
   more frequent amongst cystic fibrosis than in the normal population.
   The often positive skin tests, although of considerable immunological
   interest, do not necessarily imply additional clinical disease.
RF 001   WARNER JO             ARCH DIS CHILD                  51   507 976
   002   MCCARTHY DS           IN: LAWSON D PROC 5TH INT CF         194 969
   003   GODFREY RC            CLIN ALLERGY                     6    79 976
   004   COUNAHAN R            ARCH DIS CHILD                  50   477 975
   005   MITCHELL I            J PEDIATR                       93   744 978
   006   CHAN H                J ALLERGY CLIN IMMUNOL          56   323 975
   007   SKORECKI K            ACTA PAEDIATR SCAND             65    39 976
   008   DAY G                 ARCH DIS CHILD                  48   355 973
   009   EMPEY DW              AM REV RESPIR DIS              113   131 976
CT   1   YANKAUER A            AM J PUBLIC HEALTH              69   762 979
     2   ORMEROD LP            THORAX                          35   768 980
     3   VANASPEREN P          AM J DIS CHILD                 135   815 981
     4   CONNOLLY J            BR J HOSP MED                   33    24 985

PN 79155
RN 01135 
AN 79177182
AU Dandona-P.  Hodson-M.  Bell-J.  Ramdial-L.  Batten-J-C.
TI Serum-immunoreactive-trypsin concentrations in cystic fibrosis
   [letter].
SO Lancet. 1979 May 12. 1(8124). P 1032.
MJ CYSTIC-FIBROSIS: di.  TRYPSIN: bl.
MN ADOLESCENCE.  ADULT.  AGE-FACTORS.  CHILD.  CHILD-PRESCHOOL.
   HETEROZYGOTE-DETECTION.  HUMAN.  INFANT-NEWBORN.  TRYPSIN: im.
EX We measured immunoreactive trypsin (IRT) concentrations in 32
   patients with established cystic fibrosis and in 16 parents
   (heterozygotes) of patients with CF.  29 patients (91%) and 6 parents
   (38%) had abnormal trypsin concentrations.  We found that in only 3
   out of the 29 patients with abnormal IRT was the concentration
   supranormal.  Our data suggest that low IRT concentrations are an
   excellent index of diminished pancreatic reserve in CF and that
   serum-IRT concentration would be a useful diagnostic test.  The fact
   that CF patients at birth invariably have very high IRT
   concentrations which fall with age and the progress of the disease,
   allied with the fact that heterozygotes have high concentrations,
   supports the previous suggestion that an uncontrolled hypersecretion
   of zymogen granules is the basic cellular defect in CF.
RF 000   CROSSLEY JR           LANCET                           1   472 979
CT   1   KING DN               LANCET                           2  1217 979
     2   DOMINICI R            RIC CLIN LAB                    10   511 980
     3   FELBER JP             RIC CLIN LAB                    10    55 980
     4   BURLINA A             SCAND J GASTROENTEROL           15    35 980
     5   VEZZADINI P           SCAND J GASTROENTEROL           15    29 980
     6   FOO Y                 J CLIN PATHOL                   33  1102 980
     7   DUFFY MJ              CLIN CHIM ACTA                 103   233 980
     8   ODONNELL MD           CLIN CHIM ACTA                 104   265 980
     9   DANDONA P             LANCET                           1   380 981
    10   DURIE PR              PEDIATR RES                     15  1351 981
    11   DURIE PR              J PEDIATR GASTROENTEROL NUTR     1   337 982
    12   HEELEY AF             CLIN CHEM                       29  2011 983
    13   MASOERO G             AM J DIS CHILD                 137   167 983
    14   ANDRIULLI A           J CLIN GASTROENTEROL             6   239 984
    15   KOOP H                CLIN GASTROENTEROL              13   739 984
    16   HJELM M               CLIN BIOCHEM                    17   284 984
    17   HODSON ME             POSTGRAD MED J                  60   225 984
    18   DURIE PR              PEDIATR RES                     20   209 986

PN 79156
RN 01136 
AN 79133965
AU Walsh-M-M.  Nadler-H-L.
TI Methylumbelliferyl-guanidinobenzoate reactive proteases in amniotic
   fluid: possible marker for cystic fibrosis [letter].
SO Lancet. 1979 Mar 17. 1(8116). P 622.
MJ AMNIOCENTESIS.  AMNIOTIC-FLUID: en.  CYSTIC-FIBROSIS: di.
   HYMECROMONE: du.  PEPTIDE-HYDROLASES: an.  UMBELLIFERONES: du.
MN CYSTIC-FIBROSIS: en.  FEMALE.  HUMAN.  PREGNANCY-TRIMESTER-SECOND.
   PREGNANCY.
EX Previous studies in our laboratory have demonstrated significant
   differences in the extent of protease reactivity with MUGB
   (4-methylumbelliferyl guanidinobenzoate, a sensitive active site
   titrant of many serine proteases) when plasma and cultivated skin
   fibroblasts from patients with cystic fibrosis (CF), obligate
   heterozygotes, and controls were compared.  Because of these
   observations, and the potential value of amniotic fluid for the
   prenatal detection of cystic fibrosis, these studies were extended to
   human amniotic fluid obtained by amniocentesis done for the
   intrauterine detection of genetic and other fetal abnormalities.  An
   amniotic-fluid sample obtained from a woman who was subsequently
   delivered of a baby with CF showed a much reduced level of MUGB
   reactivity similar to the relative deficiency observed in plasma and
   cultivated skin fibroblasts from patients with CF.  These
   observations suggest that amniotic-fluid protease activity may be a
   useful marker for the prenatal detection of CF.
RF 001   JAMESON GW            BIOCHEM J                      131   107 973
   002   WALSH-PLATT M         AM J HUM GENET                  29  111A 977
   003   RAO GJS               ENZYME                          23   314 978
   004   WALSH-PLATT M         PEDIATR RES                     12   129 978
   005   WALSH-PLATT M         PEDIATR RES                     12   874 978
CT   1   DANN LG               LANCET                           2   907 979
     2   MAHONEY MJ            CLIN PERINATOL                   6   255 979
     3   WALSH MMJ             PEDIATR RES                     14   353 980
     4   FREZAL J              ARCH FR PEDIATR                 38   217 981
     5   BRANCHINI BR          PEDIATR RES                     17   850 983
     6   BRIDGES MA            ANN NY ACAD SCI                421   360 983
     7   KUZEMKO JA            J ROY SOC MED                   79     2 986

PN 79157
RN 01137 
AN 80053578
AU Patrick-A-D.  Ellis-R-B.
TI Plasma hydrolases in cystic fibrosis [letter].
SO Lancet. 1979 Nov 10. 2(8150). P 1015-6.
MJ CYSTIC-FIBROSIS: en.  HYDROLASES: bl.
MN HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.  HYDROLASES: ge.
EX Dr Hosli and Esther Vogt reported that the alpha-mannosidase and acid
   phosphatase activities of cystic fibrosis plasma assayed at pH 5.4
   are abnormally thermolabile at 41 degrees and 36.5 degrees C,
   respectively, and that the levels of residual activity after heat
   inactivation clearly distinguish between CF patients, CF carriers,
   and normal subjects.  We have repeated these experiments under
   identical conditions and found no differences between the three
   groups.
RF 000   HOSLI P               LANCET                           2   543 979
CT   1   SCANLIN TF            CLIN CHEST MED                   1   424 980
     2   SACK J                LANCET                           2   268 980
     3   BUTTERWORTH J         CLIN CHIM ACTA                 108   347 980
     4   KATZNELSON D          ISR J MED SCI                   17   687 981
     5   HULTBERG B            CLIN CHIM ACTA                 112   167 981
     6   SCANLIN TF            CLIN CHIM ACTA                 114   269 981
     7   HEELEY AF             CLIN CHEM                       29  2011 983
     8   OGLESBEE LH           CLIN CHIM ACTA                 143   135 984
     9   KUZEMKO JA            J ROY SOC MED                   79     2 986

PN 79158
RN 01138 
AN 80031544
TI Mechanical chest physiotherapy [editorial].
SO Lancet. 1979 Oct 6. 2(8145). P 729.
MJ CYSTIC-FIBROSIS: th.  PERCUSSION: is.  PHYSICAL-THERAPY: mt.
   SPUTUM.
MN ADOLESCENCE.  ADULT.  CHILD.  DRAINAGE.  HUMAN.
EX Despite some critical debate lately about the usefulness of
   physiotherapy in certain chest conditions, the fact remains that many
   patients voluntarily undertake regular postural bronchial drainage to
   help their sputum.  A substantial number also find rapid chest
   percussion over affected lung segments useful in loosening the
   sputum.  Chest percussion by a mechanical device controlled by the
   patient himself seems worthy to trial.  Maxwell and Redmond have
   compared a commercial device with manual percussion during postural
   bronchial drainage.  The two techniques resulted in expectoration of
   similar quantities of sputum, although all but one patient felt
   subjectively that the machine delivered better-quality percussion.
   Before parents and others are advised to buy percussing machines, we
   need a formal study of postural drainage with and without chest
   percussion.
RF 001   NEWTON DAG            LANCET                           2   228 978
   002   GRAHAM WGB            N ENGL J MED                   299   624 978
   003   FLOWER KA             BR MED J                         2   630 979
   004   MAXWELL M             ARCH DIS CHILD                  54   542 979
CT   1   MACHIN GA             AM J MED GENET                   9   341 981
     2   TURKEL SB             CLIN PERINATOL                   9   613 982
     3   CARSWELL F            EUR J RESPIR DIS                65    53 984

PN 79159
RN 01139 
AN 80031735
AU Hirani-S.  Winchester-B-G.
TI Detection of cystic fibrosis homozygotes and heterozygotes with
   plasma [letter].
SO Lancet. 1979 Oct 27. 2(8148). P 906-7.
MJ CYSTIC-FIBROSIS: di.  GENETIC-TECHNICS.  MANNOSIDASES: bl.
MN CHILD.  CYSTIC-FIBROSIS: fg.  HETEROZYGOTE-DETECTION.  HOMOZYGOTE.
   HUMAN.  HYDROGEN-ION-CONCENTRATION.
EX Dr Hosli and Esther Vogt base their diagnosis of heterozygotes and
   homozygotes for cystic fibrosis on the thermal stability in plasma or
   extracellular fluids of alpha-mannosidase and/or phosphatase activity
   assayed at pH 5.4.  The activity of alpha-mannosidase in plasma and
   this pH is a composite one: both acidic alpha-mannosidase, which has
   a pH optimum of 4.25 and intermediate alpha-mannosidase, which has a
   pH optimum of 5.6 - 6.0, will contribute to the activity measured at
   pH 5.4.  These two forms of alpha-mannosidase are structurally and
   genetically distinct and have different kinetics and
   thermostabilities.  Therefore the total alpha-mannosidase activity at
   pH 5.4 and the physicochemical properties of this activity will
   depend upon the relative proportions of the two types of
   alpha-mannosidase in the sample.  The proportions of the two forms
   vary widely in normal plasma, especially in plasma from children.
   Although the data of Hosli and Vogt suggest that the total
   alpha-mannosidase at pH 5.4 does not differ significantly between
   controls, CF heterozygotes and CF homozygotes, they do not show
   whether the proportions of acidic and intermediate alpha-mannosidase
   have changed.  An increase in the proportion of the thermolabile
   intermediate alpha-mannosidase in CF would be manifested as a
   decreased thermostability of alpha-mannosidase at pH 5.4.
   Alternatively a mutation in the normally stable acidic
   alpha-mannosidase leading to a less stable form would also be
   reflected as a decreased stability in the activity at pH 5.4,
   especially if the proportion of acidic alpha-mannosidase was
   increased in CF.  These situations should also be considered as
   possible explanations of the observations, in addition to the one
   favoured by Hosli and Vogt.
RF 000   HOSLI P               LANCET                           2   543 979
   001   HIRANI S              CLIN CHIM ACTA                  81   135 977
   002   HIRANI S              BIOCHEM J                      179   583 979
   003   HOSLI P               FEBS LETTERS                   104   271 979
   004   HULTBERG B            BIOCHIM BIOPHYS ACTA           481   573 977
CT   1   BUTTERWORTH J         CLIN CHIM ACTA                 108   347 980
     2   HALLINAN F            MED HYPOTHESES                   7   793 981
     3   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983

PN 79160
RN 01140 
AN 80031736
AU Dann-L-G.  Blau-K.
TI Arginine esterase in amniotic fluid: possible marker for cystic
   fibrosis [letter].
SO Lancet. 1979 Oct 27. 2(8148). P 907.
MJ AMNIOTIC-FLUID: en.  CYSTIC-FIBROSIS: di.  ESTERASES: an.
MN ARGININE.  BENZOATES: du.  COMPARATIVE-STUDY.  COUMARINS: du.
   CYSTIC-FIBROSIS: en, fg.  FEMALE.  GENETIC-MARKER.  HUMAN.  METHODS.
   PREGNANCY.
EX Following Rao and Nadlers' report of decrease arginine activity in
   the blood of patients with cystic fibrosis we have been trying to
   apply their findings to the prenatal diagnosis of cystic fibrosis.
   We were therefore most interested in the reports on the use of
   4-methylumbelliferyl-rho-guanidinobenzoate (MUGB) for assaying
   arginine esterase activity in amniotic fluid.  Our results with MUGB
   are similar to those of Brock and Haywood but are substantially
   higher than those of Walsh and Nedler.  A sample of amniotic fluid
   that had been incubated with MUGB and then assayed with
   pro-phe-arg-4-methylcoumarinyl-7-amide (PPA-MCA) showed less than 20%
   of the activity of a similarly treated control sample that had not
   been incubated with MUGB.  The activity of arginine esterase towards
   PPA-MCA both in amniotic fluid and in cultures amniotic fluid cells
   is much greater than towards CBZ-Arg-AMC.  These levels of activity
   are high enough to warrant further investigation for use in an
   antenatal diagnosis.
RF 005   RAO GJS               PEDIATR RES                      9   739 975
   006   WALSH-PLATT M         LANCET                           1   622 979
   007   BROCK DJH             LANCET                           1  1245 979
   008   JAMESON GW            BIOCHEM J                      131   107 973
   009   DANN LG               LANCET                           2   405 978
   010   BLAU K                J INHER METAB DIS                1    85 978
CT   1   NADLER HL             PEDIATRICS                      66   690 980
     2   WALSH MMJ             AM J OBSTET GYNECOL            137   978 980
     3   NADLER HL             AM J OBSTET GYNECOL            141   885 981
     4   DANN LG               LANCET                           1   619 982
     5   GREEN JR              EUR J PEDIATR                  139    35 982
     6   SEYMOUR CA            BIOESSAYS                        1    38 984

PN 79161
RN 01141 
AN 79243573
AU Hosli-P.  Vogt-E.
TI Detection of cystic fibrosis homozygotes and heterozygotes with
   plasma.
SO Lancet. 1979 Sep 15. 2(8142). P 543-5.
MJ ACID-PHOSPHATASE: bl.  CYSTIC-FIBROSIS: di.  MANNOSIDASES: bl.
MN CYSTIC-FIBROSIS: en, fg.  HEAT.  HETEROZYGOTE-DETECTION.  HOMOZYGOTE.
   HUMAN.
AB Evidence is accumulating which indicates that the basic defect in
   cystic fibrosis interferes with the formation of recognition markers
   on hydrolytic enzymes. As a result these hydrolases leak into the
   extracellular space and some of them display abnormal
   thermolabilities. By heat inactivation of plasma alpha-mannosidase at
   41 degrees C and plasma phosphatase at 36.5 degrees C, both enzymes
   being assayed at pH 5.4, it is possible to differentiate normal
   people from cystic fibrosis carriers and patients.
RF 001   WOOD RE               AM REV RESPIR DIS              113   833 976
   002   STEINBERG AG          AM J HUM GENET                  12   416 960
   003   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   004   ANDERSON CM           CF A MANUAL OF DIAGNOSIS AND             976
   005   GIBSON LE             PEDIATRICS                      23   545 959
   006   SCHWARZ V             ARCH DIS CHILD                  43   695 968
   007   STEPHAN U             PEDIATRICS                      55    35 975
   008   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      73   209 976
   009   PAPP Z                CLIN GENET                      11   431 977
   010   BRESLOW JL            SCIENCE                        201   180 978
   011   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      79   741 977
   012   HOSLI P               PROC INT CF CONG 7TH                 278 976
   013   HOSLI P               MONOGR PAEDIATR                 10    90 979
   014   NEUFELD EF            J SUPRAMOL STRUCT                6    95 977
   015   KAPLAN A              PROC NAT ACAD SCI USA           74  2026 977
   016   PAZUR JH              BIOCHEM BIOPHYS RES COMMUN      40   110 970
   017   HIRANI S              CLIN CHIM ACTA                  81   135 977
   018   KRESS BC              BIOCHEM BIOPHYS RES COMMUN      81   756 978
CT   1   KOLLBERG H            ACTA PAEDIATR SCAND SUPPL 301 1982    15 982
     2   CAREY WF              MED J AUST                       2   528 983
     3   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
     4   GUEANT JL             CLIN CHIM ACTA                 143   217 984
     5   OGLESBEE LH           CLIN CHIM ACTA                 143   135 984
     6   PERINI JM             BULL EUR PHYSIOPATH RESP        21   569 985
     7   MORSE ML              LANCET                           1   625 986
     8   KUZEMKO JA            J ROY SOC MED                   79     2 986

PN 79162
RN 01142 
AN 80010695
AU Lam-L-F.  Shapiro-B-L.
TI Differential incorporation of 3H-thymidine into DNA in cultured skin
   fibroblasts derived from patients with cystic fibrosis and controls.
SO Life-Sci. 1979 Jun 25. 24(26). P 2483-9.
MJ CYSTIC-FIBROSIS: me.  DNA: me.
MN ADOLESCENCE.  ADULT.  CELL-DIVISION.  CHILD.  COMPARATIVE-STUDY.
   FEMALE.  FIBROBLASTS: me.  HUMAN.  MALE.  THYMIDINE: me.
   TIME-FACTORS.
AB Tritiated thymidine (3H-TdR) incorporation into DNA of the
   fibroblasts derived from subjects with cystic fibrosis (CF) and
   their controls was studied with scintillation counting and
   autoradiography.  3H-TdR incorporation at 24 hours postseeding was
   significantly less (p < 0.005) in CF strains in comparison with
   cells from controls.  The percentage of labeled fibroblasts was not
   significantly difference between the two strains (p > 0.1).  The
   cell cycle time and the duration of each phase were studied by a
   mitotic selection and scintillation counting technique.  There was
   no difference in cell cycle time between CF and control fibroblasts,
   however, the duration of the synthetic phase was significantly (p <
   0.005) longer in CF subjects.
RF 001   LOBECK CC             IN: STANBURY JB                     1605 972
   002   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   003   DANKS DM              ANN HUM GENET                   28   323 965
   004   NADLER HL             IN: STANBURY JB                     1683 978
   005   SHAPIRO BL            CLIN CHIM ACTA                  82   125 978
   007   BARRANCO SC           CELL TISSUE KINET               10   335 977
   008   BARRANCO SC           J CELL PHYSIOL                  88    33 976
   009   BOLTON WE             AM J HUM GENET                  27   394 975
   010   SHAPIRO BL            GAP CONF REP TISS CULT APPR              977
   011   SHAPIRO BL            SCIENCE                        203  1251 979
CT   1   SHAPIRO BL            AM J HUM GENET                  34   846 982
     2   SHAPIRO BL            SCIENCE                        216   417 982
     3   AVIOLI LV             AM J NEPHROL                     6   151 986

PN 79163
RN 01143 
AN 79220419
AU Sordelli-D-O.  Cassino-R-J.  Pivetta-O-H.
TI Animal model for cystic fibrosis: pulmonary clearance of
   Staphylococcus aureus in mice treated with reserpine.
SO Life-Sci. 1979 May 21. 24(21). P 2003-10.
MJ CYSTIC-FIBROSIS: pp.  LUNG: mi.  RESERPINE: pd.
   STAPHYLOCOCCUS-AUREUS.
MN ANIMAL.  DISEASE-MODELS-ANIMAL.  FEMALE.  LUNG: de.  MALE.  MICE.
   MICE-INBRED-BALB-C.
AB Since it has been demonstrated that chronic administration of
   reserpine to rats produces CF-like alterations, we have studied the
   lung resistance to bacterial infections in animals treated with
   reserpine.  Mice of the BALB/c inbred strain were injected
   subcutaneously with different doses of reserpine for 7 days; after,
   they were submitted to an infective aerosol containing
   Staphylococcus aureus in a nebulization chamber.  With each pair of
   exposed animals, an individual value of the uncleared bacteria ratio
   (UBR) at 4 hours was obtained.  Reserpinized animals showed a
   significant increase in UBR values when compared to control mice (p
   < 0.05 and p < 0.01 depending on the doses), suggesting an
   impairment of the lung antibacterial defenses.  Although
   pharmacological doses of reserpine produce catecholamine depletion,
   we can not conclude that this action upon the nervous system is the
   only cause of the CF-like response we detected.  In conclusion, the
   observed UBR decrease lends support to the concept of a reserpine-
   induced CF animal model.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   002   WOOD RE               AM REV RESPIR DIS              113   833 976
   003   OPPENHEIMER EH        COMPAR PATHOL BULL             111     3 971
   004   MARTINEZ JR           PEDIATR RES                      9   463 975
   005   PIVETTA OH            PEDIATR RES                     11  1133 977
   006   THOMPSON FE           PEDIATR RES                     10   632 976
   007   SNEDECOR GW           STATISTICAL METHODS                      967
   008   FINNEY DJ             PROBIT ANALYSIS                          971
   009   TAYLOR PW JR          J PHARMACOL EXP THER           156   483 967
   010   GREEN GM              J CLIN INVEST                   43   769 964
   011   LEE JA                FED PROC                        35   262 976
   012   STITZEL RE            PHARMACOL REV                   28   179 977
   013   MARTINEZ JR           PROC WORKSHOP ON MODEL SYS CF            978
   014   MENOM AL              J PHARM PHARMACOL               28   827 976
   015   GREEN GM              BR J EXP PATHOL                 46   360 965
CT   1   HAZLETT D             PEDIATR RES                     20  1236 986

PN 79164
RN 01144 
AN 80032233
AU Shier-W-T.
TI Increased resistance to influenza as a possible source of
   heterozygote advantage in cystic fibrosis.
SO Med-Hypotheses. 1979 Jun. 5(6). P 661-7.
MJ CYSTIC-FIBROSIS: fg.  HETEROZYGOTE.  ORTHOMYXOVIRUS-INFECTIONS: im.
   PARAMYXOVIRUS-INFECTIONS: im.
MN HUMAN.  IMMUNITY-NATURAL.  INFLUENZA: im.  MEMBRANE-PROTEINS: an.
   SIALIC-ACIDS: an, me.  SIALOGLYCOPROTEINS: an.
AB Cystic fibrosis is the most common lethal or semi-lethal genetic
   disease in Caucasians of Central European origin, among whom it is
   inherited as an autosomal recessive trait at a frequency
   approximately 10 times that expected from recurrent mutation alone. A
   decreased sialic acid content has been observed in cell surface
   glycoproteins on cystic fibrosis fibroblasts and in numerous soluble
   glycoprotein preparations from cystic fibrosis homozygotes. Sialic
   acid residues on cell surface glycoconjugates play an essential role
   in the binding and infectivity of myxoviruses and paramyxoviruses,
   including those causing pandemic influenza. It is suggested that
   increased resistance to these viruses conferred by similar but
   quantitatively smaller alterations in sialoglycoconjugate structure
   in cystic fibrosis heterozygotes may have provided a selective
   advantage to maintain the high frequency of the cystic fibrosis gene
   in Caucasian populations.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   002   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   003   CONNEALLY PM          TEX REP BIOL MED                31   639 973
   004   WRIGHT SW             AM J HUM GENET                  20   157 968
   005   HIRSCHHORN K          IN: MANGOS JA                        275 976
   006   ALLISON AC            BR MED J                         1   290 954
   007   HALDANE JBS           HEREDITAS SUPPL                      267 949
   008   STEINBERG AG          AM J HUM GENET                  12   416 960
   009   GAIRDNER D            LANCET                           1   279 975
   010   CRAWFURD MDA          HEREDITY                        29   126 972
   011   STUART AB             LANCET                           2  1521 974
   012   DODGE JA              LANCET                           1   572 975
   013   CRAWFURD MDA          LANCET                           1   167 975
   014   ANDERSON CM           MOD PROBL PEDIATR               10   381 967
   015   DISCHE Z              PEDIATRICS                      24    74 959
   016   ALHADEFF JA           CLIN GENET                      14   189 978
   017   ROELFS RE             AM J DIS CHILD                 113   419 967
   018   MANDEL ID             AM J DIS CHILD                 113   431 967
   019   PEARSON RD            PEDIATR RES                     11   462 977
   020   LAMB D                J PATHOL                        98   213 969
   021   REID L                IN: PORTER R                    32    45 968
   022   POTTER JL             ANN NY ACAD SCI                106   692 963
   023   ALHADEFF JA           CLIN GENET                      13   417 978
   024   SCANLIN TF JR         PEDIATR RES ABST 549            11   463 977
   025   SPIRO RG              ADV PROT CHEM                   27   349 973
   026   GRIMES WJ             BIOCHEMISTRY                    12   990 973
   027   LURIA SE              GENERAL VIROLOGY                     307 967
   028   HIRST GK              J EXP MED                       78    99 943
   029   GOTTSCHALK A          YALE J BIOL MED                 26   352 954
   030   LEICHTENSTERN O       INFLUENZE UND DENGUE                     896
   031   STUART-HARRIS CH      INFLUENZA THE VIRUSES AND DIS            976
CT   1   BURNET M              PERSPECT BIOL MED               24   511 981

PN 79165
RN 01145 
AN 79220977
AU Danes-B-S.  Sutanto-E.
TI Pathogenesis of cystic fibrosis: possible importance of alteration
   in epithelial surface topography.
SO Med-Hypotheses. 1979 Feb. 5(2). P 289-95.
MJ CYSTIC-FIBROSIS: et.  LUNG: ul.
MN CELL-MEMBRANE: ul.  EPITHELIUM: ul.  HUMAN.
   MICROSCOPY-ELECTRON-SCANNING.  MUCOUS-MEMBRANE: ph.  MUCUS: ph.
AB As the pathogenesis in cystic fibrosis (CF) has been considered to
   lie in a disturbance in the behavior of secretions, particularly
   mucins, from exocrine glands, it has been proposed that an alteration
   in surface topography (form, number or distribution of microvilli or
   blebs) of epithelial cells lining ducts could impair distribution
   leading to retention of mucus leading to the clinical phenotype.
   Scanning electronmicroscopy of human epithelial suspension cultures
   now offers an opportunity to evaluate the role of plasmalemma
   topography in CF.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   002   ANDERSEN DH           ANN NY ACAD SCI                 93   500 962
   003   DI SANTAGNESE PA      ANN NY ACAD SCI                 93   555 962
   004   DANES BS              BIRTH DEF ORIG ART SER           8   114 972
   006   FELIX JS              AM J HUM GENET                  29   41A 977
   007   ANDREWS PM            AM J ANAT                      139   399 974
   008   ANDREWS PM            J CELL BIOL                     67   11A 975
   009   MISHIMA Y             ACTA DERM VENEREOL SUPPL 73     53    83 973
   010   DAWBER RPR            BR J DERMATOL                   86   272 972
   011   ORFANOS CE            ARCH DERMATOL                  107    38 973
   012   STEINRUD J            DAN MED BULL                    21   251 974
   013   DANKS DM              ANN HUM GENET                   28   323 965
   014   FARBER S              J MICH MED SOC                  44   587 945
   015   JOHANSEN PG           LANCET                           1   455 968
   016   GIBSON LE             LANCET                           2   189 970
   017   TILLMAN B             CELL TISSUE RES                185   279 977
   018   BAUR PS               TEX REP BIOL MED                34   113 976
   019   PORTER KR             J CELL BIOL                     57   815 973
   020   ANDREWS PM            AM J ANAT                      140    81 974
   021   SYLVEN B              ACTA HISTOCHEM SUPPL             1    79 958
   022   DANES BS              J EXP MED                      123     1 966
   023   DANES BS              BIOCHEM BIOPHYS RES COMMUN      36   919 969
   024   SPOCK A               PEDIATR RES                      1   173 967
   025   DANES BS              J EXP MED                      136  1313 972
CT   1   THEOHARIDES TC        LIFE SCI                        27   703 980
     2   MICHALSEN H           PATHOL RES PRACT               178   261 984

PN 79166
RN 01146 
AN 80099211
AU Hahnel-R.  Hosli-P.
TI Alkaline phosphatase induction in cystic fibrosis fibroblasts
   [letter].
SO Med-J-Aust. 1979 Nov 3. 2(9). P 490.
MJ ALKALINE-PHOSPHATASE: du.  CYSTIC-FIBROSIS: di.
MN ALKALINE-PHOSPHATASE: me.  FIBROBLASTS: en.  HUMAN.
EX Lysosomal acid hydrolases and alkaline phosphatase cooperate in the
   intracellular digestion of natural polymers.  A stimulus for the
   induction of these enzymes is the retention of any kind of polymer
   inside the cell.  This stimulus is long-lasting and strong if
   polymers are intracellularly retained because of a lack of digestive
   enzymes.  In previous papers it has been demonstrated that the
   alkaline phosphatase (AIP) induction with Tamm Horsfall glycoprotein
   discriminates between fibroblasts of CF homozygotes on the one hand
   and normals and CF carriers on the other hand, and a hypothesis has
   been proposed to explain these observations.  As predicted, more
   efficient inducing mixtures have since been developed; these have
   been used in the present study.  The first writer familiarized
   himself with ultramicrotechniques and then carried out double blind
   studies on 20 fibroblast cultures from French patients.  These
   findings demonstrate the reproducibility of the AIP induction and of
   the methods used, and they particularly underline the importance of
   employing the present ultramicrotechniques for a successful AIP
   induction.  It is likely that amniotic fluid cells behave like skin
   fibroblasts in this test; if this proves to be so, then the induction
   of alkaline phosphatase should provide a useful technique for the
   prenatal diagnosis of cystic fibrosis.
RF 001   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      73   209 976
   002   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      79   741 977
   003   HOSLI P               MONOGR PAEDIATR                 10    90 979
   004   HOSLI P               CLIN CHEM                       23  1476 977

PN 79167
RN 01147 
AN 79199129
AU Phelan-P-D.  Allan-J-L.  Landau-L-I.  Barnes-G-L.
TI Improved survival of patients with cystic fibrosis.
SO Med-J-Aust. 1979 Apr 7. 1(7). P 261-3.
MJ CYSTIC-FIBROSIS: mo.
MN ADOLESCENCE.  AGE-FACTORS.  ANTIBIOTICS: tu.  CHILD.
   CYSTIC-FIBROSIS: dt, th.  HUMAN.
AB The survival of 320 patients, who were born in and after 1958 with
   cystic fibrosis and managed by the Departments of Thoracic Medicine
   and Gastroenterology, Royal Children's Hospital, Melbourne, is
   reviewed. Eighty per cent of patients survived to 11 years of age,
   and 64% to 18 years. Of patients managed between 1973 and 1977, 91%
   survived to 12 years of age, and 80% to 17 years of age. In the same
   period, 79% of patients survived for 16 years after diagnosis. Forty-
   four per cent of the 240 patients currently being managed have no
   significant permanent lung disease, and only 9% have advanced
   disease.
RF 001   ANDERSON CM           MOD PROBL PEDIATR               10   344 967
   002   WARWICK WJ            IN: LAWSON D PROC 5TH INT CF         320 969
   004   ROBINSON MJ           ARCH DIS CHILD                  50   962 975
   005   CROFTON J             RESPIRATORY DISEASES                 638 975
   006   GIBSON LE             PEDIATRICS                      23   545 959
   007   ARMITAGE P            STATISTICAL METHODS IN MEDICA            971
   008   REILLY BJ             RADIOLOGY                       98   281 971
   009   ORENSTEIN DM          AM J DIS CHILD                 131   973 977
   010   WILLIAMS HE           RESPIRATORY ILLNESS IN CHILDR            975
   011   WARING WW             ADV PEDIATR                     23   401 977
   012   ALLAN JL              AUST PAEDIATR J                 10   136 974
CT   1   ALLAN JL              MED J AUST                       1   600 980
     2   ROBINSON MJ           MED J AUST                       1   580 980
     3   SHEPHERD R            J PEDIATR                       97   351 980
     4   SINCLAIR MI           MED J AUST                       2   283 981
     5   FRYDMAN MI            AUST PAEDIATR J                 17    35 981
     6   MILLER M              AM J CLIN NUTR                  36   492 982
     7   WARWICK WJ            ACTA PAEDIATR SCAND SUPPL 301 1982    27 982
     8   SHEPHERD RW           J PEDIATR GASTROENTEROL NUTR     2   439 983
     9   WILMOTT RW            ARCH DIS CHILD                  58   835 983
    10   WESLEY AW             NZ MED J                        96   651 983
    11   ANON                  LANCET                           1   663 984
    12   WELLS AL              J FOOD NUTR                     41    65 984
    13   HODGES P              J AM DIET ASSOC                 84   664 984
    14   WESLEY AW             NZ MED J                        97   773 984
    15   HOLT TL               AM J CLIN NUTR                  41  1061 985
    16   BERKIN KE             EUR J RESPIR DIS                67   103 985
    17   HILL DJS              MED J AUST                     143   230 985
    18   PEDERSEN SS           ACTA PAEDIATR SCAND             75   840 986
    19   LITTLEWOOD JM         J ROY SOC MED                   79    55 986

PN 79168
RN 01148 
AN 80120196
AU Carey-W-F.  Pollard-A-C.
TI Alkaline phosphatase induction in cystic fibrosis fibroblasts
   [letter].
SO Med-J-Aust. 1979 Dec 1. 2(11). P 604-5.
MJ ALKALINE-PHOSPHATASE: bi.  CYSTIC-FIBROSIS: en.
MN CELLS-CULTURED.  ENZYME-INDUCTION.  FIBROBLASTS: en.  HUMAN.
EX Hosli has published a hypothesis relating to the primary cause of
   cystic fibrosis (CF) based on his observations that the level of
   alkaline phosphatase (ALP) in CF-derived skin fibroblasts, but not
   fibroblasts derived from normal individuals, could be increased
   several-fold by growing the cells in the presence of the urinary
   glycoprotein, Tamm-Horsfall protein (THP).  However, we have not been
   able to show, in Adelaide, any change or induction in the level of
   ALP activity in CF-derived skin fibroblasts when grown in the
   presence of locally prepared THP under what appear to be identical
   cell culture conditions to those used by Hosli.  It thus appears that
   under the conditions currently employed in our laboratory, there is
   no diagnostic discrimination between fibroblasts of CF homozygotes
   and normal individuals.
RF 001   HOSLI P               MONOGR PAEDIATR                 10    90 978
   002   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      73   209 976
   003   CAREY WF              AUST J EXP BIOL MED SCI         57   225 979
   004   HOSLI P               CLIN CHEM                       23  1476 977
   005   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      79   741 977
   006   CAREY WF              PAEDIATR RES SOC AUST                    979
   007   CAREY WF              HUMAN GENET SOC AUST                     979
   008   WIJCIK L              BIOCHIM BIOPHYS ACTA           585   374 979
CT   1   CAREY WF              MED J AUST                       2   314 982
     2   CAREY WF              MED J AUST                       2   528 983

PN 79169
RN 01149 
AN 79221582
AU Weller-P-H.  Bush-E.  Preece-M-A.  Norman-A-P.  Matthew-D-J.
TI The short-term effects of chest physiotherapy on lung function tests
   in children with cystic fibrosis.
SO Monogr-Paediatr. 1979. 10. P 58-9.
MJ CYSTIC-FIBROSIS: th.  LUNG: pp.  PHYSICAL-THERAPY.
MN CHILD.  CYSTIC-FIBROSIS: pp.  HUMAN.  RESPIRATORY-FUNCTION-TESTS.
   THORAX.  TIME-FACTORS.
AB Chest physiotherapy is an important part of the treatment program of
   children with cystic fibrosis, but controlled studies of its effects
   are few.  27 children with cystic fibrosis, 20 being chronic sputum
   producers and 7 non-sputum producers, were studied in hospital with
   serial lung function tests on 3 consecutive days.  On the 1st day
   physiotherapy was performed twice; on the 2nd day no physiotherapy
   was performed; on the 3rd day the two periods of physiotherapy were
   preceded by an inhaled bronchodilator (Rimiterol).  Lung function
   tests included peak flow, forced vital capacity (FVC), forced
   expiratory volume in 1 sec (FEV1.0) and residual volume to total
   lung capacity ratio, and were measured at the beginning of each day
   and at similar intervals throughout the 3 days.  Sputum volume and
   cough frequency were noted on day 1 and day 3.  Physiotherapy
   resulted in significant improvement of peak flow in the sputum
   producers.  However, the FVC and FEV1.0, while improving after
   physiotherapy, also improved on the control day when no
   physiotherapy was performed.  This suggests that physiotherapy may
   be effective in removing sputum from central large airways with
   resultant improvement in peak flow, but has little added effect on
   the more peripheral airways, whose airflow improves through the day
   with normal activity.  No significant effect was shown in the non-
   sputum producers although there was a trend towards improvement in
   peak flow.  A bronchodilator before physiotherapy may be beneficial
   in those patients who demonstrate significant reduction in airflow
   obstruction at formal testing of bronchodilator response, but may
   lessen the beneficial effects of physiotherapy in those without a
   positive response.  The study illustrates the importance of
   examining difference methods of chest physiotherapy, to find ways of
   improving sputum clearance.
CT   1   GOTZ M                EUR J RESPIR DIS                61   122 980

PN 79170
RN 01150 
AN 79221583
AU Kerrebijn-K-F.  Veentjer-M-A.  Water-E-B.
TI Effect of four physiotherapy schedules on pulmonary function in
   children with cystic fibrosis.
SO Monogr-Paediatr. 1979. 10. P 60.
MJ CYSTIC-FIBROSIS: th.  LUNG: pp.  PHYSICAL-THERAPY.
MN CHILD.  CYSTIC-FIBROSIS: pp.  HUMAN.  RESPIRATORY-FUNCTION-TESTS.
AB In 17 children (group A) with cystic fibrosis (CF) the effect of the
   following treatment schedules on pulmonary function has been studied in
   random order on 4 consecutive days: (1) clapping and postural drainage
   (CP);
   (2) CP after inhaling an aerosol of 5 ml 20% N-acetylcysteine by a Monaghan
   ultrasonic device; (3) as in 2 but with the addition of 0.5 mg isoprenaline
   to the aerosol; (4) as in 3 but with an IPPB device added to the nebulizer.
   Treatment was started at 9.30 a.m. and lasted for about 1 h.  Pulmonary
   function was measured prior to and 30 min after treatment (9.00 and 11.00
   a.m., respectively).  In 8 children (group B) with CF (severity comparable
   to the previous group) pulmonary function was measured at 9.00 and 11.00
   a.m.
   but without physiotherapy in between.  The following pulmonary function
   measurements have been included in the evaluation of the results: VC, FVC,
   FEV1, TLC (body box), TLC (helium dilution), TLCBb-TLCHe, RVBb, RVHe,
   maximal
   expiratory flows at 60% TLBBb, 25% FVC, maximal midexpiratory flow, airway
   conductance.  The technique of the determinations was carefully controlled
   and initial values were reproducible in most children.  In group B, mean
   values of pulmonary function were equal at 9.00 and 11.00 a.m.  In group
   A
   none of the treatment schedules caused a significant improvement of mean
   pulmonary function values.  In some of the children, however, pulmonary
   function improved, but in others it deteriorated. The significance of these
   findings was discussed.

PN 79171
RN 01151 
AN 79221584
AU Kraemer-R.  Rudeberg-A.  Rossi-E.
TI Relationship between clinical conditions, chest radiographic
   findings and respiratory function tests in cystic fibrosis.
SO Monogr-Paediatr. 1979. 10. P 61-5.
MJ CYSTIC-FIBROSIS: di.
MN CHILD.  CYSTIC-FIBROSIS: pp, ra.  HUMAN.  LUNG: pp.
   RESPIRATORY-FUNCTION-TESTS.  THORACIC-RADIOGRAPHY.
EX We explored 44 children suffering from cystic fibrosis with
   predominant pulmonary involvement and followed in particular the
   course of illness of 30 of these patients during an average period of
   4 years.  We were impressed by the enormous variability of the
   pulmonary symptomatology in these children.  The question arose
   whether this clinical impression is supported by the finding of the
   thorax radiograph and the results of the lung functions tests and the
   blood gas measures at rest and on exercise.  From the clinical point
   of view, there is a possibility to make a classification of severity
   in pulmonary aspects of this disease.  Because of the large ranges of
   the score values a clear distinction of the severity could only be
   possible if large groups of patients were to be compared.  For the
   interindividual comparison the cumulative evaluation of a clinical
   score, the chest radiograph and the lung function tests are
   indispensable.  Only the continuous follow-up of these examinations
   allows one to notice, in time, a progressive lung involvement with
   its degenerative changes.
RF 001   KRAEMER R             PROC EWGCF 7TH ANNU MTG               31 977
   002   KRAEMER R             HELV PAEDIATR ACTA              32   107 977
   003   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   004   HUANG NN              AM J DIS CHILD                 120   289 970
   005   GEORGE L              ARCH DIS CHILD                  46   139 971
   006   ROBINSON MJ           ARCH DIS CHILD                  50   962 975
   007   KRAEMER R             TAG SCHWEIZ GES PNEUMOLOGIE L            978
   008   KRAEMER R             PADIAT FORTBILDK PRAXIS         48     7 979
   009   CHRISPIN AR           PEDIATR RADIOL                   2   101 974
   010   SCHERRER M            SCHWEIZ MED WOCHENSCHR         107  1072 977
CT   1   KRAEMER R             HELV PAEDIATR ACTA              34   417 979
     2   KRAEMER R             METH INF MED                    19    50 980

PN 79172
RN 01152 
AN 79221581
AU Flower-K-A.  Mann-N-M.  Eden-R-I.
TI A new percussion aid for cystic fibrosis patients.
SO Monogr-Paediatr. 1979. 10. P 54-7.
MJ CYSTIC-FIBROSIS: th.  PERCUSSION.
MN ADOLESCENCE.  ADULT.  HUMAN.  PHYSICAL-THERAPY.  SPUTUM.  THORAX.
EX This paper is a report on the first part of a comprehensive research
   programme.  The aim is the development of a mechanical aid which will
   enable patients with cystic fibrosis to give themselves satisfactory
   physiotherapy.  The percussor, which can be used by patients, parents
   or relatives, is portable and lightweight.  The domiciliary trial
   showed that effective percussion could be self-administered to the
   front of the chest and to a lesser extent to the sides of the chest.
   The percussor was found to be very acceptable to adolescent patients
   and especially girls with early breast development.  Further research
   work has now been completed and as a result a system has been
   developed which enables patients to treat themselves with
   satisfactory chest percussion in the five preferred positions of
   postural drainage.
RF 001   HODSON ME             BR MED J                         1   971 978
   002   FLOWER KA             PROC EWGCF 8TH ANNU MTG                  978
   003   GASKELL DV            BROMPTON HOSP GUIDE TO CHEST             973

PN 79173
RN 01153 
AN 79221580
AU Dab-I.  Alexander-F.
TI The mechanism of autogenic drainage studied with flow volume curves.
SO Monogr-Paediatr. 1979. 10. P 50-3.
MJ CYSTIC-FIBROSIS: co.  LUNG-DISEASES-OBSTRUCTIVE: th.  SPUTUM.
MN BRONCHI.  CHILD.  CYSTIC-FIBROSIS: th.  HUMAN.
   LUNG-DISEASES-OBSTRUCTIVE: et.  POSTURE.
EX In 1977, we demonstrated the efficiency of autogenic drainage with
   two bronchorrheic children, who needed bronchography for diagnostic
   purposes.  This demonstration was made possible thanks to a
   radiocinematographic study after bronchography.  The examination also
   showed the inefficacy of coughing.  The object of the present study
   is to analyze the physiologic mechanism of autogenic drainage.  For
   children older than five, this method is very simple and efficient
   and as the effort or onset is not excessive and as expiration does
   not need to be complete, autogenic drainage is not exhausting and can
   be performed for a long time, which is indispensable since the
   progression of secretions is slow.
RF 001   DAB I                 IN: BARAN D                          185 977
   002   DAB I                 PROC EWGCF 7TH ANNU MTG                  977
CT   1   EICHLER I             DTSCH MED WSCHR                111   896 986

PN 79174
RN 01154 
AN 79221579
AU Bakken-A-F.  Motzfeldt-C.
TI Intestinal lactase deficiency in newborns with cystic
   fibrosis--dietary consequences.
SO Monogr-Paediatr. 1979. 10. P 5-7.
MJ CYSTIC-FIBROSIS: co.  INTESTINES: en.  LACTOSE-INTOLERANCE: dh.
MN BETA-GALACTOSIDASES: me.  CYSTIC-FIBROSIS: dh, en.  HUMAN.  INFANT.
   INFANT-NEWBORN.  LACTOSE-INTOLERANCE: et.
EX The problem of proper diet to children and infants with cystic
   fibrosis is continuously discussed.  This paper deals with the diet
   for CF infants younger than one year.  The basic view is that the
   diet should be as close to the 'normal baby' diet as possible, partly
   to ensure normal growth and development, and partly to avoid extra
   work for the families with CF infants.  Infants suffering from CF
   were given lactose-free diet until they reached the age of one year.
   The weight increased more rapidly than in CF patients given the
   traditional CF diet with low fat and high protein.  Furthermore, it
   was not necessary to give increased amounts of calories to the
   infants given lactose-free diet, nor did they receive additional
   fat-soluble vitamins.

PN 79175
RN 01155 
AN 79221578
AU Konradova-V.  Vavrova-V.  Tomanek-A.  Houstek-J.
TI Ultrastructure of the bronchial epithelium in children with cystic
   fibrosis.
SO Monogr-Paediatr. 1979. 10. P 46-9.
MJ BRONCHI: ul.  CYSTIC-FIBROSIS: pa.
MN BRONCHI: pa.  CHILD.  CHILD-PRESCHOOL.  EPITHELIUM: pa, ul.  FEMALE.
   HUMAN.  MALE.
EX The ultrastructure of the bronchial epithelium in 3 children with
   cystic fibrosis was described.  In 2 of them a developed squamous
   metaplasia with many signs of pathological alteration of the
   epithelial cells was observed.  In the third patient severely injured
   pseudostratified epithelium with remnants of ciliary border is
   preserved.
RF 001   KONRADOVA V           FOLIA MORPHOL (PRAGUE)          24   296 976
   002   KONRADOVA V           Z ERKR ATMUNGSORGANE                 270 977
CT   1   ROBERTSON B           EUR J RESPIR DIS                63   496 982
     2   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983

PN 79176
RN 01156 
AN 79221585
AU di-SantAgnese-P-A.  Davis-P-B.
TI Recent research in cystic fibrosis.
SO Monogr-Paediatr. 1979. 10. P 66-76.
MJ CYSTIC-FIBROSIS.  RESEARCH.
MN ANIMAL.  AUTONOMIC-NERVOUS-SYSTEM.  BONE-MARROW.
   CYSTIC-FIBROSIS: et, fg, pp.  FEMALE.  HUMAN.  INFANT.  INFANT-NEWBORN.
   MICE.  ANTHROPOIDEA.  PREGNANCY.  RABBITS.  TISSUE-CULTURE.
EX This review emphasizes some of the positive accomplishments of cystic
   fibrosis research, some of the puzzles and some of the recent
   developments that have promise.  One of the major unresolved
   questions is the maintenance of this lethal gene at such a high
   frequency, perhaps because of a heterozygote advantage in the past,
   no longer operative at present.  Nothing is known of the chromosomal
   localization of the trait; except that chromosomes are
   morphologically normal, that it is autosomal, not sex linked and that
   there is no correlation with blood groups or major HLA loci.  One of
   the important achievements of the past many years is that we
   understand relatively well the pathogenesis of most clinical
   manifestations of CF.  The as yet unknown inherited basic defect or
   metabolic error of CF gives rise to two main anomalies: the
   electrolyte defect in exocrine sweat glands and the 'mucous
   secretion' abnormality.  While the results of tissue culture studies
   often have been conflicting and disparate, it does seem to be the
   consensus that the fibroblasts are affected by the basic metabolic
   error in some manner, and that they respond abnormally under
   different experimental circumstances.  Virtually all investigators
   have found some anomalies in biologic fluids of CF, although using
   different approaches and methods.  An abnormality in the function of
   the autonomic nervous system, which is so closely associated with the
   exocrine glands, has always been an attractive explanation for the
   generalized exocrinopathy of CF.  The search for a genetic animal
   model for CF has led to interesting findings.
RF 001   BARTMAN J             J PEDIATR                       76   430 970
   002   DANES BS              J EXP MED                      129   775 969
   003   DAVIS PB              PEDIATR RES                     12   703 978
   004   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   005   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   006   EPSTEIN JL            PROC NAT ACAD SCI USA           74  1676 977
   007   EPSTEIN JL            PROC NAT ACAD SCI USA           74  5642 977
   009   GUGLER EC             J PEDIATR                       71   585 967
   010   HOSLI P               MONOGR PAEDIATR                 10    90 979
   011   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      79   741 977
   012   KAISER D              LIFE SCI                        15   803 974
   013   MANGOS JA             PEDIATR RES                      2   378 968
   014   MANGOS JA             IN: LAWSON D PROC 5TH INT CF          25 969
   015   MARTINEZ JR           PEDIATR RES                      9   463 975
   016   SHAPIRA E             J BIOL CHEM                    252  7923 977
   018   ANON                  PROC WORKSHOP ON MODEL SYS CF            978
   019   WRIGHT SW             AM J HUM GENET                  20   157 968
   020   HOSLI P               ACTA PAEDIATR SCAND             67   617 978
CT   1   DAVIS PB              PEDIATR RES                     14    83 980
     2   HULTBERG B            CLIN CHIM ACTA                 112   167 981
     3   MORIARTY CM           J MED                           13   257 982
     4   KAMOUN P              BIOCHEM MED                     31   104 984
     5   NEAL JL               EVOLUTIONARY THEORY              7   153 985
     6   RUPP GM               MED HYPOTHESES                  20   245 986

PN 79177
RN 01157 
AN 79221586
AU Roscher-A.  Wiesmann-U-N.  Hadorn-B.
TI Relevance of second messengers in cystic fibrosis.
SO Monogr-Paediatr. 1979. 10. P 77-83.
MJ ADENOSINE-CYCLIC-MONOPHOSPHATE: me.  CYSTIC-FIBROSIS: me.
   ISOPROTERENOL: pd.  RECEPTORS-ADRENERGIC.  RECEPTORS-ADRENERGIC-BETA.
MN ADRENERGIC-BETA-RECEPTOR-BLOCKADERS: pd.  CYSTIC-FIBROSIS: pp.
   FIBROBLASTS: me.  HUMAN.  NEUROREGULATORS: ph.  PROSTAGLANDINS-E: ph.
EX Water, electrolyte and macromolecular secretion, which is affected in
   cystic fibrosis, is regulated by neurotransmitters of the autonomic
   nervous system stimulating the cells by binding to alpha-adrenergic,
   beta-adrenergic and cholinergic receptors.  Therefore, a genetic
   disturbance in cyclic 3'5'-adenosine monophosphate (c-AMP) response
   could eventually explain some of the manifold expressions of labile
   biochemical changes observed in CF, specially in tissue culture.  We
   further characterized beta-receptors in cultured fibroblasts of CF
   patients and normal controls and investigated isoproterenol and
   prostaglandin E1-mediated c-AMP response using defined culture
   conditions.  No significant difference was found between the two
   phenotypes on basal c-AMP values.  With the exception of one cell
   line, CF strains had 25 to 180% increased c-AMP content.  This
   difference is highly significant (p < 0.0025).  This statistically
   significant difference in response can neither be attributed to
   differences in dose- or time-response curves nor to differential
   c-AMP escape into culture medium.  Since CF cells synthesize more
   c-AMP than controls only in response to isoproterenol but not to
   prostaglandin E1, the alteration which might be responsible for the
   observed phenomenon is probably located proximal of the adenylate
   cyclase at the cells border between intra- and extracellular space.
RF 001   BERRIDGE MJ           ADV CYCLIC NUCLEO RES            6     1 975
   002   RAMWELL PW            IN: RABIN BR                         207 971
   003   BUTCHER FR            BIOCHIM BIOPHYS ACTA           392    82 975
   004   SCHRAMM M             J CYCLIC NUCLEOTIDES RES         1   181 975
   005   BUCHWALD M            PROC NAT ACAD SCI USA           73  2899 976
   006$  SHAPIRO BL            CF CONF REP                      2       978
   007   RECHLER MM            J CLIN ENDOCRINOL METAB         39   512 974
   008   MANGANIELLO VC        BIOCHIM BIOPHYS ACTA           362   509 974
   009   GILMAN AG             PROC NAT ACAD SCI USA           67   305 970
   010   KELLY LA              J BIOL CHEM                    249  3098 974
   011   DUNLOP D              BR J PHARMAC CHEMOTHER          32   201 968
   012   BARBERO GJ            IN: DI SANTAGNESE PA                 208 964
   013   LANDS AM              NATURE                         214   597 967
   014   FRANKLIN TJ           MOL PHARMACOL                   11   485 975
   015   HO RJ                 J BIOL CHEM                    246  6822 971
   016   NEWCOMBE DS           PROC NAT ACAD SCI USA           72  3124 975
CT   1   BECKER M              EUR J PEDIATR                  134   217 980

PN 79178
RN 01158 
AN 79221587
AU Aggett-P-J.  Thorn-J-M.  Delves-H-T.  Harries-J-T.  Clayton-B-E.
TI Trace element malabsorption in exocrine pancreatic insufficiency.
SO Monogr-Paediatr. 1979. 10. P 8-11.
MJ CYSTIC-FIBROSIS: me.  IRON: me.  MALABSORPTION-SYNDROMES: et.
   MANGANESE: me.  PANCREATIC-DISEASES: me.  ZINC: me.
MN CHILD.  COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: co.  FEMALE.  HUMAN.
   MALE.
EX This paper presents preliminary results from metabolic balance
   studies of iron, zinc and manganese absorption and retention in
   children with cystic fibrosis and Shwachman's syndrome.
   Malabsorption of zinc, iron and manganese in exocrine pancreatic
   insufficiency has been demonstrated by these early studies.  A
   possible relationship between this and the associated features of CF
   has been briefly discussed, and indicates areas for further research.
   If such relationships are established then some form of trace element
   supplementation should be considered.
RF 001   ALEXANDER FW          Q J MED                         43    89 974
   002   BUTTERWORTH J         CLIN CHIM ACTA                  56   159 974
   003   CAPLAN AH             J PEDIATR                       73   540 968
   004   DAVIS AE              LANCET                           2     6 962
   005   DODGE JA              BR MED J                         1   411 978
   006   EVANS GW              IN: KIRCHGESSNER M                    98 978
   007   HALSTED JA            LANCET                           1   322 970
   008   RAO GJS               PEDIATR RES                     11   981 977
   009   RHEINHOLD JG          CLIN CHEM                       21   476 975
   010   SINGER L              CLIN BIOCHEM                     7   146 974
   011   UNDERWOOD EJ          TRACE ELEMENTS IN HUMAN AND A            977
CT   1   CLAYTON BE            ADV CLIN CHEM                   21   147 980
     2   AGGETT PJ             PROC NUTR SOC                   39   241 980
     3   SOLOMONS NW           AM J CLIN NUTR                  34   462 981
     4   HURRY VJ              BIOL TRACE ELEMENT RES           4   157 982
     5   DELVES HT             ANN CLIN BIOCHEM                19   302 982
     6   SOLOMONS NW           AM J CLIN NUTR                  35  1048 982
     7   VANCAILLIEBERTRAND M  ACTA PAEDIATR SCAND             71   203 982
     8   SOLOMONS NW           J AM DIET ASSOC                 80   115 982
     9   VANDERHOOF JA         DIG DIS SCI                     28   300 983
    10   RUSSELL RM            ANN INTERN MED                  99   227 983
    11   PATRICK J             CRC CRIT REV CLIN LAB SCI       20    95 984
    12   MCCLAIN CJ            J AM COLL NUTR                   4    49 985
    13   DELVES HT             CLIN ENDOCRINOL METAB           14   725 985

PN 79179
RN 01159 
AN 79221588
AU Hamdi-I.  Bloom-A-L.  Goodchild-M-C.  Dodge-J-A.
TI Prostaglandins and cystic fibrosis.
SO Monogr-Paediatr. 1979. 10. P 84-9.
MJ CYSTIC-FIBROSIS: me.  PROSTAGLANDINS-E: me.  SWEAT: me.
MN ADENOSINE-CYCLIC-MONOPHOSPHATE: bi.  ADULT.  CHILD.
   CYSTIC-FIBROSIS: bl.  HUMAN.  PLATELET-AGGREGATION.
EX We have investigated two aspects of prostaglandin function in cystic
   fibrosis: the response of platelets to PGE1, and the concentrations
   of PGE2 and PGE-alpha in the sweat.  Low concentrations of PGE1 have
   less effect on platelet agglutination in CF patients and
   heterozygotes than in normals, but no difference is observed when
   high PG concentrations are used.  Sweat PGE2 and PGE-alpha
   concentrations are similar in normals, CF patients and heterozygotes,
   but sweat PGE2 concentrations are proportional to Na/Cl levels in CF,
   but not in control children or heterozygotes.
RF 001   BARNES GL             LANCET                           2   918 975
   002   BUCHWALD M            AM J HUM GENET                  27   22A 975
   003   CHASE HP              PEDIATRICS                      57   441 976
   004   FORSTROM L            PROSTAGLANDINS                   7   459 974
   005   FREWIN DB             AUST J EXP BIOL MED SCI         51   701 973
   006   GALABERT C            PROC INT CF CONG 7TH                 100 976
   007   ROBINSON PG           PROC INT CF CONG 7TH                 107 976
   008   ROSENLUND ML          PEDIATRICS                      59   428 977
   009   SAMUELS CE            LANCET                           2   607 975
   010   YASSA JG              PROC INT CF CONG 7TH                 323 976
CT   1   ANDERSON CM           J PEDIATR GASTROENTEROL NUTR     3    15 984
     2   DAVIS PB              J LAB CLIN MED                 104   203 984
     3   KHULLAR AK            CLIN SCI                        68   433 985
     4   STEAD RJ              PROSTAGLANDINS LEUKOTR MED      26    91 987

PN 79180
RN 01160 
AN 79221589
AU Hosli-P.  Kollberg-H.  Vogt-E.
TI Operational definition of cystic fibrosis.  I.
SO Monogr-Paediatr. 1979. 10. P 90-5.
MJ CYSTIC-FIBROSIS: di.
MN ANIMAL.  CYSTIC-FIBROSIS: en, fg, me.  FIBROBLASTS: me.
   HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.  HYDROLASES: me.  LYSOSOMES: en.
EX Recently, one of us suggested a new hypothesis concerning the 'basic
   defect' of cystic fibrosis.  The purpose of the present paper is to
   review this model and to critically discuss its eventual diagnostic
   applications.  With extensive studies, we collected experimental data
   which contribute five major arguments in favour of the proposition
   that CF may be an enzyme recognition site mutant.  With fibroblast
   cultures the three genotypes can be separated in the following way:
   CF homozygote, leaky for alkaline phosphatase (A1P) and lysosomal
   hydrolases/A1P is Tamm-Horsfall glycoprotein (THP) inducible; CF
   heterozygote, leaky for A1P and lysosomal hydrolases/A1P is not THP
   inducible; normal control, not leaky for A1P and lysosomal
   enzymes/A1P is not THP inducible.  With the exception of a second
   double-blind study, the THP induction as well as the leakage analysis
   seem to be statistically unequivocal: they strongly support our
   hypothesis concerning the basic defect in CF.
RF 001   HOSLI P               PROC INT CF CONG 7TH                 278 976
   002   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      79   741 977
   003   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      73   209 976
   004   HOSLI P               HUM HERED                       27   185 977
   005   WARD JB JR            TEX REP BIOL MED                34    11 976
   006   RENNERT OM            GAP CONF REP TISS CULT APPR            1 977
   007   HOSLI P               IN: MOTULSKY AG                      226 974
   010   HOSLI P               ADV EXP MED BIOL                68     1 976
   011   HOSLI P               CLIN CHEM                       23  1476 977
   012   BOAT TF               IN: MANGOS JA                        165 976
   013   HOSLI P               HUM GENET                       41   169 978
   015   HICKMAN S             BIOCHEM BIOPHYS RES COMMUN      57    55 974
   016   WIESMANN UN           N ENGL J MED                   284   109 971
   017   SCANLIN TF JR         PROC INT CF CONG 7TH                  44 976
   020   MANGOS JA             SCIENCE                        158   135 967
   021   PALADE GE             INT SYMP ON LYSOSOMES ABST            36 972
   022   PALADE GE             CF Q ANNOTATED REFERENCES       14    29 975
   023   HOSLI P               TISSUE CULTIVATION ON PLASTIC            972
CT   1   HOSLI P               LANCET                           2   543 979
     2   DISANTAGNESE PA       MONOGR PAEDIATR                 10    66 979
     3   HOSLI P               FEBS LETTERS                   104   271 979
     4   TEGNER H              ACTA PAEDIATR SCAND             70   629 981
     5   MALER T               J BIOL CHEM                    256  1420 981
     6   CAREY WF              MED J AUST                       2   528 983
     7   HEELEY AF             CLIN CHEM                       29  2011 983
     8   CEDER O               ACTA PAEDIATR SCAND             72   291 983
     9   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
    10   BUYS CHCM             CLIN CHIM ACTA                 136   229 984

PN 79181
RN 01161 
AN 79221590
AU Casola-L.  Di-Matteo-G.  Mastella-G.  Rutigliano-B.  Romano-M.
TI Alpha-glucosidase in cystic fibrosis.
SO Monogr-Paediatr. 1979. 10. P 96-101.
MJ CYSTIC-FIBROSIS: en.  GLUCOSIDASES: bl.
MN ADULT.  CHILD.  CYSTIC-FIBROSIS: fg.  HETEROZYGOTE.  HOMOZYGOTE.
   HUMAN.
EX Studies are presented on the serum level of several acid glycosidases
   in normal and cystic fibrosis subjects.  Levels of alpha-glucosidase
   found in serum from CF patients were significantly higher than from
   normals and heterozygotes.  The increase in alpha-glucosidase was
   directly related to the clinical gravity of the disease.  Levels of
   all other glycosidases studied in CF patients were in the normal
   range.
RF 001   ALHADEFF JA           CLIN GENET                      10    63 976
   003   ANTONOWICZ I          PEDIATR RES                      6   803 972
   004   BARTMAN J             J PEDIATR                       76   430 970
   005   DANES BS              J EXP MED                      129   775 969
   006   DI MATTEO G           MONOGR PAEDIATR                 10    19 979
   007   DI SANTAGNESE PA      N ENGL J MED                   295   534 976
   008   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      73   209 976
   009   MATALON R             BIOCHEM BIOPHYS RES COMMUN      33   954 968
   010   SHWACHMAN H           AM J DIS CHILD                  96   615 958
CT   1   DIMATTEO G            MONOGR PAEDIATR                 10    19 979
     2   HULTBERG B            CLIN CHIM ACTA                 112   167 981

PN 79182
RN 01162 
AN 79221562
AU Starkey-B-J.  Goodchild-M-C.
TI Postprandial total serum bile acid concentrations in cystic fibrosis.
SO Monogr-Paediatr. 1979. 10. P 12-8.
MJ BILE-ACIDS-AND-SALTS: bl.  CYSTIC-FIBROSIS: bl.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  EATING.  HUMAN.
   MIDDLE-AGE.  TIME-FACTORS.
EX In recent years, several workers have reported that a single 2-hour
   postprandial total serum bile acid (TSBA) concentration, in a variety
   of liver disease states, is a more sensitive index of deranged liver
   function than are the 'conventional' serum liver function tests.
   This observation seemed to us to provide a challenging situation for
   the assessment of TSBA concentrations in cystic fibrosis.  The
   distribution of results for the CF patients (mean TSBA concentration
   27.0 micromol/l) and for the age-matched controls (mean concentration
   19.9 micromol/l) shows a wider range for the CF group.  Statistical
   analysis, however, of these two groups shows no significant
   difference between them.  Many factors affect both the size and
   distribution of the bile acid pool in CF, and a consideration of
   these factors may go some way towards explaining the rather
   unspectacular TSBA results.
RF 001   BARNES S              J CLIN PATHOL                   28   506 975
   002   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   003   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   004   FAUSA O               SCAND J GASTROENTEROL           11   537 976
   005   FEIGELSON J           ACTA PAEDIATR SCAND             59   539 970
   006   GOODCHILD MC          ARCH DIS CHILD                  50   769 975
   007   HARVEY IC             CLIN RADIOL                     28   635 977
   008   HEATON KW             BILE SALTS IN HEALTH AND DISE            972
   009   KAPLOWITZ N           JAMA                           225   292 973
   010   KATTWINKEL J          J PEDIATR                       82   234 973
   011   MASHIGE F             CLIN CHIM ACTA                  70    79 976
   012   MATHIS RK             J PEDIATR                       90   864 977
   013   OPPENHEIMER EH        J PEDIATR                       86   683 975
   014   ROLLER RJ             GASTROENTEROLOGY                72   661 977
   015   SANDBERG DH           PEDIATR RES                      4   262 970
   016   SCHUSTER SR           J PEDIATR SURG                  12   201 977
   017   SMALLEY CA            ARCH DIS CHILD                  53   477 978
   018   TYSON KRT             J PEDIATR SURG                   3   271 968
   019   WATKINS JB            GASTROENTEROLOGY                67   835 974
   020   WATKINS JB            GASTROENTEROLOGY                73  1023 977
   021   WEBER AM              GUT                             17   295 976
   022   WEBER AM              GASTROENTEROLOGY                68  1066 975
   023   WEBER AM              N ENGL J MED                   289  1001 973
   024   WEBSTER R             ARCH DIS CHILD                  28   343 953
CT   1   EKLUND A              SCAND J CLIN LAB INVEST         40   595 980
     2   STRANDVIK B           SCAND J GASTROENTEROL           20   381 985

PN 79183
RN 01163 
AN 79221568
AU Carswell-F.  Oliver-J.  Silverman-M.
TI The cystic fibrosis gene, IgE and IgG4.
SO Monogr-Paediatr. 1979. 10. P 144-7.
MJ CYSTIC-FIBROSIS: fg.  GENES.  IGE: an.  IGG: an.
MN ADOLESCENCE.  ADULT.  CHILD.  CYSTIC-FIBROSIS: im.  FEMALE.  HUMAN.
   MALE.
EX We decided to survey a geographically defined population of cystic
   fibrosis patients and parents living in Avon County, England.  By
   examining the obligate heterozygotes (the parents), we would be able
   to assess the influence of the CF gene without the presence of the
   disease.  There is an increase in immediate hypersensitivity to A.
   fumigatus in CF patients but not their parents.  This increased
   sensitivity is probably IgE-mediated and a secondary effect of lung
   damage.  There is no evidence that the CF gene produces a generalised
   increase in skin reactivity (atopy), serum IgE or serum IgG4 in the
   heterozygotes.  They are not therefore likely to develop asthma.
RF 001   WARREN CPW            CLIN ALLERGY                     5     1 975
   002   WARNER JO             LANCET                           1   990 976
   003   MCFARLANE H           LANCET                           1  1241 976
   004   MCFARLANE H           CLIN ALLERGY                     7   279 977
   005   SHAKIB F              CLIN ALLERGY                     6   237 976
   006   VIJAY HM              INT ARCH ALLERGY APPL IMMUNOL   53    78 977
   007   MCCARTHY DS           IN: LAWSON D PROC 5TH INT CF         194 969
   008   ALLAN JD              CLIN ALLERGY                     5   255 975
   009   WARNER JO             ARCH DIS CHILD                  51   507 976
   010   GODFREY RC            CLIN ALLERGY                     6    79 976
   011   DAVIS JB              CLIN ALLERGY                     6   329 976

PN 79184
RN 01164
AN 79221561
AU Leupold-W.  Dietzsch-H-J.
TI Bronchial reactivity in children with cystic fibrosis and other
   recurrent or chronic bronchopulmonary diseases.
SO Monogr-Paediatr. 1979. 10. P 119-22.
MJ ASTHMA: et.  BRONCHITIS: et.  CYSTIC-FIBROSIS: co.
   RESPIRATORY-HYPERSENSITIVITY: et.
MN CHILD.  CHRONIC-DISEASE.  HUMAN.  RECURRENCE.
EX In our efforts to standardize the evaluation of bronchial reactivity
   we performed investigations into the threshold dosage of
   acetylcholine-induced bronchospasm in patients with various recurrent
   and chronic bronchopulmonary diseases.  A significantly decreased
   threshold value of acetylcholine and thus an increased bronchial
   reactivity could be proven in patients with cystic fibrosis in
   comparison with healthy children.  The cause of bronchial
   hyperreactivity in patients with CF may be due to proteases deriving
   from leucocytes of the purulent sputum.  Furthermore, we investigated
   the influence of terbutaline on the bronchial obstruction induced by
   acetylcholine in patients with bronchial asthma and cystic fibrosis.
   The groups were comparable, especially with regard to the degree of
   the initial bronchial obstruction.
RF 001   EMPEY DW              AM REV RESPIR DIS              113   131 976
   002   HALUSZKA J            RESPIRATION                     32   217 975
   003   MASTELLA G            PROC EWGCF 4TH ANNU MTG               51 973
   004   MCCARTHY DS           IN: LAWSON D PROC 5TH INT CF         194 969
   005   MCCHESNEY-YOHE R      ANN ALLERGY                     30   627 972
   006   MELLIS CM             PEDIATRICS                      61   446 978
   007$  OUELLETTE JJ          J ALLERGY                       36   558 975
   008   ROTHSTEIN RJ          J ALLERGY CLIN IMMUNOL          53   100 974
   009   THAL W                ASTHMA BRONCHIALE IM KINDESAL            977
   010   ULMER WT              DTSCH MED WSCHR                 96  1759 971
   011   WARNER JO             ARCH DIS CHILD                  51   507 976
CT   1   DARGA LL              PEDIATR PULMONOL                 2    82 986

PN 79185
RN 01165 
AN 79221560
AU Baran-D.  Wolter-R.  Bourdoux-P.  Ermans-A-M.
TI Increased serum TSH response to TRH in cystic fibrosis.
SO Monogr-Paediatr. 1979. 10. P 114-8.
MJ CYSTIC-FIBROSIS: pp.  THYROID-GLAND: pp.
   THYROTROPIN-RELEASING-HORMONE: du.  THYROTROPIN: bl.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: bl.  HUMAN.
   INFANT.  INJECTIONS-INTRAVENOUS.  THYROTROPIN-RELEASING-HORMONE: ad.
EX The aim of the present study is to reassess the peripheral pattern of
   thyroid function in subjects with cystic fibrosis with special
   reference to their responsiveness to thyrotropin-releasing hormone
   (TRH) stimulation.  In all the CF patients the basal levels of serum
   T4, T3, and TBG were within the normal range.  Mean values in CF
   patients and in control children were not significantly different.
   In CF patients there is no correlation between the TSH response area
   and the basal level of serum T4, or with grading according to
   Shwachman and Kulczycki.  We found no relation with therapy.  In
   basal conditions, our data show a completely normal pattern of the
   serum concentration of T4, T3, TBG and TSH in subjects with CF in
   absence of iodide therapy.  Thyroid status should be examined in
   patients with CF specially when they receive iodide therapy or other
   drugs which can enhance the impairment of thyroid function.
RF 001   AZIZI F               TRANS ASSOC AM PHYSICIANS       87   111 974
   002   DOLAN TF JR           J PEDIATR                       79   684 971
CT   1   SEGALLBLANK M         J PEDIATR                       98   218 981
     2   BECKER DJ             ANNU REV NUTRITION               3   187 983
     3   SACK J                ISR J MED SCI                   19    17 983
     4   KNOPFLE G             KLIN PAEDIATR                  197   481 985

PN 79186
RN 01166 
AN 79221559
AU Super-M.
TI Factors influencing the frequency of cystic fibrosis in South West
   Africa.
SO Monogr-Paediatr. 1979. 10. P 106-13.
MJ CYSTIC-FIBROSIS: oc.
MN CHILD.  CONSANGUINITY.  CYSTIC-FIBROSIS: fg.  FEMALE.
   GENE-FREQUENCY.  HUMAN.  MALE.  NAMIBIA.  PEDIGREE.
EX Drift, chance effect in a small community and consanguinity have
   resulted in South West Africa's high cystic fibrosis incidence.
   Isolated communities generations ago in Europe, e.g. Bad Gastein,
   where this congress was held, surrounded by its Alpine peaks, could
   have resulted in gene enrichment, which together with the increased
   fertility of the heterozygote could still be responsible for most of
   the CF seen wherever Europeans live today.
RF 001   SUPER M               S AFR MED J                     49   818 975
   002   SUPER M               S AFR MED J                     54    18 978
   003   FALCONER DS           INTRO TO QUANTITAT GENET             100 960
   004   GOLDBLATT I           HIST SW AFRICA FROM BEGINNING            971
   005   SUPER M               LANCET                           2  1288 977
   006   KULCZYCKI LL          AM J DIS CHILD                 127    64 974
   007   DANKS DM              ANN HUM GENET                   28   323 965
CT   1   KLINGER KW            HUM GENET                       65    94 983
     2   KLINGER KW            SEM RESPIR MED                   6   243 985

PN 79187
RN 01167 
AN 79221558
AU Morrissey-S-M.  Tymvios-M-C.
TI The effect of cystic fibrosis and non-cystic fibrosis plasma on
   electrophysiological responses in isolated frog gastric mucosa.
SO Monogr-Paediatr. 1979. 10. P 102-5.
MJ CYSTIC-FIBROSIS: bl.  GASTRIC-MUCOSA: ph.
MN ANIMAL.  CYSTIC-FIBROSIS: pp.  ELECTROPHYSIOLOGY.  ANURA.  HUMAN.
EX An alternative method for assaying the cystic fibrosis factor could
   be on the electrophysiological responses of isolated living tissues.
   The ability of the frog's gastric mucosa to secrete hydrochloric acid
   and maintain a negative potential difference is well known.  This
   potential difference across the secretory (mucosa) to the nutrient
   (serosa) side coupled with its property of transporting chloride and
   hydrogen ions against an electrochemical gradient could therefore
   serve as a useful model for investigating any induced changes in the
   presence of CF and non-CF plasma.  From the results obtained the
   short circuit current and H+ secretion responses in the presence of
   CF (whole) plasma show significant increases compared to the control.
   These findings show that in the presence of CF plasma, whole or
   plasma fraction B, there is a marked increase in the actively
   transported Cl- and H+.  The effect of CF plasma in increasing net
   Cl- flux is important considering the elevation of this electrolyte
   in the sweat of CF patients and deserved further investigation.
RF 001   ARAKI H               PEDIATR RES                      9   932 975
   002   DURBIN RP             J GEN PHYSIOL                   41   101 957
   003   HENRIQUES DE JESUS C  THESIS                                   974
   004   HOGBEN CAM            AM J PHYSIOL                   180   641 955
   005   MANGOS JA             PEDIATR RES                      1   436 967
   006   SPOCK A               PEDIATR RES                      1   173 967
CT   1   COX KL                J PEDIATR GASTROENTEROL NUTR     1   559 982
     2   ALBAZZAZ FJ           RESPIRATION                     46    88 984
     3   MINA M                J PHYSIOL (LOND)               348  P  4 984

PN 79188
RN 01168 
AN 79221557
AU Berg-U.  Kallner-A.  Kusoffsky-E.  Strandvik-B.
TI Fatty acid supplementation in cystic fibrosis.
SO Monogr-Paediatr. 1979. 10. P 1-4.
MJ CYSTIC-FIBROSIS: dt.  FAT-EMULSIONS-INTRAVENOUS: tu.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: bl.
   FAT-EMULSIONS-INTRAVENOUS: ae.  FATTY-ACIDS: bl.  HUMAN.
EX Elliott's works, together with the previous works of several authors
   reporting low essential fatty acid concentrations in the serum lipids
   of patients with cystic fibrosis, stimulated us to make a pilot study
   treating older CF patients with Intralipid for 1 year.  We found no
   side effects in treating older CF patients with Intralipid for 1
   year.  On the other hand the objective benefit was very limited and
   today confusing, i.e., only a slight but significant improvement in
   the renal sodium excretion after an oral sodium load was found.  The
   relevance of this is speculative.
RF 001   ELLIOTT RB            ARCH DIS CHILD                  50    76 975
   002   ELLIOTT RB            PEDIATRICS                      57   474 976
   003   KUO PT                J PEDIATR                       60   394 962
   004   CAREN R               J CLIN ENDOCRINOL METAB         26   470 966
   005   ROSENLUND ML          NATURE                         251   719 974
   006   GIBSON LE             PEDIATRICS                      23   545 959
   007   BERG U                ACTA PAEDIATR SCAND             62   505 973
CT   1   KUSOFFSKY E           J PEDIATR GASTROENTEROL NUTR     2   434 983

PN 79189
RN 01169 
AN 79221563
AU Price-J-F.  Weller-P-H.  Harper-S-A.  Matthew-D-J.
TI Bronchial provocation tests in cystic fibrosis.
SO Monogr-Paediatr. 1979. 10. P 123-4.
MJ ASTHMA: di.  CYSTIC-FIBROSIS: co.
   RESPIRATORY-HYPERSENSITIVITY: di.
MN ADOLESCENCE.  ASTHMA: im.  CHILD.  CYSTIC-FIBROSIS: im.  HUMAN.
   PEAK-EXPIRATORY-FLOW-RATE.  RESPIRATORY-HYPERSENSITIVITY: im.
   SKIN-TESTS.
EX Patients with cystic fibrosis have a higher incidence of positive
   skin prick tests than normal; this may be the result of defective
   antigen handling at mucosal surfaces.  Our aim was to investigate
   bronchial allergy in a group of children with CF and positive skin
   tests.  We studied 15 children aged 7 to 16 years with mild to
   moderate respiratory disease.  Only 1 child gave a history of
   wheezing not associated with chest infections and this study supports
   the hypothesis that clinical asthma is a product of bronchial allergy
   and broncholability.  The responses to bronchial provocation with
   Aspergillus suggest that allergy to this antigen may play a part in
   the pathogenesis of lung disease in some patients with CF.
CT   1   DAVIS PB              SEM RESPIR MED                   6   261 985
     2   DARGA LL              PEDIATR PULMONOL                 2    82 986

PN 79190
RN 01170 
AN 79221564
AU Pryjma-J.  Rudnik-J.  Zebrak-J.  Herman-T.  Gawe-J.
TI The local immune status in cystic fibrosis.
SO Monogr-Paediatr. 1979. 10. P 125-30.
MJ BRONCHI: im.  CYSTIC-FIBROSIS: im.
MN ANTIBODIES: an.  CHILD.  CHILD-PRESCHOOL.  HUMAN.  IMMUNITY-CELLULAR.
   IMMUNOGLOBULINS: an.  INFANT.  LUNG-DISEASES: im.  SPUTUM: im.
EX We focused our study on concentration of immunoglobulins, lysozyme,
   lactoferrin, some antiproteolytic fractions and acute phase proteins
   in bronchial secretion of children with various pulmonary diseases,
   especially with cystic fibrosis.  Secretory IgA is decreased in all
   studied groups of patients having chronic or recurrent infections of
   the respiratory tract (when compared to the group of healthy
   children).  Groups which were characterized by the infection of the
   lower part of the respiratory tract had increased lysozyme level.
   The results obtained in the group of CF children are similar to those
   obtained in groups with bronchiectasis and chronic bronchitis, which
   suggests that the observed differences are characteristic for chronic
   infection rather than for CF.  Although in CF as well as in
   bronchiectasis massive bacterial infection results in increased
   concentration of immunoglobulins, antiproteolytic fractions and acute
   phase proteins, the results seen in both groups are somewhat
   different.  These differences may indicate some difference in the
   reactivity to infection of the respiratory tract in CF in comparison
   to patients with bronchiectasis.  It seems conceivable that among
   children with CF who have very low S-IgA, chronic respiratory tract
   infections occur earlier and IgG response to permanent exposition to
   variety of antigens is less vigorous.  The presented results raise
   also a possibility that the bacterial infection in CF does not
   stimulate defence mechanisms to the same extent as in bronchiectasis.
RF 001   BROGAN TD             THORAX                          30    72 975
   003   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     1 977
   004   WALDMAN RH            IN: NETER E                          334 975
   005   WALLWORK JC           CLIN ALLERGY                     6   349 976

PN 79191
RN 01171 
AN 79221565
AU Schiotz-P-O.  Sorensen-H.  Hoiby-N.
TI Complement activation and pulmonary inflammation in CF patients.
SO Monogr-Paediatr. 1979. 10. P 131-4.
MJ COMPLEMENT-3: an.  CYSTIC-FIBROSIS: im.  LUNG: im.  PNEUMONIA: im.
MN HUMAN.  INFLAMMATION.  LUNG: pa.
EX This study examined whether biologic activation of C3 with subsequent
   pulmonary inflammation takes place in the lungs of patients with
   cystic fibrosis.  Plasma complement C3 levels were all normal.
   Eleven of the patients with the C3 split product C3c were from the
   group of 14 patients suffering from chronic infection with mucoid
   strains of Pseudomonas aeruginosa and 2 were from the group of 14 CF
   patients without P. aeruginosa infection.  This difference was
   significant (p < 0.002).  A comparison of albumin ratios between the
   13 patients with the C3 split product C3c and the remaining other 15
   patients showed a significant higher ratio in the former group (p <
   0.01) on an average 4.1 versus 1.4 per cent.  The significantly
   higher albumin ratio demonstrated in the patients with C3c in their
   sputum sol phase supports the concept of complement-induced
   inflammation with subsequent transudation of plasma proteins in these
   patients.  This study thus shows that complement-mediated
   inflammatory reactions may play an important role in the pathogenesis
   of pulmonary tissue damage in patients with CF, even when the plasma
   C3 levels are normal, and it supports the concept of chronic P.
   aeruginosa lung infection as an immune complex disease in CF
   patients.
RF 001   BROGAN TD             THORAX                          30    72 975
   002   CONOVER JH            LANCET                           2  1501 973
   003   GEWURTZ H             J EXP MED                      128  1049 968
   004   GIBSON LE             PEDIATRICS                      23   545 959
   005   GREENBLATT J          INFECT IMMUN                    19   296 978
   006   GOTZ M                EUR J PEDIATR                  127   133 978
   007   HANN S                LANCET                           2   520 974
   008   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   009   HOIBY N               SCAND J RESPIR DIS              58    65 977
   010   LAURELL CB            SCAND J CLIN LAB INVEST SUPPL  124    21 972
   011   LIEBERMAN J           AM REV RESPIR DIS              111   100 975
   012   MCFARLANE H           BR MED J                         1   423 975
   013   NELSON RA JR          IN: ZWEIFACH BW                  3    37 974
   014   SCANLIN TF JR         LANCET                           1  1382 974
   015   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   83   469 975
   016   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   86    37 978
   017   TEISBERG P            CLIN CHIM ACTA                  62    35 975
   018   WEEKE B               DAN MED BULL                    23   155 976
CT   1   HODSON ME             THORAX                          35   801 980
     2   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982

PN 79192
RN 01172 
AN 79221566
AU Hein-J.  David-A.  Grimm-J.  Gottschalk-B.
TI Protein, IgA, secretory IgA, IgG and electrolytes as parameters of
   parotid gland function in children with cystic fibrosis.
SO Monogr-Paediatr. 1979. 10. P 135-7.
MJ CYSTIC-FIBROSIS: pp.  ELECTROLYTES: me.  IGA: an.  IGA-SECRETORY: an.
   IGG: an.  PAROTID-GLAND: pp.  PROTEINS: an.  SALIVA: an.
MN CHILD.  CYSTIC-FIBROSIS: im, me.  HUMAN.
EX To study the parotid gland function in children with cystic fibrosis
   we investigated parotid saliva specimens of 18 such patients.  We
   compared the results with a control group of 12 healthy children of
   the same age and sex.  Furthermore, children with bronchial asthma
   and chronic bronchitis were examined.  The flow rate of the parotid
   and the protein output without stimulation were nearly the same for
   the four groups.  In patients with CF the protein output after
   stimulation was significantly lower.  An increased level of sodium
   was observed in the stimulated secretion and the unstimulated saliva
   as well.  In CF children we found a significant higher output of
   sodium in both stimulated parotid saliva and unstimulated parotid
   saliva.  The IgG output of the gland after stimulation was found to
   be slightly reduced in patients with CF in comparison to healthy
   children.  The output of the gland for IgA after stimulation was
   observed to be strongly reduced for the group with CF and for the
   group with bronchial asthma.  The decreased output of the gland for
   secretory IgA after stimulation was demonstrated again in CF and in
   bronchial asthma in comparison with healthy persons.  The increased
   sodium concentration in parotid saliva may be caused in a similar way
   as the electrolyte abnormality of sweat in CF patients, namely by a
   decreased net reabsorption of sodium.  Due to the result of an
   increased electrolyte output and decreased immunoglobulin output of
   parotid gland we can suppose that the molecular magnitude plays its
   role in this disturbance.
RF 002   LAKNER V              ALLERGIE IMMUNOL                23   147 977
   003   MANGOS JA             MOD PROBL PEDIATR               10   107 967
   004   MARTINEZ-TELLO FJ     J IMMUNOL                      101   989 968
CT   1   KATZ S                CELL CALC                        5   421 984

PN 79193
RN 01173 
AN 79221567
AU Hoiby-N.  Hertz-J-B.
TI Precipitating antibodies against E. coli, B. fragilis, and P.
   aeruginosa in CF patients and normal persons determined by means of
   crossed immunoelectrophoresis.
SO Monogr-Paediatr. 1979. 10. P 138-43.
MJ ANTIBODIES-BACTERIAL: an.  BACTEROIDES-FRAGILIS: im.
   CYSTIC-FIBROSIS: im.  ESCHERICHIA-COLI: im.
   PSEUDOMONAS-AERUGINOSA: im.
MN ADOLESCENCE.  ADULT.  CHILD.  FEMALE.  HUMAN.
   IMMUNOELECTROPHORESIS-TWO-DIMENSIONAL.  MALE.
EX Wallwork and co-workers have proposed that increased absorption of
   antigens takes place across the mucosal membranes of the gut and
   respiratory tract possibly due to a transient defect in the
   production of secretory IgA.  As a consequence of this hypothesis,
   one would expect cystic fibrosis patients to produce a pronounced
   antibody response against the intestinal bacterial flora.  The
   present work was therefore carried out to investigate the antibody
   response in CF patients and in normal persons against Escherichia
   coli and Bacteroides fragilis which are present in the gut in large
   numbers and against the respiratory pathogen P. aeruginosa.  A
   significantly higher prevalence of precipitins against each of the 3
   bacterial species was found in CF patients compared to normal
   persons, and the prevalence of precipitins against each of these
   bacteria increased significantly with age.  As regards P. aeruginosa
   precipitins, the prevalence and number was significantly higher in CF
   patients who have subsequently succumbed compared to CF patients who
   are still alive.  Such a correlation between the antibody response
   and the prognosis of the patients was not found as regards E. coli or
   B. fragilis.  Considering the hypothesis of Wallwork and co-workers
   concerning increased absorption of antigens from the gut, it seems
   more attractive to suppose that increased absorption of antigens from
   the gut flora occurs predominantly in CF patients with P. aeruginosa
   lung infection with a pronounced antibody response against P.
   aeruginosa.
RF 001   FINEGOLD SM           ANAEROBIC BACTERIA HUMAN DIS             977
   002   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   003   HOIBY N               SCAND J IMMUNOL SUPPL 2          4   187 975
   004   HOIBY N               ACTA PATH MICROBIOL SCAND (C)   85   142 977
   005   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     1 977
   006   MCFARLANE H           BR MED J                         1   423 975
   007   SASAKI M              JAPAN J EXP MED                 45   335 975
   008   SCHWAB JH             BACT REV                        39   121 975
   009   TOLO K                IMMUNOLOGY                      33   733 977
   010   WALLWORK JC           CLIN EXP IMMUNOL                18   303 974
   011   WALLWORK JC           CLIN ALLERGY                     6   349 976
CT   1   HODSON ME             THORAX                          35   801 980
     2   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982

PN 79194
RN 01174 
AN 79221577
AU Prosser-R.
TI Screening for cystic fibrosis in the newborn.
SO Monogr-Paediatr. 1979. 10. P 43-5.
MJ CYSTIC-FIBROSIS: pc.
MN CYSTIC-FIBROSIS: di.  ENGLAND.  HUMAN.  INFANT-NEWBORN.
EX In an 8-year period, a programme of screening for cystic fibrosis has
   been conducted over an extensive part of Wales.  The screening method
   used is based on the detection of a high level of albumen (greater
   than 20 mg%) in the meconium.  During the course of the
   investigations several different tests have been used.  Because of
   the high incidence of false-negative results (34%) the detection of
   protein in meconium is not an ideal screening test, but is the most
   satisfactory presently available, in the newborn period.  Because of
   its relative simplicity, low cost, absence of direct involvement of
   the parent or patient, and a high yield of positive cases, its use on
   a wider scale may be justified.
RF 001   GIBSON LE             PEDIATRICS                      23   545 959
   002   HARDY JD              ARCH DIS CHILD                  48   316 973
   003   KOLLBERG H            PROC INT CF CONG 7TH                  32 976
   004   PROSSER R             ARCH DIS CHILD                  49   597 974
   005   ROBINSON MJ           ARCH DIS CHILD                  50   962 975
   006   RYLEY HC              ARCH DIS CHILD                  49   901 974
CT   1   TRAVERT G             J GENET HUM                     28   141 980
     2   TRAVERT G             NOUV PRESSE MED                 10  2093 981

PN 79195
RN 01175 
AN 79221569
AU Michalsen-H.  Rolla-G.  Melsen-B.  Sonju-T.
TI Sulphated glycoproteins in the pancreas.
SO Monogr-Paediatr. 1979. 10. P 148-50.
MJ CYSTIC-FIBROSIS: me.  GLYCOPROTEINS: me.  PANCREAS: me.
   SULFATES: me.
MN ANIMAL.  CYSTIC-FIBROSIS: et.  ANTHROPOIDEA.
EX Several reports have indicated the presence of abnormally high
   amounts of sulphate in the mucous glands of patients with cystic
   fibrosis.  Bearing these facts in mind, we suspected that abnormal,
   over-sulphated, and strongly anionic, glycoproteins might be involved
   in the pathogenesis of CF.  The present study was carried out to
   determine whether sulphated blood-group substances occur in normal
   pancreatic tissue.  The distribution of sulphate over the exocrine
   part of pancreas does coincide with the distribution of blood-group
   substance previously observed by fluorescent microscopy.  We
   therefore find it very likely that the sulphate and blood-group
   substance are associated with the same glycoprotein molecule.  Since
   blood-group substance has been demonstrated in many secretions in
   man, and since high amounts of sulphate have been found in the
   mucous glands in CF, such a mechanism is possible in many locations
   and may thus offer an explanation for the multiorgan involvement in
   CF.
RF 001   HAUG A                ACTA CHEM SCAND                 24   843 970
   002   LAMB D                BR J DIS CHEST                  66   239 972
   003   LUDWIG H              SCAND J IMMUNOL                  6   724 977
   004   ROLLA G               ACTA PATH MICROBIOL SCAND       86    83 978
   005   SMIDSROD O            CHEM SOC FARADAY DISC           57   263 974
   006   SZULMAN AE            J EXP MED                      111   785 960
   007   SONJU T               ARCH ORAL BIOL                  19   897 974
   008   SONJU T               ACTA PATH MICROBIOL SCAND       83   215 975
   009   SONJU T               ARCH ORAL BIOL                  19   897 974
   010   WATKINS WM            IN: GOTTSCHALK A                     830 972
   011   WOOD RE               AM REV RESPIR DIS              113   833 976
   012   YOSIZAWA Z            IN: GOTTSCHALK A                 5  1000 972
CT   1   ENDO M                CARBOHYD RES                   151   409 986

PN 79196
RN 01176 
AN 79221570
AU Ryley-H-C.
TI An evaluation of the meconium 'lactase test' for the detection of
   cystic fibrosis in the newborn.
SO Monogr-Paediatr. 1979. 10. P 151-4.
MJ BETA-GALACTOSIDASES: an.  CYSTIC-FIBROSIS: di.  GALACTOSIDASES: an.
   MECONIUM: an.
MN ALBUMINS: an.  HUMAN.  INFANT-NEWBORN.
EX Recently, Antonowicz et al. proposed a simple test for cystic
   fibrosis that could be used to verify the Boehringer-Mannheim
   meconium test result and thus reduce the false-positive incidence.
   The test is based on the detection of lactase activity in meconium.
   The 'lactase test' may be of some value as a confirmatory test when
   used with the BM-mec test although its specificity in this study was
   not as good as previously reported.
RF 001   ANTONOWICZ I          PEDIATRICS                      56   782 975
   002   ANTONOWICZ I          LANCET                           1   746 976
   003   BRUNS WT              AM J DIS CHILD                 131    71 977
   004   RYLEY HC              CLIN CHIM ACTA                  64   117 975
   006   STEPHAN U             PEDIATRICS                      55    35 975
CT   1   MASTELLA G            RIV ITAL PEDIATR                 7   581 981
     2   PEDERZINI F           RIV ITAL PEDIATR                 9   445 983

PN 79197
RN 01177 
AN 79221571
AU Torriani-R.  Chassot-J.  Stocker-F.  Weber-J-W.
TI Two children with cystic fibrosis and myocardial fibrosis.
SO Monogr-Paediatr. 1979. 10. P 155-7.
MJ CYSTIC-FIBROSIS: co.  MYOCARDIAL-DISEASES: et.
MN CASE-REPORT.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: di.  HUMAN.  INFANT.
   MYOCARDIAL-DISEASES: di.
EX Usually cardiac affection in cystic fibrosis is secondary to
   progressive affection of the lungs (cor pulmonale).  In rare cases,
   babies and young children show a primary and severe cardiac affection
   caused by myocardial fibrosis.  We could recently observe two of
   these cases in our clinic.  The cases are presented and discussed.
   In babies and young children cardiac insufficiency  caused by
   cardiomyopathy might be the first presenting symptom in CF.
   Therefore, in all children with cardiomyopathy of unknown origin, CF
   has to be suspected and the sweat test has to be performed.  Rapidly
   progressive cardiac insufficiency responding poorly to treatment and
   rhythm disturbances are typical.  Correct early diagnosis is
   important for early genetic counseling.
RF 001   COUSIN J              J SCI MED LILLE                  5   161 975
   002   DESCHAMPS JP          ARCH FR PEDIATR                 28   417 971
   003   MCGIVEN AR            ARCH DIS CHILD                  37   656 962
   004   HIDE DW               ARCH DIS CHILD                  52   163 977
   005   NEZELOF C             ARCH FR PEDIATR                 16  1035 959
   006   OPPENHEIMER EH        JOHNS HOPKINS MED J            133   252 973
   007   NIZNIKOWSKA J         HELV PAEDIATR ACTA              26    56 971
CT   1   SCHONI M              SCHWEIZ MED WOCHENSCHR         111   658 981

PN 79198
RN 01178 
AN 79221572
AU Di-Matteo-G.  Romano-M.  Mastella-G.  Castellani-E.  Rutigliano-B.
   Casola-L.
TI Chemical comparison of normal and cystic fibrosis meconium: a
   quantitative and qualitative analysis of carbohydrate splitting
   enzymes.
SO Monogr-Paediatr. 1979. 10. P 19-26.
MJ CYSTIC-FIBROSIS: en.  GLYCOSIDE-HYDROLASES: me.  MECONIUM: en.
MN ABO-BLOOD-GROUP-SYSTEM.  COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: bl.
   HUMAN.  INFANT-NEWBORN.
EX Meconium specimens from more than 200 normal and premature and from 5
   cystic fibrosis newborns were analyzed for their level of several
   glycosidases.  Considerable scatter of activities were found in all
   three groups studied and no evidence for any relation of such scatter
   with the blood group-specific A, B, AB, H substances was found.
   Alpha-glucosidase, an acid glycosidase found elevated in CF serum and
   fibroblasts, was elevated in all CF meconium extracts including that
   which had a very low albumin content.
RF 001   ANTONOWICZ I          PEDIATR RES                      9   301 975
   002   CASOLA L              MONOGR PAEDIATR                 10    96 979
   003   HOSLI P               BIOCHEM BIOPHYS RES COMMUN      73   209 976
CT   1   CASOLA L              MONOGR PAEDIATR                 10    96 979
     2   ALHADEFF JA           CLIN CHIM ACTA                 117   227 981
     3   RYLEY HC              CLIN CHIM ACTA                 135    49 983
     4   SLOMIANY A            J BIOL CHEM                    258  8535 983
     5   CABRINI G             RIV ITAL PEDIATR                10   405 984
     6   ALHADEFF JA           PEDIATR RES                     19   171 985

PN 79199
RN 01179 
AN 79221573
AU Kulczycki-L-L.  Wientzen-R.
TI The use and abuse of antibiotics, including in management of
   pulmonary manifestations in cystic fibrosis.
SO Monogr-Paediatr. 1979. 10. P 27-30.
MJ ANTIBIOTICS: tu.  CYSTIC-FIBROSIS: dt.  LUNG-DISEASES: dt.
MN ANTIBIOTICS: ad.  CYSTIC-FIBROSIS: co.  SUBSTANCE-ABUSE.  HUMAN.
   LUNG-DISEASES: et.  TOBRAMYCIN: tu.
EX Individually and collectively opinion is expressed that antibiotics
   are among the most frequently prescribed drugs in United States,
   probably also in many other countries.  While it is adopted by many
   that the increased longevity of cystic fibrosis patients is strongly
   related to antibiotic usage, this has never been documented
   adequately.  The principles which we try to follow while using
   antibiotics in CF patients are outlined.
RF 001   ROBERTS AW            AM J HOSP PHARM                 29   828 972
   002   SCHECKLER WE          JAMA                           213   264 970
   003   ACHONG MR             CAN MED ASSOC J                116   256 977
   004   CASTLE M              JAMA                           237  2819 977
   005   KUNIN CM              ANN INTERN MED                  79   555 973
   006   FINLAND M             J INFECT DIS                   122   419 970
   007   MCGOWAN JE JR         J INFECT DIS                   130   165 974
   008   OSOL A                UNITED STATES DISPENSATORY               973
   009   LARAYA-CUASAY LR      J PEDIATR                       89    23 976
   010   DAVIS BD              MICROBIOLOGY                         783 973
   011   DI SANTAGNESE PA      AM J DIS CHILD                  72    17 946
   012   HUANG NN              J PEDIATR                       59   512 961
   013   BURNS MW              LANCET                           1   270 968
   014   DOERSHUK CF           IN: MANGOS JA                            976
   015   KULCZYCKI LL          JAMA                           240    30 978

PN 79200
RN 01180 
AN 79221574
AU Paporisz-U.  Posselt-H-G.  Wonne-R.  Ristow-W.  Roser-D.  Knothe-H.
   Bender-S-W.
TI Long-term tobramycin therapy in patients with cystic fibrosis and
   advanced pulmonary disease.
SO Monogr-Paediatr. 1979. 10. P 31-3.
MJ ANTIBIOTICS: ad.  CYSTIC-FIBROSIS: dt.  LUNG-DISEASES: dt.
   TOBRAMYCIN: ad.
MN CYSTIC-FIBROSIS: co.  HUMAN.  INFANT.  LUNG-DISEASES: et.
   PSEUDOMONAS-INFECTIONS: dt, et.  TIME-FACTORS.  TOBRAMYCIN: tu.
EX The aim of our clinical study was to find if prolonged tobramycin
   therapy can prevent further rapid deterioration in cystic fibrosis
   patients.  Eleven courses of treatment were given to the nine
   patients.  Eight of these markedly improved their physical activity
   and gained weight.  However, only in four of these patients was
   clinical improvement correlated with an improved radiogram.
   Pseudomonas was eradicated from the sputum of only four patients
   during therapy but reappeared in three of them before the end of
   therapy.  Clinical improvement and negligible side effects suggest
   treatment of exacerbating Pyocyaneus bronchopneumonia with prolonged
   tobramycin therapy.  Dosage should be higher than 5 mg/kg/day with
   strict control of tobramycin blood level and awareness of side
   effects.
RF 001   BOXERBAUM B           J INFECT DIS SUPPL             124   293 971
   002   DOGGETT RG            SOUTH MED J                     61  1347 968
   003   DOGGETT RG            J BACTERIOL                     87   427 964
   004   DOGGETT RG            SOUTH MED J                     57  1476 964
   005   DOGGETT RG            SOUTH MED J                     57  1470 964
   006   DOGGETT RG            SOUTH MED J                     61  1346 968
   007   DOGGETT RG            IN: LAWSON D PROC 5TH INT CF         175 969
   008   DOGGETT RG            BACT PROC                       69    87 969
   009   DOGGETT RG            INFECT IMMUN                     6   628 972
   010   HAWLEY HB             CURR THER RES                   16   414 974
   011   HARRISON GM           PAEDIATRICIAN                    1   180 972
   012   HOFF GE               SCAND J INFECT DIS               6   333 974
   013   HOIBY N               SCAND J RESPIR DIS              58    65 977
   014   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   015   MAY JR                CHEMOTHERAPY OF CHRONIC BRONC            968
   016   MEARNS MB             ARCH DIS CHILD                  47   902 972
   017   WAITZ JA              ANTIMICROB AGENTS CHEMOTHER      2   431 972
   018   HUMPHREY JH           ADV IMMUNOL                     11    75 969

PN 79201
RN 01181 
AN 79221575
AU Guggenbichler-J-P.  Kienel-G.
TI Bioavailability of oral antibiotics in cystic fibrosis.
SO Monogr-Paediatr. 1979. 10. P 34-40.
MJ AMPICILLIN: aa.  CEPHALEXIN: me.  CYSTIC-FIBROSIS: dt.  EPICILLIN: me.
MN ADMINISTRATION-ORAL.  BIOLOGICAL-AVAILABILITY.  CEPHALEXIN: ad, bl, tu.
   CHILD.  CYSTIC-FIBROSIS: bl, me.  EPICILLIN: ad, bl, tu.  HUMAN.
   LUNG-DISEASES: dt.
EX The present investigation was designed to assess the absorption and
   disposition in cystic fibrosis patients of two commonly used
   antibiotics: an aminopenicillin, epicillin, and a cephalexin,
   Ospexin.  The pharmacokinetic parameters of epicillin in patients
   with CF and their normal controls differ in a number of aspects.  The
   difference found in the maximal plasma concentrations could be
   accounted for by a manifold increase in the renal clearance of the
   drug.  Our data support the idea that patients with CF exhibit an
   unusually large and rapid renal clearance of certain penicillins.
RF 001   SHWACHMAN H           PEDIATR CLIN NORTH AM           22   787 975
   002   DEREN JJ              N ENGL J MED                   288   949 973
   003   WEBER AM              N ENGL J MED                   289  1001 973
   005   JUSKO WJ              PEDIATRICS                      56  1038 975
   006   JUSKO WJ              J PHARM SCI                     61  1270 972
   007   YAFFE SJ              J INFECT DIS                   135   828 977
   008   PARSONS RL            CLIN PHARMAKOKINET               2    45 977
CT   1   MICHALSEN H           ANTIMICROB AGENTS CHEMOTHER     19  1029 981
     2   LEFF RD               PEDIATR CLIN NORTH AM           30    93 983
     3   NAHATA MC             DEVELOP PHARM THER               7   221 984
     4   SPINO M               J PEDIATR                      105   829 984
     5   HARRISON CJ           PEDIATR PHARMACOL                5     7 985
     6   SPINO M               J PEDIATR                      107    64 985
     7   SORGEL F              EUR J PEDIATR                  143   249 985
     8   SMITH MJ              ANTIMICROB AGENTS CHEMOTHER     30   614 986

PN 79202
RN 01182 
AN 79221576
AU Stephan-U.
TI Progress in screening.
SO Monogr-Paediatr. 1979. 10. P 41-2.
MJ CYSTIC-FIBROSIS: pc.
MN CYSTIC-FIBROSIS: di.  HUMAN.  INFANT-NEWBORN.  MASS-SCREENING.
EX Since the Dresden Meeting in 1977 there have only been a few new
   developments of interest in special field of screening for cystic
   fibrosis.  There is no ideal screening test for CF available today.
   The BM Test Meconium is the test most widely used now but many
   technical, psychological and methodological problems remain to be
   solved before the test can be endorsed without reservation.
RF 001   ANTONOWICZ I          LANCET                           1   746 976
   002   CROSSLEY JR           LANCET                           2  1093 977
   003   ROOMANS GM            ACTA PAEDIATR SCAND             67    89 978
   004   RYLEY HC              CLIN CHIM ACTA                  64   117 975
   005   HOLSCLAW DS           PEDIATR ANN                      7    15 978

PN 79203
RN 01183 
AN 79156725
AU Davidson-A-G.  Applegarth-D-A.  Wong-L-T.
TI Diagnosing cystic fibrosis in adults [letter].
SO N-Engl-J-Med. 1979 May 17. 300(20). P 1164.
MJ CYSTIC-FIBROSIS: di.
MN ADULT.  AGE-FACTORS.  ELECTROLYTES: an.  HUMAN.  SWEAT: an.
EX Gordeuk et al. state that cystic fibrosis may be first diagnosed in
   adulthood, but we feel that a condition with such grave genetic and
   prognostic implications must be diagnosed with special caution in
   this age group.  In particular, the sweat test, which is the main
   diagnostic tool for use with children, must be interpreted in adults
   in the light of possible age-related increases in normal
   sweat-electrolyte concentration and other factors that may affect the
   assay.  Although it is generally accepted that "normal" sweat sodium
   and chloride concentrations are higher in adults than in children,
   there is no clear agreement about the upper limits of the normal
   range in adults.  The volume of sweat produced during the test may
   also have a substantial effect on electrolyte values.  For the
   diagnosis of cystic fibrosis in adults, an attempt should thus be
   made to base the diagnosis not only on "elevated" sweat-electrolyte
   values and clinical impression but also on pancreatic-function data.
RF 001   GORDEUK V             N ENGL J MED                   299  1137 978
   002   ANON                  J PEDIATR                       88   711 976
   003   LOBECK CC             PEDIATRICS                      30   172 962
   004   DOBSON RL             MOD PROBL PEDIATR               10    23 967
   005   GUP AM                ARCH INTERN MED                112   699 963
   006   HADORN B              CAN MED ASSOC J                 98   377 968
CT   1   WONG LTK              GUT                             23   744 982

PN 79204
RN 01184 
AN 79093917
TI Case records of the Massachusetts General Hospital.  Weekly
   clinicopathological exercises.  Case 8-1979.
SO N-Engl-J-Med. 1979 Feb 22. 300(8). P 420-7.
MJ CYSTIC-FIBROSIS: pa.  ESOPHAGEAL-AND-GASTRIC-VARICES: pa.
   LIVER-CIRRHOSIS: pa.
MN BRAIN-DISEASES: di, pa.  BRAIN: pa.  CASE-REPORT.  CHILD.
   CYSTIC-FIBROSIS: co, di.  DIAGNOSIS-DIFFERENTIAL.
   ESOPHAGEAL-AND-GASTRIC-VARICES: di.  FEMALE.
   HEPATIC-ENCEPHALOPATHY: di, et, pa.  HUMAN.  LIVER-CIRRHOSIS: di.
   LIVER: pa.
EX The case of a nine-year-old girl admitted to the hospital because of
   coma is presented.  She was found shortly after birth to have
   meconium ileus and a high concentration of sodium in her sweat
   indicative of cystic fibrosis.  Clinical diagnoses were cystic
   fibrosis of pancreas, cirrhosis of liver, and congestive heart
   failure secondary to electrolyte imbalance.  Anatomical diagnoses
   were cystic fibrosis of pancreas with cirrhosis of liver and
   esophageal varices, brain necrosis, metabolic encephalopathy,
   bronchiectasis, acute bronchopneumonia, and acute renal tubular
   necrosis.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   002   REYE RDK              LANCET                           2   249 963
   003   WEBSTER R             ARCH DIS CHILD                  28   343 953
   004   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   005   CRAIG JM              AM J DIS CHILD                  93   357 957
   006   COHN D                MED J AUST                       1   101 977
   007   OPPENHEIMER EH        J PEDIATR                       86   683 975
   008   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   009   BOVE KE               IN: POLLACK JD                        93 975
CT   1   ALLMAN FD             N ENGL J MED                   304  1111 981

PN 79205
RN 01185 
AN 79135047
AU Feigal-R-J.  Shapiro-B-L.
TI Mitochondrial calcium uptake and oxygen consumption in cystic
   fibrosis.
SO Nature. 1979 Mar 15. 278(5701). P 276-7.
MJ CALCIUM: me.  CYSTIC-FIBROSIS: me.  MITOCHONDRIA: me.
   OXYGEN-CONSUMPTION.
MN BIOLOGICAL-TRANSPORT-ACTIVE.  CELLS-CULTURED.  ELECTRON-TRANSPORT.
   HUMAN.  KINETICS.  SKIN: ul.  SUPPORT-U-S-GOVT-P-H-S.
EX Reports of exocrine gland secretory anomalies in cystic fibrosis and
   increased calcium ion concentrations in some CF secretions and the
   importance of cellular Ca to stimulus-secretion coupling led us to
   study cellular Ca in CF.  We report data on Ca uptake studies with
   mitochondrial and microsomal fractions isolated from skin fibroblasts
   of subjects with CF and age-, sex- and passage number-matched
   controls in which mitochondria from CF cells accumulated more Ca than
   those from control cells.  We also describe subsequent studies which
   show increased mitochondrial electron transport activity, measured as
   oxygen uptake by whole cells, in cells from subjects with CF and
   obligate heterozygotes.  One can hypothesise a mechanism to link the
   altered mitochondrial Ca in CF fibroblasts and the major signs
   associated with the disease.  Data suggest that the electron
   transport system in CF and obligate heterozygote fibroblasts is more
   active than that in respective controls, in the conditions of this
   study.  The apparent central role of Ca in several pathogenetic
   pathways in CF and the data reported here in which both mitochondrial
   Ca capacity and oxygen consumption are increased in CF suggest that
   this organelle is a suitable focus for CF investigations.
RF 001   LOBECK CC             IN: STANBURY JB                     1605 972
   002   BOTELHO SY            J PEDIATR                       83   601 973
   003   WOTMAN S              ARCH ORAL BIOL                  16   663 971
   004   ALLARS HM             PEDIATR RES                     10   578 976
   005   BLOMFIELD J           PEDIATR RES                     10   574 976
   006   DOUGLAS WW            BR J PHARMACOL                  34   451 968
   008   PENNINGTON RJ         BIOCHEM J                       80   649 961
   009   REED KC               ANAL BIOCHEM                    67    44 975
   010   MOORE L               J CELL PHYSIOL                  91   289 977
   011   KIMURA S              J BIOL CHEM                    252  1217 977
   012   SHAPIRO BL            CLIN CHIM ACTA                  82   125 978
   013   ASH GR                FEBS LETTERS                    78   166 977
   014   ROSE B                SCIENCE                        190  1204 975
   015   GIBSON LE             PEDIATRICS                      48   695 971
   016   FORSTNER JF           MOD PROBL PEDIATR               19    54 977
   017   WALLACH D             EUR J BIOCHEM                   21   433 971
   018   CARAFOLI E            EXP BIOL SYMP                   30    89 976
   019   BYGRAVE FL            BIOL REV                        53    43 978
CT   1   SHAPIRO BL            PROC NAT ACAD SCI USA           76  2979 979
     2   ANSAH TA              CELL CALC                        1   195 980
     3   DAVIS PB              PEDIATR RES                     14    83 980
     4   KATZ S                CLIN CHIM ACTA                 100   245 980
     5   CROMWELL O            LANCET                           2   164 981
     6   ROOMANS GM            ULTRASTRUCTURAL PATHOL           2    53 981
     7   HALLINAN F            MED HYPOTHESES                   7   793 981
     8   ROOMANS GM            J SUBMICROSC CYTOL              13   445 981
     9   SORSCHER EJ           LANCET                           1   368 982
    10   SANGUINETTIBRICENO NR CLIN GENET                      22   308 982
    11   FEIGAL RJ             LIFE SCI                        30    93 982
    12   SHAPIRO BL            AM J HUM GENET                  34   846 982
    13   MATKOVICS B           CLIN CHIM ACTA                 125    59 982
    14   SHAPIRO BL            SCIENCE                        216   417 982
    15   FONDACARO JD          LIFE SCI                        32  1449 983
    16   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
    17   SEYMOUR CA            BIOESSAYS                        1    38 984
    18   KATZ S                CELL CALC                        5   421 984
    19   CABRINI G             RIV ITAL PEDIATR                10   405 984
    20   DEARBORN DG           PEDIATR RES                     18   890 984
    21   VONRUECKER AA         PEDIATR RES                     18   594 984
    22   WALLER RL             LIFE SCI                        35   775 984
    23   RUSSI EW              CHEST                           86   475 984
    24   GRINSTEIN S           BIOCHIM BIOPHYS ACTA           769   270 984
    25   CABRINI G             LIFE SCI                        36  1561 985
    26   PINO JA               ANAL CHEM                       57   295 985
    27   MUALLEM S             BIOCHIM BIOPHYS ACTA           819   143 985
    28   STUTTS MJ             PEDIATR RES                     20  1316 986
    29   MORRISSEY SM          DIGESTION                       34    28 986
    30   BATTINO M             FEBS LETTERS                   199   155 986
    31   FEIGAL RJ             ANN NY ACAD SCI                488    82 986

PN 79206
RN 01186 
AN 79178685
AU Columbo-J-L.  Gibbs-G-E.
TI Cystic fibrosis and erroneous sweat tests.
SO Nebr-Med-J. 1979 Jun. 64(6). P 164-5.
MJ CYSTIC-FIBROSIS: di.  SWEATING.
MN CASE-REPORT.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: pp.  HUMAN.
   MALE.
EX Making the diagnosis of cystic fibrosis requires clinical suspicion
   and sweat tests.  Physicians today are aware of the main clinical
   features of pulmonary and pancreatic involvement and are suspecting
   the diagnosis earlier than in past years.  The accuracy of the sweat
   test is the most crucial factor in confirming the diagnosis.  The
   present case illustrates this point.  The main purpose of this paper
   is to serve as a reminder that the sweat test is often less than
   accurate as frequently performed.  The principal pitfall of sweat
   testing at present seems to be the use of a chloride electrode
   applied to the skin without assurance that an adequate amount of
   sweat is present.
RF 001   GIBSON LE             CLIN PEDIATR                    12   450 973
   002   ANON                  J PEDIATR                       88   711 976
   003   WOOD RE               AM REV RESPIR DIS              113   833 976
   004   COLTMAN CA JR         AM REV RESPIR DIS               93    63 966
   005   ANON                  GAP CONF REP PROB SWEAT TESTI            975
   006   CROZIER DN            PEDIATR CLIN NORTH AM           21   935 974
   007   GEORGE L              ARCH DIS CHILD                  46   139 971
CT   1   WEBSTER HL            CRC CRIT REV CLIN LAB SCI       18   313 983

PN 79207
RN 01187 
AN 79201313
AU Iveson-Iveson-J.
TI Cystic fibrosis: a disease of unknown causes.
SO Nurs-Mirror. 1979 May 24. 148(21). P 40.
MJ CYSTIC-FIBROSIS: nu.
MN CHILD.  COMMUNITY-HEALTH-NURSING.  HUMAN.
EX The author looks at the disease which affects two out of every 2000
   newborn children - a disease which causes most of the childhood
   chronic pulmonary disease in the Western world.  The author tells how
   the Cystic Fibrosis Research Trust can help parents of affected
   children.

PN 79208
RN 01188 
AN 80034503
AU Clement-M.  Jankowski-L-W.  Beaudry-P-H.
TI Prone immersion physical exercise therapy in three children with
   cystic fibrosis: a pilot study.
SO Nurs-Res. 1979 Nov-Dec. 28(6). P 325-9.
MJ CYSTIC-FIBROSIS: th.  EXERCISE-THERAPY: mt.  IMMERSION.
   PHYSICAL-THERAPY: mt.
MN ADOLESCENCE.  BRADYCARDIA.  CHILD.  CHILD-PRESCHOOL.
   COMPARATIVE-STUDY.  EVALUATION-STUDIES.  FEMALE.  HUMAN.  MALE.
   PILOT-PROJECTS.  POSTURE.
AB Prone immersion physical exercise therapy has been used successfully
   in the physical rehabilitation of middle-aged adults with moderate to
   severe chronic obstructive pulmonary disease. The purpose of this
   pilot project was to evaluate the effects of PIPE therapy in children
   with cystic fibrosis. Three children with CF, two boys aged 6 and 14
   years and one girl aged 15 years, voluntarily participated in the
   experimental training program. The patients performed individualized
   group exercise three times a week on alternate days for 28
   consecutive weeks at an intensity of approximately 75 percent aerobic
   capacity. Duration of exercise gradually increased from 15 (3 x 5
   minutes) to 60 (3 x 20 minutes) minutes while the rest period after
   each exercise was constant at two minutes. PIPE training resulted in
   increased physical work capacity and maximal oxygen consumption in
   all three subjects. Curiously, these changes were not accompanied by
   training bradycardia.
RF 001   ANON                  GUIDELINES GRADED EXERCISE TE            975
   002   ASTRAND PO            J APPL PHYSIOL                   7   218 954
   003   BARACH AL             BULL NY ACAD MED                28   175 973
   004   BOYLE IR              J PEDIATR                       88   318 976
   005   CHARD MA              IN: SCIPIEN GM                           975
   006   ANON                  J PEDIATR                       88   711 976
   007   CROZIER DN            PEDIATR CLIN NORTH AM           21   935 974
   008   DI SANTAGNESE PA      N ENGL J MED                   295   597 976
   009   DOUGLAS WW            AM REV RESPIR DIS              115   559 977
   010   GROSSMAN ML           CLIN PEDIATR                    14   830 975
   011   HAAS A                MED CLIN NORTH AM               53   593 969
   012   JANKOWSKI LW          MOREHOUSE C                              978
   013   JANKOWSKI LW          CAN J APPL SPORTS SCI            1   277 976
   014   JANKOWSKI LW          SCAND J REHAB MED                8   135 976
   015   KANEKO K              J APPL PHYSIOL                  21   767 966
   016   KEENS TG              AM REV RESPIR DIS              116   853 977
   017   LEFCOE NM             AM J MED                        54   343 973
   018   LORIN MI              AM J PHYS MED                   50   215 971
   019   MATTHEWS LW           J PEDIATR                       65   558 964
   020   MILLER WF             SOUTH MED J                     55  1216 962
   021   PAEZ PN               AM REV RESPIR DIS               95   944 967
   022   PARKS CR              J PEDIATR                       76   305 970
   023   PATTON RG             IN: WAECHTER EH                          976
   024   PIERCE AK             ARCH INTERN MED                113    28 964
   025   SCHOLANDER PF         J BIOL CHEM                    167   235 947
   026   VYAS GN               AM REV RESPIR DIS              103   390 971
   027   WOOD RE               AM REV RESPIR DIS              113   833 976

PN 79209
RN 01189 
AN 80121338
AU Chu-J-Y.
TI Anemia, hypoproteinemia and edema in an infant with cystic fibrosis.
SO Nutr-Rev. 1979 Nov. 37(11). P 351-2.
MJ CYSTIC-FIBROSIS: co.  INFANT-NUTRITION-DISORDERS: et.
MN ANEMIA: co.  CASE-REPORT.  EDEMA: co.  HUMAN.  HYPOPROTEINEMIA: co.
   INFANT.  MALE.
EX A patient with cystic fibrosis was encountered who presented with
   anemia, hypoproteinemia, edema and failure to thrive.  A blood
   transfusion resulted in some improvement, but the symptoms recurred
   in a few weeks.  Only after the correct diagnosis was made and
   appropriate therapy instituted did the patient show signs of
   improvement.  The account of this case illustrates the importance of
   considering the diagnosis of cystic fibrosis in any child with
   malnutrition.
RF 001   SHAHIDI NT            J PEDIATR                       59   533 961
   002   FLEISHER DS           J PEDIATR                       64   341 964
   003   DOLAN TF JR           CLIN PEDIATR                     9   295 970
   004   LEE PA                JAMA                           228   585 974
   005   BASS HN               PEDIATRICS                      59   126 977
   006   GOLDMAN AS            J PEDIATR                       59   301 961
   007   CHASE HP              J PEDIATR                       95   337 979
CT   1   NIELSEN OH            J PEDIATR GASTROENTEROL NUTR     1   355 982

PN 79210
RN 01190 
AN 80033423
TI Serum vitamin D and related mineral metabolism in cystic fibrosis.
SO Nutr-Rev. 1979 Aug. 37(8). P 247-9.
MJ CYSTIC-FIBROSIS: me.  MINERALS: me.  VITAMIN-D: bl.
MN HUMAN.
AB Two groups of investigators have independently explored the role of
   vitamin D and related mineral metabolism in patients with cystic
   fibrosis, and found relatively minor changes.
RF 001   DI SANTAGNESE PA      IN: VAUGHAN VC III                   903 975
   002   HAHN TJ               J PEDIATR                       94    38 979
   003   HUBBARD VS            J PEDIATR                       94    84 979
   004   ARNAUD SB             PEDIATRICS                      57   221 976
   005   HUBBARD VS            LANCET                           2  1302 977
   006   HAHN TJ               J CLIN ENDOCRINOL METAB         39   274 974
   007   ANON                  NUTR REV                        26   200 968
   008   REEMTSMA K            PEDIATRICS                      22   525 958
   009   WILKINS L             IN: THOMAS CC                            965
   010   ANON                  NUTR REV                        33    61 975
   011   HATHCOCK JN           NUTR REV                        34    65 976
   012   ANDERSEN DH           J PEDIATR                       15   763 939
   013   BLOMSTRAND R          ACTA CHEM SCAND                 21  1662 967
CT   1   LO CW                 AM J CLIN NUTR                  42   644 985

PN 79211
RN 01191 
AN 80121798
AU Sherman-A-H.  Amoore-J-E.  Weigel-V.
TI The pyridine scale for clinical measurement of olfactory threshold:
   a quantitative reevaluation.
SO Otolaryngol-Head-Neck-Surg. 1979 Nov-Dec. 87(6). P 717-33.
MJ PYRIDINES: du.  SMELL: ph.
MN CYSTIC-FIBROSIS: co.  EVALUATION-STUDIES.  HUMAN.
   INDICATOR-DILUTION-TECHNICS.  PERCEPTUAL-DISORDERS: di, et.
   REFERENCE-VALUES.  SENSORY-THRESHOLDS.
AB Serial dilutions of pyridine in water are employed for measuring the
   olfactory detection thresholds of patients. Experimental precautions
   are described that improve the precision and accuracy of the method.
   Existing data on the sensitivities of hyposmic patients are
   confirmed, but the sensitivities of normal subjects and of hyperosmic
   patients are believed to have been substantially overestimated in
   some earlier publications. Routine clinical applications of the
   revised pyridine odor threshold test are discussed. In the author's
   experience, the average cystic fibrosis patient is slightly hyposmic,
   and some cases of pituitary tumor are accompanied by a 100,000-fold
   hyperosmia.
RF 001   SCHNEIDER RA          N ENGL J MED                   277   299 967
   002   HENKIN RI             IN: HAYASHI T                            967
   003   HENKIN RI             IN: BOSMA JF                             970
   004   HENKIN RI             LIFE SCI                         5   331 966
   005   AMOORE JE             J CHEM ECOL                      1   299 975
   006   MITCHELL MJ           Q J EXP PSYCHOL                 22   301 970
   007   AMOORE JE             CHEM SENSES FLAVOR               3    57 978
   008   AMOORE JE             PERCEPT MOT SKILLS              26   143 968
   009   VENSTROM D            J FOOD SCI                      33   264 968
   010   CHEESMAN GH           Q J EXP PSYCHOL                  5    22 953
   011   PATTERSON PM          J HERED                         39   295 948
   012   HENKIN RI             J CLIN INVEST                   45  1631 966
   013   HENKIN RI             SCIENCE                        138  1107 962
   014   HERTZ J               PHYSIOL BEHAV                   14    89 975
   015   LEMAGNEN J            ARCH SCI PHYSIOL                 6   125 952
   016   AMOORE JE             J CHEM ECOL                      1   291 975
   017   CURTIS RF             NATURE                         235   223 972
   018   GUADAGNI DG           J FOOD SCI                      43  1347 978
   019   HENKIN RI             LANCET                           1   823 971
   020   HENKIN RI             PERFUM FLAVORIST                 1    19 976
   021   STONE H               PERCEPT PSYCHOPHYS               2   516 967
   022   PARKER GH             SMELL TASTE AND ALLIED SENSES            922
   023   HENKIN RI             LIFE SCI                         5  1031 966
   024   HENKIN RI             JAMA                           217   434 971
   025   AMOORE JE             CHEM SENSES FLAVOR               2   267 977
   026   AMOORE JE             IN: DENTON DA                            975
   027   ALTER M               PATIENT CARE                     8    76 974
CT   1   WYSOCKI CJ            PROC NAT ACAD SCI USA           81  4899 984
     2   MOOREGILLON V         J ROY SOC MED                   78   435 985
     3   DOTY RL               CHEM SENSES                     11   259 986
     4   AMOORE JE             J AM WATER WORKS ASSOC          78    70 986

PN 79212
RN 01192 
AN 80211288
AU Vawter-G-F.  Shwachman-H.
TI Cystic fibrosis in adults: an autopsy study.
SO Pathol-Annu. 1979. 14 Pt 2. P 357-82.
MJ CYSTIC-FIBROSIS: pa.
MN ADULT.  ARTERIOVENOUS-ANASTOMOSIS: pa.  AUTOPSY.  BILIARY-TRACT: pa.
   BRONCHIAL-ARTERIES: pa.  BRONCHIECTASIS: pa.  ENDOCRINE-GLANDS: pa.
   EXOCRINE-GLANDS: pa.  FEMALE.  HOARSENESS: pa.  HUMAN.
   LIVER-CIRRHOSIS-BILIARY: pa.  LUNG: pa.  MALE.  NASAL-POLYPS: pa.
   PANCREAS: pa.  TRACHEITIS: pa.  UROGENITAL-SYSTEM: pa.
AB An annotated catalog of clinical and pathologic observations in an
   adult population with CF has been presented. The spectrum of disease
   is broad, and the diagnosis usually requires the demonstration of
   abnormalities in multiple systems. Tissues of each germ layer have
   been found involved in CF. Correlation of clinical and pathologic
   observations suggests that manifestations are essentially episodic
   and focal. In this population, the most characteristic abnormalities
   recognized by the pathologist are focal biliary cirrhosis,
   distinctive obstructive lesions of the male genital tract, prolonged
   staphylococcal or pseudomonas colonization of respiratory secretions,
   and obstructive bronchopulmonary disease. Some form of pancreatic
   atrophy is usually present.
RF 001   DANKS DM              ANN HUM GENET                   28   323 965
   002   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
   003   SHWACHMAN H           PEDIATRICS                      30   389 962
   004   GELLER A              NEUROLOGY (MINN)                27   185 977
   006   MELLINS RB            PEDIATRICS                      44   315 969
   007   WARING WW             PEDIATRICS                      39   166 967
   008   FIELD WEH             BR J DIS CHEST                  60    66 966
   009   LIEBOW AA             AM J PATHOL                     25   211 949
   010   LACK EE               HUM PATHOL                       8    39 977
   012   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   013   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   014   FARBER S              ARCH PATHOL                     37   238 944
   015   DI SANTAGNESE PA      PEDIATRICS                      18   387 956
   016   ROBERTS WC            AM J MED                        32   324 962
   017   BLANC WA              PEDIATRICS                      22   494 958
   018   ESTERLY NB            AM J DIS CHILD                 123   200 972
   019   KOPITO L              PROC AM PEDIATR SOC ANNU MTG             972
   020   DUNNILL MS            J PATHOL BACTERIOL              77   299 959
   021   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   022   DOLAN TF JR           J PEDIATR                       79   684 971
   024   HOLSCLAW DS           J UROL                         106   568 971
   025   GILLES FH             J NEUROPATH EX NEUROL           25   138 966
   026   SUNG JH               J NEUROPATH EXP NEUROL          23   567 964
   027   WALLWORK JC           CLIN EXP IMMUNOL                18   303 974
   028   KOPITO LE             PEDIATR RES                     10   742 976
   029   SHWACHMAN H           PEDIATRICS                      55    86 975
CT   1   HOLSCLAW DS           CLIN CHEST MED                   1   407 980
     2   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
     3   ABDULKARIM FW         GASTROENTEROLOGY                82   758 982
     4   IANNUCCI A            HUM PATHOL                      15   278 984
     5   MCCARTHY VP           GASTROENTEROLOGY                86   564 984
     6   DAVIS PB              SEM RESPIR MED                   6   314 985
     7   CASTILE R             AM J DIS CHILD                 139   728 985
     8   STERN RC              J PEDIATR GASTROENTEROL NUTR     5    35 986
     9   DISIS ML              PEDIATR RES                     20   385 986
    10   TRAVIS WD             AM J CLIN PATHOL                85   419 986
    11   ABDULKARIM FW         ARCH PATHOL LAB MED            110   602 986
    12   MCGLENNEN RC          ARCH PATHOL LAB MED            110   879 986
    13   HERNANZSCHULMAN M     RADIOLOGY                      158   629 986
    14   GRISCOM NT            AM J ROENTGENOL                148   691 987

PN 79213
RN 01193 
AN 79157663
AU Ghadially-F-N.
TI Invited review.  The technique and scope of electron-probe X-ray
   analysis in pathology.
SO Pathology. 1979 Jan. 11(1). P 95-110. (REVIEW).
MJ ELECTRON-PROBE-MICROANALYSIS: mt.  PATHOLOGY: is.
MN ACID-PHOSPHATASE: an.  ANTIGENS: me.  BISMUTH: an.  CALCIUM: an.
   CELL-NUCLEUS: an.  COPPER: an.  CYSTIC-FIBROSIS: di.
   ELECTRON-PROBE-MICROANALYSIS: is.  FOREIGN-BODIES: pa.  GOLD: an.
   HEMOSIDERIN: an.  HEPATOLENTICULAR-DEGENERATION: pa.  HUMAN.
   LUNG: an.  METALS: an.  MINERALS: an.  MITOCHONDRIA: an.  NAILS: an.
   PROSTHESIS.  REVIEW.  STAINS-AND-STAINING.
EX The purpose of this article is to review briefly both the techniques
   and applications of electron-probe x-ray analysis, but only studies
   of interest to pathologists will be dealt with.  The principles of
   x-ray fluorescence spectrometry, the capabilities and limitations of
   energy dispersive x-ray analysis, equipment, specimen preparation,
   and the method of electron-probe x-ray analysis are discussed.
   Applications of electron-probe x-ray analysis include mineral
   deposits in lungs, intranuclear bismuth inclusions, gold deposits in
   tissues, the nature of haemosiderin, copper in Wilson's disease,
   calcium in mitochondria, surgical implants, foreign bodies in eyes
   and wounds, the specificity of v. Kossa method for calcium,
   cytochemical localization of acid phosphatase, chromaffin and
   argentaffin reactions, the transfer of antigenic material from
   macrophages to lymphocytes, and the diagnosis of cystic fibrosis by
   electron-probe x-ray analysis of nails.
RF 001   BEAVER DL             ARCH PATHOL                     76    89 963
   002   BEEUWKES R 3RD        KIDNEY INT                      12   435 977
   003   BERRY JP              AM J PATHOL                     83   427 976
   004   BORLAND RM            DEVELOP BIOL                    50   201 976
   005   BUJA LM               J HISTOCHEM CYTOCHEM            24   508 976
   006   BURR RE               TOXICOL APPL PHARMACOL           7   588 965
   007   CHANDLER JA           X-RAY MICROANALYSIS ELECTRON             977
   008   CHISHOLM IA           CAN J OPHTHALMOL                12   316 977
   009   CHONG AP              AM J OBSTET GYNECOL            128   209 977
   010   CLARKE JA             NATURE                         227    69 971
   011   ECHLIN P              NATURE                         270   102 977
   012   ELEY BM               HISTOCHEM J                      8   647 976
   013   ESSNER E              IN: HAYAT MA                     1       973
   014   FOWLER BA             J HISTOCHEM CYTOCHEM            23   722 975
   015   GARDNER DL            J PATHOL                        98   105 969
   016   GHADIALLY FN          ULTRASTRUCTURAL PATHOL CELL              975
   017   GHADIALLY FN          J PATHOL                       120   201 976
   018   GHADIALLY FN          J PATHOL                       124    77 978
   019   GHADIALLY FN          VIRCHOWS ARCH CELL PATHOL       22   135 976
   021   GHADIALLY FN          VIRCHOWS ARCH CELL PATHOL       16    43 974
   022   GHADIALLY FN          ANN RHEUM DIS                   35    67 976
   023   GHADIALLY FN          J PATHOL                       123   181 977
   024   GHADIALLY FN          VIRCHOWS ARCH CELL PATHOL       21    45 976
   025   GOLDFISCHER S         AM J PATHOL                     53   883 968
   026   GOLDFISCHER S         J HISTOCHEM CYTOCHEM            12    72 964
   027   HARRISON JD           J PATHOL                       121    83 977
   028   HESS H                KLIN WOCHENSCHR                 50   776 972
   029   LALONDE JMA           VIRCHOWS ARCH CELL PATHOL       25   221 977
   031   LANGHANS              Z CHIR                          22   575 885
   032   LECHENE CP            AM J PHYSIOL                   232  F391 977
   033   LEVER JD              J HISTOCHEM CYTOCHEM            25   275 977
   034   MAUGH TH              SCIENCE                        197   356 977
   035   NORTON WL             ARTHRITIS RHEUM                 11   436 968
   036   ORYSCHAK AF           VIRCHOWS ARCH CELL PATHOL       17   159 974
   037   ORYSCHAK AF           VIRCHOWS ARCH CELL PATHOL       20    29 976
   038   ORYSCHAK AF           J PATHOL                       119   183 976
   039   PAPPENHEIMER AM       AM J PATHOL                     10   577 934
   040   REED GB               ARCH PATHOL                     93   249 972
   041   RICHTER GW            J EXP MED                      106   203 957
   042   ROOMANS GM            ACTA PAEDIATR SCAND             67    89 978
   043   RUSS JC               PROC SCANNING ELECTRO 5TH ANN            972
   044   RYDER TA              J MICROSC                      101   143 974
   045   SALSBURY AJ           PROC R SOC MED                  65   826 972
   046   SELZER S              ORAL SURG                       35   828 973
   047   SHUMAN H              PROC NAT ACAD SCI USA           73  1193 976
   048   SIPPONEN P            ARCH PATHOL LAB MED            100   664 976
   049   STUMP IG              CLIN BIOCHEM                    10   127 977
   050   STURGEON P            IN: WOLMAN M                             969
   051   THOMAS I              VIRCHOWS ARCH CELL PATHOL       26   105 977
   052   WACHSTEIN M           AM J CLIN PATHOL                19   608 949
   053   WACHSTEIN M           AM J PATHOL                     22   603 946
   054   WOOD JG               ACTA HISTOCHEM                  52   143 975
   055   YAROM R               VIRCHOWS ARCH CELL PATHOL       15    11 973
   056   YAROM R               J HISTOCHEM CYTOCHEM            24   453 976
   057   ZS-NAGY I             J ULTRASTRUCT RES               58    22 977
CT   1   SHAW CF               INORG PERSP BIOL MED             2   287 979
     2   GHADIALLY FN          CRC CRIT REV TOXICOL             6   303 979
     3   GHADIALLY FN          J SUBMICROSC CYTOL              11   503 979
     4   HALL TA               J MICROSC                      117   145 979
     5   BACHMANN S            CELL TISSUE RES                213   109 980
     6   DODSON RF             ULTRASTRUCTURAL PATHOL           2   365 981
     7   GHADIALLY FN          J SUBMICROSC CYTOL              13   455 981
     8   MORETON RB            BIOL REV                        56   409 981
     9   DINSDALE D            EXP MOL PATH                    36   396 982
    10   GHADIALLY FN          VIRCHOWS ARCH CELL PATHOL       39    21 982
    11   DAVID H               BIOL ZENTRALBL                 101   715 982
    12   WEINER JM             MED J AUST                       1   272 983
    13   WANG NS               HUM PATHOL                      14   888 983
    14   BRAIN TJ              PATHOLOGY                       15   336 983
    15   GOLIGORSKY MS         NEPHRON                         35    89 983
    16   MUKHERJEE TM          SCANN ELECTRON MICROSC        1983   663 983
    17   GHADIALLY FN          J SUBMICROSC CYTOL              16   773 984
    18   WOZNIEWICZ B          FOLIA HISTOCHEM CYTOBIOL        22   162 984
    19   FUNAHASHI A           CHEST                           85   506 984
    20   HOOK GR               J AM COLL NUTR                   4   599 985
    21   GOLIGORSKY MS         MINERAL ELECTROL METAB          11   301 985
    22   TERZAKIS JA           ORAL SURG                       59   399 985
    23   WARLEY A              J CELL SCI                      75   401 985
    24   BAKER D               SCANN ELECTRON MICROSC        1985   659 985
    25   HALL TA               MICRON MICROSC ACTA             17    91 986
    26   HARTMAN LC            J ORAL MAXILLOFAC SURG          44   628 986

PN 79214
RN 01194 
AN 80033905
AU Cox-D-W.  Talamo-R-C.
TI Genetic aspects of pediatric lung disease.
SO Pediatr-Clin-North-Am. 1979 Aug. 26(3). P 467-80.
MJ LUNG-DISEASES: fg.
MN ALPHA-1-ANTITRYPSIN: df.  ASTHMA: fg.  CHILD.  CILIA: pa.
   CYSTIC-FIBROSIS: fg, pp.  DEFICIENCY-DISEASES: pp.  HUMAN.
   KARTAGENER-TRIAD: fg, pp.  LUNG-DISEASES: im.
AB Several genetic diseases are described which affect the lung,
   usually or at least in some cases, in the pediatric age group.
   The four disorders discussed have been selected wither for their
   high frequency or for their demonstration of the variety of ways in
   which genetic factors can influence disease: cystic fibrosis, one of
   the most common of the metabolic disorders inherited as an autosomal
   recessive trait; immotile cilia syndrome, including Kartagener's
   syndrome, single gene disorders involving structural abnormalities
   of the cilia; asthma, a common disorder in children with a genetic
   component; and alpha1-antitrypsin deficiency, an inherited protein
   deficiency commonly causing obstructive lung disease in adults and
   occasionally affecting children.
RF 001   AFZELIUS BA           SCIENCE                        193   317 976
   002   BIAS WB               IN: AUSTEN KF                            973
   003   BOIS E                CLIN GENET                      14    73 978
   004   COX DW                AM REV RESPIR DIS              113   601 976
   006   DANKS DM              ANN HUM GENET                   28   323 965
   007   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   008   ELIASSON R            N ENGL J MED                   297     1 977
   009   FAGERHOL MK           CLIN CHIM ACTA                  16   199 967
   010   FALLIERS CJ           J ALLERGY                       47   207 971
   011   FISCHER TJ            PEDIATRICS                      62   443 978
   012   GARROD AE             Q J MED                          6   242 913
   013   GORDIS L              EPIDEMIOL CHRONIC LUNG DIS IN            973
   014   GRUNDBACHER FJ        J ALLERGY CLIN IMMUNOL          56   104 975
   015   HOLMES LB             AM J MED SCI                   255    13 968
   016   HOUSTEK J             CHEST                           64   773 973
   017   KARTAGENER M          BEITR KLIN TUBERK               83   489 933
   018   KARTAGENER M          ARCH PEDIATR                    79   193 962
   019   KONIG P               J ALLERGY CLIN IMMUNOL          54   280 974
   020   KUEPPERS F            IN: LENFANT C                   13       978
   021   KUEPPERS F            AM REV RESPIR DIS              110   176 974
   022   LAURELL CB            SCAND J CLIN LAB INVEST         15   132 963
   023   LOGAN WD              DIS CHEST                       48   613 965
   024   LUCK D                PROC NAT ACAD SCI USA           74  3456 977
   025   MARSH DG              SCIENCE                        179   691 973
   026   MOROZ SP              J PEDIATR                       88    19 976
   027   MOSSBERG B            SCAND J RESPIR DIS              59    55 978
   028   MOSSBERG B            MT SINAI J MED                  44   837 977
   029   NADLER HL             IN: STANBURY JB                     1683 978
   030   PIERCE JA             ANAL BIOCHEM                    74   227 976
   031   SCHAAP T              IN: MANGOS JA                        291 976
   032   SCHWARTZ M            ACTA ALLERGOL SUPPL II           5       952
   033   SHARP HL              J LAB CLIN MED                  73   934 969
   034   STURGESS JM           N ENGL J MED                   300    53 979
   035   SVEGER T              N ENGL J MED                   294  1316 976
   036   TALAMO RC             J PEDIATR                       79    20 971
   037   TORGERSEN J           ACTA RADIOL                     28    17 947
   038   TORGERSEN J           AM J HUM GENET                   2   361 950
CT   1   AFZELIUS BA           AM J HUM GENET                  33   852 981
     2   TURNER JAP            PEDIATRICS                      67   805 981
     3   HURWITZ RC            CLIN GENET                      22     7 982
     4   YARNAL JR             POSTGRAD MED                    71   195 982
     5   RIMPELA A             ACTA PAEDIATR SCAND SUPPL     1982     1 982
     6   LEVISON H             EUR J RESPIR DIS                64   102 983
     7   CANET E               PRESSE MED                      13  1607 984
     8   NADEL HR              RADIOLOGY                      154   651 985
     9   STURGESS JM           AM J MED GENET                  25   149 986

PN 79215
RN 01195 
AN 80033914
AU Gurwitz-D.  Corey-M.  Francis-P-W.  Crozier-D.  Levison-H.
TI Perspectives in cystic fibrosis.
SO Pediatr-Clin-North-Am. 1979 Aug. 26(3). P 603-15.
MJ CYSTIC-FIBROSIS: th.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: di, fg, ra.  GROWTH.  HUMAN.  LUNG: pp.  SEX-FACTORS.
   VENTILATION-PERFUSION-RATIO.
EX It would seem that early diagnosis of cystic fibrosis and the
   institution of an aggressive treatment program before widespread
   irreversible lung damage has occurred may greatly prolong survival.
   Individual prediction at the time of diagnosis is impossible, but
   there are a number of factors which, when considered together, enable
   the clinician to place patients in a number of broadly defined risk
   groups.  It is the definition and characteristics of these groups
   which would help the physician in assessment, counseling, and
   follow-up of patients with cystic fibrosis which are addressed in
   this article.  The heterogeneity of cystic fibrosis, sex differences,
   presentation and age at diagnosis, pulmonary function, radiologic
   assessment, and projections for the future are discussed.
RF 001   BEDROSSIAN CWM        HUM PATHOL                       7   195 976
   002   CHALON J              JAMA                           218  1928 971
   003   COOPER DM             AM REV RESPIR DIS              109   519 974
   004   COREY M               AM REV RESPIR DIS              114  1085 976
   005   COREY M               CF CLUB ABST                             978
   006   CROZIER DN            PEDIATR CLIN NORTH AM           21   935 974
   007   ANON                  CF FND 1976 REP SURVI STUD PA            978
   008   DANES BS              J EXP MED                      129   775 969
   009   DI SANTAGNESE PA      AM J MED                        66   121 979
   010   FEATHERBY EA          AM REV RESPIR DIS              102   737 970
   011   FOX WW                PEDIATRICS                      54   293 974
   013   GRACEY M              AUSTRALAS ANN MED               18    91 969
   014   HAYASHI M             AM REV RESPIR DIS              115   595 977
   015   HUTCHEON M            AM REV RESPIR DIS              110   458 974
   017   KEENS TG              AM REV RESPIR DIS              116   853 977
   018   KOLLBERG H            ACTA PAEDIATR SCAND             64   477 975
   019   KOPEL FB              GASTROENTEROLOGY                62   483 972
   020   LAMARRE A             PEDIATRICS                      50   291 972
   021   LAPIERRE JG           CAN PAED SOC ANN MTG ABST             61 975
   022   LEVISON H             IN: MANGOS JA                          3 976
   023   HADORN B              CAN MED ASSOC J                 98   377 968
   024   MANSELL A             AM REV RESPIR DIS              109   190 974
   025   MITCHELL-HEGGS PF     Q J MED                         45   479 976
   026   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   027   ORENSTEIN DM          AM J DIS CHILD                 131   973 977
   028   REID L                MOD PROBL PEDIATR               10   195 967
   029   REILLY BJ             RADIOLOGY                       98   281 971
   030   SHWACHMAN H           PEDIATRICS                      36   689 965
   031   SHWACHMAN H           BIRTH DEF ORIG ART SER           8   102 972
   032   SHWACHMAN H           CURR PROB PEDIATR NO 10          8       978
   033   SHWACHMAN H           PEDIATRICS                      46   335 970
   034   STEPHAN U             PEDIATRICS                      55    35 975
   035   STERN RC              JAMA                           239  2676 978
   036   STERN RC              J PEDIATR                       89   406 976
   037   WARWICK WJ            J CHRON DIS                     28   609 975
   038   WOOD RE               AM REV RESPIR DIS              113   833 976
   039   YEAGER H JR           PROC SOC EXP BIOL MED          155   115 977
CT   1   HOLSCLAW DS           CLIN CHEST MED                   1   407 980
     2   SVENONIUS E           RESPIRATION                     40   226 980
     3   BELL L                J CAN DIET ASSOC                42    62 981
     4   CORKEY CWB            AM REV RESPIR DIS              124   544 981
     5   CORKEY CWB            AM J OBSTET GYNECOL            140   737 981
     6   GASKIN K              J PEDIATR                      100   857 982
     7   MCLAUGHLIN FJ         J PEDIATR                      100   863 982
     8   NOLAN G               J PEDIATR                      101   626 982
     9   PARSONS HG            J PEDIATR GASTROENTEROL NUTR     2    44 983
    10   PENCHARZ PB           J PEDIATR GASTROENTEROL NUTR     2   400 983
    11   SINNEMA G             ACTA PAEDIATR SCAND             72   427 983
    12   BIBERSTEIN M          AM J CLIN PATHOL                80   752 983
    13   CHACE KV              CLIN CHIM ACTA                 132   143 983
    14   BLYTHE SA             CLIN BIOCHEM                    17   277 984
    15   WELLS AL              J FOOD NUTR                     41    65 984
    16   COREY M               J INFECT DIS                   149   283 984
    17   WANG EEL              N ENGL J MED                   311  1653 984
    18   CANCIANI M            J PEDIATR GASTROENTEROL NUTR     4   735 985
    19   SCULLY BE             REV INFECT DIS                   7  S669 985
    20   CHACE KV              BIOCHEMISTRY                    24  7334 985
    21   LAMBERTY JM           ANAESTHESIA                     40   448 985
    22   SIMMONS RJ            PSYCHOSOM MED                   47   111 985
    23   LEVY LD               J PEDIATR                      107   225 985
    24   TABLAN OC             J PEDIATR                      107   382 985
    25   WIESEMANN HG          MONATSSCHR KINDERHEILKD        133   726 985
    26   MELLIS CM             MED J AUST                     143   227 985
    27   LEVY L                J PEDIATR GASTROENTEROL NUTR     5    97 986
    28   RUSH PJ               SEM ARTHRITIS RHEUM             15   213 986
    29   SOUTTER VL            CLIN GASTROENTEROL              15   137 986
    30   OLOUGHLIN E           AM J CLIN NUTR                  43   732 986
    31   TSUI LC               COLD SPRING HARBOR SYMP Q BIO   51   325 986
    32   MARCOTTE JE           CHEST                           90   375 986
    33   LEVY L                J PEDIATR                      108  1038 986
    34   SHEPHERD RW           J PEDIATR                      109   788 986
    35   WANG EEL              PEDIATR INFECT DIS J             6   256 987

PN 79216
RN 01196 
AN 80012551
AU Pearson-R-D.  Lubin-A-H.
TI Increased heparin binding in cystic fibrosis: a reflection of
   altered glycoprotein biosynthesis?.
SO Pediatr-Res. 1979 Jul. 13(7). P 834-40.
MJ BLOOD-PROTEINS: me.  CYSTIC-FIBROSIS: bl.  GLYCOPROTEINS: bi.
   HEPARIN: bl.
MN ADOLESCENCE.  ADULT.  CARBOHYDRATES: bl.  CYSTIC-FIBROSIS: me.
   FEMALE.  GLYCOPROTEINS: bl.  HUMAN.  MALE.  PROTEIN-BINDING.
AB Some of the serum proteins which bind to heparin and contribute to
   the pH 5.57 "heparin binding capacity" of human serum are
   glycoproteins; those from cystic fibrosis serum were found to be 27%
   higher in fucose (methylpentose) content, 27% lower in sialic acid
   content, and 31% lower in hexose content when compared to heparin-
   precipitated serum glycoproteins from normal control subjects.
   Hexosamine content of the heparin-precipitated serum glycoproteins
   was the same. Results of this preliminary investigation indicate that
   altered carbohydrate composition in serum glycoproteins may affect
   significantly their heparin binding capacity.
RF 001   ALTLAND K             HUMANGENETIK                    28   207 975
   002   AYALA W               J CLIN INVEST                   30   781 951
   003   BAIG MM               J PEDIATR                       86    72 975
   004   BARTMAN J             J PEDIATR                       76   430 970
   005   BENNETT G             J CELL BIOL                     60   258 974
   006   BITTER T              ANAL BIOCHEM                     4   330 962
   007   BOAT TF               AM REV RESPIR DIS              110   428 974
   008   BOWMAN BH             TEX REP BIOL MED                31   611 973
   009   BUTTERWORTH J         CLIN CHIM ACTA                  40   139 972
   010   CHANGUS JE            ARCH PATHOL LAB MED            100     7 976
   011   CHANGUS JE            AM J PATHOL                     80   317 975
   012   COBURN AF             TRANS ASSOC AM PHYSICIANS       66   308 953
   013   COBURN AF             J EXP MED                       99     1 954
   014   COBURN AF             ARCH INTERN MED                 92   185 953
   015   CONOD EJ              PEDIATR RES                      9   724 975
   016   CONNEALLY PM          TEX REP BIOL MED                31   639 973
   017   CUNNINGHAM DG         ILL MED J                      145   493 974
   018   CURRAN RC             BIOCHEM SOC SYMP                20    24 961
   019   DANES BS              LANCET                           2   765 973
   020   DANES BS              J EXP MED                      129   775 969
   021   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   022   DI SANTAGNESE PA      PEDIATRICS                      19   252 957
   023   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   024   DISCHE Z              J BIOL CHEM                    167   189 947
   025   DISCHE Z              PEDIATRICS                      24    74 959
   026   DISCHE Z              ANN NY ACAD SCI                 93   526 962
   027   DISCHE Z              J BIOL CHEM                    175   595 948
   028   DOGGETT RG            NATURE NEW BIOL                243   251 973
   029   DOGGETT RG            TEX REP BIOL MED                31   685 973
   030   DOGGETT RG            NATURE NEW BIOL                243   250 973
   031   EHRLICH J             J PHARM SCI                     62   517 973
   032   GUHA AK               CLIN BIOCHEM                    10   153 977
   033   GOLDBERG AL           ANNU REV BIOCHEM                45   835 974
   034   GOLDBERG AL           ANNU REV BIOCHEM                45   747 976
   035   GIBSON LE             PEDIATRICS                      48   695 971
   036   JOHANSEN PG           LANCET                           1   455 968
   037   KRAUS I               PEDIATRICS                      47  1010 971
   038   LOUISOT P             CLIN CHIM ACTA                  48   373 973
   039   LOWRY OH              J BIOL CHEM                    193   265 951
   040   LUSTIG B              BIOCHEM Z                      242   320 931
   041   MANGOS JA             PEDIATR RES                      2   378 968
   042   MARTIN F              DIGESTION                        1   165 968
   043   MATALON R             LANCET                           2   838 969
   044   MCCOMBS ML            TEX REP BIOL MED                31   615 973
   045   MCMANUS SP            IR J MED SCI                   143   227 974
   046   MOLNAR J              MOL CELL BIOCHEM                 6     3 975
   047   NOVAK RA              TEX REP BIOL MED                34   199 976
   048   PADDAY JF             IN: BALAZS EA                    2       970
   049   PEARSON RD            HEALTH LAB SCI                  15    32 978
   050   POLLEY MJ             J MED GENET                     11   249 974
   051   RAO GJS               PEDIATR RES                     11   981 977
   052   RIMINGTON C           BIOCHEM J                       34   931 940
   053   SHAPIRA E             PEDIATR RES                     10   812 976
   054   SLACK J               J LAB CLIN MED                  59   302 962
   055   SPIRO RG              N ENGL J MED                   281   991 969
   056   SPOCK A               PEDIATR RES                      1   173 967
   057   STURGESS JM           BIOCHIM BIOPHYS ACTA           320   123 973
   058   WEIMER HR             AM REV TUBERC                   68   594 952
   059   WIESMANN UN           J PEDIATR                       77   685 970
   060   WILSON GB             PEDIATR RES                     10    87 976
   061   WILSON GB             CLIN CHIM ACTA                  49    79 973
   062   WINZLER RJ            METHODS BIOCHEM ANAL             2   279 955
   063   WINZLER RJ            IN: JEANLOZ RW                  2A       965
   064   YOUNG MD              BIOCHIM BIOPHYS ACTA           141   374 967
CT   1   SCANLIN TF            CLIN CHEST MED                   1   424 980
     2   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      93    50 980
     3   BLITZER MG            PEDIATR RES                     16   203 982
     4   BLITZER MG            PEDIATR RES                     16   938 982
     5   MARGOLIES R           PEDIATR RES                     16   181 982
     6   SCANLIN TF            BIOCHEMISTRY                    21   491 982
     7   MARGOLIES R           PEDIATR RES                     17   931 983
     8   HARRIS A              CLIN CHIM ACTA                 128    41 983
     9   ALHADEFF JA           CLIN CHIM ACTA                 134     1 983
    10   SLOMIANY A            BIOCHIM BIOPHYS ACTA           750   253 983
    11   GUEANT JL             CLIN CHIM ACTA                 143   217 984
    12   SCANLIN TF            PEDIATR RES                     19   368 985
    13   HUHLE D               Z KLIN MED                      40  1199 985

PN 79217
RN 01197 
AN 80012535
AU Mawhinney-T-P.  Feather-M-S.  Martinez-J-R.  Barbero-G-J.
TI The chronically reserpinized rat as an animal model for cystic
   fibrosis: I. Acute effect of isoproterenol and pilocarpine upon
   pulmonary lavage fluid.
SO Pediatr-Res. 1979 Jun. 13(6). P 760-3.
MJ CYSTIC-FIBROSIS: ci.  ISOPROTERENOL: pd.  LUNG: de.  PILOCARPINE: pd.
   RESERPINE: pd.
MN ANIMAL.  CARBOHYDRATES: me.  CHOLESTEROL: me.  CYSTIC-FIBROSIS: me.
   IRRIGATION.  LIPIDS: me.  LUNG: me.  MALE.  PHOSPHATIDYLCHOLINES: me.
   PHOSPHOLIPIDS: me.  PROTEINS: me.  RATS.
AB Lung lavage samples from rats treated in a chronic fashion with
   reserpine had mean increases of 133, 170, and 120% in the total
   protein, lipid, and carbohydrate contents, respectively, when
   compared with those of untreated control animals, when these values
   were expressed in terms of body weight.  An acute single ip
   injection of the beta-adrenergic agent isoproterenol (10 mg)
   increased the glycoprotein content of pulmonary lavage fluid from
   control rats approximately 15-19%, but only 9-10% in those from
   reserpine treated rats.  By contrast, pilocarpine (10 mg),
   administered in the same manner, caused a 15% increase in the total
   protein, carbohydrate, and lipid content of lavage samples from
   control rats and increased these same constituents in the lavage
   samples of reserpine treated rats 98, 102, and 80%, respectively.
   The increased  total carbohydrate content in the lavage samples of
   the treated animals was not associated with changes in the percent
   distribution of neutral sugars, amino sugars, or sialic acid.  The
   ratio of these various sugar components did not change in the lavage
   samples of control or reserpine treated rats upon stimulation with
   either pilocarpine or isoproterenol.  The increased total lipid
   content fround in the lavage samples from the treated rats probably
   results from an increase in phospholipids.  A decrease in
   phospholipid content occurred in the lavage samples of reserpine
   treated rats upon stimulation, while the opposite was observed in
   those of control animals.  Chronic treatment of rats with reserpine,
   thus, appears to induce an enhanced production of glycoproteins in
   the airways and to interfere with phospholipid metabolism in the
   lung.  In addition, the drug treatment enhances the secretory
   response to pilocarpine in comparison with the responses of control
   animals.  The enhanced response or hypersecretion of glycoproteins
   is a quantitative one and does not seem to involve alterations in
   the ratios or distribution of the various sugar components.  This
   disturbance in the secretory function of the respiratory tract, a
   target organ which is prominently involved in cystic fibrosis (CF)
   together with alterations in other exocrine glands which resemble
   those of CF patients, makes the reserpine treated rat a useful model
   for further study of possible pathogenetic mechanisms in CF.  The
   experimental animal model for CF developed by the chronic
   administration of reserpine to rats has been found to have changes
   in the protein content of lung lavage samples, in addition to
   morphologic and secretory alterations in the salivary glands and the
   pancreas.  Further analysis of the organic composition of lung
   lavage samples shows that the protein, carbohydrate, and lipid
   contents are significantly increased after chronic reserpine
   administration and that the response to stimulation with pilocarpine
   is enhanced in the treated animals when compared to that of
   untreated control rats.  It therefore appears that chronic reserpine
   administration causes a hypersecretion of glycoproteins and changes
   in lipid metabolism in the respiratory tract of the rat and that, in
   conjunction with previous findings in other exocrine glands, these
   effects on lung function make the reserpine treated rat a useful
   tool for the study of the pathologic disturbance seen in the major
   exocrine glands affected in CF.
RF 001   BOAS NF               J BIOL CHEM                    204   553 953
   002   BOAT TF               ARCH BIOCHEM BIOPHYS           177    95 976
   003   BOAT TF               AM REV RESPIR DIS              110   428 974
   004   BARBERO GJ            IN: DI SANTAGNESE PA                 208 964
   005   CHAKRIN LW            AM REV RESPIR DIS              108    69 973
   006   CHERNICK WS           ANN NY ACAD SCI                106   698 963
   007   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   008   DUBOIS M              ANAL CHEM                       28   350 956
   009   FLEMING WW            ERGEBNISSE PHYSIOLOGIE          68    55 973
   010   HUANG TC              ANAL CHEM                       33  1405 961
   011   JANATUINEN M          EXP PATHOL                     265   112 969
   012   LAMB D                BR J DIS CHEST                  66   239 972
   013   LEV R                 AM J PATHOL                     46    23 965
   014   LOWRY OH              J BIOL CHEM                    193   265 951
   015   LOWRY RR              LIPIDS                           9   491 974
   016   MARTINEZ JR           J PHARMACOL EXP THER           194   384 975
   017   MARTINEZ JR           J PHARMACOL EXP THER           201   206 977
   018   MARTINEZ JR           PEDIATR RES                      9   463 975
   019   MARTINEZ JR           PEDIATR RES                      9   470 975
   020   PERLMUTTER J          PEDIATR RES                     12   188 978
   021   POORTHUIS JHM         J LIPID RES                     17   433 976
   022   POTTER JL             ANN NY ACAD SCI                106   692 963
   023   ROTH RH               BIOCHEM PHARMACOL               17  1581 968
   024   ROUSER G              IN: MARINETTI GV                 1    99 967
   025   SAHU S                AM REV RESPIR DIS              115   233 977
   026   STURGESS JM           BR J EXP PATHOL                 54   388 973
   027   SUN SC                J PHARMACOL EXP THER           161   210 968
   028   THOMPSON FE           PEDIATR RES                     10   632 976
   029   TUCKLEY B             LIPIDS                           9   493 974
   030   VAN GOLD LMG          AM REV RESPIR DIS              114   977 976
   031   VARMA R               J CHROMATOGR                    77   222 973
   032   WARREN L              J BIOL CHEM                    234  1971 959
CT   1   SCANLIN TF            CLIN CHEST MED                   1   424 980
     2   MAWHINNEY TP          PEDIATR RES                     14   872 980
     3   MCCURDY RE            PEDIATR RES                     15  1308 981
     4   FORSTNER J            AM J PHYSIOL                   241  G443 981
     5   FORSTNER G            ADV EXP MED BIOL               144   199 982
     6   MARTINEZ JR           PEDIATR RES                     17   523 983
     7   MODRZAKOWSKI MC       CAN J MICROBIOL                 29  1339 983
     8   BOYD RL               PEDIATR RES                     18  1028 984
     9   SPICER SS             ENVIRON HEALTH PERSPECT         55   193 984
    10   BRADY RC              EXP CELL RES                   150   141 984
    11   MARTINEZ JR           PEDIATR RES                     19   711 985
    12   BRADY RC              AM J PHYSIOL                   248  G 54 985
    13   HAZLETT D             PEDIATR RES                     20  1236 986

PN 79218
RN 01198 
AN 80055643
AU Russell-D-H.  Rosenblum-M-G.  Beckerman-R-C.  Durie-B-G.
   Taussig-L-M.  Barnett-D-R.
TI Altered polyamine metabolism in cystic fibrosis.
SO Pediatr-Res. 1979 Oct. 13(10). P 1137-40.
MJ CYSTIC-FIBROSIS: ur.  POLYAMINES: ur.
MN ADULT.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: bl.  FEMALE.
   HETEROZYGOTE.  HUMAN.  MALE.  PUTRESCINE: ur.  SPERMIDINE: ad, bl, ur.
   SPERMINE: ur.
AB Children with cystic fibrosis excreted elevated urinary levels of all
   three polyamines--putrescine, spermidine, and spermine. Heterozygote
   parents excreted intermediate concentrations of the polyamines, but
   not levels significantly different from levels in normal controls.
   Patients with cystic fibrosis who were administered a tracer amount
   of [14C]spermidine excreted 11--13% of the radiolabel within 72 hr
   whereas normal controls excreted 60--76% of the radiolabel within 72
   hr. Spermine excretion was positively correlated with increased
   pathology as assessed by the National Institutes of Health (NIH)
   clinical score, whereas urinary putrescine and spermidine levels were
   negatively correlated with increased pathology.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   002   BOWMAN BH             SCIENCE                        164   325 969
   003   COHEN LF              BLOOD                           48   469 976
   004   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   005   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   006   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   007   DURIE BGM             CANCER RES                      37   214 977
   008   LUNDGREN DW           CLIN CHIM ACTA                  62   357 975
   009   PROCTOR MS            J INVEST DERMATOL               65   409 975
   010   RENNERT OM            IN: MANGOS JA                         41 973
   011   ROSENBLUM MG          SCIENCE                        200  1496 978
   012   ROSENBLUM MG          CANCER RES                      38  3161 978
   013   RUSSELL DH            IN: RUSSELL DH                         1 973
   014   RUSSELL DH            CLIN CHEM                       23    22 977
   015   RUSSELL DH            POLYAMINES AS BIOCHEM MARKERS            978
   016   RUSSELL DH            LANCET                           2   797 975
   017   RUSSELL DH            CLIN CHEM                       21   860 975
   018   SPOCK A               PEDIATR RES                      1   173 967
   019   TAUSSIG LM            J PEDIATR                       82   380 973
   020   TAUSSIG LM            IN: KELLEY VC                    4     1 976
CT   1   SCANLIN TF            CLIN CHEST MED                   1   424 980
     2   THEOHARIDES TC        LIFE SCI                        27   703 980
     3   KAMINSKA AM           ANN NEUROL                       9   605 981
     4   PINEL JPJ             PHYSIOL BEHAV                   27   819 981
     5   RUSSELL DH            NEUROLOGY                       31    80 981
     6   RUSSELL DH            CRC CRIT REV CLIN LAB SCI       18   261 983
     7   NORDLANDER JE         J ORGANIC CHEM                  49   133 984
     8   KAMOUN PP             CLIN CHIM ACTA                 154   219 986

PN 79219
RN 01199 
AN 80055647
AU Martinez-J-R.  Martinez-A-M.  Garrett-L.  Korman-P.
TI Chronically reserpinized rat as a model for cystic fibrosis: Na+
   transport inhibitory effect in submaxillary saliva.
SO Pediatr-Res. 1979 Oct. 13(10). P 1156-9.
MJ CYSTIC-FIBROSIS: me.  RESERPINE: pd.  SALIVA: me.  SODIUM: me.
MN ANIMAL.  CYSTIC-FIBROSIS: ci, pp.  FREEZING.  HEAT.
   PAROTID-GLAND: se.  RATS.  SECRETORY-RATE.  SUBMANDIBULAR-GLAND: se.
AB The retrograde perfusion assay in the rat parotid gland was used to
   investigate the effects of salivary secretions from control and
   reserpine-treated rats on Na+ reabsorption. Results demonstrated that
   submaxillary saliva from the treated animals caused a 69% inhibition
   of Na+ reabsorption, accompanied by a 28% reduction in the volume of
   saliva secreted, and a 22% reduction in flow rate. By contrast,
   submaxillary saliva from control rats caused a 6% inhibition of Na+
   reabsorption, a 6% reduction in volume, and a 5% reduction in flow
   rate. Parotid saliva from reserpine-treated rats also inhibited Na+
   reabsorption to the extent of 39% and caused a 38% reduction in
   volume and a 33% reduction in flow. Parotid saliva from control rats
   only inhibited Na+ reabsorption to the extent of 2.7% and caused a 4--
   6% reduction in salivary volumes and flow rates. The inhibition of
   Na+ reabsorption and the reduction in salivary volume and flow rates
   caused by submaxillary saliva of reserpine-treated rats were either
   abolished or significantly reduced when the saliva was previously
   heated to 100 degrees C, frozen, and then thawed or kept in glass
   tubes at 4 degrees C for 24 hr. These results indicate that saliva
   from reserpine-treated rats have comparable effects in this assay
   system to those of saliva from cystic fibrosis (CF) patients and
   further support its use as an animal model for this disease.
RF 001   ADSHEAD PC            ANN NY ACAD SCI                253   192 975
   002   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   003   MANGOS JA             PFLUEGERS ARCH                 291    99 966
   004   MANGOS JA             PEDIATR RES                      1   436 967
   005   MARTINEZ JR           PEDIATR RES                      9   463 975
   006   MARTINEZ JR           PEDIATR RES                      9   470 975
   007   PETERSEN OH           ACTA PHYSIOL SCAND SUPPL 381           1 972
   008   PERLMUTTER J          PEDIATR RES                     12   188 978
   009   TAYLOR A              PEDIATR RES                      8   861 974
   010   THOMPSON FE           PEDIATR RES                     10   632 976
   011   YOUNG JA              PROC AUST PHYSIOL PHARMACO       4   101 973
   012   WEISMAN UN            LANCET                           1   510 972
   013   WOOD DL               PEDIATR RES                     11   827 977
CT   1   MARTINEZ JR           PEDIATR RES                     15  1439 981
     2   ROSCHER AA            J PHARMACOL EXP THER           216   419 981
     3   FORSTNER J            AM J PHYSIOL                   241  G443 981
     4   ROOMANS GM            ULTRASTRUCTURAL PATHOL           3   285 982
     5   BAUM BJ               J GERONTOL                      37   392 982
     6   ROOMANS GM            SCANN ELECTRON MICROSC        1982   229 982
     7   SHIFFMAN ML           PEDIATR RES                     17   486 983
     8   VO CP                 ARCH ORAL BIOL                  28   259 983
     9   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983
    10   MULLER RM             EXP MOL PATH                    40   391 984
    11   WATSON E              J DENT RES                      63    82 984
    12   SATO K                J CLIN INVEST                   73  1763 984
    13   MORTON AJ             BR J PHARMACOL                  86   287 985
    14   BRADY RC              AM J PHYSIOL                   248  G 54 985

PN 79220
RN 01200 
AN 80055641
AU Will-P-C.  Boat-T-F.  Hopfer-U.
TI Evidence against a specific effect of serum from patients with
   cystic fibrosis on sodium-dependent glucose transport in the rat
   jejunum.
SO Pediatr-Res. 1979 Oct. 13(10). P 1129-33.
MJ CYSTIC-FIBROSIS: bl.  GLUCOSE: me.  JEJUNUM: me.  SODIUM: pd.
MN ANIMAL.  HUMAN.  IN-VITRO.  MALE.  MICROVILLI: me.  PHLORHIZIN: pd.
   RATS.
AB Sera from patients with cystic fibrosis of the pancreas (CF) and
   normal human sera were assayed for the ability to inhibit sodium-
   dependent glucose transport in rat brush-border membrane vesicles.
   Fresh CF and age- and sex-matched control sera were both inhibitory
   when compared to physiologic saline. The inhibition by CF serum was
   44 +/- 13% (mean +/- SD) at a final serum concentration of 6.7%, 67
   +/- 34% at 10% serum, and 68 +/- 28% at 20% serum. The ratio of the
   inhibition of CF sera compared to that of control sera was 1.00,
   0.78, and 0.93 at 6.7, 10, and 20% serum concentrations,
   respectively. Although a slightly greater inhibition by CF serum was
   observed at a concentration of 10%, this is probably not significant
   because no difference could be detected at a concentration of 20%
   serum. Glucose transport in the presence of serum was sensitive to
   phlorizin indicating that the residual glucose transport was
   proceeding by the sodium-dependent glucose transport system. These
   findings suggest that CF serum does not specifically inhibit the
   sodium-dependent glucose transport system. The intravesicular space
   accessible to glucose was reduced in the presence of CF or control
   serum. Fresh CF serum was 1.4 times more effective than fresh control
   serum (P less than 0.01). The presence of substantial vesicle-
   shrinking activity in control serum indicates that this activity
   cannot be considered specific for CF.
RF 001   ARAKI H               PEDIATR RES                      9   932 975
   002   ARAKI H               PROC INT CF CONG 7TH                  28 976
   003   ARVANITAKIS S         TEX REP BIOL MED                34   175 976
   004   BARNETT DR            TEX REP BIOL MED                31   709 973
   005   BENKE PJ              PROC SOC EXP BIOL MED          137  1283 971
   006   BENSADOUN A           ANAL BIOCHEM                    70   241 976
   007   BROWN GA              LANCET                           2   639 971
   008   CONOD EJ              PEDIATR RES                     11    45 977
   009   DESJEUX JF            EUROPEAN SOC PEDIAT RES MTG              970
   010   DESJEUX JF            CF CLUB ABST                    15       974
   011   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   012   DOERSHUK CF           J PEDIATR                       65   677 964
   013   DOGGETT RG            TEX REP BIOL MED                31   685 973
   014   FRIZZELL RA           J MEMBR BIOL                    27   297 976
   015   FROMTER E             NATURE NEW BIOL                235     9 972
   016   GILMORE JP            PROC SOC EXP BIOL MED          157    70 978
   017   HOPFER U              PROC NAT ACAD SCI USA           72  2027 975
   018   HOPFER U              J SUPRAMOL STRUCT                7     1 977
   019   HOPFER U              J BIOL CHEM                    248    25 973
   020   HOPFER U              ANN NY ACAD SCI                264   414 975
   021   KAISER D              PEDIATR RES                      5   167 971
   022   LOWRY OH              J BIOL CHEM                    193   265 951
   023   MANGOS JA             TEX REP BIOL MED                31   651 973
   024   MANGOS JA             SCIENCE                        158   135 967
   025   MANGOS JA             PEDIATR RES                      1   436 967
   026   MENG K                PFLUEGERS ARCH                 357    91 975
   027   MORIN CL              BIOMEDICINE EXPRESS             19   133 973
   028   MURER H               PROC NAT ACAD SCI USA           71   484 974
   029   SCHMITZ J             BIOCHIM BIOPHYS ACTA           323    98 973
   030   SCHNEYER LH           AM J PHYSIOL                   219  1050 970
   031   SCHNEYER LH           PHYSIOL REV                     52   720 972
   032   SCHULTZ SG            PHYSIOL REV                     50   637 970
   033   SHAPIRO BL            PEDIATR RES                      9   885 975
   034   SIGRIST-NELSON K      J BIOL CHEM                    250  5674 975
   035   TANNENBAUM C          FED PROC                        36   360 977
   036   TAUSSIG LM            LANCET                           1  1367 972
   037   TAYLOR A              PEDIATR RES                      8   861 974
   038   WILSON GB             NATURE                         266   463 977
   039   WILSON GB             PEDIATR RES                     11   317 977
   040   ZAR JH                BIOSTATISTICAL ANALYSIS                  974
CT   1   WILL PC               PEDIATR RES                     14  1245 980
     2   BANCHINI G            PEDIATR RES                     15  1073 981
     3   ALBAZZAZ FJ           RESPIRATION                     46    88 984

PN 79221
RN 01201 
AN 80012536
AU Feigal-R-J.  Shapiro-B-L.
TI Altered intracellular calcium in fibroblasts from patients with
   cystic fibrosis and heterozygotes.
SO Pediatr-Res. 1979 Jun. 13(6). P 764-8.
MJ BODY-FLUIDS: me.  CALCIUM: me.  CYSTIC-FIBROSIS: me.  HETEROZYGOTE.
   INTRACELLULAR-FLUID: me.
MN CELLS-CULTURED.  CYSTIC-FIBROSIS: fg.  FIBROBLASTS: me.  HUMAN.
AB The importance of intracellular calcium (Ca) in secretion and
   transmembrane ion movement led us to study Ca in cells from patients
   with cystic fibrosis (CF) which is a lethal genetic exocrinopathy.
   Skin fibroblasts from patients with CF, obligate heterozygotes (HZ),
   and age- and sex-matched controls (C) were used in matched pair
   experiments measuring 45Ca exchange into and efflux from the cells
   over time. CF cell lines and HZ cell lines exhibit increased 45Ca
   exchange when compared with their respective controls (P less than
   0.005). The magnitude of this difference (approximately 30%) is not
   reduced when cells are washed with lanthanum chloride after the
   exchange period. This difference is likely attributable to an altered
   capacity of one or more of the intracellular Ca sequestering
   organelles. Further evidence for this explanation was seen in 45Ca
   efflux experiments in which CF cells retained a higher percent of
   their initial 0-time 45Ca than did C cells late in the efflux period
   (P less than 0.05). The finding of an altered Ca pool size in both CF
   and particularly HZ cells suggests that altered Ca metabolism is
   related to the basic gene defect in CF.
RF 001   BAUR PS               TEX REP BIOL MED                34   113 976
   002   BLOMFIELD J           ARCH DIS CHILD                  48   267 973
   003   BOGART BI             PEDIATR RES                     11   131 977
   004   BOLTON WE             TEX REP BIOL MED                34    97 976
   005   BORLE AB              METHODS ENZYMOL                 39   513 975
   006   BORLE AB              TISSUE RES SUPPL                21    21 976
   007   BOTELHO SY            J PEDIATR                       83   601 973
   008   CARAFOLI E            SOC SYMP                        39    89 974
   009   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   010   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   011   DOUGLAS WW            IN: CASE RM                              976
   012   DUNN OJ               PRIMER FOR THE BIOMED SCI                964
   013   FARRELL PM            PROC SOC EXP BIOL MED          149   340 975
   014   FLETCHER DS           CLIN CHIM ACTA                  44     5 973
   015   FOSTER DO             J BIOL CHEM                    244  2675 969
   016   GIBSON LE             PEDIATRICS                      48   695 971
   017   LEHMANN H             IN: STANBURY JB                          972
   018   LEHNINGER AL          PROC NAT ACAD SCI USA           71  1520 974
   019   LEHNINGER AL          ADV IMMUNOL                     29   259 967
   020   LOBECK CC             IN: STANBURY JB                     1605 972
   021   MANGOS JA             IN: ANDREOLI TE                          978
   022   MOORE L               J CELL PHYSIOL                  91   289 977
   023   OYAMA VI              PROC SOC EXP BIOL MED           91   305 956
   024   RASMUSSEN H           CRIT REV BIOCHEM                 1    95 972
   025   ROBBLEE LS            BIOCHIM BIOPHYS ACTA           463   448 976
   026   SHAPIRO BL            CLIN CHIM ACTA                  82   125 978
   027   VANBREEMAN C          CIRC RES                        33    44 972
   028   WOTMAN S              ARCH ORAL BIOL                  16   663 971
CT   1   SHAPIRO BL            PROC NAT ACAD SCI USA           76  2979 979
     2   ANSAH TA              CELL CALC                        1   195 980
     3   SCANLIN TF            CLIN CHEST MED                   1   424 980
     4   KATZ S                CLIN CHIM ACTA                 100   245 980
     5   ROOMANS GM            ULTRASTRUCTURAL PATHOL           2    53 981
     6   ROOMANS GM            J SUBMICROSC CYTOL              13   445 981
     7   REZNIK VM             PROC NAT ACAD SCI USA           78  7143 981
     8   SORSCHER EJ           LANCET                           1   368 982
     9   SEALE TW              ANN CLIN LAB SCI                12   415 982
    10   BOGART BI             PEDIATR RES                     16   223 982
    11   FEIGAL RJ             LIFE SCI                        30    93 982
    12   SHAPIRO BL            AM J HUM GENET                  34   846 982
    13   SHAPIRO BL            SCIENCE                        216   417 982
    14   FONDACARO JD          LIFE SCI                        32  1449 983
    15   MINER C               J PHYSIOL (LOND)               338  P 63 983
    16   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
    17   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983
    18   SEYMOUR CA            BIOESSAYS                        1    38 984
    19   KATZ S                CELL CALC                        5   421 984
    20   CABRINI G             RIV ITAL PEDIATR                10   405 984
    21   KAMOUN P              BIOCHEM MED                     31   104 984
    22   RUSSI EW              CHEST                           86   475 984
    23   GRINSTEIN S           BIOCHIM BIOPHYS ACTA           769   270 984
    24   WALLER RL             CELL CALC                        6   245 985
    25   KIRKPATRICK C         PEDIATR RES                     19  1341 985
    26   SUTER S               PEDIATR RES                     19   346 985
    27   MUALLEM S             BIOCHIM BIOPHYS ACTA           819   143 985
    28   RUPP GM               MED HYPOTHESES                  20   245 986
    29   MORRISSEY SM          DIGESTION                       34    28 986
    30   FEIGAL RJ             ANN NY ACAD SCI                488    82 986
    31   ROOMANS GM            SCANN ELECTRON MICROSC        1986   165 986

PN 79222
RN 01202 
AN 80100643
AU Van-Leuven-F.  Cassiman-J-J.  Van-Den-Berghe-H.
TI Anomalous alpha 2-macroglobulin-protease complexes in cystic
   fibrosis: decreased uptake of the complexes by fibroblasts in
   culture.
SO Pediatr-Res. 1979 Dec. 13(12). P 1384-6.
MJ ALPHA-MACROGLOBULINS: me.  CYSTIC-FIBROSIS: bl, en.
   PEPTIDE-HYDROLASES: bl.
MN FIBROBLASTS: en.  HUMAN.  MACROMOLECULAR-SYSTEMS.  TRYPSIN: bl.
AB Immunochemical and functional properties of control and Cystic
   Fibrosis (CF) alpha 2-Macroglobulin (alpha 2M) are compared. Crossed
   immunoelectrophoresis and Ouchterlony double diffusion revealed no
   qualitative differences between the two alpha 2-M preparations.
   Trypsin-esterase activity assayed with BAPNA as a substrate, in the
   presence of an excess STI, gave similar ratios between total and
   active alpha 2M. These alpha 2M-trypsin complexes were equally stable
   under various experimental conditions and maintained a constant STI
   non-inhibited esterase activity. Normal and CF-alpha 2M-trypsin
   complexes were taken up by normal human fibroblasts to a similar
   extent during a four hour period. The only significant difference was
   observed when the uptake of alpha 2M from untreated sera was
   examined. The uptake of alpha 2M from CF sera was always lower than
   from pooled control sera despite large variation. Mixing of control
   and CF serum did not affect the normal uptake and other serum
   components were taken up to the normal extent. Intracellular
   degradation of CF alpha 2M had a half life of 2.0 to 2.8 hours, which
   compares well to the normal half life of 2.2 hours. More work needs
   to be done on the nature of the interaction between alpha 2M and
   proteases before a reasonable explanation for the molecular nature of
   the abnormal behavior can be sought.
RF 001   GANROT PO             CLIN CHIM ACTA                  14   493 966
   002   ROMEO G               NATURE                         274   909 978
   003   SHAPIRA E             CLIN CHIM ACTA                  78   359 977
   004   SHAPIRA E             J BIOL CHEM                    252  7923 977
   005   SHAPIRA E             PEDIATR RES                     10   812 976
   006   STARKEY PM            IN: BARRETT AJ                       663 977
   007   VAN LEUVEN F          EXP CELL RES                   117   273 978
   008   VAN LEUVEN F          J BIOL CHEM                    254  5160 979
   009   VAN LEUVEN F          EXP CELL RES                   109   468 977
   010   WILSON GB             PEDIATR RES                     10    87 976
CT   1   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      93    50 980
     2   HUBBARD WJ            J IMMUNOL                      126   292 981
     3   VANLEUVEN F           J BIOL CHEM                    256  9016 981
     4   BLITZER MG            J PEDIATR GASTROENTEROL NUTR     1   289 982
     5   WILSON GB             MED HYPOTHESES                   8   527 982
     6   BACK SA               BIOCHEM MED                     30    34 983
     7   BRIDGES MA            ANN NY ACAD SCI                421   360 983
     8   MARYNEN P             ANN NY ACAD SCI                421   401 983
     9   SHAPIRA E             ANN NY ACAD SCI                421   352 983
    10   VANLEUVEN F           ANN NY ACAD SCI                421   434 983
    11   MARYNEN P             BIOCHIM BIOPHYS ACTA           799   187 984
    12   VANLEUVEN F           J IMMUNOL METH                  90   125 986
    13   VANLEUVEN F           J BIOL CHEM                    261  1369 986

PN 79223
RN 01203 
AN 80055675
AU Thomassen-M-J.  Boxerbaum-B.  Demko-C-A.  Kuchenbrod-P-J.
   Dearborn-D-G.  Wood-R-E.
TI Inhibitory effect of cystic fibrosis serum on pseudomonas
   phagocytosis by rabbit and human alveolar macrophages.
SO Pediatr-Res. 1979 Sep. 13(9). P 1085-8.
MJ CYSTIC-FIBROSIS: bl.  MACROPHAGES: ph.  PHAGOCYTOSIS.
   PSEUDOMONAS-AERUGINOSA: cy.
MN ADOLESCENCE.  ADULT.  AGGLUTINATION.  ANIMAL.
   ANTIBODIES-BACTERIAL: an.  CHILD.  CHILD-PRESCHOOL.  HUMAN.  INFANT.
   LUNG: cy, mi.  RABBITS.  SUPPORT-U-S-GOVT-P-H-S.
AB This report presents experimental observations indicating the
   presence of an inhibitory activity in cystic fibrosis (CF) serum
   which impairs phagocytosis of Pseudomonas aeruginosa by rabbit as
   well as human alveolar macrophages. Of the 49 patient serum samples
   studied, 40 consistently showed greater than or equal to 60%
   inhibition, 3 showed no inhibition and 6 were in the range of 20-60%
   inhibition of Pseudomonas phagocytosis. In parallel studies, the
   phagocytosis of S. aureus and S. marcescens was found not to be
   inhibited by CF serum. Mixing of CF serum with normal serum could not
   overcome the inhibitory effect, indicating the presence of an
   inhibitory factor rather than the lack of a necessary component. The
   inhibitory activity is not lost upon exposure of serum to glass, upon
   freezing the serum once, or upon heating at 56 degrees C for 30
   minutes.
RF 001   BIGGAR WD             PROC NAT ACAD SCI USA           68  1716 971
   002   BOXERBAUM B           AM REV RESPIR DIS              108   777 973
   003   BRAIN JD              J APPL PHYSIOL                  34    75 973
   004   DI SANTAGNESE PA      N ENGL J MED                   295   534 976
   005   DI SANTAGNESE PA      N ENGL J MED                   295   597 976
   006   DOERSHUK CF           IN: GREEN M                          707 968
   007   DOERSHUK CF           PEDIATRICS                      36   675 965
   008   GREEN GM              J EXP MED                      119   167 964
   009   HENNEY CS             SCIENCE                        169   696 970
   010   HOIBY N               ACTA PATH MICROBIOL SCAND (C) S262     1 977
   011   KOSKI IR              IN: BLOOM BR                             976
   012   MAY JR                ARCH DIS CHILD                  47   908 972
   013   MYRVIK QN             J IMMUNOL                       86   128 961
   014   NETER E               J INFECT DIS SUPPL             130   132 974
   015   REYNOLDS HY           J CLIN INVEST                   59   165 977
   016   REYNOLDS HY           J CLIN INVEST                   56   376 975
   017   SHWACHMAN H           PEDIATRICS                      36   689 965
   018   SORENSEN RU           INFECT IMMUN                    18   735 977
   019   SORENSEN RU           J PEDIATR                       93   201 978
   020   WALDMAN RH            J EXP MED                      134   482 971
CT   1   DEMKO CA              CURRENT MICROBIOL                4    69 980
     2   CASSINO RJJ           PEDIATR RES                     14  1212 980
     3   SEALE TW              PEDIATR RES                     14  1398 980
     4   THOMASSEN MJ          PEDIATR RES                     14   715 980
     5   FICK RB               J IMMUNOL METH                  38   103 980
     6   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
     7   FICK RB               CLIN CHEST MED                   2    91 981
     8   SORENSEN RU           PEDIATR RES                     15    14 981
     9   THOMASSEN MJ          INFECT IMMUN                    33   512 981
    10   FICK RB               J CLIN INVEST                   68   899 981
    11   LEWISTON NJ           CHEST                           80   389 981
    12   MARKS MI              J PEDIATR                       98   173 981
    13   MOSS RB               J PEDIATR                       99   215 981
    14   KONSTAN MW            AM REV RESPIR DIS              123   120 981
    15   SORENSEN RU           AM REV RESPIR DIS              123    37 981
    16   VANGEFFEL R           ANN IMMUNOL (PARIS)           D133   293 982
    17   SORDELLI DO           CLIN IMMUNOL IMMUNOPATHOL       22   153 982
    18   WOODS DE              INFECT IMMUN                    36  1223 982
    19   HOOKE AM              INFECT IMMUN                    38   136 982
    20   THOMASSEN MJ          INFECT IMMUN                    38   802 982
    21   WINNIE GB             INFECT IMMUN                    38  1088 982
    22   HARPER TB             AM REV RESPIR DIS              126   540 982
    23   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    33 982
    24   SCHIOTZ PO            ACTA PAEDIATR SCAND SUPPL 301 1982    55 982
    25   WINNIE GB             CURRENT MICROBIOL                9    63 983
    26   GOLD R                J ANTIMICROB CHEMOTHER          12   331 983
    27   SCHILLER NL           PEDIATR RES                     17   747 983
    28   FICK RB               BULL EUR PHYSIOPATH RESP        19   151 983
    29   THOMASSEN MJ          J LEUKOCYTE BIOL                35   345 984
    30   THOMASSEN MJ          INFECT IMMUN                    45   741 984
    31   PIER GB               J INFECT DIS                   150   223 984
    32   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985
    33   SHRYOCK TR            CURRENT MICROBIOL               12    91 985
    34   KLEIN TW              MICROBIOL IMMUNOL               29   671 985
    35   REYNOLDS HY           DISEASE A MONTH                 31     1 985
    36   SHERMAN JM            J PEDIATR                      106   126 985
    37   PIER GB               J INFECT DIS                   151   575 985
    38   MOSS RB               MONOGR ALLERGY                  19   202 986
    39   MOSS RB               PEDIATR RES                     20   453 986
    40   SHRYOCK TR            J CLIN MICROBIOL                23   513 986
    41   FICK RB               AM REV RESPIR DIS              133   418 986
    42   SHRYOCK TR            CURRENT MICROBIOL               14   251 987

PN 79224
RN 01204 
AN 80055648
AU Pivetta-O-H.  Labal-M-L.  Sordelli-D-O.
TI Serum ciliotoxic activity in mutant mice with some hereditary
   alterations resembling cystic fibrosis.
SO Pediatr-Res. 1979 Oct. 13(10). P 1160-2.
MJ CILIA: ph.  CYSTIC-FIBROSIS: bl.  SPERM-TAIL: ph.  SPERMATOZOA: ph.
MN ANIMAL.  CYSTIC-FIBROSIS: fg.  FEMALE.  HETEROZYGOTE.  HOMOZYGOTE.
   HUMAN.  MALE.  MICE.  MICE-INBRED-BALB-C.  MICE-INBRED-C57BL.
   MICE-INBRED-DBA.
AB Serum ciliotoxic activity (SCA), which had been described in cystic
   fibrosis (CF), was studied in mutant mice with some hereditary
   alterations resembling this inherited disease. A test was developed
   to detect SCA in biologic fluids by means of a natural vibratile
   system; it consisted in the incubation of mouse sperm with different
   CF serum dilutions under controlled conditions, in order to determine
   the sperm translation cessation time (STCT) and the sperm activity
   cessation time (SACT). As the findings of this study were similar to
   those obtained by other authors who have been employing alternative
   systems, it was decided to apply this method on mice serum. Sera were
   obtained from male and female 3- to 4-wk-old mice of DBA/2J-cri,
   C57BL/6J-bgJ, and BALB/c inbred strains; SCA was investigated in
   affected homozygotes and their +/? siblings were used as controls.
   Male 8- to 16-wk-old BALB/c mice were employed as sperm donors.
   Significant differences were found between cri/cri and +/? mice of
   the DBA/2J-cri strain in both STCT and SACT determinations at 1/10
   serum dilution. It is concluded that mouse sperm is a system
   sensitive enough to detect SCA in biologic fluids from human beings.
   Likewise, the test of the mouse sperm allowed us to detect SCA in
   cri/cri mice, turning this mutation into a possible animal model for
   CF.
RF 001   BESLEY GTN            J MED GENET                      6   278 969
   002   BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      64  1310 975
   003   BOWMAN BH             SCIENCE                        164   325 969
   004   BOWMAN BH             SCIENCE                        167   871 970
   005   COHEN FL              J MED GENET                     11   253 974
   006   CONOVER JH            LANCET                           1  1194 973
   007   DANES BS              J EXP MED                      136  1313 972
   008   DANKS DM              ANN HUM GENET                   28   323 965
   009   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   010   DIXON WJ              BIOMETRICS                       9    74 953
   011   DOGGETT RG            TEX REP BIOL MED                31   685 973
   012   GREEN MC              SCIENCE                        176   800 972
   013   KAISER D              LIFE SCI                        15   803 974
   014   LANE PW               GENETICS                        72   451 972
   015   PIVETTA OH            MEDICINA                        37   379 977
   016   PIVETTA OH            EFECTO DEL SUERO DE MUTACIONE            975
   017   PIVETTA OH            PEDIATR RES                     11  1133 977
   018   SPOCK A               PEDIATR RES                      1   173 967
   019   WILSON GB             LIFE SCI                        15   551 974
   020   WOOD RE               AM REV RESPIR DIS              113   833 976
   021   WOOD RE               LANCET                           2  1452 973
CT   1   PIVETTA OH            LIFE SCI                        26  1349 980
     2   PIVETTA OH            LIFE SCI                        28  2207 981
     3   CERQUETTI MC          IMMUNOL COMMUN                  12   375 983
     4   CATANZARO OL          LIFE SCI                        32   825 983

PN 79225
RN 01205 
AN 80055663
AU Romeo-G.  Parsons-M.  Bossen-A.  Blessing-Moore-J.
   Cavalli-Sforza-L-L.
TI Binding of 125I-labeled proteinases to plasma proteins in cystic
   fibrosis.
SO Pediatr-Res. 1979 Sep. 13(9). P 1030-6.
MJ BLOOD-PROTEINS: me.  CYSTIC-FIBROSIS: bl.
   PEPTIDE-PEPTIDOHYDROLASES: bl.  TRYPSIN: bl.
MN ALPHA-MACROGLOBULINS: me.  ARGININE.
   ELECTROPHORESIS-POLYACRYLAMIDE-GEL.  ESTERASES: bl.  HUMAN.  IGG: me.
   IMMUNOELECTROPHORESIS.  IODINE-RADIOISOTOPES.  PROTEIN-BINDING.
   SUPPORT-U-S-GOVT-P-H-S.
AB Samples of plasma or serum from 53 cystic fibrosis (CF) patients, 90
   relatives of CF patients , and 159 controls have been incubated with
   porcine or bovine 125I-trypsin, electrophoresed on polyacrylamide
   gel, and autoradiographed. In these individuals, the main binding
   protein for 125I-trypsin has been shown to be alpha 2-macroglobulin
   (alpha 2M). Using this method of analysis, no difference in
   electrophoretic migration of 125I-trypsin-alpha 2M complexes has been
   observed between CF and control individuals. However, trypsin binding
   to IgG has been observed in 80% of CF patients, 30% of their mothers,
   3% of controls, and in two patients affected with pancreatitis. These
   trypsin binding immunoglobulins are called TbIg, and specifically,
   Tb1gG when referring to the G class. Experimental evidence indicates
   that binding of trypsin to IgG occurs through the Fab portion of the
   molecule. Tb1gG must be antibodies most probably induced by the
   exogenous trypsin ingested daily by most CF patients (and by patients
   affected with chronic pancreatitis). Antibodies against porcine
   pancreatic elastase have been observed using the same analysis, but
   not as frequently as Tb1g.
RF 001   AARON R               IMMUNOCHEMISTRY                  3   451 966
   002   BORGSTROM A           SCAND J CLIN LAB INVEST         36   809 976
   003   CHAN KYH              CLIN CHIM ACTA                  74    71 977
   004   DAIGER S              PROC NAT ACAD SCI USA           72  2076 975
   005   DANES BS              J EXP MED                      137  1538 973
   006   DEBANNE MT            BR J EXP PATHOL                 54   571 973
   007   DOERSHUK CF           J PEDIATR                       65   677 964
   008   DOLAN TF JR           AM REV RESPIR DIS              110   812 974
   009   ELIAS E               LANCET                           2    66 977
   010   ERICKSON RP           IMMUNOCHEMISTRY                 11    41 974
   012   GIBBONS RA            BIOCHIM BIOPHYS ACTA           444     1 976
   013   GOLDSMITH GH          J LAB CLIN MED                  89   131 977
   014   HUNTER WM             NATURE                         194   495 962
   015   KEIL B                IN: BOYER PD                     3   249 971
   016   LAURELL CB            ANAL BIOCHEM                    10   358 965
   017   LIEBERMAN J           AM REV RESPIR DIS              109   399 974
   018   MURRAY MJ             ANN INTERN MED                  53   548 960
   019   OHLSSON K             ACTA PHYSIOL SCAND              81   269 971
   020   OUCHTERLONY O         IN: WEIR DM                              978
   021   OWEN JA               NATURE                         182  1373 958
   022   RAO GJS               PEDIATR RES                      8   684 974
   023   ROMEO G               AM J HUM GENET                  29   92A 977
   024   SCHROEDER DD          J BIOL CHEM                    243   294 968
   025   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      71   864 976
   026   SHAPIRA E             PEDIATR RES                     10   812 976
   027   STANWORTH DR          IN: WEIR DM                      6     1 978
   028   STEIN AA              J PEDIATR                       65   495 964
   029   TALAMO RC             PEDIATR RES                      6   430 972
   030   TWAROG FJ             J ALLERGY CLIN IMMUNOL          59    35 977
   031   WALSH-PLATT M         AM J HUM GENET                  29  111A 977
   032   WILSON GB             PEDIATR RES                     10    87 976
   033   YUNG BY               BIOCHEM BIOPHYS RES COMMUN      65   927 975
CT   1   DENARO M              PEDIATR RES                     14  1086 980
     2   ROMEO G               J LAB CLIN MED                  95   116 980
     3   PARSONS M             CLIN CHIM ACTA                 100   215 980
     4   THOMAS JM             CLIN CHIM ACTA                 111   199 981
     5   COX KL                J PEDIATR GASTROENTEROL NUTR     1   345 982
     6   ROBERTS RC            PEDIATR RES                     16   416 982
     7   BRIDGES MA            ANN NY ACAD SCI                421   360 983
     8   SHAPIRA E             ANN NY ACAD SCI                421   352 983

PN 79226
RN 01206 
AN 80055671
AU Wolf-R-O.  Taussig-L.
TI Serum salivary amylase in cystic fibrosis [letter].
SO Pediatr-Res. 1979 Sep. 13(9). P 1076-7.
MJ AMYLASES: an.  CYSTIC-FIBROSIS: en.  ISOENZYMES: an.  SALIVA: en.
MN AMYLASES: bl.  HUMAN.  ISOENZYMES: bl.
EX We found that cystic fibrosis (CF) patients with pancreatic
   insufficiency (PI) had a statistically lower total serum amylase
   level than normal subjects, but all values were still within the
   normal range.  Although we found that the absolute amount of salivary
   amylase, in the serum of patients with CF and PI, was the same as
   that for normal subjects, the percent of contribution was
   considerably higher.  We found that the pancreas contributed
   approximately 23% of the total serum amylase in CF patients with PI,
   a value very similar to the 34% amount found by Kamaryt et al.  We
   also found, as did Davidson et al., that CF patients without PI had
   higher total serum amylase values than did normal subjects.  Thus,
   we feel that Davidson et al. have misinterpreted the results of our
   previous study and, in fact, we feel that Davidson et al. have
   essentially confirmed our previous work by suggesting that CF
   patients with pancreatic insufficiency have an increased salivary
   amylase for reasons yet unknown.  Our experience has shown that,
   indeed, the pancreatic portion is first increased and then decreases
   as the patient with CF and apparent normal pancreatic function
   progresses, with time, toward pancreatic insufficiency.  However, the
   changes in serum amylase values in patients with CF are on the
   average due to changes in the pancreatic contribution to the serum
   and as expressed as a mean was highly significantly different for
   both normal and abnormal pancreatic function.  The second important
   point of our paper was that this mean variation occurred in serum
   samples from patients with CF that had total amylase values within
   the normal test range.  The serum salivary isoamylase in both normals
   and patients with CF and PI had a higher serum salivary percent.
RF 001   SKUDE G               SCAND J GASTROENTEROL           10   577 975
   001   DAVIDSON GP           PEDIATR RES                     12   967 978
   002   WOLF RO               J LAB CLIN MED                  87   164 976
   002   HUBBARD VS            J PEDIATR                       92   685 978
   003   KAMARYT J             CESK PEDIATR                    25    78 970
   004   WOLF RO               J LAB CLIN MED                  87   164 976
CT   1   MCGEENEY KF           PEDIATR RES                     14   967 980

PN 79227
RN 01207 
AN 79157701
AU Gabridge-M-G.  Bright-M-J.  Agee-C-C.  Nickerson-J-M.  Henderson-N-S.
TI Development of an improved tracheal explant bioassay for the
   detection of the ciliary dyskinesia factor in cystic fibrosis serum.
SO Pediatr-Res. 1979 Jan. 13(1). P 31-5.
MJ CILIA: de.  CYSTIC-FIBROSIS: bl.  CYTOTOXINS: pd.  TRACHEA: de.
MN ANIMAL.  CILIA: ph.  COMPARATIVE-STUDY.  CULTURE-MEDIA.  FEMALE.
   GUINEA-PIGS.  HAMSTERS.  HUMAN.  MALE.  MOVEMENT.  MUCUS: de.
   ORGAN-CULTURE: mt.  RABBITS.  RATS.  TRACHEA: ul.
   SUPPORT-U-S-GOVT-P-H-S.
AB A tracheal ring explant system, when used with 25% cystic fibrosis
   (CF) serum, displayed obvious ciliostasis. Hamster, rabbit, and
   guinea pig explants all had measurable decreases in ciliary activity
   after 24 hr of incubation in the serum. The differential response to
   CF serum (relative to normal serum) was greatly increased by using
   explants which were maintained 24-72 hr in minimal essential medium
   (MEM) with 10% horse serum and which were selected on the basis of
   optimal ciliary activity and vigor. With such a bioassay system of
   guinea pig tracheal explants, incubation with 25% normal serum would
   produce essentially no change in relative ciliary activity (score of
   242 of a possible 300), whereas CF serum resulted in an 86% decrease
   (score of 33). Scanning electron microscopic observation indicated
   that the explants displaying the CF-ciliostatic effect had
   significant accumulations of mucous over the ciliated epithelial
   surface. A biochemical viability assay (dehydrogenase activity)
   showed no cytonecrosis when CF serum-treated tissues were compared to
   standard explants (10% horse serum in MEM) or control explants (25%
   normal human serum).
RF 001   ARAD I                ISR J MED SCI                   11    10 975
   002   BARGMAN GJ            TEX REP BIOL MED                34    37 976
   003   BAUR PS               TEX REP BIOL MED                34   155 976
   004   BERATIS NG            PEDIATR RES                      7   958 973
   005   BOWMAN BH             LIFE SCI                        19  1289 976
   006   BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      64  1310 975
   007   CHANGUS JE            ARCH PATHOL LAB MED            100     7 976
   008   CHERRY JD             ANN NY ACAD SCI                225   290 973
   009   CHEUNG ATW            PEDIATR RES                     10   144 976
   010   CHEUNG ATW            PEDIATR RES                     10   144 976
   011   CONOVER JH            PEDIATR RES                      7   224 973
   012   CONOVER JH            PEDIATR RES                      7   220 973
   013   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   014   FORSTNER GG           CAN MED ASSOC J                113   550 975
   015   GABRIDGE MG           IN: EVANS V                      1       976
   016   GABRIDGE MG           J CLIN MICROBIOL                 3   560 976
   017   GABRIDGE MG           INFECT IMMUN                    10  1127 974
   018   GABRIDGE MG           IN VITRO                        13   510 977
   019   GABRIDGE MG           INFECT IMMUN                    13    84 976
   020   POLLEY MJ             J MED GENET                     11   249 974
   021   SPOCK A               PEDIATR RES                      1   173 967
   022   WOOD RE               AM REV RESPIR DIS              113   833 976
   023   YEATES DB             ARCH DIS CHILD                  51    28 976
CT   1   KENNEDY JR            PEDIATR RES                     14  1173 980
     2   GABRIDGE MG           IN VITRO                        17   847 981
     3   TEGNER H              ACTA PAEDIATR SCAND             70   629 981
     4   GABRIDGE MG           ENVIRON HEALTH PERSPECT         44   189 982
     5   VONEULER AM           ULTRASTRUCTURAL PATHOL           5    37 983
     6   MA DI                 LIFE SCI                        32  2849 983
     7   RUTLAND J             AM REV RESPIR DIS              128  1030 983
     8   ROOMANS GM            SCANN ELECTRON MICROSC        1983   697 983
     9   SANDERSON MJ          CELL MOTIL                       4   103 984
    10   RUDICK VL             J CELL PHYSIOL                 118    67 984
    11   WOOTEN MW             J CELL PHYSIOL                 121   490 984
    12   WOOTEN MW             IN VITRO CELL DEVEL BIOL        21   207 985
    13   HINGLEY ST            INFECT IMMUN                    51   254 986

PN 79228
RN 01208 
AN 79157717
AU Verdugo-P.  Hinds-T-R.  Vincenzi-F-F.
TI Laser light-scattering spectroscopy: preliminary results on bioassay
   of cystic fibrosis factor(s).
SO Pediatr-Res. 1979 Feb. 13(2). P 131-5.
MJ BIOLOGICAL-ASSAY: mt.  CILIA: ph.  CYSTIC-FIBROSIS: bl.  LASERS.
   SPECTRUM-ANALYSIS: mt.
MN CHILD.  EPITHELIUM.  HUMAN.  MOVEMENT.  SCATTERING-RADIATION.
   TRACHEA.  SUPPORT-U-S-GOVT-P-H-S.
AB The effect of 7 cystic fibrosis sera and 4 normal sera was
   investigated in 37 cultures of ciliated epithelium of the rabbit
   trachea. Serum was introduced in the Rose culture chambers in a
   concentration of 10% by volume. The frequency of ciliary beat was
   monitored by laser light-scattering spectroscopy. The results show
   that the response of cilia to sera can be well characterized by laser
   light scattering. Our preliminary evidence suggests that an early
   increase in the frequency of ciliary beat, followed by rapid arrest
   of ciliary activity, is a sensitive and characteristic response
   produced by cystic fibrosis serum, and not by normal serum.
RF 001   BERGE P               C R ACAD SCI (D)(PARIS)        256   889 967
   002   BESLEY GTN            J MED GENET                      6   278 969
   003   BOGART BI             PEDIATR RES                     11   131 977
   004   BOWMAN BH             IN: MANGOS JA                        277 976
   005   BOWMAN BH             SCIENCE                        164   325 969
   006   CHEUNG ATW            PEDIATR RES                     10   144 976
   007   CONOVER JH            PEDIATR RES                      7   220 973
   008   CONOVER JH            LANCET                           2  1362 976
   009   DOGGETT RG            NATURE NEW BIOL                243   250 973
   010   DUBIN SB              PROC NAT ACAD SCI USA           57  1164 967
   011   ECKERT R              J PHYSIOL (LOND)               226   699 972
   012   LEE WI                BIOPHYS J                       16  1109 976
   013   LEE WI                ANN BIOMED ENG                   5   248 977
   014   LEE WI                BIOPHYS J                       16   120 976
   015   NOSSAL R              J PHYSIQUE COLL CL              33   171 972
   016   RUMERY RE             IN: DANIEL JC JR                         970
   017   SPOCK A               PEDIATR RES                      1   173 967
   018   VERDUGO P             J CELL BIOL                     75   293 977
   019   WILSON GB             PEDIATR RES                     11   143 977
CT   1   KENNEDY JR            PEDIATR RES                     14  1173 980
     2   VERDUGO P             FERTIL STERIL                   33   193 980
     3   VERDUGO P             J APPL PHYSIOL                  48   868 980
     4   WILSON GB             J CLIN INVEST                   66  1010 980
     5   SANDERSON MJ          PEDIATR RES                     15   219 981
     6   BOGART BI             PEDIATR RES                     16   223 982
     7   MCNEELY MC            PEDIATR RES                     16    21 982
     8   DULFANO MJ            THORAX                          37   646 982
     9   HARD R                TISSUE CELL                     15   217 983
    10   RUTLAND J             AM REV RESPIR DIS              128  1030 983
    11   KATZ S                CELL CALC                        5   421 984
    12   SANDERSON MJ          CELL MOTIL                       5   267 985
    13   BRAGA PC              J PHARMACOL METHODS             16   161 986
    14   HINGLEY ST            INFECT IMMUN                    51   254 986

PN 79229
RN 01209 
AN 80100639
AU Tucker-R-D.  Gibbs-G-E.  Christensen-M-B.
TI Cystic fibrosis serum effect on the short circuit current of rat
   jejunum.
SO Pediatr-Res. 1979 Dec. 13(12). P 1371-4.
MJ CYSTIC-FIBROSIS: bl.
MN ANIMAL.  CELL-MEMBRANE: me.  COMPARATIVE-STUDY.  CYSTIC-FIBROSIS: fg.
   GENOTYPE.  HUMAN.  JEJUNUM: bs.  MALE.  MEMBRANE-POTENTIALS.  RATS.
AB Sera from 100 subjects were tested for the presence of the cystic
   fibrosis (CF) "factor" utilizing the short circuit current rat
   jejunum bioassay. Comparing the mean percent decrease in short
   circuit current, the presumed normal group differs from the
   homozygous CF group at P = 0.001 and from the heterozygous group at P
   = 0.05. The two CF genotypes are statistically different at P =
   0.004. There is, however, a large overlap among the three groups,
   which limits the assay's utility as a guide for factor purification
   as well as clinical use.
RF 001   ARAKI H               PEDIATR RES                      9   932 975
   002   ARAKI H               PROC INT CF CONG 7TH                  28 976
   003   BESLEY GTN            J MED GENET                      6   278 969
   004   BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      64  1310 975
   005   BOWMAN BH             SCIENCE                        164   325 969
   006   CHERRY JD             J PEDIATR                       79   937 971
   007   CONOVER JH            LANCET                           1  1194 973
   008   GILMORE JP            PROC SOC EXP BIOL MED          157    70 978
   009   MANGOS JA             PEDIATR RES                      1   436 967
   010   POSSELT HG            Z KINDERHEILK                  110    93 971
   011   SPOCK A               PEDIATR RES                      1   173 967
   012   USSING HH             ACTA PHYSIOL SCAND              61   484 964
CT   1   TUCKER RD             COMPUT BIOL MED                 11   153 981
     2   ALBAZZAZ FJ           RESPIRATION                     46    88 984
     3   VONEULER AM           EXP MOL PATH                    43   142 985

PN 79230
RN 01210 
AN 80055672
AU Tully-G-W.  Nevin-G-B.  Young-I-R.  Nevin-N-C.
TI Detection of cystic fibrosis protein by isoelectric focusing of
   serum [letter].
SO Pediatr-Res. 1979 Sep. 13(9). P 1078.
MJ BLOOD-PROTEINS: an.  CYSTIC-FIBROSIS: bl.  ISOELECTRIC-FOCUSING.
MN HUMAN.
EX Several cystic fibrosis research groups have independently attempted
   to reproduce the isoelectric focusing work of Wilson et al.  The
   protocol that we employed with the LKB Mulitphor electrofocusing
   apparatus was that of Wilson et al., although fixing and staining of
   the polyacrylamide gels was performed in a boiling water bath for 30
   min.  In 10 of 11 sera from patients with CF, the cystic fibrosis
   protein band was directly identified by each of two independent
   observers and in the sera from nine obligate heterozygote
   individuals, the CFP band was noted in seven and eight instances by
   each observer, respectively.  In sera from 26 normal control
   individuals, the CFP band was observed in two instances.  Our results
   would support the view that the CFP band is indeed directly
   identifiable in both CT heterozygote and homozygote sera without
   recourse to photographic image enhancement and that its frequency of
   occurrence is similar to that reported previously.
RF 001   ALTLAND K             HUMANGENETIK                    28   207 975
   002   BEARN AG              N ENGL J MED                   286   764 972
   003   DANES BS              CLIN GENET                      11    83 977
   004   POLLEY MJ             J MED GENET                     11   249 974
   005   SCHOLEY J             PEDIATR RES                     12   800 978
   006   SMITH QT              PEDIATR RES                     10   999 976
   007   THOMAS JM             PEDIATR RES                     11  1148 977
   009   WILSON GB             PEDIATR RES                     11   986 977
   010   WILSON GB             PEDIATR RES                     12   801 978
   011   WILSON GB             PEDIATR RES                      9   635 975
CT   1   TARNOKY AL            J ROY SOC MED                   73    73 980
     2   NEVIN GB              HUM GENET                       56   387 981
     3   HEELEY AF             CLIN CHEM                       29  2011 983
     4   JAMIESON A            HUM GENET                       70   168 985
     5   GETLIFFE KA           J INHERIT METAB DIS              9   348 986

PN 79231
RN 01211 
AN 80055673
AU Wilson-G-B.
TI Cystic fibrosis protein, a confirmed diagnostic marker for detecting
   heterozygote carriers: significance in relation to future screening
   and to a proposed primary defect in alpha 2-macroglobulin.
SO Pediatr-Res. 1979 Sep. 13(9). P 1079-81.
MJ ALPHA-MACROGLOBULINS: me.  BLOOD-PROTEINS: an.  CYSTIC-FIBROSIS: bl.
   HETEROZYGOTE-DETECTION.
MN CYSTIC-FIBROSIS: di, fg.  GENETIC-SCREENING.  HUMAN.
   ISOELECTRIC-FOCUSING.  SUPPORT-U-S-GOVT-P-H-S.
EX The fact that alpha2-macroglobulin and cystic fibrosis CDA are made
   by fibroblasts and monocytes points to the fact that these markers
   and the CF protein will be of value for the detection of the CF gene
   antenatally.  Screening for CFP and CF-CDA by isoelectric focusing or
   radioimmunoassay in conjunction with quantitation of the functional
   capacity of A2M could distinguish a fetus homozygous from one
   heterozygous for the CF gene.
RF 001   ASHWELL G             ADV ENZYM MOLEC BIOL            41    99 974
   002   DANES BS              TEX REP BIOL MED                34   135 976
   003   DANN LG               LANCET                           2   405 978
   004   HOVY M                J EXP MED                      145  1580 977
   005   ANON                  J PEDIATR                       88   711 976
   006   LOUISOT P             CLIN CHIM ACTA                  48   373 973
   007   MOSHER DF             J EXP MED                      143   462 976
   008   NADLER HL             IN: STANBURY JB                     1683 978
   009   OHLSSON K             CLIN SCI MOL MED                51    87 976
   010   RAO GJS               PEDIATR RES                     11   981 977
   011   SCHOLEY J             PEDIATR RES                     12   800 978
   012   SHAPIRA E             BIOCHEM BIOPHYS RES COMMUN      71   864 976
   013   SHAPIRA E             PEDIATR RES                     10   812 976
   014   SMITH QT              PEDIATR RES                     10   999 976
   015   THOMAS JM             CF CLUB ABST                    17    19 976
   016   THOMAS JM             PEDIATR RES                     11  1148 977
   017   TULLY GW              PEDIATR RES                     13  1078 979
   019   WILSON GB             PEDIATR RES                     11   986 977
   021   WILSON GB             TEX REP BIOL MED                34    51 976
   022   WILSON GB             PEDIATR RES                     10    87 976
   023   WILSON GB             NATURE                         266   463 977
   024   WILSON GB             PEDIATR RES                     12   801 978
   025   WILSON GB             J LAB CLIN MED                  92   463 978
   026   WILSON GB             PEDIATR RES                      9   635 975
   027   WILSON GB             PEDIATR RES                     11   139 977
   028   WOLFF J               ENDOCRINOLOGY                  101  1767 977
   029   ANON                  GENETIC SCREENING PROG PRIN A            975
   030   ANON                  GAP CONF REP PROB REPRO PHYSI            975
CT   1   MANSON JC             LANCET                           1   330 980
     2   WILSON GB             LANCET                           2   313 980
     3   WILSON GB             J CLIN INVEST                   66  1010 980
     4   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
     5   FREZAL J              ARCH FR PEDIATR                 38   217 981
     6   WILSON GB             J CLIN INVEST                   68   171 981
     7   HALLINAN FM           CLIN CHIM ACTA                 117   103 981
     8   HUBBARD WJ            J IMMUNOL                      126   292 981
     9   WILSON GB             MED HYPOTHESES                   8   527 982
    10   BLITZER MG            PEDIATR RES                     16   203 982
    11   BULLOCK S             CLIN GENET                      21   336 982
    12   BROCK DJH             HUM GENET                       60    30 982
    13   BURY AF               CLIN CHIM ACTA                 118    45 982
    14   HEELEY AF             CLIN CHEM                       29  2011 983
    15   BRIDGES MA            ANN NY ACAD SCI                421   360 983
    16   GRATAROLI R           PEDIATR RES                     18   130 984
    17   ANON                  LANCET                           2   249 985
    18   LAROCHE D             J PEDIATR GASTROENTEROL NUTR     5   404 986

PN 79232
RN 01212 
AN 80012528
AU Nagy-E-C.  Khan-S.  Sturgess-J-M.
TI Serum factor in cystic fibrosis: correlation with clinical
   parameters.
SO Pediatr-Res. 1979 Jun. 13(6). P 729-32.
MJ CYSTIC-FIBROSIS: bl.  PEPTIDES: bl.
MN ADOLESCENCE.  ADULT.  ANIMAL.  BIOLOGICAL-ASSAY.  CARBON-DIOXIDE: bl.
   CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: en.  FEMALE.
   GALACTOSYLTRANSFERASES: bl.  HUMAN.  INFANT.  MALE.  OXYGEN: bl.
   RABBITS.  RESPIRATORY-FUNCTION-TESTS.  TRACHEA.
AB The relationship between the activity of the cystic fibrosis serum
   ciliary dyskinesia factor, detected by the rabbit tracheal bioassay,
   and clinical status of the patient has been investigated in children,
   1-24 years old, with cystic fibrosis. No significant correlation was
   found between the amount of serum factor activity and age, clinical
   status assessed by the Schwachman score, pulmonary function (vital
   capacity, functional residual capacity, total lung capacity, residual
   volume, maximum breathing capacity, maximal midinspiratory flow, and
   maximal midexpiratory flow) or blood gas levels (pCO2, pO2). The
   activity showed no significant relationship to serum
   galactosyltransferase activity in children with cystic fibrosis.
RF 001   ADSHEAD PC            ANN NY ACAD SCI                253   192 975
   002   ARAKI H               PEDIATR RES                      9   932 975
   003   BAKER AP              IN: FALKNER F                   19       977
   004   BAUR PS               TEX REP BIOL MED                34   155 976
   005   BERATIS NG            PEDIATR RES                      7   958 973
   006   BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      64  1310 975
   007   BOWMAN BH             SCIENCE                        164   325 969
   008   CONOVER JH            PEDIATR RES                      7   224 973
   009   CZEGLEDY-NAGY E       LAB INVEST                      35   588 976
   010   DOGGETT RG            NATURE NEW BIOL                243   251 973
   011   LOUISOT P             CLIN CHIM ACTA                  48   373 973
   012   MANGOS JA             PEDIATR RES                      2   378 968
   013   RAO GJS               PEDIATR RES                     11   981 977
   014   SANCHIS J             N ENGL J MED                   289   749 974
   015   SINGER L              CLIN BIOCHEM                     7   146 974
   016   SPOCK A               PEDIATR RES                      1   173 967
   017   STURGESS JM           IN: FALKNER F                   19       977
   018   WARWICK WJ            CF CLUB ABST                    18    91 977
   019   WILSON GB             PEDIATR RES                     11   986 977
   020   WOOD RE               AM REV RESPIR DIS              113   833 976
   021   WOOD RE               AM REV RESPIR DIS              111   733 975
   022   YEATES DB             ARCH DIS CHILD                  51    28 976
CT   1   SORENSEN RU           PEDIATR RES                     15    14 981
     2   RUTLAND J             AM REV RESPIR DIS              128  1030 983
     3   WOOTEN MW             J CELL PHYSIOL                 121   490 984
     4   WOOTEN MW             IN VITRO CELL DEVEL BIOL        21   207 985

PN 79233
RN 01213 
AN 79246210
AU Chase-H-P.  Cotton-E-K.  Elliott-R-B.
TI Intravenous linoleic acid supplementation in children with cystic
   fibrosis.
SO Pediatrics. 1979 Aug. 64(2). P 207-13.
MJ CYSTIC-FIBROSIS: dh.  LINOLEIC-ACIDS: tu.
MN ARACHIDONIC-ACIDS: bl.  BODY-HEIGHT.  BODY-WEIGHT.  CALORIC-INTAKE.
   CHILD.  CHILD-PRESCHOOL.  CLINICAL-TRIALS.  CYSTIC-FIBROSIS: pa, pp.
   HUMAN.  FAT-EMULSIONS-INTRAVENOUS: tu.  LINOLEIC-ACIDS: bl.
   PLACEBOS.  RESPIRATORY-FUNCTION-TESTS.  SKINFOLD-THICKNESS.
   SODIUM: me.  SWEAT: me.  SUPPORT-U-S-GOVT-P-H-S.
AB Ten children with CF in matched pairs were infused with either
   Intralipid or with 10% glucose on a double blind basis every other
   week for one year. Although statistically there was significantly
   greater gain in height and weight in the study year compared to the
   previous year only for the test group, both groups improved more than
   expected. Cumulative data analysis showed greater improvement for the
   Intralipid group (23 of a possible 45 points) compared to the glucose
   group (-2 points; P less than .02). This study indicates the need to
   better define the role of nutrition in the pathophysiology of CF.
   Meanwhile, it is recommended that all children with CF have plasma
   linoleic acid levels measured at least once yearly, and if levels are
   low, appropriate supplements should be given.
RF 001   KUO PT                J PEDIATR                       60   394 962
   002   CAREN R               J CLIN ENDOCRINOL METAB         26   470 966
   003   UNDERWOOD BA          ANN NY ACAD SCI                203   237 972
   004   RIVERS JPW            LANCET                           2   642 975
   005   ELLIOTT RB            PEDIATRICS                      57   474 976
   006   ROSENLUND ML          PEDIATRICS                      59   428 977
   007   BERRY HK              AM J DIS CHILD                 129   165 975
   008   JELLIFFE DB           ASSESSMENT NUTRITIONAL STATUS            966
   009   FRISANCHO AR          AM J CLIN NUTR                  27  1052 974
   010   CHASE HP              LANCET                           2   236 978
   011   OBRIEN D              LAB MANUAL PEDIAT MICROBIOC              968
   012   MOORE RB              J ALLERGY CLIN IMMUNOL          49   137 972
   013   HOLLANDER M           NONPARAMET STAT METHODS                  973
   014   VERGROESEN AJ         NUTR REV                        35     1 977
   015   CAMPBELL IM           PEDIATRICS                      57   480 976
   016   HANSEN AE             PEDIATRICS                      31   171 963
   017   HOPKINS DT            PROC SOC EXP BIOL MED          114    82 963
   018   DAVIDSON M            IN: RUDOLPH AM                       994 977
   019   WEIHOFEN DM           J AM DIET ASSOC                 54   206 969
   020   KHAW K-T              CF CLUB ABST                          58 978
CT   1   KARP RJ               CLIN CHEST MED                   1   375 980
     2   PARSONS HG            PEDIATRICS                      66   812 980
     3   HUBBARD VS            J PEDIATR                       96   421 980
     4   SHEPHERD R            J PEDIATR                       97   351 980
     5   HUBBARD VS            CLIN CHIM ACTA                 102   115 980
     6   LLOYDSTILL JD         AM J CLIN NUTR                  34     1 981
     7   HARPER TB             AM REV RESPIR DIS              126   540 982
     8   KUSOFFSKY E           J PEDIATR GASTROENTEROL NUTR     2   434 983
     9   ROGIERS V             EUR J PEDIATR                  141    39 983
    10   BERTRAND JM           J PEDIATR                      104    41 984
    11   DAVIS PB              J LAB CLIN MED                 104   203 984
    12   MCKENNA MC            J PEDIATR GASTROENTEROL NUTR     4    45 985
    13   GIBSON RA             J PEDIATR GASTROENTEROL NUTR     5   408 986
    14   LESTER LA             J PARENT ENTERAL NUTR           10   289 986
    15   MISCHLER EH           PEDIATR RES                     20    36 986
    16   DUHAMEL JF            ARCH FR PEDIATR                 43   229 986
    17   CARLSTEDTDUKE J       PROC NAT ACAD SCI USA           83  9202 986

PN 79234
RN 01214 
AN 79179506
AU Brasfield-D.  Hicks-G.  Soong-S.  Tiller-R-E.
TI The chest roentgenogram in cystic fibrosis: a new scoring system.
SO Pediatrics. 1979 Jan. 63(1). P 24-9.
MJ CYSTIC-FIBROSIS: ra.  LUNG: ra.
MN CHILD.  CYSTIC-FIBROSIS: pp.  EVALUATION-STUDIES.  HUMAN.  PROGNOSIS.
   RESPIRATORY-FUNCTION-TESTS.
AB A roentgenogram scoring system is presented that is useful in the
   evaluation and follow-up of patients with cystic fibrosis. The system
   has been shown to be reproducible by and between observers and to
   correlate significantly with results of pulmonary function tests,
   Shwachman-Kulczycki scores, and, in a short-term evaluation,
   morbidity.
RF 001   HODSON CJ             CLIN RADIOL                     13    54 962
   002   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   003   REILLY BJ             RADIOLOGY                       98   281 971
   004   CHRISPIN AR           PEDIATR RADIOL                   2   101 974
   005   MATTHEW DJ            PEDIATR RADIOL                   5   198 977
   006   DOERSHUK CF           J PEDIATR                       65   677 964
   007   COOPERMAN EM          CAN MED ASSOC J                105   580 971
   008   TAUSSIG LM            J PEDIATR                       82   380 973
   009   WOOD RE               AM REV RESPIR DIS              113   833 976
   010   DOERSHUK CF           PEDIATRICS                      36   675 965
   011   KNUDSON RJ            AM REV RESPIR DIS              113   587 976
   012   ZAPLETAL A            J APPL PHYSIOL                  26   308 969
   013   DRAPER NR             APPLIED REGRESSION ANALYSIS              966
CT   1   CHIPPS BE             J PEDIATR                       95   379 979
     2   LESTER LA             J PEDIATR                       97   742 980
     3   BRASFIELD D           AM J ROENTGENOL                134  1195 980
     4   FEIGELSON J           ARCH FR PEDIATR                 38   617 981
     5   HEN J                 J PEDIATR                       99   585 981
     6   HYATT AC              J PEDIATR                       99   307 981
     7   NOLAN G               J PEDIATR                      101   626 982
     8   DANTZKER DR           AM REV RESPIR DIS              125   400 982
     9   TUMMLER B             MONATSSCHR KINDERHEILKD        130   157 982
    10   KATZ SM               JAMA                           248  2284 982
    11   PALMER J              ANN INTERN MED                  99   596 983
    12   HARMS HK              KLIN PAEDIATR                  195    24 983
    13   MCCARTHY VP           GASTROENTEROLOGY                86   564 984
    14   BERTRAND JM           J PEDIATR                      104    41 984
    15   WHEELER WB            J PEDIATR                      104   695 984
    16   MCCARTHY VP           ARCH INTERN MED                144   408 984
    17   WANG EEL              N ENGL J MED                   311  1653 984
    18   AUERBACH HS           LANCET                           2   686 985
    19   PANIDIS IP            J AM COLL CARDIOL                6   701 985
    20   TEMEERMAN GJ          PEDIATR RADIOL                  15    98 985
    21   FARRELL PM            PEDIATR RES                     19   104 985
    22   BOSSO JA              ANTIMICROB AGENTS CHEMOTHER     28   829 985
    23   JEWETT CV             J PEDIATR                      106   669 985
    24   ZACH MS               AM REV RESPIR DIS              131   537 985
    25   SMITH TF              AM J DIS CHILD                 139  1039 985
    26   BOLAND MP             LANCET                           1   232 986
    27   OBERWALDNER B         PEDIATR PULMONOL                 2   358 986
    28   RUBIO TT              J ANTIMICROB CHEMOTHER          18   147 986
    29   JACOBSEN LE           J CAN ASSOC RADIOL              37    17 986
    30   KATZ JN               J PEDIATR                      108   352 986
    31   HARDY KA              J PEDIATR                      109    51 986
    32   WATTS WJ              AM REV RESPIR DIS              134   699 986
    33   ANDREASSON B          ACTA PAEDIATR SCAND             76    70 987
    34   FIEL SB               CHEST                           91   181 987

PN 79235
RN 01215 
AN 79200786
AU Lloyd-Still-J-D.  Simon-S-H.  Wessel-H-U.  Gibson-L-E.
TI Negative effects of oral fatty acid supplementation on sweat
   chloride in cystic fibrosis.
SO Pediatrics. 1979 Jul. 64(1). P 50-2.
MJ CYSTIC-FIBROSIS: me.  OILS: pd.  SAFFLOWER-OIL: pd.
   SODIUM-CHLORIDE: an.  SWEAT: an.
MN ADOLESCENCE.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: bl, dt.
   FEMALE.  HUMAN.  INFANT.  MALE.  PROSTAGLANDINS-E: bl.
   PROSTAGLANDINS-F: bl.  SWEAT: de.
AB Essential fatty acid supplementation with oral safflower oil (1
   gm/kg/day) to 11 cystic fibrosis patients (aged 6 months to 14 years)
   for one year produced no significant change in sweat chloride
   concentration (mEq/liter) or sweat rate (gm/min/m2), Addition of
   vitamin E (10 mg/kg/day) to the safflower oil had no effect on sweat
   chloride concentration or rate compared to placebo. No clinical
   improvement could be detected compared to a control group. These
   results do not support previous reports of the effects of fatty acid
   supplementation on sweat electrolyte concentrations in cystic
   fibrosis.
RF 001   ELLIOTT RB            ARCH DIS CHILD                  50    76 975
   002   ELLIOTT RB            PEDIATRICS                      57   474 976
   003   BEVERIDGE J           PEDIATRICS                      58   465 976
   004   ROSENLUND ML          PEDIATRICS                      59   428 977
   005   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   006   GIBSON LE             PEDIATRICS                      23   545 959
   007   SCHWARTZ IL           J CLIN INVEST                   35   114 956
   008   SHWACHMAN H           MOD PROBL PEDIATR               10   158 967
   009   HOLMAN RT             PROC WEST HEM NUTR CONG 5TH              977
   010   HUBBARD VS            LANCET                           2  1302 977
   011   DUBOIS RS             GASTROENTEROLOGY                72  1052 977
   012   LEMEN RJ              AM REV RESPIR DIS              117   639 978
   013   CHASE HP              PEDIATR RES                     12   431 978
   014   HYMAN AL              AM REV RESPIR DIS              117   111 978
CT   1   ROGIERS V             PEDIATR RES                     14  1088 980
     2   LLOYDSTILL JD         AM J CLIN NUTR                  34     1 981
     3   HARPER TB             AM REV RESPIR DIS              126   540 982
     4   ROGIERS V             EUR J PEDIATR                  141    39 983
     5   ANON                  J AM COLL TOXICOL                4   171 985
     6   GIBSON RA             J PEDIATR GASTROENTEROL NUTR     5   408 986
     7   MISCHLER EH           PEDIATR RES                     20    36 986

PN 79236
RN 01216 
AN 79179608
AU Beckerman-R-C.  Taussig-L-M.
TI Hypoelectrolytemia and metabolic alkalosis in infants with cystic
   fibrosis.
SO Pediatrics. 1979 Apr. 63(4). P 580-3.
MJ ALKALOSIS: et.  CYSTIC-FIBROSIS: co.  WATER-ELECTROLYTE-IMBALANCE: et.
MN CASE-REPORT.  CHLORIDES: bl.  FEMALE.  HUMAN.  HYPOKALEMIA: et.
   HYPONATREMIA: et.  INFANT.  MALE.
AB The records of all children in the Tucson area diagnosed as having
   cystic fibrosis (CF) before the age of 12 months were reviewed to
   ascertain the prevalence of metabolic alkalosis as a major presenting
   manifestation of CF. Five of eleven infants (46%) in whom CF had been
   diagnosed between 1 and 12 months of age initially were seen with
   hypokalemia, hypochloremia, and metabolic alkalosis unassociated with
   marked dehydration, hyperpyrexia, or major pulmonary and/or
   gastrointestinal symptoms. Two infants had repeated episodes of
   metabolic alkalosis; for one of these infants, both episodes of
   metabolic alkalosis occurred before the diagnosis of CF. It is
   postulated that chronic loss of sweat electrolytes together with mild
   gastrointestinal or respiratory illness may predispose the infant
   with cystic fibrosis to a severe electrolyte and acid-base
   disturbance. The lack of shock and hyperpyrexia together with the
   apparent chronicity of electrolyte losses differentiates metabolic
   alkalosis from the heat prostration syndrome, a more acute
   complication of cystic fibrosis. Quantitative sweat testing should be
   part of the evaluation of any infant with unexplained metabolic
   alkalosis. Serum electrolytes should be assessed regularly in infants
   with cystic fibrosis during hot weather months.
RF 001   GOTTLIEB RP           J PEDIATR                       79   930 971
   002   DI SANTAGNESE PA      JAMA                           172  2014 960
   003   NOUSIA-ARVANITAKIS S  J PEDIATR                       82   535 973
   004   HOCHMAN HI            ARCH DIS CHILD                  51   390 976
   005   SHETH KJ              WIS MED J                     76/4   S47 977
   006   RENDLE-SHORT J        ARCH DIS CHILD                  31    28 956
   007   KESSLER WR            PEDIATRICS                       8   648 951
   008   SIMOPOULOS AP         PEDIATR RES                      5   626 971
   009   MONTALVO JM           J CLIN ENDOCRINOL METAB         28   582 968
CT   1   BECKERMAN RC          PEDIATRICS                      64   389 979
     2   NUSSBAUM E            AM J DIS CHILD                 133   965 979
     3   SIMOPOULOS AP         NUTR REV                        38   201 980
     4   GROSSMAN H            PEDIATRICS                      66   366 980
     5   LEBOWITZ MD           ENVIRON RES                     25   225 981
     6   GONZALEZ J            PEDIATRICS                      67   820 981
     7   LAUGHLIN JJ           PEDIATRICS                      68   203 981
     8   RAPAPORT R            J PEDIATR                       98   768 981
     9   TABACHNIK NF          SURG GYNECOL OBSTET            152   837 981
    10   SORSCHER EJ           LANCET                           1   368 982
    11   RUDDY R               CLIN PEDIATR                    21   367 982
    12   FORSYTH JS            SCOTT MED J                     27   333 982
    13   ROSENSTEIN BJ         JOHNS HOPKINS MED J            150   113 982
    14   ZAMMARCHI E           RIV ITAL PEDIATR                 9   505 983
    15   ORENSTEIN DM          PEDIATR RES                     17   267 983
    16   HILL ID               ARCH DIS CHILD                  58   224 983
    17   CARLILE JR            AM J DIS CHILD                 137   702 983
    18   ORENSTEIN DM          J APPL PHYSIOL                  57   408 984
    19   DAVIS PB              SEM RESPIR MED                   6   319 985
    20   ORENSTEIN DM          SEM RESPIR MED                   6   252 985

PN 79237
RN 01217 
AN 79179561
AU Nezelof-C.  LeSec-G.
TI Multifocal myocardial necrosis and fibrosis in pancreatic diseases
   of children.
SO Pediatrics. 1979 Mar. 63(3). P 361-8.
MJ ENDOMYOCARDIAL-FIBROSIS: pa.  MYOCARDIUM: pa.
   PANCREATIC-DISEASES: pa.
MN ACUTE-DISEASE.  CYSTIC-FIBROSIS: pa.  FEMALE.
   HEART-FAILURE-CONGESTIVE: pa.  HUMAN.  INFANT.  INFANT-NEWBORN.
   INTESTINE-SMALL: su.  LIPOMATOSIS: pa.  MALE.  MYOCARDITIS: pa.
   NECROSIS.  PANCREAS: pa.  PANCREATIC-NEOPLASMS: pa.  PANCREATITIS: pa.
   POSTOPERATIVE-COMPLICATIONS: pa.
AB From a review of 2,000 autopsies of children, 16 cases of extensive
   necrosis and scarring fibrosis of the myocardium were found. These
   lesions involved mainly the left ventricle and spared the
   endocardium, the pericardium, and the coronary vessels. These
   necrotic of fibrotic heart lesions were found to be closely
   associated with various pancreatic diseases: cystic fibrosis (11
   cases), pancreatic lipomatosis (2 cases), extensive small bowel
   resection (3 cases, 2 of which were associated with acute
   interstitial pancreatitis). To explain these unexpected associations,
   two hypotheses can be put forth: (1) The lack of absorption of some
   presently undetermined substances indispensable for the correct
   trophicity of the myocardium, and (2) the release in the blood of
   proteolytic enzymes with consecutive activation of phlogistic
   substances such as kinins.
RF 001   WISSLER H             HELV PAEDIATR ACTA SUPPL 1       1     3 945
   002   ESTAGER EM            LES LESIONS DE NECROSE MYOCAR            958
   003   HERMIER M             PEDIATRIE                       22   931 967
   004   KINTZEN W             INT Z VITAMINFORSCH             22   273 950
   005   LINHARTOVA A          ZENTRALBL ALLG PATHOL          103   405 962
   006   MOUY A                ARCH FR PEDIATR                 25   687 968
   007   FARBER S              ARCH PATHOL                     37   238 944
   008   NEZELOF C             ARCH FR PEDIATR                 16  1035 959
   009   OPPENHEIMER EH        JOHNS HOPKINS MED J            133   252 973
   010   SHWACHMAN H           N ENGL J MED                   281   500 969
   012   RICOUR C              ARCH FR PEDIATR                 30   469 973
   013   RICOUR C              ARCH FR PEDIATR                 34   154 977
   014   GALLOIS B             THESIS                                   973
   015   MCGIVEN AR            ARCH DIS CHILD                  37   656 962
   016   OPPERMANN A           ARCH FR PEDIATR                 17  1339 960
   017   CLAVER M              PATHOL EUR                       7    69 974
   018   BURDZINSKA J          KARDIOL POL                      7   233 964
   019   KUTOR J               GYOGYSZERESZET                  17   286 966
   020   DEGARCIA DADONI CR    ARCH ARGENT PEDIATR             63   188 965
   021   POWELL LW JR          VA MED                          84   178 957
   022   GIRON B               MED INFANT                       7   747 976
   023   OPPENHEIMER EH        CYSTIC FIBROSIS                 15    21 975
   024   PICANDET B            MED INFANT                       7   757 976
   025   NEZELOF C             ARCH FR PEDIATR                 18  1135 961
   026   BODIAN M              ACTA PAEDIATR SCAND             53   282 964
   027   SACREZ R              ANN PEDIATR (PARIS)             16    43 969
   028   SHWACHMAN H           J PEDIATR                       65   645 964
   029   ARGOSTI B             MED INFANT                       8   822 976
   030   MOZZICONACCI P        IN: FLAMMARION M                         966
   031   GODEAU P              SEM HOP PARIS                   51  2383 975
   032   LEVY A                PRESSE MED                      73  1345 966
   033   BLUMENSTOCK DA        PEDIATRICS                      19  1002 957
   034   HENDREN WH            ARCH DIS CHILD                  40   132 965
   035   RIEMENSCHNEIDER TA    PEDIATRICS                      41   428 968
   036   STRICKLER GB          AM J DIS CHILD                  95   206 958
   037   COHEN MI              PEDIATR RES                      7   106 973
   038   GUPTA MC              GUT                             14   438 973
   039   DESCHAMPS JP          MED INFANT                       1    27 973
   040   CLAIREAUX AE          ARCH DIS CHILD                  31    22 956
   041   BLANC WA              PEDIATRICS                      22   494 958
   042   DESJEUX JF            ANN MED INTERNE PARIS          127   353 976
   043   FEER W                SCHWEIZ MED WOCHENSCHR          82   101 952
   044   HARIDAS G             ARCH DIS CHILD                  27    23 947
   045   HEGGTVEIT HA          AM J PATHOL                     45   757 964
   046   WARTER J              PRESSE MED                      70   255 962
   047   WERLE E               MUNCH MED WOCHENSCHR           115   225 973
   048   DOS REIS L            ARCH SURG                       87   604 963
   049   SPOCK A               PEDIATR RES                      1   173 967
   050   CONOVER JH            LIFE SCI                        14   253 974
   051   LESEC G               NOUV PRESSE MED                  5  2470 976
   052   SHWACHMAN H           PEDIATRICS                      55    86 975
CT   1   BACHMAN DS            PEDIATRICS                      64   388 979
     2   ZIMMERMANN A          HELV PAEDIATR ACTA              37   183 982
     3   GUESNU M              ARCH FR PEDIATR                 39   127 982
     4   MOSS AJ               PEDIATRICS                      70   728 982
     5   ROSSI E               MONATSSCHR KINDERHEILKD        130   314 982
     6   CHERON G              ACTA PAEDIATR SCAND             73   697 984
     7   SAVILAHTI E           ACTA PAEDIATR SCAND             73   642 984
     8   MICHAEL JR            AM REV RESPIR DIS              130   516 984
     9   SULLIVAN MM           CHEST                           90   239 986

PN 79238
RN 01218 
AN 79200748
AU Phelps-D-L.
TI Vitamin E: where do we stand?.
SO Pediatrics. 1979 Jun. 63(6). P 933-5.
MJ CHILD-NUTRITION.  INFANT-NUTRITION-DISORDERS: dt.
   VITAMIN-E-DEFICIENCY: dt.  VITAMIN-E: tu.
MN ADMINISTRATION-ORAL.  ANEMIA-HEMOLYTIC: dt.  BILIARY-TRACT: ab.
   BRONCHI: ab.  CHILD.  CHILD-PRESCHOOL.  CYSTIC-FIBROSIS: bl, co.
   HUMAN.  INFANT.  INFANT-PREMATURE-DISEASES: dt.  LUNG: ab.
   MALABSORPTION-SYNDROMES: dt.  RETROLENTAL-FIBROPLASIA: dt.
   VITAMIN-E-DEFICIENCY: et.  VITAMIN-E: ad, ae, ph.
EX I propose that clinicians should have a general understanding of what
   little physiology is known about tocopherol, be able to recognize the
   circumstances that cause low tocopherol levels, understand when to
   provide physiologic replacement therapy, and accept the
   responsibility for protecting their patients from uncontrolled
   experimental use of tocopherols.  Tocopherol physiology, tocopherol
   pharmacology, tocopherol deficiency, therapy in deficiency states,
   and pharmacological doses of tocopherol are discussed.  Patients with
   prolonged fat malabsorption and some premature infants receiving iron
   must be given vitamin E.  Use of tocopherol therapy in
   bronchopulmonary dysplasia and retrolental fibroplasia, while
   promising, is unproven and should be used only in a controlled study.
   Research on the role of vitamin E in human physiology is entering a
   rapid-growth phase.
RF 001   MELHORN DK            OHIO STATE MED J                69   899 973
   002   OSKI FA               HOSP PRACT                      12    79 977
   003   BIERI JG              VITAM HORM                      34    31 976
   005   DORMANDY TL           LANCET                           1   647 978
   007   HORWITT MK            AM J CLIN NUTR                   4   408 956
   008   OSKI FA               J PEDIATR                       70   211 967
   009   RITCHIE JH            N ENGL J MED                   279  1185 968
   010   ROSENBLUM JL          PEDIATR RES                     12   555 978
   011   HILLMAN RW            AM J CLIN NUTR                   5   597 957
   012   CORRIGAN JJ JR        JAMA                           230  1300 974
   014   EHRLICH HP            ANN SURG                       175   235 972
   015   LEVY L                INFLAMMATION                     1   333 976
   016   EHRENKRANZ RA         N ENGL J MED                   299   564 978
   017   NORTHWAY WH JR        N ENGL J MED                   299   599 978
   018   PHELPS DL             PEDIATRICS                      59   998 977
   019   JOHNSON L             AM J CLIN NUTR                  27  1158 974
CT   1   HIGASHI A             PEDIATR PHARMACOL                1   129 980
     2   LEBOULANGER J         REV PRAT                        31    69 981
     3   BELL EF               AM J CLIN NUTR                  34   414 981
     4   HAGA P                EUR J PEDIATR                  136   143 981
     5   LLOYD BW              NEUROPEDIATRICS                 13   155 982
     6   ANDERSON SA           AM J CLIN NUTR                  35   381 982
     7   GUGGENHEIM MA         J PEDIATR                      100    51 982
     8   WILLE L               KLIN PAEDIATR                  194     1 982
     9   ROY CC                J PEDIATR GASTROENTEROL NUTR     2  S282 983
    10   GREGORY JG            SCIENTOMETRICS                   6   307 984
    11   VAISMAN N             NUTR RES                         5   931 985
    12   BOHLES H              KLIN PAEDIATR                  197   386 985
    13   CONWAY SP             BR J NUTR                       56   105 986

PN 79239
RN 01219 
AN 80012602
AU Beckerman-R-C.
TI Metabolic alkalosis in infants with cystic fibrosis [letter].
SO Pediatrics. 1979 Sep. 64(3). P 389.
MJ ALKALOSIS: et.  CYSTIC-FIBROSIS: co.
MN CARBON-DIOXIDE: bl.  CHLORIDES: an.  CYSTIC-FIBROSIS: di.
   ELECTROLYTES: bl.  FEMALE.  HUMAN.  INFANT.  MALE.  SWEAT: ah.
EX I have diagnosed six cystic fibrosis infants under 1 year of age,
   four of whom had documented episodes of hypoelectrolytemia and severe
   metabolic alkalosis.  These additional data support our previous
   hypothesis that chronic sweat electrolyte depletion, more frequently
   than previously recognized, can cause severe metabolic derangements
   in infants with cystic fibrosis, especially those living in both
   humid and dry, hot climates.
RF 001   BECKERMAN RC          PEDIATRICS                      63   580 979
   002   DI SANTAGNESE PA      JAMA                           172  2014 960
   003   GOTTLIEB RP           J PEDIATR                       79   930 971
   004   NOUSIA-ARVANITAKIS S  J PEDIATR                       82   535 973
   005   SHETH KJ              WIS MED J                     76/4   S47 977
CT   1   RAPAPORT R            J PEDIATR                       98   768 981
     2   FORSYTH JS            SCOTT MED J                     27   333 982

PN 79240
RN 01220 
AN 80146088
AU Pryor-J-A.  Webber-B-A.
TI An evaluation of the forced expiration technique as an adjunct to
   postural drainage.
SO Physiotherapy. 1979 Oct. 65(10). P 304-7.
MJ BRONCHIAL-SPASM: th.  CYSTIC-FIBROSIS: th.  RESPIRATORY-THERAPY: mt.
MN ADOLESCENCE.  ADULT.  FEMALE.  HUMAN.  MALE.
EX A criticism often levelled at the forced expiration technique (FET)
   is that it increases and may even produce bronchospasm.  It was our
   impression that the use of forced expiration when combined with
   periods of relaxed diaphragmatic breathing did not aggravate
   bronchospasm and shortened the postural drainage session.  Two groups
   of patients were studied: 24 with cystic fibrosis to evaluate the use
   of the FET as an independent means of postural drainage; and 20
   asthmatic patients to assess the effect of the FET on bronchospasm.
   The studies indicate that the forced expiration technique increases
   the efficiency of postural drainage, but does not increase airway
   obstruction.  This technique can be applied to both medical and
   surgical conditions when postural drainage, or a modified form of
   postural drainage, is indicated.
RF 001   ANON                  THORAX                          14   286 959
   002   COCHRANE GM           BR MED J                         2  1181 977
   003   COTES JE              LUNG FUNCTION                            975
   004   GASKELL DV            BROMPTON HOSP GUIDE TO CHEST             977
   006   MEAD J                J APPL PHYSIOL                  22    95 967
   007   PRYOR JA              BR MED J                         2   417 979
   009   THOMPSON BJ           NZ J PHYSIOTHERAPY               4     4 973
   010   THOMPSON BJ           ASTHMA AND YOUR CHILD                    978
CT   1   VANDERMEER JWM        REV INFECT DIS                   6   107 984
     2   BATTISTINI A          RIV ITAL PEDIATR                10   220 984
     3   RIVINGTONLAW BA       CHEST                           85   378 984
     4   OBERWALDNER B         PEDIATR PULMONOL                 2   358 986
     5   HOFMEYR JL            THORAX                          41   951 986
     6   VERBOON JML           EUR J RESPIR DIS                69   169 986
     7   WEBBER BA             BR J DIS CHEST                  80   353 986

PN 79241
RN 01221 
AN 79180081
AU Martodam-R-R.  Baugh-R-J.  Twumasi-D-Y.  Liener-I-E.
TI A rapid procedure for the large scale purification of elastase and
   cathepsin G from human sputum.
SO Prep-Biochem. 1979. 9(1). P 15-31.
MJ CATHEPSINS: ip.  CYSTIC-FIBROSIS: en.  PANCREATOPEPTIDASE: ip.
   SPUTUM: en.
MN AMINO-ACID-SEQUENCE.  BINDING-SITES.  CHROMATOGRAPHY-AFFINITY: mt.
   CHROMATOGRAPHY-GEL: mt.  DEOXYRIBONUCLEASES.  ELECTROPHORESIS-DISC.
   HUMAN.  LEUKOCYTES: en.  SUPPURATION.  SUPPORT-U-S-GOVT-P-H-S.
AB A procedure is described which permits the rapid isolation of large
   amounts of elastase and cathepsin G from purulent sputum. This
   procedure involves: (1) digestion of sputum with DNase, (2)
   extraction of the insoluble residue that remains with 1 M NaCl, pH 8,
   (3) affinity chromatography on Sepharose-bound Trasylol, and (4)
   separation of the two enzymes by chromatogrphy on CM-Sephadex.
   Starting with 500 g of sputum it was possible to isolate 175 mg of
   each of these two enzymes within 7 to 10 days. Active site titration
   indicated both enzymes to be at least 97% pure. Disc gel
   electrophoresis in the presence and absence of SDS and amino acid
   sequence of the N-terminal region support the conclusion that the
   elastase and cathepsin G isolated from sputum are identical to the
   same enzymes isolated directly from the leukocytes of human blood.
RF 001   JANOFF A              AM J PATHOL                     68   579 972
   002   LAZARUS GS            AM J PATHOL                     68   565 972
   003   STARKEY PM            IN: BARRETT AJ                        57 977
   004   TWUMASI DY            J BIOL CHEM                    252  1917 977
   005   BAUGH RJ              BIOCHEMISTRY                    15   836 976
   006   BIETH J               BIOCHEM MED                     11   350 974
   007   VISSER L              BIOCHIM BIOPHYS ACTA           268   257 972
   008   POWERS JC             BIOCHEM BIOPHYS RES COMMUN      67   639 975
   010   CHASE T JR            BIOCHEM BIOPHYS RES COMMUN      29   508 967
   011   BREWER JM             J CHEM EDUC                     46    41 969
   012   WEBER K               J BIOL CHEM                    244  4406 969
   013   ANON                  BECKMAN INSTRUCTION MANUAL               974
   014   SMITHIES O            BIOCHEMISTRY                    10  4912 971
   015$  WARBURG O             BIOCHEM Z                      310   384 942
   016   JANOFF A              LAB INVEST                      29   458 973
   017   SCHMIDT W             PHYSIOL CHEM                   355  1077 974
   018   OHLSSON K             EUR J BIOCHEM                   42   519 974
   019   TAYLOR JC             ARCH BIOCHEM BIOPHYS           169    91 975
   020   DRUZE D               BIOCHIM BIOPHYS ACTA           438   505 976
   021   FEINSTEIN G           BIOCHIM BIOPHYS ACTA           403   477 975
   022   RINDLER-LUDWIG R      BIOCHIM BIOPHYS ACTA           379   606 975
   023   STARKEY PM            BIOCHEM J                      155   255 976
   024   STARKEY PM            BIOCHEM J                      155   265 976
   025   STARKEY PM            BIOCHEM J                      155   273 976
CT   1   SENIOR RM             J CLIN INVEST                   66   859 980
     2   MCDONALD JA           J BIOL CHEM                    255  8848 980
     3   BOUDIER C             ARCH BIOCHEM BIOPHYS           210   790 981
     4   BOUDIER C             J BIOL CHEM                    256   256 981
     5   MARTODAM RR           BIOCHIM BIOPHYS ACTA           667   328 981
     6   BAICI A               SCAND J IMMUNOL                 16   487 982
     7   BAICI A               MOL IMMUNOL                     19   719 982
     8   BOUDIER C             BIOCHEM MED                     28    41 982
     9   CAMPBELL EJ           J CLIN INVEST                   70   845 982
    10   CAMPBELL EJ           PROC NAT ACAD SCI USA           79  6941 982
    11   LAINE A               BIOCHEM BIOPHYS RES COMMUN     105   186 982
    12   LAINE A               BIOCHEM BIOPHYS RES COMMUN     107   337 982
    13   BROWER MS             J BIOL CHEM                    257  9849 982
    14   VISCARELLO BR         PREPAR BIOCHEM                  13    57 983
    15   STERRENBERG L         THROMB RES                      31   719 983
    16   ANDREWS JL            CHEMBIOL INTERACT               47   157 983
    17   STONE PJ              CHEST                           83  S 65 983
    18   CAMPBELL EJ           J LAB CLIN MED                 101   527 983
    19   CAMPBELL EJ           AM REV RESPIR DIS              127   631 983
    20   MCGOWAN SE            AM REV RESPIR DIS              128   688 983
    21   STONE PJ              ANN NY ACAD SCI                421   398 983
    22   SNIDER GL             AM REV RESPIR DIS              129   155 984
    23   MCGOWAN SE            AM REV RESPIR DIS              130   734 984
    24   SENIOR RM             J IMMUNOL                      132  2547 984
    25   BOUDIER C             ADV EXP MED BIOL               167   313 984
    26   MIKUNITAKAGAKI Y      J BIOL CHEM                    259  6739 984
    27   BREUER R              EXP LUNG RES                     9   167 985
    28   LENTINI A             BIOCHEM INT                     10   221 985
    29   STERRENBERG L         HAEMOSTASIS                     15   126 985
    30   STEIN RL              ANNU REP MED CHEM               20   237 985
    31   BINDER R              RESPIRATION                     47   267 985
    32   JACQUOT J             INFECT IMMUN                    47   555 985
    33   DORING G              INFECT IMMUN                    49   557 985
    34   BREUER R              J LAB CLIN MED                 105   635 985
    35   LAURENT P             BIOCHEM BIOPHYS RES COMMUN     126   275 985
    36   BRUCE MC              AM REV RESPIR DIS              132   529 985
    37   LUCEY EC              AM REV RESPIR DIS              132   362 985
    38   SNIDER GL             AM REV RESPIR DIS              132  1155 985
    39   TOURNIER JM           AM REV RESPIR DIS              132   524 985
    40   SMITH CE              BIOCHEM J                      225   463 985
    41   BALDUYCK M            BIOL CHEM HOPPE SEYLER         366     9 985
    42   BALDUYCK M            BIOL CHEM HOPPE SEYLER         366     9 985
    43   VERCAIGNEMARKO D      BIOL CHEM HOPPE SEYLER         366   655 985
    44   DORING G              CLIN EXP IMMUNOL                64   597 986
    45   WELGUS HG             J CLIN INVEST                   77  1675 986
    46   NILES RM              J LAB CLIN MED                 108   489 986
    47   GOLDSTEIN W           AM REV RESPIR DIS              134    49 986
    48   LUCEY EC              AM REV RESPIR DIS              134   471 986
    49   HECK LW               ANAL BIOCHEM                   158   217 986
    50   SKINNER M             PROC SOC EXP BIOL MED          181   211 986
    51   BRUCH M               BIOCHEM J                      238   269 986
    52   BERMAN G              J BIOL CHEM                    261  4095 986
    53   JOHNSON DA            J BIOL CHEM                    261  4748 986
    54   LAURENT P             BIOCHEM PHARMACOL               36   765 987
    55   PETERSON MW           J APPL PHYSIOL                  62  1521 987
    56   BROWER MS             BLOOD                           69   813 987
    57   MORRISON HM           CLIN SCI                        72   151 987
    58   BOUDIER C             ARCH BIOCHEM BIOPHYS           253   439 987
    59   SMITH CE              ARCH BIOCHEM BIOPHYS           253   146 987
    60   SELLOUM L             BIOL CHEM HOPPE SEYLER         368    47 987

PN 79242
RN 01222 
AN 79223914
AU Shapiro-B-L.  Feigal-R-J.  Lam-L-F.
TI Mitrochondrial NADH dehydrogenase in cystic fibrosis.
SO Proc-Natl-Acad-Sci-USA. 1979 Jun. 76(6). P 2979-83.
MJ CYSTIC-FIBROSIS: en.  MITOCHONDRIA: en.
   NADH-NADPH-OXIDOREDUCTASES: me.  SKIN: en.
MN CELLS-CULTURED.  FIBROBLASTS: en.  HUMAN.
   HYDROGEN-ION-CONCENTRATION.  KINETICS.  OXYGEN-CONSUMPTION.
AB We have shown that skin fibroblast from patients with cystic fibrosis
   (CF) and from carriers for CF [heterozygotes (HZ)] consume more O2
   than do their controls. When the mitochondrial electron transport
   inhibitor rotenone was added to the cells, the relative inhibition of
   O2 consumption was CF greater than HZ greater than controls (P less
   than 0.005 in both comparisons). Because rotenone specifically
   inhibits NADH dehydrogenase, [NADH: (acceptor) oxidoreductase, EC
   1.6.99.3], which is the enzyme of energy-conserving site 1 of the
   mitochondrial electron transport system, activity and kinetics of
   this enzyme system were studied in fibroblast homogenates. NADH
   dehydrogenase activity was equal in cells from the three genotypes.
   At pH 8.0, affinity of the enzyme for its substrate was CF greater
   than HZ = controls; at pH 8.6, affinity was CF greater than HZ =
   controls (P less than 0.005 for the differences). pH optima for the
   genotypes were without exception 8.6 (CF), 8.3 (HZ), and 8.0
   (control). HZ and control lines were distinguished unequivocally in a
   blind test on the basis of differences in pH optima. Purified
   mitochondrial preparations revealed pH optima identical to those
   found in whole cell homogenates. These data suggest that the mutant
   gene responsible for CF is expressed in the complex mitochondrial
   NADH dehydrogenase system.
RF 001   NADLER HL             IN: STANBURY JB                     1683 978
   002   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   003   DI SANTAGNESE PA      N ENGL J MED                   295   534 976
   004   DI SANTAGNESE PA      N ENGL J MED                   295   597 976
   005   PALADE GE             SCIENCE                        189   347 975
   006   SHAPIRO BL            GAP CONF REP TISS CULT APPR              977
   007   SHAPIRO BL            SCIENCE                        203  1251 979
   008   SHAPIRO BL            CLIN CHIM ACTA                  82   125 978
   009   FEIGAL RJ             PEDIATR RES                     13   764 979
   010   FEIGAL RJ             NATURE                         278   276 979
   011   MITCHELL P            BIOL REV                        41   445 966
   012   BYGRAVE FL            BIOL REV                        53    43 978
   013   FEIGAL RJ             DISSERTATION                             979
   014   SLATER EC             METHODS ENZYMOL                 10    48 967
   015   LOWRY OH              J BIOL CHEM                    193   265 951
   016   KING TE               METHODS ENZYMOL                 10   275 967
   017   STANBURY JB           METABOLIC BASIS OF INHERITED             978
   018   SINGER TP             METHODS ENZYMOL                 53   397 978
   019   HATEFI Y              IN: BOYER PD                    13   175 976
   020   RAGAN CI              BIOCHIM BIOPHYS ACTA           456   249 976
   021   HATEFI Y              METHODS ENZYMOL                 53    11 976
   022   FORSTNER JF           PEDIATR RES                     10   609 976
   023   CARAFOLI E            ANN NY ACAD SCI                307   269 978
   024   LEHNINGER AL          ANN NY ACAD SCI                307   160 978
   025   WALLACH D             EUR J BIOCHEM                   21   433 971
   026   ARGENT BE             J PHYSIOL (LOND)               230   575 973
   027   MANGOS JA             IN: ANDREOLI TE                          978
CT   1   DAVIS PB              PEDIATR RES                     14    83 980
     2   SEALE TW              ANN CLIN LAB SCI                12   415 982
     3   SANGUINETTIBRICENO NR CLIN GENET                      22   308 982
     4   FEIGAL RJ             LIFE SCI                        30    93 982
     5   SHAPIRO BL            AM J HUM GENET                  34   846 982
     6   BOYCE JR              INFECT IMMUN                    37   695 982
     7   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
     8   SEYMOUR CA            BIOESSAYS                        1    38 984
     9   REGELMANN WE          PEDIATR RES                     20   619 986
    10   STUTTS MJ             PEDIATR RES                     20  1316 986
    11   KUZEMKO JA            J ROY SOC MED                   79     2 986
    12   BATTINO M             FEBS LETTERS                   199   155 986
    13   FEIGAL RJ             ANN NY ACAD SCI                488    82 986

PN 79243
RN 01223 
AN 80122681
AU Mangos-J-A.
TI Cystic fibrosis: potential management through manipulation of the
   secretory process in affected exocrine glands.
SO Prog-Clin-Biol-Res. 1979. 34. P 111-7.
MJ CYSTIC-FIBROSIS: th.  EXOCRINE-GLANDS: se.
MN ANIMAL.  CATS.  CYSTIC-FIBROSIS: pp.  EXOCRINE-GLANDS: de.  FERRETS.
   ISOPROTERENOL: pd.  MACROMOLECULAR-SYSTEMS.  MUCUS: se.
   PAROTID-GLAND: de.  RATS.  SALIVA: se.  SODIUM: se.  TRACHEA: de.
   WATER-ELECTROLYTE-BALANCE.
EX Ten years ago, we demonstrated that chronic administration of
   isoproterenol to rats results is structural and functional changes of
   their salivary glands similar to those seen in exocrine glands of
   patients with cystic fibrosis.  Recently, we began to study the
   cellular pathophysiology of these glands and managed to achieve
   pharmacological control of this abnormality.  We demonstrated that
   administration of a beta-adrenergic antagonist in these animals
   resulted in the correction of the electrolyte abnormality which is
   very similar to that seen in the sweat glands of patients with cystic
   fibrosis.  These two examples of manipulation of the secretory
   processes in exocrine glands of experimental animals demonstrate the
   feasibility of this approach in the therapy of patients with cystic
   fibrosis.
RF 001   MANGOS JA             IN: ANDREOLI TE                          978
   002   MANGOS JA             J DENT RES                      57   989 978
   004   MANGOS JA             CF PROJECTIONS INTO THE FUTUR            976
   007   MANGOS JA             AM J PHYSIOL                   225   683 973
   008   MANGOS JA             AM J PHYSIOL                   229   553 975
   009   MANGOS JA             AM J PHYSIOL                   229   560 975
   010   MANGOS JA             AM J PHYSIOL                   229   566 975
   011   MANGOS JA             IN: LAWSON D PROC 5TH INT CF          25 969
   012   NADEL JA              CIBA FOUND SYMP 54                       978
   013   STURGESS JM           BR J EXP PATHOL                 54   388 973

PN 79244
RN 01224 
AN 80122682
AU Gluckson-M-M.  Denning-C-R.
TI Changing patterns of genetic counseling in a cystic fibrosis center.
SO Prog-Clin-Biol-Res. 1979. 34. P 119-32.
MJ CYSTIC-FIBROSIS: fg.  GENETIC-COUNSELING.
MN ABORTION-LEGAL: px.  ADULT.  ATTITUDE-TO-HEALTH.  CYSTIC-FIBROSIS: px.
   FAMILY-PLANNING.  FEMALE.  HETEROZYGOTE-DETECTION.  HUMAN.
   MALE.  PRENATAL-DIAGNOSIS.  RELIGION.  RISK.
EX The change of life expectancy of cystic fibrosis patients has
   stimulated our interest in assessing the understanding and
   utilization of genetic information by adult CF patients and how this
   may affect their coping mechanism(s).  The present study was designed
   to obtain information in these areas with the expectation that more
   effective genetic counseling might be developed for this enlarging
   group of patients.  Knowledge of genetics, attitudes concerning
   reproduction, attitudes toward prenatal diagnosis, and attitudes
   toward a carrier identification study are reported for 25 males and
   15 females with proven cystic fibrosis.
RF 001   BOYLE IR              J PEDIATR                       88   318 976
   002   CARTER CO             LANCET                           1   281 971
   003   ANON                  GAP CONF REP PROB REPRO PHYSI            975
   004   DANKS DM              ANN HUM GENET                   28   323 965
   005   DENNING CR            IN: MANGOS JA                        127 976
   006   DENNING CR            PEDIATRICS                      41     7 968
   007   DODGE JA              PATIENT COUNS HEALTH EDUC        1     8 978
   008   EMERY AEH             BR MED J                         1   724 973
   009   GLUCKSON MM           CF CLUB ABST                    18       977
   010   KABACK MM             PROG MED GENET                  10   103 974
   011   LEONARD CO            N ENGL J MED                   287   433 972
   012   MERRITT AD            J LAB CLIN MED                  60   998 962
   013   MOHR I                CF CLUB ABST                    16       975
   014   SHAW MW               IN: LUBS HA                              977
   015   SIBINGA MS            PEDIATR RES                      6   331 972
   016   STEINHAUER PD         PEDIATR CLIN NORTH AM           21   825 974
CT   1   PASSARGE E            EUR J PEDIATR                  143    54 984

PN 79245
RN 01225 
AN 80080576
TI New test to detect carriers of gene for cystic fibrosis [news].
SO Public-Health-Rep. 1979 Nov-Dec. 94(6). P 577.
MJ CYSTIC-FIBROSIS: di.  HETEROZYGOTE-DETECTION: mt.
MN CYSTIC-FIBROSIS: fg.  HUMAN.
EX Development of a new test to detect carriers of the gene for cystic
   fibrosis was announced.  The test involves the interaction between
   red blood cells from a mouse and a small amount of a person's blood
   serum.  The gene for cystic fibrosis is associated with a lectin, a
   factor in the person's blood serum that acts to agglutinate (or
   cluster) the red blood cells of the mouse.

PN 79246
RN 01226 
AN 81015715
AU Swan-H-A.  Chappell-J-S.
TI Cystic fibrosis--its surgical presentation.
SO S-Afr-J-Surg. 1979 Jun. 17(2). P 51-7.
MJ CYSTIC-FIBROSIS: co.
MN ADOLESCENCE.  ADULT.  BILIARY-TRACT-DISEASES: su.  CHILD-PRESCHOOL.
   GASTROINTESTINAL-DISEASES: su.  HUMAN.  LIVER-DISEASES: su.  MALE.
   PANCREATIC-DISEASES: su.  RESPIRATORY-TRACT-DISEASES: su.
AB In a series of 62 cases of cystic fibrosis presenting at the
   Transvaal Memorial Hospital for Children, Johannesburg, during the
   10-year period 1968-1978, 15 patients required surgical treatment
   for 17 complications of the disease.  Meconium ileus, rectal
   prolapse, intussusception and ethmoiditis were the commonest
   surgical presentations, and portal hypertension, bronchial
   obstruction and nasal polyposis were also experienced.  As the basic
   defect is unknown, treatment today is still directed towards these
   usually unpredictable secondary consequences.
RF 001   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   002   PROSSER R             ARCH DIS CHILD                  49   597 974
   003   DANKS DM              ANN HUM GENET                   28   323 965
   004   MCPARTLIN JF          ARCH DIS CHILD                  47   207 972
   005   ANDERSON CM           CF A MANUAL OF DIAGNOSIS AND             976
   006   KOPEL FB              GASTROENTEROLOGY                62   483 972
   007   BERNSTEIN JG          AM J DIS CHILD                  99   804 960
   008   GRACEY M              IN: ANDERSON CM                329   359 975
   009   OPPENHEIMER EH        ARCH PATHOL                     96   149 973
   010   LLOYD-STILL JD        BR MED J                         1   110 971
   011   ALTERMAN K            AM J DIS CHILD                 101   210 961
   012   BOAT TF               JAMA                           209  1498 969
   013   TAYLOR BW             ARCH DIS CHILD                  49   133 974
   014   WANG CI               AM J DIS CHILD                 119   236 970
   015   OPPENHEIMER EH        PERSPECT PEDIATR PATHOL          2   241 975
   016   KISSANE JM            PATHOLOGY OF INFANCY AND CHIL            967
   017   GRAND RJ              CLIN PEDIATR                     9   588 970
   018   SHWACHMAN H           PEDIATRICS                      55    86 975
   019   KOMP DM               CHEST                           58   501 970
   020   ESTERLY JR            J PEDIATR                       69     3 966
   021   CRAIG JM              AM J DIS CHILD                  93   357 957
   022   TAYLOR WF             AM J DIS CHILD                 123   161 972
   023   HUANG NN              AM J DIS CHILD                 120   289 970
   024   DI SANTAGNESE PA      N ENGL J MED                   279   103 968

PN 79247
RN 01227 
AN 80103180
AU Friis-B.
TI Chemotherapy of chronic infections with mucoid Pseudomonas
   aeruginosa in lower airways of patients with cystic fibrosis.
SO Scand-J-Infect-Dis. 1979. 11(3). P 211-7.
MJ ANTIBIOTICS: tu.  CYSTIC-FIBROSIS: co.  PNEUMONIA: dt.
   PSEUDOMONAS-INFECTIONS: dt.
MN ADOLESCENCE.  ADULT.  CARBENICILLIN: tu.  CHILD.  CHILD-PRESCHOOL.
   CHRONIC-DISEASE.  COLISTIN: tu.  DRUG-EVALUATION.
   DRUG-THERAPY-COMBINATION.  FEMALE.  GENTAMICINS: tu.  HUMAN.  INFANT.
   MALE.  PNEUMONIA: co.  PRECIPITINS: an.  PSEUDOMONAS-AERUGINOSA: im.
   PSEUDOMONAS-INFECTIONS: co.  TOBRAMYCIN: tu.
AB The bacteriological effect of chemotherapy against Pseudomonas
   aeruginosa (Ps.ae.) in lungs of patients with cystic fibrosis is
   reviewed. During a 5-year period 49 children and adults were treated
   with 190 courses of different antibiotics. The mucoid strains of
   Ps.ae. disappeared in 72.0% of the courses in which a combination of
   tobramycin and carbenicillin was employed. Tobramycin given alone had
   only bacteriological effect in 26.6% of the courses. Colimycin alone
   or in combination with carbenicillin had no effect. In 18 patients
   who received subsequent courses of tobramycin and combination of
   tobramycin and carbenicillin a significant difference in favour of
   the combination therapy was found, also in cases with many
   precipitins against Ps.ae. in serum. In 74.5% of the initially
   successful courses the patients were recolonized with Ps.ae. within 1
   month. No nephrotoxic or ototoxic side effects were demonstrated in
   spite of the high doses of tobramycin (10 mg/kg/24 h) emmployed and
   the repeated courses.
RF 001   ANDERSON EL           ANTIMICROB AGENTS CHEMOTHER      8   300 975
   002   DAVIES J              J INFECT DIS SUPPL             124     7 971
   003   GIBSON LE             PEDIATRICS                      23   545 959
   004   HAWLEY HB             CURR THER RES                   16   414 974
   005   HOFF GE               SCAND J INFECT DIS               6   333 974
   006   HUANG NN              J PEDIATR                       78   338 971
   007   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   81   298 973
   008   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   541 974
   009   HOIBY N               ACTA PATH MICROBIOL SCAND (B)   82   551 974
   010   HOIBY N               SCAND J RESPIR DIS              58    65 977
   011   KLASTERSKY J          AM J MED SCI                   266    13 973
   012   KLUGE RM              ANN INTERN MED                  81   584 974
   013   KLUGE RM              ANTIMICROB AGENTS CHEMOTHER      6   442 974
   014   MARKS MI              J PEDIATR                       79   822 971
   015   MCCRAE WM             SCOTT MED J                     21    68 976
   016   MEYER RD              APPL MICROBIOL                  22  1147 971
   017   MEYERS BR             J CLIN PHARMACOL                12   321 972
CT   1   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
     2   FEIGELSON J           NOUV PRESSE MED                 10   955 981
     3   MALMBORG AS           SCAND J INFECT DIS            1981    64 981
     4   MOLLER NE             SCAND J INFECT DIS            1981    87 981
     5   DAVIDSON S            ISR J MED SCI                   18   859 982
     6   KELLY HW              J PEDIATR                      101   793 982
     7   BECK B                ACTA PAEDIATR SCAND SUPPL 301 1982   125 982
     8   HOIBY N               ACTA PAEDIATR SCAND SUPPL 301 1982    75 982
     9   PERMIN H              J ANTIMICROB CHEMOTHER          12   313 983
    10   HEILESEN AM           SCAND J INFECT DIS              15   271 983
    11   DORING G              INFECT IMMUN                    42   197 983
    12   SCHIOTZ PO            ACTA PAEDIATR SCAND             72   283 983
    13   SZAFF M               ACTA PAEDIATR SCAND             72   651 983
    14   DRUSANO GL            REV INFECT DIS                   6    13 984
    15   KELLY HW              DRUG INTEL CLIN PHARM           18   772 984
    16   FRASER GL             DRUG INTEL CLIN PHARM           19   757 985
    17   STACK BHR             THORAX                          40   358 985
    18   STOUT SA              DRUG INTEL CLIN PHARM           21   322 987

PN 79248
RN 01228 
AN 79181690
AU Gawel-J.  Rudnik-J.  Pryjma-J.  Zebrak-J.  Hauszka-J.  Rudnik-I.
   Majewska-Zalewska-H.
TI Proteins in bronchial secretion of children with chronic pulmonary
   diseases.  I. Relation to clinical diagnosis.
SO Scand-J-Respir-Dis. 1979 Apr. 60(2). P 63-8.
MJ BRONCHI: se.  IGA: se.  IGA-SECRETORY.  IGG: se.  LACTOFERRIN: se.
   LACTOGLOBULINS: se.  MURAMIDASE: se.  RESPIRATORY-TRACT-DISEASES: di.
MN ADOLESCENCE.  BRONCHI: im.  BRONCHIECTASIS: di, im.
   BRONCHITIS: di, im.  CHILD.  CHILD-PRESCHOOL.  CHRONIC-DISEASE.
   CYSTIC-FIBROSIS: di, im.  HUMAN.  IGA: an.  IGA-SECRETORY: an.
   IGG: an.  LACTOFERRIN: an.  MURAMIDASE: an.  RECURRENCE.
   RESPIRATORY-TRACT-DISEASES: im.  RESPIRATORY-TRACT-INFECTIONS: di, im.
AB Bronchial secretions from 207 children suffering from various
   pulmonary diseases and from 15 healthy controls were tested
   concentration of IgA, IgG, lactoferrin and lysozyme. The results
   obtained suggest that in many cases of chronic lung diseases in
   children the levels of lactoferrin and immunoglobulins, especially
   secretory IgA, are very low. In severe infections (cystic fibrosis,
   bronchiectases) significant increase of IgG concentration was
   observed.
RF 001$  ADINOLFI M            IMMUNOLOGY                      10   517 966
   002   ALFORD RH             J IMMUNOL                      101   984 968
   003   BISERTE G             EXP ANNU BIOCHIM MED            24    85 963
   004   BRUZDZINSKI H         MED DOSW MIKROBIOL              28   377 976
   005   BULLEN GJ             BR J HAEMATOL                   23   289 972
   006   DEUSCHL H             CLIN EXP IMMUNOL                16   401 973
   007   FALK GA               AM REV RESPIR DIS              105    14 972
   008   FLEMMING A            PROC R SOC LOND BIOL            93   306 922
   009   HEISE ER              J RETICULOENDOTHEL SOC           4   510 967
   010   HILL IR               IMMUNOLOGY                      26  1239 974
   011   KALTREIDER HB         J IMMUNOL                      116   423 976
   012   KOBAYASHI K           IMMUNOCHEMISTRY                  8   785 971
   013   LICHT W               PNEUMONOLOGY                   144   139 971
   014   LOWRY OH              J BIOL CHEM                    193   265 951
   015   MANCINI G             IMMUNOCHEMISTRY                  2   235 965
   016   MARTINEZ-TELLO FJ     J IMMUNOL                      101   989 968
   017   MASSON PL             IN: DULFANO MJ                           973
   018   MCINTOSH K            J ALLERGY CLIN IMMUNOL          57   595 976
   019   MEDICI TC             AM REV RESPIR DIS              103   784 971
   020   MESTECKY J            SCIENCE                        171  1163 971
   021   NEWHOUSE M            N ENGL J MED                   295  1045 976
   022   SIEGLER DIM           THORAX                          29   313 974
   023   SOOTHILL JF           IN: BRENT L                      5       974
   024   SOUTAR CA             THORAX                          30   239 975
   025   SZOTOWA W             CZYNNE PORADNICTWO W OPIECE Z            976
   026   THACORE H             AM REV RESPIR DIS               93   786 966
   027   TISCHENDORF FW        IN: ENGELHARDT A                 1       974
   028   WALDMAN RH            IN: NETER E                          334 975
   029   ZEBRAK J              SCAND J RESPIR DIS              60    69 979
CT   1   ZEBRAK J              SCAND J RESPIR DIS              60    69 979
     2   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C) S276     1 981
     3   GOLDSTEIN E           REV INFECT DIS                   5  1078 983
     4   JACQUOT J             BULL EUR PHYSIOPATH RESP        19   453 983
     5   MOSS RB               MONOGR ALLERGY                  19   202 986
     6   DVORETSKY LI          TER ARKH                        58    72 986
     7   DVORETSKY LI          KLIN MED                        65    79 987
     8   MOSS RB               CHEST                           91   522 987

PN 79249
RN 01229 
AN 79181691
AU Zebrak-J.  Herman-T.  Werys-R.  Pryjma-J.  Gawel-J.
TI Proteins in bronchial secretion of children with chronic pulmonary
   diseases.  II.  Relation to bronchoscopic and bronchographic
   examination.
SO Scand-J-Respir-Dis. 1979 Apr. 60(2). P 69-75.
MJ BRONCHI: se.  IGA: se.  IGA-SECRETORY.  IGG: se.  LACTOFERRIN: se.
   LACTOGLOBULINS: se.  MURAMIDASE: se.  RESPIRATORY-TRACT-DISEASES: di.
MN ADOLESCENCE.  BRONCHI: im.  BRONCHIECTASIS: di, im.
   BRONCHITIS: di, im.  BRONCHOGRAPHY.  BRONCHOSCOPY.  CHILD.
   CHILD-PRESCHOOL.  CHRONIC-DISEASE.  CYSTIC-FIBROSIS: di, im.  HUMAN.
   IGA: an.  IGA-SECRETORY: an.  IGG: an.  LACTOFERRIN: an.
   MURAMIDASE: an.  RESPIRATORY-TRACT-DISEASES: im.
AB The concentration of immunoglobulins, lactoferrin and lysozyme we
   compared in bronchial secretions obtained from children with various
   chronic lung diseases. The IgG, lactoferrin and lysozyme, but not
   secretory IgA, concentrations were shown to be increased during
   chronic inflammatory response.
RF 001   ALFORD RH             J IMMUNOL                      101   984 968
   002   DEUSCHL H             CLIN EXP IMMUNOL                16   401 973
   003   FALK GA               AM REV RESPIR DIS              105    14 972
   004   GAWEL J               SCAND J RESPIR DIS              60    63 979
   005   HAND WL               J CLIN INVEST                   53   354 974
   006   KALTREIDER HB         J CLIN INVEST                   54   263 974
   007   MARTINEZ-TELLO FJ     J IMMUNOL                      101   989 968
   008   MASSON PL             IN: DULFANO MJ                           973
   009   MASSON PL             PROTIDES BIOL FLUIDS            16   633 968
   010   MASSON PL             J EXP MED                      130   643 969
   011   MEDICI TC             AM REV RESPIR DIS              103   784 971
   012   NEWHOUSE M            N ENGL J MED                   295  1045 976
   013   SIEGLER DIM           THORAX                          29   313 974
   014   SOUTAR CA             THORAX                          30   239 975
   015   TOURVILLE DR          J EXP MED                      129   411 969
CT   1   GAWEL J               SCAND J RESPIR DIS              60    63 979
     2   AMBRUSO DR            J CLIN INVEST                   67   352 981
     3   LEE GR                SEM HEMATOL                     20    61 983
     4   KIJLSTRA A            BR J OPHTHALMOL                 67   199 983
     5   STELANDER M           EUR J RESPIR DIS                65     5 984
     6   FICK RB               J CLIN INVEST                   74   236 984
     7   PRYJMA J              ANN ALLERGY                     54    60 985

PN 79250
RN 01230 
AN 80081508
AU Kurz-J-B.  Perkins-J-P.  Buchwald-M.
TI Killing of fibroblasts by dexamethasone or dibutyryl adenosine
   3',5'-monophosphate is not a valid test for cystic fibrosis.
SO Science. 1979 Dec 14. 206(4424). P 1317-9.
MJ CYSTIC-FIBROSIS: di.  DEXAMETHASONE: pd.  DIBUTYRYL-CYCLIC-AMP: pd.
   FIBROBLASTS: de.
MN ADOLESCENCE.  ADULT.  CELL-DIVISION: de.  CELL-SURVIVAL: de.
   CELLS-CULTURED.  CHILD.  CHILD-PRESCHOOL.
   DOSE-RESPONSE-RELATIONSHIP-DRUG.  FEMALE.  HUMAN.  OUABAIN: pd.
   SKIN: cy.
AB Assays based on the counting of total cells and of colony-forming
   cells were used to demonstrate that neither dexamethasone nor
   dibutyryl adenosine 3',5'-monophosphate (cyclic AMP) kills human
   fibroblasts under a variety of conditions. These results contradict
   those of previous studies showing that dexamethasone and dibutyryl
   cyclic AMP kill a higher percentage of fibroblasts from normal humans
   than from individuals with cystic fibrosis.
RF 001   EPSTEIN JL            PROC NAT ACAD SCI USA           74  5642 977
   002   BRESLOW JL            SCIENCE                        201   180 978
   003   BRESLOW JL            CELL                            13   663 978
   004   EPSTEIN J             SOMATIC CELL GENET               4   451 978
   005   BUCHWALD M            PROC NAT ACAD SCI USA           73  2899 976
   006   ELMORE E              IN VITRO                        13   837 977
   009   SIBLEY CH             CELL                             2   213 974
   010   SIBLEY CH             CELL                             2   221 974
   011   MANKOVITZ R           CELL                             3   221 974
   012   EPSTEIN JL            PROC NAT ACAD SCI USA           74  1676 977
   016   HAM RG                IN VITRO                        14    11 978
   018   PRATT WB              J INVEST DERMATOL               71    23 978
   019   CASTOR CW             J LAB CLIN MED                  65   490 965
   020   THRASH CR             NATURE                         242   399 973
   021   KAMELY D              EXP CELL RES                    97   120 976
   022   GOSPODAROWICZ D       J CELL BIOL                     66   541 975
   023   HARVEY W              ANN RHEUM DIS                   33   427 974
   024   MILO GF               IN VITRO                        12    23 976
   025   HAYASHI I             IN VITRO                        14    23 978
   026   MACIEIRA-COELHO A     EXPERIENTIA                     22   390 966
   027   MACIEIRA-COELHO A     NATURE                         251    67 974
   028   CRISTOFALO VJ         IN VITRO                         6   396 971
   029   GROVE GL              CELL BIOL INT REP                1   147 977
CT   1   SCANLIN TF            CLIN CHEST MED                   1   424 980
     2   BUCHWALD M            ADV CYCLIC NUCLEO RES           12   243 980
     3   EPSTEIN J             PEDIATR RES                     14   964 980
     4   WEICHSELBAUM RR       J CELL PHYSIOL                 103   429 980
     5   BRESLOW JL            SCIENCE                        207  1007 980
     6   LITTLEFIELD JW        N ENGL J MED                   304    44 981
     7   SHAPIRO BL            N ENGL J MED                   304   975 981
     8   SEALE TW              ANN CLIN LAB SCI                12   415 982
     9   UNSICKER K            CELL TISSUE RES                223    73 982
    10   GRANAT M              FERTIL STERIL                   39   180 983
    11   LANGHOFF E            PEDIATR RES                     18   488 984
    12   JANSEN RPS            AM J OBSTET GYNECOL            153   363 985
    13   PINSKY L              ADV HUM GENET                   16   299 987

PN 79251
RN 01231 
AN 79138718
AU Shapiro-B-L.  Lam-L-F.  Fast-L-H.
TI Premature senescence in cultured skin fibroblasts from subjects with
   cystic fibrosis.
SO Science. 1979 Mar 23. 203(4386). P 1251-3.
MJ CELL-SURVIVAL.  CYSTIC-FIBROSIS: pa.
MN ADOLESCENCE.  ADULT.  AGING.  CELL-DIVISION.  CELLS-CULTURED.  CHILD.
   DNA: bi.  FEMALE.  HUMAN.  MALE.  SKIN: pa.
AB Cultured skin fibroblasts from subjects with cystic fibrosis
   exhibited normal population doubling times in early passages. After
   about 13 cumulative population doublings, cystic fibrosis lines
   doubled more slowly than controls and ceased doubling after about 19
   weekly passages. Control lines continued doubling for 27 passages.
   The premature senescence noted in cells from subjects with cystic
   fibrosis reconciles controversial observations of cell doubling
   reported in the literature. Data presented here demonstrate that
   experiments with cystic fibrosis cells in late passage may generate
   misleading results since differences from control lines may be
   ascribed to generalized senile changes rather than to specific
   results of the cystic fibrosis genotype.
RF 001   ANON                  GAP CONF REP TISS CULT APPR              977
   002   RAFF EC               J CELL PHYSIOL                  74   235 969
   003   HOUCK JC              PROC SOC EXP BIOL MED          135   369 970
   004   HOUCK JC              PROC SOC EXP BIOL MED          147   167 974
   005   FLETCHER DS           CLIN CHIM ACTA                  44     5 973
   006   WELCH DW              PEDIATR RES                      9   698 975
   007   FARRELL PM            PROC SOC EXP BIOL MED          149   340 975
   008   BOLTON WE             AM J HUM GENET                  27   394 975
   009   BARRANCO SC           J CELL PHYSIOL                  88    33 976
   010   SHAPIRO BL            CLIN CHIM ACTA                  82   125 978
   011   HAYFLICK L            EXP CELL RES                    25   585 961
   012   HAYFLICK L            EXP CELL RES                    37   614 965
   013   SCHNEIDER EL          PROC SOC EXP BIOL MED          141  1092 972
   014   GOLDSTEIN S           SCIENCE                        199   781 978
   015   NADLER HL             IN: STANBURY JB                     1683 978
   016   LOBECK CC             IN: STANBURY JB                     1605 972
   017   DOERING KM            EUR J PEDIATR                  126   185 977
   018   KELLER PJ             BIOCHEMISTRY                    10  4867 971
   019   ROBINSON AB           PROC NAT ACAD SCI USA           66   753 970
   019   MARTIN GM             IN: BERGSMA D                            978
   020   ARGLEBE C             CLIN OTOLARYNGOLOGY              1   249 976
   021   CHILLA R              ARCH OTO RHINO LARYNGOL        214   267 977
   022   SWENEY LR             PEDIATRICS                      40   421 967
   023   SWENEY LR             ARCH PATHOL                     86   413 968
   024   STREHLER BL           TIME CELLS AND AGING                     977
CT   1   LAM LFH               LIFE SCI                        24  2483 979
     2   SHAPIRO BL            PROC NAT ACAD SCI USA           76  2979 979
     3   HOEHN H               AM J MED GENET                   7   141 980
     4   DAVIS PB              PEDIATR RES                     14    83 980
     5   CHASE HP              METABOLISM                      29   365 980
     6   TARNOKY AL            J ROY SOC MED                   73    73 980
     7   VRACKO R              EXP CELL RES                   129   345 980
     8   ROOMANS GM            ULTRASTRUCTURAL PATHOL           2    53 981
     9   KURZ JB               PEDIATR RES                     15  1328 981
    10   SHAPIRO BL            AM J HUM GENET                  34   846 982
    11   ANDERSON PJ           BIOCHEM BIOPHYS RES COMMUN     108   182 982
    12   SHAPIRO BL            SCIENCE                        216   417 982
    13   CEDER O               SCANN ELECTRON MICROSC        1982   723 982
    14   CARMAGNOL F           PEDIATR RES                     17   181 983
    15   VRACKO R              IN VITRO                        19   504 983
    16   THOMPSON KVA          GERONTOLOGY                     29    97 983
    17   CEDER O               ACTA PAEDIATR SCAND SUPPL 309 1983     1 983
    18   KATZ S                CELL CALC                        5   421 984
    19   MATTHEWS LW           PEDIATR CLIN NORTH AM           31   133 984
    20   GRINSTEIN S           BIOCHIM BIOPHYS ACTA           769   270 984
    21   RAVIA Y               HUM GENET                       71   294 985
    22   AVIOLI LV             AM J NEPHROL                     6   151 986
    23   MATTES PM             PROC NAT ACAD SCI USA           84  3009 987

PN 79252
RN 01232 
AN 80036401
AU Howie-A-D.  Stack-B-H.
TI Cystic fibrosis in adolescents and young adults.
SO Scott-Med-J. 1979 Jul. 24(3). P 193-8.
MJ CYSTIC-FIBROSIS: di.
MN ADOLESCENCE.  ADULT.  CHILD.  CHILD-PRESCHOOL.
   CYSTIC-FIBROSIS: co, th.  FEMALE.  GASTROINTESTINAL-DISEASES: co.
   HUMAN.  INFANT.  INFANT-NEWBORN.  JOINT-DISEASES: co.
   LUNG-DISEASES: co.  LUNG: ra.  MALE.  RESPIRATORY-FUNCTION-TESTS.
   SINUSITIS: co.
AB With the early diagnosis of cystic fibrosis and the better management
   of these patients in childhood increasing numbers are surviving to
   adult life. The main problem requiring continuous medical care in the
   older cystic fibrosis patient is persisting and often progressive
   chest disease. For this reason the cystic fibrosis clinic for
   adolescents and young adults was started in the Western Infirmary in
   1975. This paper presents our observations on 13 patients who had
   attended between 1975 and 1977. Eleven patients are alive and well
   and have shown no evidence of deterioration over this period. Ten are
   at school or in regular employment. With optimum medical supervision
   it is possible to give young adults with cystic fibrosis a worthwhile
   existence.
RF 001   BOAT TF               AM REV RESPIR DIS              116     1 977
   002   BOAT TF               CLIN PEDIATR                    13   505 974
   003   BODIAN M              FIBROCYSTIC DIS OF THE PANCRE            952
   004   COOPERMAN EM          CAN MED ASSOC J                105   580 971
   005   GAYTON WF             AM J DIS CHILD                 126   856 973
   006   GRACEY M              AUSTRALAS ANN MED               18    91 969
   007   HODSON ME             BR MED J                         2   790 976
   008   LAWSON D              IN: LAWSON D PROC 5TH INT CF         225 969
   009   MCCRAE WM             SCOTT MED J                     21    68 976
   010   MCFARLANE H           BR MED J                         1   423 975
   011   MATHIEU J-P           BR J DIS CHEST                  72    57 978
   012   MILNER AD             ARCH DIS CHILD                  44   351 969
   013   MITCHELL-HEGGS PF     Q J MED                         45   479 976
   014   ROSAN RC              AM J DIS CHILD                 104   625 962
   015   SHWACHMAN H           MEDICINE (BALTIMORE)            56   129 977
   016   STERN RC              ANN INTERN MED                  87   188 977
   017   STRUNK RC             ARCH DIS CHILD                  52   687 977
   018   WARWICK WJ            JAMA                           238  2159 977
CT   1   JACOBS WH             AM J GASTROENTEROL              76   342 981
     2   MACPHERSON AIS        SCOTT MED J                     29     6 984
     3   PHILLIPS BM           J ROY SOC MED                   79    44 986

PN 79253
RN 01233 
AN 79181843
AU Frydman-M-I.
TI Implications of cystic fibrosis for health services and the
   afflicted.
SO Soc-Sci-Med. 1979 Mar. 13A(2). P 147-50. (REVIEW).
MJ CYSTIC-FIBROSIS: px.
MN ADAPTATION-PSYCHOLOGICAL.  ADULT.  CHILD.  CYSTIC-FIBROSIS: co, th.
   FAMILY.  HUMAN.  MENTAL-DISORDERS: co.  PARENT-CHILD-RELATIONS.
   REVIEW.
AB "Psychosocial" literature on cystic fibrosis (CF) is critically
   reviewed.  Major methodological shortcomings include the anecdotal
   nature of findings, overemphasis on negative consequences of the
   disease, and the lack of a suitable theoretical framework.  Avenues
   for future research are suggested.
RF 001   KRAMM ER              PEDIATRICS                      28   135 961
   002   POGUE RE              MINN MED                        52  1551 969
   003   SHWACHMAN H           AM J DIS CHILD                  96     6 958
   004   SHWACHMAN H           PEDIATRICS                      36   689 965
   005   ANON                  GAP CONF REP CHRON BRONC CF              977
   006   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   007   WOOD RE               AM REV RESPIR DIS              113   833 976
   008   LAPEY A               IN: GELLIS SS                        221 976
   009   LIFSCHITZ M           ARCH FOUND THANATOLOGY           1    23 969
   010   TOWNES BD             J PSYCHOSOM RES                 18     9 974
   011   TURK J                PEDIATRICS                      34    67 964
   012   TROPAUER A            AM J DIS CHILD                 119   424 970
   013   TEICHER JD            CALIF MED                      110   371 969
   014   BLOM G                PEDIATRICS                      22   593 958
   015   MATTSSON A            PEDIATRICS                      50   801 972
   016   FRIEDMAN SB           PEDIATRICS                      32   610 963
   017   LAWLER RH             CAN MED ASSOC J                 94  1043 966
   018   GAYTON WF             AM J DIS CHILD                 126   856 973
   019   GOLDBERG DP           DETECTION OF PSYCHIATRIC ILLN            972
   020   KULCZYCKI LL          CLIN PROC CHILD HOSP DC         25   320 969
   021   ELLIS CE              J PEDIATR                       87   565 975
   022   BURTON L              FAMILY LIFE OF SICK CHILDREN             975
   023   SPOCK A               NC MED J                        27   426 966
   024   GREEN MN              PEDIATRICS                      34    58 964
   025   MCCOLLUM AT           J PEDIATR                       77   571 970
   026   GORDON NB             J HLTH HUM BEHAV                 6   190 965
   027   BLUMENTHAL MD         ARCH GEN PSYCHIAT               21   160 969
   028   ORBACH CE             CANCER                           8    20 955
   029   LINDEMANN E           AM J PSYCHIATRY                101   141 944
   030   GLASER BG             AWARENESS OF DYING                       965
   031   NAJMAN JM             HOSP HLTH ADMIN                  5     8 973
   032   PINKERTON P           ARIZ MED                        26   348 969
   033   ROSENLUND ML          ANN INTERN MED                  78   959 973
   034   MCCRAE WM             LANCET                           2   141 973
   035   BURTON L              PRACTITIONER                   210   247 973
   036   MEYEROWITZ JH         SOC SCI MED                      1   249 967
   037   PLESS IB              CHRONIC CHILDHOOD DISORDER               975
   038   ALLAN JL              AUST PAEDIATR J                 10   136 974
   039   HALLORAN KH           J PEDIATR                       88  1054 976
   040   KUPST MJ              PEDIATRICS                      59   266 977
   041   FRASER FC             AM J HUM GENET                  26   636 974
   042   TAVORMINA JB          J ABNORM CHILD PSYCHOL           4    99 976
   043   GAYTON WF             PEDIATRICS                      59   888 977
   044   BEDELL JR             J PSYCHOSOM RES                 21   237 977
   045   CHODOFF P             AM J PSYCHIATRY                120   743 964
   046   GOFFMAN E             ASYLUMS                                  961
   047   SZASZ TS              IDEOLOGY AND INSANITY                    973
   048   DENZIN NK             IN: SPITZER SP                           968
   049   BOZEMAN MF            CANCER                           8     1 955
   050   PARSONS T             J SOC ISSUES                     8    31 952
   051   GORDON NB             J HLTH HUM BEHAV                 6   190 965
   052   PRATT L               FAMILY STRUCTURE EFFECTIVE HE            976
   053   FREIDSON E            PROF DOMINANCE THE SOCIAL STR            970
   054   STRAUSS AL            CHRONIC ILLNESS AND THE QUALI            975
   055   ANDERSEN DH           CHILDREN                         7    11 960
   056   KULCZYCKI LL          PUBL HEALTH REP                 76    88 961
   057   STEINBERG AG          AM J HUM GENET                  12   416 960
   058   WRIGHT SW             AM J HUM GENET                  20   157 968
   059   ANON                  GAP CONF REP PSYCHOSOCIAL ASP            974
   060   GOLODETZ A            MED CARE                         7   385 969
   061   PATTERSON PR          PSYCHOSOCIAL ASPECTS OF CF               973
   062   MCCRAE WM             PHYSIOTHERAPY                   61   252 975
   063   HAMBURG DA            PSYCHOTHER PSYCHOSOM            23    13 974
   064   HAGGERTY RJ           CHILD HEALTH AND THE COMMUNIT            975
   065   PLESS IB              PEDIATR CLIN NORTH AM           21   223 974
CT   1   PLESS IB              PEDIATR CLIN NORTH AM           31    33 984

PN 79254
RN 01234 
AN 79138906
AU Wood-R-E.
TI Cystic fibrosis: diagnosis, treatment, and prognosis.
SO South-Med-J. 1979 Feb. 72(2). P 189-202. (REVIEW).
MJ CYSTIC-FIBROSIS: th.
MN AEROSOLS.  ANTIBIOTICS: tu.  COUGH: et.
   CYSTIC-FIBROSIS: co, di, fg, mo, pp, px.  DIET.  HUMAN.
   INFANT-NEWBORN.  INFANT-NEWBORN-DISEASES: di.  LUNG-DISEASES: et.
   METHODS.  PANCREAS: pp.  PHYSICAL-THERAPY.  PROGNOSIS.  REVIEW.
   INFERTILITY: et.  SWEAT: an.  SUPPORT-U-S-GOVT-P-H-S.  UNITED-STATES.
EX This review is intended to present a brief summary of the important
   areas and concepts of cystic fibrosis relevant to clinical practice,
   indicating those that remain controversial and offering opinions
   based on both relevant literature and the clinical experience of the
   Cleveland Cystic Fibrosis Center.  The sweat test, tests of
   pancreatic function, tests of pulmonary function, genetics and family
   history in diagnosis, infertility as a diagnostic factor, the role of
   circulating factors in diagnosis, heterozygote detection and prenatal
   diagnosis, miscellaneous factors leading to diagnosis, neonatal
   screening, and general observations on the diagnosis of CF are
   examined.  A philosophy of treatment, physical measures,
   antimicrobial therapy, aerosol therapy, the role of hospitalization
   in a therapeutic program, other drug therapy, the treatment of cor
   pulmonale, respiratory failure, and specific pulmonary complications
   are discussed.  Enzyme replacement and obstructive phenomena, glucose
   intolerance, the treatment of the sweat defect, psychosocial therapy,
   and prognosis are also considered.
RF 001   WOOD RE               AM REV RESPIR DIS              113   833 976
   002   DI SANTAGNESE PA      N ENGL J MED                   295   481 976
   003   DI SANTAGNESE PA      PEDIATRICS                      12   549 953
   004   GIBSON LE             PEDIATRICS                      23   545 959
   005   GIBSON LE             PROC FOR QUANTITATIVE ION                975
   006   HADORN B              J PEDIATR                       73    39 968
   007   LOBER CW              CHEST                           66   332 974
   008   BARBERO GJ            AM J DIS CHILD                 112   536 966
   009   LAPEY A               J PEDIATR                       84   328 974
   010   TAUSSIG LM            PEDIATRICS                      54   229 974
   011   WOLF RO               J LAB CLIN MED                  87   164 976
   012   ANON                  CF FND 1975 REP SURVI STUD PA            977
   013   ORENSTEIN DM          AM J DIS CHILD                 131   973 977
   014   KAPLAN E              N ENGL J MED                   279    65 968
   015   COHEN LF              GAP CONF REP PROB REPRO PHYSI          6 975
   016   HERROD HG             J PEDIATR                       91   276 977
   017   OPPENHEIMER EH        J PEDIATR                       75   806 969
   018   OPPENHEIMER EH        J PEDIATR                       77   991 970
   019   KOPITO LE             FERTIL STERIL                   24   512 973
   020   DI SANTAGNESE PA      N ENGL J MED                   277  1287 967
   021   SPOCK A               PEDIATR RES                      1   173 967
   022   BOWMAN BH             SCIENCE                        164   325 969
   023   KAISER D              PEDIATR RES                      5   167 971
   024   MANGOS JA             PEDIATR RES                      1   436 967
   025   ANON                  GAP CONF REP CILIARY INHIBITO            973
   026   WOOD RE               HOSP PRACT                      11    91 976
   027   GREEN MN              PEDIATRICS                      21   635 958
   028   STEPHAN U             PEDIATRICS                      55    35 975
   029   HOLSCLAW DS           CF CLUB ABST                             977
   031   WOOD RE               AM REV RESPIR DIS              111   733 975
   032   COMROE JH JR          PHYSIOLOGY OF RESPIRATION                965
   033   MELLINS RB            AM REV RESPIR DIS SUPPL        110   137 974
   034   WOOD RE               IN: BARAN D                              977
   035   SCHWARTZ RH           AM J DIS CHILD                 120   432 970
   036   PENNINGTON JE         J INFECT DIS                   128    63 973
   037   MARKS MI              J PEDIATR                       79   822 971
   038   STERN RC              CLIN PEDIATR                    11   521 972
   039   RUCKER RW             PEDIATRICS                      54   358 974
   040   PENNINGTON JE         AM J MED                        58   629 975
   041   LANDAU LI             J PEDIATR                       82   863 973
   042   MATTHEWS LW           J PEDIATR                       65   558 964
   043   DOERSHUK CF           PEDIATRICS                      41   723 968
   044   MOTOYAMA EK           PEDIATRICS                      50   299 972
   045   CHANG N               AM REV RESPIR DIS              107   672 973
   046   WOLFSDORF J           PEDIATRICS                      43   799 969
   047   BAU SK                PEDIATRICS                      48   605 971
   048   WOOD RE               PROC INT CF CONG 7TH                     976
   049   WOOD RE               AM REV RESPIR DIS              113   833 976
   050   HUANG NN              GUIDE TO DRUG THERAPY IN PATI            972
   051   YEATES DB             AM REV RESPIR DIS              107   602 973
   052   STREIDER DJ           PROC INT CF CONG 7TH                     976
   053   HOIBY N               SCAND J RESPIR DIS              56    38 975
   054   BOWDEN DH             AM J MED                        38   226 965
   055   BLOCK AJ              AM REV RESPIR DIS SUPPL        110    71 974
   056   KELMINSON LL          PEDIATRICS                      39    24 967
   057   DAVIS PB              JAMA                           239  1851 978
   058   STOWE SM              AM REV RESPIR DIS              111   611 975
   059   HOLSCLAW DS           J PEDIATR                       76   829 970
   060   STERN RC              AM REV RESPIR DIS              117   825 978
   061   FELLOWS KE            RADIOLOGY                      114   551 975
   062   BROWN CH 3RD          N ENGL J MED                   291   265 974
   063   KYLSTRA JA            AM REV RESPIR DIS              103   651 971
   064   REGAN PT              N ENGL J MED                   297   854 977
   065   FARRELL PM            J CLIN INVEST                   60   233 977
   066   GRAHAM DY             N ENGL J MED                   296  1314 977
   067   DIMAGNO EP            N ENGL J MED                   296  1318 977
   068   ELLIOTT RB            PEDIATRICS                      57   474 976
   069   CAMPBELL IM           PEDIATRICS                      57   480 976
   070   STAPLETON FB          N ENGL J MED                   295   246 976
   071   ROSENLUND ML          PEDIATRICS                      59   428 977
   072   HUANG NN              IN: SENIOR JR                        207 968
   073   ALLAN JD              AM J DIS CHILD                 126    22 973
   074   BERRY HK              AM J DIS CHILD                 129   165 975
   075   RAEBURN JA            PROC NUTR SOC                   36    77 977
   076   WAGGET J              J PEDIATR                       77   407 970
   077   DONNISON AB           PEDIATRICS                      37   833 966
   078   STERN RC              GASTROENTEROLOGY                70   645 976
   079   HANDWERGER S          N ENGL J MED                   281   451 969
   080   LIPPE BM              J PEDIATR                       90   751 977
   081   WILMSHURST EG         PEDIATRICS                      55    75 975
   082   CHAZAN BI             J PEDIATR                       77    86 970
   083   ANON                  CF FND 1976 REP SURVI STUD PA            978
   084   TAUSSIG LM            J PEDIATR                       82   380 973
   085   DOERSHUK CF           PEDIATRICS                      36   675 965
CT   1   HOLSCLAW DS           CLIN CHEST MED                   1   407 980
     2   REED MD               PEDIATR RES                     15  1234 981
     3   CONGDEN PJ            ARCH DIS CHILD                  56   708 981
     4   KANG SB               ANESTH ANALG CLEVE              61   793 982
     5   IANNUCCI A            HUM PATHOL                      15   278 984
     6   LEEDER JS             CLIN PHARMACOL THER             36   355 984
     7   NAYLOR EW             SEM PERINATOL                    9   232 985
     8   GILLIGAN PH           J CLIN MICROBIOL                22     5 985
     9   REED MD               ANTIMICROB AGENTS CHEMOTHER     27   583 985
    10   KATZ JN               J PEDIATR                      108   352 986

PN 79255
RN 01235 
AN 80014930
AU van-Vroonhoven-T-J.  Molenaar-J-C.
TI Distal splenorenal shunt for decompression of portal hypertension in
   children with cystic fibrosis.
SO Surg-Gynecol-Obstet. 1979 Oct. 149(4). P 559-60.
MJ CYSTIC-FIBROSIS: co.  HYPERTENSION-PORTAL: su.  RENAL-VEINS: su.
   SPLENIC-VEIN: su.
MN ADOLESCENCE.  CHILD.  FEMALE.  HUMAN.  HYPERTENSION-PORTAL: co.
   MALE.  METHODS.
AB Apart from the sound physiologic basis for the distal splenorenal
   shunt as compared with the portacaval shunt and the conventional
   central splenorenal shunt, there are two important reasons why we
   think the use of this type of shunt is especially advantageous in
   children with portal hypertension secondary to cystic fibrosis.
   Firstly, the thick, fibrotic retroperitoneal area in the porta
   hepatis, where a portacaval shunt has to be constructed, can be
   avoided, which makes the distal splenorenal shunt the easier
   operation. Secondly, notwithstanding the relatively small-sized
   vessels, a wide anastomosis can be constructed with a high flow rate
   and, therefore, a minimal chance of shunt thrombosis.
RF 001   GALAMBOS JT           N ENGL J MED                   295  1089 976
   002   MAILLARD JN           ETUDE HEMODYNAMIQUE DE LANAST            978
   003   MAKSOUD JG            J PEDIATR SURG                  13   335 978
   004   SCHUSTER SR           J PEDIATR SURG                  12   201 977
   005   STERN RC              GASTROENTEROLOGY                70   645 976
   006   WARREN WD             ANN SURG                       166   437 967
CT   1   TABACHNIK NF          SURG GYNECOL OBSTET            152   837 981
     2   ROY CC                J PEDIATR GASTROENTEROL NUTR     1   469 982
     3   HENDERSON JM          SEM LIVER DIS                    3   251 983
     4   HUBBARD VS            SEM RESPIR MED                   6   299 985
     5   BERNARD O             CLIN GASTROENTEROL              14    33 985
     6   SCHRODER R            SCHWEIZ MED WOCHENSCHR         115   828 985

PN 79256
RN 01236 
AN 80124640
AU Bowman-B-H.
TI Cystic fibrosis: review of investigations of the mucociliary
   inhibitor.
SO Tex-Rep-Biol-Med. 1979. 38. P 47-53. (REVIEW).
MJ BLOOD-PROTEINS: ph.  CYSTIC-FIBROSIS: pp.
MN BIOLOGICAL-ASSAY.  BODY-FLUIDS.  CILIA: de.  CYSTIC-FIBROSIS: fg, me.
   GENES-RECESSIVE.  GILLS.  HETEROZYGOTE.  HOMOZYGOTE.  HUMAN.
   OYSTERS.  PROTEINS: an.  REVIEW.
EX Recently, we found the cystic fibrosis mucociliary inhibitor in urine
   from homozygotes and heterozygotes, but not from normals.  In recent
   studies we have attempted to compare the relative concentrations of
   CFMI in material from homozygotes and heterozygotes.  The unites of
   inhibition which reflect the concentration of the CFMI in serum and
   tissue culture medium fractions from heterozygotes is close to
   one-half of that in fractions from homozygous sources.  With
   purification of the CFMI and the generation of a monospecific
   antibody preparation, answers will become available to the questions
   of whether or not there is a normal counterpart to the CFMI and
   whether or not quantitation of the CFMI will be useful in
   heterozygote detection and prenatal diagnosis of cystic fibrosis.
RF 001   ANDERSEN DH           AM J DIS CHILD                  56   344 938
   002   BARNETT DR            TEX REP BIOL MED                31   703 973
   003   BAUR PS               TEX REP BIOL MED                34   155 976
   004   BERATIS NG            PEDIATR RES                      7   958 973
   005   BOWMAN BH             PROC NAT ACAD SCI USA           70   548 973
   006   BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      64  1310 975
   007   BOWMAN BH             SCIENCE                        164   325 969
   008   BOWMAN BH             CLIN GENET                       4   461 973
   009   BOWMAN BH             CLIN GENET                      12   333 977
   011   CARSON SD             DISSERTATION                             978
   012   COHEN FL              J MED GENET                     11   253 974
   013   CONOVER JH            PEDIATR RES                      7   220 973
   014   DANES BS              J EXP MED                      136  1313 972
   015   FANCONI G             WIEN MED WOCHENSCHR             86   753 936
   016   HIRSCHHORN K          IN: MANGOS JA                        305 976
   017   LITT M                BIOCHEM BIOPHYS RES COMMUN      43   919 971
   018   MANGOS JA             SCIENCE                        158   135 967
   019   MAYO BJ               TEX REP BIOL MED                34   107 976
   020   MCNEELY MC            DISSERTATION                             978
   021   SPOCK A               PEDIATR RES                      1   173 967
   022   WILSON GB             CLIN RES                        24   295 976
CT   1   HALLINAN F            MED HYPOTHESES                   7   793 981
     2   THOMAS JM             CLIN CHIM ACTA                 111   199 981
     3   BLITZER MG            PEDIATR RES                     16   203 982
     4   CEDER O               SCANN ELECTRON MICROSC        1982   723 982
     5   CEDER O               ULTRASTRUCTURAL PATHOL           4   305 983
     6   VONEULER AM           ULTRASTRUCTURAL PATHOL           5    37 983

PN 79257
RN 01237 
AN 80015007
AU Landau-L-I.  Mellis-C-M.  Phelan-P-D.  Bristowe-B.  McLennan-L.
TI "Small airways disease" in children: no test is best.
SO Thorax. 1979 Apr. 34(2). P 217-23.
MJ ASTHMA: di.  CYSTIC-FIBROSIS: di.
MN ADOLESCENCE.  ADULT.  ASTHMA: pp.  CHILD.  CYSTIC-FIBROSIS: pp.
   FEMALE.  HELIUM: du.  HUMAN.  LUNG: ph.  MALE.  NITROGEN: du.
   RESPIRATORY-FUNCTION-TESTS.
AB Tests claimed to detect small airway disease were evaluated in
   children.  Fifty-two subjects who were normal, 30 with cystic
   fibrosis (CF), and 35 with asthma were selected on the basis of
   normal spirometry, informed consent being obtained from them and
   their parents.  Tests undertaken were measurement of maximum
   expiratory flow volume curves breathing air and a helium-oxygen
   mixture, single breath nitrogen washout curves, lung volumes, and,
   except in the normal subjects, measurement of arterial oxygen
   tension.  Closing volumes were normal in most children with CF and
   asthma, whereas the slope of the alveolar plateau was abnormal in
   83%.  Maximum expiratory flow rate at 50% of total lung capacity was
   reduced in 65% and maximum mid-expiratory flow rate in 57%; residual
   volume increased in 51%, and results of other tests were abnormal in
   less than 50% of the children.  There was evidence suggesting that
   lung disease was more patchy in children with mild CF than in those
   with interval phase asthma.  These tests do not detect specific
   pathological processes in small airways but reflect the consequences
   of small airway abnormalities, which may vary in the same disease as
   well as in different diseases.  No one test alone appears most
   useful.  Together they contribute to understanding the functional
   abnormalities present in each individual.
RF 001   ANTHONISEN NR         CLIN SCI                        35   495 968
   002   ANTHONISEN NR         RESPIR PHYSIOL                   8    58 969
   003   ALDERSON PO           RADIOLOGY                      111   151 974
   004   BODE FR               AM J MED                        59    43 975
   005   BUIST AS              AM REV RESPIR DIS              108  1078 973
   006   BURROWS B             AM REV RESPIR DIS              115   751 977
   007   COLLEY JRT            BR MED J                         3   195 973
   008   COOPER DM             AM REV RESPIR DIS              109   519 974
   009   DEMUTH GR             AM J DIS CHILD                 103   129 962
   010   DESPAS PJ             J CLIN INVEST                   51  3235 972
   011   DUBOIS AB             J CLIN INVEST                   35   322 956
   012   FOX WW                PEDIATRICS                      54   293 974
   013   GELB AF               AM REV RESPIR DIS              112   401 975
   014   HILL DJ               AM REV RESPIR DIS              106   873 972
   015   KNUDSON RJ            AM REV RESPIR DIS              115   423 977
   016   LAMARRE A             PEDIATRICS                      50   291 972
   017   LANDAU LI             AM REV RESPIR DIS              108   593 973
   018   MCCARTHY DS           AM J MED                        52   747 972
   019   MANSELL A             J APPL PHYSIOL                  33   711 972
   020   MATSUBA K             AM REV RESPIR DIS              107   552 973
   021   MELLINS RB            PEDIATRICS                      44   315 969
   022   MELLIS CM             AUST PAEDIATR J                 12    77 976
   023   STANESCU D            J APPL PHYSIOL                  42   859 977
   024   WEST JB               VENTILATION BLOOD FLOW AND GA        107 965
   025   WOOLCOCK AJ           J CLIN INVEST                   48  1097 969
   026   ZAPLETAL A            J APPL PHYSIOL                  26   308 969
CT   1   MANSMANN HC           CLIN CHEST MED                   1   339 980
     2   THOMPSON JE           MED J AUST                       1   668 980
     3   MARTIN AJ             AM REV RESPIR DIS              122   609 980
     4   KERREBIJN KF          EUR J RESPIR DIS                63     5 982
     5   WOOLCOCK AJ           EUR J RESPIR DIS                65     1 984
     6   FELDMAN M             AVIAT SPACE ENVIRON MED         57   706 986

PN 79258
RN 01238 
AN 80237415
AU Lieberman-J.  Costea-N-V.  Jakulis-V-J.  Kaneshiro-W.
TI Detection of a lectin in the blood of cystic fibrosis homozygotes
   and heterozygotes.
SO Trans-Assoc-Am-Physicians. 1979. 92. P 121-9.
MJ CYSTIC-FIBROSIS: bl.  LECTINS: an.
MN ANIMAL.  CYSTIC-FIBROSIS: fg.  DEXTRANS: pd.  DOGS.  GUINEA-PIGS.
   HAMSTERS.  HEMAGGLUTINATION-INHIBITION-TESTS: mt.
   HEMAGGLUTINATION-TESTS: mt.  HEMAGGLUTINATION: de.  HETEROZYGOTE.
   HOMOZYGOTE.  HUMAN.  IGM: im.  LYMPHOCYTES: de, en.  MICE.  PEDIGREE.
   PHYTOHEMAGGLUTININS: pd.  RABBITS.  RATS.
   SUPPORT-U-S-GOVT-NON-P-H-S.  SUPPORT-U-S-GOVT-P-H-S.
EX We theorize that cystic fibrosis may be a disease in which a plasma
   factor with lectin-like activity stimulates mucus secretion, causes
   precipitation of mucus glycoproteins, and incidentally affects
   lymphocytes in culture.  To confirm our theory, we planned to search
   for additional lectin-like activities in CF serum.  Our experiments
   suggest that the lectin-like substance in CF blood requires IgM for
   its red-blood-cell-agglutination activity.  Thus, no difference in
   agglutination titer is observed between CF homozygotes and
   heterozygotes, because IgM is the limiting factor, and IgM
   concentrations do not differ appreciably in such subjects.  We
   suspect that CF homozygotes have a larger pool of free lectin in
   their blood than do heterozygotes, so that quantitation of this free
   lectin pool may distinguish between the two phenotypes.  Excess free
   lectin may account for the signs and symptoms of CF, whereas lesser
   amounts may theoretically be advantageous to the heterozygote.
RF 001   MARCHI AG             HELV PAEDIATR ACTA              28   427 973
   002   LIEBERMAN J           AM REV RESPIR DIS              116  1047 977
   003$  LIEBERMAN J           CHEST                          75S  220S 979
   004   FREED DLJ             LANCET                           1   585 978
   005   SHARON N              SCIENCE                        177   949 972
   006   BROOKS DE             IN: MOHN JF                           27 977
CT   1   LIEBERMAN J           J LAB CLIN MED                  97   646 981
     2   SEALE TW              ANN CLIN LAB SCI                12   415 982
     3   LIEBERMAN J           AM J MED                        77   678 984
     4   QURESHI AR            J PEDIATR                      106   913 985

PN 79259
RN 01239 
AN 80105142
AU Bohles-H.  Heid-H.  Stehr-K.  Fekl-W.
TI Deficiencies of essential fatty acids and vitamin E in cystic
   fibrosis.
SO Z-Ernahrungswiss. 1979 Jul. 18(2). P 81-7.
MJ CYSTIC-FIBROSIS: pp.  FATTY-ACIDS-ESSENTIAL: df.
   VITAMIN-E-DEFICIENCY: pp.
MN ADOLESCENCE.  BODY-HEIGHT.  CHILD.  CHILD-PRESCHOOL.
   CHOLESTEROL-ESTERS: bl.  CYSTIC-FIBROSIS: co.  FATTY-ACIDS: bl.
   FEMALE.  HUMAN.  INFANT.  MALE.  PHOSPHOLIPIDS: bl.
   TRIGLYCERIDES: bl.  VITAMIN-E-DEFICIENCY: co.  VITAMIN-E: bl.
AB In 25 children (13 male; 12 female) with cystic fibrosis aged 6
   months to 16 years and 24 matched controls total serum vitamin E
   levels and fatty acid patterns of serum cholesterol esters,
   phospholipids and triglycerides are demonstrated. Compared to
   controls (1.02 +/- 0.24 mg/dl) the total serum vitamin E levels are
   significantly decreased in patients with cystic fibrosis (0.30 +/-
   0.26 mg/dl) (p less than 0.01). There is no significant difference
   comparing the fatty acid patterns of the serum ester fractions of
   both groups. Differences can be seen best in the cholesterol ester
   fraction. In this fraction linoleic acid shows a trend to be
   decreased in the cystic fibrosis patients compared to the control
   group. A possible influence of height velocity on the levels of
   essential fatty acids is discussed.
RF 001   ANON                  NUTR REV                        17    13 959
   002   BLANC WA              PEDIATRICS                      22   494 958
   003   ELLIOTT RB            ARCH DIS CHILD                  50    76 975
   004   FOLCH J               J BIOL CHEM                    226   497 957
   005   GORDON HH             TRANS AM CLIN CLIMAT ASSOC      68   155 956
   006   GORDON HH             AM J CLIN NUTR                   4   391 956
   007   HARRIS R              ARCH DIS CHILD                  30   424 955
   008   HARRIES JT            ARCH DIS CHILD                  46   341 971
   009   HOLMAN RT             J NUTR                          70   405 960
   010   JENSEN SB             ACTA PAEDIATR SCAND             45    70 956
   011   MCWHIRTER WR          ACTA PAEDIATR SCAND             64   446 975
   012   MULLER DPR            GUT                             15   966 974
   013   NITOWSKY HM           AM J DIS CHILD                  92   164 956
   014   NITOWSKY HM           AM J CLIN NUTR                   4   397 956
   015   NITOWSKY HM           BULL JOHNS HOPKINS HOSP         98   361 956
   016   PAULSRUD JR           AM J CLIN NUTR                  25   897 972
   017   QUAIFE ML             J BIOL CHEM                    180  1229 949
   018   ROBINSON GR           LANCET                           2   919 975
   019   ROSS CAC              ARCH DIS CHILD                  30   316 955
   020   RIVERS JPW            LANCET                           2   642 975
   021   SHMERLING DH          PEDIATRICS                      46   690 970
   022   UNDERWOOD BA          ANN NY ACAD SCI                203   237 972
   023   UNDERWOOD BA          PEDIATR RES                      6    26 972
   024   WATTS R               LANCET                           2   983 975
   025   WITTING LA            AM J CLIN NUTR                  27   952 974
   026   ZOLLNER N             Z GESAMTE EXP MED              146    89 968
CT   1   CHO YW                J CLIN PHARMACOL                21   224 981
     2   BOHLES H              KLIN PAEDIATR                  197   386 985

